LY541850 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Differentiating O
the O
roles O
of O
mGlu2 B
and O
mGlu3 O
receptors O
using O
LY541850 O
, O
an O
mGlu2 O
agonist/mGlu3 O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human O
mGlu O
receptors O
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O
orthosteric O
mGlu2 O
agonist O
and O
mGlu3 O
antagonist O
. O
We O
have O
verified O
this O
pharmacological O
profile O
of O
LY541850 O
in O
hippocampal O
slices O
. O
Field O
excitatory O
post-synaptic O
potentials O
(fEPSPs) O
evoked O
by O
stimulation O
of O
the O
temporo-ammonic O
path O
(TAP) O
input O
to O
CA1 O
stratum O
lacunosum O

LY541850 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Differentiating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 B
receptors O
using O
LY54185 O
 O
, O
an O
mGlu2 O
agonist/mGlu3 O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human O
mGlu O
receptors O
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O

LY541850 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
group O
II O
agonist O
, O
DCG-IV O
, O
inhibited O
the O
fEPSP O
in O
all O
three O
genotypes O
. O
Co-application O
of O
DCG-IV O
and O
LY541850 O
in O
mGlu3-/- O
and O
wild-type O
littermates O
resulted O
in O
an O
additive O
effect O
, O
whereas O
in O
mGlu2-/- O
mice O
, O
LY541850 O
reversed O
the O
inhibitory O
action O
of O
DCG-IV O
. O
These O
results O
confirm O
the O
selective O
mGlu2 O
agonist O
and O
mGlu3 B
antagonist O
actions O
of O
LY541850 O
A O
similar O
profile O
of O
activity O
was O
seen O
in O
medial O
perforant O
path O
synapse O
to O
the O
dentate O
gyrus O
. O
Systemic O
administration O
of O
LY541850 O
to O
wild-type O
mice O
, O
reduced O
the O
increase O
in O
locomotor O
activity O
following O
both O
phencyclidine O
and O
amphetamine O
administration O
. O
These O
data O
support O
the O
hypothesis O
that O
mGlu2 O
receptors O
mediate O
the O
antipsychotic O
effects O
of O
mixed O

LY541850 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Differentiating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 B
receptors O
using O
LY541850 O
, O
an O
mGlu2 O
agonist/mGlu3 O
antagonist.Despite O
the O
potential O
therapeutic O
relevance O
of O
group O
II O
metabotropic O
glutamate O
(mGlu) O
receptors O
, O
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 O
and O
mGlu3 O
receptor O
subtypes O
. O
LY541850 O
was O
claimed O
from O
human O
mGlu O
receptors O
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O
orthosteric O
mGlu2 O
agonist O
and O
mGlu3 O
antagonist O
. O
We O
have O
verified O
this O
pharmacological O
profile O
of O
LY541850 O
in O
hippocampal O
slices O
. O
Field O
excitatory O
post-synaptic O
potentials O
(fEPSPs) O
evoked O
by O
stimulation O
of O
the O
temporo-ammonic O
path O
(TAP) O
input O
to O
CA1 O
stratum O
lacunosum O

vescalagin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
21% O
in O
the O
insulin-resistant O
FL83B O
mouse O
hepatocytes O
as O
compared O
with O
the O
TNF-α-treated O
control O
group O
. O
Vescalagin O
was O
isolated O
using O
column O
chromatography O
of O
PWFE O
. O
This O
compound O
, O
at O
the O
concentration O
of O
6.25 O
µg/mL O
, O
exhibits O
the O
same O
glucose O
uptake O
improvement O
in O
insulin-resistant O
cells O
as O
PWFE O
at O
a O
100-µg/mL O
dose O
. O
We O
postulate O
that O
vescalagin O
is O
an O
active O
component O
in O
PWFE O
that O
may O
alleviate O
the O
insulin B
resistance O
in O
mouse O
hepatocytes O
. O

(+/-)-Modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human B
dopamine I
transporter I
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O

(+/-)-Modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
R-modafinil O
(armodafinil) O
: O
a O
unique O
dopamine O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O

[(3)H]WIN O
35428 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human B
dopamine I
transporter I
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O

[(3)H]WIN O
35428 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O

R-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O

R-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F B
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O

R-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O

(+/-)- O
, O
R- O
, O
and O
S-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O

cocaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O

R-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O

S-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O

S-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
bind O
to O
the O
DAT O
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F B
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O

S-modafinil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O

cocaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A B
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O

cocaine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT B
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O

[2-(trimethylammonium)ethyl]-methanethiosulfonate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT B
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O

[2-(trimethylammonium)ethyl]-methanethiosulfonate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C B
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O

[2-(trimethylammonium)ethyl]-methanethiosulfonate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O
Y335A O
DAT O
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine O
, O
which O
was O
further O
supported O
by O
[2-(trimethylammonium)ethyl]-methanethiosulfonate O
reactivity O
on O
the O
DAT O
E2C O
I159C O
. O
Microdialysis O
studies O
demonstrated O
that O
both O
R- O
and O
S-modafinil O
produced O
increases O
in O
extracellular O
DA O
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine O
and O
with O
a O
longer O
duration O
of O
action O
. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine O
from O
saline O
. O
CONCLUSIONS O
: O

[(3)H] O
dopamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human B
dopamine I
transporter I
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O

[(3)H] O
dopamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
(DA) O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
( O
DA O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human B
dopamine I
transporter I
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
potential O
medication O
for O
psychostimulant O
abuse.BACKGROUND O
: O
(+/-)-Modafinil O
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence O
. O
The O
R-enantiomer O
of O
modafinil O
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated O
. O
METHODS O
: O
(+/-)-Modafinil O
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] O
dopamine O
( O
DA O
uptake O
and O
[(3)H]WIN O
35428 O
binding O
in O
human O
dopamine O
transporter O
(DAT) O
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
with O
altered O
conformational O
equilibria O
. O
Data O
were O
compared O
with O
cocaine O
and O
the O
atypical O
DA O
uptake O
inhibitor O
, O
JHW O
007 O
. O
R- O
and O
S-modafinil O
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine O
discrimination O
procedure O
. O
RESULTS O
: O
(+/-)- O
, O
R- O
, O
and O
S-modafinil O
bind O
to O
the O
DAT B
and O
inhibit O
DA O
uptake O
less O
potently O
than O
cocaine O
, O
with O
R-modafinil O
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer O
. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers O
. O
R-modafinil O
was O
significantly O
less O
potent O
in O
the O
DAT O
Y156F O
mutant O
compared O
with O
wild-type O
DAT O
, O
whereas O
S-modafinil O
was O
affected O
less O
. O
Studies O
with O
the O

Silibinin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
treatment O
could O
inhibit O
the O
cell O
growth O
and O
cause O
a O
prominent O
G2 O
phase O
arrest O
and O
apoptosis O
in O
dose- O
and O
time-dependent O
manner O
. O
In O
mechanistic O
studies O
, O
Silibinin O
decreased O
the O
protein O
level O
of O
p34cdc2 O
, O
which O
might O
be O
the O
possible O
molecular O
mechanism O
of O
Silibinin O
efficacy O
on O
the O
growth O
inhibition O
in O
SGC-7901 O
cells O
. O
In O
addition O
, O
Silibinin O
caused O
an O
increase O
in O
p53 B
and O
p21 O
protein O
level O
as O
well O
as O
mRNA O
levels O
. O
Interestingly O
, O
Silibinin-induced O
apoptosis O
in O
SGC-7901 O
cells O
was O
independent O
of O
caspases O
activation O
. O
These O
results O
indicated O
that O
Silibinin O
is O
a O
cell-cycle O
regulator O
and O
apoptosis O
inducer O
in O
human O
gastric O
carcinoma O
SGC-7901 O
cells O
and O
might O
be O
used O
as O
a O

Silibinin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
treatment O
could O
inhibit O
the O
cell O
growth O
and O
cause O
a O
prominent O
G2 O
phase O
arrest O
and O
apoptosis O
in O
dose- O
and O
time-dependent O
manner O
. O
In O
mechanistic O
studies O
, O
Silibinin O
decreased O
the O
protein O
level O
of O
p34cdc2 O
, O
which O
might O
be O
the O
possible O
molecular O
mechanism O
of O
Silibinin O
efficacy O
on O
the O
growth O
inhibition O
in O
SGC-7901 O
cells O
. O
In O
addition O
, O
Silibinin O
caused O
an O
increase O
in O
p53 O
and O
p21 B
protein O
level O
as O
well O
as O
mRNA O
levels O
. O
Interestingly O
, O
Silibinin-induced O
apoptosis O
in O
SGC-7901 O
cells O
was O
independent O
of O
caspases O
activation O
. O
These O
results O
indicated O
that O
Silibinin O
is O
a O
cell-cycle O
regulator O
and O
apoptosis O
inducer O
in O
human O
gastric O
carcinoma O
SGC-7901 O
cells O
and O
might O
be O
used O
as O
a O

Silibinin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
well O
elucidated O
. O
Here O
, O
we O
assessed O
the O
activity O
of O
Silibinin O
on O
apoptosis O
and O
cell-cycle O
arrest O
in O
human O
gastric O
cells O
culture O
system O
using O
SGC-7901 O
as O
the O
model O
. O
Silibinin O
treatment O
could O
inhibit O
the O
cell O
growth O
and O
cause O
a O
prominent O
G2 O
phase O
arrest O
and O
apoptosis O
in O
dose- O
and O
time-dependent O
manner O
. O
In O
mechanistic O
studies O
, O
Silibinin O
decreased O
the O
protein O
level O
of O
p34cdc2 O
, O
which O
might O
be O
the O
possible O
molecular O
mechanism O
of O
Silibinin O
efficacy O
on O
the O
growth O
inhibition O
in O
SGC-7901 O
cells O
. O
In O
addition O
, O
Silibinin O
caused O
an O
increase O
in O
p53 O
and O
p21 O
protein O
level O
as O
well O
as O
mRNA O
levels O
. O
Interestingly O
, O
Silibinin-induced O
apoptosis O
in O
SGC-7901 O
cells O
was O
independent O
of O

WAY100635 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vogel's O
conflict O
test O
, O
a O
dose-dependent O
anxiolytic-like O
effect O
was O
seen O
. O
The O
anti-hyperthermic O
effect O
of O
Lu O
AF21934 O
(5 O
mg/kg) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine O
receptor O
antagonist O
flumazenil O
(10 O
mg/kg) O
and O
was O
not O
serotonin-dependent O
, O
as O
it O
persisted O
in O
serotonin-deficient O
mice O
and O
upon O
blockade O
of O
either O
5-HT(1A) B
receptors O
by O
WAY100635 O
or O
5-HT(2A/2C) O
receptors O
by O
ritanserin O
. O
These O
results O
suggest O
that O
the O
GABAergic O
system O
, O
but O
not O
the O
serotonergic O
system O
, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic-like O
phenotype O
of O
Lu O
AF21934 O
in O
rodents O
. O
Lu O
AF21934 O
did O
not O
produce O
antidepressant-like O
effects O
in O
the O
tail O
suspension O
test O
(TST) O
in O
mice; O
however O
, O
it O
decreased O

ritanserin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
anxiolytic-like O
effect O
was O
seen O
. O
The O
anti-hyperthermic O
effect O
of O
Lu O
AF21934 O
(5 O
mg/kg) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine O
receptor O
antagonist O
flumazenil O
(10 O
mg/kg) O
and O
was O
not O
serotonin-dependent O
, O
as O
it O
persisted O
in O
serotonin-deficient O
mice O
and O
upon O
blockade O
of O
either O
5-HT(1A) O
receptors O
by O
WAY100635 O
, O
or O
5-HT(2A/2C) B
receptors O
by O
ritanserin O
These O
results O
suggest O
that O
the O
GABAergic O
system O
, O
but O
not O
the O
serotonergic O
system O
, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic-like O
phenotype O
of O
Lu O
AF21934 O
in O
rodents O
. O
Lu O
AF21934 O
did O
not O
produce O
antidepressant-like O
effects O
in O
the O
tail O
suspension O
test O
(TST) O
in O
mice; O
however O
, O
it O
decreased O
the O
basal O
locomotor O
activity O
of O

LSP1-2111 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Anxiolytic- O
but O
not O
antidepressant-like O
activity O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu₄ O
receptor.Previous O
studies O
demonstrated O
that O
the O
Group O
III O
mGlu O
receptor-selective O
orthosteric O
agonist O
, O
LSP1-2111 O
produced O
anxiolytic- O
but O
not O
antidepressant-like O
effects O
upon O
peripheral O
administration O
. O
Herein O
, O
we O
report O
the O
pharmacological O
actions O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
, O
and O
brain-penetrant O
positive O
allosteric O
modulator O
(PAM) O
of O
the O
mGlu(4) O
receptor O
in O
the O
stress-induced O
hyperthermia O
(SIH) O
, O
four-plate O
, O
marble-burying O
and O
Vogel's O
conflict O
tests O
. O
In O
all O
models O
, O
except O
Vogel's O
conflict O
test O
, O

flumazenil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
modulator O
(PAM) O
of O
the O
mGlu(4) O
receptor O
in O
the O
stress-induced O
hyperthermia O
(SIH) O
, O
four-plate O
, O
marble-burying O
and O
Vogel's O
conflict O
tests O
. O
In O
all O
models O
, O
except O
Vogel's O
conflict O
test O
, O
a O
dose-dependent O
anxiolytic-like O
effect O
was O
seen O
. O
The O
anti-hyperthermic O
effect O
of O
Lu O
AF21934 O
(5 O
mg/kg) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine B
receptor I
antagonist O
flumazenil O
(10 O
mg/kg) O
and O
was O
not O
serotonin-dependent O
, O
as O
it O
persisted O
in O
serotonin-deficient O
mice O
and O
upon O
blockade O
of O
either O
5-HT(1A) O
receptors O
by O
WAY100635 O
, O
or O
5-HT(2A/2C) O
receptors O
by O
ritanserin O
. O
These O
results O
suggest O
that O
the O
GABAergic O
system O
, O
but O
not O
the O
serotonergic O
system O
, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic-like O
phenotype O
of O
Lu O

Lu O
AF21934 O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Anxiolytic- O
but O
not O
antidepressant-like O
activity O
of O
Lu O
AF2193 O
 O
, O
a O
novel O
, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu₄ B
receptor.Previous O
studies O
demonstrated O
that O
the O
Group O
III O
mGlu O
receptor-selective O
orthosteric O
agonist O
, O
LSP1-2111 O
produced O
anxiolytic- O
but O
not O
antidepressant-like O
effects O
upon O
peripheral O
administration O
. O
Herein O
, O
we O
report O
the O
pharmacological O
actions O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
, O
and O
brain-penetrant O
positive O
allosteric O
modulator O
(PAM) O

Lu O
AF21934 O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
Anxiolytic- O
but O
not O
antidepressant-like O
activity O
of O
Lu O
AF21934 O
, O
a O
novel O
, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu₄ O
receptor.Previous O
studies O
demonstrated O
that O
the O
Group O
III O
mGlu O
receptor-selective O
orthosteric O
agonist O
, O
LSP1-2111 O
produced O
anxiolytic- O
but O
not O
antidepressant-like O
effects O
upon O
peripheral O
administration O
. O
Herein O
, O
we O
report O
the O
pharmacological O
actions O
of O
Lu O
AF21934 O
a O
novel O
, O
selective O
, O
and O
brain-penetrant O
positive O
allosteric O
modulator O
(PAM) O
of O
the O
mGlu(4) B
receptor O
in O
the O
stress-induced O
hyperthermia O
(SIH) O
, O
four-plate O
, O
marble-burying O
and O
Vogel's O
conflict O
tests O
. O
In O
all O
models O
, O
except O
Vogel's O
conflict O
test O
, O
a O
dose-dependent O
anxiolytic-like O
effect O
was O
seen O
. O
The O
anti-hyperthermic O
effect O
of O
Lu O
AF21934 O
(5 O
mg/kg) O
in O
the O
SIH O
test O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
mGluR1 B
from O
multiple O
voltage O
dependent O
calcium O
channels O
including O
Ca(V2.2) O
(N-type) O
, O
Ca(V3.2) O
(T-type) O
, O
and O
Ca(V2.1) O
(P/Q-type) O
expressed O
in O
rat O
sympathetic O
neurons O
from O
the O
superior O
cervical O
ganglion O
(SCG) O
. O
Of O
these O
, O
only O
the O
mGluR1-Ca(V2.1) O
modulatory O
pathway O
was O
insensitive O
to O
Homer-2b O
expression O
. O
Uncoupling O
from O
this O
channel O
was O
achieved O
by O
co-expression O
of O
an O
mGluR1 O
C O
terminal O
protein O
designed O
to O
disrupt O
a O
previously O
described O
direct O
interaction O
between O
these O
two O
proteins O
, O
suggesting O
that O
this O
interaction O
allows O
incorporation O
of O
Ca(V2.1) O
into O
the O
mGluR1/Homer O
signaling O
complex O
, O
thereby O
preserving O
modulation O
in O
the O
presence O
of O
scaffolding O
Homer O
proteins O
. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic O
Glutamate O
Receptors' O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
most O
well O
studied O
functions O
of O
group O
I O
mGluRs O
, O
such O
as O
initiation O
of O
multiple O
forms O
of O
mGluR-dependent O
long-term O
depression O
, O
require O
receptor O
localization O
near O
the O
post-synaptic O
density O
(PSD) O
. O
This O
localization O
is O
in O
turn O
dependent O
on O
the O
Homer O
family O
of O
scaffolding O
proteins O
which O
bind O
to O
a O
small O
motif O
on O
the O
distal O
C O
termini O
of O
mGluR1 O
and O
5 O
, O
localize O
the O
receptors O
near O
the O
PSD O
, O
strengthen O
coupling O
to O
post-synaptic O
effectors O
and O
simultaneously O
uncouple O
the O
mGluRs O
from O
extra-synaptic O
effectors O
such O
as O
voltage O
dependent O
ion O
channels O
. O
Here O
the O
selectivity O
of O
this O
uncoupling O
process O
was O
examined O
by O
testing O
the O
ability O
of O
Homer-2b O
to O
uncouple O
mGluR1 O
from O

Swertiamarin O
acts O
as O
NOT O
for O
what O
entity O
? O
anti-diabetic O
effects O
of O
swertiamarin; O
however O
, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin O
had O
a O
plasma O
half-life O
of O
1.3 O
h O
. O
Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O
The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ B
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O

Swertiamarin O
acts O
as O
NOT O
for O
what O
entity O
? O
anti-diabetic O
effects O
of O
swertiamarin; O
however O
, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin O
had O
a O
plasma O
half-life O
of O
1.3 O
h O
. O
Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O
The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ O
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O

Gentianine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Anti-diabetic O
Activity O
of O
Swertiamarin O
is O
due O
to O
an O
Active O
Metabolite O
, O
Gentianin O
 O
, O
that O
Upregulates O
PPAR-γ B
Gene O
Expression O
in O
3T3-L1 O
cells.We O
have O
previously O
shown O
the O
anti-diabetic O
effects O
of O
swertiamarin; O
however O
, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin O
had O
a O
plasma O
half-life O
of O
1.3 O
h O
. O
Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O
The O
aim O
of O
this O
study O
was O
to O

Swertiamarin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
anti-diabetic O
effects O
of O
swertiamarin; O
however O
, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin O
had O
a O
plasma O
half-life O
of O
1.3 O
h O
. O
Gentianine O
is O
an O
active O
metabolite O
of O
swertiamarin O
that O
possesses O
a O
pharmacophoric O
moiety O
. O
The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ O
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O

gentianine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ B
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
PPAR-γ O
, O
GLUT-4 O
and O
adiponectin O
. O
These O
findings O
suggest O
, O
for O
the O
first O
time O
, O
that O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
, O
an O
active O
metabolite O
of O
swertiamarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

gentianine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ O
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
PPAR-γ O
, O
GLUT-4 B
and O
adiponectin O
. O
These O
findings O
suggest O
, O
for O
the O
first O
time O
, O
that O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
, O
an O
active O
metabolite O
of O
swertiamarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

gentianine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
. O
Swertiamarin O
treatment O
had O
no O
significant O
effect O
on O
adipogenesis O
, O
or O
the O
mRNA O
expression O
of O
PPAR-γ O
and O
GLUT-4; O
however O
, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin O
. O
On O
the O
other O
hand O
, O
treatment O
with O
gentianine O
significantly O
increased O
adipogenesis O
, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
PPAR-γ O
, O
GLUT-4 O
and O
adiponectin O
. O
These O
findings O
suggest O
, O
for O
the O
first O
time O
, O
that O
the O
anti-diabetic O
effect O
of O
swertiamarin O
is O
due O
to O
gentianine O
, O
an O
active O
metabolite O
of O
swertiamarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

silymarin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase B
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O

silymarin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase O
and O
aniline B
4-hydroxylase I
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O

silymarin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase O
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O

CCl4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase B
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O
damage O
comparable O
to O
that O
of O
silymarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

CCl4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase O
and O
aniline B
4-hydroxylase I
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O
damage O
comparable O
to O
that O
of O
silymarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

CCl4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase O
and O
aniline O
4-hydroxylase O
activity O
and O
cytochrome O
P450 O
, O
compared O
to O
the O
CCl4 O
only O
group O
. O
Neither O
silymarin O
nor O
PSM O
influenced O
PC O
biotransformation O
. O
Our O
results O
suggest O
that O
PSM O
, O
obtained O
from O
A O
. O
corniculatus O
, O
Bieb O
. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 O
and O
PC-induced O
liver O
damage O
comparable O
to O
that O
of O
silymarin O
. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

CCl4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
were O
challenged O
orally O
with O
20% O
CCl4 O
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin O
(200 O
mg/kg) O
. O
A O
significant O
decrease O
of O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
lactate O
dehydrogenase O
(LDH) O
activities O
and O
glutathione O
(GSH) O
levels O
and O
an O
increase O
of O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O

CCl4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
were O
challenged O
orally O
with O
20% O
CCl4 O
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin O
(200 O
mg/kg) O
. O
A O
significant O
decrease O
of O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
lactate O
dehydrogenase O
(LDH) O
activities O
and O
glutathione O
(GSH) O
levels O
and O
an O
increase O
of O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O

CCl4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
were O
challenged O
orally O
with O
20% O
CCl4 O
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin O
(200 O
mg/kg) O
. O
A O
significant O
decrease O
of O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
lactate B
dehydrogenase I
(LDH) O
activities O
and O
glutathione O
(GSH) O
levels O
and O
an O
increase O
of O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH O
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O

CCl4 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
were O
challenged O
orally O
with O
20% O
CCl4 O
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin O
(200 O
mg/kg) O
. O
A O
significant O
decrease O
of O
aspartate O
aminotransferase O
, O
alanine O
aminotransferase O
, O
lactate O
dehydrogenase O
(LDH) O
activities O
and O
glutathione O
(GSH) O
levels O
and O
an O
increase O
of O
malondialdehyde O
(MDA) O
quantity O
was O
observed O
after O
CCl4 O
and O
PC O
administration O
alone O
. O
PSM O
pre-treatment O
decreased O
serum O
transaminases O
and O
LDH B
activities O
and O
MDA O
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH O
. O
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models O
. O
In O
the O
CCl4 O
hepatotoxicity O
model O
, O
pre-treatment O
with O
PSM O
or O
silymarin O
resulted O
in O
significantly O
increased O
activities O
of O

fenofibrate O
acts O
as O
NOT O
for O
what O
entity O
? O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP O
. O
ISO O
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated O
group O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated O
group O
. O
The O
study O
showed O
that O
fenofibrate O
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE O
, O
AII B
and O
ET1 O
but O
caused O
enhanced O
vasodilation O
by O
Ach O
, O
SNP O
and O
ISO O
. O

fenofibrate O
acts O
as O
NOT O
for O
what O
entity O
? O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP O
. O
ISO O
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated O
group O
. O
The O
effect O
of O
Ach O
, O
SNP O
and O
ISO O
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated O
group O
. O
The O
study O
showed O
that O
fenofibrate O
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE O
, O
AII O
and O
ET1 B
but O
caused O
enhanced O
vasodilation O
by O
Ach O
, O
SNP O
and O
ISO O
. O

fenofibrate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
fenofibrat O
 O
, O
a O
PPAR-α B
ligand O
, O
on O
the O
haemodynamics O
of O
glycerol-induced O
renal O
failure O
in O
rats.The O
modulating O
effect O
of O
peroxisome O
proliferator-activated O
receptor O
α O
ligand O
on O
haemodynamic O
effects O
of O
phenylepherine O
(PE) O
, O
angiotensin O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O

fenofibrate O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O
rats O
. O
The O
effect O
of O
PE O
on O
fenofibrate-treated O
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP) O
. O
For O
AII B
and O
ET1 O
, O
MAP O
was O
also O
increased O
for O
the O
fenofibrate O
group O
but O
not O
in O
a O
dose-dependent O
fashion O
. O
On O
the O
medullary O
blood O
flow O
(MBF) O
, O
while O
the O
lower O
doses O
of O
PE O
and O
AII O
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated O
group O
, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit O
. O
The O
ET1 O
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O

fenofibrate O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
II O
(AII) O
, O
endothelin O
1 O
(ET1) O
, O
acetylcholine O
(Ach) O
, O
sodium O
nitroprusside O
(SNP) O
and O
isoproterenol O
(ISO) O
were O
evaluated O
in O
glycerol-induced O
acute O
kidney O
injury O
in O
rats O
. O
The O
effect O
of O
PE O
on O
fenofibrate-treated O
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP) O
. O
For O
AII O
and O
ET1 O
, O
MAP O
was O
also O
increased O
for O
the O
fenofibrate O
group O
but O
not O
in O
a O
dose-dependent O
fashion O
. O
On O
the O
medullary O
blood O
flow O
(MBF) O
, O
while O
the O
lower O
doses O
of O
PE O
and O
AII O
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated O
group O
, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit O
. O
The O
ET1 B
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O

chloroquine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
NFATc1 O
dephosphorylation O
. O
Protein O
and O
RNA O
expression O
levels O
of O
regulator O
of O
calcineurin O
1 O
(RCAN1) O
, O
an O
endogenous O
inhibitor O
of O
NFATc1 O
activation O
and O
a O
protein O
degraded O
in O
lysosomes O
, O
were O
not O
significantly O
different O
between O
+/R740S O
and O
+/+ O
osteoclasts O
, O
but O
the O
RCAN1/NFATc1 O
ratio O
was O
significantly O
higher O
in O
+/R740S O
versus O
+/+ O
cells O
. O
The O
lysosomal O
inhibitor O
chloroquine O
significantly O
increased O
RCAN1 B
accumulation O
in O
+/+ O
cells O
, O
consistent O
with O
the O
hypothesis O
that O
higher O
lysosomal O
pH O
impairs O
RCAN1 O
degradation O
, O
leading O
to O
a O
higher O
RCAN1/NFATc1 O
ratio O
and O
consequently O
NFATc1 O
inhibition O
. O
Our O
data O
indicate O
that O
increased O
lysosomal O
pH O
in O
osteoclasts O
leads O
to O
decreased O
NFATc1 O
signaling O
and O
nuclear O
translocation O
, O
resulting O
in O
a O
cell O

PAHs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
ROS O
further O
increase O
AKRs B
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O
levels O
in O
PBLs O
from O
smokers O
. O
In O
the O
smoker O
group O
, O
there O
is O
a O
statistically O
significant O
positive O

PAHs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1 O
, O
AKR1C1 O
, O
and O
AKR1C3 O
mRNA O
induction O
and O
urine O
cotinine O
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25 O
. O
However O
, O
AKR1A1*2 O
and O
AKR1C3*2 O
alleles O
did O
not O
influence O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
mRNA O
levels O
. O
These O
results O
suggest O
that O
AKRs B
induction O
by O
PAHs O
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore O
, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' O
effects O
needs O
further O
investigation O
. O

PAHs O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AKRs B
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O

oxygen O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O

oxygen O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
AKRs B
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs B
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O

PAHs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
( O
PAHs O
 O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O

PAHs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs B
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
( O
PAHs O
 O
, O
generating O
metabolites O
(o-quinones) O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O

o-quinones O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
( O
o-quinones O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O

o-quinones O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
AKRs B
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers O
: O
The O
role O
of O
body O
mass O
index.Aldo-keto O
reductases O
(AKRs) O
metabolize O
a O
wide O
range O
of O
substrates O
, O
including O
polycyclic O
aromatic O
hydrocarbons O
(PAHs) O
, O
generating O
metabolites O
( O
o-quinones O
and O
reactive O
oxygen O
species O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs O
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O

PAHs O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(ROS) O
, O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis O
. O
Exposure O
to O
PAHs O
, O
their O
metabolites O
, O
and O
ROS O
further O
increase O
AKRs B
isoform O
expression O
that O
may O
amplify O
oxidative O
damage O
. O
Human O
AKR O
enzymes O
are O
highly O
polymorphic O
, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs O
expression O
in O
individuals O
. O
Despite O
the O
importance O
of O
AKRs O
in O
PAHs O
metabolism O
, O
there O
are O
no O
studies O
that O
evaluate O
, O
in O
general O
human O
populations O
, O
the O
effect O
of O
PAHs O
on O
AKRs O
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs) O
. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure O
, O
and O
AKR1A1*2 O
and O
AKR1C3*2 O
polymorphisms O
, O
on O
AKR1A1 O
and O
AKR1C1-AKR1C3 O
messenger O
RNA O
(mRNA) O

Thiazolidinediones O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Thiazolidinediones O
(TZDs) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD O
effects O
on O
aromatase O
. O
Thiazolidinediones O
(TZDs) O
are O
insulin B
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O
We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase O
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O

TZD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures O
. O
TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O
TZDs O
also O
inhibited O
alkaline B
phosphatase I
activity O
(58-75% O
, O
p<0.046) O
and O
osteocalcin O
production O
(52-75% O
, O
p<0.031) O
. O
For O
all O
the O
parameters O
, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures O
. O
TZD O
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O
aromatase O
. O

TZD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures O
. O
TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O
TZDs O
also O
inhibited O
alkaline O
phosphatase O
activity O
(58-75% O
, O
p<0.046) O
and O
osteocalcin B
production O
(52-75% O
, O
p<0.031) O
. O
For O
all O
the O
parameters O
, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures O
. O
TZD O
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O
aromatase O
. O

TZDs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Thiazolidinediones O
(TZDs) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD O
effects O
on O
aromatase.Thiazolidinediones O
( O
TZDs O
are O
insulin B
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O
We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase O
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O
alone O

TZD O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Thiazolidinediones O
(TZDs) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZ O
effects O
on O
aromatase.Thiazolidinediones O
(TZDs) O
are O
insulin O
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O
We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase B
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O

TZDs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
without O
HGC O
, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone O
, O
pioglitazone O
or O
rosiglitazone O
. O
Cell O
growth O
, O
oleic O
acid O
uptake O
, O
alkaline B
phosphatase I
activity O
, O
and O
osteocalcin O
production O
were O
measured O
. O
TZDs O
inhibited O
estradiol O
production O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures O
. O
TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O
TZDs O
also O
inhibited O
alkaline O
phosphatase O
activity O
(58-75% O
, O
p<0.046) O
and O
osteocalcin O
production O
(52-75% O
, O
p<0.031) O
. O
For O
all O
the O
parameters O
, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures O
. O
TZD O
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O

TZDs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
without O
HGC O
, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone O
, O
pioglitazone O
or O
rosiglitazone O
. O
Cell O
growth O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
activity O
, O
and O
osteocalcin B
production O
were O
measured O
. O
TZDs O
inhibited O
estradiol O
production O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures O
. O
TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O
TZDs O
also O
inhibited O
alkaline O
phosphatase O
activity O
(58-75% O
, O
p<0.046) O
and O
osteocalcin O
production O
(52-75% O
, O
p<0.031) O
. O
For O
all O
the O
parameters O
, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures O
. O
TZD O
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O

TZD O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures O
. O
TZDs O
induced O
mouse O
osteoblast O
death O
and O
increased O
oleic O
acid O
uptake O
. O
TZDs O
also O
inhibited O
alkaline O
phosphatase O
activity O
(58-75% O
, O
p<0.046) O
and O
osteocalcin O
production O
(52-75% O
, O
p<0.031) O
. O
For O
all O
the O
parameters O
, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures O
. O
TZD O
effects O
on O
osteoblast O
viability O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
and O
osteocalcin O
production O
are O
independent O
of O
their O
effects O
on O
aromatase O
. O

TZDs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Thiazolidinediones O
(TZDs) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD O
effects O
on O
aromatase.Thiazolidinediones O
(TZDs) O
are O
insulin O
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O
We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase B
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co-culture O
with O
HGC O
to O
determine O
whether O
TZD O
inhibition O
of O
aromatase O
plays O

TZD O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase B
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co-culture O
with O
HGC O
to O
determine O
whether O
TZD O
inhibition O
of O
aromatase O
plays O
a O
role O
in O
their O
effects O
on O
bone O
metabolism O
. O
Mouse O
osteoblasts O
were O
cultured O
with O
and O
without O
HGC O
, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone O
, O
pioglitazone O
or O
rosiglitazone O
. O
Cell O
growth O
, O
oleic O
acid O
uptake O
, O
alkaline O
phosphatase O
activity O
, O
and O
osteocalcin O
production O
were O
measured O
. O
TZDs O
inhibited O
estradiol O
production O

estrogen O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Thiazolidinediones O
(TZDs) O
affect O
osteoblast O
viability O
and O
biomarkers O
independently O
of O
the O
TZD O
effects O
on O
aromatase.Thiazolidinediones O
(TZDs) O
are O
insulin O
sensitizers O
used O
for O
treatment O
of O
diabetes O
. O
We O
have O
previously O
reported O
that O
TZDs O
reduce O
estrogen O
synthesis O
by O
inhibiting O
aromatase B
activity O
in O
human O
granulosa O
cells O
(HGC) O
. O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs O
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes O
. O
We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co-culture O
with O
HGC O
to O
determine O
whether O
TZD O
inhibition O
of O
aromatase O
plays O
a O
role O

glutathione O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
the O
enterocytes O
of O
the O
small O
intestine O
. O
Previous O
in O
vitro O
studies O
have O
revealed O
that O
BP O
phenols O
are O
excreted O
as O
Phase O
II O
metabolites O
including O
glucuronides O
and O
sulfates O
. O
This O
export O
is O
mediated O
by O
the O
breast O
cancer O
resistance O
protein O
(ABCG2) O
. O
The O
ultimate O
carcinogenic O
Phase O
I O
BP O
metabolite O
anti-BP-7,8-dihydrodiol-9,10-epoxide O
(BPDE) O
can O
be O
detoxified O
by O
glutathione O
conjugate O
formation O
catalyzed O
by O
glutathione O
S-transferases O
. O
In O
the O
present O
study O
, O
differentiated O
human O
intestinal O
Caco-2 O
cells O
were O
used O
as O
a O
model O
for O
the O
human O
small O
intestine O
to O
investigate O
the O
detoxification O
of O
BPDE O
and O
excretion O
of O
stereoisomeric O
glutathione O
conjugates O
in O
the O
presence O
of O
an O
inhibitor O
of O
the O
glutathione-cleaving O
enzyme O
γ-glutamyl O
transpeptidase O

glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Multidrug B
resistance-associated I
proteins I
are O
involved O
in O
the O
transport O
of O
the O
glutathion O
conjugates O
of O
the O
ultimate O
carcinogen O
of O
benzo[a]pyrene O
in O
human O
Caco-2 O
cells.A O
wide O
variety O
of O
contaminants O
are O
ingested O
through O
food O
, O
among O
them O
the O
pro-carcinogenic O
polycyclic O
aromatic O
hydrocarbon O
benzo[a]pyrene O
(BP) O
that O
is O
resorbed O
and O
partially O
metabolized O
in O
the O
enterocytes O
of O
the O
small O
intestine O
. O
Previous O
in O
vitro O
studies O
have O
revealed O
that O
BP O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
at O
the O
cell O
surface O
. O
The O
results O
indicate O
that O
the O
glutathione O
conjugates O
of O
BPDE O
are O
formed O
and O
excreted O
mainly O
to O
the O
apical O
and O
to O
a O
minor O
extent O
to O
the O
basolateral O
side O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug B
resistance-associated I
proteins I
(ABCCs) O
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
at O
the O
cell O
surface O
. O
The O
results O
indicate O
that O
the O
glutathione O
conjugates O
of O
BPDE O
are O
formed O
and O
excreted O
mainly O
to O
the O
apical O
and O
to O
a O
minor O
extent O
to O
the O
basolateral O
side O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance-associated O
proteins O
(ABCCs) O
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance-associated O
proteins O
(ABCCs) O
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 B
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O
both O
apical O
and O
basolateral O
directions O
. O
This O
finding O
is O
equivalent O
to O
a O
transport O
into O
feces O
as O
well O
as O
blood O
system O
in O
the O
in O
vivo O
situation O
. O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance-associated O
proteins O
(ABCCs) O
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 B
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O
both O
apical O
and O
basolateral O
directions O
. O
This O
finding O
is O
equivalent O
to O
a O
transport O
into O
feces O
as O
well O
as O
blood O
system O
in O
the O
in O
vivo O
situation O
. O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance-associated O
proteins O
(ABCCs) O
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 O
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 B
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O
both O
apical O
and O
basolateral O
directions O
. O
This O
finding O
is O
equivalent O
to O
a O
transport O
into O
feces O
as O
well O
as O
blood O
system O
in O
the O
in O
vivo O
situation O
. O

BPDE O
glutathione O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
polarized O
Caco-2 O
monolayers O
. O
Inhibition O
studies O
revealed O
that O
the O
multidrug O
resistance-associated O
proteins O
(ABCCs) O
are O
involved O
in O
the O
transport O
of O
BPDE O
glutathione O
conjugates O
. O
Stable O
ABCC1 O
, O
ABCC2 B
and O
ABCC3 O
knockdown O
cell O
lines O
were O
generated O
, O
thus O
making O
it O
possible O
to O
demonstrate O
that O
ABCC1 O
mediates O
the O
basolateral O
and O
ABCC2 O
the O
apical O
excretion O
of O
BPDE O
glutathione O
conjugates O
. O
In O
conclusion O
, O
the O
ultimate O
carcinogen O
BPDE O
is O
detoxified O
via O
glutathione O
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O
both O
apical O
and O
basolateral O
directions O
. O
This O
finding O
is O
equivalent O
to O
a O
transport O
into O
feces O
as O
well O
as O
blood O
system O
in O
the O
in O
vivo O
situation O
. O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
p53-like O
transcription O
factor O
CEP-1 O
. O
Here O
, O
we O
report O
unexpected O
rearrangements O
to O
the O
insulin/IGF-1 O
pathway O
, O
whereby O
the O
insulin-like O
receptor O
DAF-2 O
and O
3-phosphoinositide-dependent O
protein O
kinase O
PDK-1 O
oppose O
AKT-1 B
to O
promote O
DNA O
damage-induced O
apoptosis O
. O
While O
DNA O
damage O
does O
not O
affect O
phosphorylation O
at O
the O
PDK-1 O
site O
Thr350/Thr308 O
of O
AKT-1 O
, O
it O
increased O
phosphorylation O
at O
Ser O
17/Ser473 O
. O
Although O
ablation O
of O
daf-2 O
or O
pdk-1 O
completely O
suppressed O
akt-1-dependent O
apoptosis O
, O
the O
transcriptional O
activation O
of O
CEP-1 O
was O
unaffected O
, O
suggesting O
that O
daf-2 O
and O
pdk-1 O
act O
independently O
or O
downstream O
of O
cep-1 O
and O
akt-1 O
. O
Ablation O
of O
the O
akt-1 O
paralog O
akt-2 O
or O
the O
downstream O
target O
of O
the O
insulin/IGF-1 O
pathway O
daf-16 O
(a O
FOXO O
transcription O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
p53-like O
transcription O
factor O
CEP-1 O
. O
Here O
, O
we O
report O
unexpected O
rearrangements O
to O
the O
insulin/IGF-1 O
pathway O
, O
whereby O
the O
insulin-like O
receptor O
DAF-2 O
and O
3-phosphoinositide-dependent O
protein O
kinase O
PDK-1 O
oppose O
AKT-1 B
to O
promote O
DNA O
damage-induced O
apoptosis O
. O
While O
DNA O
damage O
does O
not O
affect O
phosphorylation O
at O
the O
PDK-1 O
site O
Thr350/Thr308 O
of O
AKT-1 O
, O
it O
increased O
phosphorylation O
at O
Ser517 O
/ O
Ser O
73 O
. O
Although O
ablation O
of O
daf-2 O
or O
pdk-1 O
completely O
suppressed O
akt-1-dependent O
apoptosis O
, O
the O
transcriptional O
activation O
of O
CEP-1 O
was O
unaffected O
, O
suggesting O
that O
daf-2 O
and O
pdk-1 O
act O
independently O
or O
downstream O
of O
cep-1 O
and O
akt-1 O
. O
Ablation O
of O
the O
akt-1 O
paralog O
akt-2 O
or O
the O
downstream O
target O
of O
the O
insulin/IGF-1 O
pathway O
daf-16 O
(a O
FOXO O
transcription O

2-Deoxyglucose O
acts O
as O
NOT O
for O
what O
entity O
? O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 B
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O

Thr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
mammary O
epithelial O
cells O
have O
not O
been O
characterized O
. O
The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
activation O
by O
2-deoxyglucose O
on O
protein O
synthesis O
and O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells O
. O
Phosphorylation O
of O
AMPK B
at O
Thr O
72 O
increased O
by O
1.4-fold O
within O
5 O
min O
, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course O
, O
in O
response O
to O
2-deoxyglucose O
. O
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O

2-deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
activation O
by O
2-deoxyglucose O
on O
protein O
synthesis O
and O
the O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells O
. O
Phosphorylation O
of O
AMPK B
at O
Thr172 O
increased O
by O
1.4-fold O
within O
5 O
min O
, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course O
, O
in O
response O
to O
2-deoxyglucose O
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O

2-deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
synthesis O
declined O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α B
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O

2-Deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O

2-Deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous B
sclerosis I
complex I
2 I
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O

2-Deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK O
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O

2-Deoxyglucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
78% O
of O
control O
values O
. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 O
signaling O
, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal O
protein O
S6 O
kinase O
1 O
and O
eIF4E O
binding O
protein-1 O
(4E-BP1) O
. O
Phosphorylation O
of O
ER-stress O
marker O
eIF2α O
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose O
exposure O
. O
2-Deoxyglucose O
increased O
phosphorylation O
of O
tuberous O
sclerosis O
complex O
2 O
(TSC2) O
on O
AMPK B
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 O
bound O
to O
TSC2 O
. O
Activation O
of O
AMPK O
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR O
. O
The O
inhibitory O
effects O
of O
AMPK O
activation O
on O
mTORC1 O
signaling O
were O

Cu O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
sequentially O
exposed O
cells O
to O
air-delivered O
copper O
(Cu) O
NPs O
in O
vitro O
to O
compare O
toxicity O
results O
to O
our O
prior O
in O
vivo O
inhalation O
studies O
. O
The O
evaluation O
of O
cellular O
dosimetry O
indicated O
that O
a O
large O
amount O
of O
Cu O
was O
taken O
up O
, O
dissolved O
and O
released O
into O
the O
basolateral O
medium O
(62% O
of O
total O
mass) O
. O
Exposure O
to O
Cu O
NPs O
decreased O
cell O
viability O
to O
73% O
(p<0.01) O
and O
significantly O
(p<0.05) O
elevated O
levels O
of O
lactate O
dehydrogenase O
, O
intracellular O
reactive O
oxygen O
species O
and O
interleukin-8 B
that O
mirrored O
our O
findings O
from O
subacute O
in O
vivo O
inhalation O
studies O
in O
mice O
. O
Our O
results O
show O
that O
this O
exposure O
system O
is O
useful O
for O
screening O
of O
NP O
toxicity O
in O
a O

Cu O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
sequentially O
exposed O
cells O
to O
air-delivered O
copper O
(Cu) O
NPs O
in O
vitro O
to O
compare O
toxicity O
results O
to O
our O
prior O
in O
vivo O
inhalation O
studies O
. O
The O
evaluation O
of O
cellular O
dosimetry O
indicated O
that O
a O
large O
amount O
of O
Cu O
was O
taken O
up O
, O
dissolved O
and O
released O
into O
the O
basolateral O
medium O
(62% O
of O
total O
mass) O
. O
Exposure O
to O
Cu O
NPs O
decreased O
cell O
viability O
to O
73% O
(p<0.01) O
and O
significantly O
(p<0.05) O
elevated O
levels O
of O
lactate O
dehydrogenase O
, O
intracellular O
reactive O
oxygen O
species O
and O
interleukin-8 O
that O
mirrored O
our O
findings O
from O
subacute O
in O
vivo O
inhalation O
studies O
in O
mice O
. O
Our O
results O
show O
that O
this O
exposure O
system O
is O
useful O
for O
screening O
of O
NP O
toxicity O
in O
a O

LTD4 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP B
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O
the O
CysLT(1)R O
in O
neuroinflammatory O
diseases O

LTD4 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R B
antagonist O
, O
blocked O
LTD4 O
induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O

LTD4 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB B
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O
the O
CysLT(1)R O
in O
neuroinflammatory O
diseases O

LTD4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R B
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O
the O
CysLT(1)R O
in O
neuroinflammatory O
diseases O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R B
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4 O
induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB B
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4 O
induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 B
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4 O
induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ B
peptide I
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O
the O
CysLT(1)R O
in O
neuroinflammatory O
diseases O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
mice.Amyloid O
plaques O
in O
the O
extracellular O
parenchyma O
mainly O
consist O
of O
amyloid-β O
peptides O
(Aβ) O
, O
one O
of O
the O
pathological O
hallmarks O
in O
Alzheimer's O
disease O
(AD) O
. O
In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene O
D4 O
(LTD4) O
in O
mice O
. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 B
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
mice.Amyloid O
plaques O
in O
the O
extracellular O
parenchyma O
mainly O
consist O
of O
amyloid-β O
peptides O
(Aβ) O
, O
one O
of O
the O
pathological O
hallmarks O
in O
Alzheimer's O
disease O
(AD) O
. O
In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene O
D4 O
(LTD4) O
in O
mice O
. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 B
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
mice.Amyloid O
plaques O
in O
the O
extracellular O
parenchyma O
mainly O
consist O
of O
amyloid-β O
peptides O
(Aβ) O
, O
one O
of O
the O
pathological O
hallmarks O
in O
Alzheimer's O
disease O
(AD) O
. O
In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene O
D4 O
(LTD4) O
in O
mice O
. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid B
precursor I
protein I
(APP) O
. O
LTD4 O
also O
induced O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
mice.Amyloid O
plaques O
in O
the O
extracellular O
parenchyma O
mainly O
consist O
of O
amyloid-β O
peptides O
(Aβ) O
, O
one O
of O
the O
pathological O
hallmarks O
in O
Alzheimer's O
disease O
(AD) O
. O
In O
the O
present O
study O
, O
we O
examined O
neuroinflammation O
, O
amyloidogenesis O
, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene O
D4 O
(LTD4) O
in O
mice O
. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl B
leukotriene I
receptor I
1 I
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R B
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB B
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O

LTD4 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
infusions O
of O
LTD4 O
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice O
, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 B
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O

pranlukast O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R B
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O

pranlukast O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB B
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O

pranlukast O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R O
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 B
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O
peptide O
burden O
via O
activation O
of O
CysLT(1)R O
, O
which O
further O
affects O
APP O
levels O
and O
activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB O
pathway O
. O
Our O
findings O
identify O
CysLT(1)R O
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway O
, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O

pranlukast O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
and O
caused O
the O
accumulation O
of O
Aβ1-40 O
and O
Aβ1-42 O
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid O
precursor O
protein O
(APP) O
. O
LTD4 O
also O
induced O
expression O
of O
cysteinyl O
leukotriene O
receptor O
1 O
(CysLT(1)R) O
and O
NF-κB O
p65 O
in O
the O
hippocampus O
and O
cortex O
. O
Pretreatment O
with O
pranlukast O
(1.5 O
ng/mouse O
, O
intracerebroventricularly) O
, O
a O
CysLT(1)R B
antagonist O
, O
blocked O
LTD4-induced O
amyloidogenesis O
, O
memory O
deficits O
. O
Pranlukast O
(0.6 O
μM) O
also O
prevented O
LTD4 O
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro O
. O
Moreover O
, O
LTD4-induced O
increases O
in O
CysLT(1)R O
and O
NF-κB O
p65 O
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast O
. O
These O
results O
suggest O
that O
LTD4 O
increases O
Aβ O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 B
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Swim O
training O
of O
monosodium O
L-glutamate-obese O
mice O
improves O
the O
impaired O
insulin B
receptor I
tyrosin O
phosphorylation O
in O
pancreatic O
islets.The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose O
homoeostasis O
and O
of O
the O
insulin O
receptor O
(IR) O
and O
insulin O
receptor O
substrate-1 O
(IRS-1) O
signalling O
in O
pancreatic O
islets O
from O
MSG-obese O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
treatment O
with O
MSG O
increased O
IRS-1 B
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training O
. O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR B
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
animal O
model O
. O
The O
results O
showed O
that O
IR B
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
( O
MSG O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 B
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 B
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
( O
MSG O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 B
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR B
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG O
obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR B
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
( O
MSG O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O

MSG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR B
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O

MSG O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O

MSG O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR O
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
( O
MSG O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O

MSG O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine O
phosphorylation O
of O
IRS-1 O
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin O
receptors O
. O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
( O
MSG O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
( O
MSG O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O
22.2 O
± O
1.1 O
a.u.) O
. O
Current O
research O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG O
obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Swim O
training O
of O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG O
obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
( O
MSG O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
90-day-old O
MSG O
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR O
and O
IRS-1 O
in O
islets O
are O
involved O
with O
the O
insulin O
resistance O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
( O
MSG O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O

MSG O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
and O
glucose O
intolerance O
observed O
in O
this O
obese O
animal O
model O
. O
The O
results O
showed O
that O
IR O
tyrosine O
phosphorylation O
(pIR) O
was O
reduced O
by O
42 O
% O
in O
MSG-obese O
mice O
(MSG O
, O
6.7 O
± O
0.2 O
arbitrary O
units O
(a.u.); O
control O
, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand O
, O
exercise O
training O
increased O
pIR B
by O
76 O
% O
in O
MSG O
mice O
without O
affecting O
control O
mice O
(MSG O
, O
11.8 O
± O
0.3; O
control O
, O
12.8 O
± O
0.2 O
a.u.) O
. O
Although O
the O
treatment O
with O
MSG O
increased O
IRS-1 O
tyrosine O
phosphorylation O
(pIRS-1) O
by O
96 O
% O
(MSG O
, O
17.02 O
± O
0.6; O
control O
, O
8.7 O
± O
0.2 O
a.u.) O
, O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control O
, O
13.6 O
± O
0.1; O
MSG O
, O

pioglitazone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ B
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O
also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE O
co O
administration O
. O
In O
conclusion O
, O
these O
results O
suggested O
that O
pioglitazone O
protected O
against O
cisplatin- O
induced O
nephrotoxicity O
through O
its O
interaction O
with O
PPAR-γ O
receptors O
and O
antioxidant O
effects O
. O
Furthermore O
, O
pioglitazone O
did O
not O
interfere O
but O
rather O
potentiated O
the O
cytotoxic O
effects O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
. O

pioglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
investigated O
. O
Pioglitazone O
, O
Bisphenol O
A O
diglycidyl O
ether O
, O
BADGE O
, O
IP O
injected O
(Peroxisome O
proliferator- O
activated O
receptor O
gamma O
(PPAR-γ) O
antagonist) O
, O
or O
their O
combination O
were O
administered O
to O
rats O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor B
necrosis I
factor I
alpha I
(TNF-α) O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O

pioglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
investigated O
. O
Pioglitazone O
, O
Bisphenol O
A O
diglycidyl O
ether O
, O
BADGE O
, O
IP O
injected O
(Peroxisome O
proliferator- O
activated O
receptor O
gamma O
(PPAR-γ) O
antagonist) O
, O
or O
their O
combination O
were O
administered O
to O
rats O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
(TNF-α) O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O

pioglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
investigated O
. O
Pioglitazone O
, O
Bisphenol O
A O
diglycidyl O
ether O
, O
BADGE O
, O
IP O
injected O
(Peroxisome O
proliferator- O
activated O
receptor O
gamma O
(PPAR-γ) O
antagonist) O
, O
or O
their O
combination O
were O
administered O
to O
rats O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
(TNF-α) O
, O
nuclear B
factor I
kappa I
B I
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O

pioglitazone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
investigated O
. O
Pioglitazone O
, O
Bisphenol O
A O
diglycidyl O
ether O
, O
BADGE O
, O
IP O
injected O
(Peroxisome O
proliferator- O
activated O
receptor O
gamma O
(PPAR-γ) O
antagonist) O
, O
or O
their O
combination O
were O
administered O
to O
rats O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
(TNF-α) O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O

cisplatin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor B
necrosis I
factor I
alpha I
(TNF-α) O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O
also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE O
co O
administration O
. O
In O
conclusion O
, O

cisplatin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
(TNF-α) O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O
also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE O
co O
administration O
. O
In O
conclusion O
, O

cisplatin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
(TNF-α) O
, O
nuclear B
factor I
kappa I
B I
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O
also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE O
co O
administration O
. O
In O
conclusion O
, O

cisplatin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
one O
hour O
before O
cisplatin O
injection O
. O
Moreover O
, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O
adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied O
. O
The O
obtained O
results O
showed O
that O
pioglitazone O
improved O
the O
renal O
function O
, O
structural O
changes O
, O
renal O
malondialdehyde O
(MDA) O
, O
tumor O
necrosis O
factor O
alpha O
(TNF-α) O
, O
nuclear O
factor O
kappa O
B O
(NF-κB) O
genes O
expression O
in O
cisplatin O
injected O
rats O
. O
It O
increased O
both O
renal O
reduced O
glutathione O
(GSH) O
content O
and O
PPAR-γ O
gene O
expression O
. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE O
. O
Pioglitazone O
also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin O
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE O
co O
administration O
. O
In O
conclusion O
, O

Met O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
the O
SVMP O
field O
was O
the O
characterization O
of O
the O
crystal O
structure O
of O
the O
first O
P-I O
class O
SVMP O
. O
The O
structures O
of O
other O
P-I O
SVMPs O
soon O
followed O
and O
the O
structures O
of O
P-III O
SVMPs O
have O
also O
been O
determined O
. O
The O
active O
site O
of O
the O
metalloproteinase B
domain I
has O
a O
consensus O
HEXXHXXGXXHD O
sequence O
and O
a O
Met O
turn O
. O
The O
"Met-turn" O
structure O
contains O
a O
conserved O
Met O
residue O
that O
forms O
a O
hydrophobic O
basement O
for O
the O
three O
zinc-binding O
histidines O
in O
the O
consensus O
sequence O
. O

Wogonoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular B
signal-regulated I
kinase I
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

Wogonoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 B
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

Wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

Wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated B
protein I
kinase I
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

Wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR O
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent O
. O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated B
protein-light I
chain I
3 I
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O

wogonoside O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Wogonoside O
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR O
pathway.Previous O
studies O
have O
demonstrated O
that O
wogonoside O
, O
a O
bioactive O
flavonoid O
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi O
, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities O
. O
In O
this O
study O
, O
we O
evaluated O
wogonoside-induced O
autophagy O
on O
human O
breast O
MDA-MB-231 O
cells O
. O
We O
report O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O

wogonoside O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II B
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O

wogonoside O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
that O
wogonoside O
triggered O
the O
formation O
of O
microtubule-associated O
protein-light O
chain O
3 O
(MAP-LC3) O
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells O
. O
In O
addition O
, O
cells O
treated O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O

Wogonoside O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 B
kinase I
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

Wogonoside O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

Wogonoside O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian B
target I
of I
rapamycin I
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

Wogonoside O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
wogonoside O
developed O
autophagosome-like O
characteristics O
, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris O
. O
The O
results O
showed O
that O
wogonoside O
promotes O
the O
expression O
of O
LC3-II O
and O
Beclin-1 O
. O
Furthermore O
, O
wogonoside O
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner O
, O
which O
was O
associated O
with O
wogonoside-induced O
autophagy O
. O
Wogonoside O
also O
suppressed O
the O
activation O
of O
mammalian O
target O
of O
rapamycin O
(mTOR) O
and O
p70-S6 O
kinase O
(p70S6K) O
by O
regulating O
the O
expression O
of O
the O
extracellular O
signal-regulated O
kinase O
(ERK1/2) O
and O
p38 O
involved O
mitogen-activated O
protein O
kinase O
(MAPK) O
signaling O
pathway O
. O
Taken O
together O
, O
these O
results O
suggest O
that O
wogonoside O
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O
, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O
the O
long-lived O
shut O
conformations O
, O
thereby O
reducing O
the O
open O
probability O
of O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O
, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O
the O
long-lived O
shut O
conformations O
, O
thereby O
reducing O
the O
open O
probability O
of O

ifenprodil O
, O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating.Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O
, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O

ifenprodil O
, O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating.Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B O
amino O
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism O
. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B O
receptor O
gating O
, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches O
. O
At O
pH O
7.9 O
in O
cell-attached O
patches O
, O
ifenprodil O
increased O
the O
occupancy O
of O

ifenprodil O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
area O
of O
shut O
time O
constants O
, O
but O
not O
the O
time O
constants O
themselves O
. O
Kinetic O
analyses O
suggested O
that O
ifenprodil O
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state O
. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O

ifenprodil O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
area O
of O
shut O
time O
constants O
, O
but O
not O
the O
time O
constants O
themselves O
. O
Kinetic O
analyses O
suggested O
that O
ifenprodil O
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state O
. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O

zinc O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Kinetic O
analyses O
suggested O
that O
ifenprodil O
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state O
. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B O
receptors O
, O
which O
may O
be O
responsible O
for O
its O

zinc O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Kinetic O
analyses O
suggested O
that O
ifenprodil O
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state O
. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B O
receptors O
, O
which O
may O
be O
responsible O
for O
its O

ifenprodil O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B O
receptors O
, O
which O
may O
be O
responsible O
for O
its O
usefulness O
as O
a O
context-dependent O
inhibitor O
in O
conditions O
like O
ischemia O
and O
stroke O
, O
when O
the O
pH O
of O
the O
extracellular O
milieu O
becomes O
acidic O
. O

ifenprodil O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
action O
of O
ifenprodil O
at O
GluN1/GluN2B O
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc O
on O
GluN1/GluN2A O
gating O
, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites O
. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil O
on O
gating O
. O
At O
a O
low O
pH O
(pH O
7.4) O
, O
but O
not O
pH O
7.9 O
, O
ifenprodil O
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B O
receptors O
, O
which O
may O
be O
responsible O
for O
its O
usefulness O
as O
a O
context-dependent O
inhibitor O
in O
conditions O
like O
ischemia O
and O
stroke O
, O
when O
the O
pH O
of O
the O
extracellular O
milieu O
becomes O
acidic O
. O

Ifenprodil O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating O
. O
Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O

Ifenprodil O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating O
. O
Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O

Ifenprodil O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Effect O
of O
ifenprodil O
on O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptor O
gating O
. O
Ifenprodil O
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B O
N-methyl-D-aspartate O
receptors O
. O
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments O
, O
its O
precise O
effect O
on O
GluN1/GluN2B O
gating O
is O
yet O
to O
be O
fully O
understood O
. O
Interestingly O
, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil O
, O
unlike O
zinc O
, O
binds O
at O
the O

Pulsatilla O
saponin O
D O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
SB365 O
, O
Pulsatilla O
saponin O
suppresses O
the O
proliferation O
of O
human O
colon O
cancer O
cells O
and O
induces O
apoptosis O
by O
modulating O
the O
AKT/mTOR O
signalling O
pathway.Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O
from O
the O
root O
of O

Pulsatilla O
saponin O
D O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
SB365 O
, O
Pulsatilla O
saponin O
suppresses O
the O
proliferation O
of O
human O
colon O
cancer O
cells O
and O
induces O
apoptosis O
by O
modulating O
the O
AKT/mTOR O
signalling O
pathway.Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O
from O
the O
root O
of O

SB365 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O
from O
the O
root O
of O
P O
. O
koreana O
inhibits O
the O
progression O
of O
colon O
cancer O
. O
We O
found O
that O
SB365 O
strongly O
suppressed O
the O
growth O
and O
proliferation O
of O
colon O
cancer O
cells O
and O
induced O
their O
apoptosis O
. O
Also O
, O
SB365 O
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O
of O
HIF-1α B
and O
VEGF O
. O
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O

SB365 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
of O
several O
diseases O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365 O
, O
Pulsatilla O
saponin O
D O
isolated O
from O
the O
root O
of O
P O
. O
koreana O
inhibits O
the O
progression O
of O
colon O
cancer O
. O
We O
found O
that O
SB365 O
strongly O
suppressed O
the O
growth O
and O
proliferation O
of O
colon O
cancer O
cells O
and O
induced O
their O
apoptosis O
. O
Also O
, O
SB365 O
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O
of O
HIF-1α O
and O
VEGF O
. O
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O

SB365 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O
of O
HIF-1α O
and O
VEGF O
. O
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O
SB365 O
effectively O
suppressed O
the O
AKT/mTOR O
pathway O
both O
in O
vitro O
and O
in O
vivo O
. O
Taken O
together O
, O
our O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
together O
with O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O

SB365 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O
of O
HIF-1α O
and O
VEGF O
. O
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O
SB365 O
effectively O
suppressed O
the O
AKT/mTOR O
pathway O
both O
in O
vitro O
and O
in O
vivo O
. O
Taken O
together O
, O
our O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
together O
with O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O

SB365 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O
SB365 O
effectively O
suppressed O
the O
AKT/mTOR O
pathway O
both O
in O
vitro O
and O
in O
vivo O
. O
Taken O
together O
, O
our O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
together O
with O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O
the O
treatment O
of O
colon O
cancer O
. O

SB365 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
vivo O
study O
showing O
that O
SB365 O
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU O
. O
When O
further O
examined O
for O
its O
anticancer O
mechanism O
, O
SB365 O
effectively O
suppressed O
the O
AKT/mTOR O
pathway O
both O
in O
vitro O
and O
in O
vivo O
. O
Taken O
together O
, O
our O
study O
demonstrated O
that O
SB365 O
inhibits O
the O
AKT/mTOR O
pathway O
, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O
angiogenesis O
together O
with O
induction O
of O
apoptosis O
. O
Therefore O
, O
SB365 O
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O
the O
treatment O
of O
colon O
cancer O
. O

AM4054 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O
Methanandamide O
(10.0 O
mg/kg) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 O
agonist O
AM1241 O
[1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole] O
, O
the O
anandamide O
transport O
inhibitor O
AM404 O
, O
and O
the O
CB O
antagonist O
rimonabant O
did O
not O
have O
diuretic O
effects O
. O
In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 B
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 O
antagonist O
AM630 O
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone)] O
. O

WIN O
55,212 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 B
antagonist O
AM630 O
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone)] O
. O
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 O
receptor O
mechanisms O
. O

Δ(9)-tetrahydrocannabinol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
effects O
, O
and O
analgesia O
. O
The O
present O
studies O
demonstrate O
that O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
WIN O
55,212 O
[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O

WIN O
55,212 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
and O
analgesia O
. O
The O
present O
studies O
demonstrate O
that O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O
[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O

R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
present O
studies O
demonstrate O
that O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O
[ O
R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate O
 O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O

AM2389 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
studies O
demonstrate O
that O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O
[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O

9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
that O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O
[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[ O
9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol O
 O
, O
and O
AM4054 O
[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O

AM4054 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O
[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol] O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O
Methanandamide O
(10.0 O
mg/kg) O

9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis O
. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection O
, O
and O
results O
were O
compared O
with O
hypothermic O
effects O
. O
Direct-acting O
CB1 B
agonists O
, O
including O
Δ(9)-tetrahydrocannabinol O
, O
WIN O
55,212 O
[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone O
mesylate] O
, O
AM2389 O
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol] O
, O
and O
AM4054 O
[ O
9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol O
 O
, O
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O
Methanandamide O
(10.0 O
mg/kg) O

AM1241 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O
Methanandamide O
(10.0 O
mg/kg) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 B
agonist O
AM1241 O
[1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole] O
, O
the O
anandamide O
transport O
inhibitor O
AM404 O
, O
and O
the O
CB O
antagonist O
rimonabant O
did O
not O
have O
diuretic O
effects O
. O
In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O

1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole O
acts O
as O
AGONIST O
for O
what O
entity O
? O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O
Methanandamide O
(10.0 O
mg/kg) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 B
agonist O
AM1241 O
[ O
1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole O
 O
, O
the O
anandamide O
transport O
inhibitor O
AM404 O
, O
and O
the O
CB O
antagonist O
rimonabant O
did O
not O
have O
diuretic O
effects O
. O
In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O

AM404 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
diuresis O
than O
for O
hypothermia O
. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide O
and O
3.0 O
mg/kg O
trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide O
(U50-488) O
. O
Methanandamide O
(10.0 O
mg/kg) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 B
agonist O
AM1241 O
[1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole] O
, O
the O
anandamide O
transport O
inhibitor O
AM404 O
and O
the O
CB O
antagonist O
rimonabant O
did O
not O
have O
diuretic O
effects O
. O
In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O

rimonabant O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
the O
anandamide O
transport O
inhibitor O
AM404 O
, O
and O
the O
CB O
antagonist O
rimonabant O
did O
not O
have O
diuretic O
effects O
. O
In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 B
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 O
antagonist O
AM630 O
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone)] O
. O
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 O
receptor O
mechanisms O
. O

capsazepine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
did O
not O
have O
diuretic O
effects O
. O
In O
further O
studies O
, O
the O
diuretic O
effects O
of O
the O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid B
receptor I
type I
I I
antagonist O
capsazepine O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 O
antagonist O
AM630 O
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone)] O
. O
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 O
receptor O
mechanisms O
. O

AM630 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
CB1 O
agonist O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 B
antagonist O
AM630 O
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone)] O
. O
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 O
receptor O
mechanisms O
. O

(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone) O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
AM4054 O
were O
similar O
in O
male O
and O
female O
rats O
, O
displayed O
a O
relatively O
rapid O
onset O
to O
action O
, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant O
, O
but O
not O
by O
the O
vanilloid O
receptor O
type O
I O
antagonist O
capsazepine O
, O
nor O
were O
the O
effects O
of O
WIN O
55,212 O
antagonized O
by O
the O
CB2 B
antagonist O
AM630 O
[ O
(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) O
methanone) O
 O
. O
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 O
receptor O
mechanisms O
. O

NaAsO(2) O
acts O
as O
NOT O
for O
what O
entity O
? O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O

NaAsO(2) O
acts O
as O
NOT O
for O
what O
entity O
? O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O

NaAsO(2) O
acts O
as O
NOT O
for O
what O
entity O
? O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O

NaAsO(2) O
acts O
as O
NOT O
for O
what O
entity O
? O
whether O
sodium O
arsenite O
(NaAsO(2); O
0 O
, O
1 O
, O
5 O
, O
or O
10 O
μM) O
affects O
both O
neurite O
outgrowth O
and/or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures O
. O
We O
observed O
that O
the O
area O
ratio O
of O
neurite O
to O
cell O
body O
in O
SCAT3-expressing O
cells O
was O
significantly O
reduced O
by O
5 O
and O
10 O
μM O
NaAsO(2) O
but O
not O
by O
1 O
μM O
, O
although O
the O
emission O
ratio O
of O
ECFP O
to O
Venus O
, O
an O
endpoint O
of O
caspase-3 B
activity O
, O
was O
not O
changed O
. O
However O
, O
cytological O
assay O
using O
apoptotic O
and O
necrotic O
markers O
resulted O
in O
that O
apoptosis O
, O
but O
not O
necrosis O
, O
was O
significantly O
induced O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O

NaAsO(2) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light B
and I
medium I
subunits I
of I
neurofilament I
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O

NaAsO(2) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau B
and O
tubulin O
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O

NaAsO(2) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
Neuro-2a O
cells O
when O
NaAsO(2) O
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) O
on O
neurite O
outgrowth O
were O
found O
by O
live O
imaging O
. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) O
prior O
to O
NaAsO(2)-induced O
apoptosis O
. O
Next O
, O
we O
examined O
the O
effects O
of O
NaAsO(2) O
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells O
. O
NaAsO(2) O
increased O
the O
mRNA O
levels O
of O
the O
light O
and O
medium O
subunits O
of O
neurofilament O
and O
decreased O
the O
mRNA O
levels O
of O
tau O
and O
tubulin B
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy O
subunit O
of O
neurofilament O
, O
microtubule-associated O
protein O
2 O
, O
or O
actin O
. O
The O
changes O
in O
cytoskeletal O

resveratrol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
injected O
with O
3mg/kg O
As(2)O(3) O
on O
alternate O
days; O
resveratrol O
(8mg/kg) O
was O
administered O
1h O
before O
As(2)O(3) O
. O
Rats O
were O
killed O
on O
the O
8th O
day O
to O
determine O
histological O
liver O
damage O
, O
the O
antioxidant O
enzymes O
in O
serum O
, O
the O
ratio O
of O
reduced O
glutathione O
(GSH) O
to O
oxidized O
glutathione O
(GSSG) O
, O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
In O
the O
resveratrol O
As(2)O(3) O
group O
, O
activities O
of O
superoxide O
dismutase O
, O
catalase O
in O
serum O
and O
GSH/GSSG O
were O
significantly O
increased O
, O
histopathological O
effects O
were O
reduced O
, O
and O
arsenic O
accumulation O
markedly O
decreased O
in O
the O
liver O
, O
compared O
with O
the O
As(2)O(3)-treated O
group O
. O
Thus O
, O
resveratrol O
attenuated O
As(2)O(3)-induced O
hepatotoxicity O
by O
decreasing O
oxidative O
stress O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
These O
data O
suggest O

resveratrol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
injected O
with O
3mg/kg O
As(2)O(3) O
on O
alternate O
days; O
resveratrol O
(8mg/kg) O
was O
administered O
1h O
before O
As(2)O(3) O
. O
Rats O
were O
killed O
on O
the O
8th O
day O
to O
determine O
histological O
liver O
damage O
, O
the O
antioxidant O
enzymes O
in O
serum O
, O
the O
ratio O
of O
reduced O
glutathione O
(GSH) O
to O
oxidized O
glutathione O
(GSSG) O
, O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
In O
the O
resveratrol O
As(2)O(3) O
group O
, O
activities O
of O
superoxide O
dismutase O
, O
catalase B
in O
serum O
and O
GSH/GSSG O
were O
significantly O
increased O
, O
histopathological O
effects O
were O
reduced O
, O
and O
arsenic O
accumulation O
markedly O
decreased O
in O
the O
liver O
, O
compared O
with O
the O
As(2)O(3)-treated O
group O
. O
Thus O
, O
resveratrol O
attenuated O
As(2)O(3)-induced O
hepatotoxicity O
by O
decreasing O
oxidative O
stress O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
These O
data O
suggest O

As(2)O(3) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
with O
3mg/kg O
As(2)O(3) O
on O
alternate O
days; O
resveratrol O
(8mg/kg) O
was O
administered O
1h O
before O
As(2)O(3) O
. O
Rats O
were O
killed O
on O
the O
8th O
day O
to O
determine O
histological O
liver O
damage O
, O
the O
antioxidant O
enzymes O
in O
serum O
, O
the O
ratio O
of O
reduced O
glutathione O
(GSH) O
to O
oxidized O
glutathione O
(GSSG) O
, O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
In O
the O
resveratrol+ O
As(2)O(3) O
group O
, O
activities O
of O
superoxide O
dismutase O
, O
catalase O
in O
serum O
and O
GSH/GSSG O
were O
significantly O
increased O
, O
histopathological O
effects O
were O
reduced O
, O
and O
arsenic O
accumulation O
markedly O
decreased O
in O
the O
liver O
, O
compared O
with O
the O
As(2)O(3)-treated O
group O
. O
Thus O
, O
resveratrol O
attenuated O
As(2)O(3)-induced O
hepatotoxicity O
by O
decreasing O
oxidative O
stress O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
These O
data O
suggest O
that O

As(2)O(3) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
with O
3mg/kg O
As(2)O(3) O
on O
alternate O
days; O
resveratrol O
(8mg/kg) O
was O
administered O
1h O
before O
As(2)O(3) O
. O
Rats O
were O
killed O
on O
the O
8th O
day O
to O
determine O
histological O
liver O
damage O
, O
the O
antioxidant O
enzymes O
in O
serum O
, O
the O
ratio O
of O
reduced O
glutathione O
(GSH) O
to O
oxidized O
glutathione O
(GSSG) O
, O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
In O
the O
resveratrol+ O
As(2)O(3) O
group O
, O
activities O
of O
superoxide O
dismutase O
, O
catalase B
in O
serum O
and O
GSH/GSSG O
were O
significantly O
increased O
, O
histopathological O
effects O
were O
reduced O
, O
and O
arsenic O
accumulation O
markedly O
decreased O
in O
the O
liver O
, O
compared O
with O
the O
As(2)O(3)-treated O
group O
. O
Thus O
, O
resveratrol O
attenuated O
As(2)O(3)-induced O
hepatotoxicity O
by O
decreasing O
oxidative O
stress O
and O
arsenic O
accumulation O
in O
the O
liver O
. O
These O
data O
suggest O
that O

DBDCT O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
resulted O
in O
a O
dose- O
and O
time-dependent O
growth O
inhibition O
of O
PC12 O
cells O
. O
The O
changes O
in O
cell O
morphology O
were O
observed O
using O
light O
microscopy O
, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy O
. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome B
c I
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O

DBDCT O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 B
and O
caspase-3 O
proteins O
and O
increased O
TUNEL O
positive O
staining O
. O
In O
conclusion O
, O
the O
results O
demonstrated O
that O
DBDCT O
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O
mitochondria-mediated O
pathway O
. O

DBDCT O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 B
proteins O
and O
increased O
TUNEL O
positive O
staining O
. O
In O
conclusion O
, O
the O
results O
demonstrated O
that O
DBDCT O
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O
mitochondria-mediated O
pathway O
. O

DBDCT O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diorganotin O
(IV) O
compound O
to O
investigate O
its O
neurotoxic O
mechanism O
using O
PC12 O
cells O
and O
comprehensive O
methods O
. O
Treatment O
with O
DBDCT O
resulted O
in O
a O
dose- O
and O
time-dependent O
growth O
inhibition O
of O
PC12 O
cells O
. O
The O
changes O
in O
cell O
morphology O
were O
observed O
using O
light O
microscopy O
, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy O
. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 B
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O

DBDCT O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diorganotin O
(IV) O
compound O
to O
investigate O
its O
neurotoxic O
mechanism O
using O
PC12 O
cells O
and O
comprehensive O
methods O
. O
Treatment O
with O
DBDCT O
resulted O
in O
a O
dose- O
and O
time-dependent O
growth O
inhibition O
of O
PC12 O
cells O
. O
The O
changes O
in O
cell O
morphology O
were O
observed O
using O
light O
microscopy O
, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy O
. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 B
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O

DBDCT O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK B
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O
increased O
TUNEL O
positive O
staining O
. O
In O
conclusion O
, O
the O
results O
demonstrated O
that O
DBDCT O
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O

DBDCT O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O
increased O
TUNEL O
positive O
staining O
. O
In O
conclusion O
, O
the O
results O
demonstrated O
that O
DBDCT O
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O

DBDCT O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O
increased O
TUNEL O
positive O
staining O
. O
In O
conclusion O
, O
the O
results O
demonstrated O
that O
DBDCT O
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O

DBDCT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
microscopy O
, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy O
. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O

DBDCT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
microscopy O
, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy O
. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O

DBDCT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
microscopy O
, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy O
. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O

DBDCT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
microscopy O
, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy O
. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT O
was O
confirmed O
by O
annexin O
V/propidium O
iodide O
staining O
, O
and O
characterized O
by O
cleavage O
of O
caspase-9 O
and O
caspase-3 O
proteins O
. O
DBDCT O
induced O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen O
species O
. O
DBDCT O
up-regulated O
the O
expression O
of O
Bax O
, O
down-regulated O
the O
expression O
of O
Bcl-2 O
, O
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2 O
. O
DBDCT O
also O
caused O
the O
phosphorylation O
of O
JNK O
and O
p38(MAPK) O
. O
In O
rats O
exposed O
to O
DBDCT O
, O
apoptosis O
was O
also O
observed O
in O
brain O
, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 O
and O
caspase-3 O
proteins O
and O

BNZ O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
no O
change O
in O
the O
k(cat) O
for O
the O
reaction O
, O
however O
, O
at O
higher O
concentrations O
of O
CYP2E1 O
, O
the O
apparent O
K(M) O
of O
CYP2B4 B
for O
CPR O
decreased O
to O
levels O
similar O
to O
those O
observed O
in O
the O
absence O
of O
CYP2E1 O
and O
the O
k(cat) O
also O
decreased O
by O
11-fold O
. O
Additionally O
, O
CYP2E1 O
increased O
the O
apparent O
K(M) O
of O
CYP2B4 O
for O
BNZ O
by O
8-fold O
and O
the O
apparent O
K(M) O
did O
not O
decrease O
to O
its O
original O
value O
when O
saturating O
concentrations O
of O
CPR O
were O
used O
. O
While O
the O
individual O
apparent O
K(M) O
values O
of O
CYP2B4 O
and O
CYP2E1 O
for O
CPR O
are O
similar O
, O
the O
apparent O
K(M) O
of O
CYP2E1 O
for O
CPR O
in O
the O
presence O
of O
CYP2B4 O
decreased O
significantly O
, O
thus O

benzphetamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
reconstituted O
systems O
have O
shown O
that O
the O
presence O
of O
one O
cytochrome O
P450 O
isoform O
can O
significantly O
influence O
the O
catalytic O
activity O
of O
another O
isoform O
. O
In O
this O
study O
, O
we O
assessed O
whether O
CYP2E1 O
could O
influence O
the O
catalytic O
activity O
of O
CYP2B4 B
under O
steady-state O
turnover O
conditions O
. O
The O
results O
show O
that O
CYP2E1 O
inhibits O
CYP2B4-mediated O
metabolism O
of O
benzphetamine O
(BNZ) O
with O
a O
K(i) O
of O
0.04 O
µM O
. O
However O
, O
CYP2B4 O
is O
not O
an O
inhibitor O
of O
CYP2E1-mediated O
p-nitrophenol O
hydroxylation O
. O
When O
these O
inhibition O
studies O
were O
performed O
with O
the O
artificial O
oxidant O
tert-butyl O
hydroperoxide O
, O
CYP2E1 O
did O
not O
significantly O
inhibit O
CYP2B4 O
activity O
. O
Determinations O
of O
the O
apparent O
K(M) O
and O
k(cat) O
of O
CYP2B4 O
for O
CPR O
in O
the O

BNZ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
systems O
have O
shown O
that O
the O
presence O
of O
one O
cytochrome O
P450 O
isoform O
can O
significantly O
influence O
the O
catalytic O
activity O
of O
another O
isoform O
. O
In O
this O
study O
, O
we O
assessed O
whether O
CYP2E1 O
could O
influence O
the O
catalytic O
activity O
of O
CYP2B4 B
under O
steady-state O
turnover O
conditions O
. O
The O
results O
show O
that O
CYP2E1 O
inhibits O
CYP2B4-mediated O
metabolism O
of O
benzphetamine O
( O
BNZ O
with O
a O
K(i) O
of O
0.04 O
µM O
. O
However O
, O
CYP2B4 O
is O
not O
an O
inhibitor O
of O
CYP2E1-mediated O
p-nitrophenol O
hydroxylation O
. O
When O
these O
inhibition O
studies O
were O
performed O
with O
the O
artificial O
oxidant O
tert-butyl O
hydroperoxide O
, O
CYP2E1 O
did O
not O
significantly O
inhibit O
CYP2B4 O
activity O
. O
Determinations O
of O
the O
apparent O
K(M) O
and O
k(cat) O
of O
CYP2B4 O
for O
CPR O
in O
the O
presence O

p-nitrophenol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
catalytic O
activity O
of O
another O
isoform O
. O
In O
this O
study O
, O
we O
assessed O
whether O
CYP2E1 B
could O
influence O
the O
catalytic O
activity O
of O
CYP2B4 O
under O
steady-state O
turnover O
conditions O
. O
The O
results O
show O
that O
CYP2E1 O
inhibits O
CYP2B4-mediated O
metabolism O
of O
benzphetamine O
(BNZ) O
with O
a O
K(i) O
of O
0.04 O
µM O
. O
However O
, O
CYP2B4 O
is O
not O
an O
inhibitor O
of O
CYP2E1-mediated O
p-nitrophenol O
hydroxylation O
. O
When O
these O
inhibition O
studies O
were O
performed O
with O
the O
artificial O
oxidant O
tert-butyl O
hydroperoxide O
, O
CYP2E1 O
did O
not O
significantly O
inhibit O
CYP2B4 O
activity O
. O
Determinations O
of O
the O
apparent O
K(M) O
and O
k(cat) O
of O
CYP2B4 O
for O
CPR O
in O
the O
presence O
of O
increasing O
concentrations O
of O
CYP2E1 O
revealed O
a O
mixed O
inhibition O
of O
CYP2B4 O
by O
CYP2E1 O
. O
At O
low O

paraoxon O
acts O
as O
NOT O
for O
what O
entity O
? O
developmental O
stage O
with O
minimal O
AChE B
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon O
concentrations O
as O
low O
as O
31.2 O
nM O
. O
Overall O
, O
our O
data O
suggest O
that O
(1) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon O
exposure O
, O
an O
effect O
that O
may O
be O
independent O
of O
AChE O
inhibition O
. O
Using O
a O
well-studied O
reference O
chemical O
, O
this O
study O
highlights O
the O
potential O
challenges O
in O
developing O
quantitative O
AOPs O
to O
support O
chemical O
screening O
and O
prioritization O
strategies O
. O

paraoxon O
acts O
as O
NOT O
for O
what O
entity O
? O
showed O
that O
static O
exposure O
of O
embryos O
to O
paraoxon O
(31.2-500 O
nM) O
from O
5 O
to O
96 O
hpf O
resulted O
in O
significant O
stage- O
and O
concentration-dependent O
AChE B
inhibition O
, O
albeit O
these O
effects O
were O
fully O
reversible O
within O
48 O
h O
following O
transfer O
to O
clean O
water O
. O
However O
, O
even O
in O
the O
presence O
of O
significant O
AChE O
inhibition O
, O
exposure O
to O
non-teratogenic O
paraoxon O
concentrations O
(≤250 O
nM) O
did O
not O
adversely O
impact O
secondary O
motoneuron O
development O
at O
96 O
hpf O
. O
Therefore O
, O
we O
investigated O
the O
potential O
effects O
of O
paraoxon O
exposure O
on O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
an O
early O
locomotor O
behavior O
that O
results O
from O
innervation O
of O
primary O
(not O
secondary) O
motoneuron O
axons O
to O
target O
axial O
muscles O
. O
Based O

paraoxon O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
- O
an O
early O
locomotor O
behavior O
that O
results O
from O
innervation O
of O
primary O
(not O
secondary) O
motoneuron O
axons O
to O
target O
axial O
muscles O
. O
Based O
on O
these O
studies O
, O
the O
frequency O
of O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
a O
developmental O
stage O
with O
minimal O
AChE B
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon O
concentrations O
as O
low O
as O
31.2 O
nM O
. O
Overall O
, O
our O
data O
suggest O
that O
(1) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon O
exposure O
, O
an O
effect O
that O
may O
be O
independent O
of O
AChE O
inhibition O
. O
Using O
a O
well-studied O
reference O
chemical O
, O

paraoxon O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
- O
an O
early O
locomotor O
behavior O
that O
results O
from O
innervation O
of O
primary O
(not O
secondary) O
motoneuron O
axons O
to O
target O
axial O
muscles O
. O
Based O
on O
these O
studies O
, O
the O
frequency O
of O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
a O
developmental O
stage O
with O
minimal O
AChE B
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon O
concentrations O
as O
low O
as O
31.2 O
nM O
. O
Overall O
, O
our O
data O
suggest O
that O
(1) O
normal O
AChE O
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon O
exposure O
, O
an O
effect O
that O
may O
be O
independent O
of O
AChE O
inhibition O
. O
Using O
a O
well-studied O
reference O
chemical O
, O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
(AOP) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis O
. O
Within O
normal O
zebrafish O
embryos O
, O
we O
first O
demonstrated O
that O
ache O
transcripts O
and O
AChE B
activity O
increased O
in O
a O
stage-dependent O
manner O
following O
segmentation O
. O
We O
then O
showed O
that O
static O
exposure O
of O
embryos O
to O
paraoxon O
(31.2-500 O
nM) O
from O
5 O
to O
96 O
hpf O
resulted O
in O
significant O
stage- O
and O
concentration-dependent O
AChE O
inhibition O
, O
albeit O
these O
effects O
were O
fully O
reversible O
within O
48 O
h O
following O
transfer O
to O
clean O
water O
. O
However O
, O
even O
in O
the O
presence O
of O
significant O
AChE O
inhibition O
, O
exposure O
to O
non-teratogenic O
paraoxon O
concentrations O
(≤250 O
nM) O
did O
not O
adversely O
impact O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adverse O
outcome O
pathways O
during O
zebrafish O
embryogenesis O
: O
a O
case O
study O
with O
paraoxon.Using O
paraoxon O
as O
a O
reference O
acetylcholinesterase B
(AChE) O
inhibitor O
, O
the O
objective O
of O
this O
study O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
(AOP) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis O
. O
Within O
normal O
zebrafish O
embryos O
, O
we O
first O
demonstrated O
that O
ache O
transcripts O
and O
AChE O
activity O
increased O
in O
a O
stage-dependent O
manner O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adverse O
outcome O
pathways O
during O
zebrafish O
embryogenesis O
: O
a O
case O
study O
with O
paraoxon.Using O
paraoxon O
as O
a O
reference O
acetylcholinesterase O
(AChE) O
inhibitor O
, O
the O
objective O
of O
this O
study O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
(AOP) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis O
. O
Within O
normal O
zebrafish O
embryos O
, O
we O
first O
demonstrated O
that O
ache O
transcripts O
and O
AChE B
activity O
increased O
in O
a O
stage-dependent O
manner O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated B
transcription I
factor I
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
determine O
the O
effects O
of O
artemisinic O
acid O
on O
melanogenesis O
and O
its O
mechanisms O
of O
action O
in O
human O
epidermal O
melanocytes O
. O
In O
this O
study O
, O
we O
found O
that O
artemisinic O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 B
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem B
cell I
factor I
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage B
migration I
inhibitory I
factor I
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
inhibited O
melanin O
content O
. O
The O
mRNA O
levels O
of O
microphthalmia-associated O
transcription O
factor O
(MITF) O
and O
its O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl B
CoA I
(HMG I
CoA) I
reductase I
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
. O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding B
protein I
(C/EBP) I
α I
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O

artemisinic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG B
CoA I
reductase I
gene O
, O
which O
is O
mediated O
by O
C/EBP O
α O
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor O
. O

artemisinic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein B
kinase I
A I
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O

artemisinic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
downstream O
genes O
tyrosinase O
, O
tyrosinase-related O
protein O
(TRP)-1 O
, O
and O
TRP-2 O
were O
reduced O
by O
artemisinic O
acid O
treatment O
. O
Additionally O
, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT O
, O
stem O
cell O
factor O
(SCF) O
, O
and O
macrophage O
migration O
inhibitory O
factor O
(MIF)) O
were O
down-regulated O
by O
artemisinic O
acid O
. O
Furthermore O
, O
cAMP O
production O
and O
protein O
kinase O
A O
(PKA) O
activity O
were O
suppressed O
by O
artemisinic O
acid O
Moreover O
, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O

artemisinic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
underlying O
the O
artemisinic O
acid-mediated O
effects O
revealed O
that O
artemisinic O
acid O
regulated O
melanogenesis O
by O
inhibiting O
cholesterol O
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl O
CoA O
(HMG O
CoA) O
reductase O
gene O
, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O
CCAAT/enhancer-binding O
protein O
(C/EBP) O
α O
gene O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic O
acid O
occurs O
through O
reduced O
expression O
of O
the O
HMG O
CoA O
reductase O
gene O
, O
which O
is O
mediated O
by O
C/EBP B
α I
inhibition O
and O
suggest O
that O
artemisinic O
acid O
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor O
. O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
NOT O
for O
what O
entity O
? O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin B
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O

cAMP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC B
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx.Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC B
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx.Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O

gliclazide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase B
C I
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

tolbutamide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase B
C I
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O

gliclazide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase B
C I
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O

gliclazide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O

bisindolylmaleimide O
I O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
did O
not O
stimulate O
insulin B
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

Tolbutamide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx O
. O
Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin B
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O

tolbutamide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin B
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O

gliclazide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin B
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin B
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O
however O
, O
only O
gliclazide O
did O
so O
independently O
of O

8-pCPT-2'-O-Me-cAMP-AM O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
so O
independently O
of O
its O
activity O
at O
K(ATP) O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin B
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O

tolbutamide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
channels O
, O
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin B
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O

thapsigargin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin B
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O

nicardipine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin B
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type O
Ca(2+) O
channel O
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O

2-APB O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
partially O
inhibited O
by O
pertussis O
toxin O
. O
8-pCPT-2'-O-Me-cAMP-AM O
alone O
(5 O
μM) O
did O
not O
stimulate O
insulin B
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC O
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O

bisindolylmaleimide O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
did O
not O
stimulate O
insulin O
secretion O
, O
but O
did O
increase O
intracellular O
Ca(2+) O
concentration O
significantly O
, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate O
(2-APB) O
or O
the O
removal O
of O
extracellular O
Ca(2+) O
. O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
insulin O
secretion O
stimulated O
by O
tolbutamide O
was O
markedly O
inhibited O
by O
2-APB O
(25 O
μM) O
and O
enhanced O
by O
the O
PKC B
inhibitor O
bisindolylmaleimide O
I O
(1 O
μM) O
. O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide O
and O
gliclazide O
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
, O
that O
gliclazide O
can O
stimulate O
phospholipase O
C O
activity O
via O
a O
partially O
pertussis O
toxin-sensitive O
mechanism O
, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM O
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive O
Ca(2+) O
influx O
. O

Tolbutamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx O
. O
Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) B
channel I
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O

Tolbutamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx O
. O
Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O

Tolbutamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potentiation O
of O
sulfonylurea O
action O
by O
an O
EPAC-selective O
cAMP O
analog O
in O
INS-1 O
cells O
: O
comparison O
of O
tolbutamide O
and O
gliclazide O
and O
a O
potential O
role O
for O
EPAC O
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx O
. O
Tolbutamide O
and O
gliclazide O
block O
the O
K(ATP) O
channel O
K(ir)6.2/Sur1 O
, O
causing O
membrane O
depolarization O
and O
stimulating O
insulin O
secretion O
in O
pancreatic O
beta O
cells O
. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective O
cAMP O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O

nicardipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
analog O
8-pCPT-2'-O-Me-cAMP-AM O
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it O
. O
Insulin O
secretion O
stimulated O
by O
both O
200 O
μM O
tolbutamide O
and O
20 O
μM O
gliclazide O
, O
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential O
, O
was O
inhibited O
by O
thapsigargin O
(1 O
μM) O
or O
the O
L-type B
Ca(2+) I
channel I
blocker O
nicardipine O
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells O
. O
Ca(2+) O
transients O
stimulated O
by O
either O
tolbutamide O
or O
gliclazide O
were O
inhibited O
by O
thapsigargin O
or O
nicardipine O
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM O
. O
Both O
tolbutamide O
and O
gliclazide O
stimulated O
phospholipase O
C O
activity; O

methyleugenol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
vivo O
genotoxicity O
of O
methyleugeno O
in O
gpt B
delta O
transgenic O
rats O
following O
medium-term O
exposure.Methyleugenol O
(MEG) O
, O
which O
is O
commonly O
used O
as O
a O
fragrance O
and O
flavoring O
agent O
, O
has O
been O
shown O
to O
induce O
hepatocellular O
tumors O
in O
rodents O
. O
However O
, O
the O
role O
of O
genotoxicity O
as O
a O
possible O
mechanism O
of O
action O
is O
not O
fully O
understood O
even O
though O
the O
DNA-reactive O
metabolite O
of O

MEG O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
is O
not O
fully O
understood O
even O
though O
the O
DNA-reactive O
metabolite O
of O
MEG O
has O
been O
identified O
. O
In O
this O
study O
, O
a O
gpt B
delta O
transgenic O
rat O
model O
was O
used O
to O
clarify O
whether O
genotoxic O
mechanisms O
are O
involved O
in O
MEG-induced O
hepatocarcinogenesis O
following O
medium-term O
exposure O
. O
F344 O
gpt O
delta O
rats O
were O
subjected O
to O
repeated O
oral O
administration O
of O
MEG O
at O
dosages O
of O
0 O
, O
10 O
, O
30 O
, O
or O
100mg/kg O
(a O
carcinogenic O
dose) O
for O
13 O
weeks O
. O
The O
relative O
weight O
of O
the O
liver O
of O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
and O
the O
absolute O
weight O
of O
the O
liver O
of O
the O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O

MEG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O
increased O
. O
In O
addition O
, O
the O
number O
and O
area O
of O
glutathione B
S-transferase I
placental I
form I
(GST-P) O
positive O
foci O
and O
proliferating O
cell O
nuclear O
antigen O
(PCNA) O
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
compared O
with O
the O
control O
animals O
. O
In O
the O
in O
vivo O
mutation O
assays O
, O
a O
significant O
increase O
in O
the O
gpt O
and O
Spi(-) O
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O
carcinogenic O
dose O
. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced O
hepatocarcinogenesis O
. O

MEG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O
increased O
. O
In O
addition O
, O
the O
number O
and O
area O
of O
glutathione O
S-transferase O
placental O
form O
(GST-P) O
positive O
foci O
and O
proliferating O
cell O
nuclear O
antigen O
(PCNA) O
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
compared O
with O
the O
control O
animals O
. O
In O
the O
in O
vivo O
mutation O
assays O
, O
a O
significant O
increase O
in O
the O
gpt O
and O
Spi(-) O
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O
carcinogenic O
dose O
. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced O
hepatocarcinogenesis O
. O

MEG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O
increased O
. O
In O
addition O
, O
the O
number O
and O
area O
of O
glutathione O
S-transferase O
placental O
form O
(GST-P) O
positive O
foci O
and O
proliferating B
cell I
nuclear I
antigen I
(PCNA) O
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
compared O
with O
the O
control O
animals O
. O
In O
the O
in O
vivo O
mutation O
assays O
, O
a O
significant O
increase O
in O
the O
gpt O
and O
Spi(-) O
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O
carcinogenic O
dose O
. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced O
hepatocarcinogenesis O
. O

MEG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG O
were O
significantly O
increased O
. O
In O
addition O
, O
the O
number O
and O
area O
of O
glutathione O
S-transferase O
placental O
form O
(GST-P) O
positive O
foci O
and O
proliferating O
cell O
nuclear O
antigen O
(PCNA) O
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG O
compared O
with O
the O
control O
animals O
. O
In O
the O
in O
vivo O
mutation O
assays O
, O
a O
significant O
increase O
in O
the O
gpt O
and O
Spi(-) O
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O
carcinogenic O
dose O
. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced O
hepatocarcinogenesis O
. O

acetyl O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Histone O
deacetylase O
3 O
is O
required O
for O
maintenance O
of O
bone O
mass O
during O
aging.Histone O
deacetylase O
3 O
(Hdac3) O
is O
a O
nuclear O
enzyme O
that O
removes O
acetyl O
groups O
from O
lysine O
residues O
in O
histones B
and O
other O
proteins O
to O
epigenetically O
regulate O
gene O
expression O
. O
Hdac3 O
interacts O
with O
bone-related O
transcription O
factors O
and O
co-factors O
such O
as O
Runx2 O
and O
Zfp521 O
, O
and O
thus O
is O
poised O
to O
play O
a O
key O
role O
in O
the O
skeletal O
system O
. O
To O
understand O
the O
role O
of O
Hdac3 O
in O
osteoblasts O
and O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Histone O
deacetylase O
3 O
is O
required O
for O
maintenance O
of O
bone O
mass O
during O
aging.Histone O
deacetylase O
3 O
(Hdac3) O
is O
a O
nuclear O
enzyme O
that O
removes O
acetyl O
groups O
from O
lysine O
residues O
in O
histones B
and O
other O
proteins O
to O
epigenetically O
regulate O
gene O
expression O
. O
Hdac3 O
interacts O
with O
bone-related O
transcription O
factors O
and O
co-factors O
such O
as O
Runx2 O
and O
Zfp521 O
, O
and O
thus O
is O
poised O
to O
play O
a O
key O
role O
in O
the O
skeletal O
system O
. O
To O
understand O
the O
role O
of O
Hdac3 O
in O
osteoblasts O
and O
osteocytes O
, O
Hdac3 O
conditional O

aconitine O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
exposure O
of O
highly O
toxic O
aconitin O
does O
not O
significantly O
impact O
the O
activity O
and O
expression O
of O
cytochrome B
P450 I
3A I
in O
rats O
determined O
by O
a O
novel O
ultra O
performance O
liquid O
chromatography-tandem O
mass O
spectrometric O
method O
of O
a O
specific O
probe O
buspirone.Aconitum O
species O
are O
widely O
used O
to O
treat O
rheumatism O
, O
cardiovascular O
diseases O
, O
and O
tumors O
in O
China O
and O
other O
Asian O
countries O
. O
The O
herbs O

buspirone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
the O
main O
bioactive/high-toxic O
alkaloids O
of O
Aconitum O
roots O
. O
AC O
is O
metabolized O
by O
cytochrome O
P450 O
(CYP) O
3A O
. O
However O
, O
whether O
AC O
inhibits/induces O
CYP3A O
, O
which O
causes O
drug-drug O
interaction O
(DDI) O
is O
unclear O
. O
Our O
study O
aims O
to O
explore O
the O
potent O
effects O
of O
AC O
, O
as O
a O
marker O
component O
of O
Aconitum O
, O
on O
CYP3A B
using O
the O
probe O
buspirone O
in O
rats O
. O
The O
effects O
of O
oral O
AC O
on O
pharmacokinetics O
of O
buspirone O
were O
evaluated O
. O
CYP3A O
activity O
and O
protein O
levels O
in O
rat O
liver O
microsomes O
pretreated O
with O
oral O
AC O
were O
also O
measured O
using O
in O
vitro O
buspirone O
metabolism O
and O
Western O
blot O
. O
Buspirone O
and O
its O
major O
metabolites O
1-(2-pyrimidinyl)piperazine O
and O
6'-hydroxybuspirone O
were O
determined O
using O
a O

buspirone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
potent O
effects O
of O
AC O
, O
as O
a O
marker O
component O
of O
Aconitum O
, O
on O
CYP3A B
using O
the O
probe O
buspirone O
in O
rats O
. O
The O
effects O
of O
oral O
AC O
on O
pharmacokinetics O
of O
buspirone O
were O
evaluated O
. O
CYP3A O
activity O
and O
protein O
levels O
in O
rat O
liver O
microsomes O
pretreated O
with O
oral O
AC O
were O
also O
measured O
using O
in O
vitro O
buspirone O
metabolism O
and O
Western O
blot O
. O
Buspirone O
and O
its O
major O
metabolites O
1-(2-pyrimidinyl)piperazine O
and O
6'-hydroxybuspirone O
were O
determined O
using O
a O
newly O
validated O
UPLC-MS/MS O
method O
. O
Single O
dose O
and O
7-day O
AC O
administration O
at O
0.125mg/kg O
had O
no O
effect O
on O
CYP3A O
activity O
since O
no O
change O
in O
the O
formation O
of O
1-(2-pyrimidinyl)piperazine O
and O
6'-hydroxybuspirone O
. O
CYP3A O
activity O
and O
protein O
levels O

N O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 B
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

N O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

BPs O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 B
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

BPs O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

bisphosphonates O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonate O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O

N O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim B
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O

BPs O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N- O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim B
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O

N O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim B
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

BPs O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim B
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

N O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N O
BPs O
decreased O
the O
levels O
of O
phosphorylated B
extracellular I
signal-regulated I
kinase I
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O

N O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O

N O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR B
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O

BPs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N- O
BPs O
decreased O
the O
levels O
of O
phosphorylated B
extracellular I
signal-regulated I
kinase I
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O

BPs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N- O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O

BPs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N- O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR B
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras B
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O

BPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N- O
BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras B
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N-BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras B
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras B
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR B
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O

BPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras B
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

BPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

BPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

BPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR O
via O
suppression O
of O
Ras B
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

BPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl O
pyrophosphate O
(GGPP) O
biosynthesis O
. O
Furthermore O
, O
N-BPs O
decreased O
the O
levels O
of O
phosphorylated O
extracellular O
signal-regulated O
kinase O
(ERK) O
and O
mTOR B
via O
suppression O
of O
Ras O
prenylation O
and O
enhanced O
Bim O
expression O
. O
The O
present O
results O
indicated O
that O
N- O
BPs O
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential O
, O
increasing O
the O
activation O
of O
caspase-9 O
and O
caspase-3 O
, O
and O
enhancing O
Bim O
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK O
and O
Ras/mTOR O
pathways O
. O
The O
accumulation O
of O
N-BPs O
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O

bisphosphonates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonate O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras B
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O

Nitrogen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway O
. O
Nitrogen O
containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O

bisphosphonates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N-BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
( O
N O
BPs) O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O

BPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nitrogen-containing O
bisphosphonates O
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras O
signaling O
pathways O
and O
Bim-mediated O
activation O
of O
the O
intrinsic O
apoptotic O
pathway.Nitrogen-containing O
bisphosphonates O
(N- O
BPs O
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins O
. O
However O
, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure O
. O
The O
present O
study O
showed O
that O
the O
induction O
of O
apoptosis O
by O
N-BPs O
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways O
, O
which O
are O
activated O
by O
the O
suppression O

2,3,7,8-tetrachlorodibenzo-p-dioxin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
epithelial O
cells O
. O
The O
contact O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR B
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O

2,3,7,8-tetrachlorodibenzo-p-dioxin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
epithelial O
cells O
. O
The O
contact O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR B
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O

TCDD O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
contact O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR B
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
( O
TCDD O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O

TCDD O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
contact O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR B
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
( O
TCDD O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR B
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O
TCDD O
, O
siRNA-mediated O
Cx43 O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR B
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 O
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O
TCDD O
, O
siRNA-mediated O
Cx43 O

TCDD O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 B
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O
TCDD O
siRNA-mediated O
Cx43 O
knock-down O
was O
not O
sufficient O
to O
stimulate O
proliferation O
in O
contact-inhibited O
cells O
. O
Our O
data O
suggest O
that O
downregulation O
of O
Cx43/GJIC O
in O
non-transformed O
epithelial O
cells O
is O
an O
inherent O
part O
of O
disruption O
of O
contact O
inhibition O
, O
which O
occurs O
at O
the O
post-transcriptional O
level O
. O
This O
process O
runs O
in O
parallel O
with O
alterations O
of O
other O
forms O
of O

2,3,7,8-tetrachlorodibenzo-p-dioxin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
epithelial O
cells O
. O
The O
contact O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR O
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 B
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
contact O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR O
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
( O
TCDD O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 B
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O
confluent O
non-transformed O
cells O
, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however O
, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood O
. O
Disruption O
of O
contact O
inhibition O
, O
which O
was O
induced O
by O
toxic O
AhR O
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 B
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O
TCDD O
, O
siRNA-mediated O
Cx43 O

TCDD O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
polycyclic O
aromatic O
hydrocarbons O
in O
epithelial O
WB-F344 O
cells O
, O
reduced O
Cx43 B
protein O
levels O
, O
possibly O
via O
enhanced O
proteasomal O
degradation O
, O
significantly O
decreased O
the O
amount O
of O
gap O
junction O
plaques O
and O
downregulated O
GJIC O
, O
in O
an O
AhR-dependent O
manner O
. O
Although O
both O
intracellular O
and O
membrane O
Cx43 O
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O
TCDD O
siRNA-mediated O
Cx43 O
knock-down O
was O
not O
sufficient O
to O
stimulate O
proliferation O
in O
contact-inhibited O
cells O
. O
Our O
data O
suggest O
that O
downregulation O
of O
Cx43/GJIC O
in O
non-transformed O
epithelial O
cells O
is O
an O
inherent O
part O
of O
disruption O
of O
contact O
inhibition O
, O
which O
occurs O
at O
the O
post-transcriptional O
level O
. O
This O
process O
runs O
in O
parallel O
with O
alterations O
of O
other O
forms O
of O

La(III) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
soluble O
proteins O
, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino O
acid O
in O
soybean O
seedlings O
. O
The O
change O
degree O
of O
UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)) O
. O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine O
synthetase O
, O
glutamate O
synthase O
, O
and O
glutamate O
dehydrogenase O
, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O
The O
regulation O
effect O
of O
La(III) O
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O
UV-B O
radiation O

La(III) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
soluble O
proteins O
, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino O
acid O
in O
soybean O
seedlings O
. O
The O
change O
degree O
of O
UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)) O
. O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine O
synthetase O
, O
glutamate O
synthase O
, O
and O
glutamate O
dehydrogenase O
, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O
The O
regulation O
effect O
of O
La(III) O
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O
UV-B O
radiation O

La(III) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
soluble O
proteins O
, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino O
acid O
in O
soybean O
seedlings O
. O
The O
change O
degree O
of O
UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)) O
. O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine O
synthetase O
, O
glutamate O
synthase O
, O
and O
glutamate O
dehydrogenase O
, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O
The O
regulation O
effect O
of O
La(III) O
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O
UV-B O
radiation O

La(III) O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
soluble O
proteins O
, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino O
acid O
in O
soybean O
seedlings O
. O
The O
change O
degree O
of O
UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)) O
. O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) O
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate O
reductase O
, O
glutamine O
synthetase O
, O
glutamate O
synthase O
, O
and O
glutamate O
dehydrogenase O
, O
promoting O
amino O
acid O
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings O
. O
The O
regulation O
effect O
of O
La(III) O
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O
UV-B O
radiation O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionon O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionon O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionone O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol B
3-kinase I
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionone O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Apoptosis O
initiation O
of O
β-ionone O
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT O
pathway.β-ionone O
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo O
. O
To O
investigate O
the O
effects O
of O
β-ionone O
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

β-ionone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

β-ionone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O

β-ionone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
mechanisms O
of O
action O
, O
we O
qualified O
cell O
apoptosis O
, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol O
3-kinase O
(PI3K)-AKT O
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells O
. O
The O
results O
demonstrated O
that O
β-ionone-induced O
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 B
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O

β-ionone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K B
and O
p-AKT O
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

β-ionone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
treated O
with O
β-ionone O
(25 O
, O
50 O
, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h O
. O
β-ionone O
was O
also O
shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 O
and O
inhibit O
bcl-2 O
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner O
. O
The O
significantly O
decreased O
levels O
of O
p-PI3K O
and O
p-AKT B
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone O
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01) O
. O
Thus O
, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone O
may O
be O
regulated O
through O
a O
PI3K-AKT O
pathway O
. O
These O
results O
demonstrate O
a O
potential O
mechanism O
by O
which O
β-ionone O
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells O
. O

levcromakalim O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
used O
to O
study O
the O
alterations O
in O
K(ATP) O
channels O
in O
smooth O
muscle O
cells O
in O
experimental O
colitis O
. O
Colonic O
inflammation O
was O
induced O
in O
BALB/C O
mice O
after O
intracolonic O
administration O
of O
trinitrobenzene O
sulfonic O
acid O
. O
K(ATP) O
currents O
were O
measured O
at O
a O
holding O
potential O
of O
-60 O
mV O
in O
high O
K(+) O
external O
solution O
. O
The O
concentration O
response O
to O
levcromakalim O
(LEVC) O
, O
a O
K(ATP) B
channel I
opener O
, O
was O
significantly O
shifted O
to O
the O
left O
in O
the O
inflamed O
smooth-muscle O
cells O
. O
Both O
the O
potency O
and O
maximal O
currents O
induced O
by O
LEVC O
were O
enhanced O
in O
inflammation O
. O
The O
EC(50) O
values O
in O
control O
were O
6259 O
nM O
(n O
= O
10) O
and O
422 O
nM O
(n O
= O
8) O
in O
inflamed O
colon O
, O

LEVC O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
study O
the O
alterations O
in O
K(ATP) O
channels O
in O
smooth O
muscle O
cells O
in O
experimental O
colitis O
. O
Colonic O
inflammation O
was O
induced O
in O
BALB/C O
mice O
after O
intracolonic O
administration O
of O
trinitrobenzene O
sulfonic O
acid O
. O
K(ATP) O
currents O
were O
measured O
at O
a O
holding O
potential O
of O
-60 O
mV O
in O
high O
K(+) O
external O
solution O
. O
The O
concentration O
response O
to O
levcromakalim O
( O
LEVC O
 O
, O
a O
K(ATP) B
channel I
opener O
, O
was O
significantly O
shifted O
to O
the O
left O
in O
the O
inflamed O
smooth-muscle O
cells O
. O
Both O
the O
potency O
and O
maximal O
currents O
induced O
by O
LEVC O
were O
enhanced O
in O
inflammation O
. O
The O
EC(50) O
values O
in O
control O
were O
6259 O
nM O
(n O
= O
10) O
and O
422 O
nM O
(n O
= O
8) O
in O
inflamed O
colon O
, O

NaHS O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(NaHS) O
(10-1000 O
μM) O
on O
K(ATP) O
currents O
were O
significantly O
greater O
in O
inflamed O
colon O
compared O
with O
controls O
. O
In O
control O
cells O
, O
pretreatment O
with O
100 O
µM O
NaHS O
shifted O
the O
EC(50) O
for O
LEV-induced O
currents O
from O
2838 O
(n O
= O
6) O
to O
154 O
(n O
= O
8) O
nM O
. O
Sulfhydration O
of O
sulfonylurea B
receptor I
2B I
(SUR2B) O
was O
induced O
by O
NaHS O
and O
colonic O
inflammation O
. O
These O
data O
suggest O
that O
sulfhydration O
of O
SUR2B O
induces O
allosteric O
modulation O
of O
K(ATP) O
currents O
in O
colonic O
inflammation O
. O

NaHS O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(NaHS) O
(10-1000 O
μM) O
on O
K(ATP) O
currents O
were O
significantly O
greater O
in O
inflamed O
colon O
compared O
with O
controls O
. O
In O
control O
cells O
, O
pretreatment O
with O
100 O
µM O
NaHS O
shifted O
the O
EC(50) O
for O
LEV-induced O
currents O
from O
2838 O
(n O
= O
6) O
to O
154 O
(n O
= O
8) O
nM O
. O
Sulfhydration O
of O
sulfonylurea O
receptor O
2B O
(SUR2B) O
was O
induced O
by O
NaHS O
and O
colonic O
inflammation O
. O
These O
data O
suggest O
that O
sulfhydration O
of O
SUR2B B
induces O
allosteric O
modulation O
of O
K(ATP) O
currents O
in O
colonic O
inflammation O
. O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear B
factor-kappaB I
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor B
necrosis I
factor-alpha I
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 B
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT O
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O
(NF-κB) O
, O
which O
coincided O
with O
the O
induction O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O

CCl(4) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
fibrogenesis O
in O
carbon O
tetrachloride-intoxicated O
mice.The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
therapeutic O
potential O
of O
rosmarinic O
acid O
(RA) O
, O
a O
natural O
phenolic O
, O
in O
the O
treatment O
of O
acute O
liver O
toxicity O
. O
RA O
at O
10 O
, O
25 O
and O
50mg/kg O
was O
administered O
by O
gavage O
once O
daily O
for O
2 O
consecutive O
days O
, O
6h O
after O
CCl(4) O
intoxication O
. O
CCl(4) O
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT B
activity O
. O
In O
the O
livers O
, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine O
(3-NT) O
and O
thiobarbituric O
acid O
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn O
superoxide O
dismutase O
(SOD) O
activity O
. O
CCl(4) O
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear O
factor-kappaB O

CCl(4) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
necrosis O
factor-alpha O
(TNF-α) O
and O
cyclooxygenase-2 O
(COX-2) O
. O
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue O
. O
Additionally O
, O
RA O
prevented O
transforming O
growth O
factor-beta1 O
(TGF-β1) O
and O
alpha-smooth O
muscle O
actin O
(α-SMA) O
expression O
, O
suggesting O
suppression O
of O
profibrotic O
response O
. O
Furthermore O
, O
RA O
significantly O
inhibited O
the O
CCl(4) O
induced O
apoptosis O
, O
which O
was O
evident O
from O
decreased O
cleavage O
of O
caspase-3 O
. O
The O
hepatoprotective O
activity O
of O
RA O
coincided O
with O
enhanced O
NF-E2-related O
factor O
2 O
(Nrf2) O
and O
heme O
oxygenase-1 O
(HO-1) O
expression O
. O
The O
results O
of O
this O
study O
indicates O
that O
RA O
possesses O
antioxidant O
, O
anti-inflammatory O
, O
antiapoptotic O
and O
antifibrotic O
activity O
against O
acute O
liver O
toxicity O
. O

(-)-epicatechin-3-gallate O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Antiarrhythmic O
effects O
of O
(-)-epicatechin-3-gallat O
 O
, O
a O
novel O
sodium B
channel I
agonist O
in O
cultured O
neonatal O
rat O
ventricular O
myocytes.(-)-Epicatechin-3-gallate O
(ECG) O
, O
a O
polyphenol O
extracted O
from O
green O
tea O
, O
has O
been O
proposed O
as O
an O
effective O
compound O
for O
improving O
cardiac O
contractility O
. O
However O
, O
the O
therapeutic O
potential O
of O
ECG O
on O
the O
treatment O
of O
arrhythmia O
remains O
unknown O
. O
We O
investigated O
the O
direct O
actions O
of O

[(3)H]-diprenorphine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
a O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O
(5'-AMN) O
and O
N-((Naltrindol-5-yl) O
methyl) O
pentanimidamide O
(5'-MABN) O
, O
to O
identify O
whether O
modifications O
of O
the O
naltrindole O
side O
chain O
produces O
short-acting O
κ-antagonists O
. O
Opioid B
receptor I
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O

guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O
(5'-AMN) O
and O
N-((Naltrindol-5-yl) O
methyl) O
pentanimidamide O
(5'-MABN) O
, O
to O
identify O
whether O
modifications O
of O
the O
naltrindole O
side O
chain O
produces O
short-acting O
κ-antagonists O
. O
Opioid B
receptor I
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O

[(35)S]-GTPγS O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O
(5'-AMN) O
and O
N-((Naltrindol-5-yl) O
methyl) O
pentanimidamide O
(5'-MABN) O
, O
to O
identify O
whether O
modifications O
of O
the O
naltrindole O
side O
chain O
produces O
short-acting O
κ-antagonists O
. O
Opioid B
receptor I
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
( O
[(35)S]-GTPγS O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O
and O

5'-AMN O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Opioid O
receptor O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors B
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor O
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O

5'-MABN O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors B
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor O
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O
long-lasting O
antagonist O

naltrindole O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
In O
vivo O
and O
in O
vitro O
characterization O
of O
naltrindol O
-derived O
ligands O
at O
the O
κ-opioid O
receptor.Accumulating O
evidence O
supports O
a O
role O
for O
κ-opioid B
receptor I
antagonists O
in O
the O
treatment O
of O
mood O
disorders O
. O
Standard O
κ-antagonists O
have O
an O
unusual O
pharmacodynamic O
action O
, O
with O
a O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks O
. O
Here O
, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands O
, O
5'-(2-aminomethyl) O
naltrindole O

5'-AMN O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Opioid O
receptor O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor B
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O

5'-MABN O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine O
binding O
, O
guanosine-5'-O-(3-[35S]-thio) O
triphosphate O
([(35)S]-GTPγS) O
binding O
and O
isolated O
guinea-pig O
ileum O
. O
Pharmacodynamic O
profiles O
of O
5'-AMN O
and O
5'-MABN O
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis O
. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice O
. O
Both O
5'-AMN O
and O
5'-MABN O
had O
high O
affinity O
for O
κ-receptors O
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O
0.08 O
, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18 O
, O
respectively) O
and O
μ-receptor B
antagonists O
(pA(2) O
7.62 O
and O
7.85 O
, O
respectively) O
in O
the O
ileum O
. O
Contrary O
to O
our O
hypothesis O
, O
in O
vivo O
, O
5'-AMN O
and O
5'-MABN O
displayed O
long-lasting O
antagonist O

Phillyrin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
foods O
, O
has O
anti-obesity O
activity O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol B
regulatory I
element-binding I
protein-1c I
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O

Phillyrin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
foods O
, O
has O
anti-obesity O
activity O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c B
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O

phillyrin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK B
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin O
enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS O
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

phillyrin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS O
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

phillyrin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK B
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS O
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

phillyrin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK B
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS O
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose O
induced O
fatty B
acid I
synthase I
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose O
induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O

phillyrin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c B
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS O
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

phillyrin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O
and O
FAS B
through O
LKB1/AMPK O
activation O
, O
suggesting O
that O
phillyrin O
is O
a O
novel O
AMPK O
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity O
. O

Phillyrin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
foods O
, O
has O
anti-obesity O
activity O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty B
acid I
synthase I
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O

Phillyrin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
foods O
, O
has O
anti-obesity O
activity O
in O
vivo O
. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin O
in O
the O
prevention O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O

compound O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated B
protein I
kinase I
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK O
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O

compound O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK B
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O

compound O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
high O
glucose-induced O
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
. O
We O
found O
that O
phillyrin O
suppressed O
high O
glucose-induced O
lipid O
accumulation O
in O
HepG2 O
cells O
. O
Phillyrin O
strongly O
inhibited O
high O
glucose-induced O
fatty O
acid O
synthase O
(FAS) O
expression O
by O
modulating O
sterol O
regulatory O
element-binding O
protein-1c O
(SREBP-1c) O
activation O
. O
Moreover O
, O
use O
of O
the O
pharmacological O
AMP-activated O
protein O
kinase O
(AMPK) O
inhibitor O
compound O
C O
revealed O
that O
AMPK B
is O
essential O
for O
suppressing O
SREBP-1c O
expression O
in O
phillyrin-treated O
cells O
. O
Finally O
, O
we O
found O
that O
liver O
kinase O
B1 O
(LKB1) O
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced O
activation O
of O
AMPK O
in O
HepG2 O
hepatocytes O
. O
These O
results O
indicate O
that O
phillyrin O
prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c O

[-]-Huperzine O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mechanisms O
after O
exposure O
to O
lethal O
doses O
of O
nerve O
agent O
are O
complex O
and O
involve O
multiple O
biochemical O
pathways O
. O
Effective O
treatment O
requires O
drugs O
that O
can O
simultaneously O
protect O
by O
reversible O
binding O
to O
the O
acetylcholinesterase O
(AChE) O
and O
blocking O
cascades O
of O
seizure O
related O
brain O
damage O
, O
inflammation O
, O
neuronal O
degeneration O
as O
well O
as O
promoting O
induction O
of O
neuroregeneration O
. O
[-]-Huperzine O
A O
([-]-Hup O
A) O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE B
inhibitor O
that O
penetrates O
the O
blood-brain O
barrier O
. O
It O
also O
has O
several O
neuroprotective O
effects O
including O
modification O
of O
beta-amyloid O
peptide O
, O
reduction O
of O
oxidative O
stress O
, O
anti-inflammatory O
, O
anti-apoptotic O
and O
induction O
and O
regulation O
of O
nerve O
growth O
factor O
. O
Toxicities O
at O
higher O
doses O
restrict O
the O
neuroporotective O
ability O
of O

[-]-Hup O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
lethal O
doses O
of O
nerve O
agent O
are O
complex O
and O
involve O
multiple O
biochemical O
pathways O
. O
Effective O
treatment O
requires O
drugs O
that O
can O
simultaneously O
protect O
by O
reversible O
binding O
to O
the O
acetylcholinesterase O
(AChE) O
and O
blocking O
cascades O
of O
seizure O
related O
brain O
damage O
, O
inflammation O
, O
neuronal O
degeneration O
as O
well O
as O
promoting O
induction O
of O
neuroregeneration O
. O
[-]-Huperzine O
A O
( O
[-]-Hup O
A O
 O
, O
is O
a O
naturally O
occurring O
potent O
reversible O
AChE B
inhibitor O
that O
penetrates O
the O
blood-brain O
barrier O
. O
It O
also O
has O
several O
neuroprotective O
effects O
including O
modification O
of O
beta-amyloid O
peptide O
, O
reduction O
of O
oxidative O
stress O
, O
anti-inflammatory O
, O
anti-apoptotic O
and O
induction O
and O
regulation O
of O
nerve O
growth O
factor O
. O
Toxicities O
at O
higher O
doses O
restrict O
the O
neuroporotective O
ability O
of O
[-]-Hup O

[+]-Hup O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
reversible O
AChE B
inhibitor O
that O
penetrates O
the O
blood-brain O
barrier O
. O
It O
also O
has O
several O
neuroprotective O
effects O
including O
modification O
of O
beta-amyloid O
peptide O
, O
reduction O
of O
oxidative O
stress O
, O
anti-inflammatory O
, O
anti-apoptotic O
and O
induction O
and O
regulation O
of O
nerve O
growth O
factor O
. O
Toxicities O
at O
higher O
doses O
restrict O
the O
neuroporotective O
ability O
of O
[-]-Hup O
A O
for O
treatment O
. O
The O
synthetic O
stereoisomer O
, O
[+]-Hup O
A O
is O
less O
toxic O
due O
to O
poor O
AChE O
inhibition O
and O
is O
suitable O
for O
both O
pre-/post-exposure O
treatments O
of O
nerve O
agent O
toxicity O
. O
[+]-Hup O
A O
block O
the O
N-methyl-d-aspartate O
(NMDA)-induced O
seizure O
in O
rats O
, O
reduce O
excitatory O
amino O
acid O
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement O
. O
Unique O
combinations O
of O
two O
stereo-isomers O

ADP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Neuroprotective O
role O
of O
ATP-sensitive O
potassium O
channels O
in O
cerebral O
ischemia.ATP-sensitive O
potassium O
(K(ATP)) O
channels O
are O
weak O
, O
inward O
rectifiers O
that O
couple O
metabolic O
status O
to O
cell O
membrane O
electrical O
activity O
, O
thus O
modulating O
many O
cellular O
functions O
. O
An O
increase O
in O
the O
ADP O
ATP O
ratio O
opens O
K(ATP) O
channels O
, O
leading O
to O
membrane O
hyperpolarization O
. O
K(ATP) B
channels I
are O
ubiquitously O
expressed O
in O
neurons O
located O
in O
different O
regions O
of O
the O
brain O
, O
including O
the O
hippocampus O
and O
cortex O
. O
Brief O
hypoxia O
triggers O
membrane O
hyperpolarization O
in O
these O
central O
neurons O
. O
In O
vivo O
animal O
studies O
confirmed O
that O
knocking O
out O
the O
Kir6.2 O
subunit O
of O

ATP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Neuroprotective O
role O
of O
ATP-sensitive O
potassium O
channels O
in O
cerebral O
ischemia.ATP-sensitive O
potassium O
(K(ATP)) O
channels O
are O
weak O
, O
inward O
rectifiers O
that O
couple O
metabolic O
status O
to O
cell O
membrane O
electrical O
activity O
, O
thus O
modulating O
many O
cellular O
functions O
. O
An O
increase O
in O
the O
ADP O
/ O
ATP O
ratio O
opens O
K(ATP) O
channels O
, O
leading O
to O
membrane O
hyperpolarization O
. O
K(ATP) B
channels I
are O
ubiquitously O
expressed O
in O
neurons O
located O
in O
different O
regions O
of O
the O
brain O
, O
including O
the O
hippocampus O
and O
cortex O
. O
Brief O
hypoxia O
triggers O
membrane O
hyperpolarization O
in O
these O
central O
neurons O
. O
In O
vivo O
animal O
studies O
confirmed O
that O
knocking O
out O
the O
Kir6.2 O
subunit O
of O
the O

oxygen O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
mutation O
in O
the O
FAM36A O
gene O
, O
the O
human O
ortholog O
of O
COX20 O
, O
impairs O
cytochrome O
c O
oxidase O
assembly O
and O
is O
associated O
with O
ataxia O
and O
muscle O
hypotonia.The O
mitochondrial B
respiratory I
chain I
complex I
IV I
(cytochrome O
c O
oxidase) O
is O
a O
multi-subunit O
enzyme O
that O
transfers O
electrons O
from O
cytochrome O
c O
to O
molecular O
oxygen O
yielding O
water O
. O
Its O
biogenesis O
requires O
concerted O
expression O
of O
mitochondria- O
and O
nuclear-encoded O
subunits O
and O
assembly O
factors O
. O
In O
this O
report O
, O
we O
describe O
a O
homozygous O
missense O
mutation O
in O
FAM36A O
from O
a O
patient O
who O
displays O
ataxia O
and O
muscle O
hypotonia O
. O
The O
FAM36A O
gene O
is O
a O
remote O
, O
putative O
ortholog O
of O
the O
fungal O
complex O
IV O
assembly O

oxygen O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
mutation O
in O
the O
FAM36A O
gene O
, O
the O
human O
ortholog O
of O
COX20 O
, O
impairs O
cytochrome B
c I
oxidase I
assembly O
and O
is O
associated O
with O
ataxia O
and O
muscle O
hypotonia.The O
mitochondrial O
respiratory O
chain O
complex O
IV O
(cytochrome O
c O
oxidase) O
is O
a O
multi-subunit O
enzyme O
that O
transfers O
electrons O
from O
cytochrome O
c O
to O
molecular O
oxygen O
yielding O
water O
. O
Its O
biogenesis O
requires O
concerted O
expression O
of O
mitochondria- O
and O
nuclear-encoded O
subunits O
and O
assembly O
factors O
. O
In O
this O
report O
, O
we O
describe O
a O
homozygous O
missense O
mutation O
in O
FAM36A O
from O
a O
patient O
who O
displays O
ataxia O
and O
muscle O
hypotonia O
. O
The O
FAM36A O
gene O
is O
a O
remote O
, O
putative O
ortholog O
of O
the O
fungal O
complex O
IV O
assembly O

dimethyldiguanide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
effects O
of O
14days' O
intragastrically O
given O
of O
cinnamon O
polyphenols O
(CPS) O
in O
treating O
diabetic O
mice O
induced O
by O
intraperitoneal O
injection O
of O
streptozotocin O
(150mgkg(-1)) O
and O
fed O
high-sugar O
, O
high-fat O
diet O
. O
The O
diabetic O
mice O
model O
was O
successfully O
established O
through O
determining O
on O
fasting O
blood-glucose O
(FBG) O
test O
. O
As O
revealed O
by O
glucose O
oxidase O
(GOD) O
and O
radioimmunoassay O
(RIA) O
, O
both O
dimethyldiguanide O
(DC O
, O
0.6gkg(-1)d(-1)) O
and O
CPS O
(0.3 O
, O
0.6 O
, O
1.2gkg(-1)d(-1)) O
treatments O
significantly O
resulted O
in O
down-regulation O
of O
blood O
glucose O
and O
insulin B
levels O
in O
serum O
, O
while O
the O
levels O
of O
oxidative O
stress O
markers O
were O
markedly O
lowered O
through O
ELISA O
assay O
. O
Meanwhile O
, O
the O
pathological O
damage O
in O
islet O
with O
pancreatic O
beta O
cells O
was O
ameliorated O
by O
treatment O
of O
CPS O

polyphenols O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
assay O
. O
Meanwhile O
, O
the O
pathological O
damage O
in O
islet O
with O
pancreatic O
beta O
cells O
was O
ameliorated O
by O
treatment O
of O
CPS O
at O
different O
doses O
, O
as O
shown O
in O
HE O
stain O
. O
At O
the O
same O
time O
, O
the O
treatments O
also O
caused O
notable O
reduction O
of O
iNOS O
, O
NF-κB O
expressions O
showing O
in O
Western O
blot O
analysis O
. O
These O
findings O
demonstrate O
that O
cinnamon O
polyphenols O
can O
exert O
the O
hypoglycemic O
and O
hypolipidemic O
effects O
through O
the O
mechanisms O
that O
may O
be O
associated O
with O
repairing O
pancreatic O
beta O
cells O
in O
diabetic O
mice O
and O
improving O
its O
anti-oxidative O
capacity O
, O
as O
well O
as O
attenuating O
cytotoxicity O
via O
inhibition O
of O
iNOS O
, O
NF-κB O
activation O
. O

polyphenols O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
assay O
. O
Meanwhile O
, O
the O
pathological O
damage O
in O
islet O
with O
pancreatic O
beta O
cells O
was O
ameliorated O
by O
treatment O
of O
CPS O
at O
different O
doses O
, O
as O
shown O
in O
HE O
stain O
. O
At O
the O
same O
time O
, O
the O
treatments O
also O
caused O
notable O
reduction O
of O
iNOS O
, O
NF-κB B
expressions O
showing O
in O
Western O
blot O
analysis O
. O
These O
findings O
demonstrate O
that O
cinnamon O
polyphenols O
can O
exert O
the O
hypoglycemic O
and O
hypolipidemic O
effects O
through O
the O
mechanisms O
that O
may O
be O
associated O
with O
repairing O
pancreatic O
beta O
cells O
in O
diabetic O
mice O
and O
improving O
its O
anti-oxidative O
capacity O
, O
as O
well O
as O
attenuating O
cytotoxicity O
via O
inhibition O
of O
iNOS O
, O
NF-κB O
activation O
. O

imatinib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Polymorphisms O
in O
OCTN1 O
and O
OCTN2 O
transporters O
genes O
are O
associated O
with O
prolonged O
time O
to O
progression O
in O
unresectable O
gastrointestinal O
stromal O
tumours O
treated O
with O
imatinib O
therapy.The O
two O
basic O
mainstays O
of O
gastrointestinal O
stromal O
tumours O
(GIST) O
treatment O
are O
surgery O
and O
imatinib O
a O
selective O
tyrosine B
kinase I
inhibitor O
that O
allows O
achieving O
a O
stable O
or O
responding O
disease O
in O
about O
80% O
of O
patients O
with O
unresectable/metastatic O
GIST O
. O
Response O
to O
imatinib O
mainly O
depends O
from O
KIT O
and O
PDGFRα O
mutational O
status O
. O
Nevertheless O
, O
some O
patients O
with O
a O
potentially O
responsive O
genotype O
do O
not O
respond O
, O
and O
others O
develop O
a O
pattern O
of O

N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
as O
CB2 B
agonists.3D O
ligand-based O
virtual O
screening O
was O
employed O
to O
identify O
novel O
scaffolds O
for O
cannabinoid O
receptor O
ligand O
development O
. O
A O
total O
of O
112 O
compounds O
with O
diverse O
structures O
were O
purchased O
from O
commercial O
vendors O
. O
12 O
CB1 O
receptor O
antagonists/inverse O
agonists O
and O
10 O
CB2 O
receptor O
agonists O
were O
identified O
in O
vitro O
. O
One O
of O
the O
CB2 O
agonists O
, O
N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine O
(19 O
, O
-logEC(50)=7.5 O
, O
E(max)=255%) O
was O
selected O
for O
further O
development O
. O
As O
far O
as O
we O
are O
aware O
, O
the O
compound's O
1,3,5-triazine O
scaffold O
represents O
a O
new O
core O
structure O
for O
CB2 O
agonists O
. O
A O
library O
of O
fifty-seven O
2,4,6-trisubstituted-1,3,5-triazines O
was O
created O
to O
clarify O
the O
structure-activity O
relationship O
study O
of O
the O
analogs O
. O

1,3,5-triazine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
A O
total O
of O
112 O
compounds O
with O
diverse O
structures O
were O
purchased O
from O
commercial O
vendors O
. O
12 O
CB1 O
receptor O
antagonists/inverse O
agonists O
and O
10 O
CB2 B
receptor O
agonists O
were O
identified O
in O
vitro O
. O
One O
of O
the O
CB2 O
agonists O
, O
N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine O
(19 O
, O
-logEC(50)=7.5 O
, O
E(max)=255%) O
was O
selected O
for O
further O
development O
. O
As O
far O
as O
we O
are O
aware O
, O
the O
compound's O
1,3,5-triazine O
scaffold O
represents O
a O
new O
core O
structure O
for O
CB2 O
agonists O
. O
A O
library O
of O
fifty-seven O
2,4,6-trisubstituted-1,3,5-triazines O
was O
created O
to O
clarify O
the O
structure-activity O
relationship O
study O
of O
the O
analogs O
. O

2,4,6-trisubstituted O
1,3,5-triazines O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Discovery O
of O
novel O
cannabinoid O
receptor O
ligands O
by O
a O
virtual O
screening O
approach O
: O
further O
development O
of O
2,4,6-trisubstituted O
1,3,5-triazine O
as O
CB2 B
agonists.3D O
ligand-based O
virtual O
screening O
was O
employed O
to O
identify O
novel O
scaffolds O
for O
cannabinoid O
receptor O
ligand O
development O
. O
A O
total O
of O
112 O
compounds O
with O
diverse O
structures O
were O
purchased O
from O
commercial O
vendors O
. O
12 O
CB1 O
receptor O
antagonists/inverse O
agonists O
and O
10 O
CB2 O
receptor O
agonists O
were O
identified O
in O
vitro O
. O
One O
of O
the O
CB2 O
agonists O
, O

Sar O
acts O
as O
PART-OF O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII B
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[ O
Sar O
1),Gln(2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

Sar O
acts O
as O
PART-OF O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII B
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[ O
Sar O
1),Gln(2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

Gln O
acts O
as O
PART-OF O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII B
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1) O
, O
Gln O
2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

Gln O
acts O
as O
PART-OF O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII B
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1) O
, O
Gln O
2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

Ile O
acts O
as O
PART-OF O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII B
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1),Gln(2) O
, O
Ile O
8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

Ile O
acts O
as O
PART-OF O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII B
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A O
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1),Gln(2) O
, O
Ile O
8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

cysteines O
acts O
as O
PART-OF O
for O
what O
entity O
? O
mutations O
in O
distant O
sites O
that O
alter O
the O
activation O
state O
equilibrium O
of O
the O
AT1R O
. O
Differential O
accessibility O
of O
reporter O
cysteines O
introduced O
at O
four O
conformation-sensitive O
sites O
in O
ECL2 O
of O
these O
mutants O
was O
measured O
. O
Binding O
of O
the O
agonist O
angiotensin O
II O
(AngII) O
and O
inverse O
agonist O
losartan O
in O
wild-type O
AT1R B
changed O
the O
accessibility O
of O
reporter O
cysteines O
and O
the O
pattern O
was O
consistent O
with O
ligand-specific O
"lid" O
conformations O
of O
ECL2 O
. O
Without O
agonist O
stimulation O
, O
the O
ECL2 O
in O
the O
gain O
of O
function O
mutant O
N111G O
assumed O
a O
lid O
conformation O
similar O
to O
AngII-bound O
wild-type O
AT1R O
. O
In O
the O
presence O
of O
inverse O
agonists O
, O
the O
conformation O
of O
ECL2 O
in O
the O
N111G O
mutant O
was O
similar O
to O

Sar O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII O
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A B
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[ O
Sar O
1),Gln(2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

Gln O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII O
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A B
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1) O
, O
Gln O
2),Ile(8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

Ile O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
N111G O
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R O
. O
In O
contrast O
, O
AngII O
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O
D281A B
mutant O
, O
which O
is O
consistent O
with O
the O
reduced O
AngII O
binding O
affinity O
in O
this O
mutant O
. O
However O
, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1),Gln(2) O
, O
Ile O
8)] O
AngII O
, O
a O
specific O
analog O
that O
binds O
to O
the O
D281A O
mutant O
with O
better O
affinity O
than O
AngII O
. O
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor O
. O

losartan O
acts O
as O
AGONIST-INHIBITOR O
for O
what O
entity O
? O
the O
angiotensin O
II O
type O
1 O
receptor O
(AT1R) O
by O
introducing O
mutations O
in O
distant O
sites O
that O
alter O
the O
activation O
state O
equilibrium O
of O
the O
AT1R O
. O
Differential O
accessibility O
of O
reporter O
cysteines O
introduced O
at O
four O
conformation-sensitive O
sites O
in O
ECL2 O
of O
these O
mutants O
was O
measured O
. O
Binding O
of O
the O
agonist O
angiotensin O
II O
(AngII) O
and O
inverse O
agonist O
losartan O
in O
wild-type O
AT1R B
changed O
the O
accessibility O
of O
reporter O
cysteines O
, O
and O
the O
pattern O
was O
consistent O
with O
ligand-specific O
"lid" O
conformations O
of O
ECL2 O
. O
Without O
agonist O
stimulation O
, O
the O
ECL2 O
in O
the O
gain O
of O
function O
mutant O
N111G O
assumed O
a O
lid O
conformation O
similar O
to O
AngII-bound O
wild-type O
AT1R O
. O
In O
the O
presence O
of O
inverse O
agonists O
, O
the O
conformation O

nucleotide O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
Heterometrus O
laoticus O
, O
in O
Thailand O
. O
In O
this O
study O
, O
HmTx B
was O
purified O
from O
venom O
by O
separation O
chromatography O
, O
and O
the O
PLA(2) O
activity O
of O
the O
fractions O
was O
determined O
by O
lecithin O
agar O
assay O
. O
The O
enzyme O
is O
an O
acidic O
protein O
with O
a O
pI O
of O
5.6 O
and O
an O
apparent O
molecular O
weight O
of O
14018.4 O
Da O
. O
The O
nucleotide O
sequence O
of O
HmTx O
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino O
acid O
residues-104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
the O
PLA(2) O
activity O
of O
the O
fractions O
was O
determined O
by O
lecithin O
agar O
assay O
. O
The O
enzyme O
is O
an O
acidic O
protein O
with O
a O
pI O
of O
5.6 O
and O
an O
apparent O
molecular O
weight O
of O
14018.4 O
Da O
. O
The O
nucleotide O
sequence O
of O
HmTx B
contains O
649 O
bp O
, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino O
acid O
residues-104 O
of O
which O
make O
up O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx O
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O

Lys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx B
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
( O
Lys O
4-His34) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
large O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx B
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24- O
His O
4) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx B
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
( O
Cys O
9-Asp71) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

Asp O
acts O
as O
PART-OF O
for O
what O
entity O
? O
subunit O
, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx B
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys59- O
Asp O
1) O
, O
and O
h3 O
(Ala80-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

Ala O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx B
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
( O
Ala O
0-Phe89) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
which O
make O
up O
the O
small O
subunit O
. O
The O
subunit O
structure O
of O
HmTx B
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin O
, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus O
tamulus O
phospholipase O
A(2) O
(MtPLA(2)) O
. O
The O
3D-structure O
of O
HmTx O
consists O
of O
three O
conserved O
alpha-helices O
: O
h1 O
(Lys24-His34) O
, O
h2 O
(Cys59-Asp71) O
, O
and O
h3 O
(Ala80- O
Phe O
9) O
. O
The O
beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 O
and O
b1.2 O
at O
Lys48-Asn50) O
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG- O
, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases O
. O

TCDD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
sperm O
count O
in O
the O
male O
offspring O
. O
It O
did O
not O
affect O
methylation O
but O
increased O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
, O
Igf2r O
and O
Air O
ncRNA O
. O
In O
muscle O
and O
liver O
, O
TCDD O
(10 O
ng/kg/day) O
induced O
increases O
in O
methylation O
and O
decreases O
in O
mRNA O
expression O
of O
Igf2r O
. O
These O
results O
show O
that O
the O
robust O
effects O
of O
TCDD O
on O
the O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
and O
Igf2r O
genes O
in O
the O
sperm O
and O
of O
Igf2r O
in O
the O
muscle O
and O
liver O
are O
unrelated O
to O
changes O
in O
methylation O
in O
their O
respective O
genes O
. O

TCDD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
sperm O
count O
in O
the O
male O
offspring O
. O
It O
did O
not O
affect O
methylation O
but O
increased O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
, O
Igf2r O
and O
Air O
ncRNA O
. O
In O
muscle O
and O
liver O
, O
TCDD O
(10 O
ng/kg/day) O
induced O
increases O
in O
methylation O
and O
decreases O
in O
mRNA O
expression O
of O
Igf2r O
. O
These O
results O
show O
that O
the O
robust O
effects O
of O
TCDD O
on O
the O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 B
and O
Igf2r O
genes O
in O
the O
sperm O
and O
of O
Igf2r O
in O
the O
muscle O
and O
liver O
are O
unrelated O
to O
changes O
in O
methylation O
in O
their O
respective O
genes O
. O

TCDD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
sperm O
count O
in O
the O
male O
offspring O
. O
It O
did O
not O
affect O
methylation O
but O
increased O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
, O
Igf2r B
and O
Air O
ncRNA O
. O
In O
muscle O
and O
liver O
, O
TCDD O
(10 O
ng/kg/day) O
induced O
increases O
in O
methylation O
and O
decreases O
in O
mRNA O
expression O
of O
Igf2r O
. O
These O
results O
show O
that O
the O
robust O
effects O
of O
TCDD O
on O
the O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
and O
Igf2r O
genes O
in O
the O
sperm O
and O
of O
Igf2r O
in O
the O
muscle O
and O
liver O
are O
unrelated O
to O
changes O
in O
methylation O
in O
their O
respective O
genes O
. O

TCDD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
sperm O
count O
in O
the O
male O
offspring O
. O
It O
did O
not O
affect O
methylation O
but O
increased O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
, O
Igf2r B
and O
Air O
ncRNA O
. O
In O
muscle O
and O
liver O
, O
TCDD O
(10 O
ng/kg/day) O
induced O
increases O
in O
methylation O
and O
decreases O
in O
mRNA O
expression O
of O
Igf2r O
. O
These O
results O
show O
that O
the O
robust O
effects O
of O
TCDD O
on O
the O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
and O
Igf2r O
genes O
in O
the O
sperm O
and O
of O
Igf2r O
in O
the O
muscle O
and O
liver O
are O
unrelated O
to O
changes O
in O
methylation O
in O
their O
respective O
genes O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
and O
Igf2r B
were O
analyzed O
in O
the O
sperm O
, O
skeletal O
muscle O
and O
liver O
. O
TCDD O
administration O
(10 O
ng/kg/day) O
decreased O
the O
sperm O
count O
in O
the O
male O
offspring O
. O
It O
did O
not O
affect O
methylation O
but O
increased O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
, O
Igf2r O
and O
Air O
ncRNA O
. O
In O
muscle O
and O
liver O
, O
TCDD O
(10 O
ng/kg/day) O
induced O
increases O
in O
methylation O
and O
decreases O
in O
mRNA O
expression O
of O
Igf2r O
. O
These O
results O
show O
that O
the O
robust O
effects O
of O
TCDD O
on O
the O
mRNA O
expression O
of O
Snrpn O
, O
Peg3 O
and O
Igf2r O
genes O
in O
the O
sperm O
and O
of O
Igf2r O
in O
the O
muscle O
and O
liver O
are O
unrelated O
to O
changes O
in O
methylation O

phenethylamides O
acts O
as O
NOT O
for O
what O
entity O
? O
of O
17β-HSD2 B
is O
an O
attractive O
mechanism O
for O
the O
treatment O
of O
osteoporosis O
. O
We O
report O
here O
the O
optimization O
of O
human O
17β-HSD2 O
inhibitors O
in O
the O
2,5-thiophene O
amide O
class O
by O
varying O
the O
size O
of O
the O
linker O
(n O
equals O
0 O
and O
2) O
between O
the O
amide O
moiety O
and O
the O
phenyl O
group O
. O
While O
none O
of O
the O
phenethylamides O
(n O
= O
2) O
were O
active O
, O
most O
of O
the O
anilides O
(n O
= O
0) O
turned O
out O
to O
moderately O
or O
strongly O
inhibit O
17β-HSD2 O
. O
The O
four O
most O
active O
compounds O
showed O
an O
IC₅₀ O
of O
around O
60 O
nM O
and O
a O
very O
good O
selectivity O
toward O
17β-HSD1 O
, O
17β-HSD4 O
, O
17β-HSD5 O
, O
11β-HSD1 O
, O
11β-HSD2 O
and O
the O
estrogen O
receptors O
α O
and O

2,5-thiophene O
amide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structural O
optimization O
of O
2,5-thiophene O
amides O
as O
highly O
potent O
and O
selective O
17β-hydroxysteroid O
dehydrogenase O
type O
2 O
inhibitors O
for O
the O
treatment O
of O
osteoporosis.Inhibition O
of O
17β-HSD2 O
is O
an O
attractive O
mechanism O
for O
the O
treatment O
of O
osteoporosis O
. O
We O
report O
here O
the O
optimization O
of O
human B
17β-HSD2 I
inhibitors O
in O
the O
2,5-thiophene O
amide O
class O
by O
varying O
the O
size O
of O
the O
linker O
(n O
equals O
0 O
and O
2) O
between O
the O
amide O
moiety O
and O
the O
phenyl O
group O
. O
While O
none O
of O
the O
phenethylamides O
(n O
= O
2) O
were O
active O
, O
most O
of O
the O
anilides O
(n O
= O
0) O
turned O
out O
to O
moderately O
or O
strongly O
inhibit O
17β-HSD2 O
. O
The O
four O
most O

anilides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
osteoporosis O
. O
We O
report O
here O
the O
optimization O
of O
human O
17β-HSD2 B
inhibitors O
in O
the O
2,5-thiophene O
amide O
class O
by O
varying O
the O
size O
of O
the O
linker O
(n O
equals O
0 O
and O
2) O
between O
the O
amide O
moiety O
and O
the O
phenyl O
group O
. O
While O
none O
of O
the O
phenethylamides O
(n O
= O
2) O
were O
active O
, O
most O
of O
the O
anilides O
(n O
= O
0) O
turned O
out O
to O
moderately O
or O
strongly O
inhibit O
17β-HSD2 O
. O
The O
four O
most O
active O
compounds O
showed O
an O
IC₅₀ O
of O
around O
60 O
nM O
and O
a O
very O
good O
selectivity O
toward O
17β-HSD1 O
, O
17β-HSD4 O
, O
17β-HSD5 O
, O
11β-HSD1 O
, O
11β-HSD2 O
and O
the O
estrogen O
receptors O
α O
and O
β O
. O
The O
investigated O
compounds O
inhibited O
monkey O
17β-HSD2 O
moderately O
, O
and O

2,5-thiophene O
amides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structural O
optimization O
of O
2,5-thiophene O
amide O
as O
highly O
potent O
and O
selective O
17β-hydroxysteroid B
dehydrogenase I
type I
2 I
inhibitors O
for O
the O
treatment O
of O
osteoporosis.Inhibition O
of O
17β-HSD2 O
is O
an O
attractive O
mechanism O
for O
the O
treatment O
of O
osteoporosis O
. O
We O
report O
here O
the O
optimization O
of O
human O
17β-HSD2 O
inhibitors O
in O
the O
2,5-thiophene O
amide O
class O
by O
varying O
the O
size O
of O
the O
linker O
(n O
equals O

Ly294002 O
acts O
as O
NOT O
for O
what O
entity O
? O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
, O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 B
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O

Ly294002 O
acts O
as O
NOT O
for O
what O
entity O
? O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
, O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 O
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O

clofarabine O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
of O
resveratrol O
and O
clofarabine O
produced O
a O
synergistic O
antiproliferative O
effect O
in O
MSTO-211H O
cells O
, O
but O
not O
in O
MeT-5A O
cells O
. O
In O
MSTO-211H O
cells O
, O
the O
nuclear O
accumulation O
of O
Sp1 B
and O
the O
levels O
of O
p-Akt O
, O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 O
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O

resveratrol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
clofarabine O
produced O
a O
synergistic O
antiproliferative O
effect O
in O
MSTO-211H O
cells O
, O
but O
not O
in O
MeT-5A O
cells O
. O
In O
MSTO-211H O
cells O
, O
the O
nuclear O
accumulation O
of O
Sp1 B
and O
the O
levels O
of O
p-Akt O
, O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
, O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 O
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O

clofarabine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
of O
resveratrol O
and O
clofarabine O
produced O
a O
synergistic O
antiproliferative O
effect O
in O
MSTO-211H O
cells O
, O
but O
not O
in O
MeT-5A O
cells O
. O
In O
MSTO-211H O
cells O
, O
the O
nuclear O
accumulation O
of O
Sp1 B
and O
the O
levels O
of O
p-Akt O
, O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 O
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O

resveratrol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
clofarabine O
produced O
a O
synergistic O
antiproliferative O
effect O
in O
MSTO-211H O
cells O
, O
but O
not O
in O
MeT-5A O
cells O
. O
In O
MSTO-211H O
cells O
, O
the O
nuclear O
accumulation O
of O
Sp1 B
and O
the O
levels O
of O
p-Akt O
, O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
, O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 O
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O

Ly294002 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 B
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
, O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 O
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O

resveratrol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt B
and O
Sp1 O
activities O
, O
and O
suggest O
that O
this O
combination O
may O
have O
therapeutic O
value O
in O
treatment O
of O
malignant O
mesothelioma O
. O

resveratrol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 B
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O
and O
suggest O
that O
this O
combination O
may O
have O
therapeutic O
value O
in O
treatment O
of O
malignant O
mesothelioma O
. O

clofarabine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt B
and O
Sp1 O
activities O
, O
and O
suggest O
that O
this O
combination O
may O
have O
therapeutic O
value O
in O
treatment O
of O
malignant O
mesothelioma O
. O

clofarabine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide O
3-kinase O
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 B
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O
and O
suggest O
that O
this O
combination O
may O
have O
therapeutic O
value O
in O
treatment O
of O
malignant O
mesothelioma O
. O

Ly294002 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sp1 O
, O
c-Met O
, O
cyclin O
D1 O
, O
and O
p21 O
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them O
. O
In O
combination O
with O
clofarabine O
, O
the O
ability O
of O
resveratrol O
to O
reduce O
the O
contents O
of O
Sp1 O
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment O
. O
The O
inhibition O
of O
phosphoinositide B
3-kinase I
using O
Ly294002 O
augmented O
a O
decrease O
in O
the O
p21 O
level O
induced O
by O
their O
combination O
, O
but O
it O
showed O
no O
significant O
effects O
on O
expression O
of O
Sp1 O
and O
cyclin O
D1 O
. O
Taken O
together O
, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol O
and O
clofarabine O
is O
linked O
to O
the O
inhibition O
of O
Akt O
and O
Sp1 O
activities O
, O

ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Linking O
GABA(A) O
receptor O
subunits O
to O
alcohol-induced O
conditioned O
taste O
aversion O
and O
recovery O
from O
acute O
alcohol O
intoxication.GABA O
type O
A O
receptors O
(GABA(A)-R) O
are O
important O
for O
ethanol O
actions O
and O
it O
is O
of O
interest O
to O
link O
individual O
subunits O
with O
specific O
ethanol O
behaviors O
. O
We O
studied O
null O
mutant O
mice O
for O
six O
different O
GABA(A)-R O
subunits O
(α1 O
, O
α2 O
, O
α3 O
, O
α4 O
, O
α5 O
and O
δ) O
. O
Only O
mice O
lacking O
the O
α2 O
subunit O
showed O
reduction O
of O
conditioned O
taste O
aversion O
(CTA) O
to O
ethanol O
. O
These O
results O
are O

ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Linking O
GABA(A) O
receptor O
subunits O
to O
alcohol-induced O
conditioned O
taste O
aversion O
and O
recovery O
from O
acute O
alcohol O
intoxication.GABA O
type O
A O
receptors O
(GABA(A)-R) O
are O
important O
for O
ethanol O
actions O
and O
it O
is O
of O
interest O
to O
link O
individual O
subunits O
with O
specific O
ethanol O
behaviors O
. O
We O
studied O
null O
mutant O
mice O
for O
six O
different O
GABA(A)-R B
subunits O
(α1 O
, O
α2 O
, O
α3 O
, O
α4 O
, O
α5 O
and O
δ) O
. O
Only O
mice O
lacking O
the O
α2 O
subunit O
showed O
reduction O
of O
conditioned O
taste O
aversion O
(CTA) O
to O
ethanol O
. O
These O
results O
are O

ethanol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mice O
lacking O
the O
α2 O
subunit O
showed O
reduction O
of O
conditioned O
taste O
aversion O
(CTA) O
to O
ethanol O
. O
These O
results O
are O
in O
agreement O
with O
data O
from O
knock-in O
mice O
with O
mutation O
of O
the O
ethanol-sensitive O
site O
in O
the O
α2-subunit O
(Blednov O
et O
al. O
, O
2011) O
. O
All O
together O
, O
they O
indicate O
that O
aversive O
property O
of O
ethanol O
is O
dependent O
on O
ethanol O
action O
on O
α2-containing O
GABA(A)-R O
. O
Deletion O
of O
the O
α2-subunit O
led O
to O
faster O
recovery O
whereas O
absence O
of O
the O
α3-subunit O
slowed O
recovery O
from O
ethanol-induced O
incoordination O
(rotarod) O
. O
Deletion O
of O
the O
other O
four O
subunits O
did O
not O
affect O
this O
behavior O
. O
Similar O
changes O
in O
this O
behavior O
for O
the O
α2 O
and O
α3 O
null O
mutants O
were O
found O
for O

alcohol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Linking O
GABA(A) B
receptor I
subunits O
to O
alcoho O
-induced O
conditioned O
taste O
aversion O
and O
recovery O
from O
acute O
alcohol O
intoxication.GABA O
type O
A O
receptors O
(GABA(A)-R) O
are O
important O
for O
ethanol O
actions O
and O
it O
is O
of O
interest O
to O
link O
individual O
subunits O
with O
specific O
ethanol O
behaviors O
. O
We O
studied O
null O
mutant O
mice O
for O
six O
different O
GABA(A)-R O
subunits O
(α1 O
, O
α2 O
, O
α3 O
, O
α4 O
, O
α5 O
and O
δ) O
. O

As(III) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
receptors O
were O
85% O
effective O
. O
In O
contrast O
, O
antagonists O
to O
the O
sphingosine-1-phosphate O
type O
1 O
receptor O
(previously O
shown O
to O
mediate O
As(III) O
vascular O
effects) O
or O
the O
angiotensin O
II O
type O
1 O
receptor O
were O
ineffective O
in O
blocking O
As(III) O
effects O
. O
These O
studies O
suggest O
a O
majority O
of O
arsenic-inhibited O
adipocyte O
differentiation O
, O
and O
metabolism O
requires O
endothelin-1 O
GPCRs O
and O
that O
As(III) O
effects O
on O
GPCR B
signaling O
are O
tissue O
and O
context O
specific O
. O
This O
may O
represent O
a O
significant O
mechanism O
for O
the O
contribution O
of O
arsenic O
exposure O
to O
increased O
metabolic O
and O
cardiovascular O
diseases O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
40% O
of O
the O
genes O
of O
the O
epidermal O
differentiation O
complex O
found O
on O
chromosome O
1q21 O
and O
75% O
of O
the O
genes O
required O
for O
de O
novo O
ceramide O
biosynthesis O
. O
Lipid O
analysis O
demonstrated O
that O
eight O
of O
the O
nine O
classes O
of O
ceramides O
were O
increased O
by O
TCDD O
, O
altering O
the O
ratio O
of O
ceramides O
to O
free O
fatty O
acids O
. O
TCDD O
decreased O
the O
expression O
of O
the O
glucose O
transporter O
, O
SLC2A1 O
, O
and O
most O
of O
the O
glycolytic O
transcripts O
, O
followed O
by O
decreases O
in O
glycolytic O
intermediates O
, O
including O
pyruvate O
. O
NADH O
and O
Krebs O
cycle O
intermediates O
were O
decreased O
, O
whereas O
NAD(+) O
was O
increased O
. O
Mitochondrial O
glutathione O
(GSH) O
reductase O
activity O
and O
the O
GSH/glutathione O
disulfide O
ratio O
were O
decreased O
by O
TCDD O
, O
ultimately O
leading O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
40% O
of O
the O
genes O
of O
the O
epidermal O
differentiation O
complex O
found O
on O
chromosome O
1q21 O
and O
75% O
of O
the O
genes O
required O
for O
de O
novo O
ceramide O
biosynthesis O
. O
Lipid O
analysis O
demonstrated O
that O
eight O
of O
the O
nine O
classes O
of O
ceramides O
were O
increased O
by O
TCDD O
, O
altering O
the O
ratio O
of O
ceramides O
to O
free O
fatty O
acids O
. O
TCDD O
decreased O
the O
expression O
of O
the O
glucose O
transporter O
, O
SLC2A1 O
, O
and O
most O
of O
the O
glycolytic O
transcripts O
, O
followed O
by O
decreases O
in O
glycolytic O
intermediates O
, O
including O
pyruvate O
. O
NADH O
and O
Krebs O
cycle O
intermediates O
were O
decreased O
, O
whereas O
NAD(+) O
was O
increased O
. O
Mitochondrial O
glutathione O
(GSH) O
reductase O
activity O
and O
the O
GSH/glutathione O
disulfide O
ratio O
were O
decreased O
by O
TCDD O
, O
ultimately O
leading O

TCDD O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
fatty O
acids O
. O
TCDD O
decreased O
the O
expression O
of O
the O
glucose O
transporter O
, O
SLC2A1 O
, O
and O
most O
of O
the O
glycolytic O
transcripts O
, O
followed O
by O
decreases O
in O
glycolytic O
intermediates O
, O
including O
pyruvate O
. O
NADH O
and O
Krebs O
cycle O
intermediates O
were O
decreased O
, O
whereas O
NAD(+) O
was O
increased O
. O
Mitochondrial O
glutathione B
(GSH) I
reductase I
activity O
and O
the O
GSH/glutathione O
disulfide O
ratio O
were O
decreased O
by O
TCDD O
ultimately O
leading O
to O
mitochondrial O
dysfunction O
, O
characterized O
by O
decreased O
inner O
mitochondrial O
membrane O
potential O
and O
ATP O
production O
, O
and O
increased O
production O
of O
the O
reactive O
oxygen O
species O
(ROS) O
, O
hydrogen O
peroxide O
. O
Aryl O
hydrocarbon O
receptor O
(AHR) O
antagonists O
blocked O
the O
response O
of O
many O
transcripts O
to O
TCDD O
, O
and O
the O
endpoints O
of O
decreased O
ATP O
production O
and O
differentiation O
, O
suggesting O

polyinosinic:polycytidylic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 O
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 O
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 O
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β O
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN B
to O
promote O
IL-22-induced O
STAT1 O
activation O
and O
expression O
of O
CXCL10 O
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O

polyinosinic:polycytidylic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 B
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 O
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 O
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β O
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN O
to O
promote O
IL-22-induced O
STAT1 O
activation O
and O
expression O
of O
CXCL10 O
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O

polyinosinic:polycytidylic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 O
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 B
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 O
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β O
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN O
to O
promote O
IL-22-induced O
STAT1 O
activation O
and O
expression O
of O
CXCL10 O
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O

polyinosinic:polycytidylic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 O
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 O
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 B
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β O
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN O
to O
promote O
IL-22-induced O
STAT1 O
activation O
and O
expression O
of O
CXCL10 O
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O

polyinosinic:polycytidylic O
acid O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that O
, O
upon O
IFNα O
, O
IL-22 O
converts O
into O
a O
cytokine O
robustly O
activating O
STAT1 O
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9 O
, O
CXCL10 O
, O
and O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
. O
Accordingly O
, O
only O
after O
IFNα O
pre-incubation O
was O
IL-22-induced O
STAT1 O
binding O
to O
the O
CXCL10 O
promoter O
detectable O
. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic O
acid O
and O
the O
IFNα/β B
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN O
to O
promote O
IL-22-induced O
STAT1 O
activation O
and O
expression O
of O
CXCL10 O
. O
IL-22-induced O
STAT1 O
activation O
subsequent O
to O
IFNα O
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells O
, O
HepG2 O
hepatoma O
cells O
, O
and O
primary O
keratinocytes O
. O
Current O
observations O
may O
relate O
to O

Glutaraldehyde O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Nanobody-albumin O
nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase O
inhibitor O
17864 O
to O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin B
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O

methionine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase O
inhibitor O
17864 O
to O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin B
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive O
14C O
squamous O
head O

polyethylene O
glycol O
acts O
as O
PART-OF O
for O
what O
entity O
? O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin B
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive O
14C O
squamous O
head O
and O
neck O
cancer O
cells O
in O
comparison O
to O
PEGylated O
nanoparticles O
. O
17864-L(x) O
loaded O
EGa1-PEG O
nanoparticles O
were O
internalized O
by O
clathrin-mediated O
endocytosis O

PEG O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin B
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
( O
PEG O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive O
14C O
squamous O
head O
and O
neck O
cancer O
cells O
in O
comparison O
to O
PEGylated O
nanoparticles O
. O
17864-L(x) O
loaded O
EGa1-PEG O
nanoparticles O
were O
internalized O
by O
clathrin-mediated O
endocytosis O
and O
ultimately O

17864 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nanobody-albumin O
nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase B
inhibitor O
1786 O
to O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864-L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O

17864 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nanobody-albumin O
nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase B
inhibitor O
17864 O
to O
EGFR O
overexpressing O
tumor O
cells.A O
novel O
, O
EGFR-targeted O
nanomedicine O
has O
been O
developed O
in O
the O
current O
study O
. O
Glutaraldehyde O
crosslinked O
albumin O
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase O
inhibitor O
17864 O
L(x)-a O
platinum-bound O
sunitinib O
analogue-which O
couples O
the O
drug O
to O
methionine O
residues O
of O
albumin O
and O
is O
released O
in O
a O
reductive O
environment O
. O
Albumin O
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene O
glycol O
3500 O
(PEG) O
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal O
growth O
factor O
receptor O
(EGFR) O
. O
EGa1-PEG O
functionalized O
nanoparticles O
showed O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves B
a I
1 I
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly O
X-Ser-X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves B
a I
1 I
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly-X- O
Ser O
X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
rat O
pancreatic O
lipase-related O
protein O
2 O
(1bu8A) O
as O
a O
template O
because O
it O
has O
PLA(1) O
activity O
, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β O
hydrolase O
fold O
family O
. O
The O
Ves B
a I
1 I
structure O
, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands O
, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif O
, O
which O
contains O
the O
Gly-X-Ser-X- O
Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O

proline O
acts O
as O
PART-OF O
for O
what O
entity O
? O
structural O
motif O
, O
which O
contains O
the O
Gly-X-Ser-X-Gly O
consensus O
sequence O
. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves B
a I
1 I
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O
the O
Ves O
a O
1 O
structure O
is O
rare O
. O
We O
therefore O
propose O
that O
this O
proline O
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves O
a O
1s O
. O

proline O
acts O
as O
PART-OF O
for O
what O
entity O
? O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves O
a O
1 O
structure O
, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase O
activity O
. O
Moreover O
, O
the O
observed O
insertion O
of O
proline O
into O
the O
lid O
domain O
of O
the O
Ves O
a O
1 O
structure O
is O
rare O
. O
We O
therefore O
propose O
that O
this O
proline O
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves O
a O
1s O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
found O
in O
the O
toxicities O
of O
the O
different O
isoforms O
. O
Furthermore O
, O
the O
toxicity O
of O
these O
enzymes O
does O
not O
appear O
to O
be O
correlated O
with O
their O
PLA(1) O
activity O
. O
The O
cDNAs O
of O
the O
full-length O
version O
of O
Ves B
a I
1s I
revealed O
that O
the O
Ves O
a O
1 O
gene O
consists O
of O
a O
1005-bp O
ORF O
, O
which O
encodes O
334 O
amino O
acid O
residues O
, O
and O
67- O
and O
227-bp O
5' O
and O
3' O
UTRs O
, O
respectively O
. O
The O
two O
isoforms O
are O
different O
by O
three O
nucleotide O
substitutions O
, O
resulting O
in O
the O
replacement O
of O
two O
amino O
acids O
. O
Through O
sequence O
alignment O
, O
these O
enzymes O
were O
classified O
as O
members O
of O
the O
pancreatic O
lipase O
family O
. O
The O
structural O
modelling O
of O
Ves O
a O
1 O
used O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
found O
in O
the O
toxicities O
of O
the O
different O
isoforms O
. O
Furthermore O
, O
the O
toxicity O
of O
these O
enzymes O
does O
not O
appear O
to O
be O
correlated O
with O
their O
PLA(1) O
activity O
. O
The O
cDNAs O
of O
the O
full-length O
version O
of O
Ves O
a O
1s O
revealed O
that O
the O
Ves B
a I
1 I
gene O
consists O
of O
a O
1005-bp O
ORF O
, O
which O
encodes O
334 O
amino O
acid O
residues O
, O
and O
67- O
and O
227-bp O
5' O
and O
3' O
UTRs O
, O
respectively O
. O
The O
two O
isoforms O
are O
different O
by O
three O
nucleotide O
substitutions O
, O
resulting O
in O
the O
replacement O
of O
two O
amino O
acids O
. O
Through O
sequence O
alignment O
, O
these O
enzymes O
were O
classified O
as O
members O
of O
the O
pancreatic O
lipase O
family O
. O
The O
structural O
modelling O
of O
Ves O
a O
1 O
used O

HSYA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB B
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

HSYA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 B
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

HSYA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(HSYA) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O

HSYA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(HSYA) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O

HSYA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(HSYA) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O

HSYA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(HSYA) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β B
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O

HSYA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(HSYA) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 B
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O

HSYA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(HSYA) O
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L O
. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA O
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O

HSYA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 B
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

HSYA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated B
protein I
kinase I
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

HSYA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 B
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

HSYA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
human O
alveolar O
epithelial O
A549 O
cells O
. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O
of O
HSYA O
(1 O
, O
4 O
and O
16μmol/L) O
. O
HSYA O
suppressed O
the O
expression O
of O
TLR-4 O
, O
Myd88 O
, O
ICAM-1 O
, O
TNFα O
, O
IL-1β O
and O
IL-6 O
at O
the O
mRNA O
and O
protein O
level O
, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells O
. O
HSYA O
treatment O
also O
decreased O
NF-κB O
p65 O
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
(p38 O
MAPK) O
. O
These O
findings O
suggest O
that O
HSYA O
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells O
. O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
play O
an O
important O
role O
in O
this O
process O
. O
Diazepam-binding O
inhibitor O
(DBI) O
and O
its O
processing O
product O
the O
octadecaneuropeptide O
(ODN) O
, O
collectively O
named O
endozepines O
, O
are O
secreted O
by O
astroglia O
, O
and O
ODN O
is O
a O
potent O
anorexigenic O
factor O
. O
Therefore O
, O
we O
investigated O
the O
involvement O
of O
endozepines O
in O
brain O
glucose O
sensing O
. O
First O
, O
we O
showed O
that O
intracerebroventricular O
administration O
of O
glucose O
in O
rats O
increases O
DBI B
expression O
in O
hypothalamic O
glial-like O
tanycytes O
. O
We O
then O
demonstrated O
that O
glucose O
stimulates O
endozepine O
secretion O
from O
hypothalamic O
explants O
. O
Feeding O
experiments O
indicate O
that O
the O
anorexigenic O
effect O
of O
central O
administration O
of O
glucose O
was O
blunted O
by O
coinjection O
of O
an O
ODN O
antagonist O
. O
Conversely O
, O
the O
hyperphagic O
response O
elicited O
by O
central O
glucoprivation O
was O

cinobufagin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
glycogen O
synthase O
kinase-3β/nuclear O
factor-kappa O
B O
pathway O
is O
involved O
in O
cinobufagi O
-induced O
apoptosis O
in O
cultured O
osteosarcoma O
cells.Cinobufagin O
, O
a O
major O
component O
of O
cinobufacini O
(huachansu) O
, O
is O
an O
important O
cardenolidal O
steroid O
. O
Several O
studies O
have O
suggested O
that O
cinobufagin O
has O
potent O
anti-cancer O
effects O
. O
The O
present O
study O
examines O
the O
apoptosis-inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin O
in O
osteosarcoma O
(OS) O
cells O
. O
Our O
results O
showed O

cinobufagin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
glycogen O
synthase O
kinase-3β/nuclear O
factor-kappa O
B O
pathway O
is O
involved O
in O
cinobufagi O
-induced O
apoptosis O
in O
cultured O
osteosarcoma O
cells.Cinobufagin O
, O
a O
major O
component O
of O
cinobufacini O
(huachansu) O
, O
is O
an O
important O
cardenolidal O
steroid O
. O
Several O
studies O
have O
suggested O
that O
cinobufagin O
has O
potent O
anti-cancer O
effects O
. O
The O
present O
study O
examines O
the O
apoptosis-inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin O
in O
osteosarcoma O
(OS) O
cells O
. O
Our O
results O
showed O

cinobufagin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin O
induced O
apoptosis O
. O

cinobufagin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin O
induced O
apoptosis O
. O

cinobufagin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
while O
the O
phosphorylation O
of O
GSK-3β B
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O

cinobufagin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O

cinobufagin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

SB216367 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β B
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
apoptosis O
in O
OS O
cells O
were O
also O
observed O
. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 O
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
in O
U2OS O
cells O
. O
Among O
them O
, O
xIAP O
, O
cIAP-1 O
, O
survivin O
and O
Bcl-2 O
levels O
decreased O
remarkably O
, O
while O
the O
levels O
of O
Bax O
and O
cleaved-PARP O
increased O
. O
Furthermore O
, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB O
signaling O
following O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cinobufagin O
treatment O
. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O

cinobufagin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
decrease O
in O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

SB216367 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
nuclear O
p65 B
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin O
, O
while O
the O
phosphorylation O
of O
GSK-3β O
was O
simultaneously O
increased O
. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β O
could O
protect O
against O
the O
downregulation O
of O
p65 O
and O
upregulation O
of O
cleaved-PARP O
that O
are O
induced O
by O
cinobufagin O
treatment O
. O
However O
, O
combined O
treatment O
with O
cinobufagin O
and O
SB216367 O
resulted O
in O
a O
significant O
reduction O
in O
p65 O
and O
an O
increase O
in O
cleaved-PARP O
in O
U2OS O
cells O
. O
Altogether O
, O
these O
results O
show O
that O
cinobufagin O
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS O
. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB O
pathway O
in O
cinobufagin-induced O
apoptosis O
. O

furanopyrimidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
structure O
of O
Aurora O
kinase O
A O
suggests O
the O
potential O
to O
improve O
the O
activity O
of O
the O
ligands O
by O
decreasing O
the O
steric O
clash O
with O
Val147 O
and O
Leu139 O
and O
by O
increasing O
hydrophobic O
contact O
with O
Leu139 O
and O
Gly216 O
residues O
in O
the O
solvent-exposed O
region O
of O
the O
enzyme O
. O
Based O
on O
these O
suggestions O
, O
the O
rational O
redesign O
of O
furanopyrimidine O
24 O
(clog O
P=7.41; O
Aurora O
A O
IC(50) O
=43 O
nM; O
HCT-116 O
IC(50) O
=400 O
nM) O
led O
to O
the O
identification O
of O
quinazoline O
67 O
(clog O
P=5.28; O
Aurora O
A O
IC(50) O
=25 O
nM; O
HCT-116 O
IC(50) O
=23 O
nM) O
. O
Rat O
in O
vivo O
pharmacokinetic O
studies O
showed O
that O
67 O
has O
better O
systemic O
exposure O
after O
i.v O
. O
administration O
than O
24 O
, O
and O
holds O

quinazoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
steric O
clash O
with O
Val147 O
and O
Leu139 O
and O
by O
increasing O
hydrophobic O
contact O
with O
Leu139 O
and O
Gly216 O
residues O
in O
the O
solvent-exposed O
region O
of O
the O
enzyme O
. O
Based O
on O
these O
suggestions O
, O
the O
rational O
redesign O
of O
furanopyrimidine O
24 O
(clog O
P=7.41; O
Aurora O
A O
IC(50) O
=43 O
nM; O
HCT-116 O
IC(50) O
=400 O
nM) O
led O
to O
the O
identification O
of O
quinazoline O
67 O
(clog O
P=5.28; O
Aurora O
A O
IC(50) O
=25 O
nM; O
HCT-116 O
IC(50) O
=23 O
nM) O
. O
Rat O
in O
vivo O
pharmacokinetic O
studies O
showed O
that O
67 O
has O
better O
systemic O
exposure O
after O
i.v O
. O
administration O
than O
24 O
, O
and O
holds O
potential O
for O
further O
development O
. O

pyrazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
a O
potent O
quinazoline-based O
Aurora O
kinase O
inhibitor.We O
describe O
the O
3D-QSAR-assisted O
design O
of O
an O
Aurora O
kinase O
A O
inhibitor O
with O
improved O
physicochemical O
properties O
, O
in O
vitro O
activity O
, O
and O
in O
vivo O
pharmacokinetic O
profiles O
over O
those O
of O
the O
initial O
lead O
. O
Three O
different O
3D-QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole O
(Model O
I) O
and O
furanopyrimidine O
(Model O
II) O
compounds O
with O
IC(50) O
values O
toward O
Aurora O
kinase O
A O
ranging O
from O
33 O
nM O
to O
10.5 O
μM O
. O
The O
best O
3D-QSAR O
model O
, O
Model O
III O
, O
constructed O
with O
24 O
training O
set O
compounds O
from O
both O
series O
, O
showed O
robustness O
(r(2) O
(CV) O
=0.54 O
and O
0.52 O
for O
CoMFA O
and O
CoMSIA O
, O
respectively) O
and O

furanopyrimidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Aurora O
kinase O
inhibitor.We O
describe O
the O
3D-QSAR-assisted O
design O
of O
an O
Aurora O
kinase O
A O
inhibitor O
with O
improved O
physicochemical O
properties O
, O
in O
vitro O
activity O
, O
and O
in O
vivo O
pharmacokinetic O
profiles O
over O
those O
of O
the O
initial O
lead O
. O
Three O
different O
3D-QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole O
(Model O
I) O
and O
furanopyrimidine O
(Model O
II) O
compounds O
with O
IC(50) O
values O
toward O
Aurora O
kinase O
A O
ranging O
from O
33 O
nM O
to O
10.5 O
μM O
. O
The O
best O
3D-QSAR O
model O
, O
Model O
III O
, O
constructed O
with O
24 O
training O
set O
compounds O
from O
both O
series O
, O
showed O
robustness O
(r(2) O
(CV) O
=0.54 O
and O
0.52 O
for O
CoMFA O
and O
CoMSIA O
, O
respectively) O
and O
superior O
predictive O
capacity O
for O

quinazoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
3D-QSAR-assisted O
drug O
design O
: O
identification O
of O
a O
potent O
quinazolin O
-based O
Aurora B
kinase I
inhibitor.We O
describe O
the O
3D-QSAR-assisted O
design O
of O
an O
Aurora O
kinase O
A O
inhibitor O
with O
improved O
physicochemical O
properties O
, O
in O
vitro O
activity O
, O
and O
in O
vivo O
pharmacokinetic O
profiles O
over O
those O
of O
the O
initial O
lead O
. O
Three O
different O
3D-QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole O
(Model O
I) O

arginine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O

arginine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O

arginine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc B
inhibitory O
activity O
further O
still O
. O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc O
inhibitory O
activity O
further O
still O
. O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc O
inhibitory O
activity O
further O
still O
. O

JY-3-094 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc O
inhibitory O
activity O
further O
still O
. O

10074-G5 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
( O
N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O

10074-G5 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G O
.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O

JY-3-094 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 O
(3q) O
. O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max O
heterodimer O
, O
JY-3-094 O
demonstrated O
excellent O
selectivity O
over O
Max-Max O
homodimers O
, O
with O
no O
apparent O
effect O
at O
100 O
μM O
. O
Importantly O
, O
the O
carboxylic O
acid O
of O
JY-3-094 O
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound O
, O
which O
will O
facilitate O
the O
incorporation O
of O
additional O
hydrophobicity O
that O
might O
enhance O
Myc B
inhibitory O
activity O
further O
still O
. O

10074-G5 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O

10074-G5 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
, O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc B
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
( O
N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc O
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O

N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacophore O
identification O
of O
c-Myc O
inhibitor O
10074-G5.A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc O
(Myc) O
inhibitor O
10074-G5 O
( O
N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine O
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B
oncoprotein O
that O
is O
flanked O
by O
arginine O
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore O
. O
Whilst O
the O
7-nitrobenzofurazan O
was O
found O
to O
be O
critical O
for O
inhibitory O
activity O
, O
the O
ortho-biphenyl O
could O
be O
replaced O
with O
a O
para-carboxyphenyl O
group O
to O
furnish O
the O

paraoxon O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
preventing O
entry O
into O
the O
circulation O
and O
inhibition O
of O
plasma O
BChE O
and O
AChE O
on O
red O
blood O
cells O
(RBC-AChE) O
and O
in O
cholinergic O
synapses O
. O
In O
contrast O
to O
parenteral O
delivery O
of O
rBChE O
, O
which O
currently O
requires O
posttranslational O
modification O
for O
good O
plasma O
stability O
, O
an O
unmodified O
aer-rBChE O
pretreatment O
given O
1-40h O
prior O
to O
>1 O
LD50 O
of O
aer- O
paraoxon O
(Px) O
was O
able O
to O
prevent O
inhibition O
of O
circulating O
cholinesterase B
in O
a O
dose-dependent O
manner O
. O
These O
studies O
are O
the O
first O
to O
show O
protection O
by O
rBChE O
against O
a O
pesticide O
such O
as O
paraoxon O
when O
delivered O
directly O
into O
the O
lung O
and O
bode O
well O
for O
the O
use O
of O
a O
non-invasive O
and O
consumer O
friendly O
method O
of O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH B
and O
MDA O
increase O
, O
SOD O
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ozone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
histopathological O
analyses O
. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP O
, O
MDA O
, O
CK O
, O
ET-1 O
and O
SBP O
and O
decrease O
of O
heart O
rate O
variability O
(HRV) O
, O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function O
. O
Ozone O
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators O
. O
Ozone O
plus O
PM(2.5) O
exposure O
, O
however O
, O
induced O
CRP O
, O
IL-6 O
, O
CK O
, O
LDH O
and O
MDA O
increase O
, O
SOD B
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way O
. O
Meanwhile O
, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone O
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM O
. O
In O
conclusion O
, O
PM(2.5) O
alone O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Pak1(-/-) O
mice O
, O
associated O
with O
impaired O
glucose O
tolerance O
after O
an O
ip O
or O
oral O
glucose O
challenge O
. O
These O
mice O
had O
lower O
circulating O
active O
GLP-1 O
levels O
after O
a O
glucose O
challenge O
as O
well O
as O
reduced O
distal O
ileum O
GLP-1 O
content O
after O
insulin O
treatment O
. O
Finally O
, O
the O
Pak1(-/-) O
mice O
exhibited O
reduced O
brainstem O
gcg O
level O
and O
abolished O
β-cat B
Ser O
75 O
phosphorylation O
in O
brain O
neurons O
after O
insulin O
treatment O
. O
We O
suggest O
that O
Pak1 O
mediates O
the O
cross O
talk O
between O
insulin O
and O
Wnt O
signaling O
pathways O
on O
gut O
and O
brain O
gcg O
expression O
, O
and O
its O
ablation O
impairs O
glucose O
homeostasis O
. O

Thr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
proglucagon O
(gcg) O
expression O
and O
glucagon-like O
peptide-1 O
(GLP-1) O
production O
. O
In O
several O
other O
cell O
lineages O
, O
insulin O
is O
able O
to O
stimulate O
p21-activated O
protein O
kinase O
1 O
(Pak1) O
. O
Here O
we O
determined O
the O
role O
of O
Pak1 B
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr O
23 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak O
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
(IPA3) O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O
cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O
attenuated O
by O
IPA3 O
or O
protein O
kinase O
A O
inhibition O
, O
respectively O
. O
Gut O
gcg O
levels O

2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
1 O
(Pak1) O
. O
Here O
we O
determined O
the O
role O
of O
Pak1 O
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr423 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak B
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
(IPA3) O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O
cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O
attenuated O
by O
IPA3 O
or O
protein O
kinase O
A O
inhibition O
, O
respectively O
. O
Gut O
gcg O
levels O
were O
reduced O
in O
male O
Pak1(-/-) O
mice O
, O
associated O
with O
impaired O
glucose O
tolerance O
after O
an O
ip O
or O
oral O
glucose O
challenge O
. O
These O
mice O
had O
lower O

IPA3 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Here O
we O
determined O
the O
role O
of O
Pak1 O
in O
gcg O
expression O
and O
the O
effect O
of O
Pak1 O
deletion O
on O
glucose O
homeostasis O
. O
Insulin O
stimulated O
Pak1 O
activation O
through O
increasing O
its O
Thr423 O
phosphorylation O
in O
gut O
gcg-expressing O
cell O
lines O
, O
associated O
with O
increased O
gcg O
mRNA O
levels O
. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak B
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide O
( O
IPA3 O
or O
dominant-negative O
Pak1 O
. O
Both O
insulin O
and O
cAMP-promoting O
agents O
activated O
β-cat O
Ser675 O
phosphorylation O
, O
which O
was O
attenuated O
by O
IPA3 O
or O
protein O
kinase O
A O
inhibition O
, O
respectively O
. O
Gut O
gcg O
levels O
were O
reduced O
in O
male O
Pak1(-/-) O
mice O
, O
associated O
with O
impaired O
glucose O
tolerance O
after O
an O
ip O
or O
oral O
glucose O
challenge O
. O
These O
mice O
had O
lower O
circulating O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
FUT9) O
to O
selectin-ligand O
biosynthesis O
were O
evaluated O
. O
The O
cell O
adhesion O
properties O
of O
these O
modified O
cells O
to O
L- O
, O
E- O
, O
and O
P-selectin O
under O
hydrodynamic O
shear O
were O
compared O
with O
bone O
marrow-derived O
neutrophils O
from O
Fut4(-/-)Fut7(-/-) O
dual O
knock-out O
mice O
. O
Results O
demonstrate O
that O
predominantly O
FUT7 O
, O
and O
to O
a O
lesser O
extent O
FUT4 O
, O
forms O
the O
selectin-ligand O
at O
the O
N O
terminus O
of O
leukocyte O
P-selectin B
glycoprotein I
ligand-1 I
(PSGL-1) O
in O
humans O
and O
mice O
. O
Here O
, O
85% O
reduction O
in O
leukocyte O
interaction O
was O
observed O
in O
human O
FUT4(-)7(-) O
dual O
knockdowns O
on O
P/L-selectin O
substrates O
. O
Unlike O
Fut4(-/-)Fut7(-/-) O
mouse O
neutrophils O
, O
however O
, O
human O
knockdowns O
lacking O
FUT4 O
and O
FUT7 O
only O
exhibited O
partial O
reduction O
in O
rolling O
interaction O
on O
E-selectin O
. O
In O
this O

α-MeDA O
acts O
as O
NOT O
for O
what O
entity O
? O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α- O
MeDA O
s O
owed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine B
synthetase I
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O

α-MeDA O
acts O
as O
NOT O
for O
what O
entity O
? O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α- O
MeDA O
s O
owed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O

MDMA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
contributors O
for O
MDMA O
neurotoxicity O
. O
This O
work O
studied O
the O
neurotoxicity O
of O
MDMA O
and O
its O
catechol O
metabolites O
, O
α-methyldopamine O
(α-MeDA) O
and O
N-methyl-α-methyldopamine O
(N-Me-α-MeDA) O
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic O
acid O
and O
12-O-tetradecanoyl-phorbol-13-acetate O
. O
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine O
and O
higher O
resistance O
towards O
dopamine O
neurotoxicity O
. O
MD O
MA O
c O
techol O
metabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons O
, O
leading O
to O
caspase O
3-independent O
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O

catechol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
for O
MDMA O
neurotoxicity O
. O
This O
work O
studied O
the O
neurotoxicity O
of O
MDMA O
and O
its O
catechol O
metabolites O
, O
α-methyldopamine O
(α-MeDA) O
and O
N-methyl-α-methyldopamine O
(N-Me-α-MeDA) O
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic O
acid O
and O
12-O-tetradecanoyl-phorbol-13-acetate O
. O
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine O
and O
higher O
resistance O
towards O
dopamine O
neurotoxicity O
. O
MDMA O
ca O
techol O
m O
tabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons O
, O
leading O
to O
caspase O
3-independent O
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O

BSO O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BS O
O) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O
pre-treatment O
of O
cells O
with O
BSO O
augmented O
N-Me-α-MeDA-induced O
neurotoxicity O
, O

GBR O
12909 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
death O
in O
a O
concentration- O
and O
time-dependent O
manner O
. O
MDMA O
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death O
. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione O
precursor O
, O
N-acetylcysteine O
(NAC) O
, O
resulted O
in O
strong O
protection O
against O
the O
MDMA O
metabolites' O
neurotoxicity O
. O
Neither O
the O
superoxide O
radical O
scavenger O
, O
tiron O
, O
nor O
the O
inhibitor O
of O
the O
dopamine O
(DA) O
transporter O
, O
GB O
R O
12909 O
, O
revented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
buthionine O
sulfoximine O
(BSO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O

buthionine O
sulfoximine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
dopamine O
(DA) O
transporter O
, O
GBR O
12909 O
, O
prevented O
the O
metabolites' O
toxicity O
. O
Cells O
exposed O
to O
α-MeDA O
showed O
an O
increase O
in O
intracellular O
glutathione O
(GSH) O
levels O
, O
which O
, O
at O
the O
48 O
h O
time-point O
, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine O
synthetase O
(γ-GCS) O
, O
revealing O
a O
possible O
transient O
effect O
. O
Importantly O
, O
pre-treatment O
with O
bu O
thionine O
sulfoximine O
( O
SO) O
, O
an O
inhibitor O
of O
γ-GCS O
, O
prevented O
α-MeDA O
induced O
increase O
in O
GSH O
levels O
, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity O
. O
Even O
so O
, O
BSO O
pre-treatment O
abolished O
NAC O
protective O
effects O
against O
α-MeDA O
neurotoxicity O
, O
which O
were O
, O
at O
least O
partially O
, O
due O
to O
GSH O
de O
novo O
synthesis O
. O
Inversely O
, O
pre-treatment O
of O
cells O
with O
BSO O
augmented O

sodium O
selenite O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA B
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

sodium O
selenite O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

sodium O
selenite O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx O
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

sodium O
selenite O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
neonatal O
rats O
before O
eyelid O
opening O
. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite O
cataract O
formation O
in O
rats O
, O
mRNA O
expression O
of O
GPx1 O
, O
MsrA O
and O
MsrB1 O
, O
as O
well O
as O
GPx B
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed O
, O
level O
of O
lipid O
peroxidation O
, O
extent O
of O
lens O
damage O
induced O
by O
sodium O
selenite O
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated O
. O
The O
results O
showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age O
, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum O
hydroxide O
as O
tracer O
that O
higher O

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 B
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration O
. O
(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O

KCA-1490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 B
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
( O
KCA-1490 O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N O
alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N O
alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O

pyridazinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O

pyridazinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O

6-aryl-4,5-dihydropyridazin-3(2H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O

6-aryl-4,5-dihydropyridazin-3(2H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N-alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 B
but O
suppresses O
PDE3 O
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N O
alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O
that O
suppress O
histamine-induced O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Phosphodiesterase O
inhibitors O
. O
Part O
5 O
: O
hybrid O
PDE3/4 O
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration.(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one O
(KCA-1490) O
exhibits O
moderate O
dual O
PDE3/4-inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent O
. O
N-alkylation O
of O
the O
pyridazinone O
ring O
markedly O
enhances O
potency O
against O
PDE4 O
but O
suppresses O
PDE3 B
inhibition O
. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one O
extension O
to O
the O
N O
alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O
Both O
dihydropyridazinone O
rings O
, O
in O
the O
core O
and O
extension O
, O
can O
be O
replaced O
by O
achiral O
4,4-dimethylpyrazolone O
subunits O
and O
the O
core O
pyrazolopyridine O
by O
isosteric O
bicyclic O
heteroaromatics O
. O
In O
combination O
, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 O
inhibitors O
that O
suppress O
histamine-induced O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
E2-conjugating O
enzyme O
, O
Ubc12 O
, O
to O
the O
ubiquitin O
ligase O
, O
XIAP O
or O
cIAP1 O
. O
This O
permits O
transfer O
of O
the O
rare O
ubiquitin O
homolog O
NEDD8 O
to O
the O
ubiquitin O
E3 O
substrates O
, O
allowing O
them O
to O
be O
efficiently O
purified O
for O
LC-MS/MS O
identification O
. O
We O
have O
identified O
>50 O
potential O
IAP B
substrates O
of O
both O
cytosolic O
and O
mitochondrial O
origin O
that O
bear O
hallmark O
N O
terminal O
IAP O
binding O
motifs O
. O
These O
substrates O
include O
the O
recently O
discovered O
protein O
phosphatase O
PGAM5 O
, O
which O
we O
show O
is O
proteolytically O
processed O
, O
accumulates O
in O
cytosol O
during O
apoptosis O
, O
and O
sensitizes O
cells O
to O
death O
. O
These O
studies O
reveal O
mechanisms O
and O
antagonistic O
partners O
for O
specific O
IAPs O
, O
and O
provide O
a O
powerful O
technology O
for O
labeling O
binding O
partners O
in O

benzimidazole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Identification O
of O
a O
novel O
benzimidazol O
derivative O
as O
a O
highly O
potent O
NPY B
Y5 I
receptor I
antagonist O
with O
an O
anti-obesity O
profile.Optimization O
of O
HTS O
hit O
1 O
for O
NPY O
Y5 O
receptor O
binding O
affinity O
, O
CYP450 O
inhibition O
, O
solubility O
and O
metabolic O
stability O
led O
to O
the O
identification O
of O
some O
orally O
available O
oxygen-linker O
derivatives O
for O
in O
vivo O
study O
. O
Among O
them O
, O
derivative O
4i O
inhibited O
food O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
is O
an O
unusual O
specialized O
DNA O
polymerase O
whose O
in O
vivo O
function O
is O
under O
active O
investigation O
. O
POLQ O
has O
been O
implicated O
by O
different O
experiments O
to O
play O
a O
role O
in O
resistance O
to O
ionizing O
radiation O
and O
defense O
against O
genomic O
instability O
, O
in O
base O
excision O
repair O
, O
and O
in O
immunological O
diversification O
. O
The O
protein O
is O
formed O
by O
an O
N O
terminal O
helicase-like O
domain O
, O
a O
C-terminal O
DNA O
polymerase O
domain O
, O
and O
a O
large O
central O
domain O
that O
spans O
between O
the O
two O
. O
This O
arrangement O
is O
also O
found O
in O
the O
Drosophila O
Mus308 O
protein O
, O
which O
functions O
in O
resistance O
to O
DNA O
interstrand O
crosslinking O
agents O
. O
Homologs O
of O
POLQ O
and O
Mus308 O
are O
found O
in O
multicellular O
eukaryotes O
, O
including O
plants O
, O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
DNA O
polymerase O
whose O
in O
vivo O
function O
is O
under O
active O
investigation O
. O
POLQ O
has O
been O
implicated O
by O
different O
experiments O
to O
play O
a O
role O
in O
resistance O
to O
ionizing O
radiation O
and O
defense O
against O
genomic O
instability O
, O
in O
base O
excision O
repair O
, O
and O
in O
immunological O
diversification O
. O
The O
protein O
is O
formed O
by O
an O
N-terminal O
helicase-like O
domain O
, O
a O
C O
terminal O
DNA O
polymerase O
domain O
, O
and O
a O
large O
central O
domain O
that O
spans O
between O
the O
two O
. O
This O
arrangement O
is O
also O
found O
in O
the O
Drosophila O
Mus308 O
protein O
, O
which O
functions O
in O
resistance O
to O
DNA O
interstrand O
crosslinking O
agents O
. O
Homologs O
of O
POLQ O
and O
Mus308 O
are O
found O
in O
multicellular O
eukaryotes O
, O
including O
plants O
, O
but O
a O
comparison O
of O

OMT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 B
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

OMT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA B
receptors I
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

OMT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cerebral O
artery O
occlusion O
and O
a O
24 O
h O
reperfusion O
, O
in O
vivo O
. O
In O
vitro O
cultured O
neurons O
challenged O
with O
N-methyl-D-aspartate O
(NMDA O
, O
200 O
μM) O
for O
30 O
min O
showed O
significant O
decrease O
in O
the O
viability O
of O
neurons; O
however O
, O
OMT O
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax B
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B O
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O

OMT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
N-methyl-D-aspartate O
(NMDA O
, O
200 O
μM) O
for O
30 O
min O
showed O
significant O
decrease O
in O
the O
viability O
of O
neurons; O
however O
, O
OMT O
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B B
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O

OMT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA O
exposure O
. O
Western O
blot O
analysis O
revealed O
that O
OMT O
decreased O
the O
expression O
of O
Bax O
and O
repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins O
. O
Furthermore O
, O
OMT O
significantly O
reversed O
the O
up-regulation O
of O
NR2B B
and O
inhibited O
the O
calcium O
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA O
. O
OMT O
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B O
containing O
NMDA O
receptors O
and O
up-regulation O
of O
Bcl-2 O
family O
. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia O
. O

BT-07-4M O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE B
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

TMB-4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
paraoxon O
and O
tabun O
inhibition O
. O
AChE B
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

obidoxime O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
tabun O
inhibition O
. O
AChE B
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

oximes O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

BT-05 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

BT-03 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
. O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

paraoxon O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat O
brain O
AChE B
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O

dichlorvos O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE B
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O
from O
symmetric O
oximes O
, O
and O
BT-05 O
and O
BT-03 O
possessing O
asymmetric O
structure O
. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE O
caused O
by O
dichlorvos O
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE O
, O
inhibited O
with O
this O
OPC O
, O
than O
asymmetric O
ones O
. O

dichlorvos O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
reactivators O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O

paraoxon O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
against O
OPC O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O

tabun O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
intoxication O
(tabun O
, O
paraoxon O
and O
dichlorvos) O
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes O
(obidoxime O
, O
HI-6 O
, O
2-PAM) O
. O
Experiments O
were O
carried O
out O
using O
rat O
brain O
acetylcholinesterase O
(AChE) O
. O
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B
brain I
AChE I
after O
dichlorvos O
, O
paraoxon O
and O
tabun O
inhibition O
. O
AChE O
was O
easier O
reactivated O
after O
paraoxon O
treatment O
. O
The O
best O
effect O
showed O
BT-07-4M O
, O
obidoxime O
, O
TMB-4 O
and O
BT-08 O
from O
the O
group O
of O
symmetric O
oximes O
, O
and O
Toxidin O
, O
BT-05 O
and O
BT-03 O
from O
asymmetric O
compounds O
. O
The O
reactivation O
of O
brain O
AChE O
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M O
, O
TMB-4 O
and O
obidoxime O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
uptake O
of O
TEA; O
however O
, O
uptake O
of O
phenformin O
into O
mitochondria O
of O
organic O
cation/carnitine O
transporter O
1 O
(OCTN1) O
knockout O
mice O
was O
lower O
than O
that O
in O
wild-type O
mice O
, O
whereas O
uptake O
of O
TEA O
was O
comparable O
between O
the O
two O
strains O
, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria O
. O
Inhibition O
by O
phenformin O
of O
oxygen O
consumption O
via O
complex B
I I
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Role O
of O
organic O
cation/carnitine O
transporter O
1 O
in O
uptake O
of O
phenformi O
and O
inhibitory O
effect O
on O
complex B
I I
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O

Phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Role O
of O
organic O
cation/carnitine O
transporter O
1 O
in O
uptake O
of O
phenformin O
and O
inhibitory O
effect O
on O
complex O
I O
respiration O
in O
mitochondria O
. O
Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O
I O
inhibition O
by O
phenformin O
were O
examined O
in O
isolated O
liver O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
whereas O
uptake O
of O
TEA O
was O
comparable O
between O
the O
two O
strains O
, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria O
. O
Inhibition O
by O
phenformin O
of O
oxygen O
consumption O
via O
complex B
I I
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex B
I I
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 O
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex O
I O
respiration O
. O
This O
study O
was O
, O
thus O
, O
the O
first O
to O
demonstrate O
OCTN1-mediated O
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents O
. O

phenformin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
complex B
I I
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O
I O
inhibition O
by O
phenformin O
were O
examined O
in O
isolated O
liver O
and O
heart O
mitochondria O
. O
Uptake O
of O
phenformin O
into O
isolated O
rat O
liver O
mitochondria O
was O
higher O
than O
that O
into O
heart O
mitochondria O
. O
It O
was O
inhibited O
by O
several O
cat O
ionic O
compounds O
, O
which O
suggests O
the O
involvement O
of O
multispecific O
transport O
system(s) O
. O
Similar O
characteristics O
were O
also O
observed O
for O
uptake O
of O
TEA; O
however O
, O

phenformin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Role O
of O
organic B
cation/carnitine I
transporter I
1 I
in O
uptake O
of O
phenformi O
and O
inhibitory O
effect O
on O
complex O
I O
respiration O
in O
mitochondria.Phenformin O
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial O
respiratory O
chain O
complex O
I O
. O
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver O
. O
In O
this O
study O
, O
uptake O
of O
phenformin O
and O
[(14)C]tetraethylammonium O
(TEA) O
and O
complex O

phenformin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
heart O
mitochondria O
, O
whereas O
inhibitory O
effect O
of O
phenformin O
on O
complex O
I O
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts O
. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin O
was O
weaker O
in O
octn1(-/-) O
mice O
than O
that O
in O
wild-type O
mice O
. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin O
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 B
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex O
I O
respiration O
. O
This O
study O
was O
, O
thus O
, O
the O
first O
to O
demonstrate O
OCTN1-mediated O
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents O
. O

carbohydrate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Results O
from O
the O
OmniHeart O
Trial.OBJECTIVE O
Impaired O
insulin B
sensitivity O
increases O
the O
risk O
of O
cardiovascular O
disease O
. O
Although O
calorie O
restriction O
and O
weight O
loss O
increase O
insulin O
sensitivity O
, O
the O
effects O
of O
modifying O
macronutrient O
composition O
on O
insulin O
sensitivity O
are O
uncertain O
. O
The O
purpose O
of O
this O
study O
is O
to O
determine O
the O
effects O
on O
insulin O
sensitivity O
of O
a O
carbohydrate O
rich O
diet O
(CARB; O
similar O
to O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
[DASH] O
diet) O
, O
a O
protein-rich O
diet O
(PROT; O
protein O
predominantly O
from O
plant O
sources) O
, O
and O
an O
unsaturated O
fat-rich O
diet O
(UNSAT; O
predominantly O
monounsaturated) O
. O
RESEARCH O
DESIGN O
AND O
METHODS O
This O
study O
was O
a O
randomized O
, O
controlled O
, O
three-period O
, O
crossover O
feeding O
study O
. O
The O
study O
participants O
were O
164 O

Carbohydrate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
Effects O
of O
Carbohydrat O
 O
, O
Unsaturated O
Fat O
, O
and O
Protein O
Intake O
on O
Measures O
of O
Insulin B
Sensitivity O
: O
Results O
from O
the O
OmniHeart O
Trial.OBJECTIVE O
Impaired O
insulin O
sensitivity O
increases O
the O
risk O
of O
cardiovascular O
disease O
. O
Although O
calorie O
restriction O
and O
weight O
loss O
increase O
insulin O
sensitivity O
, O
the O
effects O
of O
modifying O
macronutrient O
composition O
on O
insulin O
sensitivity O
are O
uncertain O
. O
The O
purpose O
of O
this O

carbohydrate O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
generalized O
estimating O
equations O
. O
RESULTS O
At O
baseline O
, O
mean O
(SD) O
BMI O
was O
30.2 O
(6.1) O
kg/m(2) O
, O
and O
mean O
(SD) O
QUICKI O
was O
0.35 O
(0.04) O
. O
The O
UNSAT O
diet O
increased O
QUICKI O
by O
0.005 O
, O
more O
than O
the O
CARB O
diet O
(P O
= O
0.04) O
. O
PROT O
had O
no O
significant O
effect O
compared O
with O
CARB O
. O
CONCLUSIONS O
A O
diet O
that O
partially O
replaces O
carbohydrate O
with O
unsaturated O
fat O
may O
improve O
insulin B
sensitivity O
in O
a O
population O
at O
risk O
for O
cardiovascular O
disease O
. O
Given O
the O
well-recognized O
challenges O
of O
sustaining O
weight O
loss O
, O
our O
results O
suggest O
an O
alternative O
approach O
for O
improving O
insulin O
sensitivity O
. O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak B
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine O
166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O

VK2 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O

VK2-2,3 O
epoxide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O

VK2 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak O
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O

VK2 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak B
in O
mitochondria-mediated O
apoptosis O
. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 O
and O
suggests O
that O
Bak O
may O
be O
a O
potential O
target O
of O
cancer O
therapy O
. O

VK2 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(VK2 O
, O
menaquinone) O
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo O
. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
the O
induction O
of O
apoptosis O
, O
the O
underlying O
molecular O
mechanism O
remains O
elusive O
. O
Here O
, O
we O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2 O
induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak B
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2-induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O

VK2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2 O
induced O
cytochrome B
c I
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O

VK2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
identified O
Bcl-2 O
antagonist O
killer O
1 O
(Bak) O
as O
a O
molecular O
target O
of O
VK2-induced O
apoptosis O
. O
VK2 O
directly O
interacts O
with O
Bak O
and O
induces O
mitochondrial-mediated O
apoptosis O
. O
Although O
Bak O
and O
Bcl-2-associated O
X O
protein O
(Bax) O
, O
another O
member O
of O
the O
Bcl-2 O
family O
, O
are O
generally O
thought O
to O
be O
functionally O
redundant O
, O
only O
Bak O
is O
necessary O
and O
sufficient O
for O
VK2 O
induced O
cytochrome O
c O
(cyt O
c) O
release O
and O
cell O
death O
. O
Moreover O
, O
VK2-2,3 O
epoxide O
, O
an O
intracellular O
metabolite O
of O
VK2 O
, O
was O
shown O
to O
covalently O
bind O
to O
the O
cysteine-166 O
residue O
of O
Bak O
. O
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 O
is O
critical O
for O
apoptosis O
induction O
. O
Thus O
this O
study O
reveals O
a O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
that O
deletion O
of O
either O
subunit O
of O
the O
CBC O
confers O
a O
synthetic O
growth O
defect O
when O
combined O
with O
deletion O
of O
genes O
encoding O
either O
Ctk2 O
or O
Bur2 O
, O
a O
component O
of O
the O
Saccharomyces O
cerevisiae O
ortholog O
of O
P-TEFb O
. O
The O
CBC O
physically O
associates O
with O
these O
complexes O
to O
recruit O
them O
during O
transcription O
and O
mediates O
phosphorylation O
at O
Ser O
2 O
of O
the O
C-terminal O
domain O
(CTD) O
of O
RNA O
polymerase O
II O
. O
To O
understand O
how O
these O
interactions O
influence O
downstream O
events O
, O
histone O
H3K36me3 O
was O
examined O
, O
and O
we O
demonstrate O
that O
CBCΔ O
affects O
proper O
Set2-dependent O
H3K36me3 O
. O
Consistent O
with O
this O
, O
the O
CBC O
and O
Set2 O
have O
similar O
effects O
on O
the O
ability O
to O
rapidly O
induce O
and O
sustain O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
either O
subunit O
of O
the O
CBC O
confers O
a O
synthetic O
growth O
defect O
when O
combined O
with O
deletion O
of O
genes O
encoding O
either O
Ctk2 O
or O
Bur2 O
, O
a O
component O
of O
the O
Saccharomyces O
cerevisiae O
ortholog O
of O
P-TEFb O
. O
The O
CBC O
physically O
associates O
with O
these O
complexes O
to O
recruit O
them O
during O
transcription O
and O
mediates O
phosphorylation O
at O
Ser-2 O
of O
the O
C O
terminal O
domain O
(CTD) O
of O
RNA O
polymerase O
II O
. O
To O
understand O
how O
these O
interactions O
influence O
downstream O
events O
, O
histone O
H3K36me3 O
was O
examined O
, O
and O
we O
demonstrate O
that O
CBCΔ O
affects O
proper O
Set2-dependent O
H3K36me3 O
. O
Consistent O
with O
this O
, O
the O
CBC O
and O
Set2 O
have O
similar O
effects O
on O
the O
ability O
to O
rapidly O
induce O
and O
sustain O
activated O
gene O
expression O
, O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His O
157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys O
113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 B
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys O
113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
. O
The O
present O
study O
establishes O
that O

HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O

HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O

8-alkynyl-HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O
site O
of O
HNE O
modification O
. O
Pin1 O
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O

HNE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
primary O
site O
of O
HNE O
modification O
. O
Pin1 B
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE O
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin O
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 O
antibody O
. O
Furthermore O
, O
orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 O
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
. O
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O

polyphenols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
MS O
data O
support O
the O
adduction O
of O
Cys-113 O
in O
the O
Pin1 B
active O
site O
upon O
HNE O
treatment O
of O
MDA-MB-231 O
cells O
. O
siRNA O
knockdown O
of O
Pin1 O
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced O
toxicity O
. O
Recent O
studies O
indicate O
that O
Pin1 O
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols O
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O
by O
products O
of O
lipid O
peroxidation O
. O

pSer O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
production O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

pSer O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
production O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
pThr-Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

pThr O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
/ O
pThr O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

pThr O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer O
/ O
pThr O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O

Pro O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl B
cis/trans-isomerase I
A1 I
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr- O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 O
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O

Pro O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
reactive O
aldehydes O
that O
adduct O
proteins O
and O
modulate O
their O
function O
. O
4-Hydroxynonenal O
(HNE) O
, O
a O
common O
product O
of O
oxidative O
damage O
to O
lipids O
, O
adducts O
proteins O
at O
exposed O
Cys O
, O
His O
, O
or O
Lys O
residues O
. O
Here O
, O
we O
demonstrate O
that O
peptidyl-prolyl O
cis/trans-isomerase O
A1 O
(Pin1) O
, O
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr- O
Pro O
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans O
, O
is O
highly O
susceptible O
to O
HNE O
modification O
. O
Incubation O
of O
purified O
Pin1 B
with O
HNE O
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 O
and O
Cys-113 O
. O
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 O
is O
the O
primary O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid B
receptors I
(GR) O
and O
mineralocorticoid O
receptors O
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid O
receptors O
(GR) O
and O
mineralocorticoid O
receptors O
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid O
receptors O
(GR) O
and O
mineralocorticoid B
receptors I
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
males O
has O
been O
largely O
neglected O
. O
Therefore O
, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen O
receptors O
α O
and O
β O
(ERα O
, O
β) O
in O
8-week-old O
, O
12-week-old O
and O
24-week-old O
male O
rats O
. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen O
receptor O
genes O
and O
other O
learning-related O
steroid O
receptors O
, O
androgen O
receptors O
(AR) O
, O
corticosterone O
binding O
glucocorticoid O
receptors O
(GR) O
and O
mineralocorticoid O
receptors O
(MR) O
were O
also O
measured O
. O
Furthermore O
, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol O
, O
testosterone O
and O
corticosterone O
were O
measured O
. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board O
. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
polymorphisms O
were O
associated O
with O
CYP2B6 B
activity O
. O
Evidence O
of O
dependence O
of O
CYP2B6 O
activity O
on O
ethnicity O
or O
genotype-by-ethnicity O
interactions O
was O
not O
detected O
in O
women O
. O
These O
results O
suggest O
that O
CYP2B6 O
genotype O
is O
the O
most O
important O
patient O
variable O
for O
predicting O
the O
level O
of O
CYP2B6 O
activity O
in O
women O
, O
when O
measured O
by O
the O
metabolism O
of O
bupropion O
The O
bupropion O
metabolic O
ratio O
appears O
to O
detect O
known O
differences O
in O
CYP2B6 O
activity O
associated O
with O
genetic O
polymorphism O
, O
across O
different O
ethnic O
groups O
. O
Prospective O
studies O
will O
be O
needed O
to O
validate O
the O
use O
of O
bupropion O
as O
a O
probe O
substrate O
for O
clinical O
use O
. O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
polymorphisms O
were O
associated O
with O
CYP2B6 B
activity O
. O
Evidence O
of O
dependence O
of O
CYP2B6 O
activity O
on O
ethnicity O
or O
genotype-by-ethnicity O
interactions O
was O
not O
detected O
in O
women O
. O
These O
results O
suggest O
that O
CYP2B6 O
genotype O
is O
the O
most O
important O
patient O
variable O
for O
predicting O
the O
level O
of O
CYP2B6 O
activity O
in O
women O
, O
when O
measured O
by O
the O
metabolism O
of O
bupropion O
The O
bupropion O
metabolic O
ratio O
appears O
to O
detect O
known O
differences O
in O
CYP2B6 O
activity O
associated O
with O
genetic O
polymorphism O
, O
across O
different O
ethnic O
groups O
. O
Prospective O
studies O
will O
be O
needed O
to O
validate O
the O
use O
of O
bupropion O
as O
a O
probe O
substrate O
for O
clinical O
use O
. O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
associated O
with O
CYP2B6 B
activity O
. O
Evidence O
of O
dependence O
of O
CYP2B6 O
activity O
on O
ethnicity O
or O
genotype-by-ethnicity O
interactions O
was O
not O
detected O
in O
women O
. O
These O
results O
suggest O
that O
CYP2B6 O
genotype O
is O
the O
most O
important O
patient O
variable O
for O
predicting O
the O
level O
of O
CYP2B6 O
activity O
in O
women O
, O
when O
measured O
by O
the O
metabolism O
of O
bupropion O
. O
The O
bupropion O
metabolic O
ratio O
appears O
to O
detect O
known O
differences O
in O
CYP2B6 O
activity O
associated O
with O
genetic O
polymorphism O
, O
across O
different O
ethnic O
groups O
. O
Prospective O
studies O
will O
be O
needed O
to O
validate O
the O
use O
of O
bupropion O
as O
a O
probe O
substrate O
for O
clinical O
use O
. O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
genetic O
polymorphism O
on O
hepatic O
CYP2B6 B
(cytochrome O
P450 O
2B6) O
expression O
and O
activity O
were O
previously O
demonstrated O
in O
vitro O
. O
Race/ethnic O
differences O
in O
CYP2B6 O
genotype O
and O
phenotype O
were O
observed O
only O
in O
women O
. O
To O
identify O
important O
covariates O
associated O
with O
interindividual O
variation O
in O
CYP2B6 O
activity O
in O
vivo O
, O
we O
evaluated O
these O
effects O
in O
healthy O
volunteers O
using O
bupropion O
(Wellbutrin O
SR O
GlaxoSmithKline O
, O
Research O
Triangle O
Park O
, O
NC) O
as O
a O
CYP2B6 O
probe O
substrate O
. O
A O
fixed O
150-mg O
oral O
sustained-release O
dose O
of O
bupropion O
was O
administered O
to O
100 O
healthy O
volunteers O
comprising O
four O
sex/ethnicity O
cohorts O
(n O
= O
25 O
each) O
: O
Caucasian O
men O
and O
Caucasian O
, O
African O
American O
, O
and O
Hispanic O
women O
. O
Blood O
samples O
were O
obtained O
at O
0 O

Wellbutrin O
SR O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
on O
hepatic O
CYP2B6 B
(cytochrome O
P450 O
2B6) O
expression O
and O
activity O
were O
previously O
demonstrated O
in O
vitro O
. O
Race/ethnic O
differences O
in O
CYP2B6 O
genotype O
and O
phenotype O
were O
observed O
only O
in O
women O
. O
To O
identify O
important O
covariates O
associated O
with O
interindividual O
variation O
in O
CYP2B6 O
activity O
in O
vivo O
, O
we O
evaluated O
these O
effects O
in O
healthy O
volunteers O
using O
bupropion O
( O
Wellbutrin O
SR O
GlaxoSmithKline O
, O
Research O
Triangle O
Park O
, O
NC) O
as O
a O
CYP2B6 O
probe O
substrate O
. O
A O
fixed O
150-mg O
oral O
sustained-release O
dose O
of O
bupropion O
was O
administered O
to O
100 O
healthy O
volunteers O
comprising O
four O
sex/ethnicity O
cohorts O
(n O
= O
25 O
each) O
: O
Caucasian O
men O
and O
Caucasian O
, O
African O
American O
, O
and O
Hispanic O
women O
. O
Blood O
samples O
were O
obtained O
at O
0 O
and O
6 O

bupropion O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
influence O
of O
sex O
, O
ethnicity O
, O
and O
CYP2B6 B
genotype O
on O
bupropio O
metabolism O
as O
an O
index O
of O
hepatic O
CYP2B6 O
activity O
in O
humans.The O
effects O
of O
sex O
, O
ethnicity O
, O
and O
genetic O
polymorphism O
on O
hepatic O
CYP2B6 O
(cytochrome O
P450 O
2B6) O
expression O
and O
activity O
were O
previously O
demonstrated O
in O
vitro O
. O
Race/ethnic O
differences O
in O
CYP2B6 O
genotype O
and O
phenotype O
were O
observed O
only O
in O
women O
. O
To O
identify O
important O
covariates O
associated O
with O

rifampicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Within O
14 O
days O
of O
culture O
, O
the O
HepaRG-AMC-BALs O
contained O
highly O
polarized O
viable O
liver-like O
tissue O
with O
heterogeneous O
expression O
of O
CYP3A4 O
. O
We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates O
, O
ranging O
from O
26% O
(UDP-glucuronosyltransferase O
1A1) O
, O
47% O
(CYP3A4) O
, O
to O
240% O
(CYP2C9) O
of O
primary O
human O
hepatocytes O
. O
The O
CYP3A4 B
activity O
could O
be O
induced O
2-fold O
by O
rifampicin O
whereas O
CYP2C9 O
activity O
remained O
equally O
high O
. O
The O
HepaRG-AMC-BAL O
secreted O
bile O
acids O
at O
43% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile O
salts O
. O
Concluding O
, O
culturing O
HepaRG O
cells O
in O
the O
AMC-BAL O
yields O
substantial O
phase O
1 O
and O
phase O
2 O
drug O
metabolism O
, O
while O
maintaining O
high O
viability O
, O
rendering O

rifampicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Within O
14 O
days O
of O
culture O
, O
the O
HepaRG-AMC-BALs O
contained O
highly O
polarized O
viable O
liver-like O
tissue O
with O
heterogeneous O
expression O
of O
CYP3A4 O
. O
We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates O
, O
ranging O
from O
26% O
(UDP-glucuronosyltransferase O
1A1) O
, O
47% O
(CYP3A4) O
, O
to O
240% O
(CYP2C9) O
of O
primary O
human O
hepatocytes O
. O
The O
CYP3A4 O
activity O
could O
be O
induced O
2-fold O
by O
rifampicin O
whereas O
CYP2C9 B
activity O
remained O
equally O
high O
. O
The O
HepaRG-AMC-BAL O
secreted O
bile O
acids O
at O
43% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation O
, O
conjugation O
, O
and O
transport O
of O
bile O
salts O
. O
Concluding O
, O
culturing O
HepaRG O
cells O
in O
the O
AMC-BAL O
yields O
substantial O
phase O
1 O
and O
phase O
2 O
drug O
metabolism O
, O
while O
maintaining O
high O
viability O
, O
rendering O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb O
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group) O
. O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed O
. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb O
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 O
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb O
exposure O
. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb O
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb O
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group) O
. O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed O
. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb O
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 O
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb O
exposure O
. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb O
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb O
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group) O
. O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed O
. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb O
exposure O
on O
DNMT1 O
, O
DNMT3a O
, O
and O
MeCP2 B
expression O
, O
with O
effects O
often O
seen O
at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb O
exposure O
. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb O
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases O
. O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
adulthood O
. O
Exposures O
that O
occur O
during O
fetal O
or O
early O
life O
periods O
may O
produce O
changes O
in O
brain O
related O
to O
physiological O
re-programming O
from O
an O
epigenetic O
influence O
such O
as O
altered O
DNA O
methylation O
status O
. O
Since O
DNA O
methylation O
is O
regulated O
by O
DNA B
methyltransferases I
and O
methyl O
cytosine-binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb O
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O
Long O
Evans O
dams O
were O
fed O
chow O
with O
or O
without O
added O
Pb O
acetate O
(0 O
, O
150 O
, O
375 O
, O
750 O
ppm) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O

Pb O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
adulthood O
. O
Exposures O
that O
occur O
during O
fetal O
or O
early O
life O
periods O
may O
produce O
changes O
in O
brain O
related O
to O
physiological O
re-programming O
from O
an O
epigenetic O
influence O
such O
as O
altered O
DNA O
methylation O
status O
. O
Since O
DNA O
methylation O
is O
regulated O
by O
DNA O
methyltransferases O
and O
methyl O
cytosine-binding O
proteins O
, O
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb O
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus O
. O
Long O
Evans O
dams O
were O
fed O
chow O
with O
or O
without O
added O
Pb O
acetate O
(0 O
, O
150 O
, O
375 O
, O
750 O
ppm) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
(perinatal O
exposure O
group) O
. O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 B
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O
many O
mammalian O
species O
and O
in O
frogs O
(Xenopus O
tropicalis); O
no O
evidence O
was O
found O
for O
ALDH1B1 O
in O
the O
genomes O
of O
birds O
, O
reptiles O
or O
fish O
. O
Predicted O
vertebrate O
ALDH2 O
and O
ALDH1B1 O
subunit O
sequences O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 B
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O
many O
mammalian O
species O
and O
in O
frogs O
(Xenopus O
tropicalis); O
no O
evidence O
was O
found O
for O
ALDH1B1 O
in O
the O
genomes O
of O
birds O
, O
reptiles O
or O
fish O
. O
Predicted O
vertebrate O
ALDH2 O
and O
ALDH1B1 O
subunit O
sequences O

acetaldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 O
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O

acetaldehyde O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Comparative O
genomics O
, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 O
and O
ALDH2.Vertebrate O
ALDH2 B
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde O
and O
other O
biological O
aldehydes O
in O
the O
body O
. O
Mammalian O
ALDH1B1 O
, O
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2 O
, O
is O
also O
capable O
of O
metabolizing O
acetaldehyde O
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2 O
. O
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 O
and O
ALDH1B1 O
amino O
acid O
sequences O
. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish O
, O
amphibians O
, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 O
in O

BGG O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG O
mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK B
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O

BGG O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG O
mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 B
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O

Beta-glucogallin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O

BGG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
( O
BGG O
 O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O

BGG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG-mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O

BGG O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O
decrease O
in O
sorbitol O
accumulation O
. O
In O
addition O
, O
BGG O
mediated O
inhibition O
of O
AR O
prevented O
LPS-induced O
activation O
of O
JNK O
and O
p38 O
and O
lowered O
ROS O
levels O
, O
which O
could O
inhibit O
LPS-induced O
apoptosis O
. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation O
. O
In O
this O
study O
, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG O
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O

alcohol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O

alcohol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O
measured O
by O
a O

aldehydes O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR O
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O

aldehydes O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Beta-glucogallin O
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose O
reductase O
in O
murine O
macrophages O
and O
ocular O
tissues.Aldose O
reductase O
(AR) O
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes O
to O
their O
alcohol O
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS) O
. O
Beta-glucogallin O
(BGG) O
, O
a O
recently O
described O
AR B
inhibitor O
, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis) O
. O
In O
this O
study O
, O
we O
found O
that O
BGG O
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR O
activity O
as O

valine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF B
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O

glutamic O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafenib O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF B
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O
is O
commonly O
found O
in O
metastatic O
melanoma O
. O
Clinical O
trials O
with O
dabrafenib O
have O
shown O
encouraging O
results; O
however O
, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib O
remains O
unknown O
. O
Thus O
, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O

dabrafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafeni O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O

dabrafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein O
kinase O
B-RaF(V600E) O
inhibitor O
dabrafeni O
to O
the O
brain O
: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases.Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma O
. O
Dabrafenib O
is O
a O
BRAF O
(gene O
encoding O
serine/threonine-protein O
kinase O
B-Raf) O
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine O
600 O
to O
glutamic O
acid O
substitution O
(BRAF(V600E)) O
, O
which O

vemurafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
another O
BRAF(V600E) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

vemurafenib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
0.023 O
, O
which O
increased O
by O
18-fold O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
to O
0.42 O
. O
Dabrafenib O
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 O
a/b(-/-)Bcrp1(-/-) O
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O
mg/kg); O
however O
, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25 O
. O
Further O
, O
compared O
with O
vemurafenib O
another O
BRAF(V600E) O
inhibitor O
, O
dabrafenib O
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose O
. O
In O
conclusion O
, O
the O
dabrafenib O
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model O
, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases O
. O

dabrafenib O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp B
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O

dabrafenib O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib O
in O
mice O
, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein O
(P-gp) O
and O
breast O
cancer O
resistance O
protein O
(BCRP) O
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB) O
. O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib O
is O
an O
avid O
substrate O
for O
both O
P-gp O
and O
BCRP O
. O
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp O
and O
Bcrp1 O
transfected O
cell O
lines O
. O
In O
vivo O
, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O
(AUC)(brain) O
to O
AUC(plasma) O

sulfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
that O
the O
intrinsic O
PK/PD O
properties O
of O
native O
FST315 O
are O
poorly O
suited O
for O
acting O
as O
a O
parentally O
administered O
biotherapeutic O
with O
broad O
systemic O
effects O
. O
Here O
, O
we O
leveraged O
protein O
engineering O
to O
modify O
the O
PK O
characteristics O
of O
the O
native O
molecule O
by O
fusing O
FST315 O
to O
a O
murine O
IgG(1) O
Fc O
and O
removing O
the O
intrinsic O
heparan O
sulfate O
binding O
activity O
of O
follistatin O
. O
The O
engineered O
variant O
molecule O
had O
~100- O
and O
~1600-fold O
improvements O
in O
terminal O
half-life O
and O
exposure O
, O
respectively O
. O
In O
contrast O
to O
the O
native O
FST315 O
, O
the O
variant O
showed O
a O
robust O
, O
dose-dependent O
pharmacological O
effect O
when O
administered O
subcutaneously O
on O
a O
weekly O
basis O
in O
mouse O
models O
of O
muscle O
atrophy O
and O
degeneration O
. O
These O

2'-O-methyl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
from O
crude O
cell O
lysates.Small O
interfering O
RNAs O
(siRNAs) O
direct O
Argonaute O
proteins O
, O
the O
core O
components O
of O
the O
RNA-induced O
silencing O
complex O
(RISC) O
, O
to O
cleave O
complementary O
target O
RNAs O
. O
Here O
, O
we O
describe O
a O
method O
to O
purify O
active O
RISC B
containing O
a O
single O
, O
unique O
small O
RNA O
guide O
sequence O
. O
We O
begin O
by O
capturing O
RISC O
using O
a O
complementary O
2'-O-methyl O
oligonucleotide O
tethered O
to O
beads O
. O
Unlike O
other O
methods O
that O
capture O
RISC O
but O
do O
not O
allow O
its O
recovery O
, O
our O
strategy O
purifies O
active O
, O
soluble O
RISC O
in O
good O
yield O
. O
The O
method O
takes O
advantage O
of O
the O
finding O
that O
RISC O
partially O
paired O
to O
a O
target O
through O
its O
siRNA O
guide O
dissociates O
more O
than O
300 O
times O
faster O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 B
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB B
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 B
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 B
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB B
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 B
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 B
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase O
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 B
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 B
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin O
treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin O
treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
p65 O
protein O
, O
and O
IL-27 B
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin O
treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

sulfasalazine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 B
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine O
treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

sulfasalazine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine O
treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

sulfasalazine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-27 B
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine O
treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 B
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Curcumin O
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O
IL-27 O
expression O
via O
the O
TLR4/NF-κB O
signaling O
pathway.Curcumin O
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties O
. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis O
. O
This O
study O
explored O
whether O
curcumin O
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
IL-27 O
expression O
. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene O
sulfonic O
acid O
, O
rats O
were O
intragastrically O
administered O
with O
curcumin O
or O
sulfasalazine O
daily O
for O
one O
week O
. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
and O
histological O
score O
. O
Myeloperoxidase O
activity O
was O
detected O
by O
immunohistochemistry O
, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot O
. O
Compared O
with O
the O
untreated O
colitis O
group O
, O
the O
curcumin O
treated O
group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index O
, O
colonic O
mucosa O
damage O
index O
, O
histological O
score O
, O
myeloperoxidase B
activity O
, O
and O
expressions O
of O
NF-κB O
mRNA O
, O
IL-27 O
mRNA O
, O
TLR4 O
protein O
, O
NF-κB O
p65 O
protein O
, O
and O
IL-27 O
p28 O
protein O
(p O
< O
0.05) O
. O
TLR4 O
mRNA O
expression O
did O
not O
differ O
between O
groups O
. O
Disease O
activity O
index O
decreased O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

curcumin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
the O
curcumin-treated O
group O
than O
in O
the O
sulfasalazine-treated O
group O
(p O
< O
0.05) O
. O
There O
was O
no O
significant O
difference O
in O
TLR4 O
, O
NF-κB O
, O
and O
IL-27 O
mRNA O
and O
proteins O
between O
curcumin-treated O
and O
sulfasalazine-treated O
groups O
. O
Curcumin O
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene O
sulfonic O
acid-induced O
colitis O
that O
are O
comparable O
to O
sulfasalazine O
. O
The O
anti-inflammatory O
actions O
of O
curcumin O
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB O
signaling O
pathway O
and O
of O
IL-27 O
expression O
. O

(129)I O
acts O
as O
PART-OF O
for O
what O
entity O
? O
pharmacologic O
effect O
. O
In O
microdosing O
, O
use O
is O
made O
of O
accelerator O
MS O
(AMS) O
. O
In O
this O
study O
, O
we O
investigated O
whether O
(129)I-labeling O
of O
proteins O
with O
subsequent O
AMS O
measurements O
is O
a O
suitable O
method O
to O
perform O
microdose O
studies O
with O
therapeutic O
proteins O
. O
We O
used O
erythropoietin O
(EPO) O
as O
a O
case O
study O
. O
RESULTS O
: O
In O
an O
animal O
study O
with O
(129)I O
labeled O
EPO B
in O
Han-Wistar O
rats O
, O
an O
increase O
of O
(129)I-EPO O
is O
observed O
after O
dose O
administration O
. O
The O
half-life O
was O
found O
to O
be O
2 O
and O
5.5 O
h O
for O
two O
different O
EPOs O
. O
These O
results O
are O
in O
accordance O
with O
expected O
values O
. O
CoNCLUSION O
: O
Although O
further O
research O
is O
required O
, O
(129)I-labeling O
of O
proteins O
seems O
a O
feasible O
method O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
effects O
of O
kisspeptin O
in O
human O
reproductive O
function O
- O
therapeutic O
implications.Kisspeptin O
is O
a O
54- O
amino O
acid O
peptide O
which O
is O
encoded O
by O
the O
KiSS-1 O
gene O
and O
activates O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin O
stimulates O
the O
hypothalamic-pituitary-gonadal O

gonadotrophin O
releasing O
hormone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
gene O
and O
activates O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin B
stimulates O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
whilst O
pre-administration O
of O
a O
gonadotrophin O
releasing O
hormone O
(GnRH) O
antagonist O
abolishes O
this O
effect O
. O
In O
humans O
, O
inactivating O
GPR54 O
mutations O
cause O
normosmic O
hypogonadotrophic O
hypogonadism O
whilst O
activation O
of O
GPR54 O
signalling O
is O
associated O
with O
premature O
puberty O
. O
In O
healthy O
human O
volunteers O
, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O
luteinising O
hormone O
(LH) O
levels O
and O
significantly O
increases O
plasma O
follicle O
stimulating O
hormone O

GnRH O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
G O
protein-coupled O
receptor O
GPR54 O
. O
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction O
. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient O
mice O
have O
abnormal O
sexual O
development O
. O
Central O
and O
peripheral O
administration O
of O
kisspeptin B
stimulates O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
whilst O
pre-administration O
of O
a O
gonadotrophin O
releasing O
hormone O
( O
GnRH O
antagonist O
abolishes O
this O
effect O
. O
In O
humans O
, O
inactivating O
GPR54 O
mutations O
cause O
normosmic O
hypogonadotrophic O
hypogonadism O
whilst O
activation O
of O
GPR54 O
signalling O
is O
associated O
with O
premature O
puberty O
. O
In O
healthy O
human O
volunteers O
, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O
luteinising O
hormone O
(LH) O
levels O
and O
significantly O
increases O
plasma O
follicle O
stimulating O
hormone O
(FSH) O
and O

darapladib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
tailored O
activity O
probes O
for O
lipoprotein-associated O
phospholipase O
A(2).Lipoprotein-associated O
phospholipase O
A(2) O
(Lp-PLA(2) O
or O
PLA(2)G7) O
binds O
to O
low-density O
lipoprotein O
(LDL) O
particles O
, O
where O
it O
is O
thought O
to O
hydrolyze O
oxidatively O
truncated O
phospholipids O
. O
Lp-PLA(2) B
has O
also O
been O
implicated O
as O
a O
pro-tumorigenic O
enzyme O
in O
human O
prostate O
cancer O
. O
Several O
inhibitors O
of O
Lp-PLA(2) O
have O
been O
described O
, O
including O
darapladib O
which O
is O
currently O
in O
phase O
3 O
clinical O
development O
for O
the O
treatment O
of O
atherosclerosis O
. O
The O
selectivity O
that O
darapladib O
and O
other O
Lp-PLA(2) O
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) O
and O

darapladib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
atherosclerosis O
. O
The O
selectivity O
that O
darapladib O
and O
other O
Lp-PLA(2) B
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) O
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems O
. O
We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp-PLA(2) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O
probes O
that O
are O
suitable O
for O
investigating O
Lp-PLA(2) O
function O
in O
biological O
systems O
. O

carbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitors O
display O
across O
the O
larger O
serine O
hydrolase O
family O
has O
not O
, O
however O
, O
been O
reported O
. O
Here O
, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) B
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems O
. O
We O
show O
that O
both O
darapladib O
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate O
inhibitors O
inactivate O
Lp-PLA(2) O
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity O
. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O
probes O
that O
are O
suitable O
for O
investigating O
Lp-PLA(2) O
function O
in O
biological O
systems O
. O

benzofuran O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
of O
benzofura O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O

benzofurans O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H B
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA(4)H O
inhibitor O
for O
the O
treatment O
of O
inflammatory O

Benzofuran O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA(4)H B
inhibitor O
for O
the O
treatment O
of O
inflammatory O
diseases O
, O
such O
as O
asthma O
and O
inflammatory O
bowel O
disease O
(IBD) O
. O

LTB(4) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O

LTB(4) O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene B
A(4) I
hydrolase I
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O
responsive O
target O

LTA(4) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene O
A(4) O
hydrolase O
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O

LTA(4) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Identification O
of O
benzofuran O
central O
cores O
for O
the O
inhibition O
of O
leukotriene O
A(4) O
hydrolase.Leukotrienes O
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response O
. O
Leukotriene B
A(4) I
hydrolase I
(LTA(4)H) O
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) O
to O
LTB(4) O
. O
LTB(4) O
is O
a O
known O
pro-inflammatory O
mediator O
. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans O
as O
LTH(4)H O
inhibitors O
. O
The O
benzofuran O
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) O
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling O
. O
Benzofuran O
28 O
showed O
dose O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour B
necrosis I
factor-α I
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β B
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β B
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 B
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear B
factor-κB I
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 B
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 B
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated B
protein I
kinase I
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis B
signal-regulating I
kinase I
1 I
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
, O
cyclooxygenase-2 O
(COX-2) O
, O
TNF-α O
, O
IL-1β O
and O
IL-6 O
. O
Further O
, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin O
A O
. O
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin O
A O
may O
block O
the O
phosphorylation O
of O
mitogen-activated O
protein O
kinase O
(MAPK) O
molecule O
p38 O
, O
apoptosis O
signal-regulating O
kinase O
1 O
(ASK-1) O
and O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
p65 O
and O
p50 O
subunits O
. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin O
A O
. O
Collectively O
, O
these O
results O
suggest O
that O
with O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β B
1-42 I
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O

neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
inflammation-mediated O
toxicity.A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O

indole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β B
1-42 I
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O

indole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD) O
, O
aggregation O
and O
deposition O
of O
amyloid-β O
peptides O
, O
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O

Neoechinulin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction O
. O
Therefore O
, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand O
. O
In O
this O
study O
, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin O
A O
, O
an O
indole O
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp. O
, O
to O
attenuate O
microglial O
activation O
by O
oligomeric O
amyloid-β O
1-42 O
(Aβ42) O
. O
Neoechinulin O
A O
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen O
and O
nitrogen O
species O
in O
Aβ42-activated O
BV-2 O
microglia O
cells O
. O
In O
addition O
, O
we O
found O
that O
neoechinulin O
A O
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin-1β O
(IL-1β) O
, O
interleukin-6 O
(IL-6) O
, O
and O
prostaglandin O
E2 O
(PGE2) O
in O
activated O
BV-2 O
cells O
. O
Moreover O
, O
the O

Jaspamide O
acts O
as O
NOT O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 B
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

Jaspamide O
acts O
as O
NOT O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

jaspamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
jaspamid O
on O
human O
cardiomyocyte O
function O
and O
cardiac B
ion I
channel I
activity.Jaspamide O
(jasplakinolide; O
NSC-613009) O
is O
a O
cyclodepsipeptide O
that O
has O
antitumor O
activity O
. O
A O
narrow O
margin O
of O
safety O
was O
observed O
between O
doses O
required O
for O
efficacy O
in O
mouse O
tumor O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O

Jaspamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

Jaspamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

Jaspamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs O
. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O
to O
cardiotoxicity O
. O
Jaspamide O
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac O
ion O
channels O
. O
Jaspamide O
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5% O
. O
Jaspamide O
also O
inhibited O
other O
channels O
including O
Cav1.2 O
, O
Cav3.2 O
, O
and O
HCN2; O
however O
, O
the O
Kv11.1 O
(hERG) O
channel O
was O
minimally O
affected O
. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells O
, O
effects O
on O
cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined O
. O
Jaspamide O
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O

trans-dihydromorin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
Cudrania O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase B
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O
, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

oxyresveratrol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase B
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O
, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

steppogenin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
show O
strong O
tyrosinase B
inhibitory O
activity O
, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol O
glucoside O
, O
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside O
(1) O
, O
plus O
twenty-seven O
known O
compounds O
(2-28) O
. O
Their O
structures O
were O
elucidated O
on O
the O
basis O
of O
ESI-MS O
and O
NMR O
spectral O
data O
. O
Among O
the O
isolated O
compounds O
, O
trans-dihydromorin O
(8) O
, O
oxyresveratrol O
(9) O
, O
and O
steppogenin O
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase O
inhibition O
activities O
. O
Moreover O
, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed O
. O

Cortisol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 B
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O

Cortisol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 O
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 B
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O

Cortisol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 B
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium O
. O
Some O
effects O
of O
cortisol O
and O
IFNT O
were O
mediated O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O

PF O
915275 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 B
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 O
activity O
and O

meloxicam O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O
PF O
into O
the O
uterus O
from O
day O
10 O
to O
day14 O
after O
estrus O
. O
Cortisol O
and O
IFNT O
stimulated O
endometrial O
HSD11B1 O
expression O
and O
activity O
, O
increased O
endometrial O
PTGS2 B
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen O
, O
and O
up-regulated O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 B
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep O
. O
In O
study O
1 O
, O
cyclic O
ewes O
received O
vehicle O
, O
cortisol O
, O
PF O
915275 O
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1) O
, O
cortisol O
and O
PF O
, O
meloxicam O
(a O
selective O
inhibitor O
of O
PTGS2) O
, O
cortisol O
and O
meloxicam O
, O
recombinant O
ovine O
IFNT O
, O
or O
IFNT O
and O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG B
synthase I
2 I
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG O
synthase O
2 O
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
by O
PTGS2-derived O
PG O
. O
In O
study O
2 O
, O
bred O
ewes O
received O
PF O
915275 O
or O
recombinant O
ovine O
IFNT O
and O
into O
the O
uterus O
from O
day O
10 O
to O
day O
14 O
after O
mating O
. O
Inhibition O
of O
HSD11B1 B
activity O
in O
utero O
prevented O
conceptus O
elongation O
, O
whereas O
IFNT O
rescued O
conceptus O
elongation O
in O
PF-infused O
ewes O
. O
These O
results O
suggest O
that O
HSD11B1-derived O
cortisol O
mediates O
, O
in O
part O
, O
actions O
of O
ovarian O
progesterone O
and O
the O
conceptus O
on O
endometrial O
function O
and O
support O
the O
hypothesis O
that O
IFNT O
, O
PG O
, O
and O
cortisol O
coordinately O
regulate O
endometrial O
functions O
important O
for O
conceptus O
elongation O
and O
implantation O
during O
early O
pregnancy O
in O
sheep O
. O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG O
synthase O
2 O
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid B
(11-β) I
dehydrogenase I
1 I
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 O
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Cortisol O
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep.During O
early O
pregnancy O
in O
sheep O
, O
the O
elongating O
conceptus O
secretes O
interferon-τ O
(IFNT) O
and O
the O
conceptus O
as O
well O
as O
endometrial O
epithelia O
produce O
prostaglandins O
(PG) O
via O
PG O
synthase O
2 O
(PTGS2) O
and O
cortisol O
via O
hydroxysteroid O
(11-β) O
dehydrogenase O
1 O
(HSD11B1) O
. O
Ovarian O
progesterone O
induces O
and O
PG O
and O
IFNT O
stimulates O
endometrial O
HSD11B1 B
expression O
and O
keto-reductase O
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation O
, O
migration O
, O
and O
attachment O
during O
elongation O
. O
The O
primary O
aim O
of O
these O
studies O
was O
to O
test O
the O
hypothesis O
that O
HSD11B1-derived O
cortisol O

isoflavone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
biological O
activities O
of O
an O
alcohol O
extract O
of O
groundnut O
containing O
genistein-7-O-gentiobioside O
as O
the O
main O
component O
. O
Although O
the O
groundnut O
extract O
by O
itself O
did O
not O
show O
antioxidative O
activity O
, O
it O
drove O
the O
antioxidative O
system O
in O
cells O
. O
Pretreatment O
of O
human O
breast O
carcinoma O
MCF-7 O
cells O
for O
24 O
h O
with O
the O
groundnut O
extract O
and O
soybean O
isoflavone O
increased O
gene O
expression O
of O
heme B
oxygenase-1 I
(HO-1) O
, O
a O
major O
antioxidative O
stress O
enzyme O
. O
These O
groundnut O
extract-treated O
cells O
showed O
antioxidative O
activity O
against O
free O
radicals O
derived O
from O
a O
radical O
initiator O
. O
Pretreatment O
of O
cells O
with O
100 O
μg/mL O
groundnut O
extract O
prevented O
the O
depletion O
of O
glutathione O
by O
the O
radical O
initiator; O
however O
, O
treatment O
with O
100 O
μg/mL O

isoflavone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
biological O
activities O
of O
an O
alcohol O
extract O
of O
groundnut O
containing O
genistein-7-O-gentiobioside O
as O
the O
main O
component O
. O
Although O
the O
groundnut O
extract O
by O
itself O
did O
not O
show O
antioxidative O
activity O
, O
it O
drove O
the O
antioxidative O
system O
in O
cells O
. O
Pretreatment O
of O
human O
breast O
carcinoma O
MCF-7 O
cells O
for O
24 O
h O
with O
the O
groundnut O
extract O
and O
soybean O
isoflavone O
increased O
gene O
expression O
of O
heme O
oxygenase-1 O
(HO-1) O
, O
a O
major O
antioxidative O
stress O
enzyme O
. O
These O
groundnut O
extract-treated O
cells O
showed O
antioxidative O
activity O
against O
free O
radicals O
derived O
from O
a O
radical O
initiator O
. O
Pretreatment O
of O
cells O
with O
100 O
μg/mL O
groundnut O
extract O
prevented O
the O
depletion O
of O
glutathione O
by O
the O
radical O
initiator; O
however O
, O
treatment O
with O
100 O
μg/mL O

acyl O
esters O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O
of O
alcohol B
acyl-transferase I
EEB1 I
and O
the O
acyl O
esterase O
IAH1 O
. O

acyl O
esters O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O
of O
alcohol O
acyl-transferase O
EEB1 O
and O
the O
acyl O
esterase O
IAH1 O
. O

ammonium O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O

ammonium O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases B
and O
dehydrogenases O
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O

ammonium O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
alcohol/ester O
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation O
. O
Sugar-cane O
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen O
(81 O
mg O
N/L) O
, O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium O
sulfate O
. O
Overall O
, O
higher O
alcohol O
production O
was O
reduced O
by O
ammonium O
supplementation O
, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases O
and O
dehydrogenases B
of O
the O
Ehrlich O
pathway O
. O
The O
production O
of O
acetate O
esters O
was O
enhanced O
by O
mid-range O
ammonium O
supplementation O
and O
the O
production O
of O
acyl O
esters O
by O
high O
ammonium O
supplementation O
. O
The O
acyl O
esters O
could O
be O
correlated O
with O
expression O

SCH O
900229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfone O
γ-secretase O
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
( O
SCH O
900229 O
 O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O
compound O
(-)-1a O
. O
On O
the O
right O
hand O
side O
chain O
, O
linker O
size O
and O
terminal O
substituents O
of O
the O
pendant O
sulfone O
group O
are O
also O
investigated O
. O

SCH O
900229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfone O
γ-secretase B
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
( O
SCH O
900229 O
 O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O
compound O
(-)-1a O
. O
On O
the O
right O
hand O
side O
chain O
, O
linker O
size O
and O
terminal O
substituents O
of O
the O
pendant O
sulfone O
group O
are O
also O
investigated O
. O

tricyclic O
bispyran O
sulfone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure O
activity O
relationship O
studies O
of O
tricyclic O
bispyran O
sulfon O
γ-secretase B
inhibitors.An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone O
side O
chains O
of O
compound O
(-)-1a O
(SCH O
900229) O
, O
a O
potent O
, O
PS1-selective O
γ-secretase O
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease O
. O
Specifically O
, O
4-CF(3) O
and O
4-Br O
substituted O
arylsulfone O
analogs O
, O
(-)-1b O
and O
(-)-1c O
, O
are O
equipotent O
to O

calpeptin O
acts O
as O
NOT O
for O
what O
entity O
? O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF B
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 B
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O

ALD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 B
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain B
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
( O
ALD O
-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activated O
by O
ALD O
. O
Cardiomyocytes O
that O
were O
injured O
by O
ALD O
were O
assayed O
by O
the O
MTT O
and O
LDH O
leakage O
ratio O
. O
Apoptosis O
was O
evaluated O
by O
a O
TUNEL O
assay O
, O
annexin O
V/PI O
staining O
, O
and O
caspase-3 O
activity O
. O
The O
expression O
of O
cleavage O
of O
Bid O
(tBid) O
, O
calpain B
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain B
and O
apoptosis-inducing O
factor O
in O
aldosteron O
-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain O
and O
apoptosis-inducing B
factor I
in O
aldosteron O
-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain B
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid B
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD O
induced O
increase O
of O
calpain B
and O
AIF O
levels O
. O

ALD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF B
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD O
induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

aldosterone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain B
and O
apoptosis-inducing O
factor O
in O
aldosterone-induced O
primary O
cultured O
cardiomyocytes.In O
this O
study O
, O
aldosterone O
(ALD)-induced O
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies O
, O
and O
the O
roles O
of O
calpain O
signaling O
were O
clarified O
. O
Primary O
cultured O
rat O
cardiomyocytes O
were O
injured O
by O
ALD O
(0.01-10 O
μM) O
for O
varying O
time O
periods O
. O
Then O
, O
the O
effects O
of O
ethylene O
glycol O
tetraacetic O
acid O
(EGTA) O
(0.5 O
mM) O
, O
calpeptin O
(2.5 O
μM) O
, O
and O
spironoclactone O

EGTA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(tBid) O
, O
calpain B
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O

EGTA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid B
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O

EGTA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
expression O
and O
caspase-3 O
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF B
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

spironoclactone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain B
and O
AIF O
levels O
. O

spironoclactone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF B
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O
and O
AIF O
levels O
. O

EGTA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(tBid) O
, O
calpain O
and O
apoptosis-inducing O
factor O
(AIF) O
was O
evaluated O
by O
western O
blot O
analysis O
. O
ALD O
increased O
calpain O
expression O
and O
caspase-3 B
activity O
and O
promoted O
Bid O
cleavage O
. O
It O
also O
induced O
the O
release O
of O
AIF O
from O
mitochondria O
into O
the O
cytosol O
. O
The O
upregulation O
of O
calpain O
, O
tBid O
and O
caspase-3 O
activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA O
in O
the O
presence O
of O
ALD O
. O
Additionally O
, O
AIF O
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA O
but O
not O
due O
to O
calpeptin O
. O
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis O
. O
Furthermore O
, O
treatment O
with O
spironoclactone O
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD O
but O
reversed O
the O
ALD-induced O
increase O
of O
calpain O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO O
HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O
The O
effects O
of O
SFO O
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis O
, O
a O
chronic O
inflammatory O
disease O
, O
is O
the O
main O
cause O
of O
cardiovascular O
events O
. O
In O
this O
study O
, O
we O
investigated O
SFO O
induced O
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein O
E-knockout O
(apoE(-/-)) O
mice O
. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO O
(SFO-HD) O
treated O
group O
, O
which O
is O
only O
31.2% O
in O
control O
group O
. O
SFO O
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O

SFO O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O
The O
effects O
of O
SFO O
in O
mammalian O
systems O
, O
especially O
the O
cardiovascular O
system O
, O
are O
little O
known O
. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis O
, O
a O
chronic O
inflammatory O
disease O
, O
is O
the O
main O
cause O
of O
cardiovascular O
events O
. O
In O
this O
study O
, O
we O
investigated O
SFO O
induced O
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein O
E-knockout O
(apoE(-/-)) O
mice O
. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO O
(SFO-HD) O
treated O
group O
, O
which O
is O
only O
31.2% O
in O
control O
group O
. O
SFO O
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O

SFO O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
endothelium O
level O
of O
p75(NTR) B
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 B
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO O
treatment O
. O
Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) B
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO O
HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
lesion O
composition O
to O
an O
unstable O
phenotype O
, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O
after O
SFO O
treatment O
. O
Furthermore O
, O
compared O
with O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) B
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO O
HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 B
and O
the O
main O
proinflammatory O
alpha O
chemokine O
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO O
HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

SFO O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
control O
groups O
, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) O
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) O
was O
17.4-fold O
increased O
by O
SFO-HD O
. O
Meanwhile O
, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 O
and O
the O
main O
proinflammatory O
alpha B
chemokine I
in O
mice) O
in O
apoE(-/-) O
mice O
was O
up O
to O
357pg/ml O
in O
SFO O
HD O
treated O
group O
. O
Thus O
, O
SFO O
contributes O
to O
the O
instability O
of O
atherosclerotic O
plaque O
in O
apoE(-/-) O
mice O
through O
activating O
p75(NTR) O
and O
IL-8 O
and O
cell O
apoptosis O
in O
plaque O
. O

rifampicin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase O
and O
butyrylcholinesterase O
. O
β-Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ B
fibril O
aggregation O
inhibition O
activity O
with O
a O
nearly O
similar O
potential O
as O
the O
reference O
compound O
rifampicin O
which O
makes O
them O
promising O
anti-Alzheimer O
drug O
candidates O
. O
Docking O
experiments O
were O
carried O
out O
with O
the O
aim O
to O
understand O
the O
interactions O
of O
the O
most O
active O
compounds O
with O
the O
active O
site O
of O
the O
cholinesterase O
enzymes O
. O

N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase B
and O
butyrylcholinesterase O
. O
β-Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ O
fibril O
aggregation O
inhibition O

N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase B
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase O
and O
butyrylcholinesterase O
. O
β-Amyloid O
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ O
fibril O
aggregation O
inhibition O

N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazon O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases B
and O
Aβ O
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O

N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
, O
molecular O
modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazon O
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases O
and O
Aβ B
aggregation.To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease O
, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones O
was O
designed O
, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase O
, O
butyrylcholinesterase O
and O
aggregation O
of O
amyloid O
beta O
peptides O
(1-40 O
, O
1-42 O
and O
1-40_1-42) O
. O
The O
enzyme O
inhibition O
assay O
results O
indicated O

Doxorubicin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
NF-κB-associated O
mechanisms O
underlying O
the O
response O
of O
embryonic O
cells O
to O
Doxorubici O
.The O
involvement O
of O
NF-κB B
in O
the O
regulation O
of O
teratogen-induced O
apoptosis O
has O
not O
been O
established O
yet O
. O
Therefore O
, O
we O
tried O
to O
assess O
the O
involvement O
of O
the O
p65 O
subunit O
of O
NF-κB O
in O
the O
embryonic O
response O
to O
the O
anti-cancer O
drug O
Doxorubicin O
(DOX) O
. O
Thus O
, O
exposure O
of O
p65 O
knockout O
(p65(-/-)) O
or O
wild O
type O
(WT) O
mouse O

DOX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
cell O
proliferation O
, O
which O
was O
found O
to O
be O
more O
prominent O
in O
p65(-/-) O
MEFs O
. O
Those O
phenomena O
were O
accompanied O
by O
a O
DOX-induced O
increase O
in O
the O
proportion O
of O
apoptotic O
cells O
, O
which O
was O
demonstrated O
only O
in O
p65(-/-) O
cells O
and O
a O
G2/M O
arrest O
, O
which O
was O
found O
to O
be O
more O
prominent O
in O
WT O
cells O
. O
Furthermore O
, O
DOX O
treated O
WT O
and O
p65(-/-) O
MEFs O
differed O
in O
their O
expression O
of O
various O
apoptosis-associated O
molecules O
, O
when O
the O
former O
demonstrated O
a O
decrease O
in O
the O
percentage O
of O
p65-positive O
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O
of O
p53-positive O
cells O
, O
while O
a O
decreased O
percentage O
of O
IκBα-positive O
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O

Glucose O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
G6PC2 O
: O
A O
Negative O
Regulator O
of O
Basal O
Glucos O
-Stimulated O
Insulin B
Secretion.Elevated O
fasting O
blood O
glucose O
(FBG) O
is O
associated O
with O
increased O
risk O
for O
the O
development O
of O
type O
2 O
diabetes O
and O
cardiovascular-associated O
mortality O
. O
Genome-wide O
association O
studies O
(GWAS) O
have O
linked O
polymorphisms O
in O
G6PC2 O
with O
variations O
in O
FBG O
and O
body O
fat O
, O
although O
not O
insulin O
sensitivity O
or O
glucose O
tolerance O
. O
G6PC2 O
encodes O
an O
islet-specific O
, O

glucose O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
deletion O
had O
little O
effect O
on O
insulin B
sensitivity O
and O
glucose O
tolerance O
, O
whereas O
body O
fat O
was O
reduced O
in O
female O
G6pc2 O
knockout O
(KO) O
mice O
on O
both O
a O
chow O
and O
high-fat O
diet O
, O
observations O
that O
are O
all O
consistent O
with O
human O
GWAS O
data O
. O
G6pc2 O
deletion O
resulted O
in O
a O
leftward O
shift O
in O
the O
dose-response O
curve O
for O
glucose O
stimulated O
insulin O
secretion O
(GSIS) O
. O
As O
a O
consequence O
, O
under O
fasting O
conditions O
in O
which O
plasma O
insulin O
levels O
were O
identical O
, O
blood O
glucose O
levels O
were O
reduced O
in O
G6pc2 O
KO O
mice O
, O
again O
consistent O
with O
human O
GWAS O
data O
. O
Glucose-6-phosphatase O
activity O
was O
reduced O
, O
whereas O
basal O
cytoplasmic O
calcium O
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 O
KO O

glucose-6-phosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
glucose O
levels O
were O
reduced O
in O
G6pc2 B
KO O
mice O
, O
again O
consistent O
with O
human O
GWAS O
data O
. O
Glucose-6-phosphatase O
activity O
was O
reduced O
, O
whereas O
basal O
cytoplasmic O
calcium O
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 O
KO O
mice O
. O
These O
data O
suggest O
that O
G6pc2 O
represents O
a O
novel O
, O
negative O
regulator O
of O
basal O
GSIS O
that O
acts O
by O
hydrolyzing O
glucose-6-phosphate O
thereby O
reducing O
glycolytic O
flux O
. O

Fisetin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated B
hemoglobin I
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB B
p65 O
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 B
unit O
(in O
pancreas) O
and O
IL-1β O
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

Fisetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin O
(50 O
mg/kg O
body O
weight) O
. O
Fisetin O
was O
administered O
orally O
for O
30 O
days O
. O
At O
the O
end O
of O
the O
study O
, O
all O
animals O
were O
killed O
. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations O
. O
The O
antioxidant O
status O
was O
evaluated O
. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues O
. O
Fisetin O
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose O
, O
glycosylated O
hemoglobin O
(HbA1c) O
, O
NF-kB O
p65 O
unit O
(in O
pancreas) O
and O
IL-1β B
(plasma) O
, O
serum O
nitric O
oxide O
(NO) O
with O
an O
elevation O
in O
plasma O
insulin O
. O
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O
plasma O
of O
diabetic O
rats O
indicating O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin B
dependent I
glucose I
transporter-4 I
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin O
dependent O
glucose O
transporter-4 O
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

palmatine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
, O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin B
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

glucose O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
its O
active O
compound O
in O
differentiated O
myocytes O
, O
L6 O
cells O
. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin O
dependent O
glucose O
transporter-4 O
(Glut-4) O
which O
also O
responds O
to O
exogenous O
chemicals O
, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold O
, O
by O
Tinospora O
cordifolia O
and O
palmatine O
, O
respectively O
. O
Next O
to O
Glut-4 O
, O
the O
predominant O
protein O
influencing O
glucose O
metabolism O
is O
PPARα O
and O
γ O
whose O
expressions O
were O
also O
positively O
modulated O
. O
Further O
, O
the O
inhibitors O
of O
insulin O
pathway O
prevented O
glucose O
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine O
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin O
pathway O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N-terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C O
terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) O
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) B
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O
a O
Zn²⁺-driven O
N O
terminal O
to O
C-terminal O
tertiary O
interaction O
in O
PrP(C) O
. O
The O
C-terminal O
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O
disease O
. O
Investigation O
of O
mutant O
PrPs O
finds O
a O
systematic O
relationship O
between O
the O
type O
of O
mutation O
and O
the O
apparent O
strength O
of O
this O
domain O
structure O
. O
The O
structural O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) B
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O
a O
Zn²⁺-driven O
N-terminal O
to O
C O
terminal O
tertiary O
interaction O
in O
PrP(C) O
. O
The O
C-terminal O
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O
disease O
. O
Investigation O
of O
mutant O
PrPs O
finds O
a O
systematic O
relationship O
between O
the O
type O
of O
mutation O
and O
the O
apparent O
strength O
of O
this O
domain O
structure O
. O
The O
structural O
features O
identified O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N O
terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C-terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O

copper O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N-terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C-terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) O
function O

zinc O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Zinc O
drives O
a O
tertiary O
fold O
in O
the O
prion O
protein O
with O
familial O
disease O
mutation O
sites O
at O
the O
interface.The O
cellular O
prion B
protein I
PrP(C) I
consists O
of O
two O
domains--a O
flexible O
N-terminal O
domain O
, O
which O
participates O
in O
copper O
and O
zinc O
regulation O
, O
and O
a O
largely O
helical O
C-terminal O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) O
function O
and O
misfolding O

Zn²⁺ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease O
. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting O
. O
Compelling O
cellular O
and O
biophysical O
studies O
, O
however O
, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) B
function O
and O
misfolding O
in O
disease O
. O
Here O
, O
we O
identify O
a O
Zn²⁺ O
driven O
N-terminal O
to O
C-terminal O
tertiary O
interaction O
in O
PrP(C) O
. O
The O
C-terminal O
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O
disease O
. O
Investigation O
of O
mutant O
PrPs O
finds O
a O
systematic O
relationship O
between O
the O
type O
of O
mutation O
and O
the O
apparent O
strength O
of O
this O
domain O
structure O
. O
The O

fluoride O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
opening O
of O
cell O
junctions O
, O
presence O
of O
anions) O
. O
The O
results O
indicate O
that O
fluoride O
is O
an O
element O
with O
moderate O
absorption O
(<70%) O
in O
both O
directions O
(absorptive O
and O
secretory) O
. O
Both O
in O
absorption O
(apical-basolateral) O
and O
in O
secretion O
(basolateral-apical) O
there O
is O
transport O
by O
the O
paracellular O
pathway O
, O
which O
may O
be O
considered O
predominant O
. O
Absorption O
and O
secretion O
of O
fluoride O
increase O
at O
acid O
pH O
levels O
, O
possibly O
because O
of O
its O
non-ionized O
state O
at O
these O
pHs O
and/or O
because O
of O
participation O
of O
a O
F(-)/H(+) O
cotransporter O
or O
a O
F(-)/OH(-) O
antiporter O
. O
The O
results O
also O
suggest O
transcellular O
participation O
of O
mechanisms O
involved O
in O
transport O
of O
Cl(-) O
and O
of O
an O
active O
transport O
in O
the O
secretory O
direction O
. O
The O

fluoride O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
opening O
of O
cell O
junctions O
, O
presence O
of O
anions) O
. O
The O
results O
indicate O
that O
fluoride O
is O
an O
element O
with O
moderate O
absorption O
(<70%) O
in O
both O
directions O
(absorptive O
and O
secretory) O
. O
Both O
in O
absorption O
(apical-basolateral) O
and O
in O
secretion O
(basolateral-apical) O
there O
is O
transport O
by O
the O
paracellular O
pathway O
, O
which O
may O
be O
considered O
predominant O
. O
Absorption O
and O
secretion O
of O
fluoride O
increase O
at O
acid O
pH O
levels O
, O
possibly O
because O
of O
its O
non-ionized O
state O
at O
these O
pHs O
and/or O
because O
of O
participation O
of O
a O
F(-)/H(+) B
cotransporter I
or O
a O
F(-)/OH(-) O
antiporter O
. O
The O
results O
also O
suggest O
transcellular O
participation O
of O
mechanisms O
involved O
in O
transport O
of O
Cl(-) O
and O
of O
an O
active O
transport O
in O
the O
secretory O
direction O
. O
The O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nuclear O
receptor O
CAR O
specifically O
activates O
the O
two-pore O
K+ O
channel O
Kcnk1 O
gene O
in O
male O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 B
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nuclear O
receptor O
CAR O
specifically O
activates O
the O
two-pore O
K+ O
channel O
Kcnk1 O
gene O
in O
male O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 B
as O
a O
phenobarbital O
inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
nuclear B
receptor I
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 O
( O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 O
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital-inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
nuclear O
receptor O
CAR B
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 O
( O

phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 O
( O
-/- O
) O
male O
mice O
compared O
with O
those O
of O
Kcnk1 O
( O
+/+ O
) O
males O
after O
phenobarbital O
treatment O
. O
Thus O
, O
KCNK1 B
suppresses O
phenobarbital-induced O
hyperplasia O
. O
These O
results O
indicate O
that O
phenobarbital O
treatment O
induces O
KCNK1 O
to O
elicit O
a O
male-specific O
and O
growth-suppressing O
signal O
. O
Thus O
, O
KCNK1 O
and O
Kcnk1 O
( O
-/- O
) O
mice O
provide O
an O
experimental O
tool O
for O
further O
investigation O
into O
the O
molecular O
mechanism O
of O
CAR-mediated O
promotion O
of O
the O
development O
of O
hepatocellular O
carcinoma O
in O
mice O
. O

phenobarbital O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
mouse O
livers O
, O
which O
attenuates O
phenobarbital-induced O
hepatic O
hyperplasia.KCNK1 O
, O
a O
member O
of O
the O
family O
of O
two-pore O
K(+) O
ion O
channels O
, O
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital O
treatment O
. O
Here O
, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 B
gene O
and O
characterized O
KCNK1 O
as O
a O
phenobarbital O
inducible O
antihyperplasia O
factor O
. O
Upon O
activation O
by O
phenobarbital O
, O
nuclear O
receptor O
CAR O
binds O
the O
97-bp O
response O
element O
(-2441/-2345) O
within O
the O
Kcnk1 O
promoter O
. O
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice O
, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland O
, O
because O
hypophysectomy O
abrogates O
it O
. O
Hyperplasia O
further O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
CLL/lymphoma O
2 O
(BCL-2) O
family O
are O
key O
regulators O
of O
the O
apoptotic O
process O
. O
This O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins O
, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis O
. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
a O
selective O
inhibitor O
of O
both O
BCL-2 B
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
CLL/lymphoma O
2 O
(BCL-2) O
family O
are O
key O
regulators O
of O
the O
apoptotic O
process O
. O
This O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins O
, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis O
. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
a O
selective O
inhibitor O
of O
both O
BCL-2 O
and O
BCL-2-like B
1 I
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
CLL/lymphoma O
2 O
(BCL-2) O
family O
are O
key O
regulators O
of O
the O
apoptotic O
process O
. O
This O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins O
, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis O
. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
a O
selective O
inhibitor O
of O
both O
BCL-2 O
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) B
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O

navitoclax O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proteins O
was O
unveiled O
with O
the O
development O
of O
navitoclax O
, O
a O
selective O
inhibitor O
of O
both O
BCL-2 B
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O
and O
BCL-2-selective O
inhibitor O
, O
ABT-199 O
. O
This O
compound O
inhibits O
the O
growth O
of O
BCL-2-dependent O
tumors O
in O
vivo O
and O
spares O
human O
platelets O
. O
A O
single O
dose O
of O
ABT-199 O
in O
three O
patients O
with O
refractory O
chronic O
lymphocytic O
leukemia O
resulted O
in O
tumor O
lysis O
within O
24 O
h O
. O
These O
data O
indicate O
that O

ABT-199 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
both O
BCL-2 B
and O
BCL-2-like O
1 O
(BCL-X(L)) O
, O
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent O
hematological O
cancers O
. O
However O
, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) O
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent O
. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax O
to O
create O
a O
highly O
potent O
, O
orally O
bioavailable O
and O
BCL-2-selective O
inhibitor O
, O
ABT-199 O
This O
compound O
inhibits O
the O
growth O
of O
BCL-2-dependent O
tumors O
in O
vivo O
and O
spares O
human O
platelets O
. O
A O
single O
dose O
of O
ABT-199 O
in O
three O
patients O
with O
refractory O
chronic O
lymphocytic O
leukemia O
resulted O
in O
tumor O
lysis O
within O
24 O
h O
. O
These O
data O
indicate O
that O
selective O
pharmacological O
inhibition O
of O
BCL-2 O
shows O
promise O
for O
the O
treatment O
of O

aflatoxin O
B(1) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
TA1537 O
and O
WP2 O
strains O
were O
37.70% O
and O
69.70% O
, O
respectively O
. O
According O
to O
the O
SCE O
test O
system O
, O
MEP O
reduced O
the O
genotoxic O
effects O
of O
aflatoxin O
. O
In O
order O
to O
clarify O
the O
mechanism O
underlying O
the O
antigenotoxic O
effects O
of O
MEP O
, O
the O
antioxidants O
were O
determined O
. O
Cotreatments O
of O
5 O
, O
10 O
and O
20 O
µg/mL O
concentrations O
of O
MEP O
with O
aflatoxin O
B(1) O
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde O
level O
and O
increased O
amount O
of O
superoxide O
dismutase O
, O
glutathione O
and O
glutathione O
peroxidase O
which O
were O
decreased O
by O
aflatoxin O
. O
The O
data O
obtained O
from O
this O
work O
have O
clearly O
shown O
that O
MEP O
has O
significant O
antigenotoxic O
effects O
which O
are O
thought O
to O
be O
partly O
due O
to O
the O
antioxidant O

aflatoxin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
clarify O
the O
mechanism O
underlying O
the O
antigenotoxic O
effects O
of O
MEP O
, O
the O
antioxidants O
were O
determined O
. O
Cotreatments O
of O
5 O
, O
10 O
and O
20 O
µg/mL O
concentrations O
of O
MEP O
with O
aflatoxin O
B(1) O
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde O
level O
and O
increased O
amount O
of O
superoxide O
dismutase O
, O
glutathione O
and O
glutathione B
peroxidase I
which O
were O
decreased O
by O
aflatoxin O
The O
data O
obtained O
from O
this O
work O
have O
clearly O
shown O
that O
MEP O
has O
significant O
antigenotoxic O
effects O
which O
are O
thought O
to O
be O
partly O
due O
to O
the O
antioxidant O
activities O
and O
antioxidant O
inducing O
capability O
of O
MEP O
. O
This O
is O
the O
first O
report O
indicating O
the O
antigenotoxic O
activities O
of O
MEP O
against O
several O
mutagen O
agents O
such O
as O

atRA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
early O
stage O
of O
cell O
adhesion O
by O
atRA O
treatment O
. O
Re-expression O
of O
COL8A2 B
in O
COL8A2-knocked-down O
HCC O
cells O
reversed O
the O
effect O
of O
small O
interfering O
RNA-COL8A2 O
. O
In O
addition O
, O
COL8A2 O
could O
increase O
HCC O
cell O
migration O
and O
invasion O
. O
Thus O
, O
COL8A2 O
was O
identified O
as O
the O
key O
protein O
involved O
in O
the O
enhancement O
of O
cell O
adhesion O
of O
atRA O
under O
serum-free O
conditions O
. O
In O
conclusion O
, O
atRA O
protects O
HCC O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
enhancing O
cell O
adhesion O
, O
and O
COL8A2 O
plays O
an O
important O
role O
in O
HCC O
cell O
migration O
and O
invasion O
. O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
this O
early O
short-term O
treatment O
with O
PGE2 O
. O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin O
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O
airway O
IL-13 B
and O
osteopontin O
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline O
. O
GM-CSF O
and O
Tregs O
were O
unaffected O
by O
the O
treatment O
. O
These O
findings O
suggest O
that O
the O
protection O
provided O
by O
PGE2 O
is O
a O
result O
of O
the O
modulation O
of O
early O
lung O
immunomodulatory O
mechanisms O
, O
and O
possibly O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
this O
early O
short-term O
treatment O
with O
PGE2 O
. O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin B
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O
airway O
IL-13 O
and O
osteopontin O
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline O
. O
GM-CSF O
and O
Tregs O
were O
unaffected O
by O
the O
treatment O
. O
These O
findings O
suggest O
that O
the O
protection O
provided O
by O
PGE2 O
is O
a O
result O
of O
the O
modulation O
of O
early O
lung O
immunomodulatory O
mechanisms O
, O
and O
possibly O

PGE2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
cytokine O
production O
were O
analysed O
by O
flow O
cytometry O
and O
ELISA O
, O
respectively O
. O
Airway O
hyperreactivity O
was O
sustainably O
reduced O
only O
when O
PGE2 O
administration O
was O
restricted O
to O
the O
initial O
5 O
days O
of O
exposure O
to O
HDM O
. O
Lung O
inflammation O
, O
IL-4 B
production O
, O
and O
airway O
mast O
cell O
activity O
were O
also O
prevented O
under O
this O
early O
short-term O
treatment O
with O
PGE2 O
Interestingly O
, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM O
. O
This O
was O
paralleled O
by O
GM-CSF O
and O
osteopontin O
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells O
, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 O
expression O
. O
Local O
PGE2 O
administration O
prevented O
the O
increase O
of O

TAK-441 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibitor O
TAK-441 O
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
( O
TAK-441 O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo B
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 O
and O
the O
responses O
of O
Gli1 O
mRNA O
in O
tumor-associated O

TAK-441 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 O
and O
the O
responses O
of O
Gli1 B
mRNA O
in O
tumor-associated O
stromal O
or O
skin O
cells O
and O
the O
antitumor O
effect O
of O
hedgehog O
inhibition O
. O
To O
this O
end O
, O
we O
built O
pharmacokinetic O
and O
pharmacodynamic O
models O
that O
describe O
the O
relationship O
of O
the O
concentrations O
of O
TAK-441 O
plasma O
to O
the O
responses O
of O
Gli1 O
mRNA O
in O
the O
tumor O
(target) O
and O
skin O
(surrogate) O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
(PAN-04) O
. O
The O
responses O
of O
Gli1 O
mRNA O
and O
tumor O
growth O
were O
described O
by O
an O
indirect O
response O
model O
and O
an O
exponential O
tumor O
growth O
model O
, O

TAK-441 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
(PAN-04) O
. O
The O
responses O
of O
Gli1 B
mRNA O
and O
tumor O
growth O
were O
described O
by O
an O
indirect O
response O
model O
and O
an O
exponential O
tumor O
growth O
model O
, O
respectively O
. O
The O
IC50 O
values O
for O
Gli1 O
mRNA O
inhibition O
in O
the O
tumor O
and O
skin O
by O
TAK-441 O
were O
estimated O
to O
be O
0.0457 O
and O
0.113 O
μg/ml O
, O
respectively O
. O
The O
IC90 O
value O
for O
tumor O
growth O
inhibition O
was O
estimated O
to O
be O
0.68 O
μg/ml O
. O
These O
results O
suggest O
that O
a O
>83% O
inhibition O
of O
Gli1 O
mRNA O
expression O
in O
the O
skin O
or O
a O
>94% O
inhibition O
of O
Gli1 O
mRNA O
expression O
in O
the O
tumor O
would O
be O

TAK-441 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog O
inhibitor O
TAK-44 O
for O
the O
inhibition O
of O
Gli1 B
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
(TAK-441) O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O

TAK-441 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog B
inhibitor O
TAK-441 O
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
( O
TAK-441 O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 O
and O
the O
responses O
of O
Gli1 O
mRNA O
in O
tumor-associated O

TAK-441 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog B
inhibitor O
TAK-44 O
for O
the O
inhibition O
of O
Gli1 O
messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice.6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide O
(TAK-441) O
is O
a O
potent O
, O
selective O
hedgehog O
signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo O
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O

poly(ethylene O
glycol) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
We O
demonstrate O
that O
single-walled O
CNTs O
coated O
with O
human O
serum O
albumin O
activate O
the O
complement O
system O
through O
C1q-mediated O
classical O
and O
the O
alternative O
pathways O
. O
Surface O
coating O
with O
methoxypoly(ethylene O
glycol)-based O
amphiphiles O
, O
which O
confers O
solubility O
and O
prolongs O
circulation O
profiles O
of O
CNTs O
, O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O
CNTs O
with O
linear O
poly(ethylene O
glycol) O
amphiphiles O
trigger O
the O
lectin B
pathway O
of O
the O
complement O
through O
both O
L-ficolin O
and O
mannan-binding O
lectin O
recognition O
. O
The O
lectin O
pathway O
activation O
, O
however O
, O
did O
not O
trigger O
the O
amplification O
loop O
of O
the O
alternative O
pathway O
. O
An O
amphiphile O
with O
branched O
poly(ethylene O
glycol) O
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L-ficolin O
recognition O
. O
Importantly O
, O
this O

poly(ethylene O
glycol) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
We O
demonstrate O
that O
single-walled O
CNTs O
coated O
with O
human O
serum O
albumin O
activate O
the O
complement O
system O
through O
C1q-mediated O
classical O
and O
the O
alternative O
pathways O
. O
Surface O
coating O
with O
methoxypoly(ethylene O
glycol)-based O
amphiphiles O
, O
which O
confers O
solubility O
and O
prolongs O
circulation O
profiles O
of O
CNTs O
, O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O
CNTs O
with O
linear O
poly(ethylene O
glycol) O
amphiphiles O
trigger O
the O
lectin B
pathway O
of O
the O
complement O
through O
both O
L-ficolin O
and O
mannan-binding O
lectin O
recognition O
. O
The O
lectin O
pathway O
activation O
, O
however O
, O
did O
not O
trigger O
the O
amplification O
loop O
of O
the O
alternative O
pathway O
. O
An O
amphiphile O
with O
branched O
poly(ethylene O
glycol) O
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L-ficolin O
recognition O
. O
Importantly O
, O
this O

poly(ethylene O
glycol) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activates O
the O
complement O
system O
differently O
, O
depending O
on O
the O
amphiphile O
structure O
. O
CNTs O
with O
linear O
poly(ethylene O
glycol) O
amphiphiles O
trigger O
the O
lectin B
pathway O
of O
the O
complement O
through O
both O
L-ficolin O
and O
mannan-binding O
lectin O
recognition O
. O
The O
lectin O
pathway O
activation O
, O
however O
, O
did O
not O
trigger O
the O
amplification O
loop O
of O
the O
alternative O
pathway O
. O
An O
amphiphile O
with O
branched O
poly(ethylene O
glycol) O
architecture O
also O
activated O
the O
lectin O
pathway O
but O
only O
through O
L-ficolin O
recognition O
. O
Importantly O
, O
this O
mode O
of O
activation O
neither O
generated O
anaphylatoxins O
nor O
induced O
triggering O
of O
the O
effector O
arm O
of O
the O
complement O
system O
. O
These O
observations O
provide O
a O
major O
step O
toward O
nanomaterial O
surface O
modification O
with O
polymers O
that O
have O
the O
properties O
to O
significantly O
improve O

perviridicin O
B O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
line O
, O
with O
rocaglaol O
(9) O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

perviridicin O
B O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cell O
line O
, O
with O
rocaglaol O
(9) O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

rocaglate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

rocaglate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM) O
. O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

sesquiterpene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

sesquiterpene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

2-oxaisodauc-5-en-12-al O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB B
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

2-oxaisodauc-5-en-12-al O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line O
, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM O
. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line O
, O
CCD-112CoN O
. O
In O
addition O
, O
the O
new O
compound O
perviridicin O
B O
(2) O
, O
three O
known O
rocaglate O
derivatives O
(9 O
, O
11 O
, O
12) O
, O
and O
a O
known O
sesquiterpene O
, O
2-oxaisodauc-5-en-12-al O
(17) O
, O
showed O
significant O
NF-κB O
(p65) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

sulforaphane O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 B
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane O
inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O
cell O
line O
THP-1 O
as O
well O
as O
in O
human O
primary O
blood O
CD14(+) O
monocytes O
. O
In O
conclusion O
, O
together O
with O
the O
high O
inducibility O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O

tert-butylhydroquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O

tert-butylhydroquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O

cinnamic O
aldehyde O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O

cinnamic O
aldehyde O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O

hydrogen O
peroxide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O

hydrogen O
peroxide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide O
showed O
that O
the O
aldo-keto O
reductase O
(AKR) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O

sulforaphane O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Secondly O
, O
the O
linkage O
between O
NRF2 B
and O
the O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane-inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O

sulforaphane O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O

tert-butylhydroquinone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
damage O
. O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O

cinnamic O
aldehyde O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
For O
this O
purpose O
, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
and O
hydrogen O
peroxide) O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O

hydrogen O
peroxide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 O
to O
establish O
markers O
for O
NRF2 O
activity O
in O
human O
cells O
. O
Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
(sulforaphane O
, O
tert-butylhydroquinone O
, O
cinnamic O
aldehyde O
, O
and O
hydrogen O
peroxide O
showed O
that O
the O
aldo-keto B
reductase I
(AKR) I
1C1 I
is O
highly O
inducible O
by O
all O
treatments O
. O
Accordantly O
, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs O
were O
significantly O
attenuated O
in O
NRF2-silenced O
HK-2 O
cells O
. O
Whereas O
, O
cells O
with O
stable O
KEAP1 O
knockdown O
, O
which O
causes O
a O
modest O
NRF2 O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O

sulforaphane O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activation O
, O
demonstrated O
substantially O
increased O
levels O
of O
AKR1A1 O
, O
1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Secondly O
, O
the O
linkage O
between O
NRF2 O
and O
the O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane-inducible O
expression O
of O
AKR1C1 O
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O

sulforaphane O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
AKRs O
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937 O
, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells O
. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 O
inducers O
including O
sulforaphane O
effectively O
elevated O
the O
expression O
of O
AKR1B1 O
, O
1B10 O
, O
1C1 O
, O
1C2 O
, O
and O
1C3 O
. O
Whereas O
, O
the O
levels O
of O
both O
the O
basal O
and O
sulforaphane O
inducible O
expression O
of O
AKR1C1 B
were O
significantly O
reduced O
in O
NRF2-silenced O
stable O
U937 O
cells O
compared O
to O
the O
control O
cells O
. O
Similarly O
, O
the O
inducible O
expression O
of O
AKR1C1 O
was O
observed O
in O
another O
human O
monocytic O
leukemia O
cell O
line O
THP-1 O
as O
well O
as O
in O
human O
primary O
blood O
CD14(+) O
monocytes O
. O
In O
conclusion O
, O
together O
with O
the O
high O
inducibility O

lysine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
ends O
by O
facilitating O
their O
organization O
into O
the O
protective O
capping O
structure O
. O
Post-translational O
modifications O
of O
TRF2 B
such O
as O
phosphorylation O
, O
ubiquitination O
, O
SUMOylation O
, O
methylation O
and O
poly(ADP-ribosyl)ation O
have O
been O
shown O
to O
play O
important O
roles O
in O
telomere O
function O
. O
Here O
we O
show O
that O
TRF2 O
specifically O
interacts O
with O
the O
histone O
acetyltransferase O
p300 O
, O
and O
that O
p300 O
acetylates O
the O
lysine O
residue O
at O
position O
293 O
of O
TRF2 O
. O
We O
also O
report O
that O
p300-mediated O
acetylation O
stabilizes O
the O
TRF2 O
protein O
by O
inhibiting O
its O
ubiquitin-dependent O
proteolysis O
and O
is O
required O
for O
efficient O
telomere O
binding O
of O
TRF2 O
. O
Furthermore O
, O
overexpression O
of O
the O
acetylation-deficient O
mutant O
, O
K293R O
, O
induces O
DNA-damage O
response O
foci O
at O
telomeres O
, O
thereby O
leading O
to O
induction O
of O
impaired O

Tyr O
acts O
as O
PART-OF O
for O
what O
entity O
? O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 B
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
antitumor O
activity O
against O
various O
types O
of O
cancer O
, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE O
remain O
largely O
unknown O
. O
The O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
. O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Janus O
kinase O
2/Signal O
Transducer O
and O
Activator O
of O
Transcription O
3 O
(JAK2/STAT3) O
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development O
. O
In O
this O
study O
, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE O
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 O
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE O
PTE O
treatment O
resulted O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O

PTE O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 B
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL B
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 O
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability O
. O
Additionally O
, O
PTE O
exhibited O
strong O
antitumor O
activity O
, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion O
, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index O
, O
reactive O
oxygen O
species O
(ROS) O
and O
several O
biochemical O
parameters O
. O
Furthermore O
, O
PTE O
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 B
at O
Tyr O
1007 O
and O
the O
downstream O
activation O
of O
STAT3 O
. O
PTE O
also O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O

AG490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
down-regulated O
the O
expression O
of O
STAT3 O
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

AG490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
down-regulated O
the O
expression O
of O
STAT3 B
target O
genes O
, O
including O
the O
anti-apoptotic O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
proteins O
Bcl-xL O
and O
Mcl-1 O
, O
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax O
, O
Bak O
, O
cytosolic O
Cytochrome O
c O
, O
and O
cleaved O
Caspase3) O
and O
cyclin-dependent O
kinase O
inhibitors O
such O
as O
p21 O
and O
p27 O
. O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

PTE O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PTE O
, O
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 O
inhibitor O
, O
AG490 O
, O
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells O
. O
Taken O
together O
, O
PTE O
is O
a O
potent O
inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 O
signaling O
pathway O
. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 O
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE O
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers O
. O

GW4064 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
Baat) O
, O
whereas O
Bsep O
, O
Mrp2 O
and O
Cyp27a1 O
were O
up-regulated O
. O
Human O
HepG2 O
and O
Alexander O
cell O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR B
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP O
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O

GW4064 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR B
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O
Moreover O
, O
GCs O
have O
a O
synergistic O
effect O
on O
GW4064 O
induced O
FXR O
activation O
, O
whereas O
chenodeoxycholate O
and O
GW4064 O
have O
an O
additive O
effect O
. O
In O
conclusion O
, O
GCs O
are O
able O
to O
directly O
or O
indirectly O
activate O
FXR O
but O
they O
also O
antagonize O
, O
through O
FXR-independent O
mechanisms O
, O
the O
expression O
of O
FXR O
and O
FXR O
target O
genes O
involved O
in O
the O
hepatic O
handling O
of O
BAs O
. O

GW4064 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR O
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP B
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O

GW4064 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR O
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP O
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O

GW4064 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR O
expression O
, O
respectively O
. O
In O
HepG2 O
cells O
, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR O
and O
SHP O
, O
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 O
on O
FXR-target O
genes O
. O
In O
Alexander O
cells O
, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR O
, O
GW4064 O
caused O
up-regulation O
of O
SHP O
and O
OSTβ O
, O
and O
a O
down-regulation O
of O
CYP27A1 O
. O
GCs O
had O
the O
opposite O
effect O
on O
these O
genes O
, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR O
expression O
. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR O
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR O
activity O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn-induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O
lines O
whereas O
DA O
was O
only O
toxic O
to O
cells O
containing O
DAT O
. O
DA O
toxicity O
was O
saturable O
suggesting O
that O
transport O
may O
be O
rate O
limiting O
. O
When O
Mn O
and O
DA O
were O
added O
simultaneously O
to O
the O
media O
, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn O
alone O
suggesting O
that O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
media O
, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn O
alone O
suggesting O
that O
Mn O
may O
suppress O
DA O
uptake O
in O
the O
DAT B
containing O
cells O
. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn O
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn-induced O
internalization O
of O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
DAT B
containing O
cells O
. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn O
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT O
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn-induced O
internalization O
of O
DAT O
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
two O
agents O
. O
Mn O
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced O
DA O
efflux O
in O
DAT B
containing O
cells O
. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn O
can O
promote O
trafficking O
of O
cell O
surface O
DAT O
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells O
. O
Mn O
induced O
internalization O
of O
DAT O
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum O
. O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
effect O
of O
manganese O
on O
dopamine O
toxicity O
and O
dopamine B
transporter I
(DAT) O
in O
control O
and O
DAT O
transfected O
HEK O
cells.Chronic O
exposure O
to O
Mn O
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn O
induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
effect O
of O
manganese O
on O
dopamine O
toxicity O
and O
dopamine O
transporter O
(DAT) O
in O
control O
and O
DAT B
transfected O
HEK O
cells.Chronic O
exposure O
to O
Mn O
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O
deficits O
resembling O
that O
seen O
in O
Parkinsonism O
. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact O
, O
Mn O
induced O
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced O
DA O
release O
and O
loss O
of O
the O
dopamine O
transporter O
(DAT) O
. O
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn O
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected O
HEK O
cells O
reveal O
that O
Mn O
is O
equally O
toxic O
to O
both O
cell O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridin O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridin O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun B
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O

2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridin O
(PhIP) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 B
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhI O
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhI O
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun B
and O
p16 O
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O

PhIP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhI O
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 B
in O
rat O
stomachs.2-Amino-1-methyl-6-phenylimidazo O
[4 O
, O
5-b] O
pyridine O
(PhIP) O
is O
one O
of O
the O
most O
abundant O
heterocyclic O
amines O
(HCAs) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O

PhIP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos B
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

PhIP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun B
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

PhIP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun B
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O

PhIP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 O
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos B
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O

PhIP O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase B
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide B
dismutase I
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase B
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
at O
high O
temperatures O
. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated O
stomach O
cancer O
, O
the O
effects O
of O
PhIP O
on O
morphology O
, O
oxidative O
stress O
, O
gene O
expression O
of O
c-fos O
, O
c-jun O
and O
p16 O
in O
rat O
stomachs O
were O
investigated O
. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP O
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O

PhIP O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(2) O
PhIP O
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide O
dismutase O
(SOD) O
and O
glutathioneperoxidase O
(GPx) O
activities O
, O
while O
increased O
catalase O
(CAT) O
activity O
compared O
with O
the O
control O
. O
With O
the O
elevated O
doses O
of O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 B
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O

PhIP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PhIP O
, O
malondialdehyde O
(MDA) O
contents O
, O
protein O
carbonyl O
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP O
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 B
mRNA O
and O
protein O
expression O
, O
whereas O
enhanced O
c-fos O
and O
c-jun O
expression O
relative O
to O
control O
. O
The O
data O
indicated O
that O
PhIP O
could O
cause O
stomach O
injury O
, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos O
and O
c-jun O
and O
inactivation O
of O
p16 O
, O
which O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated O
stomach O
cancer O
. O

1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium O
dimethanesulfonate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
pharmacokinetic O
model O
for O
the O
oxime O
TMB-4 O
: O
simulation O
of O
rodent O
and O
human O
data.Multiple O
oximes O
have O
been O
synthesized O
and O
evaluated O
for O
use O
as O
countermeasures O
against O
chemical O
warfare O
nerve O
agents O
. O
The O
current O
U.S O
. O
military O
and O
civilian O
oxime O
countermeasure O
, O
2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium O
chloride O
(2-PAM) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase B
reactivator O
, O
1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium O
dimethanesulfonate O
(MMB-4) O
. O
Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB-4 O
are O
limited; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
(PBPK) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime O
, O
1,1'-trimethylenebis{4-hydroximinomethyl}pyridinium O
dibromide O
. O
Based O
on O
a O
previous O
model O
structure O
for O
the O
organophosphate O
diisopropylfluorophosphate O
, O
the O
model O
includes O
key O
sites O
of O
acetylcholinesterase O
inhibition O
(brain O
and O
diaphragm) O
, O
as O

MMB-4 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
oxime O
TMB-4 O
: O
simulation O
of O
rodent O
and O
human O
data.Multiple O
oximes O
have O
been O
synthesized O
and O
evaluated O
for O
use O
as O
countermeasures O
against O
chemical O
warfare O
nerve O
agents O
. O
The O
current O
U.S O
. O
military O
and O
civilian O
oxime O
countermeasure O
, O
2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium O
chloride O
(2-PAM) O
, O
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase B
reactivator O
, O
1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium O
dimethanesulfonate O
( O
MMB-4 O
 O
. O
Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB-4 O
are O
limited; O
therefore O
, O
a O
physiologically O
based O
pharmacokinetic O
(PBPK) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime O
, O
1,1'-trimethylenebis{4-hydroximinomethyl}pyridinium O
dibromide O
. O
Based O
on O
a O
previous O
model O
structure O
for O
the O
organophosphate O
diisopropylfluorophosphate O
, O
the O
model O
includes O
key O
sites O
of O
acetylcholinesterase O
inhibition O
(brain O
and O
diaphragm) O
, O
as O

SiO(2) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 B
and O
caspase-9 O
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O
and O
A549 O
cells O
, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress O
. O

SiO(2) O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 O
and O
caspase-9 B
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O
and O
A549 O
cells O
, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress O
. O

SiO(2) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) O
and O
lactate O
dehydrogenase O
leakage O
assays O
. O
SiO(2) O
NPs O
were O
also O
found O
to O
induce O
oxidative O
stress O
in O
a O
dose-dependent O
manner O
, O
indicated O
by O
depletion O
of O
glutathione O
and O
induction O
of O
reactive O
oxygen O
species O
(ROS) O
generation O
and O
lipid O
peroxidation O
. O
Quantitative O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 B
and O
caspase-9 O
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O

SiO(2) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) O
and O
lactate O
dehydrogenase O
leakage O
assays O
. O
SiO(2) O
NPs O
were O
also O
found O
to O
induce O
oxidative O
stress O
in O
a O
dose-dependent O
manner O
, O
indicated O
by O
depletion O
of O
glutathione O
and O
induction O
of O
reactive O
oxygen O
species O
(ROS) O
generation O
and O
lipid O
peroxidation O
. O
Quantitative O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) O
NPs O
, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 O
and O
caspase-9) O
were O
upregulated O
in O
a O
dose-dependent O
manner O
. O
Moreover O
, O
activities O
of O
caspase-3 O
and O
caspase-9 B
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) O
NPs O
. O
This O
study O
suggested O
that O
SiO(2) O
NPs O
induce O
cytotoxicity O
and O
apoptosis O
in O
A431 O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
four O
new O
mouse O
cytochrome O
P450 O
enzymes O
of O
the O
CYP2J B
subfamily.The O
cytochrome O
P450 O
superfamily O
encompasses O
a O
diverse O
group O
of O
enzymes O
that O
catalyze O
the O
oxidation O
of O
various O
substrates O
. O
The O
mouse O
CYP2J O
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic O
acid O
(AA) O
, O
linoleic O
acid O
(LA) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O
The O
mouse O
Cyp2j O
locus O
contains O
seven O
genes O
and O
three O
pseudogenes O
located O
in O
a O
contiguous O
0.62 O
megabase O
cluster O
on O
chromosome O
4 O
. O
We O
describe O
four O
new O
mouse O
CYP2J O
isoforms O
(designated O
CYP2J8 O
, O
CYP2J11 O
, O
CYP2J12 O
, O
and O
CYP2J13) O
. O
The O
four O
cDNAs O
contain O
open O
reading O
frames O

linoleic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Characterization O
of O
four O
new O
mouse O
cytochrome O
P450 O
enzymes O
of O
the O
CYP2J B
subfamily.The O
cytochrome O
P450 O
superfamily O
encompasses O
a O
diverse O
group O
of O
enzymes O
that O
catalyze O
the O
oxidation O
of O
various O
substrates O
. O
The O
mouse O
CYP2J O
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic O
acid O
(AA) O
, O
linoleic O
acid O
(LA) O
, O
and O
other O
lipids O
and O
xenobiotics O
. O
The O
mouse O
Cyp2j O
locus O
contains O
seven O
genes O
and O
three O
pseudogenes O
located O
in O
a O
contiguous O
0.62 O
megabase O
cluster O
on O
chromosome O
4 O
. O
We O
describe O
four O
new O
mouse O
CYP2J O
isoforms O
(designated O
CYP2J8 O
, O
CYP2J11 O
, O
CYP2J12 O
, O
and O
CYP2J13) O
. O
The O
four O
cDNAs O
contain O
open O
reading O
frames O
that O
encode O
polypeptides O

doxycycline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
renin-angiotensin-aldosterone O
system O
and O
oxidative O
stress O
activate O
and O
upregulate O
MMPs O
. O
Therefore O
, O
MMP B
inhibition O
may O
prevent O
the O
deleterious O
consequences O
of O
hypertension O
to O
the O
cardiovascular O
system O
. O
This O
review O
article O
will O
focus O
on O
growing O
evidence O
supporting O
the O
relevance O
of O
MMPs O
in O
hypertension O
and O
the O
effects O
of O
MMP O
inhibitors O
. O
Particularly O
, O
the O
effects O
of O
doxycycline O
used O
as O
a O
non O
selective O
MMP O
inhibitor O
in O
experimental O
and O
clinical O
studies O
will O
be O
discussed O
. O

TES O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

TES O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

TES O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

TES O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine O
oxidase O
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen B
receptor I
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O

peroxynitrite O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
. O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen O
action O
in O
the O
microvasculature O
: O
TES-stimulated O
vasodilation O
mediated O
primarily O
by O
peroxynitrite O
formed O
from O
xanthine O
oxidase-generated O
superoxide O
and O
NO O
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 O
kinase-Akt O
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
. O
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated O
cGMP O
production O
in O
microvessels O
and O
, O
ultimately O
, O
vasodilation O
. O

TES O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
and O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine B
oxidase I
was O
identified O
as O
the O
likely O
source O
of O
TES O
stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
nitrotyrosine O
immunoblot O
experiments O
indicated O
that O
TES O
stimulated O
peroxynitrite O
formation O
in O
microvessels O
, O
and O
functional O
studies O
demonstrated O
that O
TES-induced O
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite O
. O
As O
predicted O
, O
TES O
enhanced O
the O
production O
of O
both O
peroxynitrite O
precursors O
(i.e. O
, O
superoxide O
and O
nitic O
oxide) O
, O
and O
xanthine B
oxidase I
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated O
superoxide O
production O
. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES O
signaling O
involved O
activity O
of O
the O
phosphoinositide O
3 O
(PI3) O
kinase-protein O
kinase O
B O
(Akt) O
cascade O
initiated O
by O
activation O
of O
the O
androgen O
receptor O
and O
culminated O
in O
enhanced O
production O
of O
cGMP O
and O
microvascular O
vasodilation O
. O
These O
findings O
, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches O
, O

butein O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein O
dependent O
HO-1 B
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O

butein O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK B
phosphorylation O
. O
These O
results O
indicate O
that O
butein O
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

Butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme B
oxygenase-1 I
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O

Butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 B
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant B
response I
elements I
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear B
factor-E2-related I
factor I
2 I
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO O
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein-induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O

butein O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
HO-1 B
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun O
NH2-terminal O
kinase O
(JNK) O
inhibitor O
also O
reduced O
butein O
induced O
HO-1 O
expression O
, O
and O
butein O
treatment O
led O
to O
increased O
JNK O
phosphorylation O
. O
These O
results O
indicate O
that O
butein O
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent O
. O

Butein O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
found O
that O
butein O
possesses O
cytoprotective O
effects O
on O
hydrogen O
peroxide O
(H2O2)-induced O
dental O
cell O
death O
. O
H2O2 O
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells O
. O
H2O2-induced O
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein O
, O
and O
these O
effects O
were O
dose O
dependent O
. O
Butein O
also O
increased O
heme O
oxygenase-1 O
(HO-1) O
protein O
expression O
and O
HO B
activity O
. O
In O
addition O
, O
butein-dependent O
HO-1 O
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced O
cell O
death O
and O
ROS O
generation O
. O
Furthermore O
, O
butein O
treatment O
caused O
nuclear O
accumulation O
of O
nuclear O
factor-E2-related O
factor O
2 O
(Nrf2) O
and O
increased O
the O
promoter O
activity O
of O
antioxidant O
response O
elements O
(AREs) O
. O

manumycin O
A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I B
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I O
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

manumycin O
A O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I B
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

manumycin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase B
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I O
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

manumycin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
siRNA O
screening O
strategy O
, O
assay O
implementation O
and O
validation O
, O
data O
triaging O
, O
and O
example O
genes O
of O
interest O
. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes O
, O
proteases O
, O
G-protein-coupled O
receptors O
, O
metabolic O
enzymes O
, O
ion O
transporters O
, O
and O
proteins O
of O
unknown O
function O
. O
Repression O
of O
farnesyltransferase O
(FNTA) O
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin O
A O
caused O
elevation O
of O
ApoA-I O
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I O
and O
cholesterol O
ester O
transfer O
protein O
transgenes O
. O
In O
total O
, O
this O
work O
underscores O
the O
power O
of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets O
. O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O

compound O
C O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O

SB216763 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O

MG132 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK B
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme B
A I
carboxylase I
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
sub-G1 O
population O
and O
the O
number O
of O
ethidium O
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP O
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells O
. O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O

Ursolic O
Acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated B
Protein I
Kinase I
and O
Phosphorylation O
of O
Glycogen O
Synthase O
Kinase3 O
β O
Mediate O
Ursolic O
Aci O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O

Ursolic O
Acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
AMP-activated O
Protein O
Kinase O
and O
Phosphorylation O
of O
Glycogen B
Synthase I
Kinase3 I
β I
Mediate O
Ursolic O
Aci O
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells.Despite O
the O
antitumour O
effect O
of O
ursolic O
acid O
observed O
in O
several O
cancers O
, O
the O
underlying O
mechanism O
remains O
unclear O
. O
Thus O
, O
in O
the O
present O
study O
, O
the O
roles O
of O
AMP-activated O
protein O
kinase O
(AMPK) O
and O
glycogen O
synthase O
kinase O
3 O
beta O
(GSK3β) O
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK B
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β B
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
AMPK B
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β B
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP B
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O

MG132 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 B
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 B
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

compound O
C O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O

SB216763 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase B
3 I
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O

ursolic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 B
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

ursolic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT B
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O

ursolic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Also O
, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose O
polymerase O
(PARP) O
and O
caspase3 O
, O
attenuated O
the O
expression O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR B
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O

compound O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
astrocyte O
elevated O
gene O
(AEG1) O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK B
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O

SB216763 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
survivin O
in O
HepG2 O
cells O
. O
Interestingly O
, O
ursolic O
acid O
increased O
the O
phosphorylation O
of O
AMPK O
and O
coenzyme O
A O
carboxylase O
and O
also O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O

MG132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β O
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK B
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

MG132 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
enhanced O
phosphorylation O
of O
GSK3β B
at O
inactive O
form O
serine O
9 O
, O
whereas O
ursolic O
acid O
attenuated O
the O
phosphorylation O
of O
AKT O
and O
mTOR O
in O
HepG2 O
cells O
. O
Conversely O
, O
AMPK O
inhibitor O
compound O
C O
or O
GSK3β O
inhibitor O
SB216763 O
blocked O
the O
cleavages O
of O
PARP O
and O
caspase O
3 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Furthermore O
, O
proteosomal O
inhibitor O
MG132 O
suppressed O
AMPK O
activation O
, O
GSK3β O
phosphorylation O
, O
cleaved O
PARP O
and O
deceased O
AEG-1 O
induced O
by O
ursolic O
acid O
in O
HepG2 O
cells O
. O
Overall O
, O
our O
findings O
suggest O
that O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK O
activation O
and O
GSK3β O
phosphorylation O
as O
a O
potent O
chemopreventive O
agent O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

quercetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O

quercetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 B
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O

Flavonoids O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O

catechins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O

quercetin O
glycosides O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O

estrone O
3-sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O

estrone O
3-sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O

dehydroepiandrosterone O
sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O

dehydroepiandrosterone O
sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O

DHEAS O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B
and O
OATP1B3 O
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
( O
DHEAS O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O

DHEAS O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O
study O
, O
the O
extent O
to O
which O
six O
substituted O
quercetin O
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 O
and O
OATP1B3 B
was O
investigated O
. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol O
17β-glucuronide O
, O
estrone O
3-sulfate O
, O
and O
dehydroepiandrosterone O
sulfate O
( O
DHEAS O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O

estradiol O
17β-glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
dehydroepiandrosterone O
sulfate O
(DHEAS) O
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O

quercetin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 B
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
querceti O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O

quercetin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 B
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallate O
and O
several O
querceti O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O
In O
the O
present O

epigallocatechin O
3-O-gallate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 B
and O
OATP1B3 O
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallat O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O

epigallocatechin O
3-O-gallate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Transport O
by O
OATP1B1 O
and O
OATP1B3 B
enhances O
the O
cytotoxicity O
of O
epigallocatechin O
3-O-gallat O
and O
several O
quercetin O
derivatives.Organic O
anion O
transporting O
polypeptides O
(OATPs) O
1B1 O
and O
1B3 O
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O
hepatocytes O
under O
normal O
conditions O
. O
OATP1B3 O
is O
also O
expressed O
in O
certain O
cancers O
. O
Flavonoids O
such O
as O
green O
tea O
catechins O
and O
quercetin O
glycosides O
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs O
. O

epigallocatechin O
3-O-gallate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O

EGCG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
expressing O
either O
OATP1B1 O
or O
OATP1B3 O
. O
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated O
uptake O
of O
all O
three O
model O
substrates O
, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 O
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
( O
EGCG O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O

EGCG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
also O
be O
potential O
substrates O
. O
Compound O
6 O
stimulated O
OATP1B3-mediated O
estradiol O
17β-glucuronide O
uptake O
by O
increasing O
the O
apparent O
affinity O
of O
OATP1B3 B
for O
its O
substrate O
. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin O
3-O-gallate O
(EGCG) O
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing O
CHO O
cells O
. O
EGCG O
, O
1 O
, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds O
, O
with O
EGCG O
and O
3 O
selectively O
killing O
OATP1B3-expressing O
cells O
. O
Given O
that O
OATP1B3 O
is O
expressed O
in O
several O
cancers O
, O
EGCG O
and O
some O
of O
the O
quercetin O
derivatives O
studied O
might O
be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs O
. O

NAc-Cys-Pro-Cys O
amide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O
NAC O
, O
AD4 O
, O
or O
ascorbic O
acid O
. O
Unable O
to O
reverse O
ERK1/2 O
phosphorylation O
, O
TXM-CB3 O
( O
NAc-Cys-Pro-Cys O
amide O
appeared O
to O
function O
in O
part O
, O
through O
inhibiting O
ASK1-Trx O
dissociation O
. O
These O
highly O
effective O
anti-apoptotic O
effects O
of O
Trx1 O
mimetic O
peptides O
exhibited O
in O
INS O
832/13 O
cells O
could O
become O
valuable O
in O
treating O
adverse O
oxidative-stress O
related O
disorders O
such O
as O
diabetes O
. O

NAc-Cys-Pro-Cys O
amide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O
NAC O
, O
AD4 O
, O
or O
ascorbic O
acid O
. O
Unable O
to O
reverse O
ERK1/2 O
phosphorylation O
, O
TXM-CB3 O
( O
NAc-Cys-Pro-Cys O
amide O
appeared O
to O
function O
in O
part O
, O
through O
inhibiting O
ASK1-Trx O
dissociation O
. O
These O
highly O
effective O
anti-apoptotic O
effects O
of O
Trx1 O
mimetic O
peptides O
exhibited O
in O
INS O
832/13 O
cells O
could O
become O
valuable O
in O
treating O
adverse O
oxidative-stress O
related O
disorders O
such O
as O
diabetes O
. O

AuF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF O
induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 B
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O

AuF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF O
induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 O
cleavage O
and O
thereby O
PARP-1 B
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O

AuF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF O
induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O

AuF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF O
induced O
MAPK O
, O
JNK B
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O

AuF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF O
induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O

AuF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR O
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF O
induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O
restored O
insulin O
secretion O
and O
displayed O
Trx1 O
denitrosylase O
activity O
. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O

auranofin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
apoptotic O
pathway O
. O
The O
potential O
mechanism O
and O
ability O
of O
tri- O
and O
tetra-oligopeptides O
derived O
from O
the O
canonical O
-CxxC- O
motif O
of O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR B
with O
auranofin O
(AuF) O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF-induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O

AuF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
potential O
mechanism O
and O
ability O
of O
tri- O
and O
tetra-oligopeptides O
derived O
from O
the O
canonical O
-CxxC- O
motif O
of O
the O
Trx1-active O
site O
to O
mimic O
and O
enhance O
Trx1 O
cellular O
activity O
was O
examined O
. O
The O
Trx O
mimetics O
peptides O
(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR B
with O
auranofin O
( O
AuF O
 O
. O
TXM O
reversed O
the O
AuF-effects O
preventing O
apoptosis O
, O
and O
increasing O
cell-viability O
. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF-induced O
MAPK O
, O
JNK O
and O
p38(MAPK) O
phosphorylation O
, O
in O
correlation O
with O
preventing O
caspase-3 O
cleavage O
and O
thereby O
PARP-1 O
dissociation O
. O
The O
ability O
to O
form O
a O
disulfide-bridge-like O
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations O
. O
The O
TXM O
peptides O

azoles O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
may O
be O
a O
role O
for O
PXR B
antagonists O
. O
However O
, O
as O
opposed O
to O
the O
discovery O
efforts O
for O
PXR O
agonists O
, O
there O
are O
only O
a O
few O
antagonists O
described O
. O
The O
mode O
of O
action O
of O
these O
antagonists O
(e.g. O
, O
sulforaphane) O
remains O
less O
clear O
. O
Our O
laboratory O
efforts O
have O
focused O
on O
this O
question O
. O
Since O
the O
original O
discovery O
of O
azoles O
analogs O
as O
PXR O
antagonists O
, O
we O
have O
preliminarily O
defined O
an O
important O
PXR O
antagonist O
pharmacophore O
and O
developed O
less-toxic O
PXR O
antagonists O
. O
In O
this O
review O
, O
we O
describe O
our O
published O
and O
unpublished O
findings O
on O
recent O
structure-function O
studies O
involving O
the O
azole O
chemical O
scaffold O
. O
Further O
work O
in O
the O
future O
is O
needed O
to O
fully O
define O
potent O
, O
more-selective O

azoles O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
may O
be O
a O
role O
for O
PXR B
antagonists O
. O
However O
, O
as O
opposed O
to O
the O
discovery O
efforts O
for O
PXR O
agonists O
, O
there O
are O
only O
a O
few O
antagonists O
described O
. O
The O
mode O
of O
action O
of O
these O
antagonists O
(e.g. O
, O
sulforaphane) O
remains O
less O
clear O
. O
Our O
laboratory O
efforts O
have O
focused O
on O
this O
question O
. O
Since O
the O
original O
discovery O
of O
azoles O
analogs O
as O
PXR O
antagonists O
, O
we O
have O
preliminarily O
defined O
an O
important O
PXR O
antagonist O
pharmacophore O
and O
developed O
less-toxic O
PXR O
antagonists O
. O
In O
this O
review O
, O
we O
describe O
our O
published O
and O
unpublished O
findings O
on O
recent O
structure-function O
studies O
involving O
the O
azole O
chemical O
scaffold O
. O
Further O
work O
in O
the O
future O
is O
needed O
to O
fully O
define O
potent O
, O
more-selective O

azoles O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
may O
be O
a O
role O
for O
PXR B
antagonists O
. O
However O
, O
as O
opposed O
to O
the O
discovery O
efforts O
for O
PXR O
agonists O
, O
there O
are O
only O
a O
few O
antagonists O
described O
. O
The O
mode O
of O
action O
of O
these O
antagonists O
(e.g. O
, O
sulforaphane) O
remains O
less O
clear O
. O
Our O
laboratory O
efforts O
have O
focused O
on O
this O
question O
. O
Since O
the O
original O
discovery O
of O
azoles O
analogs O
as O
PXR O
antagonists O
, O
we O
have O
preliminarily O
defined O
an O
important O
PXR O
antagonist O
pharmacophore O
and O
developed O
less-toxic O
PXR O
antagonists O
. O
In O
this O
review O
, O
we O
describe O
our O
published O
and O
unpublished O
findings O
on O
recent O
structure-function O
studies O
involving O
the O
azole O
chemical O
scaffold O
. O
Further O
work O
in O
the O
future O
is O
needed O
to O
fully O
define O
potent O
, O
more-selective O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
memory O
. O
It O
was O
found O
that O
expression O
of O
Sim2 B
protein O
in O
cortical O
neurons O
was O
increased O
in O
streptozotocin-induced O
diabetes O
mellitus O
rat O
model O
. O
Drebrin O
, O
down-regulated O
by O
Sim2 O
, O
was O
subsequently O
decreased O
as O
detected O
by O
confocal O
laser O
scanning O
microscopy O
and O
Western O
blot O
analysis O
. O
The O
expression O
pattern O
of O
Sim2 O
and O
Drebrin O
correspond O
to O
50mmol/L O
glucose O
(hyperglycaemia) O
was O
also O
found O
in O
primary O
cultured O
neurons O
. O
Curcumin O
, O
one O
neuroprotective O
agent O
, O
inhibited O
hyperglycaemia-induced O
neurotoxicity O
. O
Moreover O
, O
curcumin O
alleviated O
Sim2 O
expression O
, O
and O
reversely O
raised O
Drebrin O
expression O
in O
neurons O
treated O
with O
hyperglycaemia O
. O
Finally O
, O
we O
found O
that O
silencing O
Sim2 O
expression O
decreased O
hyperglycaemia-induced O
neuronal O
injury O
. O
In O
conclusion O
, O
Sim2 O
may O
mediate O
neurotoxicity O
during O
hyperglycaemia O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
memory O
. O
It O
was O
found O
that O
expression O
of O
Sim2 O
protein O
in O
cortical O
neurons O
was O
increased O
in O
streptozotocin-induced O
diabetes O
mellitus O
rat O
model O
. O
Drebrin O
, O
down-regulated O
by O
Sim2 O
, O
was O
subsequently O
decreased O
as O
detected O
by O
confocal O
laser O
scanning O
microscopy O
and O
Western O
blot O
analysis O
. O
The O
expression O
pattern O
of O
Sim2 O
and O
Drebrin B
correspond O
to O
50mmol/L O
glucose O
(hyperglycaemia) O
was O
also O
found O
in O
primary O
cultured O
neurons O
. O
Curcumin O
, O
one O
neuroprotective O
agent O
, O
inhibited O
hyperglycaemia-induced O
neurotoxicity O
. O
Moreover O
, O
curcumin O
alleviated O
Sim2 O
expression O
, O
and O
reversely O
raised O
Drebrin O
expression O
in O
neurons O
treated O
with O
hyperglycaemia O
. O
Finally O
, O
we O
found O
that O
silencing O
Sim2 O
expression O
decreased O
hyperglycaemia-induced O
neuronal O
injury O
. O
In O
conclusion O
, O
Sim2 O
may O
mediate O
neurotoxicity O
during O
hyperglycaemia O

curcumin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
diabetes O
mellitus O
rat O
model O
. O
Drebrin O
, O
down-regulated O
by O
Sim2 O
, O
was O
subsequently O
decreased O
as O
detected O
by O
confocal O
laser O
scanning O
microscopy O
and O
Western O
blot O
analysis O
. O
The O
expression O
pattern O
of O
Sim2 B
and O
Drebrin O
correspond O
to O
50mmol/L O
glucose O
(hyperglycaemia) O
was O
also O
found O
in O
primary O
cultured O
neurons O
. O
Curcumin O
, O
one O
neuroprotective O
agent O
, O
inhibited O
hyperglycaemia-induced O
neurotoxicity O
. O
Moreover O
, O
curcumin O
alleviated O
Sim2 O
expression O
, O
and O
reversely O
raised O
Drebrin O
expression O
in O
neurons O
treated O
with O
hyperglycaemia O
. O
Finally O
, O
we O
found O
that O
silencing O
Sim2 O
expression O
decreased O
hyperglycaemia-induced O
neuronal O
injury O
. O
In O
conclusion O
, O
Sim2 O
may O
mediate O
neurotoxicity O
during O
hyperglycaemia O
and O
thereby O
play O
a O
critical O
role O
in O
the O
development O
of O
hyperglycaemia-induced O
cognitive O
deficits O
. O

curcumin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
diabetes O
mellitus O
rat O
model O
. O
Drebrin O
, O
down-regulated O
by O
Sim2 O
, O
was O
subsequently O
decreased O
as O
detected O
by O
confocal O
laser O
scanning O
microscopy O
and O
Western O
blot O
analysis O
. O
The O
expression O
pattern O
of O
Sim2 O
and O
Drebrin B
correspond O
to O
50mmol/L O
glucose O
(hyperglycaemia) O
was O
also O
found O
in O
primary O
cultured O
neurons O
. O
Curcumin O
, O
one O
neuroprotective O
agent O
, O
inhibited O
hyperglycaemia-induced O
neurotoxicity O
. O
Moreover O
, O
curcumin O
alleviated O
Sim2 O
expression O
, O
and O
reversely O
raised O
Drebrin O
expression O
in O
neurons O
treated O
with O
hyperglycaemia O
. O
Finally O
, O
we O
found O
that O
silencing O
Sim2 O
expression O
decreased O
hyperglycaemia-induced O
neuronal O
injury O
. O
In O
conclusion O
, O
Sim2 O
may O
mediate O
neurotoxicity O
during O
hyperglycaemia O
and O
thereby O
play O
a O
critical O
role O
in O
the O
development O
of O
hyperglycaemia-induced O
cognitive O
deficits O
. O

streptozotocin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
elusive O
. O
Single-minded O
2 O
(Sim2) O
, O
a O
basic O
helix-loop-helix O
(bHLH)-PAS O
transcriptional O
repressor O
, O
is O
thought O
to O
be O
involved O
in O
some O
symptoms O
of O
Down O
syndrome O
. O
We O
hypothesized O
that O
Sim2 B
mediated O
hyperglycaemia-induced O
neuronal O
injury O
and O
impairment O
of O
learning O
and O
memory O
. O
It O
was O
found O
that O
expression O
of O
Sim2 O
protein O
in O
cortical O
neurons O
was O
increased O
in O
streptozotocin O
induced O
diabetes O
mellitus O
rat O
model O
. O
Drebrin O
, O
down-regulated O
by O
Sim2 O
, O
was O
subsequently O
decreased O
as O
detected O
by O
confocal O
laser O
scanning O
microscopy O
and O
Western O
blot O
analysis O
. O
The O
expression O
pattern O
of O
Sim2 O
and O
Drebrin O
correspond O
to O
50mmol/L O
glucose O
(hyperglycaemia) O
was O
also O
found O
in O
primary O
cultured O
neurons O
. O
Curcumin O
, O
one O
neuroprotective O
agent O
, O
inhibited O
hyperglycaemia-induced O
neurotoxicity O
. O

Pinosylvin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin B
dependent I
kinase I
2 I
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma B
protein I
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

Pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O

pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvi O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O

pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvi O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O

pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvi O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O

pinosylvin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Suppression O
of O
Src/ERK O
and O
GSK-3/β-catenin O
signaling O
by O
pinosylvi O
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells.Pinosylvin O
, O
a O
naturally O
occurring O
trans-stilbenoid O
mainly O
found O
in O
Pinus O
species O
, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity O
. O
However O
, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated O
. O
Therefore O
, O
the O
anti-proliferative O
activity O
of O
pinosylvin O
was O
investigated O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide B
3-kinase I
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen B
synthase I
kinase I
3β I
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

Pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cells O
. O
Pinosylvin O
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin O
D1 O
, O
cyclin O
E O
, O
cyclin O
A O
, O
cyclin O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

pinosylvin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
dependent O
kinase O
2 O
(CDK2) O
, O
CDK4 O
, O
c-Myc O
, O
and O
retinoblastoma O
protein O
(pRb) O
, O
and O
the O
upregulation O
of O
p21(WAF1/CIP1) O
and O
p53 O
. O
Pinosylvin O
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal O
adhesion O
kinase O
(FAK)/c-Src/extracellular O
signal-regulated O
kinase O
(ERK) O
signaling O
, O
and O
phosphoinositide O
3-kinase O
(PI3K)/Akt O
/ O
glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
signaling O
pathway O
. O
Subsequently O
, O
pinosylvin O
suppressed O
the O
nuclear O
translocation O
of O
β-catenin O
, O
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β O
signaling O
, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated O
transcription O
of O
target O
genes O
including O
BMP4 O
, O
ID2 O
, O
survivin O
, O
cyclin O
D1 O
, O
MMP7 O
, O
and O
c-Myc O
. O
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin O
might O
be O
associated O
with O

β-Lapachone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model O
. O
β-Lapachone O
(β-Lap) O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone B
oxidoreductase-1 I
(NQO1) O
. O
NQO1 O
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O
formulated O
β-Lap O

β-Lapachone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model O
. O
β-Lapachone O
(β-Lap) O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone O
oxidoreductase-1 O
(NQO1) O
. O
NQO1 B
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O
formulated O
β-Lap O

β-Lap O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model.β-Lapachone O
( O
β-Lap O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone B
oxidoreductase-1 I
(NQO1) O
. O
NQO1 O
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O
formulated O
β-Lap O
in O

β-Lap O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model.β-Lapachone O
( O
β-Lap O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone O
oxidoreductase-1 O
(NQO1) O
. O
NQO1 B
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O
formulated O
β-Lap O
in O

1,2-orthonaphthoquinone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model.β-Lapachone O
(β-Lap) O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone B
oxidoreductase-1 I
(NQO1) O
. O
NQO1 O
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O
formulated O
β-Lap O
in O
an O
optimal O
random O

1,2-orthonaphthoquinone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin O
ternary O
system O
induces O
apoptosis O
, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model.β-Lapachone O
(β-Lap) O
is O
a O
1,2-orthonaphthoquinone O
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone O
oxidoreductase-1 O
(NQO1) O
. O
NQO1 B
is O
overexpressed O
in O
a O
variety O
of O
tumors O
, O
as O
compared O
to O
normal O
adjacent O
tissue O
. O
However O
, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap O
limit O
its O
suitability O
for O
clinical O
assays O
. O
We O
formulated O
β-Lap O
in O
an O
optimal O
random O

ketamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
were O
supplemented O
, O
suggesting O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant-like O
effects O
of O
ketamine O
in O
female O
rats O
. O
In O
preclinical O
studies O
, O
the O
mammalian B
target I
of I
rapamycin I
(mTOR) O
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic O
elongation O
factor O
(eEF2) O
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine O
s O
rapid O
antidepressant O
actions O
. O
In O
our O
hands O
, O
the O
increased O
sensitivity O
of O
female O
rats O
to O
a O
low O
dose O
of O
ketamine O
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR O
or O
eEF2 O
. O

ketamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
were O
supplemented O
, O
suggesting O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant-like O
effects O
of O
ketamine O
in O
female O
rats O
. O
In O
preclinical O
studies O
, O
the O
mammalian O
target O
of O
rapamycin O
(mTOR) O
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic O
elongation O
factor O
(eEF2) O
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine O
s O
rapid O
antidepressant O
actions O
. O
In O
our O
hands O
, O
the O
increased O
sensitivity O
of O
female O
rats O
to O
a O
low O
dose O
of O
ketamine O
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR B
or O
eEF2 O
. O

ketamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
were O
supplemented O
, O
suggesting O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant-like O
effects O
of O
ketamine O
in O
female O
rats O
. O
In O
preclinical O
studies O
, O
the O
mammalian O
target O
of O
rapamycin O
(mTOR) O
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic B
elongation I
factor I
(eEF2) O
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine O
s O
rapid O
antidepressant O
actions O
. O
In O
our O
hands O
, O
the O
increased O
sensitivity O
of O
female O
rats O
to O
a O
low O
dose O
of O
ketamine O
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR O
or O
eEF2 O
. O

ketamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
were O
supplemented O
, O
suggesting O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant-like O
effects O
of O
ketamine O
in O
female O
rats O
. O
In O
preclinical O
studies O
, O
the O
mammalian O
target O
of O
rapamycin O
(mTOR) O
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic O
elongation O
factor O
(eEF2) O
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine O
s O
rapid O
antidepressant O
actions O
. O
In O
our O
hands O
, O
the O
increased O
sensitivity O
of O
female O
rats O
to O
a O
low O
dose O
of O
ketamine O
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR O
or O
eEF2 O
. O

ketamine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
drug O
for O
treatment O
has O
been O
determined O
, O
it O
still O
takes O
several O
weeks O
for O
it O
to O
take O
effect O
and O
improve O
mood O
. O
This O
time O
lag O
is O
a O
serious O
concern O
for O
the O
healthcare O
community O
when O
dealing O
with O
patients O
with O
suicidal O
thoughts O
. O
However O
, O
recent O
clinical O
studies O
have O
shown O
that O
a O
single O
low-dose O
injection O
of O
ketamine O
an O
N-methyl B
d-aspartate I
receptor I
(NMDAR) O
antagonist O
, O
has O
rapid O
antidepressant O
effects O
that O
are O
observed O
within O
hours O
and O
are O
long O
lasting O
. O
Although O
major O
depression O
affects O
twice O
as O
many O
women O
as O
men O
, O
all O
studies O
examining O
the O
rapid O
antidepressant O
effects O
of O
ketamine O
have O
focused O
on O
male O
subjects O
. O
Thus O
, O
we O
have O
investigated O
the O
behavioral O

ketamine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
drug O
for O
treatment O
has O
been O
determined O
, O
it O
still O
takes O
several O
weeks O
for O
it O
to O
take O
effect O
and O
improve O
mood O
. O
This O
time O
lag O
is O
a O
serious O
concern O
for O
the O
healthcare O
community O
when O
dealing O
with O
patients O
with O
suicidal O
thoughts O
. O
However O
, O
recent O
clinical O
studies O
have O
shown O
that O
a O
single O
low-dose O
injection O
of O
ketamine O
an O
N-methyl O
d-aspartate O
receptor O
(NMDAR) O
antagonist O
, O
has O
rapid O
antidepressant O
effects O
that O
are O
observed O
within O
hours O
and O
are O
long O
lasting O
. O
Although O
major O
depression O
affects O
twice O
as O
many O
women O
as O
men O
, O
all O
studies O
examining O
the O
rapid O
antidepressant O
effects O
of O
ketamine O
have O
focused O
on O
male O
subjects O
. O
Thus O
, O
we O
have O
investigated O
the O
behavioral O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A B
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX-P O
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
. O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P O
administration O
. O
On O
the O
other O
hand O
, O
a O
mild O
increase O
of O
CYP3A O
activity O
, O
which O
lasted O
for O
at O
least O
48 O
h O
, O
was O
observed O
in O
both O
tissues O
after O
administration O
of O
multiple O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
. O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A B
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P O
administration O
. O
On O
the O
other O
hand O
, O
a O
mild O
increase O
of O
CYP3A O
activity O
, O
which O
lasted O
for O
at O
least O
48 O
h O
, O
was O
observed O
in O
both O
tissues O
after O
administration O
of O
multiple O
doses O
. O
5 O
. O
Some O
physiological O
compounds O
such O
as O
cytokines O
might O
be O
involved O
in O
decreasing O
the O
CYP3A O
activity O
to O
maintain O
homeostasis O
of O
the O
body O
. O

dexamethasone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Time-dependent O
changes O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome B
P450 I
3A I
after O
administration O
of O
dexamethason O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O

dexamethasone O
21-phosphate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome B
P450 I
3A I
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O

dexamethasone O
21-phosphate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O

dexamethasone O
21-phosphate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
intestinal O
induction O
of O
cytochrome B
P450 I
3A I
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
( O
DEX-P O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
( O
DEX-P O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
( O
DEX-P O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O

midazolam O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O

MDZ O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
( O
MDZ O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A B

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A B
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX-P O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
. O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O

DEX-P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A B
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX-P O
, O
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase O
, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O
of O
the O
dose O
of O
DEX-P O
4 O
. O
Administration O
of O
a O
single O
dose O
of O
DEX-P O
showed O
a O
temporal O
increase O
in O
CYP3A O
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P O
administration O
. O
On O
the O
other O
hand O
, O
a O
mild O
increase O
of O
CYP3A O
activity O
, O
which O
lasted O
for O
at O
least O
48 O
h O
, O
was O

dexamethasone O
21-phosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O

DEX-P O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
intestinal O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
( O
DEX-P O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O

midazolam O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
induction O
of O
cytochrome B
P450 I
3A I
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O

midazolam O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O

midazolam O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
induction O
of O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
(MDZ) O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O

MDZ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
( O
MDZ O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A B

MDZ O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
cytochrome O
P450 O
3A O
after O
administration O
of O
dexamethasone O
to O
rats.Abstract O
1 O
. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome O
P450 O
3A O
(CYP3A) O
in O
rats O
using O
dexamethasone O
21-phosphate O
(DEX-P) O
and O
midazolam O
( O
MDZ O
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A O
, O
respectively O
. O
2 O
. O
The O
number O
of O
times O
DEX-P O
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; O
however O
, O
administration O
of O
DEX-P O
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P O
by O
self-induction O
of O
CYP3A O
. O
3 O
. O
CYP3A B

Camptothecin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Topoisomerase O
IIβ O
deficiency O
enhances O
camptothecin-induced O
apoptosis O
. O
Camptothecin O
(CPT) O
, O
a O
topoisomerase O
(Top) O
I-targeting O
drug O
that O
stabilizes O
Top1-DNA O
covalent O
adducts O
, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O
However O
, O
CPT-induced O
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O

Camptothecin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Topoisomerase O
IIβ O
deficiency O
enhances O
camptothecin-induced O
apoptosis O
. O
Camptothecin O
(CPT) O
, O
a O
topoisomerase O
(Top) O
I-targeting O
drug O
that O
stabilizes O
Top1-DNA O
covalent O
adducts O
, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O
However O
, O
CPT-induced O
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O

CPT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Topoisomerase O
IIβ O
deficiency O
enhances O
camptothecin-induced O
apoptosis.Camptothecin O
( O
CPT O
 O
, O
a O
topoisomerase O
(Top) O
I-targeting O
drug O
that O
stabilizes O
Top1-DNA O
covalent O
adducts O
, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O
However O
, O
CPT-induced O
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O

CPT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Topoisomerase O
IIβ O
deficiency O
enhances O
camptothecin-induced O
apoptosis.Camptothecin O
( O
CPT O
 O
, O
a O
topoisomerase O
(Top) O
I-targeting O
drug O
that O
stabilizes O
Top1-DNA O
covalent O
adducts O
, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O
However O
, O
CPT-induced O
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O

CPT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
deficiency O
enhances O
camptothecin-induced O
apoptosis.Camptothecin O
(CPT) O
, O
a O
topoisomerase O
(Top) O
I-targeting O
drug O
that O
stabilizes O
Top1-DNA O
covalent O
adducts O
, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O
However O
, O
CPT-induced O
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase B
IIβ I
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O
for O
many O
other O
cytotoxic O
agents O
, O
in O
non-S-phase O
cells O
. O
First O
, O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β O
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O

CPT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
deficiency O
enhances O
camptothecin-induced O
apoptosis.Camptothecin O
(CPT) O
, O
a O
topoisomerase O
(Top) O
I-targeting O
drug O
that O
stabilizes O
Top1-DNA O
covalent O
adducts O
, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks O
. O
However O
, O
CPT-induced O
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O
for O
many O
other O
cytotoxic O
agents O
, O
in O
non-S-phase O
cells O
. O
First O
, O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β B
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O

CPT O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
RNAP O
LS O
remained O
depleted O
without O
recovery O
in O
Top2β-deficient O
cells O
. O
Concomitant O
with O
the O
reduction O
of O
the O
RNAP O
LS O
level O
, O
the O
p53 B
protein O
level O
was O
greatly O
induced O
. O
Interestingly O
, O
RNAP O
LS O
depletion O
has O
been O
well O
documented O
to O
lead O
to O
p53-dependent O
apoptosis O
. O
Altogether O
, O
our O
findings O
support O
a O
model O
in O
which O
Top2β O
deficiency O
promotes O
CPT O
induced O
apoptosis O
in O
quiescent O
non-S-phase O
cells O
, O
possibly O
due O
to O
RNAP O
LS O
depletion O
and O
p53 O
accumulation O
. O

CPT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β O
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O
molecular O
basis O
for O
CPT O
hypersensitivity O
in O
Top2β-deficient O
cells O
, O
we O
found O
that O
upon O
CPT O
exposure O
, O
the O
RNA B
polymerase I
II I
large I
subunit I
(RNAP O
LS) O
became O
progressively O
depleted O
, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O
in O
wild-type O
MEFs O
, O
whereas O
RNAP O
LS O
remained O
depleted O
without O
recovery O
in O
Top2β-deficient O
cells O
. O
Concomitant O
with O
the O
reduction O
of O
the O
RNAP O
LS O
level O
, O
the O
p53 O
protein O
level O
was O
greatly O
induced O
. O

CPT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β O
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O
molecular O
basis O
for O
CPT O
hypersensitivity O
in O
Top2β-deficient O
cells O
, O
we O
found O
that O
upon O
CPT O
exposure O
, O
the O
RNA O
polymerase O
II O
large O
subunit O
(RNAP O
LS) O
became O
progressively O
depleted O
, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O
in O
wild-type O
MEFs O
, O
whereas O
RNAP B
LS I
remained O
depleted O
without O
recovery O
in O
Top2β-deficient O
cells O
. O
Concomitant O
with O
the O
reduction O
of O
the O
RNAP O
LS O
level O
, O
the O
p53 O
protein O
level O
was O
greatly O
induced O
. O

CPT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β O
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
, O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O
molecular O
basis O
for O
CPT O
hypersensitivity O
in O
Top2β-deficient O
cells O
, O
we O
found O
that O
upon O
CPT O
exposure O
, O
the O
RNA O
polymerase O
II O
large O
subunit O
(RNAP O
LS) O
became O
progressively O
depleted O
, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O
in O
wild-type O
MEFs O
, O
whereas O
RNAP B
LS I
remained O
depleted O
without O
recovery O
in O
Top2β-deficient O
cells O
. O
Concomitant O
with O
the O
reduction O
of O
the O
RNAP O
LS O
level O
, O
the O
p53 O
protein O
level O
was O
greatly O
induced O
. O

CPT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
RNAP B
LS I
remained O
depleted O
without O
recovery O
in O
Top2β-deficient O
cells O
. O
Concomitant O
with O
the O
reduction O
of O
the O
RNAP O
LS O
level O
, O
the O
p53 O
protein O
level O
was O
greatly O
induced O
. O
Interestingly O
, O
RNAP O
LS O
depletion O
has O
been O
well O
documented O
to O
lead O
to O
p53-dependent O
apoptosis O
. O
Altogether O
, O
our O
findings O
support O
a O
model O
in O
which O
Top2β O
deficiency O
promotes O
CPT O
induced O
apoptosis O
in O
quiescent O
non-S-phase O
cells O
, O
possibly O
due O
to O
RNAP O
LS O
depletion O
and O
p53 O
accumulation O
. O

ICRF-187 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O
for O
many O
other O
cytotoxic O
agents O
, O
in O
non-S-phase O
cells O
. O
First O
, O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β O
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
a O
Top2 B
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O
molecular O
basis O
for O
CPT O
hypersensitivity O
in O
Top2β-deficient O
cells O
, O
we O
found O
that O
upon O
CPT O
exposure O
, O
the O
RNA O
polymerase O
II O
large O
subunit O
(RNAP O
LS) O
became O
progressively O
depleted O
, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O

ICRF-187 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
well O
characterized O
. O
In O
this O
study O
, O
we O
have O
identified O
topoisomerase O
IIβ O
(Top2β) O
as O
a O
specific O
determinant O
for O
CPT O
sensitivity O
, O
but O
not O
for O
many O
other O
cytotoxic O
agents O
, O
in O
non-S-phase O
cells O
. O
First O
, O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β B
were O
shown O
to O
be O
hypersensitive O
to O
CPT O
with O
prominent O
induction O
of O
apoptosis O
. O
Second O
, O
ICRF-187 O
a O
Top2 O
catalytic O
inhibitor O
known O
to O
deplete O
Top2β O
, O
specifically O
sensitized O
MEFs O
to O
CPT O
. O
To O
explore O
the O
molecular O
basis O
for O
CPT O
hypersensitivity O
in O
Top2β-deficient O
cells O
, O
we O
found O
that O
upon O
CPT O
exposure O
, O
the O
RNA O
polymerase O
II O
large O
subunit O
(RNAP O
LS) O
became O
progressively O
depleted O
, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O

phenylalanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
RadA O
, O
and O
used O
this O
protein O
for O
fragment O
screening O
. O
The O
initial O
fragment O
hits O
were O
thoroughly O
validated O
biophysically O
by O
isothermal O
titration O
calorimetry O
(ITC) O
and O
NMR O
techniques O
and O
observed O
by O
X-ray O
crystallography O
to O
bind O
in O
a O
shallow O
surface O
pocket O
that O
is O
occupied O
in O
the O
native O
complex O
by O
the O
side O
chain O
of O
a O
phenylalanine O
from O
the O
conserved O
FxxA B
interaction I
motif I
found O
in O
BRCA2 O
. O
This O
represents O
the O
first O
report O
of O
fragments O
or O
any O
small O
molecule O
binding O
at O
this O
protein-protein O
interaction O
site O
. O

phenylalanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
RadA O
, O
and O
used O
this O
protein O
for O
fragment O
screening O
. O
The O
initial O
fragment O
hits O
were O
thoroughly O
validated O
biophysically O
by O
isothermal O
titration O
calorimetry O
(ITC) O
and O
NMR O
techniques O
and O
observed O
by O
X-ray O
crystallography O
to O
bind O
in O
a O
shallow O
surface O
pocket O
that O
is O
occupied O
in O
the O
native O
complex O
by O
the O
side O
chain O
of O
a O
phenylalanine O
from O
the O
conserved O
FxxA O
interaction O
motif O
found O
in O
BRCA2 O
. O
This O
represents O
the O
first O
report O
of O
fragments O
or O
any O
small O
molecule O
binding O
at O
this O
protein-protein O
interaction O
site O
. O

mannose O
6-phosphate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
( O
mannose O
6-phosphate O
/IGF2R O
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O
M6P/IGF2R O

mannose O
6-phosphate O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
( O
mannose O
6-phosphate O
/IGF2R O
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O
M6P/IGF2R O

M6P O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
(mannose O
6-phosphate)/IGF2R O
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O

M6P O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
mannose O
6-phosphate-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
(mannose O
6-phosphate)/IGF2R O
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells O
. O
We O
have O
now O
used O
mutant O
forms O
of O

M6P O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
a O
functional O
binding O
site O
for O
insulin-like O
growth O
factor O
II O
for O
inhibition O
of O
anchorage-independent O
growth O
and O
matrix O
invasion O
by O
SCC-VII O
cells O
. O
In O
contrast O
, O
the O
simultaneous O
mutation O
of O
both O
M6P-binding O
sites O
is O
sufficient O
to O
impair O
all O
cellular O
functions O
of O
the O
receptor O
tested O
. O
These O
findings O
highlight O
that O
the O
interaction O
between O
M6P/IGF2R O
and O
M6P O
modified O
ligands O
is O
not O
only O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O
lysosomes O
, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC-VII O
growth O
and O
invasion O
. O
The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P/IGF2R O
in O
SCC-VII O
cells O

mannose O
6-phosphate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
The O
mannose O
6-phosphat O
-binding O
sites O
of O
M6P/IGF2R O
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells.The O
M6P O
(mannose O
6-phosphate)/IGF2R O
(insulin-like O
growth O
factor O
II O
receptor) O
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis O
. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R O
reduces O
the O
tumorigenic O

M6P O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O
lysosomes O
, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC-VII O
growth O
and O
invasion O
. O
The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P/IGF2R O
in O
SCC-VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P O
binding O
site O
within O
domain O
3 O
, O
thus O
providing O
further O
evidence O
for O
the O
non-redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate-binding O
domains O
of O
the O
receptor O
. O

MPEP O
acts O
as O
PART-OF O
for O
what O
entity O
? O
role O
in O
hippocampal O
synaptic O
plasticity O
, O
specifically O
in O
long-term O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O

2-Methyl-6-(phenylethynyl)pyridine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
hippocampal O
synaptic O
plasticity O
, O
specifically O
in O
long-term O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
( O
2-Methyl-6-(phenylethynyl)pyridine O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O

CPPHA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O

N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
( O
N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide O
 O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O

NCFP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O

NCFP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 B
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP O
site O
PAMs O
. O
This O
suggests O
that O
although O
mGlu5 O

NCFP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 B
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP O
site O
PAMs O
. O
This O
suggests O
that O
although O
mGlu5 O

CPPHA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 B
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP) O
, O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP O
site O
PAMs O
. O
This O
suggests O
that O
although O
mGlu5 O
PAMs O
may O
have O
similar O
responses O
in O
some O
systems O
, O

NCFP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O

CPPHA O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O

N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
and O
long-term O
potentiation O
(LTP) O
, O
which O
is O
thought O
to O
be O
involved O
in O
cognition O
. O
Multiple O
mGlu5-positive O
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds O
. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
( O
N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide O
 O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O

CPPHA O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O

NCFP O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O

N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
( O
N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide O
 O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O

CPPHA O
acts O
as O
MODULATOR-ACTIVATOR O
for O
what O
entity O
? O
termed O
the O
MPEP O
(2-Methyl-6-(phenylethynyl)pyridine) O
binding O
site O
. O
However O
, O
one O
mGlu5 B
PAM O
, O
CPPHA O
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O
Using O
cell-based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA O
series O
termed O
NCFP O
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide) O
. O
NCFP O
binds O
to O
the O
CPPHA O
site O
on O
mGlu5 O
and O
potentiates O
mGlu5-mediated O
responses O
in O
both O
recombinant O
and O
native O
systems O
. O
However O
, O
NCFP O
provides O
greater O
mGlu5 O
subtype O
selectivity O
than O
does O
CPPHA O
, O
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 O
in O
CNS O
preparations O
. O
Of O
interest O
, O
NCFP O
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP) O
, O

EPA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
assessed O
obesity-induced O
changes O
of O
n-3-derived O
SPM O
in O
adipose O
tissue O
and O
effects O
of O
dietary O
EPA/DHA O
thereon.Moreover O
, O
we O
treated O
obese O
mice O
with O
SPM O
precursors O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation O
. O
Obesity O
significantly O
decreased O
DHA-derived O
17-hydroxydocosahexaenoic O
acid O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA O
DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin B
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
, O
increased O
adiponectin O
expression O
and O
improved O
glucose O
tolerance O
parallel O
to O
insulin O
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O

17-HDHA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation O
. O
Obesity O
significantly O
decreased O
DHA-derived O
17-hydroxydocosahexaenoic O
acid O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA/DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin O
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
, O
increased O
adiponectin B
expression O
and O
improved O
glucose O
tolerance O
parallel O
to O
insulin O
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O
impaired O
biosynthesis O
of O
certain O
SPM O
and O
SPM O
precursors O
including O
17-HDHA O
and O
protectin O
D1 O
contributes O
to O
adipose O
tissue O
inflammation O
in O
obesity O
and O
suggest O
17-HDHA O

17-HDHA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation O
. O
Obesity O
significantly O
decreased O
DHA-derived O
17-hydroxydocosahexaenoic O
acid O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA/DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin B
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
, O
increased O
adiponectin O
expression O
and O
improved O
glucose O
tolerance O
parallel O
to O
insulin O
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O
impaired O
biosynthesis O
of O
certain O
SPM O
and O
SPM O
precursors O
including O
17-HDHA O
and O
protectin O
D1 O
contributes O
to O
adipose O
tissue O
inflammation O
in O
obesity O
and O
suggest O
17-HDHA O

DHA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
obesity-induced O
changes O
of O
n-3-derived O
SPM O
in O
adipose O
tissue O
and O
effects O
of O
dietary O
EPA/DHA O
thereon.Moreover O
, O
we O
treated O
obese O
mice O
with O
SPM O
precursors O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation O
. O
Obesity O
significantly O
decreased O
DHA-derived O
17-hydroxydocosahexaenoic O
acid O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA O
/ O
DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin B
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
, O
increased O
adiponectin O
expression O
and O
improved O
glucose O
tolerance O
parallel O
to O
insulin O
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O
impaired O

17-HDHA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation O
. O
Obesity O
significantly O
decreased O
DHA-derived O
17-hydroxydocosahexaenoic O
acid O
(17-HDHA O
, O
resolvin O
D1 O
precursor) O
and O
protectin O
D1 O
levels O
in O
murine O
adipose O
tissue O
. O
Dietary O
EPA/DHA O
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin O
sensitivity O
. O
Notably O
, O
17-HDHA O
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines O
, O
increased O
adiponectin O
expression O
and O
improved O
glucose O
tolerance O
parallel O
to O
insulin O
sensitivity O
in O
obese O
mice O
. O
These O
findings O
indicate O
that O
impaired O
biosynthesis O
of O
certain O
SPM O
and O
SPM O
precursors O
including O
17-HDHA O
and O
protectin O
D1 O
contributes O
to O
adipose O
tissue O
inflammation O
in O
obesity O
and O
suggest O
17-HDHA O

pyrrolopyrazines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pyrrolopyrazines O
as O
Selective O
Spleen O
Tyrosine O
Kinase O
Inhibitors.We O
describe O
the O
discovery O
of O
several O
pyrrolopyrazines O
as O
potent O
and O
selective O
Syk B
inhibitors O
and O
the O
efforts O
that O
eventually O
led O
to O
the O
desired O
improvements O
in O
physicochemical O
properties O
and O
human O
whole O
blood O
potencies O
. O
Ultimately O
, O
our O
mouse O
model O
revealed O
unexpected O
toxicity O
that O
precluded O
us O
from O
further O
advancing O
this O
series O
. O

ATP O
acts O
as O
NOT O
for O
what O
entity O
? O
selective O
inhibitors O
as O
new O
promising O
drugs O
for O
the O
treatment O
of O
these O
pathologies O
. O
We O
describe O
here O
the O
isolation O
and O
biochemical O
characterization O
of O
the O
marine O
natural O
sesquiterpene O
palinurin O
as O
a O
GSK-3β B
inhibitor O
. O
Experimental O
studies O
performed O
for O
characterizing O
the O
inhibitory O
mechanism O
indicate O
that O
GSK-3β O
inhibition O
by O
palinurin O
cannot O
be O
competed O
out O
by O
ATP O
nor O
peptide O
substrate O
. O
Molecular O
modelling O
techniques O
have O
enabled O
us O
to O
propose O
an O
unconventional O
binding O
mode O
to O
GSK-3β O
. O
Moreover O
, O
molecular O
dynamics O
simulations O
have O
identified O
an O
allosteric O
mechanism O
by O
which O
binding O
of O
palinurin O
leads O
to O
GSK-3β O
inhibition O
. O
The O
inhibitory O
activities O
determined O
for O
a O
series O
of O
structurally O
related O
analogues O
support O
the O
proposed O

sesquiterpene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
highly O
prevalent O
disorders O
such O
as O
Alzheimer's O
disease O
, O
mood O
disorders O
, O
diabetes O
and O
cancer O
. O
Therefore O
, O
this O
enzyme O
constitutes O
a O
highly O
attractive O
therapeutic O
target O
for O
the O
development O
of O
selective O
inhibitors O
as O
new O
promising O
drugs O
for O
the O
treatment O
of O
these O
pathologies O
. O
We O
describe O
here O
the O
isolation O
and O
biochemical O
characterization O
of O
the O
marine O
natural O
sesquiterpene O
palinurin O
as O
a O
GSK-3β B
inhibitor O
. O
Experimental O
studies O
performed O
for O
characterizing O
the O
inhibitory O
mechanism O
indicate O
that O
GSK-3β O
inhibition O
by O
palinurin O
cannot O
be O
competed O
out O
by O
ATP O
nor O
peptide O
substrate O
. O
Molecular O
modelling O
techniques O
have O
enabled O
us O
to O
propose O
an O
unconventional O
binding O
mode O
to O
GSK-3β O
. O
Moreover O
, O
molecular O
dynamics O
simulations O
have O
identified O
an O

palinurin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
prevalent O
disorders O
such O
as O
Alzheimer's O
disease O
, O
mood O
disorders O
, O
diabetes O
and O
cancer O
. O
Therefore O
, O
this O
enzyme O
constitutes O
a O
highly O
attractive O
therapeutic O
target O
for O
the O
development O
of O
selective O
inhibitors O
as O
new O
promising O
drugs O
for O
the O
treatment O
of O
these O
pathologies O
. O
We O
describe O
here O
the O
isolation O
and O
biochemical O
characterization O
of O
the O
marine O
natural O
sesquiterpene O
palinurin O
as O
a O
GSK-3β B
inhibitor O
. O
Experimental O
studies O
performed O
for O
characterizing O
the O
inhibitory O
mechanism O
indicate O
that O
GSK-3β O
inhibition O
by O
palinurin O
cannot O
be O
competed O
out O
by O
ATP O
nor O
peptide O
substrate O
. O
Molecular O
modelling O
techniques O
have O
enabled O
us O
to O
propose O
an O
unconventional O
binding O
mode O
to O
GSK-3β O
. O
Moreover O
, O
molecular O
dynamics O
simulations O
have O
identified O
an O
allosteric O

palinurin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
therapeutic O
target O
for O
the O
development O
of O
selective O
inhibitors O
as O
new O
promising O
drugs O
for O
the O
treatment O
of O
these O
pathologies O
. O
We O
describe O
here O
the O
isolation O
and O
biochemical O
characterization O
of O
the O
marine O
natural O
sesquiterpene O
palinurin O
as O
a O
GSK-3β B
inhibitor O
. O
Experimental O
studies O
performed O
for O
characterizing O
the O
inhibitory O
mechanism O
indicate O
that O
GSK-3β O
inhibition O
by O
palinurin O
cannot O
be O
competed O
out O
by O
ATP O
nor O
peptide O
substrate O
. O
Molecular O
modelling O
techniques O
have O
enabled O
us O
to O
propose O
an O
unconventional O
binding O
mode O
to O
GSK-3β O
. O
Moreover O
, O
molecular O
dynamics O
simulations O
have O
identified O
an O
allosteric O
mechanism O
by O
which O
binding O
of O
palinurin O
leads O
to O
GSK-3β O
inhibition O
. O
The O
inhibitory O
activities O
determined O
for O
a O
series O
of O

palinurin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
studies O
performed O
for O
characterizing O
the O
inhibitory O
mechanism O
indicate O
that O
GSK-3β B
inhibition O
by O
palinurin O
cannot O
be O
competed O
out O
by O
ATP O
nor O
peptide O
substrate O
. O
Molecular O
modelling O
techniques O
have O
enabled O
us O
to O
propose O
an O
unconventional O
binding O
mode O
to O
GSK-3β O
. O
Moreover O
, O
molecular O
dynamics O
simulations O
have O
identified O
an O
allosteric O
mechanism O
by O
which O
binding O
of O
palinurin O
leads O
to O
GSK-3β O
inhibition O
. O
The O
inhibitory O
activities O
determined O
for O
a O
series O
of O
structurally O
related O
analogues O
support O
the O
proposed O
binding O
mode O
of O
palinurin O
, O
which O
is O
the O
first O
compound O
described O
to O
target O
this O
allosteric O
site O
. O
The O
results O
offer O
new O
opportunities O
for O
designing O
and O
developing O
selective O
inhibitors O
with O
novel O
mechanisms O
of O
action O
. O

palinurin O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Evidence O
for O
a O
new O
binding O
mode O
to O
GSK-3 O
: O
allosteric O
regulation O
by O
the O
marine O
compound O
palinuri O
.Glycogen O
synthase O
kinase O
3β O
(GSK-3β) O
is O
widely O
recognised O
as O
a O
relevant O
player O
in O
the O
pathogenesis O
of O
several O
highly O
prevalent O
disorders O
such O
as O
Alzheimer's O
disease O
, O
mood O
disorders O
, O
diabetes O
and O
cancer O
. O
Therefore O
, O
this O
enzyme O
constitutes O
a O
highly O
attractive O
therapeutic O
target O
for O
the O
development O
of O
selective O
inhibitors O
as O
new O
promising O
drugs O
for O

keto O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
have O
inhibitory O
profile O
against O
both O
COX-1 O
and O
COX-2 O
, O
some O
of O
the O
compounds O
are O
found O
to O
be O
selective O
against O
COX-2 O
, O
supported O
by O
inhibition O
of O
paw O
edema O
and O
vascular O
permeability O
. O
Docking O
studies O
were O
also O
carried O
out O
to O
determine O
the O
structural O
features O
which O
sway O
the O
anti-inflammatory O
activity O
of O
the O
tested O
compounds O
. O
The O
keto O
and O
phenolic O
-OH O
are O
major O
factors O
that O
are O
prominently O
involved O
in O
interaction O
with O
COX-2 B
active O
site O
. O

phenolic O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
profile O
against O
both O
COX-1 O
and O
COX-2 O
, O
some O
of O
the O
compounds O
are O
found O
to O
be O
selective O
against O
COX-2 O
, O
supported O
by O
inhibition O
of O
paw O
edema O
and O
vascular O
permeability O
. O
Docking O
studies O
were O
also O
carried O
out O
to O
determine O
the O
structural O
features O
which O
sway O
the O
anti-inflammatory O
activity O
of O
the O
tested O
compounds O
. O
The O
keto O
and O
phenolic O
-OH O
are O
major O
factors O
that O
are O
prominently O
involved O
in O
interaction O
with O
COX-2 B
active O
site O
. O

OH O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
both O
COX-1 O
and O
COX-2 O
, O
some O
of O
the O
compounds O
are O
found O
to O
be O
selective O
against O
COX-2 O
, O
supported O
by O
inhibition O
of O
paw O
edema O
and O
vascular O
permeability O
. O
Docking O
studies O
were O
also O
carried O
out O
to O
determine O
the O
structural O
features O
which O
sway O
the O
anti-inflammatory O
activity O
of O
the O
tested O
compounds O
. O
The O
keto O
and O
phenolic O
- O
OH O
are O
major O
factors O
that O
are O
prominently O
involved O
in O
interaction O
with O
COX-2 B
active O
site O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
CA-repeat O
in O
impaired O
glucose O
tolerance O
and O
type O
2 O
diabetes.Type O
2 O
11β-hydroxysteroid O
dehydrogenase O
encoded O
by O
the O
HSD11B2 B
gene O
converts O
cortisol O
to O
inactive O
cortisone O
, O
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose O
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids O
. O
We O
investigated O
the O
association O
of O
HSD11B2 O
variant O
with O
glucose O
homeostasis O
. O
Subjects O
with O
normal O
glucose O
tolerance O
(n=585) O
, O
impaired O
glucose O
tolerance O
(n=202) O
and O
type O
2 O
diabetes O
(n=355) O
were O
genotyped O
for O
a O
highly O
polymorphic O
CA-repeat O
polymorphism O
in O
the O
first O
intron O
of O
HSD11B2 O
. O
Allele O
and O
genotype O
frequencies O
differed O
between O
normal O
and O
impaired O
glucose O
tolerance O
(P O
= O
0.0014 O
and O
0.0407 O
, O
respectively; O
4DF) O
or O

cortisol O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Longer O
HSD11B2 O
CA-repeat O
in O
impaired O
glucose O
tolerance O
and O
type O
2 O
diabetes.Type O
2 O
11β-hydroxysteroid O
dehydrogenase O
encoded O
by O
the O
HSD11B2 O
gene O
converts O
cortisol O
to O
inactive O
cortisone O
, O
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose O
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids O
. O
We O
investigated O
the O
association O
of O
HSD11B2 O
variant O
with O
glucose O
homeostasis O
. O
Subjects O
with O
normal O
glucose O
tolerance O
(n=585) O
, O
impaired O
glucose O
tolerance O
(n=202) O
and O
type O
2 O
diabetes O
(n=355) O
were O
genotyped O

cortisol O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Longer O
HSD11B2 B
CA-repeat O
in O
impaired O
glucose O
tolerance O
and O
type O
2 O
diabetes.Type O
2 O
11β-hydroxysteroid O
dehydrogenase O
encoded O
by O
the O
HSD11B2 O
gene O
converts O
cortisol O
to O
inactive O
cortisone O
, O
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose O
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids O
. O
We O
investigated O
the O
association O
of O
HSD11B2 O
variant O
with O
glucose O
homeostasis O
. O
Subjects O
with O
normal O
glucose O
tolerance O
(n=585) O
, O
impaired O
glucose O
tolerance O
(n=202) O
and O
type O
2 O
diabetes O
(n=355) O
were O
genotyped O

cortisone O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Longer O
HSD11B2 O
CA-repeat O
in O
impaired O
glucose O
tolerance O
and O
type O
2 O
diabetes.Type O
2 O
11β-hydroxysteroid O
dehydrogenase O
encoded O
by O
the O
HSD11B2 O
gene O
converts O
cortisol O
to O
inactive O
cortisone O
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose O
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids O
. O
We O
investigated O
the O
association O
of O
HSD11B2 O
variant O
with O
glucose O
homeostasis O
. O
Subjects O
with O
normal O
glucose O
tolerance O
(n=585) O
, O
impaired O
glucose O
tolerance O
(n=202) O
and O
type O
2 O
diabetes O
(n=355) O
were O
genotyped O
for O
a O
highly O

cortisone O
acts O
as O
SUBSTRATE_PRODUCT-OF O
for O
what O
entity O
? O
Longer O
HSD11B2 B
CA-repeat O
in O
impaired O
glucose O
tolerance O
and O
type O
2 O
diabetes.Type O
2 O
11β-hydroxysteroid O
dehydrogenase O
encoded O
by O
the O
HSD11B2 O
gene O
converts O
cortisol O
to O
inactive O
cortisone O
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose O
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids O
. O
We O
investigated O
the O
association O
of O
HSD11B2 O
variant O
with O
glucose O
homeostasis O
. O
Subjects O
with O
normal O
glucose O
tolerance O
(n=585) O
, O
impaired O
glucose O
tolerance O
(n=202) O
and O
type O
2 O
diabetes O
(n=355) O
were O
genotyped O
for O
a O
highly O

atrazine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
treatments O
, O
respectively O
. O
Altered O
genes O
were O
associated O
with O
neuroendocrine O
and O
reproductive O
system O
development O
, O
function O
, O
and O
disease; O
cell O
cycle O
control; O
and O
carcinogenesis O
. O
There O
was O
a O
significant O
overlap O
(42 O
genes) O
between O
the O
3 O
and O
30 O
ppb O
differentially O
expressed O
gene O
lists O
, O
with O
two O
of O
these O
genes O
(CYP17A1 O
and O
SAMHD1) O
present O
in O
all O
three O
atrazine O
treatments O
. O
Increased O
transcript O
levels O
were O
translated O
to O
significant O
upregulation O
in O
protein O
expression O
. O
Overall O
, O
this O
study O
identifies O
genetic O
and O
molecular O
targets O
altered O
in O
response O
to O
a O
developmental O
atrazine O
exposure O
to O
further O
define O
the O
biological O
pathways O
and O
mechanisms O
of O
toxicity O
. O

atrazine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
treatments O
, O
respectively O
. O
Altered O
genes O
were O
associated O
with O
neuroendocrine O
and O
reproductive O
system O
development O
, O
function O
, O
and O
disease; O
cell O
cycle O
control; O
and O
carcinogenesis O
. O
There O
was O
a O
significant O
overlap O
(42 O
genes) O
between O
the O
3 O
and O
30 O
ppb O
differentially O
expressed O
gene O
lists O
, O
with O
two O
of O
these O
genes O
(CYP17A1 O
and O
SAMHD1) O
present O
in O
all O
three O
atrazine O
treatments O
. O
Increased O
transcript O
levels O
were O
translated O
to O
significant O
upregulation O
in O
protein O
expression O
. O
Overall O
, O
this O
study O
identifies O
genetic O
and O
molecular O
targets O
altered O
in O
response O
to O
a O
developmental O
atrazine O
exposure O
to O
further O
define O
the O
biological O
pathways O
and O
mechanisms O
of O
toxicity O
. O

xanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
xanthine O
derivatives O
on O
dipeptidyl O
peptidase O
4.A O
series O
of O
xanthine O
derivatives O
in O
which O
a O
methylene O
was O
inserted O
at O
position O
8 O
of O
xanthine O
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl B
peptidase I
4 I
(DPP-4) O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O
As O
the O
results O
of O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4-methyl-quinazoline-2-yl-methyl O
group O
at O
N-1 O

xanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
xanthine O
derivatives O
on O
dipeptidyl O
peptidase O
4.A O
series O
of O
xanthine O
derivatives O
in O
which O
a O
methylene O
was O
inserted O
at O
position O
8 O
of O
xanthine O
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl O
peptidase O
4 O
(DPP-4) O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O
As O
the O
results O
of O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4-methyl-quinazoline-2-yl-methyl O
group O
at O
N-1 O

xanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
xanthine O
derivatives O
on O
dipeptidyl O
peptidase O
4.A O
series O
of O
xanthine O
derivatives O
in O
which O
a O
methylene O
was O
inserted O
at O
position O
8 O
of O
xanthine O
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl B
peptidase I
4 I
(DPP-4) O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O
As O
the O
results O
of O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4-methyl-quinazoline-2-yl-methyl O
group O
at O
N-1 O
position O
and O
2-aminoethylaminomethyl O
group O
gave O
better O
activities O
. O
Compounds O
H4 O
and O
H9 O
showed O

xanthine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
xanthine O
derivatives O
on O
dipeptidyl O
peptidase O
4.A O
series O
of O
xanthine O
derivatives O
in O
which O
a O
methylene O
was O
inserted O
at O
position O
8 O
of O
xanthine O
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl O
peptidase O
4 O
(DPP-4) O
for O
the O
treatment O
of O
type O
2 O
diabetes O
. O
As O
the O
results O
of O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4-methyl-quinazoline-2-yl-methyl O
group O
at O
N-1 O
position O
and O
2-aminoethylaminomethyl O
group O
gave O
better O
activities O
. O
Compounds O
H4 O
and O
H9 O
showed O

8-methoxypsoralen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
derivatives O
as O
biomarkers O
of O
DCBN O
exposure O
and O
nasal O
toxicity O
in O
mouse O
models O
. O
We O
found O
that O
human O
fetal O
nasal O
mucosa O
microsomes O
catalyze O
the O
formation O
of O
GS-DCBN O
, O
with O
a O
Km O
value O
comparable O
to O
that O
of O
adult O
mouse O
nasal O
mucosa O
microsomes O
. O
The O
activity O
of O
the O
human O
nasal O
mucosa O
microsomes O
was O
inhibited O
by O
8-methoxypsoralen O
a O
known O
CYP2A B
inhibitor O
. O
GS-DCBN O
and O
its O
metabolites O
were O
detected O
in O
the O
nasal O
mucosa O
and O
nasal-wash O
fluid O
obtained O
from O
DCBN-treated O
mice O
, O
in O
amounts O
that O
increased O
with O
escalations O
in O
DCBN O
dose O
, O
and O
they O
were O
all O
still O
detectable O
at O
24 O
h O
after O
a O
DCBN O
treatment O
(at O
10 O
mg/kg) O
. O
Further O
studies O
in O

PP242 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
with O
an O
increase O
in O
TORC1 O
and O
TORC2 O
activity O
. O
Sustained O
TGFβ O
activation O
was O
required O
to O
inhibit O
association O
of O
deptor B
with O
mTOR O
, O
whereas O
rapid O
activation O
had O
no O
effect O
. O
Using O
the O
mTOR O
inhibitor O
PP242 O
, O
we O
found O
that O
TGFβ-induced O
both O
early O
and O
sustained O
activation O
of O
TORC1 O
and O
TORC2 O
was O
necessary O
for O
deptor O
suppression O
. O
PP242 O
induced O
reversal O
of O
deptor O
suppression O
by O
TGFβ O
was O
associated O
with O
a O
significant O
inhibition O
of O
TGFβ-stimulated O
protein O
synthesis O
and O
hypertrophy O
. O
Interestingly O
, O
expression O
of O
siRNA O
against O
Smad O
3 O
or O
Smad O
7 O
, O
which O
blocks O
TGFβ O
receptor-specific O
Smad O
3 O
signaling O
, O
prevented O
TGFβ-induced O
suppression O
of O
deptor O
abundance O
and O
TORC1/2 O
activities O
. O
Furthermore O
, O
overexpression O
of O
Smad O

PP242 O
, O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activity O
for O
both O
TORC1 O
and O
TORC2 O
. O
Prolonged O
incubation O
of O
mesangial O
cells O
with O
TGFβ O
reduced O
the O
levels O
of O
deptor O
concomitant O
with O
an O
increase O
in O
TORC1 O
and O
TORC2 O
activity O
. O
Sustained O
TGFβ O
activation O
was O
required O
to O
inhibit O
association O
of O
deptor O
with O
mTOR O
, O
whereas O
rapid O
activation O
had O
no O
effect O
. O
Using O
the O
mTOR B
inhibitor O
PP242 O
, O
we O
found O
that O
TGFβ-induced O
both O
early O
and O
sustained O
activation O
of O
TORC1 O
and O
TORC2 O
was O
necessary O
for O
deptor O
suppression O
. O
PP242-induced O
reversal O
of O
deptor O
suppression O
by O
TGFβ O
was O
associated O
with O
a O
significant O
inhibition O
of O
TGFβ-stimulated O
protein O
synthesis O
and O
hypertrophy O
. O
Interestingly O
, O
expression O
of O
siRNA O
against O
Smad O
3 O
or O
Smad O
7 O
, O
which O
blocks O

isatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine B
oxidase I
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O

isatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO B
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O

phthalimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine B
oxidase I
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O

phthalimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO B
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O

phthalides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A O
and O
-B O
were O
0.096 O
and O
0.0014 O
μM O
, O
respectively O
. O
In O
most O
instances O
, O
C6-substituted O
phthalides O
exhibit O
MAO-B B
specific O
inhibition O
. O
Among O
a O
series O
of O
6-benzyloxyphthalides O
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl O
ring O
the O
general O
order O
of O
potency O
was O
CF(3) O
> O
I O
> O
Br O
> O
Cl O
> O
F O
> O
CH(3) O
> O
H O
. O
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides O

phthalides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
phthalides O
exhibit O
MAO-B O
specific O
inhibition O
. O
Among O
a O
series O
of O
6-benzyloxyphthalides O
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl O
ring O
the O
general O
order O
of O
potency O
was O
CF(3) O
> O
I O
> O
Br O
> O
Cl O
> O
F O
> O
CH(3) O
> O
H O
. O
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides O
are O
reversible O
and O
competitive O
at O
both O
MAO B
isoforms O
. O
Based O
on O
these O
data O
, O
C6-substituted O
phthalides O
may O
serve O
as O
leads O
for O
the O
development O
of O
therapies O
for O
neurodegenerative O
disorders O
such O
as O
Parkinson's O
disease O
. O

phthalide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine B
oxidase I
by O
phthalid O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO O
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O

phthalide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO B
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[2-benzofuran-1(3H)-one] O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O

2-benzofuran-1(3H)-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
monoamine O
oxidase O
by O
phthalide O
analogues.Based O
on O
recent O
reports O
that O
the O
small O
molecules O
, O
isatin O
and O
phthalimide O
, O
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine O
oxidase O
(MAO) O
inhibitors O
, O
the O
present O
study O
examines O
the O
MAO B
inhibitory O
properties O
of O
a O
series O
of O
phthalide O
[ O
2-benzofuran-1(3H)-one O
analogues O
. O
Phthalide O
is O
structurally O
related O
to O
isatin O
and O
phthalimide O
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide O
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human O
MAO O
isoforms O
. O
Among O
the O
nineteen O
homologues O
evaluated O
, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A O

quinoxalines O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
protein-protein O
interaction.The O
neonatal O
Fc O
receptor O
, O
FcRn O
, O
prolongs O
the O
half-life O
of O
IgG B
in O
the O
serum O
and O
represents O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmune O
disease O
. O
Small O
molecules O
that O
block O
the O
protein-protein O
interactions O
of O
human O
IgG-human O
FcRn O
may O
lower O
pathogenic O
autoantibodies O
and O
provide O
effective O
treatment O
. O
A O
novel O
class O
of O
quinoxalines O
has O
been O
discovered O
as O
antagonists O
of O
the O
IgG:FcRn O
protein-protein O
interaction O
through O
optimization O
of O
a O
hit O
derived O
from O
a O
virtual O
ligand-based O
screen O
. O

quinoxalines O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
protein-protein O
interaction.The O
neonatal O
Fc O
receptor O
, O
FcRn O
, O
prolongs O
the O
half-life O
of O
IgG O
in O
the O
serum O
and O
represents O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmune O
disease O
. O
Small O
molecules O
that O
block O
the O
protein-protein O
interactions O
of O
human O
IgG-human O
FcRn B
may O
lower O
pathogenic O
autoantibodies O
and O
provide O
effective O
treatment O
. O
A O
novel O
class O
of O
quinoxalines O
has O
been O
discovered O
as O
antagonists O
of O
the O
IgG:FcRn O
protein-protein O
interaction O
through O
optimization O
of O
a O
hit O
derived O
from O
a O
virtual O
ligand-based O
screen O
. O

bisindole O
alkaloid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
3'-R/S-Hydroxyvoacamine O
, O
a O
potent O
acetylcholinesterase B
inhibitor O
from O
Tabernaemontana O
divaricata.Guided O
by O
the O
acetylcholinesterase O
inhibiting O
activity O
, O
the O
bisindole O
alkaloid O
3'-R/S-hydroxyvoacamine O
was O
isolated O
from O
a O
stem O
extract O
of O
Tabernaemontana O
divaricata O
, O
a O
plant O
used O
in O
Thailand O
in O
traditional O
rejuvenation O
remedies O
for O
improving O
the O
memory O
. O
The O
structure O
of O
the O
alkaloid O
was O
elucidated O
by O
extensive O
use O
of O
NMR O
spectroscopy O
and O
the O
complete O
assignment O
of O
the O
(1)H O
and O
(13)C O
NMR O
spectra O
is O
reported O
. O

3'-R/S-hydroxyvoacamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
3'-R/S-Hydroxyvoacamine O
, O
a O
potent O
acetylcholinesterase B
inhibitor O
from O
Tabernaemontana O
divaricata.Guided O
by O
the O
acetylcholinesterase O
inhibiting O
activity O
, O
the O
bisindole O
alkaloid O
3'-R/S-hydroxyvoacamine O
was O
isolated O
from O
a O
stem O
extract O
of O
Tabernaemontana O
divaricata O
, O
a O
plant O
used O
in O
Thailand O
in O
traditional O
rejuvenation O
remedies O
for O
improving O
the O
memory O
. O
The O
structure O
of O
the O
alkaloid O
was O
elucidated O
by O
extensive O
use O
of O
NMR O
spectroscopy O
and O
the O
complete O
assignment O
of O
the O
(1)H O
and O
(13)C O
NMR O
spectra O
is O
reported O
. O
The O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Stat3 B
signaling O
pathways O
was O
examined O
in O
primary O
mouse O
hepatocytes O
. O
We O
provided O
evidence O
of O
a O
novel O
link O
among O
NADPH O
oxidase O
and O
Stat3 O
signaling O
, O
mediated O
by O
Src O
, O
EGFR O
, O
and O
Erk1/2 O
. O
Cadmium O
activates O
NADPH O
oxidase O
. O
ROS O
produced O
by O
this O
oxidase O
activates O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II O
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
among O
NADPH O
oxidase O
and O
Stat3 B
signaling O
, O
mediated O
by O
Src O
, O
EGFR O
, O
and O
Erk1/2 O
. O
Cadmium O
activates O
NADPH O
oxidase O
. O
ROS O
produced O
by O
this O
oxidase O
activates O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II O
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 O
activation O
and O
the O
pro-apoptotic O
protein O
Bax O
. O

Cd O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
ROS O
produced O
by O
this O
oxidase O
activates O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II B
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 O
activation O
and O
the O
pro-apoptotic O
protein O
Bax O
. O

Cadmium O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
a O
cadmium-target O
organ O
, O
hepatocyte O
response O
involved O
in O
its O
toxicity O
is O
not O
yet O
elucidated O
. O
A O
link O
between O
this O
heavy O
metal O
treatment O
and O
Stat3 O
signaling O
pathways O
was O
examined O
in O
primary O
mouse O
hepatocytes O
. O
We O
provided O
evidence O
of O
a O
novel O
link O
among O
NADPH B
oxidase I
and O
Stat3 O
signaling O
, O
mediated O
by O
Src O
, O
EGFR O
, O
and O
Erk1/2 O
. O
Cadmium O
activates O
NADPH O
oxidase O
. O
ROS O
produced O
by O
this O
oxidase O
activates O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O

CdCl2 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II O
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 B
activation O
and O
the O
pro-apoptotic O
protein O
Bax O
. O

CdCl2 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II O
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 O
activation O
and O
the O
pro-apoptotic O
protein O
Bax O
. O

CdCl2 O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Src O
, O
enable O
that O
in O
turn O
, O
transactivates O
EGFR O
that O
activates O
Stat3 O
in O
tyrosine O
, O
allowing O
its O
dimerization O
. O
Also O
, O
ROS O
from O
NADPH O
oxidase O
favors O
ERK1/2 O
activation O
that O
phosphorylates O
Stat3 O
in O
serine O
, O
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II B
in O
short O
Cd O
exposure O
times O
. O
However O
, O
after O
12h O
CdCl2 O
treatment O
, O
cell O
viability O
diminished O
in O
50% O
, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II O
production O
, O
and O
an O
increase O
in O
p53 O
activation O
and O
the O
pro-apoptotic O
protein O
Bax O
. O

catalpol O
acts O
as O
NOT O
for O
what O
entity O
? O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 B
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB B
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα B
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte B
chemotactic I
protein-1 I
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor B
necrosis I
factor-α I
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible B
NO I
synthase I
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor B
for I
AGE I
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

Catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Rehmannia O
glutinosa O
Libosch. O
, O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O
in O
traditional O
Korean O
medicine O
, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells O
. O
In O
the O
present O
study O
, O
we O
isolated O
catalpol O
from O
R O
. O
glutinosa O
, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O

catalpol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB B
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O

Catalpol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
THP-1 O
cells O
. O
Catalpol O
reduced O
the O
expression O
of O
pro-inflammatory O
mediates O
, O
such O
as O
monocyte O
chemotactic O
protein-1 O
(MCP-1) O
, O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
inducible O
NO O
synthase O
(iNOS) O
, O
and O
receptor O
for O
AGE O
(RAGE) O
. O
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O

catalpol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activation O
of O
NF-κB O
was O
significantly O
reduced O
by O
catalpol O
treatment O
, O
while O
AP-1 O
was O
not O
. O
Catalpol O
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH B
oxidase I
activity O
. O
Our O
findings O
indicate O
that O
catalpol O
suppresses O
AGE-mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF-κB O
activity O
. O
We O
suggest O
that O
catalpol O
, O
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R O
. O
glutinosa O
, O
contributes O
to O
the O
prevention O
of O
AGE-mediated O
diabetic O

catalpol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
mitogen O
activated O
protein O
(MAP) O
kinases O
, O
degradation O
of O
IκBα O
and O
the O
nuclear O
localization O
of O
NF-κB O
. O
Moreover O
, O
the O
production O
of O
intracellular O
reactive O
oxygen O
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol O
treatment O
, O
through O
dual O
action O
of O
reducing O
ROS O
itself O
and O
inhibiting O
NADPH O
oxidase O
activity O
. O
Our O
findings O
indicate O
that O
catalpol O
suppresses O
AGE-mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF-κB B
activity O
. O
We O
suggest O
that O
catalpol O
, O
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R O
. O
glutinosa O
, O
contributes O
to O
the O
prevention O
of O
AGE-mediated O
diabetic O
complications O
. O

sibutramine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
AUC O
in O
S-enantiomer O
and O
1.8-fold O
versus O
2.0-fold O
for O
the O
R-enantiomer O
, O
respectively O
. O
The O
AUCs O
of O
S- O
and O
R-desmethyl O
metabolites O
changed O
significantly O
during O
the O
clopidogrel O
phase O
(P O
< O
.001 O
and O
P O
< O
.001 O
, O
respectively) O
but O
not O
during O
the O
clarithromycin O
phase O
(P O
= O
.099 O
and O
P O
= O
.090 O
, O
respectively) O
. O
Exposure O
to O
sibutramine O
was O
higher O
in O
subjects O
with O
the O
CYP2B6*6/*6 O
genotype O
, O
but O
no O
statistical O
difference O
was O
observed O
among O
the O
CYP2B6 B
genotypes O
. O
These O
results O
suggest O
that O
the O
enantioselective O
disposition O
of O
sibutramine O
and O
its O
active O
metabolites O
are O
influenced O
by O
the O
altered O
genetic O
and O
environmental O
factors O
of O
CYP2B6 O
and O
CYP3A O
activity O
in O
vivo O
. O

racemic O
sibutramine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 B
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O
2.2-fold O
versus O
4.1-fold O
increase O
in O
the O
AUC O
in O
S-enantiomer O
and O
1.8-fold O
versus O
2.0-fold O
for O
the O

sibutramine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
.001 O
and O
P O
< O
.001 O
, O
respectively) O
but O
not O
during O
the O
clarithromycin O
phase O
(P O
= O
.099 O
and O
P O
= O
.090 O
, O
respectively) O
. O
Exposure O
to O
sibutramine O
was O
higher O
in O
subjects O
with O
the O
CYP2B6*6/*6 O
genotype O
, O
but O
no O
statistical O
difference O
was O
observed O
among O
the O
CYP2B6 B
genotypes O
. O
These O
results O
suggest O
that O
the O
enantioselective O
disposition O
of O
sibutramine O
and O
its O
active O
metabolites O
are O
influenced O
by O
the O
altered O
genetic O
and O
environmental O
factors O
of O
CYP2B6 O
and O
CYP3A O
activity O
in O
vivo O
. O

sibutramine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
.001 O
and O
P O
< O
.001 O
, O
respectively) O
but O
not O
during O
the O
clarithromycin O
phase O
(P O
= O
.099 O
and O
P O
= O
.090 O
, O
respectively) O
. O
Exposure O
to O
sibutramine O
was O
higher O
in O
subjects O
with O
the O
CYP2B6*6/*6 O
genotype O
, O
but O
no O
statistical O
difference O
was O
observed O
among O
the O
CYP2B6 O
genotypes O
. O
These O
results O
suggest O
that O
the O
enantioselective O
disposition O
of O
sibutramine O
and O
its O
active O
metabolites O
are O
influenced O
by O
the O
altered O
genetic O
and O
environmental O
factors O
of O
CYP2B6 O
and O
CYP3A B
activity O
in O
vivo O
. O

clopidogrel O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 B
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O

clopidogrel O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 B
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O

clopidogrel O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
, O
known O
CYP2B6 O
and O
CYP3A B
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O

clarithromycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
known O
CYP2B6 B
and O
CYP3A O
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O
2.2-fold O
versus O

clarithromycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Different O
effects O
of O
clopidogrel O
and O
clarithromycin O
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine O
and O
its O
active O
metabolites O
in O
healthy O
subjects.In O
this O
study O
, O
we O
assessed O
the O
effects O
of O
clopidogrel O
and O
clarithromycin O
known O
CYP2B6 O
and O
CYP3A B
inhibitors O
, O
respectively O
, O
on O
the O
enantioselective O
disposition O
of O
racemic O
sibutramine O
in O
conjunction O
with O
CYP2B6 O
polymorphisms O
in O
humans O
. O
Sibutramine O
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers O
. O
Clopidogrel O
and O
clarithromycin O
significantly O
increased O
the O
sibutramine O
plasma O
concentration O
, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O
2.2-fold O
versus O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
International O
Union O
of O
Pharmacology O
. O
LXXXVII O
. O
Complement O
peptide O
C5a O
, O
C4a O
, O
and O
C3a O
receptors.The O
activation O
of O
the O
complement O
cascade O
, O
a O
cornerstone O
of O
the O
innate O
immune O
response O
, O
produces O
a O
number O
of O
small O
(74-77 O
amino O
acid O
fragments O
, O
originally O
termed O
anaphylatoxins O
, O
that O
are O
potent O
chemoattractants O
and O
secretagogues O
that O
act O
on O
a O
wide O
variety O
of O
cell O
types O
. O
These O
fragments O
, O
C5a O
, O
C4a O
, O
and O
C3a O
, O
participate O
at O
all O
levels O
of O
the O
immune O
response O
and O
are O
also O
involved O
in O
other O
processes O
such O
as O
neural O
development O
and O
organ O
regeneration O
. O
Their O
primary O

cyclopiazonic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
In O
the O
present O
study O
we O
have O
analyzed O
the O
effects O
of O
short-term O
arsenite O
exposure O
on O
vascular O
function O
and O
endothelium-dependent O
relaxation O
. O
Endothelium-dependent O
relaxations O
, O
nitric O
oxide O
(NO) O
and O
endothelium O
derived O
hyperpolarizing O
factor O
(EDHF)-type O
, O
were O
studied O
in O
rabbit O
iliac O
artery O
and O
aortic O
rings O
using O
the O
G O
protein-coupled O
receptor O
agonist O
acetylcholine O
(ACh) O
and O
by O
cyclopiazonic O
acid O
(CPA) O
, O
which O
promotes O
store-operated O
Ca(2+) O
entry O
by O
inhibiting O
the O
endothelial O
SERCA B
pump O
. O
Production O
of O
reactive O
oxygen O
species O
(ROS) O
in O
the O
endothelium O
of O
rabbit O
aortic O
valve O
leaflets O
and O
endothelium-denuded O
RIA O
and O
aortic O
rings O
was O
assessed O
by O
imaging O
of O
dihydroethidium O
. O
In O
the O
iliac O
artery O
, O
exposure O
to O
100μM O
arsenite O
for O
30min O
potentiated O

CPA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
study O
we O
have O
analyzed O
the O
effects O
of O
short-term O
arsenite O
exposure O
on O
vascular O
function O
and O
endothelium-dependent O
relaxation O
. O
Endothelium-dependent O
relaxations O
, O
nitric O
oxide O
(NO) O
and O
endothelium O
derived O
hyperpolarizing O
factor O
(EDHF)-type O
, O
were O
studied O
in O
rabbit O
iliac O
artery O
and O
aortic O
rings O
using O
the O
G O
protein-coupled O
receptor O
agonist O
acetylcholine O
(ACh) O
and O
by O
cyclopiazonic O
acid O
( O
CPA O
 O
, O
which O
promotes O
store-operated O
Ca(2+) O
entry O
by O
inhibiting O
the O
endothelial O
SERCA B
pump O
. O
Production O
of O
reactive O
oxygen O
species O
(ROS) O
in O
the O
endothelium O
of O
rabbit O
aortic O
valve O
leaflets O
and O
endothelium-denuded O
RIA O
and O
aortic O
rings O
was O
assessed O
by O
imaging O
of O
dihydroethidium O
. O
In O
the O
iliac O
artery O
, O
exposure O
to O
100μM O
arsenite O
for O
30min O
potentiated O

apocynin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
valve O
leaflets O
and O
endothelium-denuded O
RIA O
and O
aortic O
rings O
was O
assessed O
by O
imaging O
of O
dihydroethidium O
. O
In O
the O
iliac O
artery O
, O
exposure O
to O
100μM O
arsenite O
for O
30min O
potentiated O
EDHF-type O
relaxations O
evoked O
by O
both O
CPA O
and O
ACh O
. O
Potentiation O
was O
prevented O
by O
catalase O
, O
the O
catalase/superoxide O
dismutase O
mimetic O
manganese O
porphyrin O
and O
the O
NADPH B
oxidase I
inhibitor O
apocynin O
By O
contrast O
in O
aortic O
rings O
, O
that O
exhibited O
negligible O
EDHF-type O
responses O
, O
endothelium-dependent O
NO-mediated O
relaxations O
evoked O
by O
CPA O
and O
ACh O
were O
unaffected O
by O
arsenite O
. O
Arsenite O
induced O
apocynin-sensitive O
increases O
in O
ROS O
production O
in O
the O
aortic O
valve O
endothelium O
, O
but O
not O
in O
the O
media O
and O
adventitia O
of O
the O
iliac O
artery O
and O
aorta O
. O
Our O
results O

acetylcholine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
mechanisms O
are O
poorly O
understood O
. O
In O
the O
present O
study O
we O
have O
analyzed O
the O
effects O
of O
short-term O
arsenite O
exposure O
on O
vascular O
function O
and O
endothelium-dependent O
relaxation O
. O
Endothelium-dependent O
relaxations O
, O
nitric O
oxide O
(NO) O
and O
endothelium O
derived O
hyperpolarizing O
factor O
(EDHF)-type O
, O
were O
studied O
in O
rabbit O
iliac O
artery O
and O
aortic O
rings O
using O
the O
G B
protein-coupled I
receptor I
agonist O
acetylcholine O
(ACh) O
and O
by O
cyclopiazonic O
acid O
(CPA) O
, O
which O
promotes O
store-operated O
Ca(2+) O
entry O
by O
inhibiting O
the O
endothelial O
SERCA O
pump O
. O
Production O
of O
reactive O
oxygen O
species O
(ROS) O
in O
the O
endothelium O
of O
rabbit O
aortic O
valve O
leaflets O
and O
endothelium-denuded O
RIA O
and O
aortic O
rings O
was O
assessed O
by O
imaging O
of O
dihydroethidium O
. O
In O
the O
iliac O
artery O
, O
exposure O
to O

ACh O
acts O
as O
AGONIST O
for O
what O
entity O
? O
poorly O
understood O
. O
In O
the O
present O
study O
we O
have O
analyzed O
the O
effects O
of O
short-term O
arsenite O
exposure O
on O
vascular O
function O
and O
endothelium-dependent O
relaxation O
. O
Endothelium-dependent O
relaxations O
, O
nitric O
oxide O
(NO) O
and O
endothelium O
derived O
hyperpolarizing O
factor O
(EDHF)-type O
, O
were O
studied O
in O
rabbit O
iliac O
artery O
and O
aortic O
rings O
using O
the O
G B
protein-coupled I
receptor I
agonist O
acetylcholine O
( O
ACh O
and O
by O
cyclopiazonic O
acid O
(CPA) O
, O
which O
promotes O
store-operated O
Ca(2+) O
entry O
by O
inhibiting O
the O
endothelial O
SERCA O
pump O
. O
Production O
of O
reactive O
oxygen O
species O
(ROS) O
in O
the O
endothelium O
of O
rabbit O
aortic O
valve O
leaflets O
and O
endothelium-denuded O
RIA O
and O
aortic O
rings O
was O
assessed O
by O
imaging O
of O
dihydroethidium O
. O
In O
the O
iliac O
artery O
, O
exposure O
to O
100μM O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Arsenite O
induced O
apocynin-sensitive O
increases O
in O
ROS O
production O
in O
the O
aortic O
valve O
endothelium O
, O
but O
not O
in O
the O
media O
and O
adventitia O
of O
the O
iliac O
artery O
and O
aorta O
. O
Our O
results O
suggest O
that O
arsenite O
can O
potentiate O
EDHF-type O
relaxations O
via O
a O
mechanism O
that O
is O
dependent O
on O
hydrogen O
peroxide O
, O
thus O
demonstrating O
that O
dismutation O
of O
the O
superoxide O
anion O
generated O
by O
NADPH B
oxidase I
can O
potentially O
offset O
loss O
of O
NO O
bioavailability O
under O
conditions O
of O
reduced O
eNOS O
activity O
. O
By O
contrast O
, O
selective O
increases O
in O
endothelial O
ROS O
production O
following O
exposure O
to O
arsenite O
failed O
to O
modify O
relaxations O
mediated O
by O
endogenous O
NO O
. O

sitagliptin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O
The O
baseline O
HbA1c O
and O
glycated B
albumin I
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O
with O
sitagliptin O
These O
findings O
suggest O
that O
add-on O
therapy O
with O
sitagliptin O
can O
be O
expected O
to O
achieve O
improvement O
of O
poor O
glycemic O
control O
irrespective O
of O
a O
patient's O
demographic O
profile O
. O
Stratified O
analysis O
based O
on O
the O
insulin O
regimen O
revealed O
a O
stronger O
antidiabetic O
effect O
and O
a O
high O
efficacy O
of O
sitagliptin O
when O
it O
was O
added O
to O
basal O
insulin O

sitagliptin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O
The O
baseline O
HbA1c B
and O
glycated O
albumin O
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O
with O
sitagliptin O
These O
findings O
suggest O
that O
add-on O
therapy O
with O
sitagliptin O
can O
be O
expected O
to O
achieve O
improvement O
of O
poor O
glycemic O
control O
irrespective O
of O
a O
patient's O
demographic O
profile O
. O
Stratified O
analysis O
based O
on O
the O
insulin O
regimen O
revealed O
a O
stronger O
antidiabetic O
effect O
and O
a O
high O
efficacy O
of O
sitagliptin O
when O
it O
was O
added O
to O
basal O
insulin O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
15 O
patients O
receiving O
multiple O
daily O
insulin O
injections O
, O
and O
11 O
patients O
receiving O
basal O
insulin O
with O
oral O
antidiabetic O
drugs O
(basal O
insulin O
therapy) O
. O
Concomitant O
oral O
drugs O
included O
sulfonylureas O
, O
α-glucosidase O
inhibitors O
and O
metformin O
. O
The O
hemoglobin B
A1c I
(HbA1c) O
of O
all O
patients O
improved O
significantly O
from O
8.1±1.2% O
to O
7.6±1.1% O
after O
12 O
weeks O
of O
add-on O
therapy O
with O
sitagliptin O
(p<0.01) O
, O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O
The O
baseline O
HbA1c O
and O
glycated O
albumin O
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O

sitagliptin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
15 O
patients O
receiving O
multiple O
daily O
insulin O
injections O
, O
and O
11 O
patients O
receiving O
basal O
insulin O
with O
oral O
antidiabetic O
drugs O
(basal O
insulin O
therapy) O
. O
Concomitant O
oral O
drugs O
included O
sulfonylureas O
, O
α-glucosidase O
inhibitors O
and O
metformin O
. O
The O
hemoglobin O
A1c O
(HbA1c) O
of O
all O
patients O
improved O
significantly O
from O
8.1±1.2% O
to O
7.6±1.1% O
after O
12 O
weeks O
of O
add-on O
therapy O
with O
sitagliptin O
(p<0.01) O
, O
and O
the O
insulin O
dosage O
was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001) O
. O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed O
. O
The O
baseline O
HbA1c B
and O
glycated O
albumin O
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O

sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Add-on O
therapy O
with O
the O
DPP-4 B
inhibitor O
sitaglipti O
improves O
glycemic O
control O
in O
insulin-treated O
Japanese O
patients O
with O
type O
2 O
diabetes O
mellitus.The O
effect O
of O
add-on O
therapy O
with O
sitagliptin O
on O
glycemic O
control O
was O
prospectively O
investigated O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
receiving O
insulin O
alone O
or O
insulin O
combined O
with O
oral O
antidiabetic O
drugs O
. O
Seventy-one O
patients O
were O
evaluated O
(38 O
men O
and O

clopidogrel-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O

ibuprofen-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O

(R)-naproxen-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O

(S)-naproxen-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O

Valproate-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O

CGP O
47292-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O

diclofenac-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 B
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

acyl O
glucuronides O
acts O
as O
NOT O
for O
what O
entity O
? O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 B
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

acyl O
glucuronides O
acts O
as O
NOT O
for O
what O
entity O
? O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 B
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

Diclofenac-β-d-glucuronide O
acts O
as O
NOT O
for O
what O
entity O
? O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O

clopidogrel-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 B
by O
diclofenac-β-d-glucuronide O

ibuprofen-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 B
by O
diclofenac-β-d-glucuronide O
was O

(R)-naproxen-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 B
by O
diclofenac-β-d-glucuronide O
was O
not O

(S)-naproxen-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
, O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 B
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O

acyl O
glucuronides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 O
by O
diclofenac-β-d-glucuronide O
was O
not O
observed O
. O
Lastly O
, O
both O
hCES1 O
and O
hCES2 O
were O
shown O
not O
to O
catalyze O
the O
hydrolysis O
of O
the O
acyl O
glucuronides O
studied O
. O
Conclusion O
: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl O
glucuronides O
due O
to O
the O
potential O
inhibition O
of O
hCESs O
. O

acyl O
glucuronides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human B
carboxylesterases I
1 I
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O

acyl O
glucuronides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O

acyl O
glucuronides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O

acyl O
glucuronides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human B
carboxylesterases I
by O
acyl O
glucuronide O
.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O

Diclofenac-β-d-glucuronide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
(S)-naproxen-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
(racemic) O
, O
clopidogrel-β-d-glucuronide O
, O
and O
valproate-β-d-glucuronide O
were O
found O
to O
be O
0.252 O
, O
0.537 O
, O
0.996 O
, O
1.77 O
, O
3.67 O
, O
5.02 O
, O
and O
15.2 O
hours O
, O
respectively O
. O
Diclofenac-β-d-glucuronide O
clopidogrel-β-d-glucuronide O
, O
ibuprofen-β-d-glucuronide O
, O
(R)-naproxen-β-d-glucuronide O
, O
and O
(S)-naproxen-β-d-glucuronide O
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4.32 O
± O
0.47 O
, O
24.8 O
± O
4.2 O
, O
355 O
± O
38 O
, O
468 O
± O
21 O
, O
707 O
± O
64 O
µM O
, O
respectively O
, O
but O
did O
not O
significantly O
inhibit O
hCES2 O
. O
Valproate-β-d-glucuronide O
and O
CGP O
47292-β-d-glucuronide O
did O
not O
inhibit O
either O
hCES O
. O
Time-dependent O
inactivation O
of O
hCES1 B
by O

alcohols O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O

acyl O
glucuronides O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine B
5'-diphosphate- I
glucuronosyltransferases I
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O

acyl O
glucuronides O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases B
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O

acyl O
glucuronides O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine B
5'-diphosphate- I
glucuronosyltransferases I
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O

carboxylic O
acids O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O

amines O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O

thiols O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O

carboxylic O
acids O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine B
5'-diphosphate- I
glucuronosyltransferases I
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O

carboxylic O
acids O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases B
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O

esters O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O

amides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O

acyl O
glucuronides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human B
carboxylesterases I
1 I
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O

acyl O
glucuronides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O

acyl O
glucuronides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O

thioesters O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Reversible O
inhibition O
of O
human O
carboxylesterases O
by O
acyl O
glucuronides.Carboxylesterases O
hydrolyze O
esters O
, O
amides O
, O
and O
thioesters O
to O
produce O
carboxylic O
acids O
and O
resulting O
alcohols O
, O
amines O
, O
and O
thiols O
, O
respectively O
. O
Uridine O
5'-diphosphate- O
glucuronosyltransferases O
are O
colocalized O
with O
carboxylesterases O
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O

acyl O
glucuronides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O

acyl O
glucuronides O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
further O
metabolize O
carboxylic O
acids O
to O
acyl O
glucuronides O
, O
but O
it O
is O
currently O
unknown O
if O
acyl O
glucuronides O
, O
being O
esters O
, O
also O
interact O
with O
carboxylesterases O
. O
Objective O
: O
This O
study O
explores O
the O
ability O
of O
acyl O
glucuronides O
to O
act O
as O
substrates O
or O
inhibitors O
of O
human O
carboxylesterases O
1 O
(hCES1) O
and O
2 O
(hCES2) O
. O
Methods O
: O
The O
stability O
of O
six O
acyl O
glucuronides O
in O
the O
presence O
of O
hCES1 O
, O
hCES2 O
, O
and O
buffer O
alone O
(100 O
mM O
potassium O
phosphate O
, O
pH O
7.4 O
, O
37°C) O
were O
investigated O
. O
Reversible O
inhibition O
of O
4-nitrophenyl O
acetate O
hydrolysis O
by O
the O
acyl O
glucuronides O
was O
also O
studied O
. O
Diclofenac-β-d-glucuronide O
was O
used O
to O
explore O
potential O
time-dependent O
inactivation O
. O
Results O
: O
The O
chemical O
stability O
half-life O
values O
for O
CGP O
47292-β-d-glucuronide O
, O
diclofenac-β-d-glucuronide O
, O

BPA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
blotting O
assay O
, O
and O
were O
called O
induced O
differentiated O
mammary O
epithelial O
cells O
(iDMECs) O
based O
on O
these O
data O
. O
The O
hESCs O
were O
treated O
with O
low O
doses O
of O
BPA O
range O
10(-9)-10(-6)M O
during O
the O
differentiation O
process O
, O
with O
DMSO O
as O
the O
solvent O
control O
and O
17-β-estrodiol O
(E2) O
as O
the O
estrogen-positive O
control O
. O
Our O
results O
showed O
that O
low O
dose O
BPA O
and O
E2 O
could O
influence O
the O
mammosphere O
area O
of O
iDMECs O
and O
upregulate O
the O
expression O
level O
of O
Oct4 B
and O
Nanog O
proteins O
, O
while O
only O
BPA O
could O
downregulate O
the O
expression O
of O
E-cadherin O
protein O
. O
Taken O
together O
, O
this O
study O
provides O
some O
insights O
into O
the O
effects O
of O
low O
dose O
BPA O
on O
the O
early O
differentiation O
stage O
of O

BPA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
blotting O
assay O
, O
and O
were O
called O
induced O
differentiated O
mammary O
epithelial O
cells O
(iDMECs) O
based O
on O
these O
data O
. O
The O
hESCs O
were O
treated O
with O
low O
doses O
of O
BPA O
range O
10(-9)-10(-6)M O
during O
the O
differentiation O
process O
, O
with O
DMSO O
as O
the O
solvent O
control O
and O
17-β-estrodiol O
(E2) O
as O
the O
estrogen-positive O
control O
. O
Our O
results O
showed O
that O
low O
dose O
BPA O
and O
E2 O
could O
influence O
the O
mammosphere O
area O
of O
iDMECs O
and O
upregulate O
the O
expression O
level O
of O
Oct4 O
and O
Nanog B
proteins O
, O
while O
only O
BPA O
could O
downregulate O
the O
expression O
of O
E-cadherin O
protein O
. O
Taken O
together O
, O
this O
study O
provides O
some O
insights O
into O
the O
effects O
of O
low O
dose O
BPA O
on O
the O
early O
differentiation O
stage O
of O

BPA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
BPA O
range O
10(-9)-10(-6)M O
during O
the O
differentiation O
process O
, O
with O
DMSO O
as O
the O
solvent O
control O
and O
17-β-estrodiol O
(E2) O
as O
the O
estrogen-positive O
control O
. O
Our O
results O
showed O
that O
low O
dose O
BPA O
and O
E2 O
could O
influence O
the O
mammosphere O
area O
of O
iDMECs O
and O
upregulate O
the O
expression O
level O
of O
Oct4 O
and O
Nanog O
proteins O
, O
while O
only O
BPA O
could O
downregulate O
the O
expression O
of O
E-cadherin B
protein O
. O
Taken O
together O
, O
this O
study O
provides O
some O
insights O
into O
the O
effects O
of O
low O
dose O
BPA O
on O
the O
early O
differentiation O
stage O
of O
mammary O
epithelial O
cells O
and O
suggests O
an O
easier O
canceration O
status O
of O
iDMECs O
under O
the O
effect O
of O
low O
dose O
BPA O
during O
its O
early O
differentiation O

25-OHD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
total O
cohort) O
progressed O
to O
diabetes O
. O
A O
multivariable O
model O
adjusted O
for O
age O
, O
sex O
, O
population O
group O
, O
immigrant O
status O
, O
BMI O
, O
season O
of O
vitamin O
D O
measurement O
, O
LDL B
and O
HDL O
cholesterol O
, O
triglycerides O
, O
estimated O
glomerular O
filtration O
rate O
, O
history O
of O
hypertension O
or O
cardiovascular O
disease O
, O
Charlson O
comorbidity O
index O
, O
smoking O
, O
and O
socioeconomic O
status O
revealed O
an O
inverse O
association O
between O
25-OHD O
and O
the O
risk O
of O
progression O
to O
IFG O
and O
diabetes O
. O
The O
odds O
of O
transitioning O
from O
normoglycemia O
to O
IFG O
, O
from O
normoglycemia O
to O
diabetes O
, O
and O
from O
IFG O
to O
diabetes O
in O
subjects O
with O
a O
25-OHD O
level O
≤25 O
nmol/L O
were O
greater O
than O
those O
of O
subjects O
with O
a O
25-OHD O
level O
>75 O
nmol/L O
[odds O
ratio O
1.13 O

25-OHD O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
total O
cohort) O
progressed O
to O
diabetes O
. O
A O
multivariable O
model O
adjusted O
for O
age O
, O
sex O
, O
population O
group O
, O
immigrant O
status O
, O
BMI O
, O
season O
of O
vitamin O
D O
measurement O
, O
LDL O
and O
HDL B
cholesterol O
, O
triglycerides O
, O
estimated O
glomerular O
filtration O
rate O
, O
history O
of O
hypertension O
or O
cardiovascular O
disease O
, O
Charlson O
comorbidity O
index O
, O
smoking O
, O
and O
socioeconomic O
status O
revealed O
an O
inverse O
association O
between O
25-OHD O
and O
the O
risk O
of O
progression O
to O
IFG O
and O
diabetes O
. O
The O
odds O
of O
transitioning O
from O
normoglycemia O
to O
IFG O
, O
from O
normoglycemia O
to O
diabetes O
, O
and O
from O
IFG O
to O
diabetes O
in O
subjects O
with O
a O
25-OHD O
level O
≤25 O
nmol/L O
were O
greater O
than O
those O
of O
subjects O
with O
a O
25-OHD O
level O
>75 O
nmol/L O
[odds O
ratio O
1.13 O

harmaline O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine B
oxidase I
A I
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine O
Oxidase O
A O
Inhibitor O
Harmaline O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mg/kg) O
and O
active O
metabolite O
bufotenine O
. O
This O
study O
is O
aimed O
at O
delineating O
harmaline O
and O
5-MeO-DMT O
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels O
, O
as O
well O
as O
the O
impact O
of O
CYP2D6 O
that O
affects O
harmaline O
PK O
and O
determines O
5-MeO-DMT O
O-demethylation O
to O
produce O
bufotenine O
. O
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A-mediated O
metabolic O
elimination O
by O
harmaline O
(2 O
, O
5 O
, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT O
(2 O
and O
10 O
mg/kg) O
at O
all O
dose O
combinations O
. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O

Harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacokinetic O
Interactions O
between O
Monoamine B
Oxidase I
A I
Inhibitor O
Harmalin O
and O
5-Methoxy-N,N-Dimethyltryptamine O
, O
and O
the O
Impact O
of O
CYP2D6 O
Status.5-Methoxy-N,N-dimethyltryptamine O
(5-MeO-DMT O
or O
street O
name O
"5-MEO") O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines O
. O
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine O
oxidase O
A O
(MAO-A) O
inhibitor O
harmaline O
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT O
(2 O
mg/kg) O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
5-MeO-DMT O
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

harmaline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

bufotenine O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

bufotenine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
was O
associated O
with O
greater O
exposure O
to O
harmaline O
in O
wild-type O
mice O
than O
CYP2D6-humanized O
(Tg-CYP2D6) O
mice O
. O
Harmaline O
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine O
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 O
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

5-MeO-DMT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
were O
generally O
higher O
in O
Tg-CYP2D6 O
mice O
. O
Surprisingly O
, O
greater O
harmaline O
dose O
(15 O
mg/kg) O
reduced O
bufotenine O
levels O
. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline O
on O
CYP2D6-catalyzed O
bufotenine O
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6 O
. O
Given O
these O
findings O
, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- O
and O
CYP2D6-catalyzed O
5-MeO-DMT O
metabolism O
by O
harmaline O
was O
developed O
to O
describe O
blood O
harmaline O
, O
5-MeO-DMT O
, O
and O
bufotenine O
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 O
mouse O
models O
. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O
harmaline O
and O
5-MeO-DMT O
PK O
interactions O
at O
various O
doses O
, O
define O
the O
impact O
of O
CYP2D6 B
status O
, O
and O
drive O
harmaline-5-MeO-DMT O
pharmacodynamics O
. O

alcohol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O
(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA B
methyltransferases I
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O

alcohol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O
(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O

alcohol O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
CpG-/CpG O
domain-binding O
proteins O
in O
murine O
embryonic O
fibroblasts.Fetal O
alcohol O
syndrome O
(FAS) O
, O
presenting O
with O
a O
constellation O
of O
neuro-/psychological O
, O
craniofacial O
and O
cardiac O
abnormalities O
, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol O
during O
pregnancy O
, O
with O
a O
prevalence O
of O
1-3 O
per O
1000 O
livebirths O
. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA B
methyltransferases I
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl B
CpG-binding I
proteins I
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 B
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

ethanol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
to O
test O
the O
hypothesis O
that O
alcohol O
alters O
global O
DNA O
methylation O
, O
and O
modulates O
expression O
of O
the O
DNA O
methyltransferases O
(DNMTs) O
and O
various O
methyl O
CpG-binding O
proteins O
. O
Murine O
embryonic O
fibroblasts O
(MEFs) O
, O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system O
, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol O
. O
In O
addition O
, O
ethanol O
induced O
degradation O
of O
DNA O
methyltransferases O
(DNMT-1 O
, O
DNMT-3a O
, O
and O
DNMT-3b) O
, O
as O
well O
as O
the O
methyl O
CpG-binding O
proteins O
(MeCP-2 O
, O
MBD-2 O
and O
MBD-3) O
, O
in O
MEF O
cells O
by O
the O
proteasomal O
pathway O
. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG-132 O
. O
These O
data O
support O
a O
potential O
epigenetic O

adenosine O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs B
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
α2ARs O
, O
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA-salt O
hypertension O
. O

adenosine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs B
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
α2ARs O
, O
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA-salt O
hypertension O
. O

Adenosine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA-salt O
hypertensive O
rats.Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone O
acetate O
(DOCA)-salt O
hypertension O
in O
rats O
. O
ATP O
and O
norepinephrine O
(NE) O
are O
coreleased O
from O
perivascular O
sympathetic O
nerves O
. O
NE O
acts O
at O
prejunctional O
α2-adrenergic O
receptors O
(α2ARs) O
to O
inhibit O
NE O
release O
, O
and O
α2AR O
function O
is O
impaired O
in O
DOCA-salt O
rats O
. O
Adenosine O
an O
enzymatic O
ATP O
degradation O
product O
, O
acts O
at O
prejunctional O
A1 B
adenosine I
receptors I
(A1Rs) O
to O
inhibit O
NE O
release O
. O
We O
tested O
the O
hypothesis O
that O
prejunctional O
A1R O
function O
is O
impaired O
in O
sympathetic O
nerves O
supplying O
mesenteric O
arteries O
(MAs) O
and O
veins O
(MVs) O
of O
DOCA-salt O
rats O
. O
Electrically O
evoked O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O

C23H29N7O6.HCl.xH2O O
acts O
as O
AGONIST O
for O
what O
entity O
? O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R O
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A B
adenosine I
receptor I
agonist O
CGS21680 O
( O
C23H29N7O6.HCl.xH2O O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs O
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O

CPA O
acts O
as O
AGONIST O
for O
what O
entity O
? O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy O
, O
respectively O
. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine O
hydroxylase O
(TH) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O
TH O
and O
A1Rs O
colocalized O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
( O
CPA O
A1R B
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O

Adenosine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Electrically O
evoked O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy O
, O
respectively O
. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine O
hydroxylase O
(TH) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O
TH O
and O
A1Rs O
colocalized O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R B
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O

N(6)-cyclopentyl-adenosine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy O
, O
respectively O
. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine O
hydroxylase O
(TH) O
and O
A1Rs O
in O
perivascular O
sympathetic O
nerves O
. O
TH O
and O
A1Rs O
colocalized O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R B
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A O
adenosine O
receptor O
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O

CGS21680 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
to O
perivascular O
sympathetic O
nerves O
. O
Adenosine O
and O
N(6)-cyclopentyl-adenosine O
(CPA O
, O
A1R O
agonist) O
constricted O
MVs O
but O
not O
MAs O
. O
Adenosine O
and O
CPA O
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs O
. O
DOCA-salt O
arteries O
were O
resistant O
to O
adenosine O
and O
CPA-mediated O
inhibition O
of O
NE O
release O
and O
constriction O
. O
The O
A2A B
adenosine I
receptor I
agonist O
CGS21680 O
(C23H29N7O6.HCl.xH2O) O
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O
currents O
. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs O
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs O
in O
veins; O
thus O
, O
adenosine O
selectively O
constricts O
the O
veins O
. O
Prejunctional O
A1R O
function O
is O
impaired O
in O
arteries O
, O
but O
not O
veins O
, O
from O
DOCA-salt O
rats O
. O
Sympathetic O
autoreceptor O
dysfunction O
is O

VP-16 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(·)NO O
in O
chloroform O
in O
the O
presence O
of O
oxygen O
. O
Separation O
and O
spectral O
analysis O
of O
VP-16 O
reaction O
extracts O
by O
electron O
spin O
resonance O
and O
UV-vis O
indicated O
the O
generation O
of O
the O
phenoxy O
radical O
and O
the O
o-quinone O
of O
VP-16 O
, O
as O
well O
as O
putative O
nitroxide O
, O
iminoxyl O
, O
and O
other O
nitrogen O
oxide O
intermediates O
. O
Nitric O
oxide O
products O
of O
VP-16 O
displayed O
significantly O
diminished O
topoisomerase O
II-dependent O
cleavage O
of O
DNA O
and O
cytotoxicity O
to O
human O
HL-60 O
leukemia O
cells O
. O
LPS-mediated O
induction O
of O
nitric O
oxide O
synthase O
in O
murine O
macrophages O
resulted O
in O
VP-16 O
resistance O
compared O
to O
Raw O
cells O
. O
Furthermore O
, O
(·)NO O
products O
derived O
from O
iNOS O
rapidly O
reacted O
with O
VP-16 O
leading O
to O
decreased O
DNA O
damage O
and O
cytotoxicity O
. O

STX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(LPO) O
and O
protein O
carbonylation O
(PCO) O
. O
In O
the O
blood O
was O
analyzed O
the O
genotoxic O
and O
hematological O
parameters O
. O
The O
hepatosomatic O
index O
and O
the O
relative O
condition O
factor O
did O
not O
show O
a O
significant O
difference O
between O
the O
exposed O
and O
control O
groups O
. O
The O
values O
of O
mean O
corpuscular O
hemoglobin B
concentration O
and O
mean O
corpuscular O
hemoglobin O
increased O
in O
the O
STX O
group O
. O
The O
hepatic O
tissue O
from O
both O
groups O
exhibited O
a O
typical O
pattern O
that O
have O
been O
already O
described O
for O
most O
teleost O
fish O
. O
The O
results O
suggested O
the O
generation O
of O
reactive O
oxygen O
species O
, O
with O
increased O
activity O
of O
GPx O
and O
concentrations O
of O
LPO O
and O
GSH; O
whereas O
the O
specific O
activity O
of O
SOD O
decreased O
. O
However O
, O
no O

STX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(LPO) O
and O
protein O
carbonylation O
(PCO) O
. O
In O
the O
blood O
was O
analyzed O
the O
genotoxic O
and O
hematological O
parameters O
. O
The O
hepatosomatic O
index O
and O
the O
relative O
condition O
factor O
did O
not O
show O
a O
significant O
difference O
between O
the O
exposed O
and O
control O
groups O
. O
The O
values O
of O
mean O
corpuscular O
hemoglobin B
concentration O
and O
mean O
corpuscular O
hemoglobin O
increased O
in O
the O
STX O
group O
. O
The O
hepatic O
tissue O
from O
both O
groups O
exhibited O
a O
typical O
pattern O
that O
have O
been O
already O
described O
for O
most O
teleost O
fish O
. O
The O
results O
suggested O
the O
generation O
of O
reactive O
oxygen O
species O
, O
with O
increased O
activity O
of O
GPx O
and O
concentrations O
of O
LPO O
and O
GSH; O
whereas O
the O
specific O
activity O
of O
SOD O
decreased O
. O
However O
, O
no O

NH4Cl O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
manner O
following O
antofine O
treatment O
. O
Double-labeling O
immunofluorescence O
microscopy O
showed O
that O
antofine O
(10ng/ml) O
induced O
endocytosis O
of O
surface O
gap O
junctions O
into O
the O
cytoplasm O
, O
where O
Cx43 B
was O
co-localized O
with O
the O
early O
endosome O
marker O
EEA1 O
. O
Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co-treatment O
with O
antofine O
and O
their O
respective O
specific O
inhibitors O
, O
NH4Cl O
or O
MG132 O
, O
partially O
inhibited O
the O
antofine-induced O
decrease O
in O
Cx43 O
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine-induced O
inhibition O
of O
GJIC O
. O
After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) O
concentration O
and O
activation O
of O
protein O
kinase O
C O
(PKC)α/βII O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O
Co-treatment O

MG132 O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
dose- O
and O
time-dependent O
manner O
following O
antofine O
treatment O
. O
Double-labeling O
immunofluorescence O
microscopy O
showed O
that O
antofine O
(10ng/ml) O
induced O
endocytosis O
of O
surface O
gap O
junctions O
into O
the O
cytoplasm O
, O
where O
Cx43 B
was O
co-localized O
with O
the O
early O
endosome O
marker O
EEA1 O
. O
Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co-treatment O
with O
antofine O
and O
their O
respective O
specific O
inhibitors O
, O
NH4Cl O
or O
MG132 O
partially O
inhibited O
the O
antofine-induced O
decrease O
in O
Cx43 O
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine-induced O
inhibition O
of O
GJIC O
. O
After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) O
concentration O
and O
activation O
of O
protein O
kinase O
C O
(PKC)α/βII O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O

antofine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 B
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKCβ O
signaling O
pathway O
. O
Inhibition O
of O
GJIC O
by O
antofine O
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS O
. O

antofine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ B
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKCβ O
signaling O
pathway O
. O
Inhibition O
of O
GJIC O
by O
antofine O
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS O
. O

BAPTA-AM O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine-induced O
inhibition O
of O
GJIC O
. O
After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) O
concentration O
and O
activation O
of O
protein O
kinase O
C O
(PKC)α/βII O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 B
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKCβ O
signaling O
pathway O
. O
Inhibition O
of O
GJIC O

antofine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
cytotoxic O
for O
various O
cancer O
cell O
lines O
. O
In O
this O
study O
, O
we O
demonstrated O
that O
treatment O
of O
rat O
primary O
astrocytes O
with O
antofine O
induced O
dose-dependent O
inhibition O
of O
gap O
junction O
intercellular O
communication O
(GJIC) O
, O
as O
assessed O
by O
scrape-loading O
6-carboxyfluorescein O
dye O
transfer O
. O
Levels O
of O
Cx43 B
protein O
were O
also O
decreased O
in O
a O
dose- O
and O
time-dependent O
manner O
following O
antofine O
treatment O
. O
Double-labeling O
immunofluorescence O
microscopy O
showed O
that O
antofine O
(10ng/ml) O
induced O
endocytosis O
of O
surface O
gap O
junctions O
into O
the O
cytoplasm O
, O
where O
Cx43 O
was O
co-localized O
with O
the O
early O
endosome O
marker O
EEA1 O
. O
Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co-treatment O
with O
antofine O
and O
their O
respective O
specific O
inhibitors O
, O
NH4Cl O
or O
MG132 O
, O
partially O
inhibited O
the O
antofine-induced O
decrease O

antofine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
inhibited O
the O
antofine-induced O
decrease O
in O
Cx43 B
protein O
levels O
, O
but O
did O
not O
inhibit O
the O
antofine-induced O
inhibition O
of O
GJIC O
. O
After O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) O
concentration O
and O
activation O
of O
protein O
kinase O
C O
(PKC)α/βII O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O

antofine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
30min O
of O
treatment O
, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) O
concentration O
and O
activation O
of O
protein O
kinase O
C O
(PKC)α/βII O
, O
which O
was O
maintained O
for O
at O
least O
6h O
. O
Co-treatment O
of O
astrocytes O
with O
antofine O
and O
the O
intracellular O
Ca(2+) O
chelator O
BAPTA-AM O
prevented O
downregulation O
of O
Cx43 B
and O
inhibition O
of O
GJIC O
. O
Moreover O
, O
co-treatment O
with O
antofine O
and O
a O
specific O
PKCβ O
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions O
, O
downregulation O
of O
Cx43 O
, O
and O
inhibition O
of O
GJIC O
. O
Taken O
together O
, O
these O
findings O
indicate O
that O
antofine O
induces O
Cx43 O
gap O
junction O
disassembly O
by O
the O
PKCβ O
signaling O
pathway O
. O
Inhibition O
of O
GJIC O
by O
antofine O
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
spatial O
and O
temporal O
control O
of O
proteomic O
labeling O
and O
identification O
of O
proteins O
made O
in O
specific O
cellular O
subpopulations O
. O
The O
approach O
is O
demonstrated O
by O
selective O
labeling O
of O
proteins O
in O
bacterial O
cells O
immobilized O
in O
the O
center O
of O
a O
laminar-flow O
microfluidic O
channel O
, O
where O
they O
are O
exposed O
to O
overlapping O
, O
opposed O
gradients O
of O
inducers O
of O
the O
N O
and O
C-terminal O
MetRS B
fragments O
. O
The O
observed O
labeling O
profile O
is O
predicted O
accurately O
from O
the O
strengths O
of O
the O
individual O
input O
signals O
. O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
temporal O
control O
of O
proteomic O
labeling O
and O
identification O
of O
proteins O
made O
in O
specific O
cellular O
subpopulations O
. O
The O
approach O
is O
demonstrated O
by O
selective O
labeling O
of O
proteins O
in O
bacterial O
cells O
immobilized O
in O
the O
center O
of O
a O
laminar-flow O
microfluidic O
channel O
, O
where O
they O
are O
exposed O
to O
overlapping O
, O
opposed O
gradients O
of O
inducers O
of O
the O
N- O
and O
C O
terminal O
MetRS B
fragments O
. O
The O
observed O
labeling O
profile O
is O
predicted O
accurately O
from O
the O
strengths O
of O
the O
individual O
input O
signals O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
gate O
for O
cell-targeted O
metabolic O
labeling O
and O
proteomic O
analysis O
in O
complex O
cellular O
systems O
. O
The O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl-tRNA O
synthetase O
(MetRS) O
that O
charges O
the O
Met O
surrogate O
azidonorleucine O
(Anl) O
to O
tRNA(Met) O
. O
Cellular O
protein O
labeling O
occurs O
only O
upon O
activation O
of O
two O
different O
promoters O
that O
drive O
expression O
of O
the O
N O
and O
C-terminal O
fragments O
of O
the O
bisected O
MetRS O
. O
Anl-labeled O
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper-catalyzed O
or O
strain-promoted O
azide-alkyne O
cycloaddition O
. O
Protein O
labeling O
is O
apparent O
within O
5 O
min O
after O
addition O
of O
Anl O
to O
bacterial O
cells O
in O
which O
the O
AND O
gate O
has O
been O
activated O
. O
This O
method O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
cell-targeted O
metabolic O
labeling O
and O
proteomic O
analysis O
in O
complex O
cellular O
systems O
. O
The O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl-tRNA O
synthetase O
(MetRS) O
that O
charges O
the O
Met O
surrogate O
azidonorleucine O
(Anl) O
to O
tRNA(Met) O
. O
Cellular O
protein O
labeling O
occurs O
only O
upon O
activation O
of O
two O
different O
promoters O
that O
drive O
expression O
of O
the O
N- O
and O
C O
terminal O
fragments O
of O
the O
bisected O
MetRS O
. O
Anl-labeled O
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper-catalyzed O
or O
strain-promoted O
azide-alkyne O
cycloaddition O
. O
Protein O
labeling O
is O
apparent O
within O
5 O
min O
after O
addition O
of O
Anl O
to O
bacterial O
cells O
in O
which O
the O
AND O
gate O
has O
been O
activated O
. O
This O
method O
allows O

fatty O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
to O
the O
more O
complex O
challenge O
of O
identifying O
allosteric O
leads O
and O
their O
often O
flat O
or O
confusing O
SAR O
. O
The O
present O
review O
will O
consider O
the O
advantages O
and O
challenges O
associated O
with O
allosteric O
GPCR O
ligands O
, O
and O
examine O
how O
the O
particular O
properties O
of O
these O
ligands O
may O
be O
exploited O
to O
uncover O
the O
therapeutic O
potential O
for O
free O
fatty O
acid O
sensitive O
GPCRs O
. O

fatty O
acid O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
therapeutic O
potential O
of O
allosteric O
ligands O
for O
free O
fatty O
aci O
sensitive O
GPCRs.G O
protein O
coupled O
receptors O
(GPCRs) O
are O
the O
most O
historically O
successful O
therapeutic O
targets O
. O
Despite O
this O
success O
there O
are O
many O
important O
aspects O
of O
GPCR O
pharmacology O
and O
function O
that O
have O
yet O
to O
be O
exploited O
to O
their O
full O
therapeutic O
potential O
. O
One O
in O
particular O
that O
has O
been O
gaining O
attention O
in O
recent O
times O
is O

LY294002 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
substituted O
5-morpholino-7H-thieno[3,2-b]pyran-7-ones O
designed O
as O
next O
generation O
PI3K B
inhibitors.Dysregulation O
of O
the O
phosphatidylinositol-3-kinase O
(PI3K) O
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K O
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials O
. O
Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
resulted O
in O
the O
only O
PI3K O
vascular-targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 O
, O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O
This O
inhibitor O
has O
properties O
that O
impart O
more O
in O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K O
inhibitors O
. O
We O

LY294002 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
substituted O
5-morpholino-7H-thieno[3,2-b]pyran-7-ones O
designed O
as O
next O
generation O
PI3K B
inhibitors.Dysregulation O
of O
the O
phosphatidylinositol-3-kinase O
(PI3K) O
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K O
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials O
. O
Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
resulted O
in O
the O
only O
PI3K O
vascular-targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 O
, O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O
This O
inhibitor O
has O
properties O
that O
impart O
more O
in O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K O
inhibitors O
. O
We O

SF1126 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
phosphatidylinositol-3-kinase O
(PI3K) O
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K B
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials O
. O
Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
, O
resulted O
in O
the O
only O
PI3K O
vascular-targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O
This O
inhibitor O
has O
properties O
that O
impart O
more O
in O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K O
inhibitors O
. O
We O
embarked O
on O
the O
exploration O
of O
scaffolds O
that O
retained O
such O
properties O

SF1126 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
phosphatidylinositol-3-kinase O
(PI3K) O
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K B
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials O
. O
Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
, O
resulted O
in O
the O
only O
PI3K O
vascular-targeted O
PI3K O
inhibitor O
prodrug O
, O
SF1126 O
which O
has O
now O
completed O
Phase O
I O
clinical O
trials O
. O
This O
inhibitor O
has O
properties O
that O
impart O
more O
in O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K O
inhibitors O
. O
We O
embarked O
on O
the O
exploration O
of O
scaffolds O
that O
retained O
such O
properties O

5-morpholino-7H-thieno[3,2-b]pyran-7-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K B
inhibitors O
. O
We O
embarked O
on O
the O
exploration O
of O
scaffolds O
that O
retained O
such O
properties O
while O
simultaneously O
exhibiting O
an O
increased O
potency O
toward O
PI3K O
. O
This O
work O
resulted O
in O
the O
discovery O
of O
the O
5-morpholino-7H-thieno[3,2-b]pyran-7-one O
system O
as O
the O
foundation O
of O
a O
new O
compound O
class O
of O
potential O
PI3K O
inhibitors O
having O
improved O
potency O
toward O
PI3K O
. O
The O
synthesis O
and O
cancer O
stem O
cell-based O
activity O
of O
these O
compounds O
are O
reported O
herein O
. O

5-morpholino-7H-thieno[3,2-b]pyran-7-one O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency O
, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K B
inhibitors O
. O
We O
embarked O
on O
the O
exploration O
of O
scaffolds O
that O
retained O
such O
properties O
while O
simultaneously O
exhibiting O
an O
increased O
potency O
toward O
PI3K O
. O
This O
work O
resulted O
in O
the O
discovery O
of O
the O
5-morpholino-7H-thieno[3,2-b]pyran-7-one O
system O
as O
the O
foundation O
of O
a O
new O
compound O
class O
of O
potential O
PI3K O
inhibitors O
having O
improved O
potency O
toward O
PI3K O
. O
The O
synthesis O
and O
cancer O
stem O
cell-based O
activity O
of O
these O
compounds O
are O
reported O
herein O
. O

5-morpholino-7H-thieno[3,2-b]pyran-7-ones O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
cancer O
stem O
cell-based O
activity O
of O
substituted O
5-morpholino-7H-thieno[3,2-b]pyran-7-one O
designed O
as O
next O
generation O
PI3K B
inhibitors.Dysregulation O
of O
the O
phosphatidylinositol-3-kinase O
(PI3K) O
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K O
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials O
. O
Our O
previous O
work O
, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002 O
, O
resulted O
in O

N-indolylmethyl O
spiroindoline-3,2'-quinazolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Spiro O
heterocycles O
as O
potential O
inhibitors O
of O
SIRT1 O
: O
Pd/C-mediated O
synthesis O
of O
novel O
N-indolylmethyl O
spiroindoline-3,2'-quinazoline O
.Novel O
N-indolylmethyl O
substituted O
spiroindoline-3,2'-quinazolines O
were O
designed O
as O
potential O
inhibitiors O
of O
SIRT1 O
. O
These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd/C-Cu O
mediated O
coupling-cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O
1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione O
with O
2-iodoanilides O
. O
Some O
of O
the O
compounds O
synthesized O
have O
shown O
encouraging O
inhibition O
of O
Sir O
2 O
protein O
(a O

N-indolylmethyl O
substituted O
spiroindoline-3,2'-quinazolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Spiro O
heterocycles O
as O
potential O
inhibitors O
of O
SIRT1 O
: O
Pd/C-mediated O
synthesis O
of O
novel O
N-indolylmethyl O
spiroindoline-3,2'-quinazolines.Novel O
N-indolylmethyl O
substituted O
spiroindoline-3,2'-quinazolines O
were O
designed O
as O
potential O
inhibitiors O
of O
SIRT1 O
. O
These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd/C-Cu O
mediated O
coupling-cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O
1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione O
with O
2-iodoanilides O
. O
Some O
of O
the O
compounds O
synthesized O
have O
shown O
encouraging O
inhibition O
of O
Sir O
2 O
protein O
(a O
yeast O
homologue O
of O

procyanidin O
acts O
as O
NOT O
for O
what O
entity O
? O
in O
AP O
were O
investigated O
for O
their O
immunomodulatory O
effects O
using O
THP-1-derived O
human O
dendritic O
cells O
(TDDCs) O
. O
The O
expression O
levels O
of O
HLA-DR O
(MHC O
class O
II) O
and O
CD86 B
(costimulatory O
molecule) O
were O
measured O
as O
an O
indicator O
of O
antigen O
presentation O
in O
TDDCs O
. O
A O
significant O
decrease O
in O
HLA-DR O
expression O
was O
observed O
in O
the O
AP O
and O
fractionated O
procyanidin O
treated O
cells O
in O
the O
presence O
of O
ovalbumin O
(OVA) O
, O
but O
no O
effect O
on O
CD86 O
expression O
was O
observed O
. O
The O
uptake O
of O
OVA O
was O
not O
inhibited O
by O
AP O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O

procyanidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
OVA O
was O
not O
inhibited O
by O
AP O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O
suppresses O
HLA-DR O
expression O
via O
the O
ubiquitin-proteasome O
pathway O
. O
Furthermore O
, O
the O
up-regulation O
of O
IL-12 B
and O
TNF-α O
was O
found O
in O
the O
procyanidin O
trimers-treated O
cells O
in O
the O
presence O
of O
OVA O
. O
These O
results O
suggest O
that O
apple O
polyphenols O
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation O
. O

procyanidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
OVA O
was O
not O
inhibited O
by O
AP O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O
suppresses O
HLA-DR O
expression O
via O
the O
ubiquitin-proteasome O
pathway O
. O
Furthermore O
, O
the O
up-regulation O
of O
IL-12 O
and O
TNF-α B
was O
found O
in O
the O
procyanidin O
trimers-treated O
cells O
in O
the O
presence O
of O
OVA O
. O
These O
results O
suggest O
that O
apple O
polyphenols O
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation O
. O

polyphenols O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Apple O
polyphenol O
suppress O
antigen O
presentation O
of O
ovalbumin B
by O
THP-1-derived O
dendritic O
cells.Apple O
polyphenol O
extract O
(AP) O
and O
procyanidin O
contained O
in O
AP O
were O
investigated O
for O
their O
immunomodulatory O
effects O
using O
THP-1-derived O
human O
dendritic O
cells O
(TDDCs) O
. O
The O
expression O
levels O
of O
HLA-DR O
(MHC O
class O
II) O
and O
CD86 O
(costimulatory O
molecule) O
were O
measured O
as O
an O
indicator O
of O
antigen O
presentation O

procyanidin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
AP O
were O
investigated O
for O
their O
immunomodulatory O
effects O
using O
THP-1-derived O
human O
dendritic O
cells O
(TDDCs) O
. O
The O
expression O
levels O
of O
HLA-DR B
(MHC O
class O
II) O
and O
CD86 O
(costimulatory O
molecule) O
were O
measured O
as O
an O
indicator O
of O
antigen O
presentation O
in O
TDDCs O
. O
A O
significant O
decrease O
in O
HLA-DR O
expression O
was O
observed O
in O
the O
AP O
and O
fractionated O
procyanidin O
treated O
cells O
in O
the O
presence O
of O
ovalbumin O
(OVA) O
, O
but O
no O
effect O
on O
CD86 O
expression O
was O
observed O
. O
The O
uptake O
of O
OVA O
was O
not O
inhibited O
by O
AP O
treatment O
, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH O
ubiquitin O
E3 O
ligase O
, O
MARCH1 O
, O
was O
up-regulated O
by O
AP O
treatment O
. O
It O
can O
therefore O
be O
presumed O
that O
AP O

zinc O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
uptake O
of O
zinc) O
in O
Caco-2 O
cells O
. O
α-CPP O
and O
β-CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco-2 O
cells O
versus O
iron O
sulphate O
, O
β-CN(1-25)4P O
being O
the O
most O
effective O
. O
In O
relation O
to O
zinc O
bioavailability O
, O
α-CPPs O
, O
β-CPPs O
, O
α(s1)-CN(64-74)4P O
and O
β-CN(1-25)4P O
increased O
zinc O
uptake O
. O
However O
, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc O
sulphate O
. O

zinc O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
uptake O
of O
zinc) O
in O
Caco-2 O
cells O
. O
α-CPP O
and O
β-CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco-2 O
cells O
versus O
iron O
sulphate O
, O
β-CN(1-25)4P O
being O
the O
most O
effective O
. O
In O
relation O
to O
zinc O
bioavailability O
, O
α-CPPs O
, O
β-CPPs O
, O
α(s1)-CN(64-74)4P O
and O
β-CN(1-25)4P O
increased O
zinc O
uptake O
. O
However O
, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc O
sulphate O
. O

zinc O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
uptake O
of O
zinc) O
in O
Caco-2 O
cells O
. O
α-CPP O
and O
β-CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco-2 O
cells O
versus O
iron O
sulphate O
, O
β-CN(1-25)4P O
being O
the O
most O
effective O
. O
In O
relation O
to O
zinc O
bioavailability O
, O
α-CPPs O
, O
β-CPPs O
, O
α(s1)-CN(64-74)4P O
and O
β-CN(1-25)4P O
increased O
zinc O
uptake O
. O
However O
, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc O
sulphate O
. O

zinc O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
uptake O
of O
zinc) O
in O
Caco-2 O
cells O
. O
α-CPP O
and O
β-CPP O
pools O
did O
not O
improve O
ferritin O
synthesis O
, O
but O
the O
three O
specific O
CPPs O
showed O
an O
increase O
in O
ferritin O
synthesis O
in O
Caco-2 O
cells O
versus O
iron O
sulphate O
, O
β-CN(1-25)4P O
being O
the O
most O
effective O
. O
In O
relation O
to O
zinc O
bioavailability O
, O
α-CPPs O
, O
β-CPPs O
, O
α(s1)-CN(64-74)4P O
and O
β-CN(1-25)4P O
increased O
zinc O
uptake O
. O
However O
, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc O
sulphate O
. O

procyanidins O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Oligomeric O
procyanidins O
of O
lotus O
seedpod O
inhibits O
the O
formation O
of O
advanced O
glycation O
end-products O
by O
scavenging O
reactive O
carbonyls.It O
has O
been O
reported O
that O
oligomeric O
procyanidins O
of O
lotus O
seedpod O
(LSOPC) O
is O
effective O
in O
the O
alleviation O
of O
Alzheimer's O
disease O
and O
diabetes O
through O
its O
antioxidant O
and O
insulin-potentiating O
activities O
. O
This O
study O
investigated O
the O
anti-glycative O
activity O
of O
LSOPC O
in O
a O
bovine O
serum O
albumin O
(BSA)-glucose O
model O
. O
The O
level O
of O
glycation O
and O
conformational O
alterations O
were O
assessed O
by O
specific O
fluorescence O
, O
Congo O
red O

vegfrecine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vegfrecine O
, O
an O
Inhibitor O
of O
VEGF O
Receptor O
Tyrosine O
Kinases O
Isolated O
from O
the O
Culture O
Broth O
of O
Streptomyces O
sp.A O
new O
inhibitor O
of O
VEGF O
receptor O
tyrosine O
kinases O
, O
vegfrecine O
(1) O
, O
was O
isolated O
from O
the O
culture O
broth O
of O
Streptomyces O
sp O
. O
MK931-CF8 O
. O
The O
molecular O
structure O
of O
1 O
was O
determined O
by O
NMR O
and O
MS O
analysis O
combined O
with O
synthesis O
. O
Compound O
1 O
showed O
potent O
inhibitory O
activity O
against O
vascular O
endothelial O
growth O
factor O
receptor O
(VEGFR) O
tyrosine O
kinases O
in O
in O
vitro O
enzyme O
assays O
, O
but O
platelet-derived O
growth O

aurothioglucose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin B
reductase I
(TRR) O
inhibitors O
( O
aurothioglucose O
and O
Sb(III)) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH O
. O
Such O
experiments O

aurothioglucose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
(TRR) O
inhibitors O
( O
aurothioglucose O
and O
Sb(III)) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR B
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH O
. O
Such O
experiments O

Sb(III) O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin B
reductase I
(TRR) O
inhibitors O
(aurothioglucose O
and O
Sb(III) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH O
. O
Such O
experiments O
also O
suggested O

Sb(III) O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase O
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
(TRR) O
inhibitors O
(aurothioglucose O
and O
Sb(III) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR B
plus O
NADPH O
, O
alone O
or O
when O
added O
to O
the O
cytosol O
, O
failed O
to O
support O
DMAs(V) O
reduction O
. O
On O
ultrafiltration O
of O
the O
cytosol O
through O
a O
3 O
kDa O
filter O
, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH O
. O
Such O
experiments O
also O
suggested O

adenosine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
90 O
min O
31% O
of O
the O
injected O
50 O
μmol/kg O
DMAs(V) O
dose O
was O
converted O
to O
DMAs(III) O
that O
was O
sequestered O
by O
the O
circulating O
erythrocytes O
. O
Pretreatment O
of O
rats O
with O
glutathione O
(GSH) O
depletors O
(phorone O
or O
BSO) O
delayed O
the O
elimination O
of O
DMAs(V) O
and O
the O
accumulation O
of O
RBC-bound O
DMAs O
, O
whereas O
the O
indirect O
methyltransferase B
inhibitor O
periodate-oxidized O
adenosine O
was O
without O
effect O
. O
Assessment O
of O
DMAs(V)-reducing O
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O
DMAs(V) O
required O
cytosolic O
protein O
and O
GSH O
and O
was O
inhibited O
by O
thiol O
reagents O
, O
GSSG O
and O
dehydroascorbate O
. O
Although O
thioredoxin O
reductase O
(TRR) O
inhibitors O
(aurothioglucose O
and O
Sb(III)) O
inhibited O
cytosolic O
DMAs(V) O
reduction O
, O
recombinant O
rat O
TRR O
plus O
NADPH O
, O
alone O
or O

DMAs(V) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
highly O
toxic O
dimethylarsinous O
acid O
by O
rats O
and O
rat O
liver O
cytosol.Dimethylarsinic O
acid O
(DMAs(V)) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic O
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous O
acid O
(DMAs(III)) O
, O
is O
highly O
toxic O
. O
Although O
glutathione B
S-transferase I
omega I
1 I
(GSTO1) O
and O
arsenic O
methyltransferase O
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs(V) O
reduction O
, O
their O
role O
in O
DMAs(V) O
reduction O
in O
vivo O
, O
or O
in O
cell O
extracts O
is O
uncertain O
. O
Therefore O
, O
the O
reduction O
of O
DMAs(V) O
to O
DMAs(III) O
in O
rats O
and O
in O
rat O
liver O
cytosol O
was O
studied O
to O
better O
understand O
its O
mechanism O
. O
To O
assess O
DMAs(V) O
reduction O
in O
rats O
, O
a O
novel O
procedure O
was O
devised O
based O
on O
following O

DMAs(V) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
highly O
toxic O
dimethylarsinous O
acid O
by O
rats O
and O
rat O
liver O
cytosol.Dimethylarsinic O
acid O
(DMAs(V)) O
, O
the O
major O
urinary O
metabolite O
of O
inorganic O
arsenic O
, O
is O
weakly O
cytotoxic O
, O
whereas O
its O
reduced O
form O
, O
dimethylarsinous O
acid O
(DMAs(III)) O
, O
is O
highly O
toxic O
. O
Although O
glutathione O
S-transferase O
omega O
1 O
(GSTO1) O
and O
arsenic B
methyltransferase I
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs(V) O
reduction O
, O
their O
role O
in O
DMAs(V) O
reduction O
in O
vivo O
, O
or O
in O
cell O
extracts O
is O
uncertain O
. O
Therefore O
, O
the O
reduction O
of O
DMAs(V) O
to O
DMAs(III) O
in O
rats O
and O
in O
rat O
liver O
cytosol O
was O
studied O
to O
better O
understand O
its O
mechanism O
. O
To O
assess O
DMAs(V) O
reduction O
in O
rats O
, O
a O
novel O
procedure O
was O
devised O
based O
on O
following O

2-hydroxydiarylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Discovery O
of O
novel O
2-hydroxydiarylamide O
derivatives O
as O
TMPRSS4 B
inhibitors.TMPRSS4 O
is O
a O
novel O
type O
II O
transmembrane O
serine O
protease O
that O
has O
been O
implicated O
in O
the O
invasion O
and O
metastasis O
of O
colon O
cancer O
cells O
. O
In O
this O
study O
, O
a O
novel O
series O
of O
2-hydroxydiarylamide O
derivatives O
were O
synthesized O
and O
evaluated O
for O
inhibiting O
TMPRSS4 O
serine O
protease O
activity O
and O
suppressing O
cancer O
cell O
invasion O
. O
These O
derivatives O
demonstrated O
good O
inhibitory O
activity O
against O
TMPRSS4 O
serine O
protease O
, O
which O
correlated O
with O
the O
promising O
anti-invasive O
activity O
of O
colon O
cancer O
cells O
overexpressing O
TMPRSS4 O
. O

2-hydroxydiarylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Discovery O
of O
novel O
2-hydroxydiarylamide O
derivatives O
as O
TMPRSS4 O
inhibitors.TMPRSS4 O
is O
a O
novel O
type O
II O
transmembrane O
serine B
protease I
that O
has O
been O
implicated O
in O
the O
invasion O
and O
metastasis O
of O
colon O
cancer O
cells O
. O
In O
this O
study O
, O
a O
novel O
series O
of O
2-hydroxydiarylamide O
derivatives O
were O
synthesized O
and O
evaluated O
for O
inhibiting O
TMPRSS4 O
serine O
protease O
activity O
and O
suppressing O
cancer O
cell O
invasion O
. O
These O
derivatives O
demonstrated O
good O
inhibitory O
activity O
against O
TMPRSS4 O
serine O
protease O
, O
which O
correlated O
with O
the O
promising O
anti-invasive O
activity O
of O
colon O
cancer O
cells O
overexpressing O
TMPRSS4 O
. O

2-hydroxydiarylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Discovery O
of O
novel O
2-hydroxydiarylamid O
derivatives O
as O
TMPRSS4 B
inhibitors.TMPRSS4 O
is O
a O
novel O
type O
II O
transmembrane O
serine O
protease O
that O
has O
been O
implicated O
in O
the O
invasion O
and O
metastasis O
of O
colon O
cancer O
cells O
. O
In O
this O
study O
, O
a O
novel O
series O
of O
2-hydroxydiarylamide O
derivatives O
were O
synthesized O
and O
evaluated O
for O
inhibiting O
TMPRSS4 O
serine O
protease O
activity O
and O
suppressing O
cancer O
cell O
invasion O
. O

calcium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
a O
passive O
thermodynamic O
process O
. O
Here O
, O
we O
challenge O
this O
view O
in O
C O
. O
elegans O
by O
showing O
that O
genetic O
programs O
actively O
promote O
longevity O
at O
cold O
temperatures O
. O
We O
find O
that O
TRPA-1 O
, O
a O
cold-sensitive O
TRP O
channel O
, O
detects O
temperature O
drop O
in O
the O
environment O
to O
extend O
lifespan O
. O
This O
effect O
requires O
cold-induced O
, O
TRPA-1-mediated O
calcium O
influx O
and O
a O
calcium O
sensitive O
PKC B
that O
signals O
to O
the O
transcription O
factor O
DAF-16/FOXO O
. O
Human O
TRPA1 O
can O
functionally O
substitute O
for O
worm O
TRPA-1 O
in O
promoting O
longevity O
. O
Our O
results O
reveal O
a O
previously O
unrecognized O
function O
for O
TRP O
channels O
, O
link O
calcium O
signaling O
to O
longevity O
, O
and O
, O
importantly O
, O
demonstrate O
that O
genetic O
programs O
contribute O
to O
lifespan O
extension O
at O
cold O
temperatures O
. O

alcohol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
transaminase O
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases O
. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol O
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF O
. O
Co-administration O
of O
CNF O
maintained O
SOD O
activity O
, O
GSH O
and O
malondialdehyde O
levels O
close O
to O
those O
of O
the O
normal O
diet O
group O
. O
Chronic O
consumption O
of O
alcohol O
also O
stimulated O
abrupt O
increases O
in O
pro-inflammatory O
cytokines O
such O
as O
nuclear O
factor O
(NF)-κB O
, O
tumor O
necrosis O
factor O
(TNF)-α O
and O
interleukin O
(IL)-1β O
in O
liver O
otherwise O
co-administration O
of O
CNF O
effectively O
suppressed O
production O
of O
these O
cytokines O
dose-dependently O
. O
These O
results O
indicate O
that O
co-administration O
of O
CNF O
with O
alcohol O
can O
alleviate O
alcohol O
induced O
liver O
damage O
through O
preventing O

alcohol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
transaminase O
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases O
. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol O
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF O
. O
Co-administration O
of O
CNF O
maintained O
SOD O
activity O
, O
GSH O
and O
malondialdehyde O
levels O
close O
to O
those O
of O
the O
normal O
diet O
group O
. O
Chronic O
consumption O
of O
alcohol O
also O
stimulated O
abrupt O
increases O
in O
pro-inflammatory O
cytokines O
such O
as O
nuclear O
factor O
(NF)-κB O
, O
tumor B
necrosis I
factor I
(TNF)-α I
and O
interleukin O
(IL)-1β O
in O
liver O
otherwise O
co-administration O
of O
CNF O
effectively O
suppressed O
production O
of O
these O
cytokines O
dose-dependently O
. O
These O
results O
indicate O
that O
co-administration O
of O
CNF O
with O
alcohol O
can O
alleviate O
alcohol O
induced O
liver O
damage O
through O
preventing O

alcohol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
transaminase O
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases O
. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol O
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF O
. O
Co-administration O
of O
CNF O
maintained O
SOD O
activity O
, O
GSH O
and O
malondialdehyde O
levels O
close O
to O
those O
of O
the O
normal O
diet O
group O
. O
Chronic O
consumption O
of O
alcohol O
also O
stimulated O
abrupt O
increases O
in O
pro-inflammatory O
cytokines O
such O
as O
nuclear O
factor O
(NF)-κB O
, O
tumor O
necrosis O
factor O
(TNF)-α O
and O
interleukin B
(IL)-1β I
in O
liver O
otherwise O
co-administration O
of O
CNF O
effectively O
suppressed O
production O
of O
these O
cytokines O
dose-dependently O
. O
These O
results O
indicate O
that O
co-administration O
of O
CNF O
with O
alcohol O
can O
alleviate O
alcohol O
induced O
liver O
damage O
through O
preventing O

alcohol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
unshiu O
against O
ethanol-induced O
hepatic O
damage O
through O
an O
animal O
study O
. O
Citrus O
narirutin O
fraction O
(CNF) O
, O
contained O
75% O
of O
narirutin O
, O
was O
obtained O
by O
an O
ultra-sonicated O
extraction O
and O
further O
purification O
. O
ICR O
mice O
were O
divided O
into O
four O
groups; O
normaldiet O
control O
, O
ethanol O
control O
(6.5g O
ethanol/kg) O
, O
low-CNF O
(ethanol+150mg O
CNF/kg) O
and O
high-CNF O
(ethanol+300mg O
CNF/kg) O
groups O
. O
Consumption O
of O
alcohol O
for O
8weeks O
induced O
severe O
liver O
damage O
with O
increases O
in O
prognostic O
indicators O
such O
as O
aspartate O
transaminase O
, O
alanine O
transaminase O
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases O
. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol O
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF O
. O
Co-administration O
of O
CNF O
maintained O
SOD O

alcohol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
unshiu O
against O
ethanol-induced O
hepatic O
damage O
through O
an O
animal O
study O
. O
Citrus O
narirutin O
fraction O
(CNF) O
, O
contained O
75% O
of O
narirutin O
, O
was O
obtained O
by O
an O
ultra-sonicated O
extraction O
and O
further O
purification O
. O
ICR O
mice O
were O
divided O
into O
four O
groups; O
normaldiet O
control O
, O
ethanol O
control O
(6.5g O
ethanol/kg) O
, O
low-CNF O
(ethanol+150mg O
CNF/kg) O
and O
high-CNF O
(ethanol+300mg O
CNF/kg) O
groups O
. O
Consumption O
of O
alcohol O
for O
8weeks O
induced O
severe O
liver O
damage O
with O
increases O
in O
prognostic O
indicators O
such O
as O
aspartate O
transaminase O
, O
alanine B
transaminase I
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases O
. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol O
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF O
. O
Co-administration O
of O
CNF O
maintained O
SOD O

BPA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O
in O
all O
BPA O
males O
and O
BPA O
0.5 O
females O
and O
reduced O
in O
BPA O
200 O
females O
. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA O
0.5 O
males O
and O
reduced O
in O
BPA O
0.5 O
females O
. O
BPA O
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG O
pairs O
in O
the O
calsequestrin B
2 I
CpG O
island O
. O
These O
results O
suggest O
that O
continual O
exposure O
to O
BPA O
impacts O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
epigenetic O
DNA O
methylation O
marks O
in O
males O
and O
females O
. O

BPA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA B
methyltransferase I
3a I
expression O
was O
increased O
in O
all O
BPA O
males O
and O
BPA O
0.5 O
females O
and O
reduced O
in O
BPA O
200 O
females O
. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA O
0.5 O
males O
and O
reduced O
in O
BPA O
0.5 O
females O
. O
BPA O
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG O
pairs O
in O
the O
calsequestrin O
2 O
CpG O
island O
. O
These O
results O
suggest O
that O
continual O
exposure O
to O

BPA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA B
methyltransferase I
3a I
expression O
was O
increased O
in O
all O
BPA O
males O
and O
BPA O
0.5 O
females O
and O
reduced O
in O
BPA O
200 O
females O
. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA O
0.5 O
males O
and O
reduced O
in O
BPA O
0.5 O
females O
. O
BPA O
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG O
pairs O
in O
the O
calsequestrin O
2 O
CpG O
island O
. O
These O
results O
suggest O
that O
continual O
exposure O
to O
BPA O
impacts O
cardiac O

BPA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA B
methyltransferase I
3a I
expression O
was O
increased O
in O
all O
BPA O
males O
and O
BPA O
0.5 O
females O
and O
reduced O
in O
BPA O
200 O
females O
. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA O
0.5 O
males O
and O
reduced O
in O
BPA O
0.5 O
females O
. O
BPA O
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG O
pairs O
in O
the O
calsequestrin O
2 O
CpG O
island O
. O
These O
results O
suggest O
that O
continual O
exposure O
to O
BPA O
impacts O
cardiac O
structure/function O
, O
protein O
expression O
, O
and O
epigenetic O
DNA O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin B
2 I
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic B
reticulum I
ATPase I
2a I
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban O
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O

calcium O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
and O
adiposity O
. O
Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated O
males O
. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar O
, O
but O
lifelong O
BPA O
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral O
. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA O
females O
. O
The O
calcium O
homeostasis O
proteins O
sarcoendoplasmic O
reticulum O
ATPase O
2a O
(SERCA2a) O
, O
sodium O
calcium O
exchanger-1 O
, O
phospholamban B
(PLB) O
, O
phospho-PLB O
, O
and O
calsequestrin O
2 O
are O
important O
for O
contraction O
and O
relaxation O
. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium O
mobility O
in O
males O
and O
reduced O
calcium O
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes O
. O
DNA O
methyltransferase O
3a O
expression O
was O
increased O

EtOAc O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
× O
10(4) O
cells O
/ O
well O
on O
HeLa O
cells O
in O
96-well O
plates O
were O
used O
, O
respectively O
. O
Furthermore O
, O
the O
quality O
of O
high-throughput O
screening O
(HTS) O
in O
stability O
and O
reliability O
was O
evaluated O
by O
the O
Z'-factor O
. O
Additionally O
, O
different O
extracts O
of O
Rhizoma O
Coptis O
and O
berberine O
were O
tested O
by O
the O
developed O
method O
. O
The O
results O
suggested O
that O
both O
the O
EtOAc O
extract O
and O
berberine O
were O
able O
to O
activate O
PPARα/β/γ O
, O
and O
Rhizoma O
Coptis O
contains O
potential O
natural O
agonists O
of O
PPARs O
besides O
berberine O
. O
In O
conclusion O
, O
the O
developed O
HTS O
assay O
is O
a O
simple O
, O
rapid O
, O
stable O
, O
and O
specific O
method O
for O
the O
screening O
of O
PPARs O
natural O
agonists O
. O

berberine O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
well O
on O
HeLa O
cells O
in O
96-well O
plates O
were O
used O
, O
respectively O
. O
Furthermore O
, O
the O
quality O
of O
high-throughput O
screening O
(HTS) O
in O
stability O
and O
reliability O
was O
evaluated O
by O
the O
Z'-factor O
. O
Additionally O
, O
different O
extracts O
of O
Rhizoma O
Coptis O
and O
berberine O
were O
tested O
by O
the O
developed O
method O
. O
The O
results O
suggested O
that O
both O
the O
EtOAc O
extract O
and O
berberine O
were O
able O
to O
activate O
PPARα/β/γ O
, O
and O
Rhizoma O
Coptis O
contains O
potential O
natural O
agonists O
of O
PPARs O
besides O
berberine O
. O
In O
conclusion O
, O
the O
developed O
HTS O
assay O
is O
a O
simple O
, O
rapid O
, O
stable O
, O
and O
specific O
method O
for O
the O
screening O
of O
PPARs O
natural O
agonists O
. O

berberine O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
(HTS) O
in O
stability O
and O
reliability O
was O
evaluated O
by O
the O
Z'-factor O
. O
Additionally O
, O
different O
extracts O
of O
Rhizoma O
Coptis O
and O
berberine O
were O
tested O
by O
the O
developed O
method O
. O
The O
results O
suggested O
that O
both O
the O
EtOAc O
extract O
and O
berberine O
were O
able O
to O
activate O
PPARα/β/γ O
, O
and O
Rhizoma O
Coptis O
contains O
potential O
natural O
agonists O
of O
PPARs O
besides O
berberine O
In O
conclusion O
, O
the O
developed O
HTS O
assay O
is O
a O
simple O
, O
rapid O
, O
stable O
, O
and O
specific O
method O
for O
the O
screening O
of O
PPARs O
natural O
agonists O
. O

berberine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
(HTS) O
in O
stability O
and O
reliability O
was O
evaluated O
by O
the O
Z'-factor O
. O
Additionally O
, O
different O
extracts O
of O
Rhizoma O
Coptis O
and O
berberine O
were O
tested O
by O
the O
developed O
method O
. O
The O
results O
suggested O
that O
both O
the O
EtOAc O
extract O
and O
berberine O
were O
able O
to O
activate O
PPARα/β/γ O
, O
and O
Rhizoma O
Coptis O
contains O
potential O
natural O
agonists O
of O
PPARs B
besides O
berberine O
In O
conclusion O
, O
the O
developed O
HTS O
assay O
is O
a O
simple O
, O
rapid O
, O
stable O
, O
and O
specific O
method O
for O
the O
screening O
of O
PPARs O
natural O
agonists O
. O

anthocyanidins O
acts O
as O
NOT O
for O
what O
entity O
? O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR B
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

anthocyanidins O
acts O
as O
NOT O
for O
what O
entity O
? O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 B
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

pelargonidin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR B
and O
AhR-dependent O
gene O

pelargonidin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR B
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

pelargonidin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR B
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

cyanidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
( O
cyanidin O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O

cyanidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
( O
cyanidin O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O

cyanidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 B
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
( O
cyanidin O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O

delphinidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O

delphinidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O

delphinidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 B
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O

malvidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O

malvidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O

malvidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 B
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O

peonidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
petunidin O
, O
pelargonidin) O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O

peonidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O

peonidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 B
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O

petunidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
pelargonidin) O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O

petunidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O

petunidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 B
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O

pelargonidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O

pelargonidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O

pelargonidin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 B
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O

anthocyanidins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl B
hydrocarbon I
receptor I
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O

anthocyanidins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR B
and O
induces O
CYP1A1 O
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O

anthocyanidins O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Pelargonidin O
activates O
the O
AhR O
and O
induces O
CYP1A1 B
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O

2,3,7,8-tetrachlorodibenzodioxin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
( O
TCDD O
 O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O

pelargonidin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR B
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

pelargonidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O

2,3,7,8-tetrachlorodibenzodioxin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O

pelargonidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O

pelargonidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 B
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O

pelargonidin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T.We O
examined O
the O
effects O
of O
anthocyanidins O
(cyanidin O
, O
delphinidin O
, O
malvidin O
, O
peonidin O
, O
petunidin O
, O
pelargonidin) O
on O
the O
aryl O
hydrocarbon O
receptor O
(AhR)-CYP1A1 O
signaling O
pathway O
in O
human O
hepatocytes O
, O
hepatic O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
HepG2 O
and O
intestinal O
LS174T O
cancer O
cells O
. O
AhR-dependent O
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
( O
TCDD O
 O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O

pelargonidin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O

pelargonidin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
was O
increased O
by O
pelargonidin O
in O
a O
concentration-dependent O
manner O
at O
24h O
. O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 O
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 B
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Similarly O
, O
pelargonidin O
induced O
the O
expression O
of O
CYP1A1 B
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin O
(TCDD) O
, O
the O
most O
potent O
activator O
of O
AhR O
. O
CYP1A1 O
and O
CYP1A2 O
mRNAs O
were O
also O
increased O
by O
pelargonidin O
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 O
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O

delphinidin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
TCDD O
potency) O
and O
the O
increase O
in O
CYP1A1 B
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

pelargonidin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
CYP1A1 B
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 O
enzyme O
. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin O
was O
a O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 O
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

pelargonidin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
weak O
ligand O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 B
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

delphinidin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
AhR O
. O
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 B
activity O
by O
delphinidin O
(IC50 O
78 O
μM) O
and O
pelargonidin O
(IC50 O
33 O
μM) O
. O
Overall O
, O
although O
most O
anthocyanidins O
had O
no O
effects O
on O
AhR-CYP1A1 O
signaling O
, O
pelargonidin O
can O
bind O
to O
and O
activate O
the O
AhR O
and O
AhR-dependent O
gene O
expression O
, O
and O
pelargonidin O
and O
delphinidin O
inhibit O
the O
CYP1A1 O
catalytic O
activity O
. O

metformin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
Sulfonylureas O
in O
Relation O
to O
Cancer O
Risk O
in O
Type O
II O
Diabetes O
Patients O
: O
A O
Meta-analysis O
using O
primary O
data O
of O
published O
studies.INTRODUCTION O
: O
Accumulating O
evidence O
suggests O
that O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
hyperinsulinemia O
are O
at O
increased O
risk O
for O
developing O
malignancies O
. O
It O
remains O
to O
be O
fully O
elucidated O
whether O
use O
of O
metformin O
an O
insulin B
sensitizer O
, O
and/or O
sulfonylureas O
, O
insulin O
secretagogues O
, O
affect O
cancer O
incidence O
in O
subjects O
with O
T2DM O
. O
MATERIAL O
& O
METHODS O
: O
We O
performed O
a O
meta-analysis O
using O
PubMed O
, O
of O
randomized O
control O
trials O
(RCTs) O
, O
cohorts O
, O
and O
case-control O
studies O
published O
through O
July O
2012 O
that O
assess O
effects O
of O
metformin O
and/or O
sulfonylurea O
sulfonylureas O
on O
cancer O
risk O
at O
any O

sulfonylureas O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Cancer O
Risk O
in O
Type O
II O
Diabetes O
Patients O
: O
A O
Meta-analysis O
using O
primary O
data O
of O
published O
studies.INTRODUCTION O
: O
Accumulating O
evidence O
suggests O
that O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
hyperinsulinemia O
are O
at O
increased O
risk O
for O
developing O
malignancies O
. O
It O
remains O
to O
be O
fully O
elucidated O
whether O
use O
of O
metformin O
, O
an O
insulin B
sensitizer O
, O
and/or O
sulfonylureas O
insulin O
secretagogues O
, O
affect O
cancer O
incidence O
in O
subjects O
with O
T2DM O
. O
MATERIAL O
& O
METHODS O
: O
We O
performed O
a O
meta-analysis O
using O
PubMed O
, O
of O
randomized O
control O
trials O
(RCTs) O
, O
cohorts O
, O
and O
case-control O
studies O
published O
through O
July O
2012 O
that O
assess O
effects O
of O
metformin O
and/or O
sulfonylurea O
sulfonylureas O
on O
cancer O
risk O
at O
any O
site O
, O
in O
subjects O
with O
T2DM O
. O

apocynin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 B
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O

resveratrol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 B
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O

resveratrol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 B
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH O
oxidase-derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O

nicotinamide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH O
oxidase-derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O
the O
vascular O
aging O
phenotype O
. O
Moreover O
, O
a O
new O
mechanism O
for O
controlling O
endothelial O
function O
after O
SIRT1 O
activation O
involves O

resveratrol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH B
oxidase I
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O

resveratrol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) B
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O

resveratrol O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O

resveratrol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH B
oxidase I
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O

resveratrol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) B
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O

resveratrol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
. O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O

nicotinamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
conserved O
NAD(+)-dependent O
deacetylase O
SIRT1 B
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
( O
nicotinamide O
sirtinol O
, O
EX527) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O

sirtinol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
conserved O
NAD(+)-dependent O
deacetylase O
SIRT1 B
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
EX527) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O

EX527 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NAD(+)-dependent O
deacetylase O
SIRT1 B
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
, O
EX527 O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O

apocynin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH B
oxidase I
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O

resveratrol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O
the O
PPARα O
coactivator O
PGC-1α O
, O
which O
was O
suppressed O
by O
resveratrol O
In O
conclusion O
, O
impaired O
activity O
of O
SIRT1 O
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH O
oxidase-derived O
ROS O
production O
in O
the O
vascular O
wall O
, O
mimicking O
the O
vascular O
aging O
phenotype O
. O
Moreover O
, O
a O
new O
mechanism O
for O
controlling O
endothelial O
function O
after O
SIRT1 O
activation O
involves O
a O
decreased O
PGC-1α B
acetylation O
and O
the O
subsequent O
PPARα O
activation O
, O
resulting O
in O
both O
decreased O

oxygen O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
by O
up-regulation O
of O
NADPH O
oxidase O
, O
oxidative O
stress O
and O
endothelial O
dysfunction O
. O
Previous O
studies O
demonstrate O
that O
the O
activity O
of O
the O
evolutionarily O
conserved O
NAD(+)-dependent O
deacetylase O
SIRT1 O
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 O
confer O
significant O
anti-aging O
cardiovascular O
effects O
. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 O
promotes O
NADPH O
oxidase-dependent O
production O
of O
reactive O
oxygen O
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 O
(nicotinamide O
, O
sirtinol O
, O
EX527) O
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats O
. O
Inhibition O
of O
SIRT1 O
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O

superoxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
SIRT1 B
induced O
endothelial O
dysfunction O
, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine O
and O
the O
calcium O
ionophore O
A23187 O
. O
Endothelial O
dysfunction O
induced O
by O
SIRT1 O
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH O
oxidase O
inhibitor O
apocynin O
or O
superoxide O
dismutase O
. O
Inhibition O
of O
SIRT1 O
significantly O
increased O
vascular O
superoxide O
production O
, O
enhanced O
NADPH O
oxidase O
activity O
, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) O
and O
NOX4 O
, O
which O
were O
prevented O
by O
resveratrol O
. O
Peroxisome O
proliferator-activated O
receptor-α O
(PPARα) O
activation O
mimicked O
the O
effects O
of O
resveratrol O
while O
PPARα O
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 O
activator O
. O
SIRT1 O
co-precipitated O
with O
PPARα O
and O
nicotinamide O
increased O
the O
acetylation O
of O

peramivir O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Balancing O
societal O
needs O
and O
regulatory O
certainty O
: O
the O
case O
study O
of O
peramivir O
in O
Japan.Regulators O
must O
balance O
societal O
and O
medical O
requirements O
against O
the O
need O
for O
certainty O
about O
benefit O
and O
risk O
for O
new O
medicines O
. O
This O
is O
described O
in O
a O
case O
study O
of O
the O
expedited O
review O
and O
approval O
of O
peramivir O
a O
novel O
neuraminidase B
inhibitor O
, O
in O
Japan O
in O
the O
context O
of O
the O
emergence O
of O
new O
strain O
of O
influenza O
in O
2009 O
. O
The O
case O
illustrates O
the O
importance O
of O
regulatory O
science O
and O
transparency O
in O
supporting O
such O
decision O
making O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
healing O
. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O
is O
associated O
with O
enhanced O
healing O
. O
We O
hypothesized O
that O
increased O
neutrophil O
recruitment O
by O
keratinocytes O
may O
contribute O
to O
the O
delayed O
healing O
of O
diabetic O
wound O
. O
Using O
cultured O
human O
keratinocytes O
and O
diabetic O
rat O
model O
, O
the O
current O
study O
showed O
that O
high- O
glucose O
environment O
enhanced O
IL-8 O
production O
via O
epidermal O
growth O
factor O
receptor O
(EGFR) O
-extracelluar O
signal-regulated O
kinase O
(ERK) O
pathway O
in O
a O
reactive O
oxygen O
species O
(ROS)-dependent O
manner O
in O
keratinocytes O
. O
In O
addition O
, O
diabetic O
rat O
skin O
showed O
enhanced O
EGFR O
, O
ERK O
and O
IL-8 O
expression O
as O
compared O
to O
control O
rats O
. O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound O
, O
as O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
healing O
. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O
is O
associated O
with O
enhanced O
healing O
. O
We O
hypothesized O
that O
increased O
neutrophil O
recruitment O
by O
keratinocytes O
may O
contribute O
to O
the O
delayed O
healing O
of O
diabetic O
wound O
. O
Using O
cultured O
human O
keratinocytes O
and O
diabetic O
rat O
model O
, O
the O
current O
study O
showed O
that O
high- O
glucose O
environment O
enhanced O
IL-8 O
production O
via O
epidermal O
growth O
factor O
receptor O
(EGFR) O
-extracelluar O
signal-regulated O
kinase O
(ERK) O
pathway O
in O
a O
reactive O
oxygen O
species O
(ROS)-dependent O
manner O
in O
keratinocytes O
. O
In O
addition O
, O
diabetic O
rat O
skin O
showed O
enhanced O
EGFR O
, O
ERK B
and O
IL-8 O
expression O
as O
compared O
to O
control O
rats O
. O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound O
, O
as O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
healing O
. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O
is O
associated O
with O
enhanced O
healing O
. O
We O
hypothesized O
that O
increased O
neutrophil O
recruitment O
by O
keratinocytes O
may O
contribute O
to O
the O
delayed O
healing O
of O
diabetic O
wound O
. O
Using O
cultured O
human O
keratinocytes O
and O
diabetic O
rat O
model O
, O
the O
current O
study O
showed O
that O
high- O
glucose O
environment O
enhanced O
IL-8 O
production O
via O
epidermal B
growth I
factor I
receptor I
(EGFR) O
-extracelluar O
signal-regulated O
kinase O
(ERK) O
pathway O
in O
a O
reactive O
oxygen O
species O
(ROS)-dependent O
manner O
in O
keratinocytes O
. O
In O
addition O
, O
diabetic O
rat O
skin O
showed O
enhanced O
EGFR O
, O
ERK O
and O
IL-8 O
expression O
as O
compared O
to O
control O
rats O
. O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound O
, O
as O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
healing O
. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O
is O
associated O
with O
enhanced O
healing O
. O
We O
hypothesized O
that O
increased O
neutrophil O
recruitment O
by O
keratinocytes O
may O
contribute O
to O
the O
delayed O
healing O
of O
diabetic O
wound O
. O
Using O
cultured O
human O
keratinocytes O
and O
diabetic O
rat O
model O
, O
the O
current O
study O
showed O
that O
high- O
glucose O
environment O
enhanced O
IL-8 O
production O
via O
epidermal O
growth O
factor O
receptor O
(EGFR) O
-extracelluar O
signal-regulated O
kinase O
(ERK) O
pathway O
in O
a O
reactive O
oxygen O
species O
(ROS)-dependent O
manner O
in O
keratinocytes O
. O
In O
addition O
, O
diabetic O
rat O
skin O
showed O
enhanced O
EGFR O
, O
ERK O
and O
IL-8 O
expression O
as O
compared O
to O
control O
rats O
. O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound O
, O
as O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound O
, O
as O
represented O
by O
expression O
of O
myeloperoxidase O
level O
, O
was O
also O
significantly O
higher O
in O
diabetic O
rats O
. O
Treating O
diabetic O
rats O
with O
dapsone O
, O
an O
agent O
known O
to O
inhibit O
neutrophil O
function O
, O
was O
associated O
with O
improved O
healing O
. O
In O
conclusion O
, O
IL-8 B
production O
and O
neutrophil O
infiltration O
are O
increased O
in O
high- O
glucose O
environment O
due O
to O
elevated O
ROS O
level O
and O
contributed O
to O
impaired O
wound O
healing O
in O
diabetic O
skin O
. O
Targeting O
these O
dysfunctions O
may O
present O
novel O
therapeutic O
approaches O
. O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
healing O
. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O
is O
associated O
with O
enhanced O
healing O
. O
We O
hypothesized O
that O
increased O
neutrophil O
recruitment O
by O
keratinocytes O
may O
contribute O
to O
the O
delayed O
healing O
of O
diabetic O
wound O
. O
Using O
cultured O
human O
keratinocytes O
and O
diabetic O
rat O
model O
, O
the O
current O
study O
showed O
that O
high- O
glucose O
environment O
enhanced O
IL-8 B
production O
via O
epidermal O
growth O
factor O
receptor O
(EGFR) O
-extracelluar O
signal-regulated O
kinase O
(ERK) O
pathway O
in O
a O
reactive O
oxygen O
species O
(ROS)-dependent O
manner O
in O
keratinocytes O
. O
In O
addition O
, O
diabetic O
rat O
skin O
showed O
enhanced O
EGFR O
, O
ERK O
and O
IL-8 O
expression O
as O
compared O
to O
control O
rats O
. O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound O
, O
as O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
High O
-glucos O
environment O
enhanced O
oxidative O
stress O
and O
increased O
interleukin-8 B
secretion O
from O
keratinocytes O
: O
New O
insights O
on O
impaired O
diabetic O
wound O
healing.Impaired O
wound O
healing O
frequently O
occurs O
in O
patients O
with O
diabetes O
. O
Interluekin-8 O
(IL-8) O
production O
by O
keratinocyte O
is O
responsible O
for O
recruiting O
neutrophils O
during O
healing O
. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O

V(5+) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O

V(5+) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O

V(5+) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 B
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O

vanadium O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome O
P450 O
1 O
(Cyp1) O
by O
vanadium O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 B
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O

V(5+) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome O
P450 O
1 O
(Cyp1) O
by O
vanadium O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
( O
V(5+) O
on O
Cyp1 B
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O
2,3,7,8-tetrachlorodibenzo-p-dioxin O
(TCDD) O
(15 O
μg/kg) O
for O
6 O
and O
24 O
h O
. O
Furthermore O
, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O

vanadium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome B
P450 I
1 I
(Cyp1) O
by O
vanadiu O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 O
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O

vanadium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Modulation O
of O
cytochrome O
P450 O
1 O
(Cyp1) O
by O
vanadiu O
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice.The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium O
(V(5+)) O
on O
Cyp1 B
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes O
. O
For O
this O
purpose O
, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) O
(5 O
mg/kg) O
in O
the O
absence O

V(5+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 B
by O
V(5+) O
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb O
as O
an O
in O
vivo O
specific O
modulator O
. O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 B
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 B
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 B
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 B
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 B
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 B
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD O
mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 B
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD O
mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 B
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD O
mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum B
hemoglobin I
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O

V(5+) O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb B
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD O
mediated O
induction O
of O
Cyp1a1 B
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD O
induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) O
in O
the O
presence O
of O
TCDD O
, O
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb O
, O
there O
was O
further O
potentiation O
to O
the O
TCDD-mediated O
effect O
. O
The O
present O
study O
demonstrates O
that O
there O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 B
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O

TCDD O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
mice O
were O
treated O
with O
V(5+) O
(5 O
, O
10 O
, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD O
(1 O
nM) O
for O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 B
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O

V(5+) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
24 O
h O
. O
In O
vivo O
, O
V(5+) O
alone O
did O
not O
significantly O
alter O
Cyp1a1 O
, O
Cyp1a2 O
, O
or O
Cyp1b1 O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 B
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O

V(5+) O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
mRNA O
, O
protein O
, O
or O
catalytic O
activity O
levels O
. O
Upon O
co-exposure O
to O
V(5+) O
and O
TCDD O
, O
V(5+) O
significantly O
potentiated O
the O
TCDD-mediated O
induction O
of O
the O
Cyp1a1 O
, O
Cyp1a2 O
, O
and O
Cyp1b1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
at O
24 O
h O
. O
In O
vitro O
, O
V(5+) O
decreased O
the O
TCDD-mediated O
induction O
of O
Cyp1a1 O
mRNA O
, O
protein O
, O
and O
catalytic O
activity O
levels O
. O
Furthermore O
, O
V(5+) O
significantly O
inhibited O
the O
TCDD-induced O
AhR-dependent O
luciferase O
activity O
. O
V(5+) O
also O
increased O
serum O
hemoglobin O
(Hb) O
levels O
in O
animals O
treated O
for O
24 O
h O
. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb O
alone O
or O
in O
the O
presence O
of O
TCDD O
, O
there O
was O
an O
increase O
in O
the O
AhR-dependent O
luciferase O
activity O
. O
When O
isolated O
hepatocytes O
were O
treated O
for O

TCDD O
acts O
as O
NOT O
for O
what O
entity O
? O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs B
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O

TCDD O
acts O
as O
NOT O
for O
what O
entity O
? O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
Thus O
, O
the O
TCDD-induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O

TCDD O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD O
induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O

TCDD O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD O
induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O

TCDD O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD O
induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O

TCDD O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD O
induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO B
receptor I
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins B
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
with O
known O
inhibitors O
of O
canonical O
Wnt O
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt O
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1 O
, O
Tcf1 O
, O
and O
Wif1 O
, O
established O
canonical O
Wnt B
target O
genes O
, O
is O
decreased; O
(3) O
expression O
of O
Lgr5 O
, O
a O
RSPO O
receptor O
that O
activates O
canonical O
Wnt O
signaling O
, O
is O
reduced; O
and O
(4) O
expression O
of O
Dickkopfs O
(Dkks) O
, O
inhibitors O
of O
canonical O
Wnt O
signaling O
, O
is O
not O
increased O
by O
TCDD O
. O
Thus O
, O
the O
TCDD O
induced O
reduction O
in O
canonical O
Wnt O
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
canonical O
Wnt B
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 O
and O
Rspo3) O
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
Dkk2) O
of O
the O
pathway O
. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed O
UGS O
organ O
cultures O
with O
RSPO2 O
and/or O
RSPO3 O
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD O
on O
canonical O
Wnt B
signaling O
and O
prostatic O
bud O
formation O
. O
We O
discovered O
that O
each O
RSPO O
alone O
or O
in O
combination O
partially O
rescues O
TCDD O
inhibition O
of O
both O
canonical O
Wnt O
signaling O
and O
prostatic O
bud O
formation O
. O

TCDD O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
prostate O
agenesis O
. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD O
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown O
. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt B
signaling O
also O
inhibits O
prostatic O
bud O
formation O
. O
In O
support O
of O
the O
hypothesis O
that O
TCDD O
decreases O
canonical O
Wnt O
signaling O
, O
we O
identify O
inhibitory O
effects O
of O
TCDD O
on O
multiple O
components O
of O
the O
canonical O
Wnt O
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD O
on O
prostatic O
bud O
formation O
: O
(1) O
expression O
of O
R-spondins O
(Rspo2 O
and O
Rspo3) O
that O
promote O
canonical O
Wnt O
signaling O
is O
reduced; O

tunicamycin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
PDR O
(T2DM-PDR) O
and O
756 O
T2DM O
patients O
without O
diabetic O
retinopathy O
(T2DM-no O
DR) O
were O
genotyped O
with O
rs7903146 O
in O
TCF7L2 O
. O
We O
found O
that O
risk O
allele O
(T) O
frequency O
of O
rs7903146 O
was O
significantly O
higher O
in O
T2DM-PDR O
patients O
(allelic O
P O
= O
2.52E-04) O
. O
In O
lymphoblastoid O
cells O
induced O
to O
undergo O
endoplasmic O
reticulum O
(ER) O
stress O
by O
treatment O
of O
tunicamycin O
higher O
fold O
change O
of O
TCF7L2 B
and O
VEGFA O
mRNA O
levels O
were O
observed O
in O
rs7903146-TT O
cells O
than O
that O
in O
rs7903146-CC O
cells O
(P O
= O
0.02 O
for O
TCF7L2; O
P O
= O
0.004 O
for O
VEGFA) O
, O
suggesting O
ER O
stress O
plays O
a O
role O
in O
PDR O
pathogenesis O
. O
Silencing O
TCF7L2 O
resulted O
in O
decreased O
mRNA O
levels O
of O
both O
TCF7L2 O
and O

tunicamycin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
PDR O
(T2DM-PDR) O
and O
756 O
T2DM O
patients O
without O
diabetic O
retinopathy O
(T2DM-no O
DR) O
were O
genotyped O
with O
rs7903146 O
in O
TCF7L2 O
. O
We O
found O
that O
risk O
allele O
(T) O
frequency O
of O
rs7903146 O
was O
significantly O
higher O
in O
T2DM-PDR O
patients O
(allelic O
P O
= O
2.52E-04) O
. O
In O
lymphoblastoid O
cells O
induced O
to O
undergo O
endoplasmic O
reticulum O
(ER) O
stress O
by O
treatment O
of O
tunicamycin O
higher O
fold O
change O
of O
TCF7L2 O
and O
VEGFA B
mRNA O
levels O
were O
observed O
in O
rs7903146-TT O
cells O
than O
that O
in O
rs7903146-CC O
cells O
(P O
= O
0.02 O
for O
TCF7L2; O
P O
= O
0.004 O
for O
VEGFA) O
, O
suggesting O
ER O
stress O
plays O
a O
role O
in O
PDR O
pathogenesis O
. O
Silencing O
TCF7L2 O
resulted O
in O
decreased O
mRNA O
levels O
of O
both O
TCF7L2 O
and O

8Br-cAMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 B
could O
bind O
to O
the O
FDX1 O
promoter O
in O
differentiated O
hMSCs O
. O
Luciferase O
reporter O
assays O
showed O
that O
transcription O
of O
FDX1 O
was O
synergistically O
activated O
by O
the O
NR5A O
family O
and O
8Br-cAMP O
treatment O
through O
two O
SF-1 O
binding O
sites O
and O
a O
CRE-like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O
Knockdown O
of O
FDX1 O
attenuated O
progesterone O
production O
in O
KGN O
cells O
. O
These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP O
signaling O
, O
and O
participates O
in O
steroid O
hormone O
production O
in O

8Br-cAMP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O
could O
bind O
to O
the O
FDX1 B
promoter O
in O
differentiated O
hMSCs O
. O
Luciferase O
reporter O
assays O
showed O
that O
transcription O
of O
FDX1 O
was O
synergistically O
activated O
by O
the O
NR5A O
family O
and O
8Br-cAMP O
treatment O
through O
two O
SF-1 O
binding O
sites O
and O
a O
CRE-like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O
Knockdown O
of O
FDX1 O
attenuated O
progesterone O
production O
in O
KGN O
cells O
. O
These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP O
signaling O
, O
and O
participates O
in O
steroid O
hormone O
production O
in O

cAMP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
synergistically O
activated O
by O
the O
NR5A O
family O
and O
8Br-cAMP O
treatment O
through O
two O
SF-1 O
binding O
sites O
and O
a O
CRE-like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O
Knockdown O
of O
FDX1 B
attenuated O
progesterone O
production O
in O
KGN O
cells O
. O
These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP O
signaling O
, O
and O
participates O
in O
steroid O
hormone O
production O
in O
ovarian O
granulosa O
cells O
. O

steroid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
(FDX1; O
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 B
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O

steroid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
(FDX1; O
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 O
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O

steroid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
(FDX1; O
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 O
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O

steroid O
hormone O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
(FDX1; O
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 B
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O
could O

steroid O
hormone O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
(FDX1; O
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 O
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O
could O

steroid O
hormone O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Transcriptional O
regulation O
of O
human O
ferredoxin O
1 O
in O
ovarian O
granulosa O
cells.Ferredoxin O
1 O
(FDX1; O
adrenodoxin) O
is O
an O
iron-sulfur O
protein O
that O
is O
involved O
in O
various O
metabolic O
processes O
, O
including O
steroid O
hormone O
synthesis O
in O
mammalian O
tissues O
. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 O
in O
ovarian O
granulosa O
cells O
. O
Previously O
, O
we O
reported O
that O
the O
NR5A O
family O
, O
including O
steroidogenic O
factor-1 O
(SF-1) O
and O
liver O
receptor O
homolog-1 O
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells O
. O
A O
ChIP O
assay O
showed O
that O
SF-1 O
could O

steroid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
NR5A O
family O
and O
8Br-cAMP O
treatment O
through O
two O
SF-1 O
binding O
sites O
and O
a O
CRE-like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O
Knockdown O
of O
FDX1 B
attenuated O
progesterone O
production O
in O
KGN O
cells O
. O
These O
results O
indicate O
transcription O
of O
FDX1 O
is O
regulated O
by O
the O
NR5A O
family O
and O
cAMP O
signaling O
, O
and O
participates O
in O
steroid O
hormone O
production O
in O
ovarian O
granulosa O
cells O
. O

sinapic O
acid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
and O
antifibrotic O
effects O
of O
sinapic O
acid O
on O
dimethylnitrosamine O
(DMN)-induced O
chronic O
liver O
injury O
in O
rats O
. O
Sinapic O
acid O
remarkably O
prevented O
DMN-induced O
loss O
of O
body O
weight O
. O
This O
was O
accompanied O
by O
a O
significant O
increase O
in O
levels O
of O
serum O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
liver O
malondialdehyde O
content O
. O
Furthermore O
, O
sinapic O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type O
I O
collagen B
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming O
growth O
factor-β1 O
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O

sinapic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
this O
study O
, O
we O
investigated O
the O
hepatoprotective O
and O
antifibrotic O
effects O
of O
sinapic O
acid O
on O
dimethylnitrosamine O
(DMN)-induced O
chronic O
liver O
injury O
in O
rats O
. O
Sinapic O
acid O
remarkably O
prevented O
DMN-induced O
loss O
of O
body O
weight O
. O
This O
was O
accompanied O
by O
a O
significant O
increase O
in O
levels O
of O
serum O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
liver O
malondialdehyde O
content O
. O
Furthermore O
, O
sinapic O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type B
I I
collagen I
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming O
growth O
factor-β1 O
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O

sinapic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type O
I O
collagen O
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth B
muscle I
actin I
and O
transforming O
growth O
factor-β1 O
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O
acid O
Sinapic O
acid O
exhibited O
strong O
scavenging O
activity O
. O
In O
conclusion O
, O
we O
find O
that O
sinapic O
acid O
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced O
liver O
injury O
, O
most O
likely O
due O
to O
its O
antioxidant O
activities O
of O
scavenging O
radicals O
, O
its O
capacity O
to O
suppress O
TGF-β1 O
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells O
. O
This O
suggests O

sinapic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type O
I O
collagen O
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming B
growth I
factor-β1 I
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O
acid O
Sinapic O
acid O
exhibited O
strong O
scavenging O
activity O
. O
In O
conclusion O
, O
we O
find O
that O
sinapic O
acid O
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced O
liver O
injury O
, O
most O
likely O
due O
to O
its O
antioxidant O
activities O
of O
scavenging O
radicals O
, O
its O
capacity O
to O
suppress O
TGF-β1 O
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells O
. O
This O
suggests O

sinapic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
acid O
reduced O
hepatic O
hydroxyproline O
content O
, O
which O
correlated O
with O
a O
reduction O
in O
the O
expression O
of O
type O
I O
collagen O
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming O
growth O
factor-β1 O
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O
acid O
Sinapic O
acid O
exhibited O
strong O
scavenging O
activity O
. O
In O
conclusion O
, O
we O
find O
that O
sinapic O
acid O
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced O
liver O
injury O
, O
most O
likely O
due O
to O
its O
antioxidant O
activities O
of O
scavenging O
radicals O
, O
its O
capacity O
to O
suppress O
TGF-β1 B
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells O
. O
This O
suggests O

sinapic O
acid O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
type O
I O
collagen O
mRNA O
and O
histological O
analysis O
of O
collagen O
in O
liver O
tissue O
. O
Additionally O
, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth O
muscle O
actin O
and O
transforming O
growth O
factor-β1 O
(TGF-β1) O
, O
were O
reduced O
in O
rats O
treated O
with O
sinapic O
acid O
. O
Sinapic O
acid O
exhibited O
strong O
scavenging O
activity O
. O
In O
conclusion O
, O
we O
find O
that O
sinapic O
acid O
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced O
liver O
injury O
, O
most O
likely O
due O
to O
its O
antioxidant O
activities O
of O
scavenging O
radicals O
, O
its O
capacity O
to O
suppress O
TGF-β1 B
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells O
. O
This O
suggests O
that O
sinapic O
acid O
is O
a O
potentially O
useful O
agent O
for O
the O
protection O
against O
liver O

Genistin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin B
light I
chain I
kinase I
(MLCK) O
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O

Genistin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK) O
protein O
contents O
and O
MLCK B
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O

Genistin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK) O
protein O
contents O
and O
MLCK B
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O

genistin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK) O
protein O
contents O
and O
MLCK B
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin O
induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O
implications O
of O
genistin O
in O
relieving O
intestinal O
hypercontractility O
. O

Genistin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
correlated O
with O
the O
stimulation O
of O
alpha O
adrenergic O
and O
beta O
adrenergic O
receptors O
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine O
and O
propranolol O
respectively O
. O
No O
further O
inhibitory O
effects O
of O
genistin O
were O
observed O
in O
the O
presence O
of O
verapamil O
or O
in O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK) O
protein O
contents O
and O
MLCK O
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin-induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O

genistin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Ca(2+)-free O
condition O
, O
indicating O
genistin-induced O
inhibitory O
effects O
are O
Ca(2+)-dependent O
. O
Genistin O
decreased O
myosin O
light O
chain O
kinase O
(MLCK) O
protein O
contents O
and O
MLCK B
mRNA O
expression O
in O
IJS O
, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase O
activity O
of O
purified O
myosin O
, O
implicating O
that O
the O
decrease O
of O
MLCK O
contents O
and O
inhibition O
of O
MLCK O
activity O
are O
involved O
in O
the O
genistin O
induced O
inhibitory O
effects O
. O
The O
study O
suggests O
the O
potential O
clinical O
implications O
of O
genistin O
in O
relieving O
intestinal O
hypercontractility O
. O

prostaglandin O
E2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
NADPH O
Oxidase O
NOX5-S O
and O
Nuclear O
Factor O
κB1 O
Mediate O
Acid-Induced O
Microsomal O
Prostaglandin O
E O
Synthase-1 O
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells.The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O
known O
. O
Cycloxygenase-2 B
(COX-2)-derived O
prostaglandin O
E2 O
(PGE2) O
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis O
. O
We O
have O
shown O
that O
COX-2 O
mediates O
acid-induced O
PGE2 O
production O
. O
The O
prostaglandin O
E O
synthase O
(PGES) O
responsible O
for O
acid-induced O
PGE2 O
production O
in O
BE O
, O
however O
, O
is O
not O
known O
. O
We O
found O
that O
microsomal O
PGES1 O
(mPGES1) O
, O
mPGES2 O
, O
and O
cytosolic O
PGES O
(cPGES) O
were O
present O
in O

prostaglandin O
E2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
NADPH O
Oxidase O
NOX5-S O
and O
Nuclear O
Factor O
κB1 O
Mediate O
Acid-Induced O
Microsomal O
Prostaglandin O
E O
Synthase-1 O
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells.The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O
known O
. O
Cycloxygenase-2 O
(COX-2)-derived O
prostaglandin O
E2 O
(PGE2) O
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis O
. O
We O
have O
shown O
that O
COX-2 B
mediates O
acid-induced O
PGE2 O
production O
. O
The O
prostaglandin O
E O
synthase O
(PGES) O
responsible O
for O
acid-induced O
PGE2 O
production O
in O
BE O
, O
however O
, O
is O
not O
known O
. O
We O
found O
that O
microsomal O
PGES1 O
(mPGES1) O
, O
mPGES2 O
, O
and O
cytosolic O
PGES O
(cPGES) O
were O
present O
in O

PGE2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(NF-κB) O
in O
vivo O
activation O
reporter O
plasmid O
pNF-κB-Luc O
. O
Knockdown O
of O
NF-κB1 O
p50 O
by O
p50 O
siRNA O
significantly O
decreased O
acid-induced O
increase O
in O
mPGES1 B
expression O
, O
thymidine O
incorporation O
, O
and O
PGE2 O
production O
. O
Two O
novel O
NF-κB O
binding O
elements O
, O
GGAGTCTCCC O
and O
CGGGACACCC O
, O
were O
identified O
in O
the O
mPGES1 O
gene O
promoter O
. O
We O
conclude O
that O
mPGES1 O
mediates O
acid-induced O
increase O
in O
PGE2 O
production O
and O
cell O
proliferation O
. O
Acid-induced O
mPGES1 O
expression O
depends O
on O
activation O
of O
NOX5-S O
and O
NF-κB1 O
p50 O
. O
Microsomal O
PGES1 O
may O
be O
a O
potential O
target O
to O
prevent O
or O
treat O
EA O
. O

PGE2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
NADPH O
Oxidase O
NOX5-S O
and O
Nuclear O
Factor O
κB1 O
Mediate O
Acid-Induced O
Microsomal O
Prostaglandin O
E O
Synthase-1 O
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells.The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O
known O
. O
Cycloxygenase-2 B
(COX-2)-derived O
prostaglandin O
E2 O
( O
PGE2 O
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis O
. O
We O
have O
shown O
that O
COX-2 O
mediates O
acid-induced O
PGE2 O
production O
. O
The O
prostaglandin O
E O
synthase O
(PGES) O
responsible O
for O
acid-induced O
PGE2 O
production O
in O
BE O
, O
however O
, O
is O
not O
known O
. O
We O
found O
that O
microsomal O
PGES1 O
(mPGES1) O
, O
mPGES2 O
, O
and O
cytosolic O
PGES O
(cPGES) O
were O
present O
in O
FLO O

PGE2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
NADPH O
Oxidase O
NOX5-S O
and O
Nuclear O
Factor O
κB1 O
Mediate O
Acid-Induced O
Microsomal O
Prostaglandin O
E O
Synthase-1 O
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells.The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O
known O
. O
Cycloxygenase-2 O
(COX-2)-derived O
prostaglandin O
E2 O
( O
PGE2 O
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis O
. O
We O
have O
shown O
that O
COX-2 B
mediates O
acid-induced O
PGE2 O
production O
. O
The O
prostaglandin O
E O
synthase O
(PGES) O
responsible O
for O
acid-induced O
PGE2 O
production O
in O
BE O
, O
however O
, O
is O
not O
known O
. O
We O
found O
that O
microsomal O
PGES1 O
(mPGES1) O
, O
mPGES2 O
, O
and O
cytosolic O
PGES O
(cPGES) O
were O
present O
in O
FLO O

PGE2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Factor O
κB1 O
Mediate O
Acid-Induced O
Microsomal O
Prostaglandin O
E O
Synthase-1 O
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells.The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O
known O
. O
Cycloxygenase-2 O
(COX-2)-derived O
prostaglandin O
E2 O
(PGE2) O
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis O
. O
We O
have O
shown O
that O
COX-2 B
mediates O
acid-induced O
PGE2 O
production O
. O
The O
prostaglandin O
E O
synthase O
(PGES) O
responsible O
for O
acid-induced O
PGE2 O
production O
in O
BE O
, O
however O
, O
is O
not O
known O
. O
We O
found O
that O
microsomal O
PGES1 O
(mPGES1) O
, O
mPGES2 O
, O
and O
cytosolic O
PGES O
(cPGES) O
were O
present O
in O
FLO O
EA O
cells O
. O
Pulsed O
acid O
treatment O
significantly O
increased O
mPGES1 O
mRNA O
and O
protein O
levels O
but O
had O
little O
or O
no O

GSK2251052 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Disposition O
and O
Metabolism O
of O
GSK2251052 O
in O
Humans O
: O
A O
Novel O
Boron-Containing O
Antibiotic.(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole O
( O
GSK2251052 O
is O
a O
novel O
boron-containing O
antibiotic O
that O
inhibits O
bacterial O
leucyl O
tRNA O
synthetase O
, O
and O
that O
has O
been O
in O
development O
for O
the O
treatment O
of O
serious O
Gram-negative O
infections O
. O
In O
this O
study O
, O
six O
healthy O
adult O
male O
subjects O
received O
a O
single O
i.v O
. O
dose O
of O
[(14)C]GSK2251052 O
, O
1500 O
mg O
infused O
over O
1 O
hour O
. O
Blood O
, O
urine O
, O
and O
feces O

(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Disposition O
and O
Metabolism O
of O
GSK2251052 O
in O
Humans O
: O
A O
Novel O
Boron-Containing O
Antibiotic O
. O
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole O
(GSK2251052) O
is O
a O
novel O
boron-containing O
antibiotic O
that O
inhibits O
bacterial O
leucyl O
tRNA O
synthetase O
, O
and O
that O
has O
been O
in O
development O
for O
the O
treatment O
of O
serious O
Gram-negative O
infections O
. O
In O
this O
study O
, O
six O
healthy O
adult O
male O
subjects O
received O
a O
single O
i.v O
. O
dose O
of O
[(14)C]GSK2251052 O
, O
1500 O
mg O
infused O
over O
1 O
hour O
. O
Blood O
, O
urine O
, O
and O

4-methylpyrazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
area O
under O
the O
plasma O
versus O
time O
concentration O
curve O
from O
time O
zero O
to O
infinity O
, O
respectively O
. O
Additionally O
, O
M3 O
was O
eliminated O
renally O
, O
and O
was O
demonstrated O
to O
be O
responsible O
for O
the O
long O
plasma O
radioactivity O
elimination O
half-life O
. O
A O
combination O
of O
in O
vitro O
metabolism O
experiments O
and O
a O
pharmacokinetic O
study O
in O
monkeys O
with O
the O
inhibitor O
4-methylpyrazole O
provided O
strong O
evidence O
that O
alcohol O
dehydrogenase O
, O
potentially O
in O
association O
with O
aldehyde O
dehydrogenase O
, O
is O
the O
primary O
enzyme O
involved O
in O
the O
formation O
of O
the O
M3 O
metabolite O
. O

Fe-NTA O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Protective O
effect O
of O
butylated O
hydroxytoluene O
on O
ferric O
nitrilotriacetate O
induced O
hepatotoxicity O
and O
oxidative O
stress O
in O
mice.The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
possible O
ameliorating O
effect O
of O
butylated O
hydroxyl O
toluene O
(BHT) O
, O
associated O
with O
ferric O
nitrilotriacetate O
(Fe-NTA)-induced O
oxidative O
stress O
and O
liver O
injury O
in O
mice O
. O
The O
treatment O
of O
mice O
with O
Fe-NTA O
alone O
enhances O
ornithine B
decarboxylase I
activity O
to O
4.6 O
folds O
, O
protein O
carbonyl O
formation O
increased O
up O
to O
2.9 O
folds O
and O
DNA O
synthesis O
expressed O
in O
terms O
of O
[(3)H] O
thymidine O
incorporation O
increased O
to O
3.2 O
folds O
, O
and O
antioxidants O
and O
antioxidant O
enzymes O
decreased O
to O
1.8-2.5 O
folds O
, O
compared O
with O
the O
corresponding O
saline-treated O
controls O
. O
These O
changes O
were O
reversed O

EETs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
led O
to O
an O
abundant O
aortic O
CYP2J2 O
expression O
and O
increased O
EETs O
generation O
. O
It O
was O
shown O
that O
CYP2J2 O
overexpression O
attenuated O
matrix O
metalloproteinase O
expression O
and O
activity O
, O
elastin O
degradation O
, O
and O
AAA O
formation O
, O
which O
was O
associated O
with O
reduced O
aortic O
inflammation O
and O
macrophage O
infiltration O
. O
In O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs) O
, O
rAAV-mediated O
CYP2J2 O
overexpression O
and O
EETs O
markedly O
suppressed O
Ang O
II-induced O
inflammatory O
cytokine B
expression O
. O
Moreover O
, O
overexpressed O
CYP2J2 O
and O
EETs O
inhibited O
Ang O
II-induced O
macrophage O
migration O
in O
a O
VSMC-macrophage O
coculture O
system O
. O
We O
further O
indicated O
that O
these O
protective O
effects O
were O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
(PPAR)γ O
activation O
. O
Taken O
together O
, O
these O
results O
provide O
evidence O
that O
rAAV-mediated O
CYP2J2 O
overexpression O
prevents O
AAA O

EETs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
was O
shown O
that O
CYP2J2 O
overexpression O
attenuated O
matrix O
metalloproteinase O
expression O
and O
activity O
, O
elastin O
degradation O
, O
and O
AAA O
formation O
, O
which O
was O
associated O
with O
reduced O
aortic O
inflammation O
and O
macrophage O
infiltration O
. O
In O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs) O
, O
rAAV-mediated O
CYP2J2 O
overexpression O
and O
EETs O
markedly O
suppressed O
Ang O
II-induced O
inflammatory O
cytokine O
expression O
. O
Moreover O
, O
overexpressed O
CYP2J2 O
and O
EETs O
inhibited O
Ang O
II-induced O
macrophage O
migration O
in O
a O
VSMC-macrophage O
coculture O
system O
. O
We O
further O
indicated O
that O
these O
protective O
effects O
were O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
(PPAR)γ O
activation O
. O
Taken O
together O
, O
these O
results O
provide O
evidence O
that O
rAAV-mediated O
CYP2J2 O
overexpression O
prevents O
AAA O
development O
which O
is O
likely O
via O
PPARγ O
activation O
and O
anti-inflammatory O
action O
, O
suggesting O
that O

EETs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
led O
to O
an O
abundant O
aortic O
CYP2J2 O
expression O
and O
increased O
EETs O
generation O
. O
It O
was O
shown O
that O
CYP2J2 O
overexpression O
attenuated O
matrix O
metalloproteinase O
expression O
and O
activity O
, O
elastin O
degradation O
, O
and O
AAA O
formation O
, O
which O
was O
associated O
with O
reduced O
aortic O
inflammation O
and O
macrophage O
infiltration O
. O
In O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs) O
, O
rAAV-mediated O
CYP2J2 O
overexpression O
and O
EETs O
markedly O
suppressed O
Ang O
II-induced O
inflammatory O
cytokine O
expression O
. O
Moreover O
, O
overexpressed O
CYP2J2 O
and O
EETs O
inhibited O
Ang O
II-induced O
macrophage O
migration O
in O
a O
VSMC-macrophage O
coculture O
system O
. O
We O
further O
indicated O
that O
these O
protective O
effects O
were O
mediated O
by O
peroxisome O
proliferator-activated O
receptor O
(PPAR)γ O
activation O
. O
Taken O
together O
, O
these O
results O
provide O
evidence O
that O
rAAV-mediated O
CYP2J2 O
overexpression O
prevents O
AAA O

EETs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
CYP2J2 O
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
( O
EETs O
 O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O
in O
apoE-deficient O
mice O
. O
rAAV-CYP2J2 O

EETs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
CYP2J2 B
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
( O
EETs O
 O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O
in O
apoE-deficient O
mice O
. O
rAAV-CYP2J2 O

EETs O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
CYP2J2 B
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O
in O
apoE-deficient O
mice O
. O
rAAV-CYP2J2 O
delivery O
led O
to O
an O
abundant O
aortic O
CYP2J2 O
expression O
and O
increased O
EETs O
generation O
. O
It O
was O

epoxyeicosatrienoic O
acids O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
CYP2J2 O
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O
in O
apoE-deficient O
mice O
. O
rAAV-CYP2J2 O

epoxyeicosatrienoic O
acids O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
CYP2J2 B
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O
in O
apoE-deficient O
mice O
. O
rAAV-CYP2J2 O

arachidonic O
acids O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
CYP2J2 O
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O

arachidonic O
acids O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
CYP2J2 B
overexpression O
increases O
EETs O
and O
protects O
against O
angiotensin O
II-induced O
abdominal O
aortic O
aneurysm O
in O
mice.Cytochrome O
P450 O
epoxygenase O
2J2 O
(CYP2J2) O
metabolizes O
arachidonic O
acids O
to O
form O
epoxyeicosatrienoic O
acids O
(EETs) O
, O
which O
possess O
various O
beneficial O
effects O
on O
the O
cardiovascular O
system O
. O
However O
, O
whether O
increasing O
EETs O
production O
by O
CYP2J2 O
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown O
. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 O
overexpression O
on O
angiotensin O
(Ang) O
II-induced O
AAA O

calcium O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
regucalcin O
in O
lipid O
metabolism O
and O
diabetes.Regucalcin O
(RGN/SMP30) O
was O
originally O
discovered O
in O
1978 O
as O
a O
unique O
calcium O
binding O
protein O
that O
does O
not O
contain O
the O
EF-hand O
motif O
of O
calcium-binding O
domain O
. O
The O
regucalcin O
gene O
(rgn) O
is O
localized O
on O
the O
X O
chromosome O
and O
is O
identified O
in O
over O
15 O
species O
consisting O
the O
regucalcin O
family O
. O
Regucalcin B
has O
been O
shown O
to O
play O
a O
multifunctional O
role O
in O
cell O
regulation; O
maintaining O
of O
intracellular O
calcium O

calcium O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
regucalcin O
in O
lipid O
metabolism O
and O
diabetes.Regucalcin O
(RGN/SMP30) O
was O
originally O
discovered O
in O
1978 O
as O
a O
unique O
calcium O
binding O
protein O
that O
does O
not O
contain O
the O
EF-hand O
motif O
of O
calcium-binding O
domain O
. O
The O
regucalcin O
gene O
(rgn) O
is O
localized O
on O
the O
X O
chromosome O
and O
is O
identified O
in O
over O
15 O
species O
consisting O
the O
regucalcin O
family O
. O
Regucalcin O
has O
been O
shown O
to O
play O
a O
multifunctional O
role O
in O
cell O
regulation; O
maintaining O
of O
intracellular O
calcium O

calcium O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Involvement O
of O
regucalcin O
in O
lipid O
metabolism O
and O
diabetes.Regucalcin O
(RGN/SMP30) O
was O
originally O
discovered O
in O
1978 O
as O
a O
unique O
calcium O
binding O
protein O
that O
does O
not O
contain O
the O
EF-hand O
motif O
of O
calcium-binding O
domain O
. O
The O
regucalcin O
gene O
(rgn) O
is O
localized O
on O
the O
X O
chromosome O
and O
is O
identified O
in O
over O
15 O
species O
consisting O
the O
regucalcin O
family O
. O
Regucalcin O
has O
been O
shown O
to O
play O
a O
multifunctional O
role O
in O
cell O
regulation; O
maintaining O
of O
intracellular O
calcium O

streptozotocin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
apoptosis O
in O
many O
cell O
types O
. O
Moreover O
, O
regucalcin B
may O
play O
a O
pathophysiological O
role O
in O
metabolic O
disorder O
. O
The O
expression O
of O
regucalcin O
is O
stimulated O
through O
the O
action O
of O
insulin O
in O
liver O
cells O
in O
vitro O
and O
in O
vivo O
and O
it O
is O
decreased O
in O
the O
liver O
of O
rats O
with O
type O
I O
diabetes O
induced O
by O
streptozotocin O
administration O
in O
vivo O
. O
Overexpression O
of O
endogenous O
regucalcin O
stimulates O
glucose O
utilization O
and O
lipid O
production O
in O
liver O
cells O
with O
glucose O
supplementation O
in O
vitro O
. O
Regucalcin O
reveals O
insulin O
resistance O
in O
liver O
cells O
. O
Deficiency O
of O
regucalcin O
induces O
an O
impairment O
of O
glucose O
tolerance O
and O
lipid O
accumulation O
in O
the O
liver O
of O
mice O
in O
vivo O
. O
Overexpression O
of O

BRN-103 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
nicotinamide O
derivative O
as O
anti-angiogenic O
agents.Previously O
, O
we O
have O
found O
that O
BRN-103 O
a O
nicotinamide O
derivative O
, O
inhibits O
vascular O
endothelial O
growth O
factor O
(VEGF)-mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O

BRN-103 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
nicotinamide O
derivative O
as O
anti-angiogenic O
agents.Previously O
, O
we O
have O
found O
that O
BRN-103 O
a O
nicotinamide O
derivative O
, O
inhibits O
vascular B
endothelial I
growth I
factor I
(VEGF)-mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O

nicotinamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
nicotinamide O
derivative O
as O
anti-angiogenic O
agents.Previously O
, O
we O
have O
found O
that O
BRN-103 O
, O
a O
nicotinamide O
derivative O
, O
inhibits O
vascular O
endothelial O
growth O
factor O
(VEGF)-mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O

nicotinamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
nicotinamide O
derivative O
as O
anti-angiogenic O
agents.Previously O
, O
we O
have O
found O
that O
BRN-103 O
, O
a O
nicotinamide O
derivative O
, O
inhibits O
vascular B
endothelial I
growth I
factor I
(VEGF)-mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O

BRN-250 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10-100 O
nM O
. O
Furthermore O
, O
BRN-250 O
inhibited O
the O
VEGF-induced O
phosphorylation O
and O
intracellular O
tyrosine O
kinase O
activity O
of O
VEGF B
receptor O
2 O
(VEGFR2) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
BRN-250 O
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

BRN-250 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10-100 O
nM O
. O
Furthermore O
, O
BRN-250 O
inhibited O
the O
VEGF-induced O
phosphorylation O
and O
intracellular O
tyrosine B
kinase I
activity O
of O
VEGF O
receptor O
2 O
(VEGFR2) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
BRN-250 O
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

BRN-250 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10-100 O
nM O
. O
Furthermore O
, O
BRN-250 O
inhibited O
the O
VEGF-induced O
phosphorylation O
and O
intracellular O
tyrosine O
kinase O
activity O
of O
VEGF B
receptor I
2 I
(VEGFR2) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
BRN-250 O
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

BRN-250 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10-100 O
nM O
. O
Furthermore O
, O
BRN-250 O
inhibited O
the O
VEGF-induced O
phosphorylation O
and O
intracellular O
tyrosine O
kinase O
activity O
of O
VEGF O
receptor O
2 O
(VEGFR2) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
BRN-250 O
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

BRN-250 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents O
, O
we O
synthesized O
various O
nicotinamide O
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects O
. O
We O
found O
that O
2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) O
pyridine-3-carboxamide O
(BRN-250) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10-100 O
nM O
. O
Furthermore O
, O
BRN-250 O
inhibited O
the O
VEGF-induced O
phosphorylation O
and O
intracellular O
tyrosine O
kinase O
activity O
of O
VEGF O
receptor O
2 O
(VEGFR2) O
and O
the O
activation O
of O
its O
downstream O
AKT B
pathway O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
BRN-250 O
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

DMBT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
angiogenesis O
and O
invasion O
by O
DMB O
is O
mediated O
by O
downregulation O
of O
VEGF B
and O
MMP-9 O
through O
Akt O
pathway O
in O
MDA-MB-231 O
breast O
cancer O
cells.Invasion O
, O
either O
directly O
or O
via O
metastasis O
formation O
, O
is O
the O
main O
cause O
of O
death O
in O
cancer O
patients O
, O
development O
of O
efficient O
anti-invasive O
agents O
is O
an O
important O
research O
challenge O
. O
In O
order O
to O
obtain O
more O
potent O
inhibitors O
, O
a O

DMBT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
angiogenesis O
and O
invasion O
by O
DMB O
is O
mediated O
by O
downregulation O
of O
VEGF O
and O
MMP-9 B
through O
Akt O
pathway O
in O
MDA-MB-231 O
breast O
cancer O
cells.Invasion O
, O
either O
directly O
or O
via O
metastasis O
formation O
, O
is O
the O
main O
cause O
of O
death O
in O
cancer O
patients O
, O
development O
of O
efficient O
anti-invasive O
agents O
is O
an O
important O
research O
challenge O
. O
In O
order O
to O
obtain O
more O
potent O
inhibitors O
, O
a O

DMBT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis O
. O

DMBT O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis O
. O

DMBT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
DMBT O
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated O
. O
MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O

DMBT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
DMBT O
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated O
. O
MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O

DMBT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
DMBT O
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated O
. O
MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O

DMBT O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
DMBT O
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated O
. O
MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O

DMBT O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cancer O
cells O
were O
not O
known O
. O
In O
this O
study O
, O
the O
effects O
of O
DMBT O
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated O
. O
MTT O
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt O
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O

DMBT O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
angiogenesis O
and O
invasion O
by O
DMB O
is O
mediated O
by O
downregulation O
of O
VEGF O
and O
MMP-9 O
through O
Akt B
pathway O
in O
MDA-MB-231 O
breast O
cancer O
cells.Invasion O
, O
either O
directly O
or O
via O
metastasis O
formation O
, O
is O
the O
main O
cause O
of O
death O
in O
cancer O
patients O
, O
development O
of O
efficient O
anti-invasive O
agents O
is O
an O
important O
research O
challenge O
. O
In O
order O
to O
obtain O
more O
potent O
inhibitors O
, O
a O

DMBT O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT O
was O
found O
. O
DMBT O
could O
inhibit O
invasion O
, O
migration O
and O
tube O
formation O
of O
HUVECs O
. O
Gelatin O
zymography O
showed O
that O
DMBT O
inhibited O
secretion O
and O
activity O
of O
MMP-9 O
. O
Western O
blotting O
demonstrated O
that O
DMBT O
effectively O
suppressed O
the O
expression O
of O
VEGF O
, O
p-VEGFR-2 O
, O
p-EGFR O
, O
and O
p-Akt O
. O
These O
results O
suggested O
that O
DMBT O
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand O
MMP-9 O
, O
resulting O
from O
the O
inhibition O
of O
Akt B
pathway O
. O
DMBT O
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis O
. O

AOH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
control O
. O
Both O
cyclin O
B1 O
and O
p-cdc2 O
levels O
increased O
, O
while O
cyclin O
B1 O
remained O
in O
the O
cytoplasm; O
suggesting O
arrest O
in O
the O
G2/M O
transition O
point O
. O
Remarkably O
, O
after O
exposure O
to O
AOH O
for O
24h O
, O
most O
of O
the O
cells O
exhibited O
abnormally O
shaped O
nuclei O
, O
as O
evidenced O
by O
partly O
divided O
nuclei O
, O
nuclear O
blebs O
, O
polyploidy O
and O
micronuclei O
(MN) O
. O
AOH O
treatment O
also O
induced O
abnormal O
Aurora B
B I
bridges O
, O
suggesting O
that O
cytokinesis O
was O
interfered O
within O
cells O
undergoing O
karyokinesis O
. O
A O
minor O
part O
of O
the O
resultant O
G1 O
tetraploid O
(4N) O
cells O
re-entered O
the O
S-phase O
and O
progressed O
to O
8N O
cells O
. O

CIQ O
acts O
as O
NOT O
for O
what O
entity O
? O
exogenous O
small O
molecules O
. O
Elucidating O
the O
structural O
determinants O
and O
mechanism O
of O
action O
by O
which O
allosteric O
regulators O
control O
gating O
will O
enhance O
our O
understanding O
of O
NMDA B
receptor I
activation O
and O
facilitate O
the O
development O
of O
novel O
therapeutics O
. O
Here O
, O
we O
investigated O
the O
structural O
determinants O
for O
(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone O
(CIQ) O
, O
a O
GluN2C/2D-selective O
positive O
allosteric O
modulator O
. O
We O
show O
that O
CIQ O
does O
not O
bind O
to O
the O
amino-terminal O
domain O
of O
the O
NMDA O
receptor O
and O
does O
not O
share O
structural O
determinants O
with O
modulators O
acting O
at O
the O
agonist-binding O
domain O
dimer O
interface O
or O
ion O
channel O
pore O
. O
Rather O
, O
we O
identified O
critical O
determinants O
of O
CIQ O
modulation O
in O
the O
region O
near O
the O
first O
transmembrane O
helix O
of O
GluN2D O
, O
including O

CIQ O
acts O
as O
NOT O
for O
what O
entity O
? O
exogenous O
small O
molecules O
. O
Elucidating O
the O
structural O
determinants O
and O
mechanism O
of O
action O
by O
which O
allosteric O
regulators O
control O
gating O
will O
enhance O
our O
understanding O
of O
NMDA O
receptor O
activation O
and O
facilitate O
the O
development O
of O
novel O
therapeutics O
. O
Here O
, O
we O
investigated O
the O
structural O
determinants O
for O
(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone O
(CIQ) O
, O
a O
GluN2C/2D-selective O
positive O
allosteric O
modulator O
. O
We O
show O
that O
CIQ O
does O
not O
bind O
to O
the O
amino-terminal O
domain O
of O
the O
NMDA O
receptor O
and O
does O
not O
share O
structural O
determinants O
with O
modulators O
acting O
at O
the O
agonist-binding O
domain O
dimer O
interface O
or O
ion B
channel I
pore O
. O
Rather O
, O
we O
identified O
critical O
determinants O
of O
CIQ O
modulation O
in O
the O
region O
near O
the O
first O
transmembrane O
helix O
of O
GluN2D O
, O
including O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
determinants O
and O
mechanism O
of O
action O
by O
which O
allosteric O
regulators O
control O
gating O
will O
enhance O
our O
understanding O
of O
NMDA B
receptor I
activation O
and O
facilitate O
the O
development O
of O
novel O
therapeutics O
. O
Here O
, O
we O
investigated O
the O
structural O
determinants O
for O
(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone O
(CIQ) O
, O
a O
GluN2C/2D-selective O
positive O
allosteric O
modulator O
. O
We O
show O
that O
CIQ O
does O
not O
bind O
to O
the O
amino O
terminal O
domain O
of O
the O
NMDA O
receptor O
and O
does O
not O
share O
structural O
determinants O
with O
modulators O
acting O
at O
the O
agonist-binding O
domain O
dimer O
interface O
or O
ion O
channel O
pore O
. O
Rather O
, O
we O
identified O
critical O
determinants O
of O
CIQ O
modulation O
in O
the O
region O
near O
the O
first O
transmembrane O
helix O
of O
GluN2D O
, O
including O
in O
a O
putative O
pre-M1 O
cuff O

baicalin O
acts O
as O
NOT O
for O
what O
entity O
? O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D B
and O
CYP3A O
activities O
. O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicali O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicali O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin O
(P<0.05) O
. O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin O
(0.90g/kg O
, O
i.v. O
, O
12days) O
on O
the O
metabolism O
of O
DXM O
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A B
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D B
and O
CYP3A O
activities O
. O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
single O
dose O
in O
rats O
. O
The O
activity O
of O
CYP3A B
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A B
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O

baicalin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A B
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O
(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorpha O
 O
, O
a O
dual O
probe O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorpha O
 O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O

DXM O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
activity O
of O
CYP3A O
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D B
and O
CYP3A O
activities O
. O

DXM O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
activity O
of O
CYP3A B
in O
excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin O
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05) O
, O
whereas O
multiple O
doses O
of O
baicalin O
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D O
. O
Taken O
together O
, O
these O
data O
demonstrate O
that O
baicalin O
inhibits O
the O
metabolism O
of O
DXM O
in O
a O
concentration-dependent O
manner O
in O
rats O
, O
possibly O
through O
inhibiting O
hepatic O
CYP2D O
and O
CYP3A O
activities O
. O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O

dextromethorphan O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
(DXM) O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A B
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O

DXM O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D B
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
( O
DXM O
 O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A O
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O

DXM O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
, O
a O
dual O
probe O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats.Baicalin O
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects O
, O
including O
antiviral O
, O
antioxidant O
, O
anti-cancer O
and O
anti-inflammatory O
properties O
. O
In O
the O
current O
study O
, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin O
on O
the O
metabolism O
of O
dextromethorphan O
( O
DXM O
 O
, O
a O
dual O
probe O
substrate O
of O
CYP2D O
and O
CYP3A O
, O
in O
rats O
. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin O
inhibited O
the O
activities O
of O
CYP2D O
and O
CYP3A B
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs) O
. O
Concomitant O
administration O
of O
baicalin O
(0.90g/kg O
, O
i.v.) O
and O
DXM O
(10mg/kg O
, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differential O
phosphoproteome O
of O
the O
striatum O
from O
pleiotrophin B
knockout O
and O
midkine O
knockout O
mice O
treated O
with O
amphetamine O
: O
Correlations O
with O
amphetamine-induced O
neurotoxicity.The O
neurotrophic O
factors O
pleiotrophin O
(PTN) O
and O
midkine O
(MK) O
have O
been O
shown O
to O
modulate O
amphetamine O
induced O
neurotoxicity O
. O
Accordingly O
, O
PTN-/- O
and O
MK-/- O
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine-induced O
neurotoxic O
effects O
. O
In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation O
, O
in O
which O
we O
combined O
phosphoprotein O
enrichment O
, O
by O
immobilized O
metal O
affinity O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differential O
phosphoproteome O
of O
the O
striatum O
from O
pleiotrophin O
knockout O
and O
midkine O
knockout O
mice O
treated O
with O
amphetamine O
: O
Correlations O
with O
amphetamine-induced O
neurotoxicity.The O
neurotrophic O
factors O
pleiotrophin O
(PTN) O
and O
midkine O
(MK) O
have O
been O
shown O
to O
modulate O
amphetamine O
induced O
neurotoxicity O
. O
Accordingly O
, O
PTN-/- O
and O
MK-/- O
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine-induced O
neurotoxic O
effects O
. O
In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation O
, O
in O
which O
we O
combined O
phosphoprotein O
enrichment O
, O
by O
immobilized O
metal O
affinity O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differential O
phosphoproteome O
of O
the O
striatum O
from O
pleiotrophin O
knockout O
and O
midkine B
knockout O
mice O
treated O
with O
amphetamine O
: O
Correlations O
with O
amphetamine-induced O
neurotoxicity.The O
neurotrophic O
factors O
pleiotrophin O
(PTN) O
and O
midkine O
(MK) O
have O
been O
shown O
to O
modulate O
amphetamine O
induced O
neurotoxicity O
. O
Accordingly O
, O
PTN-/- O
and O
MK-/- O
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine-induced O
neurotoxic O
effects O
. O
In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation O
, O
in O
which O
we O
combined O
phosphoprotein O
enrichment O
, O
by O
immobilized O
metal O
affinity O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differential O
phosphoproteome O
of O
the O
striatum O
from O
pleiotrophin O
knockout O
and O
midkine O
knockout O
mice O
treated O
with O
amphetamine O
: O
Correlations O
with O
amphetamine-induced O
neurotoxicity.The O
neurotrophic O
factors O
pleiotrophin O
(PTN) O
and O
midkine O
(MK) O
have O
been O
shown O
to O
modulate O
amphetamine O
induced O
neurotoxicity O
. O
Accordingly O
, O
PTN-/- O
and O
MK-/- O
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine-induced O
neurotoxic O
effects O
. O
In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O
amphetamine O
neurotoxic O
effects O
, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation O
, O
in O
which O
we O
combined O
phosphoprotein O
enrichment O
, O
by O
immobilized O
metal O
affinity O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
with O
two-dimensional O
gel O
electrophoresis O
and O
mass O
spectrometry O
, O
in O
order O
to O
identify O
the O
phosphoproteins O
regulated O
in O
the O
striatum O
of O
PTN-/- O
, O
MK-/- O
and O
wild O
type O
(WT) O
mice O
treated O
with O
amphetamine O
. O
We O
identified O
13 O
differentially O
expressed O
phosphoproteins O
that O
are O
judged O
to O
be O
relevant O
in O
the O
neuroprotective O
roles O
of O
PTN B
and O
MK O
against O
amphetamine O
induced O
neurotoxicity O
. O
It O
is O
very O
interesting O
to O
note O
that O
4 O
of O
these O
phosphoproteins O
, O
annexin O
A7 O
(ANXA7) O
, O
COP9 O
signalosome O
subunit O
5 O
(COPS5) O
, O
aldehyde O
dehydrogenase O
family O
1 O
member O
A1 O
(ALDH1A1) O
and O
creatine O
kinase O
U-type O
(CKMT1) O
, O
are O
known O
to O
be O
involved O
in O
Parkinson's O
disease O
, O
a O
result O
of O
significant O
importance O
since O
PTN O
and O

amphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
with O
two-dimensional O
gel O
electrophoresis O
and O
mass O
spectrometry O
, O
in O
order O
to O
identify O
the O
phosphoproteins O
regulated O
in O
the O
striatum O
of O
PTN-/- O
, O
MK-/- O
and O
wild O
type O
(WT) O
mice O
treated O
with O
amphetamine O
. O
We O
identified O
13 O
differentially O
expressed O
phosphoproteins O
that O
are O
judged O
to O
be O
relevant O
in O
the O
neuroprotective O
roles O
of O
PTN O
and O
MK B
against O
amphetamine O
induced O
neurotoxicity O
. O
It O
is O
very O
interesting O
to O
note O
that O
4 O
of O
these O
phosphoproteins O
, O
annexin O
A7 O
(ANXA7) O
, O
COP9 O
signalosome O
subunit O
5 O
(COPS5) O
, O
aldehyde O
dehydrogenase O
family O
1 O
member O
A1 O
(ALDH1A1) O
and O
creatine O
kinase O
U-type O
(CKMT1) O
, O
are O
known O
to O
be O
involved O
in O
Parkinson's O
disease O
, O
a O
result O
of O
significant O
importance O
since O
PTN O
and O

dihydroisoquinoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure-based O
design O
of O
novel O
dihydroisoquinoline O
BACE-1 B
inhibitors O
that O
do O
not O
engage O
the O
catalytic O
aspartates.The O
structure-activity O
relationship O
of O
a O
series O
of O
dihydroisoquinoline O
BACE-1 O
inhibitors O
is O
described O
. O
Application O
of O
structure-based O
design O
to O
screening O
hit O
1 O
yielded O
sub-micromolar O
inhibitors O
. O
Replacement O
of O
the O
carboxylic O
acid O
of O
1 O
was O
guided O
by O
X-ray O
crystallography O
, O
which O
allowed O
the O
replacement O
of O
a O
key O
water-mediated O
hydrogen O
bond O
. O
This O
work O
culminated O
in O
compounds O
such O
as O
31 O
, O
which O
possess O
good O
BACE-1 O

dihydroisoquinoline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Structure-based O
design O
of O
novel O
dihydroisoquinolin O
BACE-1 B
inhibitors O
that O
do O
not O
engage O
the O
catalytic O
aspartates.The O
structure-activity O
relationship O
of O
a O
series O
of O
dihydroisoquinoline O
BACE-1 O
inhibitors O
is O
described O
. O
Application O
of O
structure-based O
design O
to O
screening O
hit O
1 O
yielded O
sub-micromolar O
inhibitors O
. O
Replacement O
of O
the O
carboxylic O
acid O
of O
1 O
was O
guided O
by O
X-ray O
crystallography O
, O
which O
allowed O
the O
replacement O
of O
a O

dihydroquinolinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
for O
structure-based O
drug O
design O
: O
identification O
of O
new O
pyrazole O
series O
of O
irreversible O
KAT B
II I
inhibitors O
with O
improved O
lipophilic O
efficiency.The O
structure-based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone O
core O
to O
a O
tetrahydropyrazolopyridinone O
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT O
II O
inhibitors O
with O
excellent O
physicochemical O
properties O
. O
Compound O
20 O
is O
the O
most O
potent O
and O
lipophilically O
efficient O
of O
these O
new O
pyrazole O
analogs O
, O
with O
a O
k(inact)/K(i) O
value O
of O
112,000 O
M(-1)s(-1) O
and O
lipophilic O
efficiency O
(LipE) O
of O
8.53 O
. O
The O

tetrahydropyrazolopyridinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
identification O
of O
new O
pyrazole O
series O
of O
irreversible O
KAT B
II I
inhibitors O
with O
improved O
lipophilic O
efficiency.The O
structure-based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone O
core O
to O
a O
tetrahydropyrazolopyridinone O
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT O
II O
inhibitors O
with O
excellent O
physicochemical O
properties O
. O
Compound O
20 O
is O
the O
most O
potent O
and O
lipophilically O
efficient O
of O
these O
new O
pyrazole O
analogs O
, O
with O
a O
k(inact)/K(i) O
value O
of O
112,000 O
M(-1)s(-1) O
and O
lipophilic O
efficiency O
(LipE) O
of O
8.53 O
. O
The O
X-ray O
crystal O
structure O
of O

pyrazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PF-04859989 O
as O
a O
template O
for O
structure-based O
drug O
design O
: O
identification O
of O
new O
pyrazole O
series O
of O
irreversible O
KAT B
II I
inhibitors O
with O
improved O
lipophilic O
efficiency.The O
structure-based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone O
core O
to O
a O
tetrahydropyrazolopyridinone O
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT O
II O
inhibitors O
with O
excellent O
physicochemical O
properties O
. O
Compound O
20 O
is O
the O
most O
potent O

pyrazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PF-04859989 O
as O
a O
template O
for O
structure-based O
drug O
design O
: O
identification O
of O
new O
pyrazol O
series O
of O
irreversible O
KAT B
II I
inhibitors O
with O
improved O
lipophilic O
efficiency.The O
structure-based O
design O
, O
synthesis O
, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole O
series O
of O
irreversible O
KAT O
II O
inhibitors O
are O
described O
herein O
. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone O
core O
to O
a O
tetrahydropyrazolopyridinone O
core O
led O
to O

5-(p-toluenesulfonylamino)phthalimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
α-glycosidase O
. O
Almost O
all O
the O
compounds O
had O
strong O
inhibitory O
activities O
against O
yeast O
α-glycosidase O
. O
Regarding O
rat O
intestinal O
α-glycosidase O
, O
only O
analogs O
with O
N2-aromatic O
substituents O
displayed O
varying O
degrees O
of O
inhibitory O
activities O
on O
rat O
intestinal O
maltase O
and O
lactase O
and O
nearly O
all O
compounds O
showed O
no O
inhibition O
against O
rat O
intestinal O
α-amylase O
. O
Structure-activity O
relationship O
studies O
indicated O
that O
5-(p-toluenesulfonylamino)phthalimide O
moiety O
is O
a O
favorable O
scaffold O
to O
exert O
the O
α-glucosidase B
inhibitory O
activity O
and O
substituents O
at O
the O
N2 O
position O
have O
considerable O
influence O
on O
the O
efficacy O
of O
the O
inhibition O
activities O
. O

5-(p-toluenesulfonylamino)phthalimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
new O
series O
of O
N2-substituted-5-(p-toluenesulfonylamino)phthalimide O
analogues O
as O
α-glucosidase O
inhibitors.Several O
members O
of O
a O
new O
family O
of O
non-sugar-type O
α-glycosidase B
inhibitors O
, O
bearing O
a O
5-(p-toluenesulfonylamino)phthalimide O
moiety O
and O
various O
substituent O
at O
the O
N2 O
position O
, O
were O
synthesized O
and O
their O
activities O
were O
investigated O
. O
The O
newly O
synthesized O
compounds O
displayed O
different O
inhibition O
profile O
towards O
yeast O
α-glycosidase O
and O
rat O
intestinal O
α-glycosidase O
. O
Almost O
all O
the O
compounds O
had O
strong O
inhibitory O
activities O
against O
yeast O
α-glycosidase O
. O
Regarding O
rat O
intestinal O
α-glycosidase O
, O
only O
analogs O
with O
N2-aromatic O

N2-substituted-5-(p-toluenesulfonylamino)phthalimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
new O
series O
of O
N2-substituted-5-(p-toluenesulfonylamino)phthalimid O
analogues O
as O
α-glucosidase B
inhibitors.Several O
members O
of O
a O
new O
family O
of O
non-sugar-type O
α-glycosidase O
inhibitors O
, O
bearing O
a O
5-(p-toluenesulfonylamino)phthalimide O
moiety O
and O
various O
substituent O
at O
the O
N2 O
position O
, O
were O
synthesized O
and O
their O
activities O
were O
investigated O
. O
The O
newly O
synthesized O
compounds O
displayed O
different O
inhibition O
profile O
towards O
yeast O
α-glycosidase O
and O
rat O
intestinal O
α-glycosidase O
. O
Almost O
all O
the O

citrate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
vivo O
HIF-mediated O
reductive O
carboxylation O
is O
regulated O
by O
citrat O
levels O
and O
sensitizes O
VHL-deficient O
cells O
to O
glutamine O
deprivation.Hypoxic O
and O
VHL-deficient O
cells O
use O
glutamine O
to O
generate O
citrate O
and O
lipids O
through O
reductive O
carboxylation O
(RC) O
of O
α-ketoglutarate O
. O
To O
gain O
insights O
into O
the O
role O
of O
HIF B
and O
the O
molecular O
mechanisms O
underlying O
RC O
, O
we O
took O
advantage O
of O
a O
panel O
of O
disease-associated O
VHL O
mutants O
and O

thiourea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA B
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA O
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
, O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O
with O
LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB O
. O

thiourea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA O
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA O
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
, O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O
with O
LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB O
. O

thiourea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
actin-like O
protein O
, O
MreB O
. O
Herein O
, O
we O
demonstrate O
that O
the O
antibacterial O
activity O
of O
MAC13243 O
and O
the O
thiourea O
compounds O
are O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA B
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA O
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
, O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O
with O
LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB O
. O

MAC13243 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
we O
demonstrate O
that O
the O
antibacterial O
activity O
of O
MAC13243 O
and O
the O
thiourea O
compounds O
are O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA B
copy O
number O
, O
respectively O
. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA O
and O
the O
thiourea O
degradation O
product O
of O
MAC13243 O
with O
a O
Kd O
of O
~150 O
μM O
. O
Taken O
together O
, O
we O
conclude O
that O
the O
thiourea O
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O
that O
includes O
interaction O
with O
LolA O
in O
addition O
to O
the O
well-characterized O
target O
MreB O
. O

thiourea O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resulting O
thioure O
compounds O
with O
the O
lipoprotein O
targeting O
chaperone B
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O

thiourea O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resulting O
thioure O
compounds O
with O
the O
lipoprotein O
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O

thiourea O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Degradation O
of O
MAC13243 O
and O
studies O
of O
the O
interaction O
of O
resulting O
thioure O
compounds O
with O
the O
lipoprotein B
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O

MAC13243 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lipoprotein O
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule O
, O
MAC13243 O
as O
a O
likely O
inhibitor O
of O
the O
bacterial B
lipoprotein I
targeting O
chaperone O
, O
LolA O
. O
Here O
, O
we O
report O
on O
the O
degradation O
of O
MAC13243 O
into O
the O
active O
species O
, O
S-(4-chlorobenzyl)isothiourea O
. O
Analogs O
of O
this O
compound O
(e.g. O
, O
A22) O
have O
previously O
been O
characterized O
as O
inhibitors O
of O
the O
bacterial O
actin-like O
protein O
, O
MreB O
. O
Herein O
, O
we O
demonstrate O
that O
the O
antibacterial O
activity O

MAC13243 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lipoprotein O
targeting O
chaperone B
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule O
, O
MAC13243 O
as O
a O
likely O
inhibitor O
of O
the O
bacterial O
lipoprotein O
targeting O
chaperone O
, O
LolA O
. O
Here O
, O
we O
report O
on O
the O
degradation O
of O
MAC13243 O
into O
the O
active O
species O
, O
S-(4-chlorobenzyl)isothiourea O
. O
Analogs O
of O
this O
compound O
(e.g. O
, O
A22) O
have O
previously O
been O
characterized O
as O
inhibitors O
of O
the O
bacterial O
actin-like O
protein O
, O
MreB O
. O
Herein O
, O
we O
demonstrate O
that O
the O
antibacterial O
activity O

MAC13243 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
lipoprotein O
targeting O
chaperone O
LolA.The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O
antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action O
. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule O
, O
MAC13243 O
as O
a O
likely O
inhibitor O
of O
the O
bacterial O
lipoprotein O
targeting O
chaperone O
, O
LolA O
. O
Here O
, O
we O
report O
on O
the O
degradation O
of O
MAC13243 O
into O
the O
active O
species O
, O
S-(4-chlorobenzyl)isothiourea O
. O
Analogs O
of O
this O
compound O
(e.g. O
, O
A22) O
have O
previously O
been O
characterized O
as O
inhibitors O
of O
the O
bacterial O
actin-like O
protein O
, O
MreB O
. O
Herein O
, O
we O
demonstrate O
that O
the O
antibacterial O
activity O

7KC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(7βOHC) O
, O
are O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt B
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O

7KC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(7βOHC) O
, O
are O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O

7βOHC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt B
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O
rise O
was O

7βOHC O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O
rise O
was O

oxysterols O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
rafts O
. O
Although O
not O
cytotoxic O
, O
27OHC O
was O
mainly O
detected O
in O
lipid O
rafts O
. O
It O
is O
noteworthy O
that O
α-tocopherol O
(but O
not O
ellagic O
acid O
and O
resveratrol) O
was O
able O
to O
counteract O
7KC- O
and O
7βOHC-induced O
apoptosis O
and O
to O
decrease O
the O
accumulation O
of O
7KC O
and O
27OHC O
in O
lipid O
rafts O
. O
Thus O
, O
in O
158N O
cells O
, O
the O
ability O
of O
oxysterols O
to O
trigger O
a O
mode O
of O
cell O
death O
by O
apoptosis O
involving O
GSK-3 B
and O
caspase-3 O
activation O
is O
independent O
of O
the O
increase O
in O
the O
Ca(2+) O
level O
and O
of O
their O
accumulation O
in O
lipid O
raft O
microdomains O
. O

oxysterols O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
rafts O
. O
Although O
not O
cytotoxic O
, O
27OHC O
was O
mainly O
detected O
in O
lipid O
rafts O
. O
It O
is O
noteworthy O
that O
α-tocopherol O
(but O
not O
ellagic O
acid O
and O
resveratrol) O
was O
able O
to O
counteract O
7KC- O
and O
7βOHC-induced O
apoptosis O
and O
to O
decrease O
the O
accumulation O
of O
7KC O
and O
27OHC O
in O
lipid O
rafts O
. O
Thus O
, O
in O
158N O
cells O
, O
the O
ability O
of O
oxysterols O
to O
trigger O
a O
mode O
of O
cell O
death O
by O
apoptosis O
involving O
GSK-3 O
and O
caspase-3 B
activation O
is O
independent O
of O
the O
increase O
in O
the O
Ca(2+) O
level O
and O
of O
their O
accumulation O
in O
lipid O
raft O
microdomains O
. O

7KC O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(7βOHC) O
, O
are O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O

7KC O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(7βOHC) O
, O
are O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 B
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O

7βOHC O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 O
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O
rise O
was O

7βOHC O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS) O
. O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols O
on O
oligodendrocytes O
, O
the O
myelin-forming O
cells O
in O
the O
CNS O
. O
To O
this O
end O
, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC O
or O
7βOHC O
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei O
, O
dephosphorylation O
of O
Akt O
and O
GSK3 O
, O
mitochondrial O
depolarization O
involving O
Mcl-1 O
, O
and O
caspase-3 B
activation O
. O
In O
contrast O
, O
under O
treatment O
with O
27-hydroxycholesterol O
(27OHC) O
, O
no O
cell O
death O
was O
observed O
. O
When O
the O
cells O
were O
stained O
with O
Fura-2 O
, O
no O
significant O
Ca(2+) O
rise O
was O

EtOH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
ST1283-treated O
mice O
had O
similar O
BECs O
. O
CONCLUSION O
: O
Our O
results O
show O
that O
ST1283 O
may O
decrease O
voluntary O
EtOH O
consumption O
and O
EtOH-CPP O
by O
altering O
its O
reinforcing O
effects O
, O
suggesting O
a O
novel O
role O
for O
histamine O
signaling O
in O
regulation O
of O
alcoholism O
. O
Lastly O
, O
the O
results O
add O
to O
the O
growing O
literature O
on O
H3R B
modulation O
in O
the O
pharmacotherapy O
of O
EtOH O
addiction O
. O

R-(alpha)-methyl-histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
alcohol O
consumption O
and O
preference O
. O
Importantly O
, O
vehicle- O
and O
ST1283 O
(5 O
mg/kg)-treated O
mice O
showed O
similar O
consumption O
and O
preference O
to O
increasing O
concentration O
of O
both O
sweet O
and O
bitter O
tastes O
. O
More O
interestingly O
, O
systemic O
administration O
of O
ST1283 O
inhibited O
EtOH-CPP O
and O
EtOH-enhanced O
locomotion O
. O
This O
inhibition O
was O
blocked O
when O
mice O
were O
pretreated O
with O
the O
selective O
H3R B
agonist O
R-(alpha)-methyl-histamine O
(10 O
mg/kg) O
. O
Finally O
, O
vehicle- O
and O
ST1283-treated O
mice O
had O
similar O
BECs O
. O
CONCLUSION O
: O
Our O
results O
show O
that O
ST1283 O
may O
decrease O
voluntary O
EtOH O
consumption O
and O
EtOH-CPP O
by O
altering O
its O
reinforcing O
effects O
, O
suggesting O
a O
novel O
role O
for O
histamine O
signaling O
in O
regulation O
of O
alcoholism O
. O
Lastly O
, O
the O
results O
add O
to O
the O
growing O
literature O
on O
H3R O

cucurbitacin O
I O
acts O
as O
NOT O
for O
what O
entity O
? O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 B
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O

Cucurbitacin O
I O
acts O
as O
NOT O
for O
what O
entity O
? O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 B
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O

Cucurbitacin O
I O
acts O
as O
NOT O
for O
what O
entity O
? O
anticancer O
agent O
cucurbitacin O
I O
, O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin B
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O

cucurbitacin O
I O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA B
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O

cucurbitacin O
I O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho B
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O

cucurbitacin O
I O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho B
kinase I
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O

cucurbitacin O
I O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O

cucurbitacin O
I O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA B
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 O
pathway O
. O
Moreover O
, O
they O
established O

N-acetyl O
l-cysteine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 B
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 O
pathway O
. O
Moreover O
, O
they O
established O
that O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activity O
involves O
the O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
I O
also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 O
by O
heregulin O
. O
Subsequent O
analysis O
revealed O
that O
cucurbitacin O
I O
strongly O
activates O
RhoA O
and O
the O
Rho O
effector O
Rho O
kinase O
(ROCK) O
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers O
. O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 B
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Interestingly O
, O
disruption O
of O
the O
RhoA-ROCK O
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 B
activation O
by O
heregulin O
. O
Lastly O
, O
we O
found O
that O
RhoA O
activation O
by O
cucurbitacin O
I O
is O
mediated O
by O
reactive O
oxygen O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 O
pathway O
. O
Moreover O
, O
they O
established O
that O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activity O
involves O
the O
alteration O
of O
the O
balance O
between O
Rho O
and O
Rac O
. O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
species O
(ROS) O
. O
The O
ROS O
scavenger O
N-acetyl O
l-cysteine O
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 B
activation O
. O
In O
conclusion O
, O
these O
results O
indicate O
that O
ErbB-driven O
Rac1 O
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 O
pathway O
. O
Moreover O
, O
they O
established O
that O
the O
inhibitory O
effect O
of O
cucurbitacin O
I O
on O
Rac1 O
activity O
involves O
the O
alteration O
of O
the O
balance O
between O
Rho O
and O
Rac O
. O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
exchange O
factor O
P-Rex1 O
. O
As O
the O
Janus O
tyrosine O
kinase O
2 O
(Jak2)/signal O
transducer O
and O
activator O
of O
transcription O
3 O
(Stat3) O
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB O
receptors O
, O
we O
asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 O
activation O
in O
response O
to O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
a O
Jak2 B
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 O
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O

cucurbitacin O
I O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
exchange O
factor O
P-Rex1 O
. O
As O
the O
Janus O
tyrosine O
kinase O
2 O
(Jak2)/signal O
transducer O
and O
activator O
of O
transcription O
3 O
(Stat3) O
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB O
receptors O
, O
we O
asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 O
activation O
in O
response O
to O
ErbB O
ligands O
. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin O
I O
a O
Jak2 O
inhibitor O
, O
reduced O
the O
activation O
of O
Rac1 B
and O
motility O
in O
response O
to O
the O
ErbB3 O
ligand O
heregulin O
in O
breast O
cancer O
cells O
. O
However O
, O
Rac1 O
activation O
was O
not O
affected O
by O
Jak2 O
or O
Stat3 O
RNA O
interference O
, O
suggesting O
that O
the O
effect O
of O
cucurbitacin O
I O
occurs O
through O
a O
Jak2-independent O
mechanism O
. O
Cucurbitacin O
I O
also O
failed O

[6]-gingerol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Roscoe O
(ginger) O
was O
identified O
as O
a O
novel O
angiotensin B
II I
type I
1 I
receptor I
antagonist O
, O
with O
an O
IC50 O
value O
of O
8.173 O
µM O
. O
The O
hit O
was O
further O
tested O
by O
a O
specificity O
assay O
indicating O
that O
it O
had O
no O
antagonistic O
effects O
on O
other O
evaluated O
GPCRs O
, O
such O
as O
endothelin O
receptors O
. O
The O
major O
ingredient O
of O
ginger O
, O
[6]-gingerol O
could O
inhibit O
angiotensin O
II O
type O
1 O
receptor O
activation O
, O
which O
partially O
clarified O
the O
mechanism O
of O
ginger O
regulating O
blood O
pressure O
and O
strengthening O
heart O
in O
the O
cardiovascular O
system O
. O

[6]-Gingerol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
this O
study O
aimed O
to O
find O
novel O
compounds O
targeting O
the O
angiotensin O
II O
type O
1 O
receptor O
, O
accepted O
as O
a O
therapeutic O
target O
in O
cardiovascular O
disease O
. O
A O
small O
library O
consisting O
of O
89 O
compounds O
from O
39 O
Chinese O
herbs O
was O
profiled O
using O
a O
cell-based O
calcium O
mobilization O
assay O
which O
was O
developed O
and O
characterized O
for O
high-throughput O
screening O
. O
[6]-Gingerol O
derived O
from O
Zingiber O
officinale O
Roscoe O
(ginger) O
was O
identified O
as O
a O
novel O
angiotensin B
II I
type I
1 I
receptor I
antagonist O
, O
with O
an O
IC50 O
value O
of O
8.173 O
µM O
. O
The O
hit O
was O
further O
tested O
by O
a O
specificity O
assay O
indicating O
that O
it O
had O
no O
antagonistic O
effects O
on O
other O
evaluated O
GPCRs O
, O
such O
as O
endothelin O
receptors O
. O
The O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B B
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B B
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B B
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
( O
Ser O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B B
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B B
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
AKt O
and O
PTP1B B
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B B
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O
is O
shown O
. O

triglycerides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[ O
triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O

TAGs O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
( O
TAGs O
 O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O

diglycerides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O

DAGs O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
( O
DAGs O
] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O

ceramides O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O

triglycerides O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin B
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[ O
triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O

triglycerides O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
secretion O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[ O
triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O

TAGs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin B
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
( O
TAGs O
 O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O

TAGs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
( O
TAGs O
 O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O

diglycerides O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin B
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O

diglycerides O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
effective O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O

DAGs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin B
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
( O
DAGs O
] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O

DAGs O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
glucose O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
( O
DAGs O
] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O

ceramides O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin B
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O

ceramides O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
uptake/disposal O
. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle O
, O
liver O
and O
adipose O
tissue O
- O
may O
attenuate O
insulin O
signaling O
through O
the O
protein O
kinase O
B O
(AKt) O
pathway O
and O
up-regulate O
protein O
tyrosine O
phosphatase O
1B O
(PTP1B) O
, O
a O
negative O
regulator O
of O
insulin O
signaling O
. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O

palmitic O
and O
stearic O
acids O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B B
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O

palmitic O
and O
stearic O
acids O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt B
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O

palmitic O
and O
stearic O
acids O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
evaluated O
in O
the O
presence O
of O
wortmannin O
, O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B B
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O

wortmannin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
an O
inhibitor O
of O
phosphatidylinositol O
3-kinases O
and O
thus O
AKt B
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O

ceramides O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt B
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O

wortmannin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
accumulation O
of O
lipid O
metabolites O
[triglycerides O
(TAGs) O
, O
diglycerides O
(DAGs)] O
and O
ceramides O
in O
relation O
to O
insulin O
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B O
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O
fatty O
acids O
(FFAs) O
(200 O
μM) O
. O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin O
an O
inhibitor O
of O
phosphatidylinositol B
3-kinases I
and O
thus O
AKt O
(0-100 O
nM) O
. O
Unsaturated O
FFAs O
increased O
DAGs O
, O
TAGs O
and O
PTP1B O
expression O
significantly O
, O
but O
cells O
remained O
insulin O
sensitive O
as O
assessed O
by O
robust O
AKt O
and O
PTP1B O
phosphorylation O
at O
serine O
(Ser) O
50 O
, O
Ser O
398 O
and O
tyrosine O
152 O
. O
Saturated O
palmitic O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O

ceramides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
stearic O
acids O
increased O
ceramides O
, O
up-regulated O
PTP1B O
, O
and O
had O
AKt O
and O
PTP1B B
phosphorylation O
at O
Ser O
50 O
impaired O
. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt O
and O
of O
PTP1B O
at O
Ser O
50 O
(R(2)=0.84 O
, O
P<.05) O
. O
The O
same O
was O
observed O
with O
increasing O
wortmannin O
dose O
(R(2)=0.73 O
, O
P<.05) O
. O
Only O
FFAs O
that O
increased O
ceramides O
caused O
impairment O
of O
AKt O
and O
PTP1B O
phosphorylation O
at O
Ser O
50 O
. O
PTP1B O
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin O
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B O
phosphorylation O
. O
A O
clear O
relationship O
between O
PTP1B O
phosphorylation O
levels O
at O
Ser O
50 O
and O
its O
negative O
effect O
on O
insulin O
signaling O

telmisartan O
acts O
as O
AGONIST O
for O
what O
entity O
? O
The O
physicochemical O
differences O
between O
ARBs O
also O
manifest O
in O
different O
tissue O
penetration O
, O
including O
passage O
through O
the O
blood-brain O
barrier O
. O
Differences O
in O
binding O
mode O
and O
tissue O
penetration O
are O
also O
associated O
with O
differences O
in O
pharmacokinetic O
profile O
, O
particularly O
duration O
of O
action O
. O
Although O
generally O
highly O
specific O
for O
angiotensin O
II O
type O
1 O
receptors O
, O
some O
ARBs O
, O
particularly O
telmisartan O
are O
partial O
agonists O
at O
peroxisome O
proliferator-activated O
receptor-γ O
. O
All O
of O
these O
properties O
are O
comprehensively O
reviewed O
in O
this O
article O
. O
Although O
there O
is O
general O
consensus O
that O
a O
continuous O
receptor O
blockade O
over O
a O
24-hour O
period O
is O
desirable O
, O
the O
clinical O
relevance O
of O
other O
pharmacological O
differences O
between O
individual O
ARBs O
remains O
to O
be O
assessed O
. O

telmisartan O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
The O
physicochemical O
differences O
between O
ARBs O
also O
manifest O
in O
different O
tissue O
penetration O
, O
including O
passage O
through O
the O
blood-brain O
barrier O
. O
Differences O
in O
binding O
mode O
and O
tissue O
penetration O
are O
also O
associated O
with O
differences O
in O
pharmacokinetic O
profile O
, O
particularly O
duration O
of O
action O
. O
Although O
generally O
highly O
specific O
for O
angiotensin O
II O
type O
1 O
receptors O
, O
some O
ARBs O
, O
particularly O
telmisartan O
are O
partial O
agonists O
at O
peroxisome O
proliferator-activated O
receptor-γ O
. O
All O
of O
these O
properties O
are O
comprehensively O
reviewed O
in O
this O
article O
. O
Although O
there O
is O
general O
consensus O
that O
a O
continuous O
receptor O
blockade O
over O
a O
24-hour O
period O
is O
desirable O
, O
the O
clinical O
relevance O
of O
other O
pharmacological O
differences O
between O
individual O
ARBs O
remains O
to O
be O
assessed O
. O

glucose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
There O
appear O
to O
be O
no O
major O
safety O
concerns O
and O
so O
it O
seems O
reasonable O
to O
continue O
insulin B
glargine O
if O
required O
to O
achieve O
excellent O
glycaemic O
control O
. O
A O
head-to-head O
comparison O
between O
insulin O
detemir O
and O
NPH O
insulin O
in O
women O
with O
type O
1 O
diabetes O
showed O
that O
while O
foetal O
outcomes O
did O
not O
differ O
, O
fasting O
plasma O
glucose O
improved O
with O
insulin O
detemir O
without O
an O
increased O
incidence O
of O
hypoglycaemia O
. O
The O
greater O
evidence O
base O
supports O
the O
use O
of O
insulin O
detemir O
as O
the O
first O
line O
long-acting O
analogue O
in O
pregnancy O
but O
the O
lack O
of O
definitive O
foetal O
benefits O
means O
that O
there O
is O
no O
strong O
need O
to O
switch O
a O
woman O
who O
is O
well O

N-(thiophen-2-yl) O
benzamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthesis O
of O
N-(thiophen-2-yl) O
benzamide O
derivatives O
as O
BRAF(V600E) O
inhibitors.The O
V600E O
BRAF B
kinase O
mutation O
, O
which O
activates O
the O
downstream O
MAPK O
signaling O
pathway O
, O
commonly O
occurs O
in O
about O
8% O
of O
all O
human O
malignancies O
and O
about O
50% O
of O
all O
melanomas O
. O
In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O
synthesis O
to O
identify O
a O
series O
of O
N-(thiophen-2-yl) O
benzamide O
derivatives O
as O
potent O
BRAF(V600E) O
inhibitors O
. O
Structure-activity O
relationship O
studies O
of O
these O
derivatives O
revealed O
that O
compounds O
b40 O
and O
b47 O
are O
the O
two O
most O
potent O
BRAF(V600E) O
inhibitors O
in O
this O
series O
. O

N-(thiophen-2-yl) O
benzamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthesis O
of O
N-(thiophen-2-yl) O
benzamide O
derivatives O
as O
BRAF(V600E) O
inhibitors.The O
V600E B
BRAF O
kinase O
mutation O
, O
which O
activates O
the O
downstream O
MAPK O
signaling O
pathway O
, O
commonly O
occurs O
in O
about O
8% O
of O
all O
human O
malignancies O
and O
about O
50% O
of O
all O
melanomas O
. O
In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O
synthesis O
to O
identify O
a O
series O
of O
N-(thiophen-2-yl) O
benzamide O
derivatives O
as O
potent O
BRAF(V600E) O
inhibitors O
. O
Structure-activity O
relationship O
studies O
of O
these O
derivatives O
revealed O
that O
compounds O
b40 O
and O
b47 O
are O
the O
two O
most O
potent O
BRAF(V600E) O
inhibitors O
in O
this O
series O
. O

N-(thiophen-2-yl) O
benzamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
and O
synthesis O
of O
N-(thiophen-2-yl) O
benzamid O
derivatives O
as O
BRAF(V600E) O
inhibitors.The O
V600E O
BRAF B
kinase O
mutation O
, O
which O
activates O
the O
downstream O
MAPK O
signaling O
pathway O
, O
commonly O
occurs O
in O
about O
8% O
of O
all O
human O
malignancies O
and O
about O
50% O
of O
all O
melanomas O
. O
In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O
synthesis O
to O
identify O
a O
series O
of O
N-(thiophen-2-yl) O
benzamide O
derivatives O
as O

N-(thiophen-2-yl) O
benzamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Identification O
and O
synthesis O
of O
N-(thiophen-2-yl) O
benzamid O
derivatives O
as O
BRAF(V600E) O
inhibitors.The O
V600E B
BRAF O
kinase O
mutation O
, O
which O
activates O
the O
downstream O
MAPK O
signaling O
pathway O
, O
commonly O
occurs O
in O
about O
8% O
of O
all O
human O
malignancies O
and O
about O
50% O
of O
all O
melanomas O
. O
In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O
synthesis O
to O
identify O
a O
series O
of O
N-(thiophen-2-yl) O
benzamide O
derivatives O
as O

(m)CpGs O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 B
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3- O
(m)CpGs O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O

(m)CpGs O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3- O
(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 B
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O

(m)CpG O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3- O
(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 B
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O

(m)CpG O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 B
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3- O
(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O
escape O
from O
(m)CpG-induced O
gene O
suppression O
, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 O
gene O
transcription O
and O
expression O
. O

CpG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
transporter O
isoform O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA B
methyl I
transferase I
3a I
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O

(m)CpG O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
3 O
expression.The O
murine O
neuronal O
facilitative O
glucose O
transporter O
isoform O
3 O
(Glut3) O
is O
developmentally O
regulated O
, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14 O
. O
In O
the O
present O
study O
, O
we O
characterized O
a O
canonical O
CpG O
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 O
gene O
. O
Methylation-specific O
PCR O
and O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
( O
(m)CpG O
island O
of O
the O
glut3 O
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA B
methyl I
transferase I
3a I
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O

(m)CpGs O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
bisulfite O
sequencing O
identified O
methylation O
of O
this O
CpG O
((m)CpG) O
island O
of O
the O
glut3 B
gene O
, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA O
methyl O
transferase O
3a O
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3) O
. O
5'-flanking O
region O
of O
glut3-luciferase O
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs O
inhibit O
glut3 O
transcription O
. O
Contrary O
to O
this O
biological O
function O
, O
glut3 O
expression O
rises O
synchronously O
with O
(m)CpGs O
in O
PN14 O
vs O
PN3 O
neurons O
. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O
methyl-CpG O
binding O
protein O
2 O
(Mecp2) O
bound O
the O
glut3-(m)CpGs O
. O
Depending O
on O
association O
with O
specific O
coregulators O
, O
Mecp2 O
, O
a O
dual O
regulator O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O

5-aza-2'-deoxycytidine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 B
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O

5-aza-2'-deoxycytidine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
gene O
transcription O
, O
may O
repress O
or O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 B
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O

trichostatin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 B
exponentially O
upon O
recruitment O
of O
Creb1 O
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3-(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O

trichostatin O
A O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
activate O
a O
downstream O
gene O
. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs O
to O
bind O
Mecp2 O
exponentially O
upon O
recruitment O
of O
Creb1 B
rather O
than O
histone O
deacetylase O
1 O
. O
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 O
associated O
with O
Mecp2 O
and O
cotransfection O
with O
glut3-(m)CpG O
in O
HT22 O
cells O
enhanced O
glut3 O
transcription O
. O
Separate O
5-aza-2'-deoxycytidine O
pretreatment O
or O
in O
combination O
with O
trichostatin O
A O
reduced O
(m)CpG O
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 O
and O
Creb1 O
separately O
or O
together O
depleting O
Mecp2 O
and/or O
Creb1 O
binding O
of O
glut3-(m)CpGs O
reduced O
glut3 O
expression O
in O
HT22 O
cells O
. O
We O
conclude O
that O
Glut3 O
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2 O
. O
Recruitment O
of O
Creb1-Mecp2 O
by O
glut3-(m)CpG O
contributes O
towards O
transactivation O
, O
formulating O
an O

ezetimibe O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
risk O
in O
almost O
all O
patient O
categories O
, O
with O
the O
exception O
of O
heart O
and O
kidney O
failure O
as O
well O
as O
advanced O
aortic O
stenosis O
. O
As O
a O
consequence O
, O
statins O
have O
become O
the O
cornerstone O
in O
current O
prevention O
guidelines O
. O
In O
patients O
who O
do O
not O
reach O
the O
LDL-C O
target O
, O
combination O
therapy O
with O
additional O
LDL-C O
lowering O
drugs O
(e.g O
. O
ezetimibe O
bile O
acid O
sequestrants O
or O
fibrates) O
should O
be O
considered O
. O
Guidelines O
provide O
different O
LDL-C O
levels O
to O
strive O
for O
, O
depending O
on O
the O
CVD O
risk O
. O
In O
this O
review O
, O
we O
describe O
the O
rationale O
for O
these O
LDL-C O
targets O
and O
how O
these O
goals O
might O
be O
reached O
by O
current O
and O
future O
therapies O
. O

bile O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
almost O
all O
patient O
categories O
, O
with O
the O
exception O
of O
heart O
and O
kidney O
failure O
as O
well O
as O
advanced O
aortic O
stenosis O
. O
As O
a O
consequence O
, O
statins O
have O
become O
the O
cornerstone O
in O
current O
prevention O
guidelines O
. O
In O
patients O
who O
do O
not O
reach O
the O
LDL-C O
target O
, O
combination O
therapy O
with O
additional O
LDL-C O
lowering O
drugs O
(e.g O
. O
ezetimibe O
, O
bile O
acid O
sequestrants O
or O
fibrates) O
should O
be O
considered O
. O
Guidelines O
provide O
different O
LDL-C O
levels O
to O
strive O
for O
, O
depending O
on O
the O
CVD O
risk O
. O
In O
this O
review O
, O
we O
describe O
the O
rationale O
for O
these O
LDL-C O
targets O
and O
how O
these O
goals O
might O
be O
reached O
by O
current O
and O
future O
therapies O
. O

fibrates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
categories O
, O
with O
the O
exception O
of O
heart O
and O
kidney O
failure O
as O
well O
as O
advanced O
aortic O
stenosis O
. O
As O
a O
consequence O
, O
statins O
have O
become O
the O
cornerstone O
in O
current O
prevention O
guidelines O
. O
In O
patients O
who O
do O
not O
reach O
the O
LDL-C O
target O
, O
combination O
therapy O
with O
additional O
LDL-C O
lowering O
drugs O
(e.g O
. O
ezetimibe O
, O
bile O
acid O
sequestrants O
or O
fibrates O
should O
be O
considered O
. O
Guidelines O
provide O
different O
LDL-C O
levels O
to O
strive O
for O
, O
depending O
on O
the O
CVD O
risk O
. O
In O
this O
review O
, O
we O
describe O
the O
rationale O
for O
these O
LDL-C O
targets O
and O
how O
these O
goals O
might O
be O
reached O
by O
current O
and O
future O
therapies O
. O

imidazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O
with O
a O
difluoromethylene O
linker O
, O
replacement O
of O
the O
para-cyanophenyl O
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl O
group O
with O
an O
imidazolyl O
group O
. O
The O
most O
potent O
in O
vitro O
DASI O
discovered O
is O
an O
imidazole O
derivative O
with O
IC50 O
values O
against O
aromatase B
and O
steroid O
sulfatase O
in O
a O
JEG-3 O
cell O
preparation O
of O
0.2 O
and O
2.5 O
nM O
, O
respectively O
. O
The O
parent O
phenol O
of O
this O
compound O
inhibits O
aromatase O
with O
an O
IC50 O
value O
of O
0.028 O
nM O
in O
the O
same O
assay O
. O

imidazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O
with O
a O
difluoromethylene O
linker O
, O
replacement O
of O
the O
para-cyanophenyl O
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl O
group O
with O
an O
imidazolyl O
group O
. O
The O
most O
potent O
in O
vitro O
DASI O
discovered O
is O
an O
imidazole O
derivative O
with O
IC50 O
values O
against O
aromatase O
and O
steroid B
sulfatase I
in O
a O
JEG-3 O
cell O
preparation O
of O
0.2 O
and O
2.5 O
nM O
, O
respectively O
. O
The O
parent O
phenol O
of O
this O
compound O
inhibits O
aromatase O
with O
an O
IC50 O
value O
of O
0.028 O
nM O
in O
the O
same O
assay O
. O

phenol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
para-cyanophenyl O
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl O
group O
with O
an O
imidazolyl O
group O
. O
The O
most O
potent O
in O
vitro O
DASI O
discovered O
is O
an O
imidazole O
derivative O
with O
IC50 O
values O
against O
aromatase B
and O
steroid O
sulfatase O
in O
a O
JEG-3 O
cell O
preparation O
of O
0.2 O
and O
2.5 O
nM O
, O
respectively O
. O
The O
parent O
phenol O
of O
this O
compound O
inhibits O
aromatase O
with O
an O
IC50 O
value O
of O
0.028 O
nM O
in O
the O
same O
assay O
. O

F O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
( O
F O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase B
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O

F O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
( O
F O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase B
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamat O
.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamat O
.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
. O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase B
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
. O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase B
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O

Cl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase B
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O

Cl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
Br) O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase B
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O

Br O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br O
derivatives O
are O
first-generation O
dual O
aromatase B
and O
sulfatase O
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O
with O

Br O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase O
Inhibitor O
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate.4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl O
sulfamate O
and O
its O
ortho-halogenated O
(F O
, O
Cl O
, O
Br O
derivatives O
are O
first-generation O
dual O
aromatase O
and O
sulfatase B
inhibitors O
(DASIs) O
. O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen O
atom O
, O
introduction O
of O
more O
halogen O
atoms O
, O
replacement O
of O
the O
halogen O
with O
another O
group O
, O
replacement O
of O
the O
methylene O
linker O
with O

pyrido-quinazolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
evaluation O
of O
N-Aryl O
pyrido-quinazolines O
derivatives O
as O
potent O
EGFR B
inhibitors.A O
series O
of O
pyrido-quinazolines O
have O
been O
synthesised O
, O
characterised O
and O
tested O
for O
their O
in O
vitro O
EGFR O
tyrosine O
kinase O
inhibitory O
activity O
. O
The O
compounds O
were O
prepared O
from O
Alkylideno/arylideno-bis-ureas O
. O
Their O
final O
structure O
of O
the O
compounds O
were O
elucidated O
on O
the O
basis O
of O
spectral O
studies O
(IR. O
, O
1H O
NMR O
, O
FT-IR O
and O
EI-MS) O
. O
The O
cellular O
EGFR O
internalization O
response O
of O
selected O
compounds O

pyrido-quinazolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
evaluation O
of O
N-Aryl O
pyrido-quinazolines O
derivatives O
as O
potent O
EGFR O
inhibitors.A O
series O
of O
pyrido-quinazolines O
have O
been O
synthesised O
, O
characterised O
and O
tested O
for O
their O
in O
vitro O
EGFR O
tyrosine B
kinase I
inhibitory O
activity O
. O
The O
compounds O
were O
prepared O
from O
Alkylideno/arylideno-bis-ureas O
. O
Their O
final O
structure O
of O
the O
compounds O
were O
elucidated O
on O
the O
basis O
of O
spectral O
studies O
(IR. O
, O
1H O
NMR O
, O
FT-IR O
and O
EI-MS) O
. O
The O
cellular O
EGFR O
internalization O
response O
of O
selected O
compounds O

N-Aryl O
pyrido-quinazolines O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
in O
vitro O
evaluation O
of O
N-Aryl O
pyrido-quinazoline O
derivatives O
as O
potent O
EGFR B
inhibitors.A O
series O
of O
pyrido-quinazolines O
have O
been O
synthesised O
, O
characterised O
and O
tested O
for O
their O
in O
vitro O
EGFR O
tyrosine O
kinase O
inhibitory O
activity O
. O
The O
compounds O
were O
prepared O
from O
Alkylideno/arylideno-bis-ureas O
. O
Their O
final O
structure O
of O
the O
compounds O
were O
elucidated O
on O
the O
basis O
of O
spectral O
studies O
(IR. O
, O
1H O
NMR O
, O
FT-IR O
and O
EI-MS) O
. O

kinsenoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic B
dehydrogenase I
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide B
dismutase I
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase B
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O

glucose O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic B
dehydrogenase I
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide B
dismutase I
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase B
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
major O
active O
ingredient O
, O
kinsenoside O
, O
in O
high O
glucose O
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments O
. O
In O
in O
vivo O
tests O
, O
kinsenoside O
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose O
and O
cholesterol O
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin O
. O
In O
the O
in O
vitro O
assay O
, O
kinsenoside O
(20 O
and O
50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear B
factor I
kappa I
B I
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O
Moreover O
, O
histological O
examination O
, O
including O
hematoxylin-eosin O
(H&E) O
staining O
, O
masson O
trichrome O
(Masson) O
staining O
, O
and O
periodic O
Schiff-methenamine O
(PASM) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O

kinsenoside O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
various O
biochemical O
substances O
(nitric O
oxide O
(NO) O
, O
lactic O
dehydrogenase O
(LDH) O
, O
superoxide O
dismutase O
(SOD) O
, O
and O
catalase O
(CAT)) O
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose O
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix O
metalloproteinases-the O
tissue O
inhibitors O
of O
matrix O
metalloproteinases O
(MMP-TIMP) O
system O
. O
The O
vascular O
protective O
effects O
of O
kinsenoside O
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear O
factor O
kappa O
B O
(NF-κB) O
mRNA O
expression O
levels O
in O
high O
glucose O
conditions O
. O
Moreover O
, O
histological O
examination O
, O
including O
hematoxylin-eosin O
(H&E) O
staining O
, O
masson O
trichrome O
(Masson) O
staining O
, O
and O
periodic O
Schiff-methenamine O
(PASM) O
staining O
, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O

oxysterols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
there O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog O
and O
wnt O
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O
provoke O
its O
eradication O
. O
Therefore O
, O
the O
two O
facets O
of O

Oxysterols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog O
and O
wnt O
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O
provoke O
its O
eradication O
. O
Therefore O
, O
the O
two O
facets O
of O
oxysterol O

Oxysterols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog B
and O
wnt O
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O
provoke O
its O
eradication O
. O
Therefore O
, O
the O
two O
facets O
of O
oxysterol O

Oxysterols O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog O
and O
wnt B
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O
provoke O
its O
eradication O
. O
Therefore O
, O
the O
two O
facets O
of O
oxysterol O

Cholesterol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
are O
thought O
to O
be O
generated O
in O
proportion O
to O
the O
rate O
of O
cholesterol O
synthesis O
. O
Although O
there O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols O
are O
generated O
in O
vivo O
, O
it O
clearly O
has O
to O
be O
ubiquitous O
. O
The O
25- O
and O
the O
27-cholesterol O
hydroxylases O
, O
present O
in O
almost O
all O
tissues O
, O
are O
possible O
candidates O
. O
Cholesterol O
uptake O
from O
lipoproteins O
, O
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols O
. O
Oxysterols O
interfere O
with O
ERK O
, O
hedgehog O
and O
wnt O
pathways O
of O
proliferation O
and O
differentiation O
. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines O
, O
oxysterols O
invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death O
. O
Perhaps O
is O
it O
sufficient O
to O

ethanol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
ALDH2 B
with O
ethano O
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats.This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 O
expression O
in O
the O
diabetic O
rat O
, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 O
activator O
ethanol O
(EtOH) O
. O
The O
rats O
were O
divided O
into O
six O
groups O
: O
control O
, O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O

ethanol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
ALDH2 B
with O
ethanol O
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats.This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 O
expression O
in O
the O
diabetic O
rat O
, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 O
activator O
ethanol O
(EtOH) O
. O
The O
rats O
were O
divided O
into O
six O
groups O
: O
control O
, O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O
week O
(DM12W) O
and O
EtOH+DM8W O
groups O
. O
Compared O
with O
control O
group O
, O
fasting O
blood O
glucose O
(FBG) O
and O
glycosylated O
hemoglobin O
(HbA1c) O
levels O
were O
increased O
in O
DM O
groups O
. O
HbA1c O
level O
in O
DM12W O
group O

EtOH O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activation O
of O
ALDH2 B
with O
ethanol O
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats.This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 O
expression O
in O
the O
diabetic O
rat O
, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 O
activator O
ethanol O
( O
EtOH O
 O
. O
The O
rats O
were O
divided O
into O
six O
groups O
: O
control O
, O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O
week O
(DM12W) O
and O
EtOH+DM8W O
groups O
. O
Compared O
with O
control O
group O
, O
fasting O
blood O
glucose O
(FBG) O
and O
glycosylated O
hemoglobin O
(HbA1c) O
levels O
were O
increased O
in O
DM O
groups O
. O
HbA1c O
level O
in O
DM12W O
group O

EtOH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD B
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD O
and O
ALDH2 O
in O
EtOH O
DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O
. O
However O
, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O
be O
one O
key O
endogenous O
cardiac O
protective O
factor O
in O
diabetic O
individuals O
. O

EtOH O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 B
mRNA O
and O
protein O
levels O
were O
reduced O
, O
MDA O
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed O
. O
Compared O
with O
DM8W O
group O
, O
SOD O
and O
ALDH2 O
in O
EtOH O
DM8W O
group O
was O
increased O
, O
MDA O
was O
decreased O
. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes O
, O
myocardial O
ALDH2 O
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function O
. O
However O
, O
activation O
of O
ALDH2 O
can O
decrease O
diabetes O
induced O
myocardial O
injury O
. O
ALDH2 O
may O
be O
one O
key O
endogenous O
cardiac O
protective O
factor O
in O
diabetic O
individuals O
. O

EtOH O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
EtOH O
control O
, O
diabetic O
rat O
at O
4th O
week O
(DM4W) O
, O
8th O
week O
(DM8W) O
, O
12th O
week O
(DM12W) O
and O
EtOH+DM8W O
groups O
. O
Compared O
with O
control O
group O
, O
fasting O
blood O
glucose O
(FBG) O
and O
glycosylated O
hemoglobin O
(HbA1c) O
levels O
were O
increased O
in O
DM O
groups O
. O
HbA1c B
level O
in O
DM12W O
group O
was O
higher O
than O
in O
DM4W O
group O
, O
HbA1c O
level O
in O
EtOH O
DM8W O
group O
was O
lower O
than O
in O
DM8W O
group O
. O
Compared O
with O
control O
group O
, O
there O
were O
no O
changes O
of O
LVDP O
, O
HR O
and O
±dp/dtmax O
in O
DM4W O
group O
, O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups O
, O
and O
increased O
in O
the O
EtOH+DM8W O
group O
. O
In O
DM O
groups O
, O
SOD O
activity O
, O
ALDH2 O
mRNA O
and O
protein O
levels O

PHH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
considered O
as O
a O
sensitive O
, O
convenient O
and O
non-destructive O
approach O
for O
(i) O
evaluating O
EROD O
activity O
in O
liver O
, O
which O
was O
found O
to O
represent O
98% O
of O
the O
observed O
EROD O
activities O
in O
the O
three O
tested O
matrices O
and O
(ii) O
evaluating O
oral O
exposure O
of O
homogeneous O
groups O
of O
farm O
animals O
(race O
, O
diet) O
to O
CYP B
inducing O
PAH O
and O
PHH O

polycyclic O
aromatic O
hydrocarbons O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
EROD B
activity O
induction O
in O
peripheral O
blood O
lymphocytes O
, O
liver O
and O
brain O
tissues O
of O
rats O
orally O
exposed O
to O
polycyclic O
aromatic O
hydrocarbon O
.Little O
is O
known O
in O
terms O
of O
multi-matrix O
cytochrome O
P450 O
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated O
and O
polycyclic O
aromatic O
hydrocarbons O
(PHH O
, O
PAH) O
. O
In O
the O
present O
study O
, O
60 O
rats O
were O
daily O
exposed O
, O
during O
28days O
, O
to O
oral O
ingestion O
of O
a O
mixture O
consisting O
of O
phenanthrene O
, O
pyrene O
and O
benzo(a)pyrene O
at O

halogenated O
and O
polycyclic O
aromatic O
hydrocarbons O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
EROD O
activity O
induction O
in O
peripheral O
blood O
lymphocytes O
, O
liver O
and O
brain O
tissues O
of O
rats O
orally O
exposed O
to O
polycyclic O
aromatic O
hydrocarbons.Little O
is O
known O
in O
terms O
of O
multi-matrix O
cytochrome B
P450 I
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated O
and O
polycyclic O
aromatic O
hydrocarbons O
(PHH O
, O
PAH) O
. O
In O
the O
present O
study O
, O
60 O
rats O
were O
daily O
exposed O
, O
during O
28days O
, O
to O
oral O
ingestion O
of O
a O
mixture O
consisting O
of O
phenanthrene O
, O
pyrene O
and O
benzo(a)pyrene O
at O
0 O
, O
6 O
or O
600μg/day O
. O
EROD O
activity O
, O
reflecting O
almost O
exclusively O
CYP1A1 O
and O
CYP1B1 O
activities O
, O
was O
measured O
in O
brain O
and O
liver O
microsomes O
as O

PAH O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
EROD O
activity O
induction O
in O
peripheral O
blood O
lymphocytes O
, O
liver O
and O
brain O
tissues O
of O
rats O
orally O
exposed O
to O
polycyclic O
aromatic O
hydrocarbons.Little O
is O
known O
in O
terms O
of O
multi-matrix O
cytochrome B
P450 I
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated O
and O
polycyclic O
aromatic O
hydrocarbons O
(PHH O
, O
PAH O
 O
. O
In O
the O
present O
study O
, O
60 O
rats O
were O
daily O
exposed O
, O
during O
28days O
, O
to O
oral O
ingestion O
of O
a O
mixture O
consisting O
of O
phenanthrene O
, O
pyrene O
and O
benzo(a)pyrene O
at O
0 O
, O
6 O
or O
600μg/day O
. O
EROD O
activity O
, O
reflecting O
almost O
exclusively O
CYP1A1 O
and O
CYP1B1 O
activities O
, O
was O
measured O
in O
brain O
and O
liver O
microsomes O
as O
well O
as O
in O

1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
sulfate O
sodium-induced O
murine O
experimental O
colitis O
via O
inhibition O
of O
NLRP3 B
inflammasome.NLRP3 O
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis O
. O
However O
, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis O
. O
In O
the O
present O
study O
, O
we O
aimed O
at O
examining O
the O
effect O
of O
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole O
a O
synthetic O
small O
molecular O
compound O
also O
named O
Fc11a-2 O
, O
for O
the O
treatment O
of O
dextran O
sulfate O
sodium O
(DSS)-induced O
experimental O
colitis O
in O
mice O
via O
targeting O
NLRP3 O
inflammasome O
. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O

Fc11a-2 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
NLRP3 B
inflammasome.NLRP3 O
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis O
. O
However O
, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis O
. O
In O
the O
present O
study O
, O
we O
aimed O
at O
examining O
the O
effect O
of O
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole O
, O
a O
synthetic O
small O
molecular O
compound O
also O
named O
Fc11a-2 O
for O
the O
treatment O
of O
dextran O
sulfate O
sodium O
(DSS)-induced O
experimental O
colitis O
in O
mice O
via O
targeting O
NLRP3 O
inflammasome O
. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β B
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 B
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines B
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A B
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O

Fc11a-2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O

benzo[d]imidazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
A O
novel O
benzo[d]imidazol O
derivate O
prevents O
the O
development O
of O
dextran O
sulfate O
sodium-induced O
murine O
experimental O
colitis O
via O
inhibition O
of O
NLRP3 B
inflammasome.NLRP3 O
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis O
. O
However O
, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis O
. O
In O
the O
present O
study O
, O
we O

Fc11a O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 B
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a O
2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 O
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O

Fc11a-2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 B
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

Fc11a-2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O
Fc11a-2 O
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1 O
, O
pro-IL-1β O
and O
pro-IL-18 O
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 B
inflammasome O
. O
Taken O
together O
, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 O
to O
inhibit O
NLRP3 O
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases O
. O

Fc11a-2 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
treatment O
of O
dextran O
sulfate O
sodium O
(DSS)-induced O
experimental O
colitis O
in O
mice O
via O
targeting O
NLRP3 O
inflammasome O
. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS O
. O
In O
addition O
, O
the O
disease O
activity O
index O
, O
histopathologic O
scores O
and O
myeloperoxidase B
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 O
treatment O
. O
Moreover O
, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines O
in O
colon O
, O
including O
TNF-α O
, O
IL-1β O
, O
IL-18 O
, O
IL-17A O
and O
IFN-γ O
, O
were O
markedly O
suppressed O
by O
Fc11a-2 O
. O
Furthermore O
, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 O
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated O
mice O
. O
The O
mechanism O
of O
action O
of O

5-HT O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
functional O
SERT B
in O
blood O
cells O
suggests O
strict O
relationships O
between O
the O
nervous O
and O
the O
immune O
system O
that O
need O
to O
be O
better O
clarified O
in O
MD O
, O
as O
well O
as O
the O
possibility O
of O
reciprocal O
modulation O
of O
the O
two O
systems O
by O
different O
drugs O
. O
This O
paper O
aims O
to O
review O
briefly O
the O
literature O
on O
the O
5-HT O
hypothesis O
of O
depression O
with O
a O
major O
focus O
on O
the O
possible O
role O
of O
SERT O
in O
this O
disorder O
, O
while O
highlighting O
how O
recent O
data O
are O
more O
oriented O
on O
dimensional O
rather O
than O
nosological O
involvement O
of O
this O
structure O
in O
different O
conditions O
spanning O
from O
normality O
to O
pathology O
. O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 B
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase B
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa B
ribosomal I
protein I
S6 I
kinase I
1 I
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 B
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 B
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 B
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR B
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt B
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR B
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
fisetin O
treatment O
inhibits O
mTORC1 B
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Fisetin O
regulates O
obesity O
by O
targeting O
mTORC1 O
signaling.Fisetin O
, O
a O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian B
target I
of I
rapamycin I
complex I
1 I
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O

fisetin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Fisetin O
regulates O
obesity O
by O
targeting O
mTORC1 B
signaling.Fisetin O
, O
a O
flavonol O
present O
in O
vegetables O
and O
fruits O
, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties O
. O
In O
this O
study O
, O
we O
have O
demonstrated O
that O
fisetin O
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O

fisetin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
whether O
fisetin O
regulates O
mTORC1 B
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O

fisetin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR B
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O
in O
adipose O
tissue O
. O
Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin O
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice O
. O
Therefore O
, O
fisetin O
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity O
. O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 O
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 B
and O
mTORC1 O
in O
adipose O
tissue O
. O
Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin O
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice O
. O
Therefore O
, O
fisetin O
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity O
. O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides O
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 B
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O
in O
adipose O
tissue O
. O
Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin O
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice O
. O
Therefore O
, O
fisetin O
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity O
. O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mTORC1 B
signaling O
. O
Fisetin O
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue O
. O
We O
also O
observed O
that O
fisetin O
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt O
, O
S6K1 O
and O
mTORC1 O
in O
adipose O
tissue O
. O
Collectively O
, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 O
signaling O
by O
fisetin O
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice O
. O
Therefore O
, O
fisetin O
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity O
. O

Fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 O
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 B
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O

Fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
signaling O
of O
mammalian O
target O
of O
rapamycin O
complex O
1 O
(mTORC1) O
, O
a O
central O
mediator O
of O
cellular O
growth O
, O
cellular O
proliferation O
and O
lipid O
biosynthesis O
. O
To O
evaluate O
whether O
fisetin O
regulates O
mTORC1 B
signaling O
, O
we O
investigated O
the O
phosphorylation O
and O
kinase O
activity O
of O
the O
70-kDa O
ribosomal O
protein O
S6 O
kinase O
1 O
(S6K1) O
and O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mTORC1 B
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt O
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O

fisetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mTORC1 O
in O
3T3-L1 O
preadipocytes O
. O
Fisetin O
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 O
and O
mTORC1 O
in O
a O
time- O
and O
concentration-dependent O
manner O
. O
To O
further O
our O
understanding O
of O
how O
fisetin O
negatively O
regulates O
mTORC1 O
signaling O
, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1 O
, O
mTOR O
and O
Akt B
in O
fisetin-treated O
TSC2-knockdown O
cells O
. O
The O
results O
suggested O
that O
fisetin O
treatment O
inhibits O
mTORC1 O
activity O
in O
an O
Akt-dependent O
manner O
. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 O
activity O
. O
Fisetin O
treatment O
inhibited O
adipocyte O
differentiation O
, O
consistent O
with O
the O
negative O
effect O
of O
fisetin O
on O
mTOR O
. O
The O
inhibitory O
effect O
of O
fisetin O
on O
adipogenesis O
is O
dependent O
of O
mTOR O
activity O
, O
suggesting O
that O
fisetin O

amprenavir O
acts O
as O
NOT O
for O
what O
entity O
? O
PI O
, O
as O
a O
potent O
PXR-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR B
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O
Short-term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O
in O
PXR-deficient O
mice O
. O
Amprenavir-mediated O
PXR O
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O
in O
lipid O
homeostasis O
. O
These O
findings O
provide O
critical O
mechanistic O
insight O
for O
understanding O
the O
impact O
of O
PIs O
on O
cardiovascular O
disease O

amprenavir O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
important O
role O
in O
the O
regulation O
of O
lipid O
homeostasis O
. O
In O
the O
present O
study O
, O
we O
identified O
amprenavir O
, O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR B
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O
Short-term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O
in O
PXR-deficient O
mice O
. O
Amprenavir-mediated O
PXR O
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O

Amprenavir O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
binding O
pocket O
of O
PXR B
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O
Short-term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O
in O
PXR-deficient O
mice O
. O
Amprenavir O
mediated O
PXR O
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O
in O
lipid O
homeostasis O
. O
These O
findings O
provide O
critical O
mechanistic O
insight O
for O
understanding O
the O
impact O
of O
PIs O
on O
cardiovascular O
disease O
and O
demonstrate O
a O
potential O
role O
of O
PXR O
in O
mediating O
adverse O
effects O
of O
HIV O
PIs O
in O
humans O
. O

Amprenavir O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
role O
in O
the O
regulation O
of O
lipid O
homeostasis O
. O
In O
the O
present O
study O
, O
we O
identified O
amprenavir O
, O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR B
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O
Short-term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O
in O
PXR-deficient O
mice O
. O
Amprenavir-mediated O
PXR O
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O

Amprenavir O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
role O
in O
the O
regulation O
of O
lipid O
homeostasis O
. O
In O
the O
present O
study O
, O
we O
identified O
amprenavir O
, O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR B
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O
vivo O
. O
Short-term O
exposure O
to O
amprenavir O
significantly O
increased O
plasma O
total O
cholesterol O
and O
atherogenic O
low-density O
lipoprotein O
cholesterol O
levels O
in O
wild-type O
mice O
, O
but O
not O
in O
PXR-deficient O
mice O
. O
Amprenavir-mediated O
PXR O
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O

Amprenavir O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pregnane O
X O
Receptor O
Mediates O
Dyslipidemia O
Induced O
by O
the O
HIV B
Protease I
Inhibitor O
Amprenavi O
in O
Mice.HIV O
protease O
inhibitors O
(PIs) O
have O
been O
used O
successfully O
in O
extending O
the O
lifespan O
of O
people O
infected O
with O
HIV O
. O
The O
use O
of O
PIs O
has O
also O
been O
associated O
with O
dyslipidemia O
and O
an O
increased O
risk O
of O
cardiovascular O
disease O
but O
the O
underlying O
mechanisms O
remain O
elusive O
. O
Several O
PIs O
have O
been O
implicated O
to O
activate O
the O

amprenavir O
acts O
as O
AGONIST O
for O
what O
entity O
? O
been O
implicated O
to O
activate O
the O
nuclear O
receptor O
pregnane O
X O
receptor O
(PXR) O
, O
which O
acts O
as O
a O
xenobiotic O
sensor O
to O
regulate O
xenobiotic O
metabolism O
in O
the O
liver O
and O
intestine O
. O
Recent O
studies O
indicate O
that O
PXR B
may O
also O
play O
an O
important O
role O
in O
the O
regulation O
of O
lipid O
homeostasis O
. O
In O
the O
present O
study O
, O
we O
identified O
amprenavir O
a O
widely O
used O
HIV O
PI O
, O
as O
a O
potent O
PXR-selective O
agonist O
. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR O
that O
constitute O
points O
of O
interaction O
with O
amprenavir O
. O
Amprenavir O
efficiently O
activated O
PXR O
and O
induced O
PXR O
target O
gene O
expression O
in O
vitro O
and O
in O

tranexamic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic O
Acid.Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention O
. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles O
. O
One O
exception O
is O
tranexamic O
acid O
(TXA) O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen B
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O

tranexamic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic O
Acid.Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention O
. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles O
. O
One O
exception O
is O
tranexamic O
acid O
(TXA) O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen O
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O

TXA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic O
Acid.Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention O
. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles O
. O
One O
exception O
is O
tranexamic O
acid O
( O
TXA O
 O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen B
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O

TXA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic O
Acid.Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention O
. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles O
. O
One O
exception O
is O
tranexamic O
acid O
( O
TXA O
 O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen O
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O

lysine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic O
Acid.Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention O
. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles O
. O
One O
exception O
is O
tranexamic O
acid O
(TXA) O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen B
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O
computational O
technique O
with O
a O
high-quality O

lysine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic O
Acid.Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention O
. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles O
. O
One O
exception O
is O
tranexamic O
acid O
(TXA) O
, O
which O
, O
as O
a O
lysine O
mimetic O
, O
inhibits O
binding O
of O
plasminogen O
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O
computational O
technique O
with O
a O
high-quality O

5-(4-piperidyl)-3-isoxazolol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
plasminogen B
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O
computational O
technique O
with O
a O
high-quality O
low-throughput O
screen O
identified O
5-(4-piperidyl)-3-isoxazolol O
(4-PIOL) O
as O
a O
potent O
plasminogen O
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders O
. O
Remarkably O
, O
4-PIOL O
was O
found O
to O
be O
more O
than O
four O
times O
as O
potent O
as O
the O
drug O
TXA O
. O

4-PIOL O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
fibrin O
. O
However O
, O
the O
daily O
dose O
of O
TXA O
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties O
. O
In O
this O
study O
, O
we O
report O
a O
computational O
approach O
, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA O
. O
Coupling O
this O
computational O
technique O
with O
a O
high-quality O
low-throughput O
screen O
identified O
5-(4-piperidyl)-3-isoxazolol O
( O
4-PIOL O
as O
a O
potent O
plasminogen B
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders O
. O
Remarkably O
, O
4-PIOL O
was O
found O
to O
be O
more O
than O
four O
times O
as O
potent O
as O
the O
drug O
TXA O
. O

dihydropteridinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Design O
and O
synthesis O
of O
highly O
selective O
, O
orally O
active O
Polo-like O
kinase-2 O
(Plk-2) O
inhibitors.Polo-like O
kinase-2 O
(Plk-2) O
is O
a O
potential O
therapeutic O
target O
for O
Parkinson's O
disease O
and O
this O
Letter O
describes O
the O
SAR O
of O
a O
series O
of O
dihydropteridinone O
based O
Plk-2 B
inhibitors O
. O
By O
optimizing O
both O
the O
N-8 O
substituent O
and O
the O
biaryl O
region O
of O
the O
inhibitors O
we O
obtained O
single O
digit O
nanomolar O
compounds O
such O
as O
37 O
with O
excellent O
selectivity O
for O
Plk-2 O
over O
Plk-1 O
. O
When O
dosed O
orally O
in O
rats O
, O
compound O
37 O
demonstrated O
a O
41-45% O
reduction O
of O
pS129-α-synuclein O
levels O
in O
the O
cerebral O

DZN O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
release O
to O
the O
cytosol O
and O
activation O
caspase B
3 I
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

Crocin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase B
3 I
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O

DZN O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
phosphokinase O
MB O
(CK-MB) O
, O
malondealdehyde O
(MDA) O
and O
glutathione O
(GSH) O
levels O
were O
evaluated O
in O
heart O
tissue O
at O
the O
end O
of O
treatments O
. O
Levels O
of O
apoptotic O
proteins O
(Bax O
, O
Bcl2 O
, O
caspase O
3) O
and O
cytosolic O
cytochrome O
c O
were O
analyzed O
by O
Western O
blotting O
. O
Transcript O
levels O
of O
Bax O
and O
Bcl2 O
were O
also O
determined O
using O
qRT O
PCR O
. O
RESULTS O
: O
DZN O
induced O
histophatological O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O

vitamin O
E O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase B
3 I
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O

DZN O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome B
c I
to O
the O
cytosol O
induced O
by O
DZN O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

DZN O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

Crocin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome B
c I
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O

DZN O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O
antioxidant O
, O
showed O
protective O
effects O
against O
DZN O
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis O
. O

Crocin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O

Crocin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O

Crocin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O

vitamin O
E O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O

vitamin O
E O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O

vitamin O
E O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
cardiac O
marker O
CK-MB O
. O
These O
effects O
were O
associated O
with O
increased O
MDA O
level O
, O
lower O
level O
of O
reduced O
GSH O
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 O
ratio O
(both O
protein O
and O
mRNA O
levels) O
, O
cytochrome O
c O
release O
to O
the O
cytosol O
and O
activation O
caspase O
3 O
in O
cardiac O
tissue O
. O
Crocin O
(25 O
and O
50mg/kg) O
or O
vitamin O
E O
improved O
histopathological O
damages O
, O
decreased O
MDA O
and O
CK-MB O
, O
increased O
GSH O
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 O
ratio O
, O
activation O
of O
caspase O
3 O
and O
release O
of O
cytochrome O
c O
to O
the O
cytosol O
induced O
by O
DZN O
. O
In O
summary O
, O
DZN O
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure O
. O
Crocin O
, O
as O
an O

Cobalt O
chloride O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
between O
CAR B
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
a O
typical O
HIF O
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O

Phenobarbital O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF B

Cobalt O
chloride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
between O
CAR B
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
a O
typical O
HIF O
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O

Cobalt O
chloride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
a O
typical O
HIF O
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive B
enhancer I
module I
with O
HIF-1α O

Phenobarbital O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR B
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF O

Cobalt O
chloride O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
a O
typical O
HIF B
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O

Phenobarbital O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF O

Phenobarbital O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme B
oxygenase-1 I
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF O

Phenobarbital O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
expression.Hypoxia O
inducible O
factor O
(HIF) O
and O
5'-AMP-activated O
protein O
kinase O
are O
often O
activated O
under O
similar O
physiological O
conditions O
. O
Constitutive O
androstane O
receptor O
(CAR) O
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated O
protein O
kinase O
and O
thus O
confers O
transactivation O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
, O
a O
typical O
HIF O

Cobalt O
chloride O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
a O
typical O
HIF O
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 B
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O

Cobalt O
chloride O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
between O
CAR O
and O
HIFα O
. O
Phenobarbital O
(PB) O
, O
a O
typical O
CAR O
activator O
, O
increased O
the O
gene O
expression O
of O
HIF-target O
genes O
in O
the O
livers O
of O
mice O
, O
including O
erythropoietin O
, O
heme O
oxygenase-1 O
and O
vascular O
endothelial O
growth O
factor-a O
. O
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α O
and O
an O
increase O
in O
the O
HIF-responsive O
element-mediated O
transactivation O
in O
HepG2 O
cells O
. O
Cobalt O
chloride O
a O
typical O
HIF O
activator O
, O
induced O
the O
gene O
expression O
of O
CAR-target O
genes O
, O
including O
cyp2b9 O
and O
cyp2b10 O
, O
an O
accumulation O
of O
nuclear O
CAR O
and O
an O
increase O
in O
the O
PB-responsive O
enhancer O
module-mediated O
transactivation O
in O
the O
mouse O
liver O
. O
Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR O
binds O
to O
the O
PB-responsive O
enhancer O
module O
with O
HIF-1α O

CGP O
acts O
as O
NOT O
for O
what O
entity O
? O
by O
>50% O
(III-1 O
, O
V-3 O
, O
-4 O
, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23% O
. O
These O
five O
CGPs O
also O
inhibited O
[(3)H]E217βG O
uptake O
by O
MRP4 O
. O
In O
contrast O
, O
their O
effects O
on O
MRP2 B
varied O
with O
two O
(V-4 O
, O
V-6) O
inhibiting O
E217βG O
transport O
(IC50's O
2.0 O
, O
9.2 O
μM) O
, O
two O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O
structurally O
identical O
except O
for O
their O
chalcogen O
atom O
(Se O
versus O
Te) O
. O
This O
study O
is O
the O
first O
to O
identify O
Class O
V O
CGPs O
with O
their O
distinctive O
methine O
or O
trimethine O
linkage O
between O
two O
disubstituted O
pyrylium O
moieties O

CGPs O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Chalcogenopyrylium O
Dyes O
as O
Differential O
Modulators O
of O
Organic O
Anion O
Transport O
by O
MRP1 O
, O
MRP2 O
and O
MRP4.Multidrug O
resistance O
proteins O
(MRPs) O
mediate O
the O
ATP-dependent O
efflux O
of O
structurally O
diverse O
compounds O
, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
( O
CGPs O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP B
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O

methine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
μM) O
, O
two O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O
structurally O
identical O
except O
for O
their O
chalcogen O
atom O
(Se O
versus O
Te) O
. O
This O
study O
is O
the O
first O
to O
identify O
Class O
V O
CGPs O
with O
their O
distinctive O
methine O
or O
trimethine O
linkage O
between O
two O
disubstituted O
pyrylium O
moieties O
as O
a O
particularly O
potent O
class O
of O
MRP B
modulators O
and O
also O
show O
that O
within O
this O
core O
structure O
, O
differences O
in O
the O
electronegativity O
associated O
with O
a O
chalcogen O
atom O
can O
be O
the O
sole O
determinant O
of O
whether O
a O
compound O
will O
stimulate O
or O
inhibit O
MRP2 O
. O

trimethine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O
structurally O
identical O
except O
for O
their O
chalcogen O
atom O
(Se O
versus O
Te) O
. O
This O
study O
is O
the O
first O
to O
identify O
Class O
V O
CGPs O
with O
their O
distinctive O
methine O
or O
trimethine O
linkage O
between O
two O
disubstituted O
pyrylium O
moieties O
as O
a O
particularly O
potent O
class O
of O
MRP B
modulators O
and O
also O
show O
that O
within O
this O
core O
structure O
, O
differences O
in O
the O
electronegativity O
associated O
with O
a O
chalcogen O
atom O
can O
be O
the O
sole O
determinant O
of O
whether O
a O
compound O
will O
stimulate O
or O
inhibit O
MRP2 O
. O

pyrylium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O
structurally O
identical O
except O
for O
their O
chalcogen O
atom O
(Se O
versus O
Te) O
. O
This O
study O
is O
the O
first O
to O
identify O
Class O
V O
CGPs O
with O
their O
distinctive O
methine O
or O
trimethine O
linkage O
between O
two O
disubstituted O
pyrylium O
moieties O
as O
a O
particularly O
potent O
class O
of O
MRP B
modulators O
and O
also O
show O
that O
within O
this O
core O
structure O
, O
differences O
in O
the O
electronegativity O
associated O
with O
a O
chalcogen O
atom O
can O
be O
the O
sole O
determinant O
of O
whether O
a O
compound O
will O
stimulate O
or O
inhibit O
MRP2 O
. O

chalcogenopyrylium O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Chalcogenopyrylium O
Dyes O
as O
Differential O
Modulators O
of O
Organic O
Anion O
Transport O
by O
MRP1 O
, O
MRP2 O
and O
MRP4.Multidrug O
resistance O
proteins O
(MRPs) O
mediate O
the O
ATP-dependent O
efflux O
of O
structurally O
diverse O
compounds O
, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP B
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O

CGPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP O
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O

CGPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O
>50% O
(III-1 O
, O
V-3 O
, O
-4 O
, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23% O
. O
These O
five O
CGPs O
also O
inhibited O
[(3)H]E217βG O
uptake O
by O
MRP4 O
. O
In O
contrast O
, O
their O
effects O
on O
MRP2 O
varied O
with O
two O
(V-4 O
, O
V-6) O
inhibiting O
E217βG O
transport O
(IC50's O
2.0 O
, O
9.2 O
μM) O
, O

CGPs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
two O
belonged O
to O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O
>50% O
(III-1 O
, O
V-3 O
, O
-4 O
, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23% O
. O
These O
five O
CGPs O
also O
inhibited O
[(3)H]E217βG O
uptake O
by O
MRP4 O
. O
In O
contrast O
, O
their O
effects O
on O
MRP2 O
varied O
with O
two O
(V-4 O
, O
V-6) O
inhibiting O
E217βG O
transport O
(IC50's O
2.0 O
, O
9.2 O
μM) O
, O
two O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O

[(3)H]estradiol O
glucuronide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Chalcogenopyrylium O
Dyes O
as O
Differential O
Modulators O
of O
Organic O
Anion O
Transport O
by O
MRP1 O
, O
MRP2 O
and O
MRP4.Multidrug O
resistance O
proteins O
(MRPs) O
mediate O
the O
ATP-dependent O
efflux O
of O
structurally O
diverse O
compounds O
, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP B
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O

E217βG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Dyes O
as O
Differential O
Modulators O
of O
Organic O
Anion O
Transport O
by O
MRP1 O
, O
MRP2 O
and O
MRP4.Multidrug O
resistance O
proteins O
(MRPs) O
mediate O
the O
ATP-dependent O
efflux O
of O
structurally O
diverse O
compounds O
, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
( O
E217βG O
(a O
prototypical O
MRP B
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O
two O

E217βG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
organic O
anions O
. O
Five O
classes O
of O
chalcogenopyrylium O
dyes O
(CGPs) O
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol O
glucuronide O
(E217βG) O
(a O
prototypical O
MRP O
substrate) O
into O
MRP-enriched O
inside-out O
membrane O
vesicles O
. O
Additionally O
, O
some O
CGPs O
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein O
efflux O
assay O
. O
Sixteen O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O
>50% O
(III-1 O
, O
V-3 O
, O

calcein O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
34 O
CGPs O
inhibited O
MRP1-mediated O
E217βG O
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM) O
. O
Of O
9 O
CGPs O
with O
IC50's O
≤2 O
μM O
, O
two O
belonged O
to O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O
>50% O
(III-1 O
, O
V-3 O
, O
-4 O
, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23% O
. O
These O
five O
CGPs O
also O
inhibited O
[(3)H]E217βG O
uptake O
by O
MRP4 O
. O
In O
contrast O
, O
their O
effects O
on O
MRP2 O
varied O
with O
two O
(V-4 O
, O
V-6) O
inhibiting O
E217βG O
transport O
(IC50's O
2.0 O
, O
9.2 O
μM) O
, O
two O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O

[(3)H]E217βG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Class O
I O
, O
two O
to O
Class O
III O
and O
five O
to O
Class O
V O
. O
When O
tested O
in O
the O
intact O
cells O
, O
only O
4 O
of O
16 O
CGPs O
(at O
10 O
μM) O
inhibited O
MRP1-mediated O
calcein O
efflux O
by O
>50% O
(III-1 O
, O
V-3 O
, O
-4 O
, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23% O
. O
These O
five O
CGPs O
also O
inhibited O
[(3)H]E217βG O
uptake O
by O
MRP4 O
. O
In O
contrast O
, O
their O
effects O
on O
MRP2 O
varied O
with O
two O
(V-4 O
, O
V-6) O
inhibiting O
E217βG O
transport O
(IC50's O
2.0 O
, O
9.2 O
μM) O
, O
two O
(V-3 O
, O
III-1) O
stimulating O
transport O
(>2-fold) O
, O
while O
CGP O
I-5 O
had O
no O
effect O
. O
Strikingly O
, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 O
activity O
, O
they O
are O
structurally O
identical O
except O

LBH589 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
PCR O
(RT-PCR); O
NIS B
promoter O
activity O
was O
determined O
with O
a O
luciferase O
reporter O
assay; O
and O
protein O
expression O
was O
assessed O
through O
immunofluorescence O
. O
We O
tested O
the O
protein O
function O
by O
125I O
uptake O
and O
efflux O
experiments; O
finally O
the O
cytotoxic O
effect O
of O
131I O
was O
determined O
with O
a O
clonogenic O
assay O
. O
Results O
: O
Our O
results O
demonstrate O
that O
treatment O
with O
LBH589 O
leads O
to O
NIS O
RNA O
expression O
as O
shown O
by O
RT-PCR O
and O
luciferase O
assay O
, O
and O
to O
protein O
expression O
as O
determined O
by O
immunofluorescence O
in O
vitro O
and O
by O
immunohistochemistry O
in O
xenograft O
tumors O
. O
Moreover O
, O
125I O
uptake O
and O
efflux O
experiments O
show O
the O
correct O
protein O
function O
and O
iodine O
retention O
, O
that O
translate O
into O
cytotoxicity O
effects O
, O
as O
demonstrated O

LBH589 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
cancer O
. O
Histone O
deacetylase O
inhibitors O
have O
been O
demonstrated O
as O
potent O
anticancer O
drugs O
with O
several O
different O
effects O
on O
cell O
viability O
and O
differentiation O
. O
Methods O
: O
Stabilized O
anaplastic O
thyroid O
cancer O
cell O
lines O
(BHT-101 O
and O
CAL-62) O
and O
primary O
cultures O
from O
patients O
who O
underwent O
thyroidectomy O
for O
anaplastic O
thyroid O
cancer O
were O
treated O
with O
the O
histone B
deacetylase I
inhibitor O
LBH589 O
After O
treatment O
, O
we O
evaluated O
the O
expression O
and O
function O
of O
NIS O
. O
Gene O
expression O
was O
evaluated O
by O
real-time O
PCR O
(RT-PCR); O
NIS O
promoter O
activity O
was O
determined O
with O
a O
luciferase O
reporter O
assay; O
and O
protein O
expression O
was O
assessed O
through O
immunofluorescence O
. O
We O
tested O
the O
protein O
function O
by O
125I O
uptake O
and O
efflux O
experiments; O
finally O
the O
cytotoxic O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
platelets O
. O
Recently O
, O
it O
has O
been O
shown O
that O
differential O
promoter O
usage O
in O
tissues O
results O
in O
expression O
of O
five O
OATP2B1 O
transcriptional O
start O
site O
variants O
which O
utilize O
distinct O
first O
exons O
but O
share O
common O
subsequent O
exons O
. O
These O
variants O
are O
expected O
to O
encode O
either O
a O
full O
length O
(OATP2B1-FL) O
or O
shortened O
protein O
lacking O
22 O
N O
terminus O
amino O
acids O
(OATP2B-Short) O
. O
Little O
is O
known O
regarding O
the O
transport O
activity O
and O
regulation O
of O
OATP2B1 O
variants O
with O
N-terminus O
truncation O
. O
Here O
, O
using O
absolute O
quantitative O
polymerase O
chain O
reaction O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver O
. O
Using O
a O
transient O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
platelets O
. O
Recently O
, O
it O
has O
been O
shown O
that O
differential O
promoter O
usage O
in O
tissues O
results O
in O
expression O
of O
five O
OATP2B1 O
transcriptional O
start O
site O
variants O
which O
utilize O
distinct O
first O
exons O
but O
share O
common O
subsequent O
exons O
. O
These O
variants O
are O
expected O
to O
encode O
either O
a O
full O
length O
(OATP2B1-FL) O
or O
shortened O
protein O
lacking O
22 O
N O
terminus O
amino O
acids O
(OATP2B-Short) O
. O
Little O
is O
known O
regarding O
the O
transport O
activity O
and O
regulation O
of O
OATP2B1 O
variants O
with O
N-terminus O
truncation O
. O
Here O
, O
using O
absolute O
quantitative O
polymerase O
chain O
reaction O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver O
. O
Using O
a O
transient O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
platelets O
. O
Recently O
, O
it O
has O
been O
shown O
that O
differential O
promoter O
usage O
in O
tissues O
results O
in O
expression O
of O
five O
OATP2B1 O
transcriptional O
start O
site O
variants O
which O
utilize O
distinct O
first O
exons O
but O
share O
common O
subsequent O
exons O
. O
These O
variants O
are O
expected O
to O
encode O
either O
a O
full O
length O
(OATP2B1-FL) O
or O
shortened O
protein O
lacking O
22 O
N-terminus O
amino O
acids O
(OATP2B-Short) O
. O
Little O
is O
known O
regarding O
the O
transport O
activity O
and O
regulation O
of O
OATP2B1 O
variants O
with O
N-terminus O
truncation O
. O
Here O
, O
using O
absolute O
quantitative O
polymerase O
chain O
reaction O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver O
. O
Using O
a O
transient O
heterologous O
cell O
expression O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
five O
OATP2B1 B
transcriptional O
start O
site O
variants O
which O
utilize O
distinct O
first O
exons O
but O
share O
common O
subsequent O
exons O
. O
These O
variants O
are O
expected O
to O
encode O
either O
a O
full O
length O
(OATP2B1-FL) O
or O
shortened O
protein O
lacking O
22 O
N-terminus O
amino O
acids O
(OATP2B-Short) O
. O
Little O
is O
known O
regarding O
the O
transport O
activity O
and O
regulation O
of O
OATP2B1 O
variants O
with O
N O
terminus O
truncation O
. O
Here O
, O
using O
absolute O
quantitative O
polymerase O
chain O
reaction O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver O
. O
Using O
a O
transient O
heterologous O
cell O
expression O
system O
, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short O
OATP2B1 O
variant O
towards O
substrates O

estrone O
sulfate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
N-terminus O
truncation O
. O
Here O
, O
using O
absolute O
quantitative O
polymerase O
chain O
reaction O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver O
. O
Using O
a O
transient O
heterologous O
cell O
expression O
system O
, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short B
OATP2B1 I
variant O
towards O
substrates O
estrone O
sulfate O
and O
rosuvastatin O
are O
similar O
to O
the O
well-characterized O
full O
length O
variant O
. O
Transcriptional O
activity O
screening O
of O
the O
liver O
enriched O
OATP2B1 O
variant O
promoter O
identified O
hepatocyte O
nuclear O
factor O
4 O
alpha O
(HNF4α) O
as O
a O
novel O
transacting O
factor O
. O
With O
a O
combination O
of O
in O
silico O
screening O
, O
promoter O
mutation O
in O
cell-based O
reporter O
assays O
, O
siRNA O
knockdown O
and O
chromatin O

rosuvastatin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
using O
absolute O
quantitative O
polymerase O
chain O
reaction O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver O
. O
Using O
a O
transient O
heterologous O
cell O
expression O
system O
, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short B
OATP2B1 I
variant O
towards O
substrates O
estrone O
sulfate O
and O
rosuvastatin O
are O
similar O
to O
the O
well-characterized O
full O
length O
variant O
. O
Transcriptional O
activity O
screening O
of O
the O
liver O
enriched O
OATP2B1 O
variant O
promoter O
identified O
hepatocyte O
nuclear O
factor O
4 O
alpha O
(HNF4α) O
as O
a O
novel O
transacting O
factor O
. O
With O
a O
combination O
of O
in O
silico O
screening O
, O
promoter O
mutation O
in O
cell-based O
reporter O
assays O
, O
siRNA O
knockdown O
and O
chromatin O
immunoprecipitation O
studies O
, O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(ΔDHEA-S) O
responses O
were O
evaluated O
. O
Forty-one O
patients O
[22 O
females O
, O
49.5 O
± O
15.2 O
years O
old O
, O
32 O
Graves O
disease O
, O
nine O
toxic O
nodular O
goiter] O
had O
similar O
Cor0 O
, O
DHEA-S0 O
, O
CFC O
, O
FCI O
, O
and O
DHEA-S60 O
in O
hyperthyroid O
and O
euthyroid O
states O
. O
Cor60 O
, O
ΔCor O
, O
and O
ΔDHEA-S O
were O
lower O
in O
hyperthyroidism O
. O
In O
four O
(10 O
%) O
patients O
the O
peak O
ACTH-stimulated O
cortisol O
values O
were O
lower O
than O
18 O
μg/dL O
. O
When O
the O
test O
repeated O
after O
attainment O
of O
euthyroidism O
, O
all O
of O
the O
patients O
had O
normal O
cortisol O
response O
. O
Regression O
analysis O
demonstrated O
an O
independent O
association O
of O
Cor60 O
with O
free O
T3 O
in O
hyperthyroidism O
. O
However O
, O
the O
predictors O
of O
CFC O
, O
FCI O
, O
and O
DHEA-S O
levels O
were O
serum O
creatinine O
levels O
in O

cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
attainment O
of O
euthyroidism O
, O
all O
of O
the O
patients O
had O
normal O
cortisol O
response O
. O
Regression O
analysis O
demonstrated O
an O
independent O
association O
of O
Cor60 O
with O
free O
T3 O
in O
hyperthyroidism O
. O
However O
, O
the O
predictors O
of O
CFC O
, O
FCI O
, O
and O
DHEA-S O
levels O
were O
serum O
creatinine O
levels O
in O
hyperthyroidism O
, O
and O
both O
creatinine O
and O
transaminase O
levels O
in O
euthyroidism O
. O
ACTH-stimulated O
peak O
cortisol O
delta O
cortisol O
, O
and O
delta O
DHEA-S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O
Since O
about O
10 O
% O
of O
the O
subjects O
with O
hyperthyroidism O
are O
at O
risk O
for O
adrenal O
insufficiency O
, O
clinicians O
dealing O
with O
Graves' O
disease O
should O
be O
alert O
to O
the O
possibility O
of O
adrenal O
insufficiency O
during O
hyperthyroid O
stage O
. O

delta O
cortisol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
euthyroidism O
, O
all O
of O
the O
patients O
had O
normal O
cortisol O
response O
. O
Regression O
analysis O
demonstrated O
an O
independent O
association O
of O
Cor60 O
with O
free O
T3 O
in O
hyperthyroidism O
. O
However O
, O
the O
predictors O
of O
CFC O
, O
FCI O
, O
and O
DHEA-S O
levels O
were O
serum O
creatinine O
levels O
in O
hyperthyroidism O
, O
and O
both O
creatinine O
and O
transaminase O
levels O
in O
euthyroidism O
. O
ACTH-stimulated O
peak O
cortisol O
, O
delta O
cortisol O
and O
delta O
DHEA-S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O
Since O
about O
10 O
% O
of O
the O
subjects O
with O
hyperthyroidism O
are O
at O
risk O
for O
adrenal O
insufficiency O
, O
clinicians O
dealing O
with O
Graves' O
disease O
should O
be O
alert O
to O
the O
possibility O
of O
adrenal O
insufficiency O
during O
hyperthyroid O
stage O
. O

delta O
DHEA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
the O
patients O
had O
normal O
cortisol O
response O
. O
Regression O
analysis O
demonstrated O
an O
independent O
association O
of O
Cor60 O
with O
free O
T3 O
in O
hyperthyroidism O
. O
However O
, O
the O
predictors O
of O
CFC O
, O
FCI O
, O
and O
DHEA-S O
levels O
were O
serum O
creatinine O
levels O
in O
hyperthyroidism O
, O
and O
both O
creatinine O
and O
transaminase O
levels O
in O
euthyroidism O
. O
ACTH-stimulated O
peak O
cortisol O
, O
delta O
cortisol O
, O
and O
delta O
DHEA O
S O
levels O
are O
decreased O
during O
hyperthyroidism O
, O
probably O
due O
to O
increased O
turnover O
. O
Since O
about O
10 O
% O
of O
the O
subjects O
with O
hyperthyroidism O
are O
at O
risk O
for O
adrenal O
insufficiency O
, O
clinicians O
dealing O
with O
Graves' O
disease O
should O
be O
alert O
to O
the O
possibility O
of O
adrenal O
insufficiency O
during O
hyperthyroid O
stage O
. O

fluorescein O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B B
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O
the O
relationships O
between O
receptor O
localisation O
and O
physiological O
importance O
. O
Ifenprodil O
, O
known O
as O
the O
GluNR2B O
antagonist O
of O
reference O
, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes O
. O
We O
had O
previously O
reported O
a O
fluorescein O
conjugate O
that O
was O
shown O
(by O
confocal O
microscopy O
imaging O
of O
DS-red-labelled O
cortical O
neurons) O
to O
bind O
specifically O
to O
GluN2B O
. O
To O
elaborate O
this O
probe O
, O
we O
explored O
the O
influence O
of O
both O
the O
nature O
and O
the O
attachment O
point O
of O
the O
spacer O
between O
the O
fluorophore O
and O
the O
parent O
compound O
, O
ifenprodil O
. O
We O
performed O
chemical O
modifications O
of O

Ifenprodil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodi O
-Based O
Fluorescein O
Conjugates O
as O
GluN1/GluN2B O
N-Methyl-D-aspartate O
Receptor O
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O

Ifenprodil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodi O
-Based O
Fluorescein O
Conjugates O
as O
GluN1/GluN2B O
N-Methyl-D-aspartate O
Receptor O
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B B
subunit O
selectively O
in O
order O
to O
allow O
better O

Ifenprodil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodi O
-Based O
Fluorescein O
Conjugates O
as O
GluN1/GluN2B O
N-Methyl-D-aspartate B
Receptor I
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O

Fluorescein O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil-Based O
Fluorescei O
Conjugates O
as O
GluN1/GluN2B O
N-Methyl-D-aspartate O
Receptor O
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O

Fluorescein O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil-Based O
Fluorescei O
Conjugates O
as O
GluN1/GluN2B O
N-Methyl-D-aspartate O
Receptor O
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B B
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O

Fluorescein O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil-Based O
Fluorescei O
Conjugates O
as O
GluN1/GluN2B O
N-Methyl-D-aspartate B
Receptor I
Antagonists.GluN2B-containing O
NMDA O
receptors O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O

Ifenprodil O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders O
. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B O
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O
the O
relationships O
between O
receptor O
localisation O
and O
physiological O
importance O
. O
Ifenprodil O
known O
as O
the O
GluNR2B B
antagonist O
of O
reference O
, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes O
. O
We O
had O
previously O
reported O
a O
fluorescein O
conjugate O
that O
was O
shown O
(by O
confocal O
microscopy O
imaging O
of O
DS-red-labelled O
cortical O
neurons) O
to O
bind O
specifically O
to O
GluN2B O
. O
To O
elaborate O
this O
probe O
, O
we O
explored O
the O
influence O
of O

nitrooxyalkyl O
ester O
and O
ether O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
on O
compounds O
9a,c O
and O
17a O
highlighted O
good O
anti-inflammatory O
and O
antinociceptive O
activities O
. O
Compound O
9c O
was O
able O
to O
inhibit O
glycosaminoglycan O
(GAG) O
release O
induced O
by O
interleukin-1β O
(IL-1β) O
, O
showing O
cartilage O
protective O
properties O
. O
Finally O
, O
molecular O
modeling O
and O
(1)H- O
and O
(13)C-NMR O
studies O
performed O
on O
compounds O
6c,d O
, O
9c O
, O
and O
10b O
allowed O
the O
right O
conformation O
of O
nitrooxyalkyl O
ester O
and O
ether O
side O
chain O
of O
these O
molecules O
within O
the O
COX-2 B
active O
site O
to O
be O
assessed O
. O

Nitrooxy O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 B
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O
while O
most O
of O
the O
compounds O
proved O
to O
be O
very O
potent O
and O
selective O
COX-2 O
inhibitors O
in O
in O
vitro O
experimental O
models O
. O
Further O
in O
vivo O
studies O
on O
compounds O
9a,c O
and O
17a O
highlighted O
good O
anti-inflammatory O
and O
antinociceptive O
activities O
. O
Compound O
9c O
was O
able O
to O
inhibit O
glycosaminoglycan O
(GAG) O
release O
induced O

nitric O
oxide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 B
inhibiting O
nitric O
oxid O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 O
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O

1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ether O
and O
related O
compounds O
as O
cyclooxygenase-2 B
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 O
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O

pyrrole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 O
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole O
derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 B
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O

nitrooxyalkyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 O
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 B
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O
while O
most O

esters O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 O
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 B
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O
while O
most O
of O
the O

carbonates O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 O
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
and O
ethers O
(7-10) O
as O
COX-2 B
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O
while O
most O
of O
the O
compounds O

ethers O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Novel O
analgesic/anti-inflammatory O
agents O
: O
1,5-diarylpyrrole O
nitrooxyalkyl O
ethers O
and O
related O
compounds O
as O
cyclooxygenase-2 O
inhibiting O
nitric O
oxide O
donors.A O
series O
of O
3-substituted O
1,5-diarylpyrroles O
bearing O
a O
nitrooxyalkyl O
side O
chain O
linked O
to O
different O
spacers O
were O
designed O
. O
New O
classes O
of O
pyrrole-derived O
nitrooxyalkyl O
inverse O
esters O
, O
carbonates O
, O
and O
ethers O
(7-10) O
as O
COX-2 B
selective O
inhibitors O
and O
NO O
donors O
were O
synthesized O
and O
are O
herein O
reported O
. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl O
ethers O
(9 O
, O
10) O
into O
corresponding O
alcohols O
, O
derivatives O
17 O
and O
18 O
were O
also O
studied O
. O
Nitrooxy O
derivatives O
showed O
NO-dependent O
vasorelaxing O
properties O
, O
while O
most O
of O
the O
compounds O
proved O
to O

pyripyropene O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
structure-activity O
relationship O
of O
pyripyropene O
derivatives O
as O
potent O
and O
selective O
acyl-CoA:cholesterol B
acyltransferase I
2 I
(ACAT2) O
inhibitors O
: O
Part O
2.Synthesis O
and O
structure-activity O
relationships O
of O
7-O-p-cyanobenzoyl O
pyripyropene O
A O
derivatives O
with O
modification O
at O
C1 O
and O
11 O
are O
described O
. O
Regioselective O
mono-deprotection O
of O
di-tert-butylsilylene O
acetal O
was O
critical O
in O
their O
synthesis O
. O

pyripyropene O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
structure-activity O
relationship O
of O
pyripyropene O
derivatives O
as O
potent O
and O
selective O
acyl-CoA:cholesterol O
acyltransferase O
2 O
(ACAT2) O
inhibitors O
: O
Part O
2.Synthesis O
and O
structure-activity O
relationships O
of O
7-O-p-cyanobenzoyl O
pyripyropene O
A O
derivatives O
with O
modification O
at O
C1 O
and O
11 O
are O
described O
. O
Regioselective O
mono-deprotection O
of O
di-tert-butylsilylene O
acetal O
was O
critical O
in O
their O
synthesis O
. O

saxitoxin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
PST O
production O
in O
freshwater O
systems O
, O
while O
eukaryotic O
dinoflagellates O
are O
the O
main O
producers O
in O
marine O
waters O
. O
Bioaccumulation O
by O
filter-feeding O
bivalves O
and O
fish O
and O
subsequent O
transfer O
through O
the O
food O
web O
results O
in O
the O
potentially O
fatal O
human O
illnesses O
, O
paralytic O
shellfish O
poisoning O
and O
saxitoxin O
pufferfish O
poisoning O
. O
These O
illnesses O
are O
a O
result O
of O
saxitoxin O
s O
ability O
to O
bind O
to O
the O
voltage-gated O
sodium O
channel O
, O
blocking O
the O
passage O
of O
nerve O
impulses O
and O
leading O
to O
death O
via O
respiratory O
paralysis O
. O
Recent O
advances O
in O
saxitoxin O
research O
are O
discussed O
, O
including O
the O
molecular O
biology O
of O
toxin O
synthesis O
, O
new O
protein O
targets O
, O
association O
with O
metal-binding O
motifs O
and O
methods O
of O
detection O
. O
The O
eco-evolutionary O

saxitoxin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
through O
the O
food O
web O
results O
in O
the O
potentially O
fatal O
human O
illnesses O
, O
paralytic O
shellfish O
poisoning O
and O
saxitoxin O
pufferfish O
poisoning O
. O
These O
illnesses O
are O
a O
result O
of O
saxitoxin's O
ability O
to O
bind O
to O
the O
voltage-gated O
sodium O
channel O
, O
blocking O
the O
passage O
of O
nerve O
impulses O
and O
leading O
to O
death O
via O
respiratory O
paralysis O
. O
Recent O
advances O
in O
saxitoxin O
research O
are O
discussed O
, O
including O
the O
molecular O
biology O
of O
toxin O
synthesis O
, O
new O
protein O
targets O
, O
association O
with O
metal-binding B
motifs I
and O
methods O
of O
detection O
. O
The O
eco-evolutionary O
role(s) O
PSTs O
may O
serve O
for O
phytoplankton O
species O
that O
produce O
them O
are O
also O
discussed O
. O

Nle O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[ O
Nle O
4) O
, O
D-Phe(7)]α-melanocyte-stimulating O
hormone O
(NDP-α-MSH) O
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O

Nle O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[ O
Nle O
4) O
, O
D-Phe(7)]α-melanocyte-stimulating O
hormone O
(NDP-α-MSH) O
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O

D-Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[Nle(4) O
, O
D-Phe O
7)]α-melanocyte-stimulating O
hormone O
(NDP-α-MSH) O
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O
the O

D-Phe O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
inflammatory O
mediator O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
the O
pro-apoptotic O
factors O
BAX O
and O
c-jun O
N-terminal O
kinases O
(pJNK) O
, O
the O
anti-apoptotic O
protein O
Bcl-XL O
, O
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme O
oxygenase-1 O
(HO-1) O
, O
was O
performed O
in O
the O
left O
ventricle O
and O
spleen O
. O
Intravenous O
treatment O
, O
during O
coronary O
artery O
occlusion O
, O
with O
the O
melanocortin O
analogs O
[Nle(4) O
, O
D-Phe O
7)]α-melanocyte-stimulating O
hormone O
(NDP-α-MSH) O
and O
adrenocorticotropic O
hormone O
1-24 O
[ACTH-(1-24)] O
, O
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2 O
, O
pERK1/2 O
and O
pTyr-STAT3 O
(JAK-dependent) O
, O
and O
a O
reduction O
in O
pJNK O
and O
TNF-α O
levels; O
these O
effects O
of O
NDP-α-MSH O
and O
ACTH-(1-24) O
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 O
and O
Bcl-XL O
, O
and O
marked O
decrease O
of O
the O

AG490 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
decrease O
of O
the O
myocardial O
infarct O
size O
. O
Melanocortin O
treatment O
did O
not O
affect O
left O
ventricle O
pSer-STAT3 O
(ERK1/2-dependent) O
and O
BAX O
levels O
. O
In O
the O
spleen O
, O
NDP-α-MSH O
and O
ACTH-(1-24) O
induced O
similar O
effects O
on O
the O
expression O
of O
the O
above O
transcription O
factors/proteins O
, O
except O
for O
pERK1/2 O
(down-regulated) O
and O
HO-1 O
(unaffected) O
. O
Blockade O
of O
JAK B
and O
ERK O
pathways O
with O
AG490 O
and O
U0126 O
, O
respectively O
, O
abrogated O
the O
myocardial O
infarct O
size O
reduction O
by O
NDP-α-MSH O
. O
These O
results O
indicate O
that O
melanocortins O
inhibit O
local O
and O
systemic O
inflammatory O
and O
apoptotic O
cascades O
triggered O
by O
prolonged O
myocardial O
ischemia/reperfusion O
, O
with O
consequent O
reduction O
in O
myocardium O
infarct O
size O
, O
seemingly O
via O
activation O
of O
the O
JAK/STAT O
signaling O
and O
with O
modulation O
of O
an O
ERK O

U0126 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
myocardial O
infarct O
size O
. O
Melanocortin O
treatment O
did O
not O
affect O
left O
ventricle O
pSer-STAT3 O
(ERK1/2-dependent) O
and O
BAX O
levels O
. O
In O
the O
spleen O
, O
NDP-α-MSH O
and O
ACTH-(1-24) O
induced O
similar O
effects O
on O
the O
expression O
of O
the O
above O
transcription O
factors/proteins O
, O
except O
for O
pERK1/2 O
(down-regulated) O
and O
HO-1 O
(unaffected) O
. O
Blockade O
of O
JAK O
and O
ERK B
pathways O
with O
AG490 O
and O
U0126 O
respectively O
, O
abrogated O
the O
myocardial O
infarct O
size O
reduction O
by O
NDP-α-MSH O
. O
These O
results O
indicate O
that O
melanocortins O
inhibit O
local O
and O
systemic O
inflammatory O
and O
apoptotic O
cascades O
triggered O
by O
prolonged O
myocardial O
ischemia/reperfusion O
, O
with O
consequent O
reduction O
in O
myocardium O
infarct O
size O
, O
seemingly O
via O
activation O
of O
the O
JAK/STAT O
signaling O
and O
with O
modulation O
of O
an O
ERK O
(STAT O
unrelated) O

organoselenium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one O
(C21H2HOSe; O
organoselenium) O
and O
sodium O
selenate O
(inorganic O
Se) O
on O
adenosine O
deaminase O
(ADA) O
activity O
, O
cell O
viability O
, O
lipid O
peroxidation O
, O
scavenger O
of O
nitric O
oxide O
(NO) O
and O
nonprotein O
thiols O
(NP-SH) O
content O
in O
the O
cerebral O
cortex O
slices O
of O
the O
young O
rats O
. O
A O
decrease O
in O
ADA B
activity O
was O
observed O
when O
the O
slices O
were O
exposed O
to O
organoselenium O
at O
the O
concentrations O
of O
1 O
, O
10 O
and O
30 O
µM O
. O
The O
same O
compound O
showed O
higher O
scavenger O
capacity O
of O
NO O
than O
the O
inorganic O
compound O
. O
Inorganic O
Se O
was O
able O
to O
protect O
against O
sodium O
nitroprusside-induced O
oxidative O
damage O
and O
increased O
the O
NP-SH O
content O
. O
Both O
the O
compounds O
displayed O
distinctive O
antioxidant O
capacities O
and O
were O
not O
cytotoxic O

Rg1 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O

Rg1 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1 O
rotective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O
might O
play O
an O
important O
role O
in O
it O
. O

Rg1 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK B
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1 O
rotective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O
might O
play O
an O
important O
role O
in O
it O
. O

Rg1 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK B
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O

ginsenoside O
Rg1 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activating O
glucocorticoid O
receptor-ERK O
signaling O
pathway O
contributes O
to O
ginsenoside O
Rg O
protection O
against O
β-amyloid O
peptide-induced O
human O
endothelial O
cells O
apoptosis.The O
deposition O
of O
β-amyloid O
(Aβ) O
in O
neurons O
and O
vascular O
cells O
of O
the O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O
Present O
study O

ginsenoside O
Rg1 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Activating O
glucocorticoid O
receptor-ERK O
signaling O
pathway O
contributes O
to O
ginsenoside O
Rg O
protection O
against O
β-amyloid O
peptide-induced O
human O
endothelial O
cells O
apoptosis.The O
deposition O
of O
β-amyloid O
(Aβ) O
in O
neurons O
and O
vascular O
cells O
of O
the O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O
Present O
study O

Rg1 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α B
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O

Rg1 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O
Present O
study O
attempted O
to O
evaluate O
the O
potential O
mechanisms O
of O
Aβ-mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α B
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O

Rg1 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O

ginsenoside O
Rg1 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Activating O
glucocorticoid O
receptor-ERK O
signaling O
pathway O
contributes O
to O
ginsenoside O
Rg O
protection O
against O
β-amyloid O
peptide-induced O
human O
endothelial O
cells O
apoptosis.The O
deposition O
of O
β-amyloid O
(Aβ) O
in O
neurons O
and O
vascular O
cells O
of O
the O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O
Present O
study O

Rg1 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1 O
rotective O
effects O
on O
Aβ25-35-induced O
endothelial O
cells O
apoptosis O
, O
suggesting O
that O
GR-ERK O
signaling O
pathway O
might O
play O
an O
important O
role O
in O
it O
. O

Rg1 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease O
. O
Ginsenoside O
Rg1 O
(Rg1) O
is O
an O
active O
components O
in O
Panax O
ginseng O
, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica O
. O
Present O
study O
attempted O
to O
evaluate O
the O
potential O
mechanisms O
of O
Aβ-mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O

U0126 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
Aβ-mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK B
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O

ICI O
82,780 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen B
receptor I
α I
antagonist O
ICI O
82,780 O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective O
effects O
on O
Aβ25-35-induced O
endothelial O

RU486 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
evaluate O
the O
potential O
mechanisms O
of O
Aβ-mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid B
receptor I
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O

RU486 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
evaluate O
the O
potential O
mechanisms O
of O
Aβ-mediated O
insult O
and O
the O
protective O
effects O
of O
Rg1 O
on O
human O
endothelial O
cells O
. O
Rg1 O
attenuated O
the O
Aβ25-35-associated O
mitochondrial O
apoptotic O
events O
, O
accompanied O
by O
inhibiting O
HIF-1α O
expression O
followed O
by O
intracellular O
reactive O
nitrogen O
species O
generation O
, O
and O
protein O
nitrotyrosination O
. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid O
receptor O
(GR) O
antagonist O
RU486 O
or O
p-ERK O
inhibitor O
U0126 O
rather O
than O
estrogen O
receptor O
α O
antagonist O
ICI O
82,780 O
. O
Taken O
together O
, O
our O
results O
suggested O
that O
Rg1 O
protected O
against O
Aβ25-35-induced O
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent O
ERK O
phosphorylation O
pathways O
: O
(1) O
down-regulating O
HIF-1α O
initiated O
protein O
nitrotyrosination O
, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades O
. O
These O
data O
provided O

anisomycin O
acts O
as O
NOT O
for O
what O
entity O
? O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 B
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O

anisomycin O
acts O
as O
NOT O
for O
what O
entity O
? O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 O
or O
UDP-glucuronosyltransferase B
1A1 I
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O

anisomycin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
activated O
protein O
kinase O
(MAPK) O
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells O
. O
Liganded-CAR O
induced O
CYP2B6 O
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR B
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activated O
protein O
kinase O
(MAPK) O
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells O
. O
Liganded-CAR O
induced O
CYP2B6 O
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 B
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activated O
protein O
kinase O
(MAPK) O
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells O
. O
Liganded-CAR O
induced O
CYP2B6 O
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK B
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
activated O
protein O
kinase O
(MAPK) O
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells O
. O
Liganded-CAR O
induced O
CYP2B6 B
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR O
. O
Here O
, O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 B
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 O
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 B
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 O
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 B
and O
CYP2C9 O
mRNAs O
but O
not O
CYP3A4 O
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O

anisomycin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
we O
have O
now O
found O
that O
activation O
of O
p38 O
MAPK O
by O
anisomycin O
potentiated O
induction O
of O
CYP2B6 O
mRNA O
by O
CAR O
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes O
. O
siRNA O
knockdown O
of O
p38 O
MAPK O
abrogated O
the O
ability O
of O
anisomycin O
to O
synergistically O
induce O
CYP2B6 O
mRNA O
. O
In O
addition O
to O
CYP2B6 O
, O
anisomycin O
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 O
and O
CYP2C9 B
mRNAs O
but O
not O
CYP3A4 O
or O
UDP-glucuronosyltransferase O
1A1 O
mRNAs O
. O
Thus O
, O
activated O
p38 O
MAPK O
is O
required O
for O
liganded-CAR O
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes O
. O
Our O
present O
results O
suggest O
that O
CAR-mediated O
induction O
of O
these O
enzymes O
can O
not O
be O

nitric O
oxide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible B
nitric I
oxide I
synthase I
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O

nitric O
oxide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
from O
fingered O
citron O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O

NO O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
( O
NO O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible B
nitric I
oxide I
synthase I
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O

NO O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(Citrus O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
( O
NO O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O

prostaglandin O
E2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
medica O
L O
. O
var O
. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
(PGE2) O
by O
suppressing O
the O
protein O
expression O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O
activation O
of O
c-Jun O

PGE2 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells O
. O
Fifteen O
compounds O
, O
representing O
98.97% O
of O
the O
essential O
oil O
, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene O
(52.44%) O
and O
γ-terpinene O
(28.41%) O
. O
FCEO O
significantly O
inhibited O
nitric O
oxide O
(NO) O
and O
prostaglandin O
E2 O
( O
PGE2 O
by O
suppressing O
the O
protein O
expression O
of O
inducible O
nitric O
oxide O
synthase O
(iNOS) O
and O
cyclooxygenase O
(COX)-2 O
, O
respectively O
. O
Additionally O
, O
FCEO O
suppressed O
the O
production O
of O
tumor O
necrosis O
factor-α O
(TNF-α) O
, O
interleukin O
(IL)-1β O
, O
and O
IL-6 O
. O
FCEO O
attenuated O
LPS-induced O
nuclear O
factor-κB O
(NF-κB) O
activation O
via O
inhibition O
of O
inhibitor O
κB-α O
phosphorylation O
. O
Furthermore O
, O
FCEO O
blocked O
activation O
of O
c-Jun O
N-terminal O

aldosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
plasma O
membrane O
after O
30min O
aldosterone O
treatment O
in O
polarized O
M1 O
cortical O
collecting O
duct O
cells O
, O
which O
was O
significantly O
impaired O
in O
PKD1 B
shRNA-mediated O
knockdown O
cells O
. O
In O
PKD1-deficient O
cells O
, O
the O
ouabain-sensitive O
current O
was O
significantly O
reduced O
and O
Na(+)/K(+)-ATPase O
α O
and O
β O
subunits O
showed O
aberrant O
localization O
. O
PKD1 O
and O
PI4KIIIβ O
localize O
to O
the O
TGN O
, O
and O
aldosterone O
induced O
an O
interaction O
between O
PKD1 O
and O
PI4KIIIβ O
following O
aldosterone O
treatment O
. O
This O
study O
reveals O
a O
novel O
mechanism O
for O
rapid O
regulation O
of O
ENaC O
and O
the O
Na(+)/K(+)-ATPase O
, O
via O
directed O
trafficking O
through O
PKD1-PI4KIIIβ O
signalling O
at O
the O
level O
of O
the O
TGN O
. O

aldosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
plasma O
membrane O
after O
30min O
aldosterone O
treatment O
in O
polarized O
M1 O
cortical O
collecting O
duct O
cells O
, O
which O
was O
significantly O
impaired O
in O
PKD1 O
shRNA-mediated O
knockdown O
cells O
. O
In O
PKD1-deficient O
cells O
, O
the O
ouabain-sensitive O
current O
was O
significantly O
reduced O
and O
Na(+)/K(+)-ATPase O
α O
and O
β O
subunits O
showed O
aberrant O
localization O
. O
PKD1 O
and O
PI4KIIIβ B
localize O
to O
the O
TGN O
, O
and O
aldosterone O
induced O
an O
interaction O
between O
PKD1 O
and O
PI4KIIIβ O
following O
aldosterone O
treatment O
. O
This O
study O
reveals O
a O
novel O
mechanism O
for O
rapid O
regulation O
of O
ENaC O
and O
the O
Na(+)/K(+)-ATPase O
, O
via O
directed O
trafficking O
through O
PKD1-PI4KIIIβ O
signalling O
at O
the O
level O
of O
the O
TGN O
. O

Aldosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Aldosterone-induced O
ENaC O
and O
basal O
Na(+)/K(+)-ATPase O
trafficking O
via O
protein O
kinase O
D1-phosphatidylinositol O
4-kinaseIIIβ O
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells O
. O
Aldosterone O
regulates O
Na(+) O
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium B
channel I
(ENaC) O
and O
Na(+)/K(+)-ATPase O
subunits O
. O
Aldosterone O
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein O
Kinase O
D1 O
(PKD1) O
. O
PKD O
isoforms O
regulate O
protein O
trafficking O
, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O
trans O
Golgi O

Aldosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Aldosterone-induced O
ENaC B
and O
basal O
Na(+)/K(+)-ATPase O
trafficking O
via O
protein O
kinase O
D1-phosphatidylinositol O
4-kinaseIIIβ O
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells O
. O
Aldosterone O
regulates O
Na(+) O
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium O
channel O
(ENaC) O
and O
Na(+)/K(+)-ATPase O
subunits O
. O
Aldosterone O
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein O
Kinase O
D1 O
(PKD1) O
. O
PKD O
isoforms O
regulate O
protein O
trafficking O
, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O
trans O
Golgi O

Aldosterone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Aldosterone-induced O
ENaC O
and O
basal O
Na(+)/K(+)-ATPase B
trafficking O
via O
protein O
kinase O
D1-phosphatidylinositol O
4-kinaseIIIβ O
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells O
. O
Aldosterone O
regulates O
Na(+) O
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium O
channel O
(ENaC) O
and O
Na(+)/K(+)-ATPase O
subunits O
. O
Aldosterone O
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein O
Kinase O
D1 O
(PKD1) O
. O
PKD O
isoforms O
regulate O
protein O
trafficking O
, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O
trans O
Golgi O

Aldosterone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Aldosterone-induced O
ENaC O
and O
basal O
Na(+)/K(+)-ATPase O
trafficking O
via O
protein O
kinase O
D1-phosphatidylinositol O
4-kinaseIIIβ O
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells.Aldosterone O
regulates O
Na(+) O
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium O
channel O
(ENaC) O
and O
Na(+)/K(+)-ATPase O
subunits O
. O
Aldosterone O
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein B
Kinase I
D1 I
(PKD1) O
. O
PKD O
isoforms O
regulate O
protein O
trafficking O
, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O
trans O
Golgi O
network O
(TGN) O
through O
activation O
of O
phosphatidylinositol O
4-kinaseIIIβ O
(PI4KIIIβ) O
. O
We O
report O
rapid O
ENaCγ O
translocation O
to O
the O
plasma O
membrane O
after O
30min O
aldosterone O
treatment O
in O
polarized O
M1 O

Aldosterone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Aldosterone-induced O
ENaC O
and O
basal O
Na(+)/K(+)-ATPase O
trafficking O
via O
protein O
kinase O
D1-phosphatidylinositol O
4-kinaseIIIβ O
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells.Aldosterone O
regulates O
Na(+) O
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium O
channel O
(ENaC) O
and O
Na(+)/K(+)-ATPase O
subunits O
. O
Aldosterone O
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein O
Kinase O
D1 O
(PKD1) O
. O
PKD O
isoforms O
regulate O
protein O
trafficking O
, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O
trans O
Golgi O
network O
(TGN) O
through O
activation O
of O
phosphatidylinositol O
4-kinaseIIIβ O
(PI4KIIIβ) O
. O
We O
report O
rapid O
ENaCγ O
translocation O
to O
the O
plasma O
membrane O
after O
30min O
aldosterone O
treatment O
in O
polarized O
M1 O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
IKKα/β O
at O
S176/180 O
, O
p38 O
at O
T180/Y182 O
and O
p65 B
at O
S536 O
, O
but O
not O
p65 O
at O
S276 O
. O
This O
was O
confirmed O
by O
their O
ability O
to O
selectively O
abrogate O
the O
induction O
of O
IL-8 O
transcription O
, O
whereas O
the O
ICAM-1 O
gene O
, O
which O
is O
not O
transcribed O
selectively O
by O
an O
NF-κB O
complex O
containing O
a O
form O
of O
p65 O
phosphorylated O
on O
Ser O
36 O
, O
did O
not O
change O
. O
Finally O
, O
the O
plant O
extracts O
at O
200μg/mg O
could O
normalize O
the O
LPS-induced O
elevation O
of O
spleen O
index O
as O
well O
as O
NF-κB O
and O
p38 O
activations O
in O
CD1 O
mice O
. O
CONCLUSION O
: O
The O
present O
studies O
presents O
the O
potential O
utilization O
of O
this O
plant O
extracts O
, O
as O
a O
natural O
resources O
for O
the O
development O
of O
an O

5HHMF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS B
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O

5HHMF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear B
factor-erythroid I
2-related I
factor I
2 I
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O

5HHMF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O

cobalt O
protoporphyrin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O

CoPP O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
( O
CoPP O
 O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O

5HHMF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 B
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 B
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(ZnPP) O
, O
a O
specific O
HO-1 B
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme B
oxygenase-1 I
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O

5HHMF O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O

5HHMF O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 B
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 B
siRNA O
subsequently O
reversed O
5HHMF O
induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 B
siRNA O
subsequently O
reversed O
5HHMF O
induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

NO O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB B
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

NO O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 B
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

NO O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
specific O
HO-1 B
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

NO O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear B
factor-κB I
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB B
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 B
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O

5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible B
NO I
synthase I
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O

5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O

Pyrrolidine O
dithiocarbamate O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS B
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O

PDTC O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS B
expression O
. O
Pyrrolidine O
dithiocarbamate O
( O
PDTC O
 O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS B
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
( O
5HHMF O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible B
NO I
synthase I
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O

5HHMF O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
( O
5HHMF O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O

5HHMF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
inhibits O
nitric O
oxide O
production O
in O
lipopolysaccharide-stimulated O
BV2 O
microglia O
via O
NF-κB O
suppression O
and O
Nrf-2-dependent O
heme O
oxygenase-1 O
induction.In O
this O
study O
, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone O
(5HHMF) O
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB O
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O

Pyrrolidine O
dithiocarbamate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NO O
production O
by O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB B
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O

PDTC O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
suppressing O
the O
expression O
of O
inducible O
NO O
synthase O
(iNOS) O
in O
BV2 O
microglia O
. O
In O
addition O
, O
5HHMF O
blocked O
LPS-induced O
phosphorylation O
of O
IκB O
, O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
( O
PDTC O
 O
, O
a O
specific O
NF-κB B
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O

5HHMF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear O
factor-κB O
(NF-κB) O
subunits O
, O
namely O
p65 O
and O
p50 O
, O
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS O
expression O
. O
Pyrrolidine O
dithiocarbamate O
(PDTC) O
, O
a O
specific O
NF-κB B
inhibitor O
, O
along O
with O
20S O
proteasome O
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 O
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O

zinc O
protoporphyrin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
LPS-induced O
iNOS O
expression O
, O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O

ZnPP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
which O
indirectly O
suggested O
that O
5HHMF O
downregulated O
iNOS O
expression O
by O
suppressing O
NF-κB O
activity O
. O
Thus O
, O
we O
found O
that O
5HHMF O
enhances O
heme O
oxygenase-1 O
(HO-1) O
expression O
via O
nuclear O
factor-erythroid O
2-related O
factor O
2 O
(Nrf2) O
activation O
. O
In O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
( O
ZnPP O
 O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O

5HHMF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
addition O
, O
cobalt O
protoporphyrin O
(CoPP) O
, O
a O
specific O
HO-1 B
inducer O
, O
predominantly O
suppressed O
LPS-induced O
NO O
production O
. O
In O
contrast O
, O
zinc O
protoporphyrin O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF O
induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB O
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

5HHMF O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(ZnPP) O
, O
a O
specific O
HO-1 O
inhibitor O
, O
showed O
a O
partial O
suppressive O
effect O
of O
5HHMF O
on O
LPS-induced O
NO O
production O
. O
Further O
, O
5HHMF O
increased O
specific O
DNA-binding O
activity O
of O
Nrf2 O
, O
and O
transient O
knockdown O
with O
Nrf2 O
siRNA O
subsequently O
reversed O
5HHMF-induced O
NO O
inhibition O
, O
which O
was O
followed O
by O
suppression O
of O
HO-1 O
activity O
. O
Taken O
together O
, O
our O
findings O
indicate O
that O
5HHMF O
suppresses O
NO O
production O
through O
modulation O
of O
iNOS O
, O
consequently O
suppressing O
NF-κB B
activity O
and O
induction O
of O
Nrf2-dependent O
HO-1 O
activity O
. O

GTX2,3-aldehyde O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
immunogenicity.In O
this O
paper O
, O
a O
novel O
method O
was O
proposed O
to O
prepare O
artificial O
antigens O
of O
gonyaulax O
parlaytic O
shellfish O
toxin O
2 O
and O
3 O
(GTX2,3) O
. O
An O
intermediate O
GTX2,3-aldehyde O
was O
first O
synthesized O
by O
activating O
the O
NH2 O
group O
of O
the O
2nd O
and O
8th O
amino O
acid O
residues O
with O
three O
different O
aldehydes O
and O
two O
artificial O
complete O
antigens O
GTX2,3-aldehyde O
bovine B
serum I
albumin I
(BSA) O
and O
GTX2,3-aldehyde- O
keyhole O
limpet O
hemocyanin O
(KLH) O
were O
then O
prepared O
by O
cross-linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O
The O
successful O
preparation O
of O
the O
two O
complete O
antigens O
was O
confirmed O
by O
UV O
spectral O
scanning O
, O
HPLC O
, O
production O
of O
antibodies O
with O
titer O
of O
1.28 O
× O
10(4) O
from O
mice O
immunized O
with O

GTX2,3-aldehyde O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
immunogenicity.In O
this O
paper O
, O
a O
novel O
method O
was O
proposed O
to O
prepare O
artificial O
antigens O
of O
gonyaulax O
parlaytic O
shellfish O
toxin O
2 O
and O
3 O
(GTX2,3) O
. O
An O
intermediate O
GTX2,3-aldehyde O
was O
first O
synthesized O
by O
activating O
the O
NH2 O
group O
of O
the O
2nd O
and O
8th O
amino O
acid O
residues O
with O
three O
different O
aldehydes O
and O
two O
artificial O
complete O
antigens O
GTX2,3-aldehyde O
bovine O
serum O
albumin O
(BSA) O
and O
GTX2,3-aldehyde- O
keyhole O
limpet O
hemocyanin O
(KLH) O
were O
then O
prepared O
by O
cross-linking O
the O
intermediate O
with O
BSA B
or O
KLH O
. O
The O
successful O
preparation O
of O
the O
two O
complete O
antigens O
was O
confirmed O
by O
UV O
spectral O
scanning O
, O
HPLC O
, O
production O
of O
antibodies O
with O
titer O
of O
1.28 O
× O
10(4) O
from O
mice O
immunized O
with O

GTX2,3-aldehyde O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
method O
was O
proposed O
to O
prepare O
artificial O
antigens O
of O
gonyaulax O
parlaytic O
shellfish O
toxin O
2 O
and O
3 O
(GTX2,3) O
. O
An O
intermediate O
GTX2,3-aldehyde O
was O
first O
synthesized O
by O
activating O
the O
NH2 O
group O
of O
the O
2nd O
and O
8th O
amino O
acid O
residues O
with O
three O
different O
aldehydes O
and O
two O
artificial O
complete O
antigens O
GTX2,3-aldehyde-bovine O
serum O
albumin O
(BSA) O
and O
GTX2,3-aldehyde O
keyhole B
limpet I
hemocyanin I
(KLH) O
were O
then O
prepared O
by O
cross-linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O
The O
successful O
preparation O
of O
the O
two O
complete O
antigens O
was O
confirmed O
by O
UV O
spectral O
scanning O
, O
HPLC O
, O
production O
of O
antibodies O
with O
titer O
of O
1.28 O
× O
10(4) O
from O
mice O
immunized O
with O
the O
two O
complete O
antigens O
, O
indirect O
ELISA O

GTX2,3-aldehyde O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
method O
was O
proposed O
to O
prepare O
artificial O
antigens O
of O
gonyaulax O
parlaytic O
shellfish O
toxin O
2 O
and O
3 O
(GTX2,3) O
. O
An O
intermediate O
GTX2,3-aldehyde O
was O
first O
synthesized O
by O
activating O
the O
NH2 O
group O
of O
the O
2nd O
and O
8th O
amino O
acid O
residues O
with O
three O
different O
aldehydes O
and O
two O
artificial O
complete O
antigens O
GTX2,3-aldehyde-bovine O
serum O
albumin O
(BSA) O
and O
GTX2,3-aldehyde O
keyhole O
limpet O
hemocyanin O
(KLH) O
were O
then O
prepared O
by O
cross-linking O
the O
intermediate O
with O
BSA O
or O
KLH O
. O
The O
successful O
preparation O
of O
the O
two O
complete O
antigens O
was O
confirmed O
by O
UV O
spectral O
scanning O
, O
HPLC O
, O
production O
of O
antibodies O
with O
titer O
of O
1.28 O
× O
10(4) O
from O
mice O
immunized O
with O
the O
two O
complete O
antigens O
, O
indirect O
ELISA O

platinum O
acts O
as O
NOT O
for O
what O
entity O
? O
have O
also O
compared O
the O
effects O
of O
extracellular O
copper O
, O
which O
causes O
regulatory O
endocytosis O
of O
hCTR1 O
, O
to O
those O
of O
cDDP O
. O
We O
confirm O
the O
correlation O
between O
higher O
hCTR1 B
levels O
and O
higher O
Pt-drug O
uptake O
in O
tumor O
cells O
sensitive O
to O
the O
drug O
. O
However O
, O
we O
show O
that O
hCTR1 O
is O
not O
the O
major O
entry O
route O
of O
platinum O
drugs O
and O
that O
the O
copper O
transporter O
is O
not O
internalized O
in O
response O
to O
extracellular O
drug O
. O
Our O
data O
suggest O
the O
major O
entry O
pathway O
for O
platinum-drugs O
is O
not O
saturable O
at O
relevant O
concentrations O
and O
not O
protein-mediated O
. O
Clinical O
trials O
have O
been O
initiated O
that O
depend O
upon O
regulating O
membrane O
levels O
of O
hCTR1 O
. O
If O
reduced O
drug O
uptake O

Pt O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
embryonic O
fibroblasts O
(mefs) O
that O
do O
or O
do O
not O
express O
CTR1 O
, O
and O
human O
ovarian O
tumor O
cells O
, O
sensitive O
or O
resistant O
to O
cDDP O
. O
We O
have O
also O
compared O
the O
effects O
of O
extracellular O
copper O
, O
which O
causes O
regulatory O
endocytosis O
of O
hCTR1 O
, O
to O
those O
of O
cDDP O
. O
We O
confirm O
the O
correlation O
between O
higher O
hCTR1 B
levels O
and O
higher O
Pt O
drug O
uptake O
in O
tumor O
cells O
sensitive O
to O
the O
drug O
. O
However O
, O
we O
show O
that O
hCTR1 O
is O
not O
the O
major O
entry O
route O
of O
platinum-drugs O
and O
that O
the O
copper O
transporter O
is O
not O
internalized O
in O
response O
to O
extracellular O
drug O
. O
Our O
data O
suggest O
the O
major O
entry O
pathway O
for O
platinum-drugs O
is O
not O
saturable O
at O
relevant O

cDDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
a O
number O
of O
malignancies O
including O
testicular O
, O
ovarian O
, O
cervical O
, O
bladder O
, O
lung O
, O
head O
, O
and O
neck O
cancers O
. O
Its O
use O
is O
limited O
by O
the O
development O
of O
resistance O
, O
often O
rationalized O
via O
effects O
on O
cellular O
uptake O
. O
It O
has O
been O
claimed O
that O
hCTR1 O
, O
the O
human O
high O
affinity O
copper O
transporter O
, O
is O
the O
major O
entry O
pathway O
for O
cDDP O
and O
related O
drugs O
via O
a O
mechanism O
that O
mimics O
copper O
. O
This O
is O
an O
unexpected O
property O
of O
hCTR1 O
, O
a O
highly O
selective O
copper O
(I) O
transporter O
. O
We O
compared O
the O
uptake O
rates O
of O
copper O
with O
cDDP O
(and O
several O
analogs) O
into O
HEK293 O
cells O
over-expressing O
wild-type O
or O
mutant O
hCTR1 O
, O
mouse O
embryonic O
fibroblasts O
(mefs) O
that O
do O
or O

cDDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
in O
a O
number O
of O
malignancies O
including O
testicular O
, O
ovarian O
, O
cervical O
, O
bladder O
, O
lung O
, O
head O
, O
and O
neck O
cancers O
. O
Its O
use O
is O
limited O
by O
the O
development O
of O
resistance O
, O
often O
rationalized O
via O
effects O
on O
cellular O
uptake O
. O
It O
has O
been O
claimed O
that O
hCTR1 O
, O
the O
human O
high O
affinity O
copper O
transporter O
, O
is O
the O
major O
entry O
pathway O
for O
cDDP O
and O
related O
drugs O
via O
a O
mechanism O
that O
mimics O
copper O
. O
This O
is O
an O
unexpected O
property O
of O
hCTR1 O
, O
a O
highly O
selective O
copper O
(I) O
transporter O
. O
We O
compared O
the O
uptake O
rates O
of O
copper O
with O
cDDP O
(and O
several O
analogs) O
into O
HEK293 O
cells O
over-expressing O
wild-type O
or O
mutant O
hCTR1 O
, O
mouse O
embryonic O
fibroblasts O
(mefs) O
that O
do O
or O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
studied O
, O
and O
the O
regions O
involved O
in O
their O
interactions O
with O
ligands O
have O
been O
elucidated O
. O
However O
, O
these O
analyses O
have O
been O
performed O
using O
short O
peptides O
comprising O
phosphotyrosine O
followed O
by O
a O
few O
amino O
acids O
, O
which O
are O
described O
as O
the O
canonical O
recognition O
sites O
. O
Here O
we O
report O
the O
solution O
structure O
of O
the O
SH2 O
domain O
of O
C O
terminal O
Src O
kinase O
(Csk) O
in O
complex O
with O
a O
longer O
phosphopeptide O
from O
Csk-binding O
protein O
(Cbp) O
. O
This O
structure O
, O
together O
with O
biochemical O
experiments O
, O
revealed O
the O
existence O
of O
a O
novel O
binding O
region O
in O
addition O
to O
the O
canonical O
phosphotyrosine-314 O
binding O
site O
of O
Cbp O
. O
Mutational O
analysis O
of O
this O
second O
region O
in O
cells O
showed O
that O
both O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
studied O
, O
and O
the O
regions O
involved O
in O
their O
interactions O
with O
ligands O
have O
been O
elucidated O
. O
However O
, O
these O
analyses O
have O
been O
performed O
using O
short O
peptides O
comprising O
phosphotyrosine O
followed O
by O
a O
few O
amino O
acids O
, O
which O
are O
described O
as O
the O
canonical O
recognition O
sites O
. O
Here O
we O
report O
the O
solution O
structure O
of O
the O
SH2 O
domain O
of O
C O
terminal O
Src O
kinase O
(Csk) O
in O
complex O
with O
a O
longer O
phosphopeptide O
from O
Csk-binding O
protein O
(Cbp) O
. O
This O
structure O
, O
together O
with O
biochemical O
experiments O
, O
revealed O
the O
existence O
of O
a O
novel O
binding O
region O
in O
addition O
to O
the O
canonical O
phosphotyrosine-314 O
binding O
site O
of O
Cbp O
. O
Mutational O
analysis O
of O
this O
second O
region O
in O
cells O
showed O
that O
both O

phosphotyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
as O
the O
canonical O
recognition O
sites O
. O
Here O
we O
report O
the O
solution O
structure O
of O
the O
SH2 O
domain O
of O
C-terminal O
Src O
kinase O
(Csk) O
in O
complex O
with O
a O
longer O
phosphopeptide O
from O
Csk-binding O
protein O
(Cbp) O
. O
This O
structure O
, O
together O
with O
biochemical O
experiments O
, O
revealed O
the O
existence O
of O
a O
novel O
binding O
region O
in O
addition O
to O
the O
canonical O
phosphotyrosine O
314 O
binding O
site O
of O
Cbp O
. O
Mutational O
analysis O
of O
this O
second O
region O
in O
cells O
showed O
that O
both O
canonical O
and O
novel O
binding O
sites O
are O
required O
for O
tumor O
suppression O
through O
the O
Cbp-Csk O
interaction O
. O
Furthermore O
, O
the O
data O
indicate O
an O
allosteric O
connection O
between O
Cbp B
binding O
and O
Csk O
activation O
that O
arises O
from O
residues O
in O
the O

2-hydroxy-3-methylanthraquinone O
acts O
as O
NOT O
for O
what O
entity O
? O
H O
. O
diffusa O
Willd O
showed O
apoptosis-inducing O
effects O
against O
cancer O
cells O
. O
However O
, O
the O
cellular O
and O
molecular O
mechanisms O
responsible O
for O
this O
phenomenon O
are O
poorly O
understood O
. O
The O
current O
study O
determines O
the O
role O
of O
mitogen-activated O
protein O
kinases O
(MAPK) O
in O
human O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2-hydroxy-3-methylanthraquinone O
from O
H O
. O
diffusa O
. O
Our O
results O
showed O
that O
2-hydroxy-3-methylanthraquinone O
decreased O
phosphorylation-ERK1/2 O
(p-ERK1/2) O
, O
and O
increased O
p-p38MAPK O
, O
but O
did O
not O
affect O
expressions O
of O
p-JNK1/2 B
in O
U937 O
cells O
. O
Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone O
resulted O
in O
activation O
of O
caspase-3 O
. O
Furthermore O
, O
PD98059 O
(ERK1/2 O
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase-3 O
inhibitor O
or O
SB203580 O
(p-p38MAPK O
inhibitor) O
, O
decreased O
apoptosis O
in O

2-hydroxy-3-methylanthraquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
p-JNK1/2 O
in O
U937 O
cells O
. O
Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone O
resulted O
in O
activation O
of O
caspase-3 O
. O
Furthermore O
, O
PD98059 O
(ERK1/2 O
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase-3 O
inhibitor O
or O
SB203580 O
(p-p38MAPK O
inhibitor) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O
Taken O
together O
, O
our O
study O
for O
the O
first O
time O
suggests O
that O
2-hydroxy-3-methylanthraquinone O
is O
able O
to O
enhance O
apoptosis O
of O
U937 O
cells O
, O
at O
least O
in O
part O
, O
through O
activation O
of O
p-p38MAPK B
and O
downregulation O
of O
p-ERK1/2 O
. O
Moreover O
, O
the O
triggering O
of O
caspase-3 O
activation O
mediated O
apoptotic O
induction O
. O

2-hydroxy-3-methylanthraquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
H O
. O
diffusa O
Willd O
showed O
apoptosis-inducing O
effects O
against O
cancer O
cells O
. O
However O
, O
the O
cellular O
and O
molecular O
mechanisms O
responsible O
for O
this O
phenomenon O
are O
poorly O
understood O
. O
The O
current O
study O
determines O
the O
role O
of O
mitogen-activated O
protein O
kinases O
(MAPK) O
in O
human O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2-hydroxy-3-methylanthraquinone O
from O
H O
. O
diffusa O
. O
Our O
results O
showed O
that O
2-hydroxy-3-methylanthraquinone O
decreased O
phosphorylation-ERK1/2 O
(p-ERK1/2) O
, O
and O
increased O
p-p38MAPK O
, O
but O
did O
not O
affect O
expressions O
of O
p-JNK1/2 O
in O
U937 O
cells O
. O
Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone O
resulted O
in O
activation O
of O
caspase-3 O
. O
Furthermore O
, O
PD98059 O
(ERK1/2 O
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase-3 O
inhibitor O
or O
SB203580 O
(p-p38MAPK O
inhibitor) O
, O
decreased O
apoptosis O
in O

2-hydroxy-3-methylanthraquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
current O
study O
determines O
the O
role O
of O
mitogen-activated O
protein O
kinases O
(MAPK) O
in O
human O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2-hydroxy-3-methylanthraquinone O
from O
H O
. O
diffusa O
. O
Our O
results O
showed O
that O
2-hydroxy-3-methylanthraquinone O
decreased O
phosphorylation-ERK1/2 O
(p-ERK1/2) O
, O
and O
increased O
p-p38MAPK O
, O
but O
did O
not O
affect O
expressions O
of O
p-JNK1/2 O
in O
U937 O
cells O
. O
Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone O
resulted O
in O
activation O
of O
caspase-3 O
. O
Furthermore O
, O
PD98059 O
(ERK1/2 O
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase-3 B
inhibitor O
or O
SB203580 O
(p-p38MAPK O
inhibitor) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O
Taken O
together O
, O
our O
study O
for O
the O
first O
time O
suggests O
that O
2-hydroxy-3-methylanthraquinone O
is O
able O
to O
enhance O
apoptosis O
of O
U937 O
cells O
, O
at O
least O

SB203580 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
diffusa O
. O
Our O
results O
showed O
that O
2-hydroxy-3-methylanthraquinone O
decreased O
phosphorylation-ERK1/2 O
(p-ERK1/2) O
, O
and O
increased O
p-p38MAPK O
, O
but O
did O
not O
affect O
expressions O
of O
p-JNK1/2 O
in O
U937 O
cells O
. O
Moreover O
, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone O
resulted O
in O
activation O
of O
caspase-3 O
. O
Furthermore O
, O
PD98059 O
(ERK1/2 O
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced O
apoptosis O
in O
U937 O
cells O
, O
whereas O
caspase-3 O
inhibitor O
or O
SB203580 O
(p-p38MAPK O
inhibitor) O
, O
decreased O
apoptosis O
in O
U937 O
cells O
. O
Taken O
together O
, O
our O
study O
for O
the O
first O
time O
suggests O
that O
2-hydroxy-3-methylanthraquinone O
is O
able O
to O
enhance O
apoptosis O
of O
U937 O
cells O
, O
at O
least O
in O
part O
, O
through O
activation O
of O
p-p38MAPK B
and O
downregulation O
of O
p-ERK1/2 O
. O
Moreover O
, O
the O
triggering O
of O
caspase-3 O
activation O
mediated O
apoptotic O
induction O
. O

ThioTEPA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
intrinsic O
clearance O
for O
both O
ketamine O
enantiomers O
by O
the O
high O
affinity O
enzyme O
in O
HLMs O
with O
CYP2B6*1/*1 O
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher O
, O
respectively O
, O
than O
those O
for O
CYP2B6*1/*6 O
genotype O
and O
CYP2B6*6/*6 O
genotype O
. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 O
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6 O
, O
respectively O
. O
ThioTEPA O
(CYP2B6 O
inhibitor O
, O
25 O
μM) O
and O
the O
monoclonal O
antibody O
against O
CYP2B6 B
but O
not O
troleandomycin O
(CYP3A4 O
inhibitor O
, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O
CYP3A4 O
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 O
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O

troleandomycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
with O
CYP2B6*1/*1 O
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher O
, O
respectively O
, O
than O
those O
for O
CYP2B6*1/*6 O
genotype O
and O
CYP2B6*6/*6 O
genotype O
. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 O
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6 O
, O
respectively O
. O
ThioTEPA O
(CYP2B6 O
inhibitor O
, O
25 O
μM) O
and O
the O
monoclonal O
antibody O
against O
CYP2B6 O
but O
not O
troleandomycin O
(CYP3A4 O
inhibitor O
, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O
CYP3A4 B
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 O
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 O
in O
ketamine O
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O

ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
CYP-selective O
inhibitors O
on O
norketamine O
formation O
were O
also O
determined O
in O
HLMs O
. O
The O
two-enzyme O
Michaelis-Menten O
model O
best O
fitted O
the O
HLM O
kinetic O
data O
. O
The O
Km O
value O
for O
the O
high O
affinity O
enzyme O
and O
the O
low O
affinity O
enzyme O
were O
similar O
to O
those O
for O
the O
expressed O
CYP2B6 O
and O
CYP3A4 O
, O
respectively O
. O
The O
intrinsic O
clearance O
for O
both O
ketamine O
enantiomers O
by O
the O
high O
affinity O
enzyme O
in O
HLMs O
with O
CYP2B6*1/*1 O
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher O
, O
respectively O
, O
than O
those O
for O
CYP2B6*1/*6 O
genotype O
and O
CYP2B6*6/*6 O
genotype O
. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 O
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6 O
, O
respectively O
. O
ThioTEPA O
(CYP2B6 O
inhibitor O
, O
25 O
μM) O

Ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 B
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamin O
Enantiomers O
In O
Vitro.Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O

Ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 O
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro O
. O
Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome B
P450 I
(CYP) I
2B6 I
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O

Ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
CYP2B6*6 O
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro O
. O
Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 O
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O

ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
monoclonal O
antibody O
against O
CYP2B6 B
but O
not O
troleandomycin O
(CYP3A4 O
inhibitor O
, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O
CYP3A4 O
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 O
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 O
in O
ketamine O
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O
of O
the O
CYP2B6*6 O
allele O
on O
enzyme-ketamine O
binding O
and O
catalytic O
activity O
. O

ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
monoclonal O
antibody O
against O
CYP3A4 O
inhibited O
ketamine O
N-demethylation O
at O
clinically O
relevant O
concentrations O
. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 B
allele O
(gene-dose O
P<0.05) O
. O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 O
in O
ketamine O
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O
of O
the O
CYP2B6*6 O
allele O
on O
enzyme- O
ketamine O
binding O
and O
catalytic O
activity O
. O

ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Alters O
the O
N-demethylation O
of O
Ketamine O
Enantiomers O
In O
Vitro.Ketamine O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 B
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O
ketamine O
enantiomers O
using O
human O
liver O
microsomes O
(HLMs) O
genotyped O
for O
the O
CYP2B6*6 O
allele O
, O
insect O
cell O
expressed O
recombinant O
CYP2B6 O
and O
CYP3A4 O
enzymes O
and O
COS-1 O
cell O
expressed O
recombinant O
CYP2B6.1 O
and O
CYP2B6.6 O
protein O
variant O
. O
Effects O
of O
CYP-selective O
inhibitors O
on O
norketamine O
formation O
were O
also O
determined O
in O
HLMs O
. O

ketamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
is O
primarily O
metabolized O
to O
norketamine O
by O
hepatic O
cytochrome O
P450 O
(CYP) O
2B6 O
and O
CYP3A4-mediated O
N-demethylation O
. O
However O
, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial O
. O
The O
CYP2B6*6 B
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine O
metabolism O
. O
We O
examined O
the O
N-demethylation O
of O
individual O
ketamine O
enantiomers O
using O
human O
liver O
microsomes O
(HLMs) O
genotyped O
for O
the O
CYP2B6*6 O
allele O
, O
insect O
cell O
expressed O
recombinant O
CYP2B6 O
and O
CYP3A4 O
enzymes O
and O
COS-1 O
cell O
expressed O
recombinant O
CYP2B6.1 O
and O
CYP2B6.6 O
protein O
variant O
. O
Effects O
of O
CYP-selective O
inhibitors O
on O
norketamine O
formation O
were O
also O
determined O
in O
HLMs O
. O
The O
two-enzyme O
Michaelis-Menten O
model O
best O
fitted O
the O
HLM O

HFC O
acts O
as O
NOT O
for O
what O
entity O
? O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 B
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O

HFC O
acts O
as O
NOT O
for O
what O
entity O
? O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 B
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 B
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 B
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
method O
to O
screen O
11 O
recombinant O
human O
UGTs O
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 B
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
method O
to O
screen O
11 O
recombinant O
human O
UGTs B
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O

7-hydroxy-4-trifluoromethylcoumarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7-hydroxy-4-trifluoromethylcoumari O
by O
recombinant O
human B
UDP-glucuronosyltransferases I
and O
liver O
microsomes.Abstract O
1 O
. O
UDP-glucuronosyltransferases O
(UGTs) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O
2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin O
(HFC) O
for O
several O
UGTs O
. O
3 O
. O
We O
have O
used O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs B
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
>UGT2A1 O
, O
whereas O
at O
300 O
µM O
UGT1A6 B
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP-glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

UDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
at O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs B
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP O
glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

UDP O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
at O
300 O
µM O
UGT1A6 B
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP O
glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

glucuronic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
300 O
µM O
UGT1A6 O
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs B
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP- O
glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

glucuronic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
300 O
µM O
UGT1A6 B
was O
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O
UGTs O
. O
The O
activities O
of O
UGTs O
1A3 O
, O
1A8 O
, O
1A9 O
, O
2B4 O
and O
2B7 O
were O
low O
, O
whereas O
UGT1A1 O
and O
UGT2B17 O
exhibited O
no O
HFC O
glucuronidation O
activity O
. O
UGT1A6 O
exhibited O
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and O
UDP- O
glucuronic O
acid O
than O
the O
other O
UGTs O
. O
5 O
. O
Human O
, O
pig O
and O
rabbit O
, O
but O
not O
rat O
liver O
microsomes O
, O
catalyzed O
HFC O
glucuronidation O
at O
high O
rates O
. O
6 O
. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6 O
, O
1A7 O
, O
1A10 O
and O
2A1 O
and O
HFC O
glucuronidation O
activity O
determination O
from O
various O
samples O
. O

7-hydroxy-4-trifluoromethylcoumarin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7-hydroxy-4-trifluoromethylcoumarin O
by O
recombinant O
human O
UDP-glucuronosyltransferases O
and O
liver O
microsomes.Abstract O
1 O
. O
UDP-glucuronosyltransferases O
(UGTs) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O
2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin O
(HFC) O
for O
several O
UGTs O
. O
3 O
. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human O
UGTs B
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
throughput O
assay O
for O
the O
glucuronidation O
of O
7-hydroxy-4-trifluoromethylcoumarin O
by O
recombinant O
human O
UDP-glucuronosyltransferases O
and O
liver O
microsomes.Abstract O
1 O
. O
UDP-glucuronosyltransferases O
(UGTs) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O
2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin O
( O
HFC O
for O
several O
UGTs O
. O
3 O
. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human O
UGTs B
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O

HFC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
(UGTs) O
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics O
. O
2 O
. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin O
(HFC) O
for O
several O
UGTs O
. O
3 O
. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human B
UGTs I
for O
HFC O
glucuronidation O
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes O
. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation O
activity O
of O
liver O
microsomes O
from O
human O
, O
pig O
, O
rabbit O
and O
rat O
. O
4 O
. O
At O
a O
substrate O
concentration O
of O
20 O
µM O
, O
the O
most O
active O
HFC O
glucuronidation O
catalysts O
were O
UGT1A10 O
followed O
by O
UGT1A6 O
>UGT1A7 O

DEX O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
well O
Bcl-2 B
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX O
treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX O
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX O
treatment O
activates O
pro-survival O
signalling O
pathway O
but O
does O
not O

DEX O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax B
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX O
treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX O
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX O
treatment O
activates O
pro-survival O
signalling O
pathway O
but O
does O
not O

DEX O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro-survival O
Bcl-2 B
protein O
and O
enhanced O
Bcl-2/Bax O
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O

DEX O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro-survival O
Bcl-2 O
protein O
and O
enhanced O
Bcl-2/Bax O
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O

DEX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro-survival O
Bcl-2 B
protein O
and O
enhanced O
Bcl-2/Bax O
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O

DEX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro-survival O
Bcl-2 B
protein O
and O
enhanced O
Bcl-2/Bax O
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O

DEX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
expression O
of O
cell O
death-promoting O
molecules O
(poly O
(ADP-ribose) O
polymerase O
(PARP) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax) O
and O
cell-survival O
molecules O
(AKT O
, O
Bcl-2) O
. O
Our O
results O
revealed O
that O
body O
, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone O
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX O
injection O
. O
In O
PFC O
, O
DEX O
caused O
activation O
of O
AKT O
, O
augmentation O
of O
pro-survival O
Bcl-2 O
protein O
and O
enhanced O
Bcl-2/Bax O
protein O
ratio O
, O
as O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax B
was O
detected O
, O
while O
the O
p53 O
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
well O
Bcl-2 O
translocation O
to O
mitochondria O
. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP O
, O
procaspase O
3 O
and O
Bax O
was O
detected O
, O
while O
the O
p53 B
protein O
was O
decreased O
. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 O
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 O
and O
Bax O
mRNA O
expressions O
in O
DEX O
treated O
rats O
. O
Finally O
, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O
staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC O
. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX O
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX O
treatment O
activates O
pro-survival O
signalling O
pathway O
but O
does O
not O

phosphatidylinositol-4,5-bisphosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B B
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O

phosphatidylinositol-4,5-bisphosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol B
4-phosphate I
5-kinase I
β I
type I
I I
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O

phosphatidylinositol-4,5-bisphosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β B
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O

PI(4,5)P2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
spreads O
in O
cis O
over O
the O
PIP5K1B B
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[ O
PI(4,5)P2 O
 O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O

PI(4,5)P2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol B
4-phosphate I
5-kinase I
β I
type I
I I
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[ O
PI(4,5)P2 O
 O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O

PI(4,5)P2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[ O
PI(4,5)P2 O
 O
. O
Accordingly O
, O
loss O
of O
pip5k1β B
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O

PI(4,5)P2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β B
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O
but O
not O
FXN O
, O
suppressed O
this O
phenotype O
in O
FRDA O
cells O
. O
In O
addition O
to O
provide O
new O
insights O
into O
the O

phosphatidylinositol O
4-phosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
unknown O
. O
We O
show O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B B
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O

phosphatidylinositol O
4-phosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
unknown O
. O
We O
show O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol B
4-phosphate I
5-kinase I
β I
type I
I I
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O

phosphatidylinositol O
4-phosphate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
unknown O
. O
We O
show O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[PI(4)P] O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β B
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O

PI(4)P O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B B
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[ O
PI(4)P O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O

PI(4)P O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol B
4-phosphate I
5-kinase I
β I
type I
I I
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[ O
PI(4)P O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β O
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O

PI(4)P O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
here O
that O
gene O
silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B O
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts) O
, O
correlating O
with O
expanded O
GAA O
repeat O
size O
. O
PIP5K1B O
encodes O
phosphatidylinositol O
4-phosphate O
5-kinase O
β O
type O
I O
(pip5k1β) O
, O
an O
enzyme O
functionally O
linked O
to O
actin O
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol O
4-phosphate O
[ O
PI(4)P O
to O
generate O
phosphatidylinositol-4,5-bisphosphate O
[PI(4,5)P2] O
. O
Accordingly O
, O
loss O
of O
pip5k1β B
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 O
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading O
. O
Knockdown O
of O
PIP5K1B O
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin O
cytoskeleton O
remodeling O
, O
whereas O
over-expression O
of O
PIP5K1B O
, O

n-butanol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
against O
LOX O
, O
urease O
, O
acetylcholinesterase O
(AChE) O
and O
butyrylcholinesterase O
(BChE) O
using O
standard O
experimental O
protocols O
. O
When O
checked O
against O
lipoxygenase O
, O
the O
extracts O
revealed O
significant O
attenuation O
. O
Of O
the O
tested O
extracts O
, O
the O
ethyl O
acetate O
fraction O
was O
the O
most O
potent O
(half-maximal O
inhibitory O
concentration O
(IC50) O
: O
97 O
µg/mL) O
followed O
by O
aqueous O
fraction O
IC50 O
: O
109 O
µg/mL) O
. O
Regarding O
urease B
inhibition O
, O
n-butanol O
was O
the O
most O
potent O
fraction O
(IC50 O
: O
97 O
µg/mL) O
. O
However O
, O
the O
extracts O
did O
not O
show O
significant O
inhibition O
on O
AChE O
and O
BChE O
. O
In O
the O
preliminary O
phytochemical O
tests O
, O
the O
aerial O
parts O
of O
the O
plant O
showed O
the O
presence O
of O
saponins O
, O
alkaloids O
, O
flavonoids O
, O
phenols O
, O
tannins O
and O
terpenoids O
. O
The O
current O
findings O
could O
be O
attributed O
to O

Dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 B
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin O
induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

Dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 B
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin O
induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 B
and O
JNK1/2 O
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin O
induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

dioscin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O
and O
JNK1/2 B
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin O
induced O
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction O
. O

dioscin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
related O
signaling O
pathways O
during O
dioscin-induced O
apoptosis O
in O
human O
lung O
cancer O
cells O
was O
investigated O
. O
Results O
from O
4'-6-diamidino-2-phenylindole O
and O
annexin-V/PI O
double-staining O
assay O
showed O
that O
caspase-3- O
and O
caspase-8-dependent O
, O
and O
dose-dependent O
apoptoses O
were O
detected O
after O
a O
24-h O
dioscin O
treatment O
. O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II B
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O

dioscin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
related O
signaling O
pathways O
during O
dioscin-induced O
apoptosis O
in O
human O
lung O
cancer O
cells O
was O
investigated O
. O
Results O
from O
4'-6-diamidino-2-phenylindole O
and O
annexin-V/PI O
double-staining O
assay O
showed O
that O
caspase-3- O
and O
caspase-8-dependent O
, O
and O
dose-dependent O
apoptoses O
were O
detected O
after O
a O
24-h O
dioscin O
treatment O
. O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 B
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O

dioscin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 B
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O

dioscin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 B
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O

dioscin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K B
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O

dioscin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt B
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O

dioscin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Meanwhile O
, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin O
, O
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II O
and O
beclin-1 O
proteins O
. O
Blockade O
of O
autophagy O
with O
bafilomycin O
A1 O
or O
3-methyladenine O
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis O
. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin O
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 O
and O
JNK1/2 O
activity O
, O
accompanied O
with O
a O
decreased O
PI3K O
expression O
and O
decreased O
phosphorylation O
of O
Akt O
and O
mTOR O
. O
Taken O
together O
, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced O
human O
lung O
cancer O
cell O
line O
apoptosis O
. O
Dioscin-induced O
autophagy O
via O
ERK1/2 O

FUR O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
dramatically O
down-regulated O
expression O
of O
integrin O
β4 O
, O
focal O
adhesion O
kinase O
and O
paxillin O
might O
partially O
contribute O
to O
the O
synergic O
effect O
. O
Though O
FUR O
alone O
obviously O
induced O
endoplasmic O
reticulum O
stress O
, O
this O
signaling O
pathway O
may O
not O
contribute O
to O
the O
synergetic O
anti-proliferative O
effect O
as O
the O
protein O
expression O
of O
CHOP B
and O
BIP O
was O
similar O
in O
FUR O
alone O
and O
combined O
treatment O
group O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

FUR O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
The O
dramatically O
down-regulated O
expression O
of O
integrin O
β4 O
, O
focal O
adhesion O
kinase O
and O
paxillin O
might O
partially O
contribute O
to O
the O
synergic O
effect O
. O
Though O
FUR O
alone O
obviously O
induced O
endoplasmic O
reticulum O
stress O
, O
this O
signaling O
pathway O
may O
not O
contribute O
to O
the O
synergetic O
anti-proliferative O
effect O
as O
the O
protein O
expression O
of O
CHOP O
and O
BIP B
was O
similar O
in O
FUR O
alone O
and O
combined O
treatment O
group O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
. O

Paclitaxel O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Furanodiene O
Presents O
Synergistic O
Anti-proliferative O
Activity O
With O
Paclitaxe O
Via O
Altering O
Cell O
Cycle O
and O
Integrin B
Signaling O
in O
95-D O
Lung O
Cancer O
Cells.Furanodiene O
(FUR) O
is O
a O
natural O
terpenoid O
isolated O
from O
Rhizoma O
Curcumae O
, O
a O
well-known O
Chinese O
medicinal O
herb O
that O
presents O
anti-proliferative O
activities O
in O
several O
cancer O
cell O
lines O
. O
Recently O
, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR O
with O
paclitaxel O
(TAX) O
showed O
synergetic O

glucose O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
mTOR B
Regulates O
Nox4-Mediated O
Podocyte O
Depletion O
in O
Diabetic O
Renal O
Injury.Podocyte O
apoptosis O
is O
a O
critical O
mechanism O
for O
excessive O
loss O
of O
urinary O
albumin O
that O
eventuates O
in O
kidney O
fibrosis O
. O
Pharmacological O
doses O
of O
the O
mTOR O
inhibitor O
rapamycin O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O

glucose O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
mTOR O
Regulates O
Nox4-Mediated O
Podocyte O
Depletion O
in O
Diabetic O
Renal O
Injury.Podocyte O
apoptosis O
is O
a O
critical O
mechanism O
for O
excessive O
loss O
of O
urinary O
albumin O
that O
eventuates O
in O
kidney O
fibrosis O
. O
Pharmacological O
doses O
of O
the O
mTOR O
inhibitor O
rapamycin O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin B
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O

rapamycin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 B
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O
effect O
on O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR O
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O

rapamycin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 B
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O
effect O
on O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR O
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O

rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mTOR B
Regulates O
Nox4-Mediated O
Podocyte O
Depletion O
in O
Diabetic O
Renal O
Injury.Podocyte O
apoptosis O
is O
a O
critical O
mechanism O
for O
excessive O
loss O
of O
urinary O
albumin O
that O
eventuates O
in O
kidney O
fibrosis O
. O
Pharmacological O
doses O
of O
the O
mTOR O
inhibitor O
rapamycin O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O

glucose O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mTOR O
Regulates O
Nox4-Mediated O
Podocyte O
Depletion O
in O
Diabetic O
Renal O
Injury.Podocyte O
apoptosis O
is O
a O
critical O
mechanism O
for O
excessive O
loss O
of O
urinary O
albumin O
that O
eventuates O
in O
kidney O
fibrosis O
. O
Pharmacological O
doses O
of O
the O
mTOR O
inhibitor O
rapamycin O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK B
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O

rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR B
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O
effect O
on O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR O
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O

rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
reduce O
albuminura O
in O
diabetes O
. O
We O
explored O
the O
hypothesis O
that O
mTOR O
mediates O
podocyte O
injury O
in O
diabetes O
. O
High O
glucose O
(HG) O
induces O
apoptosis O
of O
podocytes O
, O
inhibits O
AMPK O
activation O
, O
inactivates O
tuberin O
and O
activates O
mTOR O
. O
HG O
also O
increases O
the O
levels O
of O
Nox4 O
and O
Nox1 O
and O
NADPH B
oxidase I
activity O
. O
Inhibition O
of O
mTOR O
by O
low O
dose O
rapamycin O
decreases O
HG-induced O
Nox4 O
and O
Nox1 O
, O
NADPH O
oxidase O
activity O
and O
podocyte O
apoptosis O
. O
Inhibition O
of O
mTOR O
had O
no O
effect O
on O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR O
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O

rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
AMPK O
or O
tuberin O
phosphorylation O
indicating O
that O
mTOR B
is O
downstream O
of O
these O
signaling O
molecules O
. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice O
, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O
AMPK O
and O
tuberin O
and O
activation O
of O
mTOR O
with O
increase O
in O
Nox4 O
and O
NADPH O
oxidase O
activity O
. O
Inhibition O
of O
mTOR O
by O
small O
dose O
of O
rapamycin O
reduces O
podocyte O
apoptosis O
, O
attenuates O
glomerular O
injury O
and O
albuminuria O
. O
Our O
data O
provide O
evidence O
for O
a O
novel O
function O
of O
mTOR O
in O
Nox4-derived O
ROS O
generation O
and O
podocyte O
apoptosis O
that O
contributes O
to O
urinary O
albumin O
excretion O
in O
type O
1 O
diabetes O
. O
Thus O
mTOR O
and O
or O
NADPH O
oxidase O
inhibition O
may O
represent O
a O
therapeutic O
modality O
of O
diabetic O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
with O
methylated O
or O
non-methylated O
chromatin O
regions O
and O
the O
structural O
characteristics O
of O
the O
resulting O
DNA O
associations O
in O
vivo O
remain O
poorly O
understood O
. O
We O
analysed O
the O
role O
of O
the O
MBD O
in O
MeCP2-chromatin O
associations O
in O
vivo O
using O
an O
MeCP2 B
mutant O
Rett O
syndrome O
mouse O
model O
(Mecp2(tm)(1)(.)(1)(Jae)) O
in O
which O
exon O
3 O
deletion O
results O
in O
an O
N O
terminal O
truncation O
of O
the O
protein O
, O
including O
most O
of O
the O
MBD O
. O
Our O
results O
show O
that O
in O
mutant O
mice O
, O
the O
truncated O
form O
of O
MeCP2 O
(ΔMeCP2) O
is O
expressed O
in O
different O
regions O
of O
the O
brain O
and O
liver O
, O
albeit O
at O
50% O
of O
its O
wild-type O
(wt) O
counterpart O
. O
In O
contrast O
to O
the O
punctate O
nuclear O
distribution O
characteristic O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
with O
methylated O
or O
non-methylated O
chromatin O
regions O
and O
the O
structural O
characteristics O
of O
the O
resulting O
DNA O
associations O
in O
vivo O
remain O
poorly O
understood O
. O
We O
analysed O
the O
role O
of O
the O
MBD O
in O
MeCP2-chromatin O
associations O
in O
vivo O
using O
an O
MeCP2 B
mutant O
Rett O
syndrome O
mouse O
model O
(Mecp2(tm)(1)(.)(1)(Jae)) O
in O
which O
exon O
3 O
deletion O
results O
in O
an O
N O
terminal O
truncation O
of O
the O
protein O
, O
including O
most O
of O
the O
MBD O
. O
Our O
results O
show O
that O
in O
mutant O
mice O
, O
the O
truncated O
form O
of O
MeCP2 O
(ΔMeCP2) O
is O
expressed O
in O
different O
regions O
of O
the O
brain O
and O
liver O
, O
albeit O
at O
50% O
of O
its O
wild-type O
(wt) O
counterpart O
. O
In O
contrast O
to O
the O
punctate O
nuclear O
distribution O
characteristic O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
with O
methylated O
or O
non-methylated O
chromatin O
regions O
and O
the O
structural O
characteristics O
of O
the O
resulting O
DNA O
associations O
in O
vivo O
remain O
poorly O
understood O
. O
We O
analysed O
the O
role O
of O
the O
MBD O
in O
MeCP2-chromatin O
associations O
in O
vivo O
using O
an O
MeCP2 O
mutant O
Rett O
syndrome O
mouse O
model O
(Mecp2(tm)(1)(.)(1)(Jae)) O
in O
which O
exon O
3 O
deletion O
results O
in O
an O
N O
terminal O
truncation O
of O
the O
protein O
, O
including O
most O
of O
the O
MBD O
. O
Our O
results O
show O
that O
in O
mutant O
mice O
, O
the O
truncated O
form O
of O
MeCP2 O
(ΔMeCP2) O
is O
expressed O
in O
different O
regions O
of O
the O
brain O
and O
liver O
, O
albeit O
at O
50% O
of O
its O
wild-type O
(wt) O
counterpart O
. O
In O
contrast O
to O
the O
punctate O
nuclear O
distribution O
characteristic O

thiazolidinediones O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Correlation O
between O
activation O
of O
PPARγ B
and O
resistin O
downregulation O
in O
a O
mouse O
adipocyte O
cell O
line O
by O
a O
series O
of O
thiazolidinedione O
.The O
present O
study O
shows O
significant O
correlations O
between O
the O
EC50 O
for O
PPARγ O
activation O
in O
a O
reporter O
gene O
cell O
line O
and O
resistin O
downregulation O
in O
mouse O
adipocytes O
, O
and O
between O
the O
IC50 O
for O
resistin O
downregulation O
and O
the O
already O
published O
minimum O
effective O
dose O
for O
antihyperglycemic O
activity O
in O
a O
mouse O
model O
. O
These O
correlations O
indicate O
that O

thiazolidinediones O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Correlation O
between O
activation O
of O
PPARγ O
and O
resistin B
downregulation O
in O
a O
mouse O
adipocyte O
cell O
line O
by O
a O
series O
of O
thiazolidinedione O
.The O
present O
study O
shows O
significant O
correlations O
between O
the O
EC50 O
for O
PPARγ O
activation O
in O
a O
reporter O
gene O
cell O
line O
and O
resistin O
downregulation O
in O
mouse O
adipocytes O
, O
and O
between O
the O
IC50 O
for O
resistin O
downregulation O
and O
the O
already O
published O
minimum O
effective O
dose O
for O
antihyperglycemic O
activity O
in O
a O
mouse O
model O
. O
These O
correlations O
indicate O
that O

serotonin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
No O
mutations O
in O
the O
serotoni O
related O
TPH1 B
and O
HTR1B O
genes O
in O
patients O
with O
monogenic O
sclerosing O
bone O
disorders.Since O
the O
identification O
of O
LRP5 O
as O
the O
causative O
gene O
for O
the O
osteoporosis O
pseudoglioma O
syndrome O
(OPPG) O
as O
well O
as O
the O
high O
bone O
mass O
(HBM) O
phenotype O
, O
LRP5 O
and O
the O
Wnt/β-catenin O
signaling O
have O
been O
extensively O
studied O
for O
their O
role O
in O
the O

vinblastine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O
Thus O
, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome B
c I
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O

vinblastine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O
Thus O
, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O

vinblastine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
can O
metastasize O
to O
any O
distant O
organ O
. O
Currently O
, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit O
. O
Thus O
, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor B
of I
kappaBα I
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase B
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
of O
metastatic O
melanoma O
. O
In O
the O
present O
study O
, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine O
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O
potential O
, O
the O
release O
of O
both O
cytochrome O
c O
and O
apoptosis O
inducing O
factor O
, O
activation O
of O
caspase-9 O
and O
3 O
, O
and O
cleavage O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O

vinblastine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 B
and O
Bax O
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O

vinblastine O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
Poly O
(ADP-ribose)-Polymerase O
. O
Also O
, O
vinblastine O
enhances O
the O
phosphorylation O
of O
Ras O
homologous O
protein O
A O
, O
the O
accumulation O
of O
reactive O
oxygen O
species O
, O
the O
release O
of O
intracellular O
Ca(2+) O
, O
as O
well O
as O
the O
activation O
of O
apoptosis O
signal-regulating O
kinase O
1 O
, O
c-jun-N-terminal O
kinase O
, O
p38 O
, O
inhibitor O
of O
kappaBα O
(IκBα) O
kinase O
, O
and O
inositol O
requiring O
enzyme O
1α O
. O
In O
addition O
, O
vinblastine O
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB O
, O
HSF1 O
, O
AP-1 O
, O
and O
ATF-2 O
, O
together O
with O
the O
expression O
of O
HSP70 O
and O
Bax B
proteins O
. O
Moreover O
, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho O
A O
in O
the O
regulation O
of O
vinblastine-induced O
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms O
. O
In O
conclusion O
, O
the O

thiazolidinediones O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Treatment O
Effects--iHOMA2.OBJECTIVETo O
describe O
and O
make O
available O
an O
interactive O
, O
24-variable O
homeostasis O
model O
assessment O
(iHOMA2) O
that O
extends O
the O
HOMA2 O
model O
, O
enabling O
the O
modeling O
of O
physiology O
and O
treatment O
effects O
, O
to O
present O
equations O
of O
the O
HOMA2 O
and O
iHOMA2 O
models O
, O
and O
to O
exemplify O
iHOMA2 O
in O
two O
widely O
differing O
scenarios O
: O
changes O
in O
insulin B
sensitivity O
with O
thiazolidinediones O
and O
changes O
in O
renal O
threshold O
with O
sodium O
glucose O
transporter O
(SGLT2) O
inhibition.RESEARCH O
DESIGN O
AND O
METHODSiHOMA2 O
enables O
a O
user O
of O
the O
available O
software O
to O
examine O
and O
modify O
the O
mathematical O
functions O
describing O
the O
organs O
and O
tissues O
involved O
in O
the O
glucose O
and O
hormonal O
compartments O
. O
We O
exemplify O
this O
with O
SGLT2 O
inhibition O
modeling O
(by O
changing O

thiazolidinediones O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Treatment O
Effects--iHOMA2.OBJECTIVETo O
describe O
and O
make O
available O
an O
interactive O
, O
24-variable O
homeostasis O
model O
assessment O
(iHOMA2) O
that O
extends O
the O
HOMA2 O
model O
, O
enabling O
the O
modeling O
of O
physiology O
and O
treatment O
effects O
, O
to O
present O
equations O
of O
the O
HOMA2 O
and O
iHOMA2 O
models O
, O
and O
to O
exemplify O
iHOMA2 O
in O
two O
widely O
differing O
scenarios O
: O
changes O
in O
insulin O
sensitivity O
with O
thiazolidinediones O
and O
changes O
in O
renal O
threshold O
with O
sodium B
glucose I
transporter I
(SGLT2) O
inhibition.RESEARCH O
DESIGN O
AND O
METHODSiHOMA2 O
enables O
a O
user O
of O
the O
available O
software O
to O
examine O
and O
modify O
the O
mathematical O
functions O
describing O
the O
organs O
and O
tissues O
involved O
in O
the O
glucose O
and O
hormonal O
compartments O
. O
We O
exemplify O
this O
with O
SGLT2 O
inhibition O
modeling O
(by O
changing O

thiazolidinediones O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Treatment O
Effects--iHOMA2.OBJECTIVETo O
describe O
and O
make O
available O
an O
interactive O
, O
24-variable O
homeostasis O
model O
assessment O
(iHOMA2) O
that O
extends O
the O
HOMA2 O
model O
, O
enabling O
the O
modeling O
of O
physiology O
and O
treatment O
effects O
, O
to O
present O
equations O
of O
the O
HOMA2 O
and O
iHOMA2 O
models O
, O
and O
to O
exemplify O
iHOMA2 O
in O
two O
widely O
differing O
scenarios O
: O
changes O
in O
insulin O
sensitivity O
with O
thiazolidinediones O
and O
changes O
in O
renal O
threshold O
with O
sodium O
glucose O
transporter O
(SGLT2) O
inhibition.RESEARCH O
DESIGN O
AND O
METHODSiHOMA2 O
enables O
a O
user O
of O
the O
available O
software O
to O
examine O
and O
modify O
the O
mathematical O
functions O
describing O
the O
organs O
and O
tissues O
involved O
in O
the O
glucose O
and O
hormonal O
compartments O
. O
We O
exemplify O
this O
with O
SGLT2 B
inhibition O
modeling O
(by O
changing O

N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium O
bromide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
ammonium O
salts O
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
effects O
involving O
induction O
of O
RhoB O
. O
Most O
of O
these O
compounds O
, O
featuring O
open-ring O
forms O
of O
aliphatic O
amido-quaternary O
ammonium O
salts O
, O
exhibited O
potent O
anti-proliferative O
activities O
in O
human O
cancer O
cell O
lines O
, O
including O
PC-3 O
, O
NUGC-3 O
, O
MDA-MB-231 O
, O
ACHN O
, O
HCT-15 O
, O
and O
NCI-H23 O
. O
In O
further O
evaluation O
, O
the O
representative O
compound O
N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium O
bromide O
(3b) O
exhibited O
potent O
pro-apoptotic O
activity O
, O
through O
RhoB B
activation O
, O
in O
HeLa O
cells O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Structural O
and O
functional O
characterization O
of O
a O
phosphatase O
domain O
within O
yeast O
general O
transcription O
factor O
TFIIIC.Saccharomyces O
cerevisiae O
τ55 O
, O
a O
subunit O
of O
the O
RNA O
polymerase O
III-specific O
general O
transcription O
factor O
TFIIIC O
, O
comprises O
an O
N O
terminal O
histidine O
phosphatase O
domain O
(τ55-HPD) O
whose O
catalytic O
activity O
and O
cellular O
function O
is O
poorly O
understood O
. O
We O
solved O
the O
crystal O
structures O
of O
τ55-HPD O
and O
its O
closely O
related O
paralogue O
Huf O
and O
used O
in O
silico O
docking O
methods O
to O
identify O
phospho-serine O
and O
phospho-tyrosine O
containing O
peptides O
as O
possible O
substrates O
that O
were O
subsequently O
validated O
using O
in O

histidine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Structural O
and O
functional O
characterization O
of O
a O
phosphatase O
domain O
within O
yeast O
general O
transcription O
factor O
TFIIIC.Saccharomyces O
cerevisiae O
τ55 O
, O
a O
subunit O
of O
the O
RNA O
polymerase O
III-specific O
general O
transcription O
factor O
TFIIIC O
, O
comprises O
an O
N-terminal O
histidine O
phosphatase O
domain O
(τ55-HPD) O
whose O
catalytic O
activity O
and O
cellular O
function O
is O
poorly O
understood O
. O
We O
solved O
the O
crystal O
structures O
of O
τ55-HPD O
and O
its O
closely O
related O
paralogue O
Huf O
and O
used O
in O
silico O
docking O
methods O
to O
identify O
phospho-serine O
and O
phospho-tyrosine O
containing O
peptides O
as O
possible O
substrates O
that O
were O
subsequently O
validated O
using O
in O
vitro O
phosphatase O

bleomycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
irreversible O
lung O
injury O
with O
obscure O
etiologic O
mechanisms O
and O
no O
effective O
treatment O
to O
date O
. O
This O
study O
explored O
a O
crucial O
link O
between O
oxidative O
stress O
and O
pulmonary O
fibrogenesis O
, O
focusing O
on O
nuclear O
factor O
erythroid O
2-related O
factor O
2 O
(Nrf2) O
, O
a O
core O
transcription O
factor O
in O
antioxidative O
regulation O
systems O
. O
Treatment O
of O
C57 O
BL/6 O
mice O
with O
bleomycin O
increased O
fibroblast O
viability O
and O
collagen B
production O
and O
significantly O
downregulated O
Nrf2 O
. O
In O
addition O
, O
prominent O
oxidative O
stress O
was O
indicated O
by O
changes O
in O
superoxide O
dismutase O
, O
catalase O
activity O
, O
and O
glutathione O
and O
thiobarbituric O
acid-reactive O
substance O
levels O
. O
In O
a O
cell-based O
model O
, O
bleomycin O
suppressed O
Nrf2 O
activation O
via O
extracellular O
signal-related O
kinase O
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O

caffeic O
acid O
phenethyl O
ester O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nrf2 B
activation O
via O
extracellular O
signal-related O
kinase O
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O
in O
lung O
fibroblasts O
and O
stimulating O
abnormal O
cell O
proliferation O
and O
collagen O
secretion O
. O
To O
confirm O
this O
novel O
mechanism O
of O
bleomycin-induced O
fibrogenesis O
, O
we O
attempted O
to O
upregulate O
Nrf2 O
and O
related O
antioxidant O
proteins O
in O
bleomycin-treated O
fibroblasts O
using O
a O
putative O
Nrf2 O
activator O
, O
caffeic O
acid O
phenethyl O
ester O
and O
the O
results O
showed O
that O
bleomycin-induced O
fibroblast O
proliferation O
and O
collagen O
content O
were O
attenuated O
through O
improved O
redox O
balance O
. O
Collectively O
, O
these O
results O
disclose O
a O
potential O
regulatory O
mechanism O
in O
pulmonary O
fibrosis O
that O
will O
aid O
the O
development O
of O
new O
therapies O
. O

bleomycin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
core O
transcription O
factor O
in O
antioxidative O
regulation O
systems O
. O
Treatment O
of O
C57 O
BL/6 O
mice O
with O
bleomycin O
increased O
fibroblast O
viability O
and O
collagen O
production O
and O
significantly O
downregulated O
Nrf2 O
. O
In O
addition O
, O
prominent O
oxidative O
stress O
was O
indicated O
by O
changes O
in O
superoxide O
dismutase O
, O
catalase O
activity O
, O
and O
glutathione O
and O
thiobarbituric O
acid-reactive O
substance O
levels O
. O
In O
a O
cell-based O
model O
, O
bleomycin O
suppressed O
Nrf2 O
activation O
via O
extracellular B
signal-related I
kinase I
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O
in O
lung O
fibroblasts O
and O
stimulating O
abnormal O
cell O
proliferation O
and O
collagen O
secretion O
. O
To O
confirm O
this O
novel O
mechanism O
of O
bleomycin-induced O
fibrogenesis O
, O
we O
attempted O
to O
upregulate O
Nrf2 O
and O
related O
antioxidant O
proteins O
in O
bleomycin-treated O
fibroblasts O
using O
a O
putative O
Nrf2 O
activator O
, O

bleomycin O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
by O
changes O
in O
superoxide O
dismutase O
, O
catalase O
activity O
, O
and O
glutathione O
and O
thiobarbituric O
acid-reactive O
substance O
levels O
. O
In O
a O
cell-based O
model O
, O
bleomycin O
suppressed O
Nrf2 B
activation O
via O
extracellular O
signal-related O
kinase O
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O
in O
lung O
fibroblasts O
and O
stimulating O
abnormal O
cell O
proliferation O
and O
collagen O
secretion O
. O
To O
confirm O
this O
novel O
mechanism O
of O
bleomycin O
induced O
fibrogenesis O
, O
we O
attempted O
to O
upregulate O
Nrf2 O
and O
related O
antioxidant O
proteins O
in O
bleomycin-treated O
fibroblasts O
using O
a O
putative O
Nrf2 O
activator O
, O
caffeic O
acid O
phenethyl O
ester O
, O
and O
the O
results O
showed O
that O
bleomycin-induced O
fibroblast O
proliferation O
and O
collagen O
content O
were O
attenuated O
through O
improved O
redox O
balance O
. O
Collectively O
, O
these O
results O
disclose O
a O
potential O
regulatory O
mechanism O
in O

bleomycin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
and O
irreversible O
lung O
injury O
with O
obscure O
etiologic O
mechanisms O
and O
no O
effective O
treatment O
to O
date O
. O
This O
study O
explored O
a O
crucial O
link O
between O
oxidative O
stress O
and O
pulmonary O
fibrogenesis O
, O
focusing O
on O
nuclear O
factor O
erythroid O
2-related O
factor O
2 O
(Nrf2) O
, O
a O
core O
transcription O
factor O
in O
antioxidative O
regulation O
systems O
. O
Treatment O
of O
C57 O
BL/6 O
mice O
with O
bleomycin O
increased O
fibroblast O
viability O
and O
collagen O
production O
and O
significantly O
downregulated O
Nrf2 O
. O
In O
addition O
, O
prominent O
oxidative O
stress O
was O
indicated O
by O
changes O
in O
superoxide O
dismutase O
, O
catalase O
activity O
, O
and O
glutathione O
and O
thiobarbituric O
acid-reactive O
substance O
levels O
. O
In O
a O
cell-based O
model O
, O
bleomycin O
suppressed O
Nrf2 B
activation O
via O
extracellular O
signal-related O
kinase O
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O

bleomycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
core O
transcription O
factor O
in O
antioxidative O
regulation O
systems O
. O
Treatment O
of O
C57 O
BL/6 O
mice O
with O
bleomycin O
increased O
fibroblast O
viability O
and O
collagen O
production O
and O
significantly O
downregulated O
Nrf2 O
. O
In O
addition O
, O
prominent O
oxidative O
stress O
was O
indicated O
by O
changes O
in O
superoxide O
dismutase O
, O
catalase O
activity O
, O
and O
glutathione O
and O
thiobarbituric O
acid-reactive O
substance O
levels O
. O
In O
a O
cell-based O
model O
, O
bleomycin O
suppressed O
Nrf2 B
activation O
via O
extracellular O
signal-related O
kinase O
phosphorylation O
, O
enhancing O
intracellular O
reactive O
oxygen O
species O
in O
lung O
fibroblasts O
and O
stimulating O
abnormal O
cell O
proliferation O
and O
collagen O
secretion O
. O
To O
confirm O
this O
novel O
mechanism O
of O
bleomycin-induced O
fibrogenesis O
, O
we O
attempted O
to O
upregulate O
Nrf2 O
and O
related O
antioxidant O
proteins O
in O
bleomycin-treated O
fibroblasts O
using O
a O
putative O
Nrf2 O
activator O
, O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
carrier O
formation O
. O
However O
, O
the O
nature O
of O
the O
signal(s) O
that O
initiate O
carrier O
biogenesis O
remains O
unknown O
. O
We O
examined O
the O
specificity O
and O
initial O
sites O
of O
recruitment O
of O
Arf-dependent O
adaptors O
(AP-1 O
and O
GGAs) O
in O
response O
to O
the O
Golgi O
or O
endosomal O
localization O
of O
specific O
cargo O
proteins O
(furin O
, O
mannose-6-phosphate O
receptor O
(M6PR) O
and O
M6PR O
lacking O
a O
C O
terminal O
domain O
M6PRΔC) O
. O
We O
find O
that O
cargo O
promotes O
the O
recruitment O
of O
specific O
adaptors O
, O
suggesting O
that O
it O
is O
part O
of O
an O
upstream O
signaling O
event O
. O
Cargos O
do O
not O
promote O
adaptor O
recruitment O
to O
all O
compartments O
in O
which O
they O
reside O
and O
thus O
additional O
factors O
regulate O
the O
cargo's O
ability O
to O
promote O
Arf O
activation O
and O

doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
doxorubicin O
in O
control O
and O
EEC O
rats O
. O
3 O
. O
The O
significantly O
greater O
AUC O
(58.7% O
increase) O
of O
doxorubicin O
in O
EEC O
rats O
was O
due O
to O
the O
slower O
CL O
(32.9% O
decrease) O
. O
The O
slower O
CL O
was O
due O
to O
the O
reduction O
of O
hepatic O
biliary O
excretion O
(67.0% O
decrease) O
and O
hepatic O
CYP3A B
subfamily-mediated O
metabolism O
(21.9% O
decrease) O
of O
doxorubicin O
These O
results O
might O
have O
broader O
implications O
to O
understand O
the O
altered O
pharmacokinetics O
and/or O
pharmacologic O
effects O
of O
doxorubicin O
via O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
experimental O
and O
clinical O
estrogen-induced O
cholestasis O
. O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
hepatic O
metabolism O
of O
doxorubicin.Abstract O
1 O
. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein B
(P-gp) O
and O
multidrug O
resistance-associated O
protein O
2 O
(Mrp2) O
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
. O
Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
hepatic O
metabolism O
of O
doxorubicin.Abstract O
1 O
. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein O
(P-gp) O
and O
multidrug O
resistance-associated O
protein O
2 O
(Mrp2) O
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
. O
Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
hepatic O
metabolism O
of O
doxorubicin.Abstract O
1 O
. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein O
(P-gp) O
and O
multidrug B
resistance-associated I
protein I
2 I
(Mrp2) O
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
. O
Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
hepatic O
metabolism O
of O
doxorubicin.Abstract O
1 O
. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein O
(P-gp) O
and O
multidrug O
resistance-associated O
protein O
2 O
(Mrp2) O
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome O
P450 O
(CYP) O
3A O
subfamily O
. O
Also O
the O
hepatic O
Mrp2 B
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
. O
Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O

Doxorubicin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
hepatic O
metabolism O
of O
doxorubicin.Abstract O
1 O
. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen O
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis O
, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol O
(EE O
, O
an O
oral O
contraceptive) O
and O
doxorubicin O
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety O
. O
Doxorubicin O
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein O
(P-gp) O
and O
multidrug O
resistance-associated O
protein O
2 O
(Mrp2) O
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome B
P450 I
(CYP) I
3A I
subfamily O
. O
Also O
the O
hepatic O
Mrp2 O
(not O
P-gp) O
and O
CYP3A O
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats O
. O
Thus O
, O
we O
herein O
report O
the O
pharmacokinetic O

Fluoride O
acts O
as O
NOT O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
manner O
. O
Exposure O
of O
cells O
to O
4mM O
NaF O
for O
24h O
induced O
caspase-3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride O
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK O
or O
ERK O
inhibitors O
, O
respectively O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
NaF O
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK-dependent O
mitochondrial O
pathway O
. O

NaF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
effect O
on O
odontoblasts O
may O
lead O
to O
harmful O
side-effects O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
pro-apoptotic O
effects O
of O
NaF O
in O
odontoblasts O
and O
elucidate O
the O
possible O
underlying O
molecular O
mechanisms O
. O
NaF O
generated O
cytotoxic O
effects O
in O
odontoblast-lineage O
cell O
(OLC) O
in O
a O
dose- O
and O
time-dependent O
manner O
. O
Exposure O
of O
cells O
to O
4mM O
NaF O
for O
24h O
induced O
caspase-3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax B
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
, O
but O
not O
p38 O
, O

NaF O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
effect O
on O
odontoblasts O
may O
lead O
to O
harmful O
side-effects O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
pro-apoptotic O
effects O
of O
NaF O
in O
odontoblasts O
and O
elucidate O
the O
possible O
underlying O
molecular O
mechanisms O
. O
NaF O
generated O
cytotoxic O
effects O
in O
odontoblast-lineage O
cell O
(OLC) O
in O
a O
dose- O
and O
time-dependent O
manner O
. O
Exposure O
of O
cells O
to O
4mM O
NaF O
for O
24h O
induced O
caspase-3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome B
c I
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
, O
but O
not O
p38 O
, O

NaF O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK B
and O
ERK O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride O
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK O
or O
ERK O
inhibitors O
, O
respectively O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
NaF O
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK-dependent O
mitochondrial O
pathway O
. O

NaF O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
effect O
on O
odontoblasts O
may O
lead O
to O
harmful O
side-effects O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
pro-apoptotic O
effects O
of O
NaF O
in O
odontoblasts O
and O
elucidate O
the O
possible O
underlying O
molecular O
mechanisms O
. O
NaF O
generated O
cytotoxic O
effects O
in O
odontoblast-lineage O
cell O
(OLC) O
in O
a O
dose- O
and O
time-dependent O
manner O
. O
Exposure O
of O
cells O
to O
4mM O
NaF O
for O
24h O
induced O
caspase-3 B
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
, O
but O
not O
p38 O
, O

Fluoride O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
manner O
. O
Exposure O
of O
cells O
to O
4mM O
NaF O
for O
24h O
induced O
caspase-3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK B
and O
ERK O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride O
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK O
or O
ERK O
inhibitors O
, O
respectively O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
NaF O
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK-dependent O
mitochondrial O
pathway O
. O

Fluoride O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
a O
dose- O
and O
time-dependent O
manner O
. O
Exposure O
of O
cells O
to O
4mM O
NaF O
for O
24h O
induced O
caspase-3 O
activation O
, O
ultrastructural O
alterations O
, O
and O
resulted O
in O
the O
translocation O
of O
Bax O
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome O
c O
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol O
, O
indicating O
that O
fluoride-mediated O
apoptosis O
is O
mitochondria-dependent O
. O
Fluoride O
treatment O
also O
increased O
phosphorylation O
of O
JNK O
and O
ERK O
, O
but O
not O
p38 O
, O
and O
apoptosis O
induced O
by O
fluoride O
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK O
or O
ERK B
inhibitors O
, O
respectively O
. O
Taken O
together O
, O
these O
findings O
suggest O
that O
NaF O
induces O
apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK-dependent O
mitochondrial O
pathway O
. O

GS-6-DHSG O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
and O
6-shogaol O
, O
6-DHSG O
showed O
the O
most O
potent O
anti-inflammatory O
effect O
in O
lipopolysaccharide O
(LPS)-stimulated O
RAW O
264.7 O
cells O
. O
The O
biological O
activities O
of O
6-DHSG O
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
(GSH) O
or O
N-acetyl O
cysteine O
(NAC) O
, O
but O
not O
ascorbic O
acid O
(ASC) O
. O
6-DHSG O
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
( O
GS-6-DHSG O
in O
RAW O
264.7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione-S-transferase B
(GST) O
. O
GS-6-DHSG O
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG O
in O
multiple O
biological O
assays O
. O
Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O
6-DHSG O
and O
other O
α,β-unsaturated O
carbonyl O
compounds O
. O

GS-6-DHSG O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
and O
6-shogaol O
, O
6-DHSG O
showed O
the O
most O
potent O
anti-inflammatory O
effect O
in O
lipopolysaccharide O
(LPS)-stimulated O
RAW O
264.7 O
cells O
. O
The O
biological O
activities O
of O
6-DHSG O
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
(GSH) O
or O
N-acetyl O
cysteine O
(NAC) O
, O
but O
not O
ascorbic O
acid O
(ASC) O
. O
6-DHSG O
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
( O
GS-6-DHSG O
in O
RAW O
264.7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione-S-transferase O
(GST) O
. O
GS-6-DHSG O
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG O
in O
multiple O
biological O
assays O
. O
Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O
6-DHSG O
and O
other O
α,β-unsaturated O
carbonyl O
compounds O
. O

6-DHSG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
activities O
of O
6-DHSG O
. O
Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6-gingerol O
and O
6-shogaol O
, O
6-DHSG O
showed O
the O
most O
potent O
anti-inflammatory O
effect O
in O
lipopolysaccharide O
(LPS)-stimulated O
RAW O
264.7 O
cells O
. O
The O
biological O
activities O
of O
6-DHSG O
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
(GSH) O
or O
N-acetyl O
cysteine O
(NAC) O
, O
but O
not O
ascorbic O
acid O
(ASC) O
. O
6-DHSG O
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
(GS-6-DHSG) O
in O
RAW O
264.7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione-S-transferase B
(GST) O
. O
GS-6-DHSG O
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG O
in O
multiple O
biological O
assays O
. O
Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O

6-DHSG O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
activities O
of O
6-DHSG O
. O
Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6-gingerol O
and O
6-shogaol O
, O
6-DHSG O
showed O
the O
most O
potent O
anti-inflammatory O
effect O
in O
lipopolysaccharide O
(LPS)-stimulated O
RAW O
264.7 O
cells O
. O
The O
biological O
activities O
of O
6-DHSG O
were O
attenuated O
by O
sulfhydryl O
antioxidants O
such O
as O
glutathione O
(GSH) O
or O
N-acetyl O
cysteine O
(NAC) O
, O
but O
not O
ascorbic O
acid O
(ASC) O
. O
6-DHSG O
was O
metabolised O
by O
GSH O
to O
form O
a O
GSH O
conjugate O
(GS-6-DHSG) O
in O
RAW O
264.7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione-S-transferase O
(GST) O
. O
GS-6-DHSG O
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG O
in O
multiple O
biological O
assays O
. O
Together O
, O
these O
results O
indicate O
that O
GSH O
conjugation O
attenuates O
the O
biological O
activities O
of O

carbamoylmethylene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
carbamoylmethylene O
linked O
prodrugs O
of O
BMS-582949 O
, O
a O
clinical O
p38α B
inhibitor.A O
series O
of O
carbamoylmethylene O
linked O
prodrugs O
of O
1 O
(BMS-582949) O
, O
a O
clinical O
p38α O
inhibitor O
, O
were O
synthesized O
and O
evaluated O
. O
Though O
the O
phosphoryloxymethylene O
carbamates O
(3 O
, O
4 O
, O
and O
5) O
and O
α-aminoacyloxymethylene O
carbamates O
(22 O
, O
23 O
, O
and O
26) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric O
acid O
derived O
acyloxymethylene O
carbamates O
(2 O
, O
28 O
, O
and O
31) O
were O
highly O
stable O
under O
both O

BMS-582949 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
carbamoylmethylene O
linked O
prodrugs O
of O
BMS-582949 O
, O
a O
clinical O
p38α B
inhibitor.A O
series O
of O
carbamoylmethylene O
linked O
prodrugs O
of O
1 O
( O
BMS-582949 O
 O
, O
a O
clinical O
p38α O
inhibitor O
, O
were O
synthesized O
and O
evaluated O
. O
Though O
the O
phosphoryloxymethylene O
carbamates O
(3 O
, O
4 O
, O
and O
5) O
and O
α-aminoacyloxymethylene O
carbamates O
(22 O
, O
23 O
, O
and O
26) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric O
acid O
derived O
acyloxymethylene O
carbamates O
(2 O
, O
28 O
, O
and O
31) O
were O
highly O
stable O
under O
both O
acidic O
and O
neutral O
conditions O
. O

carbamoylmethylene O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
carbamoylmethylen O
linked O
prodrugs O
of O
BMS-582949 O
, O
a O
clinical O
p38α B
inhibitor.A O
series O
of O
carbamoylmethylene O
linked O
prodrugs O
of O
1 O
(BMS-582949) O
, O
a O
clinical O
p38α O
inhibitor O
, O
were O
synthesized O
and O
evaluated O
. O
Though O
the O
phosphoryloxymethylene O
carbamates O
(3 O
, O
4 O
, O
and O
5) O
and O
α-aminoacyloxymethylene O
carbamates O
(22 O
, O
23 O
, O
and O
26) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric O
acid O
derived O

BMS-582949 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
evaluation O
of O
carbamoylmethylene O
linked O
prodrugs O
of O
BMS-58294 O
 O
, O
a O
clinical O
p38α B
inhibitor.A O
series O
of O
carbamoylmethylene O
linked O
prodrugs O
of O
1 O
(BMS-582949) O
, O
a O
clinical O
p38α O
inhibitor O
, O
were O
synthesized O
and O
evaluated O
. O
Though O
the O
phosphoryloxymethylene O
carbamates O
(3 O
, O
4 O
, O
and O
5) O
and O
α-aminoacyloxymethylene O
carbamates O
(22 O
, O
23 O
, O
and O
26) O
were O
found O
unstable O
at O
neutral O
pH O
values O
, O
fumaric O
acid O
derived O
acyloxymethylene O
carbamates O
(2 O
, O

JZL184 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
plasma O
corticosterone O
levels O
, O
anxiety O
and O
locomotor O
activity O
in O
male O
CD1 O
mice.The O
hypothalamus-pituitary-adrenal-axis O
is O
strongly O
controlled O
by O
the O
endocannabinoid O
system O
. O
The O
specific O
impact O
of O
enhanced O
2-arachidonoylglycerol O
signaling O
on O
corticosterone O
plasma O
levels O
, O
however O
, O
was O
not O
investigated O
so O
far O
. O
Here O
we O
studied O
the O
effects O
of O
the O
recently O
developed O
monoacylglycerol B
lipase I
inhibitor O
JZL184 O
on O
basal O
and O
stress-induced O
corticosterone O
levels O
in O
male O
CD1 O
mice O
, O
and O
found O
that O
this O
compound O
dramatically O
increased O
basal O
levels O
without O
affecting O
stress O
responses O
. O
Since O
acute O
changes O
in O
corticosterone O
levels O
can O
affect O
behavior O
, O
JZL184 O
was O
administered O
concurrently O
with O
the O
corticosterone O
synthesis O
inhibitor O
metyrapone O
, O
to O
investigate O
whether O
the O
previously O
shown O
behavioral O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
combined O
(M+S).RESEARCH O
DESIGN O
AND O
METHODSWe O
randomized O
16 O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
to O
four O
6-week O
treatments O
with O
placebo O
(P) O
, O
M O
, O
S O
, O
and O
M+S O
. O
After O
each O
period O
, O
subjects O
received O
a O
6-h O
meal O
tolerance O
test O
(MTT) O
with O
[(14)C]glucose O
to O
calculate O
glucose O
kinetics O
. O
Fasting O
plasma O
glucose O
(FPG) O
, O
fasting O
plasma O
insulin O
, O
C O
peptide O
(insulin O
secretory O
rate O
[ISR]) O
, O
fasting O
plasma O
glucagon O
, O
and O
bioactive O
glucagon-like O
peptide O
(GLP-1) O
and O
gastrointestinal O
insulinotropic O
peptide O
(GIP) O
was O
measured.RESULTSFPG O
decreased O
from O
P O
, O
160 O
± O
4 O
to O
M O
, O
150 O
± O
4; O
S O
, O
154 O
± O
4; O
and O
M+S O
, O
125 O
± O
3 O
mg/dL O
. O
Mean O
post-MTT O
PG O
decreased O
from O
P O
, O
207 O
± O

Sitagliptin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanisms O
of O
Glucose O
Lowering O
of O
Dipeptidyl B
Peptidase-4 I
Inhibitor O
Sitaglipti O
When O
Used O
Alone O
or O
With O
Metformin O
in O
Type O
2 O
Diabetes O
: O
A O
double-tracer O
study.OBJECTIVETo O
assess O
glucose-lowering O
mechanisms O
of O
sitagliptin O
(S) O
, O
metformin O
(M) O
, O
and O
the O
two O
combined O
(M+S).RESEARCH O
DESIGN O
AND O
METHODSWe O
randomized O
16 O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
to O
four O
6-week O
treatments O
with O
placebo O
(P) O
, O
M O
, O
S O
, O
and O
M+S O
. O

rofecoxib O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
rapidly O
adhered O
to O
cancer O
cells O
and O
induced O
COX-2 O
mRNA O
expression O
, O
but O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF O
and O
COX-2 O
mRNA O
stabilization O
. O
Platelet-induced O
COX-2-dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib O
a O
selective O
COX-2 O
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2 O
. O
Galectin-3 O
, O
highly O
expressed O
in O
HT29 O
cells O
, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like O
domain O
. O
Thus O
, O
we O
studied O
the O
role O
of O
galectin-3 O
and O
platelet O
collagen O
receptors O
in O
platelet-induced O
COX-2 O
overexpression O
. O
Inhibitors O
of O
galectin-3 O
function(β-lactose O
, O
a O
dominant-negative O
form O
of O
galectin-3,Gal-3C O
, O

rofecoxib O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
rapidly O
adhered O
to O
cancer O
cells O
and O
induced O
COX-2 O
mRNA O
expression O
, O
but O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF O
and O
COX-2 O
mRNA O
stabilization O
. O
Platelet-induced O
COX-2-dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib O
a O
selective O
COX-2 O
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2 O
. O
Galectin-3 O
, O
highly O
expressed O
in O
HT29 O
cells O
, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like O
domain O
. O
Thus O
, O
we O
studied O
the O
role O
of O
galectin-3 O
and O
platelet O
collagen O
receptors O
in O
platelet-induced O
COX-2 O
overexpression O
. O
Inhibitors O
of O
galectin-3 O
function(β-lactose O
, O
a O
dominant-negative O
form O
of O
galectin-3,Gal-3C O
, O

rofecoxib O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
rapidly O
adhered O
to O
cancer O
cells O
and O
induced O
COX-2 O
mRNA O
expression O
, O
but O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF O
and O
COX-2 O
mRNA O
stabilization O
. O
Platelet-induced O
COX-2-dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib O
a O
selective O
COX-2 O
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2 O
. O
Galectin-3 O
, O
highly O
expressed O
in O
HT29 O
cells O
, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like O
domain O
. O
Thus O
, O
we O
studied O
the O
role O
of O
galectin-3 O
and O
platelet O
collagen O
receptors O
in O
platelet-induced O
COX-2 O
overexpression O
. O
Inhibitors O
of O
galectin-3 O
function(β-lactose O
, O
a O
dominant-negative O
form O
of O
galectin-3,Gal-3C O
, O

rofecoxib O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
rapidly O
adhered O
to O
cancer O
cells O
and O
induced O
COX-2 O
mRNA O
expression O
, O
but O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF O
and O
COX-2 O
mRNA O
stabilization O
. O
Platelet-induced O
COX-2-dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib O
a O
selective O
COX-2 O
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2 O
. O
Galectin-3 O
, O
highly O
expressed O
in O
HT29 O
cells O
, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like O
domain O
. O
Thus O
, O
we O
studied O
the O
role O
of O
galectin-3 O
and O
platelet O
collagen O
receptors O
in O
platelet-induced O
COX-2 O
overexpression O
. O
Inhibitors O
of O
galectin-3 O
function(β-lactose O
, O
a O
dominant-negative O
form O
of O
galectin-3,Gal-3C O
, O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
rapidly O
adhered O
to O
cancer O
cells O
and O
induced O
COX-2 B
mRNA O
expression O
, O
but O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF O
and O
COX-2 O
mRNA O
stabilization O
. O
Platelet-induced O
COX-2-dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib O
a O
selective O
COX-2 O
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2 O
. O
Galectin-3 O
, O
highly O
expressed O
in O
HT29 O
cells O
, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like O
domain O
. O
Thus O
, O
we O
studied O
the O
role O
of O
galectin-3 O
and O
platelet O
collagen O
receptors O
in O
platelet-induced O
COX-2 O
overexpression O
. O
Inhibitors O
of O
galectin-3 O
function(β-lactose O
, O
a O
dominant-negative O
form O
of O
galectin-3,Gal-3C O
, O

prostanoids O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Pharmacological O
Inhibition O
of O
Platelet-tumor O
Cell O
Cross-talk O
Prevents O
Platelet-induced O
Overexpression O
of O
Cyclooxygenase-2 O
in O
HT29 O
Human O
Colon O
Carcinoma O
Cells.Cyclooxygenase(COX)-2-derived O
prostanoids O
can O
influence O
several O
processes O
that O
are O
linked O
to O
carcinogenesis O
. O
We O
aimed O
to O
address O
the O
hypothesis O
that O
platelets O
contribute O
to O
aberrant O
COX-2 O
expression O
in O
HT29 O
colon O
carcinoma O
cells O
and O
to O
reveal O
the O
role O
of O
platelet-induced O
COX-2 O
on O
the O
expression O
of O
proteins O
involved O
in O
malignancy O
and O
marker O
genes O
of O
epithelial-mesenchymal O
transition(EMT) O
. O

PGE2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
COX-2 B
on O
the O
expression O
of O
proteins O
involved O
in O
malignancy O
and O
marker O
genes O
of O
epithelial-mesenchymal O
transition(EMT) O
. O
Human O
platelets O
co-cultured O
with O
HT29 O
cells O
rapidly O
adhered O
to O
cancer O
cells O
and O
induced O
COX-2 O
mRNA O
expression O
, O
but O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF O
and O
COX-2 O
mRNA O
stabilization O
. O
Platelet-induced O
COX-2-dependent O
PGE2 O
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) O
and O
upregulation O
of O
cyclinB1 O
, O
since O
these O
effects O
were O
prevented O
by O
rofecoxib(a O
selective O
COX-2 O
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2 O
. O
Galectin-3 O
, O
highly O
expressed O
in O
HT29 O
cells O
, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like O
domain O
. O
Thus O
, O
we O
studied O
the O

1,3,4-oxadiazole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
antitumor O
activity O
of O
1,3,4-oxadiazol O
possessing O
1,4-benzodioxan O
moiety O
as O
a O
novel O
class O
of O
potent O
methionine B
aminopeptidase I
type I
II I
inhibitors.A O
series O
of O
1,3,4-oxadiazole O
derivatives O
containing O
1,4-benzodioxan O
moiety O
(7a-7q) O
have O
been O
designed O
, O
synthesized O
and O
evaluated O
for O
their O
antitumor O
activity O
. O
Most O
of O
the O
synthesized O
compounds O
were O
proved O
to O
have O
potent O
antitumor O
activity O
and O
low O
toxicity O
. O
Among O
them O
, O

1,4-benzodioxan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
antitumor O
activity O
of O
1,3,4-oxadiazole O
possessing O
1,4-benzodioxa O
moiety O
as O
a O
novel O
class O
of O
potent O
methionine B
aminopeptidase I
type I
II I
inhibitors.A O
series O
of O
1,3,4-oxadiazole O
derivatives O
containing O
1,4-benzodioxan O
moiety O
(7a-7q) O
have O
been O
designed O
, O
synthesized O
and O
evaluated O
for O
their O
antitumor O
activity O
. O
Most O
of O
the O
synthesized O
compounds O
were O
proved O
to O
have O
potent O
antitumor O
activity O
and O
low O
toxicity O
. O
Among O
them O
, O
compound O
7a O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 B
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide O
bridge O
( O
Cys O
26 O
, O
Cys270) O
located O
in O
the O
extracellular O
E-loop O
of O
Nox4 O
. O
Such O
model O
of O
Nox4 O
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i.e. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O

Cys O
acts O
as O
PART-OF O
for O
what O
entity O
? O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 B
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide O
bridge O
(Cys226 O
, O
Cys O
70) O
located O
in O
the O
extracellular O
E-loop O
of O
Nox4 O
. O
Such O
model O
of O
Nox4 O
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i.e. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O
quinones O

quinones O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
(Cys226 O
, O
Cys270) O
located O
in O
the O
extracellular O
E-loop O
of O
Nox4 O
. O
Such O
model O
of O
Nox4 B
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme O
, O
i.e. O
, O
its O
potential O
redox O
regulation O
, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O
quinones O
and O
Nox4 O
are O
implicated O
. O

quinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O

quinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 O
oxidase B
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O

quinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O

AA-861 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
as O
intracellular O
messengers O
. O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
( O
AA-861 O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O

tBuBHQ O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
as O
intracellular O
messengers O
. O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O

tBuBQ O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
intracellular O
messengers O
. O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O

duroquinone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O
we O
showed O
that O
NAD(P)H:quinone O
oxidoreductase O
(NQO1) O
may O
participate O
in O
this O
stimulation O
. O
Interestingly O
, O
Nox4 O
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O

quinone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 B
oxidase O
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O

quinone O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen O
species O
(ROS) O
as O
intracellular O
messengers O
. O
Nox4 O
oxidase B
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however O
, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone O
derivatives O
could O
modulate O
this O
activity O
. O
In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone O
derivatives O
(AA-861 O
, O
tBuBHQ O
, O
tBuBQ O
, O
and O
duroquinone) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T-REx™ O
, O
and O
chondrocyte O
cell O
lines O
. O
Our O
results O
indicate O
that O
the O
effect O
is O
specific O
toward O
Nox4 O
versus O
Nox2 O
. O
Furthermore O
, O

Allicin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
2h O
. O
Treatment O
with O
FRGE O
and O
HRGE O
significantly O
reduced O
the O
LPS-induced O
increase O
in O
the O
pro-inflammatory O
cytokine O
concentration O
(TNF-α O
, O
IL-1β O
, O
and O
IL-6) O
and O
NO O
through O
HO-1 B
upregulation O
in O
RAW O
264.7 O
macrophages O
. O
The O
anti-inflammatory O
effect O
was O
greater O
in O
FRGE O
than O
in O
HRGE O
. O
The O
allicin O
concentration O
was O
higher O
in O
FRGE O
than O
in O
HRGE O
. O
Allicin O
treatment O
showed O
reduced O
production O
of O
pro-inflammatory O
cytokines O
and O
NO O
and O
increased O
HO-1 O
activity O
. O
The O
results O
show O
that O
the O
decrease O
in O
LPS-induced O
NO O
and O
pro-inflammatory O
cytokines O
in O
RAW O
264.7 O
macrophages O
through O
HO-1 O
induction O
was O
greater O
for O
FRGE O
compared O
with O
HRGE O
. O
Additionally O
, O
the O
results O
indicate O
that O
allicin O
is O
responsible O
for O
the O

Allicin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
2h O
. O
Treatment O
with O
FRGE O
and O
HRGE O
significantly O
reduced O
the O
LPS-induced O
increase O
in O
the O
pro-inflammatory O
cytokine O
concentration O
(TNF-α O
, O
IL-1β O
, O
and O
IL-6) O
and O
NO O
through O
HO-1 O
upregulation O
in O
RAW O
264.7 O
macrophages O
. O
The O
anti-inflammatory O
effect O
was O
greater O
in O
FRGE O
than O
in O
HRGE O
. O
The O
allicin O
concentration O
was O
higher O
in O
FRGE O
than O
in O
HRGE O
. O
Allicin O
treatment O
showed O
reduced O
production O
of O
pro-inflammatory O
cytokines B
and O
NO O
and O
increased O
HO-1 O
activity O
. O
The O
results O
show O
that O
the O
decrease O
in O
LPS-induced O
NO O
and O
pro-inflammatory O
cytokines O
in O
RAW O
264.7 O
macrophages O
through O
HO-1 O
induction O
was O
greater O
for O
FRGE O
compared O
with O
HRGE O
. O
Additionally O
, O
the O
results O
indicate O
that O
allicin O
is O
responsible O
for O
the O

Ca(2+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
. O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine B
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[ O
Ca(2+) O
i O
in O
HAPI O
microglial O
cells O
. O

Ca(2+) O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
NF-κB B
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
. O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine O
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[ O
Ca(2+) O
i O
in O
HAPI O
microglial O
cells O
. O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
cyclooxygenase-2 O
(COX-2) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD O
treatment O
. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca(2+) O
blockers O
, O
bis-(o-aminophenoxy) O
ethane-N,N,N',N'-tetra-acetic O
acid O
acetoxymethyl O
ester O
(BAPTA-AM) O
and O
nifedipine O
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) O
([Ca(2+)]i) O
. O
Further O
, O
TCDD O
exposure O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O
and O
the O
translocation O
of O
NF-κB O
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) O
([Ca(2+)]i) O
. O
Further O
, O
TCDD O
exposure O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O
and O
the O
translocation O
of O
NF-κB B
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
. O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine O
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i O
in O
HAPI O
microglial O
cells O
. O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O
and O
the O
translocation O
of O
NF-κB B
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine O
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i O
in O
HAPI O
microglial O
cells O
. O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
. O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine B
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i O
in O
HAPI O
microglial O
cells O
. O

TCDD O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB B
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
. O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine O
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i O
in O
HAPI O
microglial O
cells O
. O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
microglial O
cells.2,3,7,8-Tetrachlorodibenzo-p-dioxin O
(TCDD) O
has O
been O
known O
to O
induce O
inflammatory O
signaling O
in O
a O
number O
of O
cell O
types O
and O
tissues O
. O
However O
, O
the O
adverse O
effects O
of O
TCDD O
on O
the O
central O
nervous O
system O
(CNS) O
have O
not O
been O
entirely O
elucidated O
. O
In O
this O
study O
, O
using O
reverse O
transcriptase O
PCR O
(RT-PCR) O
and O
ELISA O
, O
we O
showed O
that O
TCDD O
up-regulated O
the O
expression O
and O
secretion O
of O
tumor B
necrosis I
factor-alpha I
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
microglial O
cells.2,3,7,8-Tetrachlorodibenzo-p-dioxin O
(TCDD) O
has O
been O
known O
to O
induce O
inflammatory O
signaling O
in O
a O
number O
of O
cell O
types O
and O
tissues O
. O
However O
, O
the O
adverse O
effects O
of O
TCDD O
on O
the O
central O
nervous O
system O
(CNS) O
have O
not O
been O
entirely O
elucidated O
. O
In O
this O
study O
, O
using O
reverse O
transcriptase O
PCR O
(RT-PCR) O
and O
ELISA O
, O
we O
showed O
that O
TCDD O
up-regulated O
the O
expression O
and O
secretion O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
adverse O
effects O
of O
TCDD O
on O
the O
central O
nervous O
system O
(CNS) O
have O
not O
been O
entirely O
elucidated O
. O
In O
this O
study O
, O
using O
reverse O
transcriptase O
PCR O
(RT-PCR) O
and O
ELISA O
, O
we O
showed O
that O
TCDD O
up-regulated O
the O
expression O
and O
secretion O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic B
phospholipase I
A2 I
(cPLA2) O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O
cyclooxygenase-2 O
(COX-2) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD O
treatment O
. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
adverse O
effects O
of O
TCDD O
on O
the O
central O
nervous O
system O
(CNS) O
have O
not O
been O
entirely O
elucidated O
. O
In O
this O
study O
, O
using O
reverse O
transcriptase O
PCR O
(RT-PCR) O
and O
ELISA O
, O
we O
showed O
that O
TCDD O
up-regulated O
the O
expression O
and O
secretion O
of O
tumor O
necrosis O
factor-alpha O
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O
cyclooxygenase-2 O
(COX-2) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD O
treatment O
. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O
cyclooxygenase-2 B
(COX-2) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD O
treatment O
. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca(2+) O
blockers O
, O
bis-(o-aminophenoxy) O
ethane-N,N,N',N'-tetra-acetic O
acid O
acetoxymethyl O
ester O
(BAPTA-AM) O
and O
nifedipine O
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) O
([Ca(2+)]i) O
. O
Further O
, O
TCDD O
exposure O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
(TNF-α) O
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells O
. O
TCDD O
also O
caused O
a O
fast O
(within O
30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
. O
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O
cyclooxygenase-2 O
(COX-2) O
, O
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD O
treatment O
. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca(2+) O
blockers O
, O
bis-(o-aminophenoxy) O
ethane-N,N,N',N'-tetra-acetic O
acid O
acetoxymethyl O
ester O
(BAPTA-AM) O
and O
nifedipine O
, O
thus O
, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) O
([Ca(2+)]i) O
. O
Further O
, O
TCDD O
exposure O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O

TCDD O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα O
, O
and O
the O
translocation O
of O
NF-κB B
p65 O
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line O
. O
Thus O
, O
the O
NF-κB O
signaling O
pathway O
can O
be O
activated O
after O
TCDD O
treatment O
. O
However O
, O
Ca(2+) O
blockers O
also O
obviously O
attenuated O
NF-κB O
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD O
In O
concert O
with O
these O
results O
, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine O
and O
NF-κB O
activation O
induced O
by O
TCDD O
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i O
in O
HAPI O
microglial O
cells O
. O

Vandetanib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
(Caprelsa(®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine O
kinase O
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor O
receptor O
tyrosine O
kinase O
RET O
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O

Vandetanib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
(Caprelsa(®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine B
kinase I
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor O
receptor O
tyrosine O
kinase O
RET O
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O

Vandetanib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
(Caprelsa(®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine O
kinase O
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor B
receptor I
tyrosine I
kinase I
RET O
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O

Vandetanib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
(Caprelsa(®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine O
kinase O
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor O
receptor O
tyrosine O
kinase O
RET B
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O

Caprelsa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
( O
Caprelsa O
®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine O
kinase O
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor O
receptor O
tyrosine O
kinase O
RET O
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O

Caprelsa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vandetanib O
: O
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma.Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage O
, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
% O
. O
Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival O
. O
Vandetanib O
( O
Caprelsa O
®) O
, O
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine B
kinase I
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor O
receptor O
tyrosine O
kinase O
RET O
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs) O
, O
vascular O
endothelial O
growth-factor O
receptors O
2 O
and O
3 O
, O
and O
epidermal O
growth-factor O
receptors O
. O
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O

Ca2+ O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
longer O
treatment O
reduced O
both O
surface O
and O
total O
expression O
. O
APV O
blocked O
NMDA O
effects O
on O
δ O
subunit O
expression O
. O
Chelation O
of O
calcium O
ions O
by O
BAPTA-AM O
or O
blockade O
of O
ERK1/2 O
activation O
by O
UO126 O
also O
prevented O
the O
NMDA O
effects O
. O
Thus O
prolonged O
activation O
of O
NMDA O
receptors O
in O
hippocampal O
neurons O
reduced O
GABAR B
δ I
subunit I
expression O
through O
Ca2+ O
entry O
and O
at O
least O
in O
part O
by O
ERK1/2 O
activation O
. O

UO126 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
course O
of O
NMDA O
effects O
on O
surface O
and O
total O
δ O
subunit O
expression O
were O
distinct; O
shorter O
(6 O
hrs) O
treatment O
decreased O
surface O
expression O
, O
whereas O
longer O
treatment O
reduced O
both O
surface O
and O
total O
expression O
. O
APV O
blocked O
NMDA O
effects O
on O
δ O
subunit O
expression O
. O
Chelation O
of O
calcium O
ions O
by O
BAPTA-AM O
or O
blockade O
of O
ERK1/2 B
activation O
by O
UO126 O
also O
prevented O
the O
NMDA O
effects O
. O
Thus O
prolonged O
activation O
of O
NMDA O
receptors O
in O
hippocampal O
neurons O
reduced O
GABAR O
δ O
subunit O
expression O
through O
Ca2+ O
entry O
and O
at O
least O
in O
part O
by O
ERK1/2 O
activation O
. O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
with O
itself O
or O
the O
other O
two O
GLRs O
. O
Mutations O
in O
GLR3.2 O
, O
GLR3.4 O
, O
or O
GLR3.2 B
and O
GLR3.4 O
caused O
the O
same O
and O
equally O
severe O
phenotype O
, O
namely O
, O
a O
large O
overproduction O
and O
aberrant O
placement O
of O
lateral O
root O
primordia O
. O
Loss O
of O
GLR3.3 O
did O
not O
affect O
lateral O
root O
primordia O
. O
These O
results O
support O
the O
hypothesis O
that O
apoplastic O
amino O
acids O
acting O
through O
heteromeric O
GLR3.2/GLR3.4 O
channels O
affect O
lateral O
root O
development O
via O
Ca(2+) O
signaling O
in O
the O
phloem O
. O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
with O
itself O
or O
the O
other O
two O
GLRs O
. O
Mutations O
in O
GLR3.2 O
, O
GLR3.4 O
, O
or O
GLR3.2 O
and O
GLR3.4 B
caused O
the O
same O
and O
equally O
severe O
phenotype O
, O
namely O
, O
a O
large O
overproduction O
and O
aberrant O
placement O
of O
lateral O
root O
primordia O
. O
Loss O
of O
GLR3.3 O
did O
not O
affect O
lateral O
root O
primordia O
. O
These O
results O
support O
the O
hypothesis O
that O
apoplastic O
amino O
acids O
acting O
through O
heteromeric O
GLR3.2/GLR3.4 O
channels O
affect O
lateral O
root O
development O
via O
Ca(2+) O
signaling O
in O
the O
phloem O
. O

prunetin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB B
kinase I
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

prunetin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

prunetin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

prunetin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

prunetin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
investigated O
by O
NF-κB B
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

prunetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
western O
blot O
and O
or O
realtime-PCR O
(RT-PCR) O
. O
To O
elucidate O
its O
underlying O
mechanism O
, O
nuclear O
factor-kappa O
B O
(NF-κb) O
activation O
and O
its O
downstream O
pathways O
were O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS B
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O

prunetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
western O
blot O
and O
or O
realtime-PCR O
(RT-PCR) O
. O
To O
elucidate O
its O
underlying O
mechanism O
, O
nuclear O
factor-kappa O
B O
(NF-κb) O
activation O
and O
its O
downstream O
pathways O
were O
investigated O
by O
NF-κB O
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 B
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O

prunetin O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines B
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

prunetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Anti-inflammatory O
effect O
of O
pruneti O
via O
the O
suppression O
of O
NF-κB B
pathway.Prunetin O
is O
an O
O-methylated O
isoflavone O
, O
which O
is O
found O
in O
Prunus O
yedoensis O
. O
To O
date O
no O
report O
has O
been O
published O
on O
anti-inflammatory O
activities O
of O
prunetin O
. O
In O
the O
present O
study O
, O
the O
anti-inflammatory O
effect O
of O
prunetin O
on O
LPS-stimulated O
RAW O
264.7 O
macrophage O
and O
LPS-induced O
septic O
shock O
model O
were O
investigated O
. O

prunetin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
investigated O
by O
NF-κB B
transcription O
factor O
assay O
, O
reporter O
gene O
expression O
, O
and O
western O
blot O
. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin O
were O
evaluated O
in O
LPS-induced O
endotoxemia O
. O
Promoter O
assay O
revealed O
that O
prunetin O
inhibits O
LPS-induced O
nitric O
oxide O
and O
prostaglandin O
E2 O
production O
through O
the O
suppression O
of O
iNOS O
and O
COX-2 O
at O
the O
transcriptional O
level O
. O
In O
addition O
, O
prunetin O
inhibits O
NF-κB-dependent O
inflammatory O
responses O
by O
modulating O
IκB O
kinase O
(IKK)-inhibitor O
κBα O
(IκBα)-NF-κB O
signaling O
. O
Consistent O
with O
these O
results O
, O
prunetin O
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines O
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide O
. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin O
. O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
5-Lipoxygenase O
inhibitors O
: O
a O
review O
of O
recent O
patents O
(2010 O
- O
2012).Introduction O
: O
5-Lipoxygenase O
(5-LO) O
is O
a O
crucial O
enzyme O
of O
the O
arachidonic O
acid O
(AA) O
cascade O
and O
catalyzes O
the O
formation O
of O
bioactive O
leukotrienes O
(LTs) O
with O
the O
help O
of O
FLAP O
, O
the O
5-LO-activating O
protein O
. O
LTs O
are O
inflammatory O
mediators O
playing O
a O
pathophysiological O
role O
in O
different O
diseases O
like O
asthma O
, O
allergic O
rhinitis O
as O
well O
as O
cardiovascular O
diseases O
and O
certain O
types O
of O
cancer O
. O
With O
the O
rising O
number O
of O
indications O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
5-Lipoxygenase B
inhibitors O
: O
a O
review O
of O
recent O
patents O
(2010 O
- O
2012).Introduction O
: O
5-Lipoxygenase O
(5-LO) O
is O
a O
crucial O
enzyme O
of O
the O
arachidonic O
acid O
(AA) O
cascade O
and O
catalyzes O
the O
formation O
of O
bioactive O
leukotrienes O
(LTs) O
with O
the O
help O
of O
FLAP O
, O
the O
5-LO-activating O
protein O
. O
LTs O
are O
inflammatory O
mediators O
playing O
a O
pathophysiological O
role O
in O
different O
diseases O
like O
asthma O
, O
allergic O
rhinitis O
as O
well O
as O
cardiovascular O
diseases O
and O
certain O
types O
of O
cancer O
. O
With O
the O
rising O
number O
of O
indications O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
protein O
kinase O
CASK O
in O
interacting O
and O
controlling O
P2X3 B
receptor O
expression O
and O
function O
in O
mouse O
trigeminal O
ganglia O
. O
Most O
ganglion O
neurons O
in O
situ O
or O
in O
culture O
co-expressed O
P2X3 O
and O
CASK O
. O
CASK O
was O
immunoprecipitated O
with O
P2X3 O
receptors O
from O
trigeminal O
ganglia O
and O
from O
P2X3/CASK-cotransfected O
HEK O
cells O
. O
Recombinant O
P2X3/CASK O
expression O
in O
HEK O
cells O
increased O
serine O
phosphorylation O
of O
P2X3 O
receptors O
, O
typically O
associated O
with O
receptor O
upregulation O
. O
CASK O
deletion O
mutants O
also O
enhanced O
P2X3 O
subunit O
expression O
. O
After O
silencing O
CASK O
, O
cell O
surface O
P2X3 O
receptor O
expression O
was O
decreased O
, O
which O
is O
consistent O
with O
depressed O
P2X3 O
currents O
. O
The O
reduction O
of O
P2X3 O
expression O
levels O
was O
reversed O
by O
the O
proteasomal O
inhibitor O
MG-132 O
. O
Moreover O
, O
neuronal O

MG-132 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
cells O
increased O
serine O
phosphorylation O
of O
P2X3 B
receptors O
, O
typically O
associated O
with O
receptor O
upregulation O
. O
CASK O
deletion O
mutants O
also O
enhanced O
P2X3 O
subunit O
expression O
. O
After O
silencing O
CASK O
, O
cell O
surface O
P2X3 O
receptor O
expression O
was O
decreased O
, O
which O
is O
consistent O
with O
depressed O
P2X3 O
currents O
. O
The O
reduction O
of O
P2X3 O
expression O
levels O
was O
reversed O
by O
the O
proteasomal O
inhibitor O
MG-132 O
Moreover O
, O
neuronal O
CASK/P2X3 O
interaction O
was O
upregulated O
by O
NGF O
signaling O
and O
downregulated O
by O
P2X3 O
agonist-induced O
desensitization O
. O
These O
data O
suggest O
a O
novel O
interaction O
between O
CASK O
and O
P2X3 O
receptors O
with O
positive O
outcome O
for O
receptor O
stability O
and O
function O
. O
As O
CASK-mediated O
control O
of O
P2X3 O
receptors O
was O
dependent O
on O
the O
receptor O
activation O
state O
, O
CASK O
represents O

calcium O
acts O
as O
NOT O
for O
what O
entity O
? O
had O
only O
a O
minimal O
effect O
on O
autoactivation O
. O
The O
tetra-aspartate O
motif O
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium O
(KD O
~1.6 O
mM) O
, O
which O
stimulates O
autoactivation O
. O
Unexpectedly O
, O
calcium O
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O
peptide O
mutations O
. O
Despite O
normal O
binding O
, O
autoactivation O
of O
mutants O
D22G B
and O
K23_I24insIDK O
was O
not O
stimulated O
by O
calcium O
Finally O
, O
the O
activation O
peptide O
mutants O
exhibited O
reduced O
secretion O
from O
transfected O
cells O
, O
and O
secreted O
trypsinogen O
levels O
were O
inversely O
proportional O
with O
autoactivation O
rates O
. O
We O
conclude O
that O
D19A O
, O
D22G O
, O
K23R O
and O
K23_I24insIDK O
form O
a O
mechanistically O
distinct O
subset O
of O
hereditary O
pancreatitis O
associated O
mutations O
, O
which O
exert O
their O
effect O
primarily O
through O
direct O
stimulation O
of O
autoactivation O
, O

calcium O
acts O
as O
NOT O
for O
what O
entity O
? O
had O
only O
a O
minimal O
effect O
on O
autoactivation O
. O
The O
tetra-aspartate O
motif O
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium O
(KD O
~1.6 O
mM) O
, O
which O
stimulates O
autoactivation O
. O
Unexpectedly O
, O
calcium O
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O
peptide O
mutations O
. O
Despite O
normal O
binding O
, O
autoactivation O
of O
mutants O
D22G O
and O
K23_I24insIDK B
was O
not O
stimulated O
by O
calcium O
Finally O
, O
the O
activation O
peptide O
mutants O
exhibited O
reduced O
secretion O
from O
transfected O
cells O
, O
and O
secreted O
trypsinogen O
levels O
were O
inversely O
proportional O
with O
autoactivation O
rates O
. O
We O
conclude O
that O
D19A O
, O
D22G O
, O
K23R O
and O
K23_I24insIDK O
form O
a O
mechanistically O
distinct O
subset O
of O
hereditary O
pancreatitis O
associated O
mutations O
, O
which O
exert O
their O
effect O
primarily O
through O
direct O
stimulation O
of O
autoactivation O
, O

calcium O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
presence O
and O
absence O
of O
CTRC O
. O
Degradation O
of O
the O
mutants O
by O
CTRC O
was O
unchanged O
and O
processing O
of O
the O
activation O
peptide O
was O
increased O
only O
in O
the O
D19A O
mutant O
by O
4-fold O
. O
Surprisingly O
, O
however O
, O
this O
increased O
processing O
had O
only O
a O
minimal O
effect O
on O
autoactivation O
. O
The O
tetra-aspartate B
motif I
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium O
(KD O
~1.6 O
mM) O
, O
which O
stimulates O
autoactivation O
. O
Unexpectedly O
, O
calcium O
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O
peptide O
mutations O
. O
Despite O
normal O
binding O
, O
autoactivation O
of O
mutants O
D22G O
and O
K23_I24insIDK O
was O
not O
stimulated O
by O
calcium O
. O
Finally O
, O
the O
activation O
peptide O
mutants O
exhibited O
reduced O
secretion O
from O
transfected O
cells O
, O
and O
secreted O
trypsinogen O
levels O
were O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol B
esterase I
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase B
over O
AChE O
, O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase B
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O

flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
phosphorylated O
flavonoids O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase B
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase B
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol O
esterase O
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase O
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O

hydroxyl O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
these O
phosphorylated O
flavonoids O
demonstrated O
good O
to O
high O
selectivity O
for O
CEase B
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O
position O
5 O
and O
phosphate O
group O
at O
position O
7 O
of O
the O
phosphorylated O
flavonoids O
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O
The O
inhibition O
mechanism O
and O
kinetic O
characterization O
studies O
indicated O
that O
they O
are O
irreversible O
competitive O
inhibitors O
of O
CEase O
. O

phosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
high O
selectivity O
for O
CEase B
over O
AChE O
, O
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase O
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O
position O
5 O
and O
phosphate O
group O
at O
position O
7 O
of O
the O
phosphorylated O
flavonoids O
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O
The O
inhibition O
mechanism O
and O
kinetic O
characterization O
studies O
indicated O
that O
they O
are O
irreversible O
competitive O
inhibitors O
of O
CEase O
. O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE O
. O
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase B
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase O
over O
AChE O
. O
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl O
group O
at O
position O
5 O
and O
phosphate O
group O
at O
position O
7 O
of O
the O
phosphorylated O
flavonoids O
are O
favorable O
to O
the O
inhibition O
of O
CEase O
. O
The O
inhibition O
mechanism O
and O
kinetic O
characterization O
studies O
indicated O
that O
they O
are O
irreversible O
competitive O
inhibitors O
of O
CEase O
. O

phosphorylated O
flavonoids O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated O
flavonoid O
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol O
esterase.A O
series O
of O
phosphorylated O
flavonoids O
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol B
esterase I
(CEase) O
and O
acetylcholinesterase O
(AChE) O
. O
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O
CEase O
, O
much O
better O
than O
the O
parent O
flavonoids O
. O
Furthermore O
, O

Pasireotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pasireotide O
: O
A O
Review O
of O
Its O
Use O
in O
Cushing's O
Disease O
. O
Pasireotide O
(Signifor(®)) O
is O
a O
new O
subcutaneous O
somatostatin O
analogue O
that O
acts O
via O
somatostatin B
receptors I
to O
inhibit O
the O
secretion O
of O
corticotropin O
from O
the O
pituitary O
adenoma O
in O
patients O
with O
Cushing's O
disease O
. O
Pasireotide O
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin O
analogues O
, O
binding O
with O
high O
affinity O
to O
somatostatin O
receptor O

Signifor O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pasireotide O
: O
A O
Review O
of O
Its O
Use O
in O
Cushing's O
Disease.Pasireotide O
( O
Signifor O
®)) O
is O
a O
new O
subcutaneous O
somatostatin O
analogue O
that O
acts O
via O
somatostatin B
receptors I
to O
inhibit O
the O
secretion O
of O
corticotropin O
from O
the O
pituitary O
adenoma O
in O
patients O
with O
Cushing's O
disease O
. O
Pasireotide O
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin O
analogues O
, O
binding O
with O
high O
affinity O
to O
somatostatin O
receptor O

Pasireotide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pasireotide O
: O
A O
Review O
of O
Its O
Use O
in O
Cushing's O
Disease.Pasireotide O
(Signifor(®)) O
is O
a O
new O
subcutaneous O
somatostatin O
analogue O
that O
acts O
via O
somatostatin O
receptors O
to O
inhibit O
the O
secretion O
of O
corticotropin O
from O
the O
pituitary O
adenoma O
in O
patients O
with O
Cushing's O
disease O
. O
Pasireotide O
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin O
analogues O
, O
binding O
with O
high O
affinity O
to O
somatostatin O
receptor O
subtype O
5 O
, O
which O
is O
strongly O
over O
expressed O
in O
corticotroph O
adenoma O
cells O
. O
Pasireotide O
is O
the O
first O
pituitary-directed O
agent O
to O
be O
approved O
for O
use O
in O
Cushing's O
disease O
. O
In O
a O
phase O

Pasireotide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pasireotide O
: O
A O
Review O
of O
Its O
Use O
in O
Cushing's O
Disease O
. O
Pasireotide O
(Signifor(®)) O
is O
a O
new O
subcutaneous O
somatostatin O
analogue O
that O
acts O
via O
somatostatin O
receptors O
to O
inhibit O
the O
secretion O
of O
corticotropin B
from O
the O
pituitary O
adenoma O
in O
patients O
with O
Cushing's O
disease O
. O
Pasireotide O
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin O
analogues O
, O
binding O
with O
high O
affinity O
to O
somatostatin O
receptor O

Signifor O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Pasireotide O
: O
A O
Review O
of O
Its O
Use O
in O
Cushing's O
Disease.Pasireotide O
( O
Signifor O
®)) O
is O
a O
new O
subcutaneous O
somatostatin O
analogue O
that O
acts O
via O
somatostatin O
receptors O
to O
inhibit O
the O
secretion O
of O
corticotropin B
from O
the O
pituitary O
adenoma O
in O
patients O
with O
Cushing's O
disease O
. O
Pasireotide O
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin O
analogues O
, O
binding O
with O
high O
affinity O
to O
somatostatin O
receptor O

crizotinib O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
targets O
for O
anticancer O
therapy O
. O
Recently O
, O
several O
molecularly O
distinct O
phenotypes O
of O
NSCLC O
based O
on O
specific O
and O
mutually O
exclusive O
genetic O
derangements O
have O
been O
described O
. O
Few O
targets O
like O
epidermal O
growth O
factor O
receptor O
(EGFR) O
mutations O
and O
anaplastic B
lymphoma I
kinase I
(ALK) O
gene O
rearrangements O
have O
successfully O
been O
targeted O
with O
EGFR O
tyrosine O
kinase O
inhibitors O
(TKIs) O
and O
crizotinib O
respectively O
. O
Many O
more O
inhibitors O
of O
specific O
driver O
mutations O
involving O
genes O
like O
ROS O
, O
c-MET O
, O
FGFR O
, O
mTOR O
, O
IGFR O
and O
RET O
are O
currently O
under O
development O
. O
However O
, O
efforts O
to O
target O
some O
mutated O
genes O
like O
K-RAS O
have O
been O
unsuccessful O
. O
Moreover O
, O
the O
emerging O
challenge O
of O
acquired O
resistance O
to O
initially O
effective O
therapy O
is O
becoming O
another O
major O

crizotinib O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
targets O
for O
anticancer O
therapy O
. O
Recently O
, O
several O
molecularly O
distinct O
phenotypes O
of O
NSCLC O
based O
on O
specific O
and O
mutually O
exclusive O
genetic O
derangements O
have O
been O
described O
. O
Few O
targets O
like O
epidermal O
growth O
factor O
receptor O
(EGFR) O
mutations O
and O
anaplastic O
lymphoma O
kinase O
(ALK) O
gene O
rearrangements O
have O
successfully O
been O
targeted O
with O
EGFR O
tyrosine O
kinase O
inhibitors O
(TKIs) O
and O
crizotinib O
respectively O
. O
Many O
more O
inhibitors O
of O
specific O
driver O
mutations O
involving O
genes O
like O
ROS O
, O
c-MET O
, O
FGFR O
, O
mTOR O
, O
IGFR O
and O
RET O
are O
currently O
under O
development O
. O
However O
, O
efforts O
to O
target O
some O
mutated O
genes O
like O
K-RAS O
have O
been O
unsuccessful O
. O
Moreover O
, O
the O
emerging O
challenge O
of O
acquired O
resistance O
to O
initially O
effective O
therapy O
is O
becoming O
another O
major O

fenclozic O
acid O
acts O
as O
NOT O
for O
what O
entity O
? O
observed O
in O
incubations O
undertaken O
with O
dog O
and O
rat O
hepatocytes O
, O
where O
a O
taurine O
conjugate O
of O
the O
drug O
was O
detected O
. O
Although O
an O
acyl O
glucuronide O
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human O
, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA O
, O
there O
was O
no O
detectable O
UDPGA-dependent O
covalent O
binding O
. O
No O
effects O
were O
observed O
when O
fenclozic O
acid O
was O
assessed O
for O
P450-dependent O
and O
P450-independent O
cytotoxicity O
to O
THLE O
cell O
lines O
, O
time-dependent O
inhibition O
of O
five O
major O
human O
cytochrome O
P450 B
enzymes O
, O
inhibition O
of O
the O
biliary O
efflux O
transporters O
BSEP O
and O
MRP2 O
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells O
. O
These O
data O
suggest O
that O
Phase O
1 O
bioactivation O
plays O
a O
role O
in O
the O

fenclozic O
acid O
acts O
as O
NOT O
for O
what O
entity O
? O
observed O
in O
incubations O
undertaken O
with O
dog O
and O
rat O
hepatocytes O
, O
where O
a O
taurine O
conjugate O
of O
the O
drug O
was O
detected O
. O
Although O
an O
acyl O
glucuronide O
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human O
, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA O
, O
there O
was O
no O
detectable O
UDPGA-dependent O
covalent O
binding O
. O
No O
effects O
were O
observed O
when O
fenclozic O
acid O
was O
assessed O
for O
P450-dependent O
and O
P450-independent O
cytotoxicity O
to O
THLE O
cell O
lines O
, O
time-dependent O
inhibition O
of O
five O
major O
human O
cytochrome O
P450 B
enzymes O
, O
inhibition O
of O
the O
biliary O
efflux O
transporters O
BSEP O
and O
MRP2 O
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells O
. O
These O
data O
suggest O
that O
Phase O
1 O
bioactivation O
plays O
a O
role O
in O
the O

fenclozic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
observed O
in O
incubations O
undertaken O
with O
dog O
and O
rat O
hepatocytes O
, O
where O
a O
taurine O
conjugate O
of O
the O
drug O
was O
detected O
. O
Although O
an O
acyl O
glucuronide O
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human O
, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA O
, O
there O
was O
no O
detectable O
UDPGA-dependent O
covalent O
binding O
. O
No O
effects O
were O
observed O
when O
fenclozic O
acid O
was O
assessed O
for O
P450-dependent O
and O
P450-independent O
cytotoxicity O
to O
THLE O
cell O
lines O
, O
time-dependent O
inhibition O
of O
five O
major O
human B
cytochrome I
P450 I
enzymes O
, O
inhibition O
of O
the O
biliary O
efflux O
transporters O
BSEP O
and O
MRP2 O
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells O
. O
These O
data O
suggest O
that O
Phase O
1 O
bioactivation O
plays O
a O
role O
in O
the O

fenclozic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
observed O
in O
incubations O
undertaken O
with O
dog O
and O
rat O
hepatocytes O
, O
where O
a O
taurine O
conjugate O
of O
the O
drug O
was O
detected O
. O
Although O
an O
acyl O
glucuronide O
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human O
, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA O
, O
there O
was O
no O
detectable O
UDPGA-dependent O
covalent O
binding O
. O
No O
effects O
were O
observed O
when O
fenclozic O
acid O
was O
assessed O
for O
P450-dependent O
and O
P450-independent O
cytotoxicity O
to O
THLE O
cell O
lines O
, O
time-dependent O
inhibition O
of O
five O
major O
human O
cytochrome O
P450 O
enzymes O
, O
inhibition O
of O
the O
biliary O
efflux B
transporters I
BSEP O
and O
MRP2 O
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells O
. O
These O
data O
suggest O
that O
Phase O
1 O
bioactivation O
plays O
a O
role O
in O
the O

fenclozic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
observed O
in O
incubations O
undertaken O
with O
dog O
and O
rat O
hepatocytes O
, O
where O
a O
taurine O
conjugate O
of O
the O
drug O
was O
detected O
. O
Although O
an O
acyl O
glucuronide O
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human O
, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA O
, O
there O
was O
no O
detectable O
UDPGA-dependent O
covalent O
binding O
. O
No O
effects O
were O
observed O
when O
fenclozic O
acid O
was O
assessed O
for O
P450-dependent O
and O
P450-independent O
cytotoxicity O
to O
THLE O
cell O
lines O
, O
time-dependent O
inhibition O
of O
five O
major O
human O
cytochrome O
P450 O
enzymes O
, O
inhibition O
of O
the O
biliary O
efflux O
transporters O
BSEP B
and O
MRP2 O
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells O
. O
These O
data O
suggest O
that O
Phase O
1 O
bioactivation O
plays O
a O
role O
in O
the O

fenclozic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
observed O
in O
incubations O
undertaken O
with O
dog O
and O
rat O
hepatocytes O
, O
where O
a O
taurine O
conjugate O
of O
the O
drug O
was O
detected O
. O
Although O
an O
acyl O
glucuronide O
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human O
, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA O
, O
there O
was O
no O
detectable O
UDPGA-dependent O
covalent O
binding O
. O
No O
effects O
were O
observed O
when O
fenclozic O
acid O
was O
assessed O
for O
P450-dependent O
and O
P450-independent O
cytotoxicity O
to O
THLE O
cell O
lines O
, O
time-dependent O
inhibition O
of O
five O
major O
human O
cytochrome O
P450 O
enzymes O
, O
inhibition O
of O
the O
biliary O
efflux O
transporters O
BSEP O
and O
MRP2 B
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells O
. O
These O
data O
suggest O
that O
Phase O
1 O
bioactivation O
plays O
a O
role O
in O
the O

S1P O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P O
induced O
nuclear O
localization O
of O
β-catenin O
. O
We O
further O
investigated O
the O
effects O
of O
PI3K/Akt O
signaling O
on O
the O
Wnt/β-catenin O
signaling O
pathway O
, O
since O
β-catenin B
takes O
a O
central O
role O
in O
this O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O

S1P O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O

S1P O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O

S1P O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O

S1P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K B
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

S1P O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt B
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
suppressed O
S1P-induced O
nuclear O
localization O
of O
β-catenin O
. O
We O
further O
investigated O
the O
effects O
of O
PI3K/Akt O
signaling O
on O
the O
Wnt/β-catenin O
signaling O
pathway O
, O
since O
β-catenin O
takes O
a O
central O
role O
in O
this O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin B
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin B
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin B
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
signaling O
pathway O
. O
Both O
inhibitors O
for O
PI3K O
and O
Akt O
suppressed O
the O
nuclear O
localization O
of O
β-catenin O
and O
T-cell O
factor O
transcriptional O
activity O
induced O
by O
Wnt-3a O
. O
S1P O
increased O
the O
amount O
of O
osteoprotegerin O
at O
both O
mRNA O
and O
protein O
levels O
, O
and O
increased O
the O
activity O
of O
alkaline O
phosphatase O
, O
leading O
to O
the O
mineralization O
. O
These O
findings O
suggest O
that O
S1P O
activates O
the O
PI3K/Akt O
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin O
in O
osteoblast-like O
cells O
, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin O
and O
osteoblast O
differentiation O
markers O
including O
alkaline O
phosphatase O
, O
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization O
, O
respectively O
. O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol B
3-kinase I
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K B
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O

S1P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen O
synthase O
kinase-3β O
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt B
suppressed O
S1P-induced O
nuclear O
localization O

S1P O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
bioactive O
lipid O
mediator O
. O
Recently O
, O
it O
was O
reported O
that O
S1P O
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption O
. O
On O
the O
other O
hand O
, O
S1P O
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known O
. O
In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
S1P O
on O
osteoblasts O
, O
using O
two O
osteoblast-like O
cell O
lines O
, O
SaOS-2 O
and O
MC3T3-E1 O
. O
S1P O
activated O
phosphatidylinositol O
3-kinase O
(PI3K)/Akt O
signaling O
, O
leading O
to O
the O
inhibition O
of O
glycogen B
synthase I
kinase-3β I
and O
the O
nuclear O
translocation O
of O
β-catenin O
, O
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell O
factor O
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O
MC3T3-E1 O
cells O
. O
The O
inhibitors O
of O
PI3K O
and O
Akt O
suppressed O
S1P-induced O
nuclear O
localization O

pyrethroid O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
to O
return O
to O
normal O
after O
72 O
h O
. O
Significant O
increases O
in O
the O
levels O
of O
CK O
, O
γ-GT O
, O
SOD O
, O
NO O
, O
MDA O
, O
AFP O
, O
IL-2 O
, O
and O
TNFα O
were O
recorded O
. O
CA O
and O
CEA O
did O
not O
exhibit O
any O
change O
. O
Conclusions O
: O
Continuous O
inhalation O
to O
prallethrin O
1.6% O
insecticides O
poses O
toxicity O
on O
hematological O
variables O
. O
It O
is O
also O
concluded O
that O
pyrethroid O
group O
of O
insecticide O
may O
cause O
hematological O
, O
biochemical O
, O
cytokine B
disturbances O
and O
possible O
mutagenic O
damage O
to O
the O
tissues O
. O

prallethrin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
1.6% O
w/w O
by O
inhalation O
for O
72 O
consecutive O
hours O
. O
Total O
blood O
count O
, O
blood O
indices O
of O
creatine O
kinase O
(CK) O
, O
gamma-glutamyltranspeptidase O
(γ-GT) O
, O
superoxide O
dismutase O
(SOD) O
, O
nitric O
oxide O
(NO) O
, O
malondialdehyde O
(MDA) O
, O
interleukin O
(IL)-2 O
, O
tumor O
necrosis O
factors O
(TNF)α O
, O
alpha-fetoprotein O
(AFP) O
, O
carbohydrate O
antigen O
(CA) O
19.9 O
and O
carcinoembrionic O
antigen O
(CEA) O
were O
assayed O
. O
Results O
: O
The O
administration O
of O
prallethrin O
1.6% O
w/w O
created O
significant O
increased O
changes O
in O
the O
levels O
of O
total O
WBC O
, O
lymphocytes O
, O
RBC O
, O
hemoglobin O
, O
packed O
cell O
volume O
, O
platelets O
, O
mean O
corpuscular O
volume O
, O
and O
mean O
corpuscular O
hemoglobin B
in O
rats O
after O
24 O
, O
48 O
, O
and O
72 O
h O
of O
continuous O
inhalation; O
however O
, O
there O
was O
a O
significant O
reduction O
in O
neutrophils O
at O
transient O
reduction O
in O

prallethrin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
1.6% O
w/w O
by O
inhalation O
for O
72 O
consecutive O
hours O
. O
Total O
blood O
count O
, O
blood O
indices O
of O
creatine O
kinase O
(CK) O
, O
gamma-glutamyltranspeptidase O
(γ-GT) O
, O
superoxide O
dismutase O
(SOD) O
, O
nitric O
oxide O
(NO) O
, O
malondialdehyde O
(MDA) O
, O
interleukin O
(IL)-2 O
, O
tumor O
necrosis O
factors O
(TNF)α O
, O
alpha-fetoprotein O
(AFP) O
, O
carbohydrate O
antigen O
(CA) O
19.9 O
and O
carcinoembrionic O
antigen O
(CEA) O
were O
assayed O
. O
Results O
: O
The O
administration O
of O
prallethrin O
1.6% O
w/w O
created O
significant O
increased O
changes O
in O
the O
levels O
of O
total O
WBC O
, O
lymphocytes O
, O
RBC O
, O
hemoglobin O
, O
packed O
cell O
volume O
, O
platelets O
, O
mean O
corpuscular O
volume O
, O
and O
mean O
corpuscular O
hemoglobin B
in O
rats O
after O
24 O
, O
48 O
, O
and O
72 O
h O
of O
continuous O
inhalation; O
however O
, O
there O
was O
a O
significant O
reduction O
in O
neutrophils O
at O
transient O
reduction O
in O

vitamin O
C O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
examined O
the O
level O
of O
I-κBε O
and O
sub-cellular O
distribution O
of O
c-Rel O
by O
western O
blotting O
and O
immunofluorescence O
respectively O
in O
CSE-treated O
A549 O
cells O
with O
or O
without O
vitamin O
C O
pretreatment O
. O
We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF-κB B
DNA O
binding O
, O
I-κBε O
degradation O
and O
c-Rel O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin O
C O
To O
further O
validate O
the O
result O
, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel O
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin O
C O
. O
Result O
showed O
that O
vitamin O
C O
treatment O
resulted O
in O
markedly O
reduced O
c-Rel O
nuclear O
translocation O
. O
All O
these O
results O
demonstrate O
that O
vitamin O
C O
prevents O
CS(E)-induced O
NF-κB O
activation O
and O
thus O

vitamin O
C O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Vitamin O
C O
forestalls O
cigarette O
smoke O
induced O
NF-κB O
activation O
in O
alveolar O
epithelial O
cells.Cigarette O
smoking O
causes O
cellular O
oxidative O
stress O
resulting O
in O
inflammatory O
diseases O
of O
lung O
wherein O
transcription O
factor O
NF-κB O
plays O
an O
important O
role O
. O
It O
is O
possible O
that O
vitamin O
C O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
(CS)-induced O
NF-κB O
activation O
that O
involves O
degradation O
of O
I-κBε O
and O
nuclear O
translocation O
of O
c-Rel/p50 O
in O
alveolar O
epithelial O
cells O
. O
Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin O
C O
on O
CS-induced O
expression O
of O
NF-κB O
driven O
luciferase O
reporter O
and O
NF-κB O
binding O
at O
its O
target O

vitamin O
C O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Vitamin O
C O
forestalls O
cigarette O
smoke O
induced O
NF-κB O
activation O
in O
alveolar O
epithelial O
cells.Cigarette O
smoking O
causes O
cellular O
oxidative O
stress O
resulting O
in O
inflammatory O
diseases O
of O
lung O
wherein O
transcription O
factor O
NF-κB O
plays O
an O
important O
role O
. O
It O
is O
possible O
that O
vitamin O
C O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
(CS)-induced O
NF-κB O
activation O
that O
involves O
degradation O
of O
I-κBε O
and O
nuclear O
translocation O
of O
c-Rel/p50 O
in O
alveolar O
epithelial O
cells O
. O
Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin O
C O
on O
CS-induced O
expression O
of O
NF-κB O
driven O
luciferase O
reporter O
and O
NF-κB O
binding O
at O
its O
target O

vitamin O
C O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
examined O
the O
level O
of O
I-κBε O
and O
sub-cellular O
distribution O
of O
c-Rel B
by O
western O
blotting O
and O
immunofluorescence O
respectively O
in O
CSE-treated O
A549 O
cells O
with O
or O
without O
vitamin O
C O
pretreatment O
. O
We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF-κB O
DNA O
binding O
, O
I-κBε O
degradation O
and O
c-Rel O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin O
C O
To O
further O
validate O
the O
result O
, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel O
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin O
C O
. O
Result O
showed O
that O
vitamin O
C O
treatment O
resulted O
in O
markedly O
reduced O
c-Rel O
nuclear O
translocation O
. O
All O
these O
results O
demonstrate O
that O
vitamin O
C O
prevents O
CS(E)-induced O
NF-κB O
activation O
and O
thus O

vitamin O
C O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
Vitamin O
C O
forestalls O
cigarette O
smoke O
induced O
NF-κB O
activation O
in O
alveolar O
epithelial O
cells.Cigarette O
smoking O
causes O
cellular O
oxidative O
stress O
resulting O
in O
inflammatory O
diseases O
of O
lung O
wherein O
transcription O
factor O
NF-κB O
plays O
an O
important O
role O
. O
It O
is O
possible O
that O
vitamin O
C O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
(CS)-induced O
NF-κB O
activation O
that O
involves O
degradation O
of O
I-κBε B
and O
nuclear O
translocation O
of O
c-Rel/p50 O
in O
alveolar O
epithelial O
cells O
. O
Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin O
C O
on O
CS-induced O
expression O
of O
NF-κB O
driven O
luciferase O
reporter O
and O
NF-κB O
binding O
at O
its O
target O

vitamin O
C O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
examined O
the O
level O
of O
I-κBε B
and O
sub-cellular O
distribution O
of O
c-Rel O
by O
western O
blotting O
and O
immunofluorescence O
respectively O
in O
CSE-treated O
A549 O
cells O
with O
or O
without O
vitamin O
C O
pretreatment O
. O
We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF-κB O
DNA O
binding O
, O
I-κBε O
degradation O
and O
c-Rel O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin O
C O
To O
further O
validate O
the O
result O
, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel O
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin O
C O
. O
Result O
showed O
that O
vitamin O
C O
treatment O
resulted O
in O
markedly O
reduced O
c-Rel O
nuclear O
translocation O
. O
All O
these O
results O
demonstrate O
that O
vitamin O
C O
prevents O
CS(E)-induced O
NF-κB O
activation O
and O
thus O

vitamin O
C O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression O
, O
NF-κB O
DNA O
binding O
, O
I-κBε O
degradation O
and O
c-Rel B
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin O
C O
. O
To O
further O
validate O
the O
result O
, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel O
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin O
C O
. O
Result O
showed O
that O
vitamin O
C O
treatment O
resulted O
in O
markedly O
reduced O
c-Rel O
nuclear O
translocation O
. O
All O
these O
results O
demonstrate O
that O
vitamin O
C O
prevents O
CS(E)-induced O
NF-κB O
activation O
and O
thus O
it O
could O
be O
used O
for O
the O
prevention O
of O
CS-induced O
inflammatory O
diseases O
. O

vitamin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin O
C O
. O
To O
further O
validate O
the O
result O
, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel O
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin O
C O
. O
Result O
showed O
that O
vitamin O
C O
treatment O
resulted O
in O
markedly O
reduced O
c-Rel O
nuclear O
translocation O
. O
All O
these O
results O
demonstrate O
that O
vitamin O
C O
prevents O
CS(E)-induced O
NF-κB B
activation O
and O
thus O
it O
could O
be O
used O
for O
the O
prevention O
of O
CS-induced O
inflammatory O
diseases O
. O

vitamin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Vitamin O
C O
forestalls O
cigarette O
smoke O
induced O
NF-κB B
activation O
in O
alveolar O
epithelial O
cells.Cigarette O
smoking O
causes O
cellular O
oxidative O
stress O
resulting O
in O
inflammatory O
diseases O
of O
lung O
wherein O
transcription O
factor O
NF-κB O
plays O
an O
important O
role O
. O
It O
is O
possible O
that O
vitamin O
C O
an O
antioxidant O
, O
may O
prevent O
cigarette O
smoke O
(CS)-induced O
NF-κB O
activation O
that O
involves O
degradation O
of O
I-κBε O
and O
nuclear O
translocation O
of O
c-Rel/p50 O
in O
alveolar O
epithelial O
cells O
. O
Therefore O
, O
to O
examine O
the O
hypothesis O
, O
we O
verified O
the O
effect O
of O
vitamin O
C O
on O
CS-induced O
expression O
of O
NF-κB O
driven O
luciferase O
reporter O
and O
NF-κB O
binding O
at O
its O
target O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Selective O
Bisubstrate O
Inhibitors O
with O
Sub-nanomolar O
Affinity O
for O
Protein O
Kinase O
Pim-1.Potent O
and O
selective O
: O
The O
unique O
nature O
of O
the O
ATP O
binding O
pocket O
structure O
of O
Pim B
family O
protein O
kinases O
(PKs) O
was O
used O
for O
the O
development O
of O
bisubstrate O
inhibitors O
and O
a O
fluorescent O
probe O
with O
sub-nanomolar O
affinity O
. O
Conjugates O
of O
arginine-rich O
peptides O
with O
two O
ATP O
mimetic O
scaffolds O
were O
synthesized O
and O
tested O
as O
inhibitors O
of O
Pim-1 O
. O
Against O
a O
panel O
of O
124 O
protein O
kinases O
, O
a O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Selective O
Bisubstrate O
Inhibitors O
with O
Sub-nanomolar O
Affinity O
for O
Protein O
Kinase O
Pim-1.Potent O
and O
selective O
: O
The O
unique O
nature O
of O
the O
ATP O
binding O
pocket O
structure O
of O
Pim O
family O
protein B
kinases I
(PKs) O
was O
used O
for O
the O
development O
of O
bisubstrate O
inhibitors O
and O
a O
fluorescent O
probe O
with O
sub-nanomolar O
affinity O
. O
Conjugates O
of O
arginine-rich O
peptides O
with O
two O
ATP O
mimetic O
scaffolds O
were O
synthesized O
and O
tested O
as O
inhibitors O
of O
Pim-1 O
. O
Against O
a O
panel O
of O
124 O
protein O
kinases O
, O
a O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Selective O
Bisubstrate O
Inhibitors O
with O
Sub-nanomolar O
Affinity O
for O
Protein O
Kinase O
Pim-1.Potent O
and O
selective O
: O
The O
unique O
nature O
of O
the O
ATP O
binding O
pocket O
structure O
of O
Pim O
family O
protein O
kinases O
(PKs) O
was O
used O
for O
the O
development O
of O
bisubstrate O
inhibitors O
and O
a O
fluorescent O
probe O
with O
sub-nanomolar O
affinity O
. O
Conjugates O
of O
arginine-rich O
peptides O
with O
two O
ATP O
mimetic O
scaffolds O
were O
synthesized O
and O
tested O
as O
inhibitors O
of O
Pim-1 O
. O
Against O
a O
panel O
of O
124 O
protein O
kinases O
, O
a O

Nicotine O
acts O
as O
NOT O
for O
what O
entity O
? O
the O
pharmacological O
inhibitor O
(SB431542) O
markedly O
reduced O
VEGF B
release O
by O
HFL-1 O
in O
response O
to O
CSE O
and O
this O
effect O
was O
confirmed O
by O
TβR1 O
siRNA O
. O
In O
contrast O
, O
nicotine O
inhibited O
VEGF O
release O
by O
HFL-1 O
in O
a O
dose O
and O
time O
dependent O
manner O
. O
Our O
findings O
indicate O
that O
CSE O
stimulates O
Smad3-mediated O
VEGF O
release O
by O
lung O
fibroblasts O
. O
Nicotine O
does O
not O
account O
for O
the O
CSE O
stimulation O
of O
VEGF O
in O
HFL-1 O
. O
The O
ability O
of O
lung O
fibroblasts O
to O
produce O
VEGF O
may O
play O
a O
role O
in O
pathogenesis O
of O
cigarette O
smoke O
induced O
lung O
disease O
. O

SB431542 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
two O
additional O
types O
of O
primary O
human O
fetal O
lung O
fibroblasts O
. O
CSE O
induced O
Smad3 O
phosphorylation O
and O
nuclear O
translocation O
in O
HFL-1 O
cells O
. O
Silencing O
of O
Smad3 O
by O
siRNA O
not O
only O
eliminated O
the O
stimulatory O
effect O
of O
CSE O
on O
VEGF B
release O
but O
also O
inhibited O
baseline O
VEGF O
production O
. O
Suppression O
of O
TβR1 O
by O
the O
pharmacological O
inhibitor O
( O
SB431542 O
markedly O
reduced O
VEGF O
release O
by O
HFL-1 O
in O
response O
to O
CSE O
and O
this O
effect O
was O
confirmed O
by O
TβR1 O
siRNA O
. O
In O
contrast O
, O
nicotine O
inhibited O
VEGF O
release O
by O
HFL-1 O
in O
a O
dose O
and O
time O
dependent O
manner O
. O
Our O
findings O
indicate O
that O
CSE O
stimulates O
Smad3-mediated O
VEGF O
release O
by O
lung O
fibroblasts O
. O
Nicotine O
does O
not O
account O

SB431542 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
two O
additional O
types O
of O
primary O
human O
fetal O
lung O
fibroblasts O
. O
CSE O
induced O
Smad3 O
phosphorylation O
and O
nuclear O
translocation O
in O
HFL-1 O
cells O
. O
Silencing O
of O
Smad3 O
by O
siRNA O
not O
only O
eliminated O
the O
stimulatory O
effect O
of O
CSE O
on O
VEGF O
release O
but O
also O
inhibited O
baseline O
VEGF O
production O
. O
Suppression O
of O
TβR1 B
by O
the O
pharmacological O
inhibitor O
( O
SB431542 O
markedly O
reduced O
VEGF O
release O
by O
HFL-1 O
in O
response O
to O
CSE O
and O
this O
effect O
was O
confirmed O
by O
TβR1 O
siRNA O
. O
In O
contrast O
, O
nicotine O
inhibited O
VEGF O
release O
by O
HFL-1 O
in O
a O
dose O
and O
time O
dependent O
manner O
. O
Our O
findings O
indicate O
that O
CSE O
stimulates O
Smad3-mediated O
VEGF O
release O
by O
lung O
fibroblasts O
. O
Nicotine O
does O
not O
account O

rapamycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
allosterically O
regulated O
element O
responsible O
for O
the O
intake O
of O
substrates O
. O
Interestingly O
, O
we O
showed O
that O
rapamycin O
shares O
all O
the O
proteasome O
targeting O
properties O
not O
only O
with O
other O
two-domain O
, O
closed-ring O
analogs O
(rapalogs) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco-rapamycin O
. O
The O
latter O
is O
the O
first O
in O
vivo O
open-ring O
metabolite O
of O
rapamycin O
that O
does O
not O
affect O
mTOR O
. O
We O
hypothesize O
that O
the O
rapamycin O
and O
related O
compounds O
bind O
to O
the O
α O
face O
and O
allosterically O
impact O
the O
proteasome O
function O
. O
The O
implications O
of O
our O
finding O
for O
mechanism O
of O
in O
vivo O
actions O
of O
rapamycin O
and O
for O
design O
of O
novel O
allosteric O
drugs O
targeting O
the O
proteasome O
are O
discussed O
. O

rapamycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome B
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O

rapamycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O

rapamycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome B
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O

rapamycin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
complexes O
are O
known O
to O
bind O
to O
specific O
grooves O
on O
the O
α O
face O
region O
of O
the O
20S O
core O
. O
A O
treatment O
with O
rapamycin O
affects O
conformational O
dynamics O
of O
the O
proteasomal O
gate O
, O
a O
centrally O
positioned O
within O
the O
α O
face O
and O
allosterically O
regulated O
element O
responsible O
for O
the O
intake O
of O
substrates O
. O
Interestingly O
, O
we O
showed O
that O
rapamycin O
shares O
all O
the O
proteasome B
targeting O
properties O
not O
only O
with O
other O
two-domain O
, O
closed-ring O
analogs O
(rapalogs) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco-rapamycin O
. O
The O
latter O
is O
the O
first O
in O
vivo O
open-ring O
metabolite O
of O
rapamycin O
that O
does O
not O
affect O
mTOR O
. O
We O
hypothesize O
that O
the O
rapamycin O
and O
related O
compounds O
bind O

Rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase B
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O
the O
20S O
catalytic O
core O
proteasome O
. O
These O
protein O
complexes O
are O
known O
to O
bind O
to O

Rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase B
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O
the O
20S O
catalytic O
core O
proteasome O
. O
These O
protein O
complexes O
are O
known O
to O
bind O
to O

Rapamycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome.Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome B
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates O
, O
and O
the O
PA200 O
activator O
to O
the O
20S O
catalytic O
core O
proteasome O
. O
These O
protein O
complexes O
are O
known O
to O
bind O
to O

rapamycin O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Interestingly O
, O
we O
showed O
that O
rapamycin O
shares O
all O
the O
proteasome B
targeting O
properties O
not O
only O
with O
other O
two-domain O
, O
closed-ring O
analogs O
(rapalogs) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco-rapamycin O
. O
The O
latter O
is O
the O
first O
in O
vivo O
open-ring O
metabolite O
of O
rapamycin O
that O
does O
not O
affect O
mTOR O
. O
We O
hypothesize O
that O
the O
rapamycin O
and O
related O
compounds O
bind O
to O
the O
α O
face O
and O
allosterically O
impact O
the O
proteasome O
function O
. O
The O
implications O
of O
our O
finding O
for O
mechanism O
of O
in O
vivo O
actions O
of O
rapamycin O
and O
for O
design O
of O
novel O
allosteric O
drugs O
targeting O
the O
proteasome O
are O
discussed O
. O

rapamycin O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
with O
seco-rapamycin O
. O
The O
latter O
is O
the O
first O
in O
vivo O
open-ring O
metabolite O
of O
rapamycin O
that O
does O
not O
affect O
mTOR O
. O
We O
hypothesize O
that O
the O
rapamycin O
and O
related O
compounds O
bind O
to O
the O
α O
face O
and O
allosterically O
impact O
the O
proteasome B
function O
. O
The O
implications O
of O
our O
finding O
for O
mechanism O
of O
in O
vivo O
actions O
of O
rapamycin O
and O
for O
design O
of O
novel O
allosteric O
drugs O
targeting O
the O
proteasome O
are O
discussed O
. O

Rapamycin O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome O
. O
Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR B
kinase O
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O

Rapamycin O
acts O
as O
MODULATOR-INHIBITOR O
for O
what O
entity O
? O
Rapamycin O
allosterically O
inhibits O
the O
proteasome O
. O
Rapamycin O
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR O
kinase B
with O
immunosuppressive O
and O
pro-apoptotic O
activities O
. O
We O
found O
that O
in O
vitro O
rapamycin O
also O
regulates O
the O
proteasome O
, O
an O
essential O
intracellular O
protease O
of O
the O
ubiquitin-proteasome O
pathway O
. O
Rapamycin O
inhibits O
proteinase O
and O
selected O
peptidase O
activities O
of O
the O
catalytic O
core O
proteasome O
at O
low O
micromolar O
concentrations O
. O
Moreover O
, O

MNU O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
to O
a O
malignant O
phenotype O
over O
time O
and O
tumor O
latency O
was O
decreased O
by O
MNU O
+ O
testosterone O
administration O
. O
Three-dimensional O
reconstruction O
of O
the O
prostatic O
complex O
showed O
that O
the O
DL O
developed O
tumors O
exclusively O
in O
the O
periurethral O
area O
and O
showed O
intense O
AR O
, O
PCNA O
, O
and O
MGMT B
immunostaining O
. O
Moreover O
, O
VL O
lesions O
emerged O
throughout O
the O
entire O
lobe O
. O
MNU O
induced O
lesions O
presented O
markers O
indicative O
of O
an O
aggressive O
phenotype O
: O
lack O
of O
basal O
cells O
, O
rupture O
of O
the O
smooth O
muscle O
cell O
layer O
, O
loss O
of O
E-cadherin O
, O
and O
high O
MGMT O
staining O
. O
CONCLUSIONS O
: O
There O
are O
distinct O
pathways O
involved O
in O
tumor O
progression O
in O
gerbil O
prostate O
lobes O
. O
This O
animal O
provides O
a O
good O
model O
for O
prostate O
cancer O

MNU O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
to O
a O
malignant O
phenotype O
over O
time O
and O
tumor O
latency O
was O
decreased O
by O
MNU O
+ O
testosterone O
administration O
. O
Three-dimensional O
reconstruction O
of O
the O
prostatic O
complex O
showed O
that O
the O
DL O
developed O
tumors O
exclusively O
in O
the O
periurethral O
area O
and O
showed O
intense O
AR O
, O
PCNA O
, O
and O
MGMT O
immunostaining O
. O
Moreover O
, O
VL O
lesions O
emerged O
throughout O
the O
entire O
lobe O
. O
MNU O
induced O
lesions O
presented O
markers O
indicative O
of O
an O
aggressive O
phenotype O
: O
lack O
of O
basal O
cells O
, O
rupture O
of O
the O
smooth O
muscle O
cell O
layer O
, O
loss O
of O
E-cadherin O
, O
and O
high O
MGMT O
staining O
. O
CONCLUSIONS O
: O
There O
are O
distinct O
pathways O
involved O
in O
tumor O
progression O
in O
gerbil O
prostate O
lobes O
. O
This O
animal O
provides O
a O
good O
model O
for O
prostate O
cancer O

methylphenidate O
acts O
as O
NOT O
for O
what O
entity O
? O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT B
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O

methylphenidate O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
prefrontal O
cortex O
play O
a O
role O
in O
this O
response O
. O
Importantly O
, O
prefrontal O
cortex O
subregions O
, O
orbitofrontal O
cortex O
(OFC) O
and O
medial O
prefrontal O
cortex O
(mPFC) O
, O
have O
been O
shown O
to O
have O
distinct O
roles O
in O
ADHD O
and O
cocaine O
self-administration O
. O
In O
the O
current O
study O
, O
SHR O
, O
Wistar-Kyoto O
(WKY) O
and O
Wistar O
(WIS) O
rats O
received O
a O
therapeutically O
relevant O
dose O
of O
methylphenidate O
(1.5mg/kg O
, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT B
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O

methylphenidate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
, O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT B
function O
in O
prefrontal O
cortex O
play O
a O
role O
in O
this O
response O
. O
Importantly O
, O
prefrontal O
cortex O
subregions O
, O
orbitofrontal O
cortex O
(OFC) O
and O
medial O
prefrontal O
cortex O
(mPFC) O
, O
have O
been O
shown O
to O
have O
distinct O
roles O
in O
ADHD O
and O
cocaine O
self-administration O
. O
In O
the O

methylphenidate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT B
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O
behavior O
including O
the O
observed O
increases O
in O
cocaine O
self-administration O
. O

Methylphenidate O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
relevant O
dose O
of O
methylphenidate O
(1.5mg/kg O
, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT B
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O

methylphenidate O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT B
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O
behavior O
including O
the O
observed O
increases O
in O
cocaine O
self-administration O
. O

Methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
an O
inhibitor O
of O
dopamine B
and I
norepinephrine I
transporters I
(DAT O
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT O
function O

Methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT B
function O

Methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Adolescence O
methylphenidate O
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder O
: O
Dopamine O
transporter O
function O
and O
cellular O
distribution O
in O
adulthood.Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O
prefrontal O
cortex O
. O
Methylphenidate O
an O
inhibitor O
of O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
, O
is O
a O
standard O
treatment O
for O
ADHD O
. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD O
. O
Our O
previous O
results O
showed O
that O
methylphenidate O
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine O
self-administration O
during O
adulthood O
, O
and O
alterations O
in O
DAT O
function O

Methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
relevant O
dose O
of O
methylphenidate O
(1.5mg/kg O
, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT B
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O

methylphenidate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
DAT B
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood O
. O
In O
both O
OFC O
and O
mPFC O
, O
no O
strain O
differences O
in O
Vmax O
or O
Km O
for O
dopamine O
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR O
, O
WKY O
and O
WIS O
. O
Methylphenidate O
increased O
DAT O
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT O
Vmax O
in O
WKY O
OFC O
. O
Also O
, O
methylphenidate O
decreased O
DAT O
Km O
in O
WIS O
OFC O
. O
Further O
, O
methylphenidate O
did O
not O
alter O
DAT O
cellular O
localization O
, O
indicating O
that O
methylphenidate O
treatment O
during O
adolescence O
regulated O
DAT O
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner O
. O
Thus O
, O
the O
increase O
in O
mPFC O
DAT O
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate O
treatment O
during O
adolescence O
, O
which O

IB-MECA O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
at O
48 O
, O
24 O
, O
12 O
and O
1 O
h O
before O
and O
1 O
h O
after O
the O
injection O
of O
5 O
% O
sodium O
taurocholate O
solution O
into O
the O
biliary-pancreatic O
duct O
. O
Serum O
for O
α-amylase B
and O
lipase O
determinations O
and O
tissue O
samples O
for O
morphological O
examinations O
were O
collected O
at O
2 O
, O
6 O
, O
and O
24 O
h O
of O
the O
experiment O
. O
In O
the O
IB-MECA O
group O
, O
α-amylase O
activity O
was O
decreased O
with O
statistically O
high O
significance O
compared O
to O
group O
I O
. O
The O
activity O
of O
lipase O
was O
not O
significantly O
different O
among O
the O
experimental O
groups O
but O
higher O
than O
in O
the O
control O
group O
. O
The O
administration O
of O
IB-MECA O
attenuated O
the O
histological O
parameters O
of O
inflammation O
as O
compared O
to O
untreated O
animals O
. O
The O
use O

IB-MECA O
acts O
as O
AGONIST O
for O
what O
entity O
? O
the O
effects O
of O
the O
adenosine B
A3 I
receptor I
agonist O
on O
the O
course O
of O
sodium O
taurocholate-induced O
experimental O
acute O
pancreatitis O
(EAP) O
. O
The O
experiments O
were O
performed O
on O
80 O
male O
Wistar O
rats O
, O
58 O
of O
which O
survived O
, O
subdivided O
into O
3 O
groups O
: O
C-control O
rats O
, O
I-EAP O
group O
, O
and O
II-EAP O
group O
treated O
with O
the O
adenosine O
A3 O
receptor O
agonist O
IB-MECA O
(1-deoxy-1-6[[(3-iodophenyl) O
methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide O
at O
a O
dose O
of O
0.75 O
mg/kg O
b.w O
. O
i.p O
. O
at O
48 O
, O
24 O
, O
12 O
and O
1 O
h O
before O
and O
1 O
h O
after O
the O
injection O
of O
5 O
% O
sodium O
taurocholate O
solution O
into O
the O
biliary-pancreatic O
duct O
. O
Serum O
for O
α-amylase O
and O
lipase O
determinations O
and O
tissue O
samples O
for O
morphological O
examinations O
were O
collected O
at O

(1-deoxy-1-6[[(3-iodophenyl) O
methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide O
acts O
as O
AGONIST O
for O
what O
entity O
? O
effects O
of O
the O
adenosine B
A3 I
receptor I
agonist O
on O
the O
course O
of O
sodium O
taurocholate-induced O
experimental O
acute O
pancreatitis O
(EAP) O
. O
The O
experiments O
were O
performed O
on O
80 O
male O
Wistar O
rats O
, O
58 O
of O
which O
survived O
, O
subdivided O
into O
3 O
groups O
: O
C-control O
rats O
, O
I-EAP O
group O
, O
and O
II-EAP O
group O
treated O
with O
the O
adenosine O
A3 O
receptor O
agonist O
IB-MECA O
(1-deoxy-1-6[[(3-iodophenyl) O
methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide O
at O
a O
dose O
of O
0.75 O
mg/kg O
b.w O
. O
i.p O
. O
at O
48 O
, O
24 O
, O
12 O
and O
1 O
h O
before O
and O
1 O
h O
after O
the O
injection O
of O
5 O
% O
sodium O
taurocholate O
solution O
into O
the O
biliary-pancreatic O
duct O
. O
Serum O
for O
α-amylase O
and O
lipase O
determinations O
and O
tissue O
samples O
for O
morphological O
examinations O
were O
collected O
at O
2 O
, O
6 O
, O

IB-MECA O
acts O
as O
AGONIST O
for O
what O
entity O
? O
The O
effects O
of O
the O
adenosine B
A3 I
receptor I
agonist O
IB-MEC O
on O
sodium O
taurocholate-induced O
experimental O
acute O
pancreatitis.The O
role O
of O
adenosine O
A3 O
receptors O
and O
their O
distribution O
in O
the O
gastrointestinal O
tract O
have O
been O
widely O
investigated O
. O
Most O
of O
the O
reports O
discuss O
their O
role O
in O
intestinal O
inflammations O
. O
However O
, O
the O
role O
of O
adenosine O
A3 O
receptor O
agonist O
in O
pancreatitis O
has O
not O
been O
well O
established O
. O
The O
aim O

IB-MECA O
acts O
as O
AGONIST O
for O
what O
entity O
? O
decreased O
with O
statistically O
high O
significance O
compared O
to O
group O
I O
. O
The O
activity O
of O
lipase O
was O
not O
significantly O
different O
among O
the O
experimental O
groups O
but O
higher O
than O
in O
the O
control O
group O
. O
The O
administration O
of O
IB-MECA O
attenuated O
the O
histological O
parameters O
of O
inflammation O
as O
compared O
to O
untreated O
animals O
. O
The O
use O
of O
A3 B
receptor I
agonist O
IB-MECA O
attenuates O
EAP O
. O
Our O
findings O
suggest O
that O
stimulation O
of O
adenosine O
A3 O
receptors O
plays O
a O
positive O
role O
in O
the O
sodium O
taurocholate-induced O
EAP O
in O
rats O
. O

CP[c]Ph O
acts O
as O
NOT O
for O
what O
entity O
? O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα B
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O
activity O
when O
investigated O
in O
the O
Ames O
test O
, O
and O
exhibit O
genotoxic O
properties O
in O
in O
vitro O
micronucleus O
assay O
. O
The O
above O
characteristics O
suggest O
that O
CP-PAHs O
are O
chemicals O
of O
concern O
for O
which O
potential O
pathways O
of O
exposure O
should O
be O
further O

CP[c]Ph O
acts O
as O
NOT O
for O
what O
entity O
? O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα O
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O
activity O
when O
investigated O
in O
the O
Ames O
test O
, O
and O
exhibit O
genotoxic O
properties O
in O
in O
vitro O
micronucleus O
assay O
. O
The O
above O
characteristics O
suggest O
that O
CP-PAHs O
are O
chemicals O
of O
concern O
for O
which O
potential O
pathways O
of O
exposure O
should O
be O
further O

estrogen O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα B
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
, O
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O
activity O
when O
investigated O
in O
the O
Ames O
test O
, O
and O
exhibit O
genotoxic O
properties O
in O
in O
vitro O
micronucleus O
assay O
. O
The O
above O
characteristics O
suggest O
that O
CP-PAHs O

estrogen O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα O
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
, O
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O
activity O
when O
investigated O
in O
the O
Ames O
test O
, O
and O
exhibit O
genotoxic O
properties O
in O
in O
vitro O
micronucleus O
assay O
. O
The O
above O
characteristics O
suggest O
that O
CP-PAHs O

CP[c]Ph O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
as O
a O
phenanthrene O
skeleton O
with O
an O
electrodonating O
alkyl O
substituent O
in O
the O
bay-region O
of O
the O
molecule O
. O
The O
second O
thread O
, O
providing O
available O
data O
on O
the O
adverse O
effects O
of O
CP[c]Ph O
compounds O
on O
cells O
and O
tissues O
of O
living O
organisms O
, O
mainly O
fish O
, O
improves O
our O
understanding O
of O
these O
possible O
environmental O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A B
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O

benzo[a]pyrene O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
molecule O
. O
The O
second O
thread O
, O
providing O
available O
data O
on O
the O
adverse O
effects O
of O
CP[c]Ph O
compounds O
on O
cells O
and O
tissues O
of O
living O
organisms O
, O
mainly O
fish O
, O
improves O
our O
understanding O
of O
these O
possible O
environmental O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A B
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O

B[a]P O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
The O
second O
thread O
, O
providing O
available O
data O
on O
the O
adverse O
effects O
of O
CP[c]Ph O
compounds O
on O
cells O
and O
tissues O
of O
living O
organisms O
, O
mainly O
fish O
, O
improves O
our O
understanding O
of O
these O
possible O
environmental O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A B
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
( O
B[a]P O
 O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O

CP[c]Ph O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
on O
the O
adverse O
effects O
of O
CP[c]Ph O
compounds O
on O
cells O
and O
tissues O
of O
living O
organisms O
, O
mainly O
fish O
, O
improves O
our O
understanding O
of O
these O
possible O
environmental O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A B
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα O
and O
VTG O
, O

CP[c]Ph O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
these O
possible O
environmental O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A O
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
, O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα O
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
, O
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O

B[a]P O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
hazards O
. O
The O
data O
show O
that O
CP[c]Ph O
is O
less O
potent O
at O
inducing O
CYP1A O
gene O
expression O
in O
rainbow O
trout O
than O
benzo[a]pyrene O
(B[a]P) O
, O
a O
well-known O
Ah-receptor O
agonist O
. O
Interestingly O
, O
the O
CP[c]Ph O
dependent O
up-regulation O
of O
CYP1A O
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes O
. O
CP[c]Ph O
has O
, O
comparably O
to O
B[a]P O
a O
potential O
to O
repress O
expression O
of O
tumor O
suppressor O
p53 O
, O
in O
the O
head O
kidney O
of O
rainbow O
trout O
. O
Furthermore O
, O
estrogen O
responsive O
genes O
in O
fish O
liver O
, O
ERα O
and O
VTG O
, O
are O
not O
induced O
by O
CP[c]Ph O
, O
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential O
. O
However O
, O
some O
CP[c]Phs O
show O
mutagenic O
activity O
when O
investigated O
in O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
Parkinsonism O
which O
includes O
ATP13A2 O
and O
parkin O
have O
already O
been O
suggested O
to O
promote O
development O
of O
Mn O
toxicity O
. O
Of O
the O
other O
Parkinson-linked O
genes O
, O
mutations O
in O
LRRK2 O
, O
an O
autosomal O
dominant O
gene O
, O
represent O
another O
likely O
candidate O
involved O
in O
the O
development O
of O
manganism O
. O
In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 O
knock-down O
on O
Mn O
toxicity O
was O
examined O
in O
control O
and O
DAT B
transfected O
HEK293 O
cells O
. O
Results O
demonstrate O
that O
LRRK2 O
down-regulation O
potentiates O
Mn O
toxicity O
in O
both O
control O
and O
DAT-transfected O
cell O
as O
well O
as O
potentiates O
DA O
toxicity O
. O
Combined O
treatment O
of O
Mn O
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O
JNK O
phosphorylation O
in O
LRRK2 O
deficient O
cells O

Mn O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Of O
the O
other O
Parkinson-linked O
genes O
, O
mutations O
in O
LRRK2 O
, O
an O
autosomal O
dominant O
gene O
, O
represent O
another O
likely O
candidate O
involved O
in O
the O
development O
of O
manganism O
. O
In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 O
knock-down O
on O
Mn O
toxicity O
was O
examined O
in O
control O
and O
DAT B
transfected O
HEK293 O
cells O
. O
Results O
demonstrate O
that O
LRRK2 O
down-regulation O
potentiates O
Mn O
toxicity O
in O
both O
control O
and O
DAT-transfected O
cell O
as O
well O
as O
potentiates O
DA O
toxicity O
. O
Combined O
treatment O
of O
Mn O
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O
JNK O
phosphorylation O
in O
LRRK2 O
deficient O
cells O
compared O
to O
controls O
. O
Consistent O
with O
studies O
demonstrating O
that O
LRRK2 O
plays O
a O
role O
in O
the O
phosphorylation O
of O
p38 O
, O

Mn O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
in O
the O
development O
of O
manganism O
. O
In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 O
knock-down O
on O
Mn O
toxicity O
was O
examined O
in O
control O
and O
DAT O
transfected O
HEK293 O
cells O
. O
Results O
demonstrate O
that O
LRRK2 O
down-regulation O
potentiates O
Mn O
toxicity O
in O
both O
control O
and O
DAT-transfected O
cell O
as O
well O
as O
potentiates O
DA O
toxicity O
. O
Combined O
treatment O
of O
Mn O
and O
DA O
further O
augments O
cell O
toxicity O
, O
ROS O
production O
and O
JNK B
phosphorylation O
in O
LRRK2 O
deficient O
cells O
compared O
to O
controls O
. O
Consistent O
with O
studies O
demonstrating O
that O
LRRK2 O
plays O
a O
role O
in O
the O
phosphorylation O
of O
p38 O
, O
our O
results O
similarly O
demonstrate O
a O
decrease O
in O
p38 O
activation O
in O
LRRK2 O
knock-down O
cells O
. O
Our O
findings O
suggest O
that O

TCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
at O
51600 O
ng/g O
. O
TDCPP O
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length O
, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver O
fatty-acid O
binding O
protein O
and O
cytochrome O
P450 O
(CYP) O
3A37 O
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
while O
TDCPP O
induced O
CYP3A37 O
and O
CYP2H1 O
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O
19 O
. O
The O
observed O
phenotypic O
responses O
to O
TCPP O

TCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
at O
51600 O
ng/g O
. O
TDCPP O
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length O
, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver B
fatty-acid I
binding I
protein I
and O
cytochrome O
P450 O
(CYP) O
3A37 O
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
while O
TDCPP O
induced O
CYP3A37 O
and O
CYP2H1 O
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O
19 O
. O
The O
observed O
phenotypic O
responses O
to O
TCPP O

TCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
at O
51600 O
ng/g O
. O
TDCPP O
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length O
, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver O
fatty-acid O
binding O
protein O
and O
cytochrome B
P450 I
(CYP) I
3A37 I
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
while O
TDCPP O
induced O
CYP3A37 O
and O
CYP2H1 O
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O
19 O
. O
The O
observed O
phenotypic O
responses O
to O
TCPP O

TDCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
ng/g O
. O
TDCPP O
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length O
, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver O
fatty-acid O
binding O
protein O
and O
cytochrome O
P450 O
(CYP) O
3A37 O
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
, O
while O
TDCPP O
induced O
CYP3A37 B
and O
CYP2H1 O
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O
19 O
. O
The O
observed O
phenotypic O
responses O
to O
TCPP O
and O
TDCPP O

TDCPP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
ng/g O
. O
TDCPP O
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length O
, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O
ng/g O
. O
Type O
I O
deiodinase O
, O
liver O
fatty-acid O
binding O
protein O
and O
cytochrome O
P450 O
(CYP) O
3A37 O
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP O
, O
while O
TDCPP O
induced O
CYP3A37 O
and O
CYP2H1 O
. O
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0 O
, O
5 O
, O
11 O
, O
18 O
, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP O
or O
TDCPP O
concentration O
was O
detectable O
up O
to O
day O
5; O
however O
, O
<1% O
was O
detected O
by O
day O
19 O
. O
The O
observed O
phenotypic O
responses O
to O
TCPP O
and O
TDCPP O

AlCl3 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
P O
. O
nigrum O
extract O
at O
a O
dose O
of O
187.5 O
and O
93.75 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
Levels O
of O
brain O
acetylcholine O
(Ach) O
, O
serum O
and O
brain O
acetylcholinesterase O
(AchE) O
activity O
, O
C-reactive O
protein O
(CRP) O
, O
total O
nuclear O
factor O
kappa-B O
(NF-κB) O
, O
and O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
were O
estimated O
. O
The O
results O
showed O
that O
administration O
of O
AlCl3 O
resulted O
in O
a O
significant O
elevation O
in O
the O
levels O
of O
AchE O
activity O
, O
CRP O
, O
NF-κB O
, O
and O
MCP-1 O
accompanied O
with O
a O
significant O
depletion O
in O
the O
Ach O
level O
. O
Treatment O
of O
AD O
rats O
with O
each O
of O
the O
selected O
medicinal O
plant O
extracts O
caused O
marked O
improvement O
in O
the O
measured O
biochemical O
parameters O
. O
In O
conclusion O
, O
S O
. O
triloba O
and O

AlCl3 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
P O
. O
nigrum O
extract O
at O
a O
dose O
of O
187.5 O
and O
93.75 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
Levels O
of O
brain O
acetylcholine O
(Ach) O
, O
serum O
and O
brain O
acetylcholinesterase O
(AchE) O
activity O
, O
C-reactive O
protein O
(CRP) O
, O
total O
nuclear O
factor O
kappa-B O
(NF-κB) O
, O
and O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
were O
estimated O
. O
The O
results O
showed O
that O
administration O
of O
AlCl3 O
resulted O
in O
a O
significant O
elevation O
in O
the O
levels O
of O
AchE O
activity O
, O
CRP O
, O
NF-κB O
, O
and O
MCP-1 O
accompanied O
with O
a O
significant O
depletion O
in O
the O
Ach O
level O
. O
Treatment O
of O
AD O
rats O
with O
each O
of O
the O
selected O
medicinal O
plant O
extracts O
caused O
marked O
improvement O
in O
the O
measured O
biochemical O
parameters O
. O
In O
conclusion O
, O
S O
. O
triloba O
and O

AlCl3 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
the O
P O
. O
nigrum O
extract O
at O
a O
dose O
of O
187.5 O
and O
93.75 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
Levels O
of O
brain O
acetylcholine O
(Ach) O
, O
serum O
and O
brain O
acetylcholinesterase O
(AchE) O
activity O
, O
C-reactive O
protein O
(CRP) O
, O
total O
nuclear O
factor O
kappa-B O
(NF-κB) O
, O
and O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
were O
estimated O
. O
The O
results O
showed O
that O
administration O
of O
AlCl3 O
resulted O
in O
a O
significant O
elevation O
in O
the O
levels O
of O
AchE O
activity O
, O
CRP O
, O
NF-κB O
, O
and O
MCP-1 B
accompanied O
with O
a O
significant O
depletion O
in O
the O
Ach O
level O
. O
Treatment O
of O
AD O
rats O
with O
each O
of O
the O
selected O
medicinal O
plant O
extracts O
caused O
marked O
improvement O
in O
the O
measured O
biochemical O
parameters O
. O
In O
conclusion O
, O
S O
. O
triloba O
and O

AlCl3 O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
the O
P O
. O
nigrum O
extract O
at O
a O
dose O
of O
187.5 O
and O
93.75 O
mg/kg O
b.w O
. O
daily O
for O
3 O
months O
. O
Levels O
of O
brain O
acetylcholine O
(Ach) O
, O
serum O
and O
brain O
acetylcholinesterase O
(AchE) O
activity O
, O
C-reactive O
protein O
(CRP) O
, O
total O
nuclear O
factor O
kappa-B O
(NF-κB) O
, O
and O
monocyte O
chemoattractant O
protein-1 O
(MCP-1) O
were O
estimated O
. O
The O
results O
showed O
that O
administration O
of O
AlCl3 O
resulted O
in O
a O
significant O
elevation O
in O
the O
levels O
of O
AchE B
activity O
, O
CRP O
, O
NF-κB O
, O
and O
MCP-1 O
accompanied O
with O
a O
significant O
depletion O
in O
the O
Ach O
level O
. O
Treatment O
of O
AD O
rats O
with O
each O
of O
the O
selected O
medicinal O
plant O
extracts O
caused O
marked O
improvement O
in O
the O
measured O
biochemical O
parameters O
. O
In O
conclusion O
, O
S O
. O
triloba O
and O

3,4-methylenedioxy-N-methylamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
for O
small-molecule O
modulators O
of O
SERT B
function O
. O
In O
functional O
transport O
assays O
, O
we O
found O
that O
one O
of O
the O
identified O
molecules O
, O
ATM7 O
, O
increased O
the O
reuptake O
of O
serotonin O
, O
possibly O
by O
facilitating O
the O
interaction O
of O
serotonin O
with O
transport-ready O
conformations O
of O
SERT O
when O
concentrations O
of O
serotonin O
were O
low O
and O
rate O
limiting O
. O
In O
addition O
, O
ATM7 O
potentiates O
3,4-methylenedioxy-N-methylamphetamine O
(MDMA O
, O
"Ecstasy")-induced O
reversed O
transport O
by O
SERT O
. O
Taking O
advantage O
of O
a O
conformationally O
sensitive O
residue O
in O
transmembrane O
domain O
6 O
, O
we O
demonstrate O
that O
ATM7 O
mechanistically O
stabilizes O
an O
outward-facing O
conformation O
of O
SERT O
. O
Taken O
together O
these O
observations O
demonstrate O
that O
ATM7 O
acts O
through O
a O
novel O
mechanism O
that O
involves O
allosteric O
modulation O
of O
SERT O
function O
. O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
modulators O
of O
SERT B
function O
. O
In O
functional O
transport O
assays O
, O
we O
found O
that O
one O
of O
the O
identified O
molecules O
, O
ATM7 O
, O
increased O
the O
reuptake O
of O
serotonin O
, O
possibly O
by O
facilitating O
the O
interaction O
of O
serotonin O
with O
transport-ready O
conformations O
of O
SERT O
when O
concentrations O
of O
serotonin O
were O
low O
and O
rate O
limiting O
. O
In O
addition O
, O
ATM7 O
potentiates O
3,4-methylenedioxy-N-methylamphetamine O
( O
MDMA O
"Ecstasy")-induced O
reversed O
transport O
by O
SERT O
. O
Taking O
advantage O
of O
a O
conformationally O
sensitive O
residue O
in O
transmembrane O
domain O
6 O
, O
we O
demonstrate O
that O
ATM7 O
mechanistically O
stabilizes O
an O
outward-facing O
conformation O
of O
SERT O
. O
Taken O
together O
these O
observations O
demonstrate O
that O
ATM7 O
acts O
through O
a O
novel O
mechanism O
that O
involves O
allosteric O
modulation O
of O
SERT O
function O
. O

serotonin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
We O
performed O
molecular O
dynamics O
simulations O
to O
further O
characterize O
the O
allosteric O
pocket O
that O
was O
identified O
by O
site-directed O
mutagenesis O
studies O
and O
employed O
this O
pocket O
in O
a O
virtual O
screen O
for O
small-molecule O
modulators O
of O
SERT B
function O
. O
In O
functional O
transport O
assays O
, O
we O
found O
that O
one O
of O
the O
identified O
molecules O
, O
ATM7 O
, O
increased O
the O
reuptake O
of O
serotonin O
possibly O
by O
facilitating O
the O
interaction O
of O
serotonin O
with O
transport-ready O
conformations O
of O
SERT O
when O
concentrations O
of O
serotonin O
were O
low O
and O
rate O
limiting O
. O
In O
addition O
, O
ATM7 O
potentiates O
3,4-methylenedioxy-N-methylamphetamine O
(MDMA O
, O
"Ecstasy")-induced O
reversed O
transport O
by O
SERT O
. O
Taking O
advantage O
of O
a O
conformationally O
sensitive O
residue O
in O
transmembrane O
domain O
6 O
, O
we O
demonstrate O
that O
ATM7 O
mechanistically O
stabilizes O

serotonin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
characterize O
the O
allosteric O
pocket O
that O
was O
identified O
by O
site-directed O
mutagenesis O
studies O
and O
employed O
this O
pocket O
in O
a O
virtual O
screen O
for O
small-molecule O
modulators O
of O
SERT B
function O
. O
In O
functional O
transport O
assays O
, O
we O
found O
that O
one O
of O
the O
identified O
molecules O
, O
ATM7 O
, O
increased O
the O
reuptake O
of O
serotonin O
, O
possibly O
by O
facilitating O
the O
interaction O
of O
serotonin O
with O
transport-ready O
conformations O
of O
SERT O
when O
concentrations O
of O
serotonin O
were O
low O
and O
rate O
limiting O
. O
In O
addition O
, O
ATM7 O
potentiates O
3,4-methylenedioxy-N-methylamphetamine O
(MDMA O
, O
"Ecstasy")-induced O
reversed O
transport O
by O
SERT O
. O
Taking O
advantage O
of O
a O
conformationally O
sensitive O
residue O
in O
transmembrane O
domain O
6 O
, O
we O
demonstrate O
that O
ATM7 O
mechanistically O
stabilizes O
an O
outward-facing O
conformation O
of O
SERT O
. O
Taken O
together O

serotonin O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
mutagenesis O
studies O
and O
employed O
this O
pocket O
in O
a O
virtual O
screen O
for O
small-molecule O
modulators O
of O
SERT B
function O
. O
In O
functional O
transport O
assays O
, O
we O
found O
that O
one O
of O
the O
identified O
molecules O
, O
ATM7 O
, O
increased O
the O
reuptake O
of O
serotonin O
, O
possibly O
by O
facilitating O
the O
interaction O
of O
serotonin O
with O
transport-ready O
conformations O
of O
SERT O
when O
concentrations O
of O
serotonin O
were O
low O
and O
rate O
limiting O
. O
In O
addition O
, O
ATM7 O
potentiates O
3,4-methylenedioxy-N-methylamphetamine O
(MDMA O
, O
"Ecstasy")-induced O
reversed O
transport O
by O
SERT O
. O
Taking O
advantage O
of O
a O
conformationally O
sensitive O
residue O
in O
transmembrane O
domain O
6 O
, O
we O
demonstrate O
that O
ATM7 O
mechanistically O
stabilizes O
an O
outward-facing O
conformation O
of O
SERT O
. O
Taken O
together O
these O
observations O
demonstrate O
that O
ATM7 O
acts O
through O
a O
novel O

STZ O
acts O
as O
NOT O
for O
what O
entity O
? O
CCGs O
Dbp O
and O
RevErbα O
revealed O
a O
diurnal O
rhythm O
in O
all O
investigated O
groups O
. O
Insulin O
administration O
to O
Iddm O
rats O
normalized O
the O
enhanced O
MESOR O
in O
the O
expression O
of O
Dbp O
, O
RevErbα O
, O
and O
E4bp4 O
to O
the O
levels O
of O
normoglycemic O
controls O
. O
Cosinor O
analysis O
indicated O
no O
diurnal O
rhythm O
of O
Pparγ B
expression O
in O
the O
livers O
of O
diabetic O
STZ O
or O
Iddm O
rats O
or O
in O
those O
of O
insulin-substituted O
Iddm O
rats O
. O
Also O
, O
insulin O
substitution O
could O
not O
reverse O
the O
decreased O
MESOR O
of O
Pparγ O
expression O
in O
Iddm O
rats O
. O
In O
consequence O
of O
the O
diabetic O
disease O
, O
changes O
in O
the O
expression O
of O
clock O
genes O
and O
CCGs O
suggest O
alterations O
in O
the O
hepatic O
peripheral O
clock O
mechanism O
. O

streptozotocin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
the O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock B
genes O
and O
clock-controlled O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O

streptozotocin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
the O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled B
genes I
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O

streptozotocin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
the O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs B
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O

STZ O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock B
genes O
and O
clock-controlled O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
( O
STZ O
-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O

STZ O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled B
genes I
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
( O
STZ O
-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O

STZ O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Liver O
of O
Streptozotocin-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
( O
STZ O
-treated O
rats O
, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock O
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs B
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O

STZ O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
LEW.1AR1-iddm O
(Iddm) O
rats O
, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin O
. O
Hepatic O
mRNA O
was O
extracted O
, O
and O
the O
relative O
expression O
of O
clock B
genes O
(Per1 O
, O
Per2 O
, O
Bmal1 O
, O
Clock O
, O
Cry1) O
, O
as O
well O
as O
CCGs O
(Dbp O
, O
E4bp4 O
, O
RevErbα O
, O
Rorα O
, O
Pparγ) O
, O
was O
analyzed O
by O
reverse O
transcription O
followed O
by O
real-time O
polymerase O
chain O
reaction O
. O
Diabetic O
STZ O
and O
Iddm O
rats O
, O
as O
well O
as O
insulin-substituted O
Iddm O
rats O
, O
exhibited O
a O
significant O
diurnal O
expression O
pattern O
of O
clock O
genes O
as O
determined O
by O
Cosinor O
analysis; O
however O
, O
the O
MESOR O
(midline O
estimating O
statistic O
of O
rhythm) O
of O
Bmal1 O
, O
Per2 O
, O
and O
Clock O
transcript O
expression O
was O
altered O
in O
Iddm O
and O
insulin-substituted O
Iddm O
rats O
. O
The O
hepatic O
expression O

Streptozotocin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Clock B
Gene O
Expression O
in O
the O
Liver O
of O
Streptozotoci O
-induced O
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats.Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock O
. O
We O
investigated O
the O
diurnal O
expression O
of O
clock O
genes O
and O
clock-controlled O
genes O
(CCGs) O
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin O
(STZ)-treated O
rats O
, O
male O

citalopram O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
the O
LC O
(Emax O
= O
157 O
± O
25 O
%) O
and O
PFC O
(Emax O
= O
175 O
± O
24 O
%) O
. O
Local O
citalopram O
(0.1-100 O
μM) O
into O
the O
LC O
induced O
NA O
increase O
in O
the O
LC O
(Emax O
= O
210 O
± O
25 O
%) O
and O
decrease O
in O
the O
PFC O
(Emax O
= O
-38 O
± O
9 O
%) O
. O
Local O
LC O
citalopram O
effect O
was O
abolished O
by O
LC O
presence O
of O
the O
5-HT3 B
receptor O
antagonist O
MDL72222 O
(1 O
μM) O
but O
not O
the O
5-HT1/2 O
receptor O
antagonist O
methiothepin O
(1 O
μM) O
. O
Systemic O
citalopram O
in O
the O
LC O
presence O
of O
MDL72222 O
did O
not O
modify O
NA O
in O
the O
LC O
but O
increased O
NA O
in O
the O
PFC O
(Emax O
= O
158 O
± O
26 O

citalopram O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
the O
LC O
presence O
of O
MDL72222 O
did O
not O
modify O
NA O
in O
the O
LC O
but O
increased O
NA O
in O
the O
PFC O
(Emax O
= O
158 O
± O
26 O
%) O
. O
Local O
citalopram O
into O
the O
PFC O
enhanced O
NA O
(Emax O
= O
376 O
± O
18 O
%) O
in O
the O
area O
, O
which O
was O
prevented O
by O
MDL72222 O
. O
CONCLUSIONS O
: O
The O
SSRI O
citalopram O
modulates O
central O
noradrenergic O
neurotransmission O
by O
activation O
, O
through O
endogenous O
serotonin O
, O
of O
5-HT3 B
receptors O
expressed O
in O
the O
somatodendritic O
(LC) O
and O
terminal O
(PFC) O
areas O
, O
which O
subsequently O
promote O
an O
enhancement O
of O
local O
NA O
. O
Therefore O
, O
5-HT3 O
receptors O
and O
somatodendritic O
α2-adrenoceptors O
in O
the O
LC O
play O
an O
important O
role O
in O
the O
global O
effect O
of O
SSRIs O
. O

RS79948 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
was O
performed O
in O
freely O
awake O
rats O
. O
RESULTS O
: O
Systemic O
citalopram O
(10 O
mg/kg O
, O
i.p.) O
increased O
noradrenaline O
(NA) O
in O
the O
LC O
(E O
max O
= O
141 O
± O
13 O
%) O
and O
simultaneously O
decreased O
NA O
in O
the O
PFC O
(Emax O
= O
-46 O
± O
7 O
%) O
. O
In O
the O
local O
presence O
into O
the O
LC O
of O
the O
α2-adrenoceptor B
antagonist O
RS79948 O
(1 O
μM) O
, O
systemic O
citalopram O
increased O
NA O
in O
the O
LC O
(Emax O
= O
157 O
± O
25 O
%) O
and O
PFC O
(Emax O
= O
175 O
± O
24 O
%) O
. O
Local O
citalopram O
(0.1-100 O
μM) O
into O
the O
LC O
induced O
NA O
increase O
in O
the O
LC O
(Emax O
= O
210 O
± O
25 O
%) O
and O
decrease O
in O
the O
PFC O
(Emax O
= O

MDL72222 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
= O
175 O
± O
24 O
%) O
. O
Local O
citalopram O
(0.1-100 O
μM) O
into O
the O
LC O
induced O
NA O
increase O
in O
the O
LC O
(Emax O
= O
210 O
± O
25 O
%) O
and O
decrease O
in O
the O
PFC O
(Emax O
= O
-38 O
± O
9 O
%) O
. O
Local O
LC O
citalopram O
effect O
was O
abolished O
by O
LC O
presence O
of O
the O
5-HT3 B
receptor O
antagonist O
MDL72222 O
(1 O
μM) O
but O
not O
the O
5-HT1/2 O
receptor O
antagonist O
methiothepin O
(1 O
μM) O
. O
Systemic O
citalopram O
in O
the O
LC O
presence O
of O
MDL72222 O
did O
not O
modify O
NA O
in O
the O
LC O
but O
increased O
NA O
in O
the O
PFC O
(Emax O
= O
158 O
± O
26 O
%) O
. O
Local O
citalopram O
into O
the O
PFC O
enhanced O
NA O
(Emax O
= O
376 O
± O

methiothepin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
into O
the O
LC O
induced O
NA O
increase O
in O
the O
LC O
(Emax O
= O
210 O
± O
25 O
%) O
and O
decrease O
in O
the O
PFC O
(Emax O
= O
-38 O
± O
9 O
%) O
. O
Local O
LC O
citalopram O
effect O
was O
abolished O
by O
LC O
presence O
of O
the O
5-HT3 O
receptor O
antagonist O
MDL72222 O
(1 O
μM) O
but O
not O
the O
5-HT1/2 B
receptor O
antagonist O
methiothepin O
(1 O
μM) O
. O
Systemic O
citalopram O
in O
the O
LC O
presence O
of O
MDL72222 O
did O
not O
modify O
NA O
in O
the O
LC O
but O
increased O
NA O
in O
the O
PFC O
(Emax O
= O
158 O
± O
26 O
%) O
. O
Local O
citalopram O
into O
the O
PFC O
enhanced O
NA O
(Emax O
= O
376 O
± O
18 O
%) O
in O
the O
area O
, O
which O
was O
prevented O
by O

MPTP O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
. O
In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast O
, O
both O
CRE O
and O
17β-estradiol O
benzoate O
(EB) O
recovered O
these O
parameters O
to O
normal O
levels O
. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH O
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP O
toxicity O
. O
Additionally O
, O
MPTP O
significantly O
down-regulated O
Bcl-2 O
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O
increase O
in O
Bax O
expression O
, O
cytochrome B
C I
translocation O
to O
the O
cytosol O
, O
andcleaved-caspase-3 O
expression O
, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment O
. O
CONCLUSIONS O
: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O
has O
estrogen-like O
and O

MPTP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
dopaminergic O
cell O
line O
, O
in O
a O
dose-dependent O
manner O
. O
In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast O
, O
both O
CRE O
and O
17β-estradiol O
benzoate O
(EB) O
recovered O
these O
parameters O
to O
normal O
levels O
. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH B
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP O
toxicity O
. O
Additionally O
, O
MPTP O
significantly O
down-regulated O
Bcl-2 O
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O
increase O
in O
Bax O
expression O
, O
cytochrome O
C O
translocation O
to O
the O
cytosol O
, O
andcleaved-caspase-3 O
expression O
, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment O
. O
CONCLUSIONS O
: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O

MPTP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
. O
In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast O
, O
both O
CRE O
and O
17β-estradiol O
benzoate O
(EB) O
recovered O
these O
parameters O
to O
normal O
levels O
. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH O
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP O
toxicity O
. O
Additionally O
, O
MPTP O
significantly O
down-regulated O
Bcl-2 O
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O
increase O
in O
Bax B
expression O
, O
cytochrome O
C O
translocation O
to O
the O
cytosol O
, O
andcleaved-caspase-3 O
expression O
, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment O
. O
CONCLUSIONS O
: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O
has O
estrogen-like O
and O

MPTP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
. O
In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast O
, O
both O
CRE O
and O
17β-estradiol O
benzoate O
(EB) O
recovered O
these O
parameters O
to O
normal O
levels O
. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH O
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP O
toxicity O
. O
Additionally O
, O
MPTP O
significantly O
down-regulated O
Bcl-2 O
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O
increase O
in O
Bax O
expression O
, O
cytochrome O
C O
translocation O
to O
the O
cytosol O
, O
andcleaved-caspase-3 O
expression O
, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment O
. O
CONCLUSIONS O
: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O
has O
estrogen-like O
and O

MPTP O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
. O
In O
mice O
, O
MPTP O
significantly O
decreased O
the O
levels O
of O
dopamine O
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast O
, O
both O
CRE O
and O
17β-estradiol O
benzoate O
(EB) O
recovered O
these O
parameters O
to O
normal O
levels O
. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH O
immunopositive O
fibers O
and O
cells O
, O
respectively O
, O
from O
MPTP O
toxicity O
. O
Additionally O
, O
MPTP O
significantly O
down-regulated O
Bcl-2 B
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN O
, O
followed O
by O
an O
increase O
in O
Bax O
expression O
, O
cytochrome O
C O
translocation O
to O
the O
cytosol O
, O
andcleaved-caspase-3 O
expression O
, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment O
. O
CONCLUSIONS O
: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O
has O
estrogen-like O
and O

PEC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzyme-responsive O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
for O
controlled O
drug O
release.Cholesterol O
esterase O
(CE) O
induced O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
( O
PEC O
and O
drug O
release O
from O
PEC O
under O
mild O
physiological O
environment O
was O
investigated O
. O
The O
degradation O
process O
was O
monitored O
by O
changes O
of O
mass O
and O
molecular O
weight O
(MW) O
and O
surface O
morphology O
of O
polymer O
films O
. O
During O
the O
whole O
period O
of O
degradation O
, O
MW O
of O
PEC O
was O
unchanged O
. O
Water O
uptake O
of O
the O
polymer O
was O
only O
2.8 O

PEC O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzyme-responsive O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
for O
controlled O
drug O
release.Cholesterol O
esterase O
(CE) O
induced O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
( O
PEC O
and O
drug O
release O
from O
PEC O
under O
mild O
physiological O
environment O
was O
investigated O
. O
The O
degradation O
process O
was O
monitored O
by O
changes O
of O
mass O
and O
molecular O
weight O
(MW) O
and O
surface O
morphology O
of O
polymer O
films O
. O
During O
the O
whole O
period O
of O
degradation O
, O
MW O
of O
PEC O
was O
unchanged O
. O
Water O
uptake O
of O
the O
polymer O
was O
only O
2.8 O

poly(ethylene O
carbonate) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzyme-responsive O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
for O
controlled O
drug O
release.Cholesterol O
esterase O
(CE) O
induced O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
(PEC) O
and O
drug O
release O
from O
PEC O
under O
mild O
physiological O
environment O
was O
investigated O
. O
The O
degradation O
process O
was O
monitored O
by O
changes O
of O
mass O
and O
molecular O
weight O
(MW) O
and O
surface O
morphology O
of O
polymer O
films O
. O
During O
the O
whole O
period O
of O
degradation O
, O
MW O
of O
PEC O
was O
unchanged O
. O
Water O
uptake O
of O
the O
polymer O
was O
only O

poly(ethylene O
carbonate) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzyme-responsive O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
for O
controlled O
drug O
release.Cholesterol O
esterase O
(CE) O
induced O
surface O
erosion O
of O
poly(ethylene O
carbonate) O
(PEC) O
and O
drug O
release O
from O
PEC O
under O
mild O
physiological O
environment O
was O
investigated O
. O
The O
degradation O
process O
was O
monitored O
by O
changes O
of O
mass O
and O
molecular O
weight O
(MW) O
and O
surface O
morphology O
of O
polymer O
films O
. O
During O
the O
whole O
period O
of O
degradation O
, O
MW O
of O
PEC O
was O
unchanged O
. O
Water O
uptake O
of O
the O
polymer O
was O
only O

benzenesulfonamides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O

benzenesulfonamides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA B
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O

benzenesulfonamides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O

benzenesulfonamides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O

cyanoacrylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O

cyanoacrylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA B
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O

cyanoacrylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O

cyanoacrylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O

tyrphostine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
( O
tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O
hCA O
I O

tyrphostine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
( O
tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA B
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O
hCA O
I O

tyrphostine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
( O
tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic B
anhydrase I
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O
hCA O
I O

tyrphostine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
( O
tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O
hCA O
I O

Benzenesulfonamides O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamide O
incorporating O
cyanoacrylamide O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O

cyanoacrylamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Carbonic O
anhydrase O
inhibitors O
. O
Benzenesulfonamides O
incorporating O
cyanoacrylamid O
moieties O
strongly O
inhibit O
Saccharomyces O
cerevisiae O
β-carbonic O
anhydrase.A O
series O
of O
benzenesulfonamides O
incorporating O
cyanoacrylamide O
moieties O
(tyrphostine O
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic O
anhydrase O
(CA O
, O
EC O
4.2.1.1) O
from O
Saccharomyces O
cerevisiae O
, O
ScCA O
. O
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA O
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen B
receptor I
(AR) O
and O
prostate-specific O
antigen O
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR O
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR B
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific B
antigen I
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR O
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR O
and O
PSA B
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR B
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
The O
result O
shown O
that O
juglone O
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner O
. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone O
treatment O
were O
observed O
by O
Hoechst O
33342 O
staining O
. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR O
and O
PSA B
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O

juglone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
membrane O
potential O
, O
and O
caspase-3 O
, O
-9 O
activation O
. O
Moreover O
, O
we O
found O
that O
juglone O
significantly O
inhibited O
the O
expression O
levels O
of O
androgen O
receptor O
(AR) O
and O
prostate-specific O
antigen O
(PSA) O
in O
a O
dose-dependent O
manner O
, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR B
and O
PSA O
genes O
with O
and/or O
without O
dihydrotestosterone O
(DHT) O
. O
Take O
together O
, O
our O
results O
demonstrated O
that O
juglone O
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O
AR O
expression O
. O
Therefore O
, O
our O
results O
indicated O
that O
juglone O
may O
be O
a O
potential O
candidate O
of O
drug O
for O
androgen-sensitive O
prostate O
cancer O
. O

Z-Val-Ala-Asp-fluoromethylketone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
with O
ClpP O
resulted O
in O
hypodiploid O
DNA O
contents O
, O
increased O
Bax O
/ O
Bcl-2 O
ratio O
and O
induction O
of O
reactive O
oxygen O
species O
(ROS) O
production O
. O
The O
release O
of O
cytochrome O
c O
from O
mitochondria O
into O
the O
cytosol O
, O
which O
is O
an O
initiator O
of O
the O
activation O
of O
caspase B
cascades O
, O
was O
not O
observed O
in O
ClpP-treated O
cells O
. O
In O
addition O
, O
pretreatment O
with O
Z-Val-Ala-Asp-fluoromethylketone O
(Z-VAD-fmk) O
, O
a O
broad O
spectrum O
of O
caspase O
inhibitor O
, O
could O
not O
rescue O
apoptotic O
cells O
from O
ClpP O
toxicity O
. O
Coincidently O
, O
caspase-3 O
and O
-8 O
activation O
and O
cleavage O
of O
PARP O
were O
not O
detected O
. O
Moreover O
, O
caspase O
independent O
apoptosis-inducing O
factor O
(AIF) O
was O
released O
from O
mitochondria O
and O
translocated O
to O
the O
nucleus O
in O
response O
to O
ClpP O
. O
We O
also O
found O

Z-VAD-fmk O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
resulted O
in O
hypodiploid O
DNA O
contents O
, O
increased O
Bax O
/ O
Bcl-2 O
ratio O
and O
induction O
of O
reactive O
oxygen O
species O
(ROS) O
production O
. O
The O
release O
of O
cytochrome O
c O
from O
mitochondria O
into O
the O
cytosol O
, O
which O
is O
an O
initiator O
of O
the O
activation O
of O
caspase B
cascades O
, O
was O
not O
observed O
in O
ClpP-treated O
cells O
. O
In O
addition O
, O
pretreatment O
with O
Z-Val-Ala-Asp-fluoromethylketone O
( O
Z-VAD-fmk O
 O
, O
a O
broad O
spectrum O
of O
caspase O
inhibitor O
, O
could O
not O
rescue O
apoptotic O
cells O
from O
ClpP O
toxicity O
. O
Coincidently O
, O
caspase-3 O
and O
-8 O
activation O
and O
cleavage O
of O
PARP O
were O
not O
detected O
. O
Moreover O
, O
caspase O
independent O
apoptosis-inducing O
factor O
(AIF) O
was O
released O
from O
mitochondria O
and O
translocated O
to O
the O
nucleus O
in O
response O
to O
ClpP O
. O
We O
also O
found O

TSA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
adjacent O
noncancerous O
tissues O
, O
uc002mbe.2 B
expression O
level O
was O
significantly O
lower O
in O
the O
HCC O
cell O
lines O
and O
liver O
cancer O
tissues O
. O
The O
TSA-induced O
uc002mbe.2 O
expression O
was O
positively O
correlated O
with O
the O
apoptotic O
effect O
of O
TSA O
in O
HCC O
cells O
. O
In O
addition O
, O
knockdown O
the O
expression O
of O
uc002mbe.2 O
significantly O
reduced O
TSA-induced O
apoptosis O
of O
Huh7cells O
. O
Therefore O
, O
TSA O
induced O
apoptosis O
of O
HCC O
cells O
is O
uc002mbe.2 O
dependent O
and O
reduced O
expression O
of O
uc002mbe.2 O
may O
be O
associated O
with O
liver O
carcinogenesis O
. O

TSA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
lncRNA O
and O
6.1% O
(1849) O
of O
protein O
coding O
gene O
were O
significantly O
differentially O
expressed O
. O
The O
differential O
expressions O
of O
lncRNA O
and O
protein O
coding O
genes O
had O
distinguishable O
hierarchical O
clustering O
expression O
profiling O
pattern O
. O
Among O
these O
differentially O
expressed O
lncRNAs O
, O
the O
greatest O
change O
was O
noted O
for O
uc002mbe.2 O
, O
which O
had O
more O
than O
300 O
folds O
induction O
upon O
TSA O
treatment O
. O
TSA O
selectively O
induced O
uc002mbe.2 B
in O
four O
studied O
HCC O
cell O
lines O
. O
Compared O
with O
normal O
human O
hepatocytes O
and O
adjacent O
noncancerous O
tissues O
, O
uc002mbe.2 O
expression O
level O
was O
significantly O
lower O
in O
the O
HCC O
cell O
lines O
and O
liver O
cancer O
tissues O
. O
The O
TSA-induced O
uc002mbe.2 O
expression O
was O
positively O
correlated O
with O
the O
apoptotic O
effect O
of O
TSA O
in O

TSA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
and O
6.1% O
(1849) O
of O
protein O
coding O
gene O
were O
significantly O
differentially O
expressed O
. O
The O
differential O
expressions O
of O
lncRNA O
and O
protein O
coding O
genes O
had O
distinguishable O
hierarchical O
clustering O
expression O
profiling O
pattern O
. O
Among O
these O
differentially O
expressed O
lncRNAs O
, O
the O
greatest O
change O
was O
noted O
for O
uc002mbe.2 O
, O
which O
had O
more O
than O
300 O
folds O
induction O
upon O
TSA O
treatment O
. O
TSA O
selectively O
induced O
uc002mbe.2 B
in O
four O
studied O
HCC O
cell O
lines O
. O
Compared O
with O
normal O
human O
hepatocytes O
and O
adjacent O
noncancerous O
tissues O
, O
uc002mbe.2 O
expression O
level O
was O
significantly O
lower O
in O
the O
HCC O
cell O
lines O
and O
liver O
cancer O
tissues O
. O
The O
TSA-induced O
uc002mbe.2 O
expression O
was O
positively O
correlated O
with O
the O
apoptotic O
effect O
of O
TSA O
in O
HCC O
cells O
. O

TSA O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
was O
noted O
for O
uc002mbe.2 O
, O
which O
had O
more O
than O
300 O
folds O
induction O
upon O
TSA O
treatment O
. O
TSA O
selectively O
induced O
uc002mbe.2 B
in O
four O
studied O
HCC O
cell O
lines O
. O
Compared O
with O
normal O
human O
hepatocytes O
and O
adjacent O
noncancerous O
tissues O
, O
uc002mbe.2 O
expression O
level O
was O
significantly O
lower O
in O
the O
HCC O
cell O
lines O
and O
liver O
cancer O
tissues O
. O
The O
TSA O
induced O
uc002mbe.2 O
expression O
was O
positively O
correlated O
with O
the O
apoptotic O
effect O
of O
TSA O
in O
HCC O
cells O
. O
In O
addition O
, O
knockdown O
the O
expression O
of O
uc002mbe.2 O
significantly O
reduced O
TSA-induced O
apoptosis O
of O
Huh7cells O
. O
Therefore O
, O
TSA-induced O
apoptosis O
of O
HCC O
cells O
is O
uc002mbe.2 O
dependent O
and O
reduced O
expression O
of O
uc002mbe.2 O
may O
be O
associated O
with O
liver O
carcinogenesis O
. O

Trichostatin O
A O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Induction O
of O
the O
liver O
cancer-down-regulated O
long O
noncoding O
RNA O
uc002mbe.2 O
mediates O
trichostatin-induced O
apoptosis O
of O
liver O
cancer O
cells.Differential O
expression O
of O
long O
non-coding O
RNAs O
(lncRNAs) O
plays O
critical O
roles O
in O
hepatocarcinogenesis O
. O
Considerable O
attention O
has O
focused O
on O
the O
antitumor O
effect O
of O
histone B
deacetylase I
inhibitor O
( O
Trichostatin O
A O
TSA) O
as O
well O
as O
the O
coding O
gene O
expression-induced O
apoptosis O
of O
cancer O
cells O
. O
However O
, O
it O
is O
not O
known O
whether O
lncRNA O
has O
a O
role O
in O
TSA-induced O
apoptosis O
of O
human O
hepatocellular O
carcinoma O
(HCC) O
cells O
. O
The O
global O
expression O
of O
lncRNAs O
and O
coding O
genes O
was O
analyzed O
with O
the O
Human O
LncRNA O
Array O
V2.0 O
after O
24h O

TSA O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Induction O
of O
the O
liver O
cancer-down-regulated O
long O
noncoding O
RNA O
uc002mbe.2 O
mediates O
trichostatin-induced O
apoptosis O
of O
liver O
cancer O
cells.Differential O
expression O
of O
long O
non-coding O
RNAs O
(lncRNAs) O
plays O
critical O
roles O
in O
hepatocarcinogenesis O
. O
Considerable O
attention O
has O
focused O
on O
the O
antitumor O
effect O
of O
histone B
deacetylase I
inhibitor O
(Trichostatin O
A O
, O
TSA O
as O
well O
as O
the O
coding O
gene O
expression-induced O
apoptosis O
of O
cancer O
cells O
. O
However O
, O
it O
is O
not O
known O
whether O
lncRNA O
has O
a O
role O
in O
TSA-induced O
apoptosis O
of O
human O
hepatocellular O
carcinoma O
(HCC) O
cells O
. O
The O
global O
expression O
of O
lncRNAs O
and O
coding O
genes O
was O
analyzed O
with O
the O
Human O
LncRNA O
Array O
V2.0 O
after O
24h O
treatment O
. O

steroidal O
glycoalkaloids O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
migration O
assay O
. O
Cytotoxicity O
was O
evaluated O
with O
methyl O
thiazole O
tetrazolium O
(MTT) O
. O
To O
gain O
insight O
into O
the O
mode O
of O
action O
of O
the O
steroidal O
glycosides O
, O
nitric O
oxide O
(NO) O
production O
, O
and O
expression O
of O
genes O
for O
transforming O
growth O
factor O
beta-1 O
(TGF-β) O
and O
its O
receptors O
were O
evaluated O
. O
RESULTS O
: O
Fractionated O
bulb O
extracts O
and O
the O
two O
isolated O
steroidal O
glycoalkaloids O
(1) O
and O
(2) O
induced O
NO O
production O
and O
TGF-β B
receptor I
I I
mRNA O
expression O
in O
fibroblast O
cell O
culture O
. O
In O
a O
cytotoxicity O
assay O
, O
steroidal O
glycosides O
(1) O
and O
(3) O
had O
IC50 O
values O
of O
8.2 O
and O
8.7µM O
, O
but O
the O
natural O
acetylation O
of O
the O
C-6″' O
hydroxy O
of O
the O
terminal O
glucose O
unit O
in O
(2) O
resulted O
in O

brexpiprazole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin B
(5-HT) I
receptor I
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O

brexpiprazole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A B
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O

brexpiprazole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O

brexpiprazole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O

brexpiprazole O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Acute O
effects O
of O
brexpiprazole O
on O
serotonin O
, O
dopamine O
, O
and O
norepinephrine O
systems O
: O
an O
in O
vivo O
electrophysiologic O
characterization.Brexpiprazole O
, O
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole O
, O
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression O
. O
Using O
electrophysiologic O
techniques O
, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
serotonin O
(5-HT) O
receptor O
subtypes O
5-HT1A O
, O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A O
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O

brexpiprazole O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O
at O
5-HT1A O
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O
displayed O
alpha1B-adrenoceptor O
antagonistic O
action O
. O
Taken O
together O
, O
these O
results O

brexpiprazole O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O
at O
5-HT1A B
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O
displayed O
alpha1B-adrenoceptor O
antagonistic O
action O
. O
Taken O
together O
, O
these O
results O
provide O
insight O
into O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O

brexpiprazole O
acts O
as O
AGONIST O
for O
what O
entity O
? O
5-HT1B O
, O
and O
5-HT2A; O
dopamine O
(DA) O
D2 O
autoreceptors O
, O
and O
alpha1- O
and O
alpha2-adrenergic O
receptors O
. O
In O
addition O
, O
the O
effects O
on O
5-HT1A B
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A O
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O

aripiprazole O
acts O
as O
AGONIST O
for O
what O
entity O
? O
on O
5-HT1A B
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 O
autoreceptors O
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole O
, O
an O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A O
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O

DOI O
acts O
as O
AGONIST O
for O
what O
entity O
? O
aripiprazole O
, O
an O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A B
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O

2,5-dimethoxy-4-iodoamphetamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
agent O
in O
wide O
clinical O
use O
. O
In O
the O
DRN O
, O
brexpiprazole O
completely O
inhibited O
the O
firing O
of O
5-HT O
neurons O
via O
5-HT1A O
agonism O
and O
was O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A B
receptor O
agonist O
DOI O
( O
2,5-dimethoxy-4-iodoamphetamine O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O

apomorphine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
more O
potent O
than O
aripiprazole O
(ED50 O
= O
230 O
and O
700 O
mug/kg O
, O
respectively) O
. O
In O
the O
locus O
coeruleus O
, O
brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A O
receptor O
agonist O
DOI O
(2,5-dimethoxy-4-iodoamphetamine) O
on O
norepinephrine O
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg) O
, O
demonstrating O
5-HT2A O
antagonistic O
action O
. O
Brexpiprazole O
reversed O
the O
inhibitory O
effect O
of O
the O
DA O
agonist O
apomorphine O
on O
VTA O
DA O
neurons O
(ED50 O
= O
61 O
mug/kg) O
, O
whereas O
it O
was O
ineffective O
when O
administered O
alone O
, O
indicating O
partial O
agonistic O
action O
on O
D2 O
receptors O
. O
Compared O
with O
aripiprazole O
, O
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O

brexpiprazole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
inhibited O
the O
firing O
activity O
of O
VTA O
DA O
neurons O
, O
brexpiprazole O
displayed O
less O
efficacy O
at O
D2 O
receptors O
. O
In O
the O
hippocampus O
, O
brexpiprazole O
acted O
as O
a O
full O
agonist O
at O
5-HT1A O
receptors O
on O
pyramidal O
neurons O
. O
Furthermore O
, O
it O
increased O
5-HT O
release O
by O
terminal O
alpha2-adrenergic O
heteroceptor O
but O
not O
5-HT1B O
autoreceptor O
antagonism O
. O
In O
the O
lateral O
geniculate O
nucleus O
, O
brexpiprazole O
displayed O
alpha1B-adrenoceptor B
antagonistic O
action O
. O
Taken O
together O
, O
these O
results O
provide O
insight O
into O
the O
in O
vivo O
action O
of O
brexpiprazole O
on O
monoamine O
targets O
relevant O
in O
the O
treatment O
of O
depression O
and O
schizophrenia O
. O

minaprine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
cycloheximide-induced O
memory O
impairment O
was O
also O
antagonized O
by O
a O
serotonin O
(5-HT) O
releaser O
, O
p-chloroamphetamine O
, O
and O
by O
a O
5-HT O
precursor O
, O
5-hydroxytryptophan O
, O
whereas O
a O
5-HT1A-selective O
agonist O
, O
8-hydroxy-2-(di-n-propylamino)tetralin O
, O
was O
inactive O
. O
The O
memory-improving O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
was O
potentiated O
by O
a O
selective O
5-HT2 O
antagonist O
, O
ritanserin O
. O
These O
results O
suggest O
that O
the O
beneficial O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
may O
be O
related O
not O
only O
to O
cholinergic O
but O
also O
serotonergic O
neuronal O
systems O
(5-HT2 O
receptors) O
. O

cycloheximide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
impairment O
was O
also O
antagonized O
by O
a O
serotonin O
(5-HT) O
releaser O
, O
p-chloroamphetamine O
, O
and O
by O
a O
5-HT O
precursor O
, O
5-hydroxytryptophan O
, O
whereas O
a O
5-HT1A-selective O
agonist O
, O
8-hydroxy-2-(di-n-propylamino)tetralin O
, O
was O
inactive O
. O
The O
memory-improving O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
was O
potentiated O
by O
a O
selective O
5-HT2 O
antagonist O
, O
ritanserin O
. O
These O
results O
suggest O
that O
the O
beneficial O
effect O
of O
minaprine O
on O
cycloheximide O
induced O
amnesia O
may O
be O
related O
not O
only O
to O
cholinergic O
but O
also O
serotonergic O
neuronal O
systems O
(5-HT2 O
receptors) O
. O

8-hydroxy-2-(di-n-propylamino)tetralin O
acts O
as O
AGONIST O
for O
what O
entity O
? O
avoidance O
task O
in O
mice O
. O
Minaprine O
significantly O
improved O
cycloheximide-induced O
amnesia O
. O
This O
effect O
was O
inhibited O
by O
scopolamine O
, O
but O
was O
potentiated O
by O
physostigmine O
. O
The O
anti-amnesic O
effect O
of O
minaprine O
on O
the O
cycloheximide-induced O
memory O
impairment O
was O
also O
antagonized O
by O
a O
serotonin O
(5-HT) O
releaser O
, O
p-chloroamphetamine O
, O
and O
by O
a O
5-HT O
precursor O
, O
5-hydroxytryptophan O
, O
whereas O
a O
5-HT1A-selective O
agonist O
, O
8-hydroxy-2-(di-n-propylamino)tetralin O
was O
inactive O
. O
The O
memory-improving O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
was O
potentiated O
by O
a O
selective O
5-HT2 O
antagonist O
, O
ritanserin O
. O
These O
results O
suggest O
that O
the O
beneficial O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
may O
be O
related O
not O
only O
to O
cholinergic O
but O
also O
serotonergic O
neuronal O
systems O
(5-HT2 O
receptors) O
. O

ritanserin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
by O
physostigmine O
. O
The O
anti-amnesic O
effect O
of O
minaprine O
on O
the O
cycloheximide-induced O
memory O
impairment O
was O
also O
antagonized O
by O
a O
serotonin O
(5-HT) O
releaser O
, O
p-chloroamphetamine O
, O
and O
by O
a O
5-HT O
precursor O
, O
5-hydroxytryptophan O
, O
whereas O
a O
5-HT1A-selective O
agonist O
, O
8-hydroxy-2-(di-n-propylamino)tetralin O
, O
was O
inactive O
. O
The O
memory-improving O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
was O
potentiated O
by O
a O
selective O
5-HT2 B
antagonist O
, O
ritanserin O
These O
results O
suggest O
that O
the O
beneficial O
effect O
of O
minaprine O
on O
cycloheximide-induced O
amnesia O
may O
be O
related O
not O
only O
to O
cholinergic O
but O
also O
serotonergic O
neuronal O
systems O
(5-HT2 O
receptors) O
. O

terfenadine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
astemizole O
, O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O

astemizole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
, O
astemizole O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O

loratadine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
, O
astemizole O
, O
loratadine O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O
rather O

acrivastine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
, O
astemizole O
, O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O
rather O
than O
inhibiting O

Terfenadine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
, O
astemizole O
, O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O
rather O
than O
inhibiting O
histamine O
release O
. O
All O

astemizole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
, O
astemizole O
, O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O
rather O
than O
inhibiting O
histamine O
release O
. O
All O
four O
drugs O

diphenhydramine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
, O
astemizole O
, O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
. O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O
rather O
than O
inhibiting O
histamine O
release O
. O
All O
four O
drugs O
have O
relatively O
long O
half-lives O
and O
are O
rapidly O
absorbed O
after O
oral O

chlorpheniramine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Nonsedating O
histamine B
H1-receptor I
antagonists.The O
chemistry O
, O
pharmacology O
, O
pharmacokinetics O
, O
clinical O
efficacy O
, O
adverse O
effects O
, O
and O
dosages O
of O
the O
nonsedating O
histamine O
H1-receptor O
antagonists O
terfenadine O
, O
astemizole O
, O
loratadine O
, O
and O
acrivastine O
are O
reviewed O
. O
Terfenadine O
and O
astemizole O
are O
chemically O
unrelated O
to O
histamine O
H1-receptor O
antagonists O
such O
as O
diphenhydramine O
and O
chlorpheniramine O
Loratadine O
is O
structurally O
related O
to O
the O
antihistamine O
azatadine O
, O
and O
acrivastine O
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine O
. O
Like O
other O
histamine O
H1-receptor O
antagonists O
, O
they O
competitively O
block O
histamine O
receptor O
sites O
rather O
than O
inhibiting O
histamine O
release O
. O
All O
four O
drugs O
have O
relatively O
long O
half-lives O
and O
are O
rapidly O
absorbed O
after O
oral O
administration O
. O
Terfenadine O
, O

Esmolol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
a O
beta O
blocker O
within O
the O
first O
24 O
hours O
of O
the O
patient's O
admission O
to O
the O
coronary O
care O
unit O
can O
reduce O
overall O
morbidity O
and O
mortality O
within O
the O
first O
7 O
days O
by O
about O
15% O
. O
Maintenance O
therapy O
with O
an O
oral O
beta O
blocker O
can O
reduce O
mortality O
within O
the O
succeeding O
3 O
years O
by O
about O
25% O
. O
Esmolol O
a O
unique O
cardioselective O
beta B
1-adrenergic I
receptor I
blocker O
with O
a O
half-life O
of O
9 O
minutes O
, O
can O
enable O
some O
patients O
with O
relative O
contraindications O
to O
beta O
blockers O
to O
nevertheless O
benefit O
from O
early O
beta-blocking O
therapy O
. O
It O
also O
is O
useful O
in O
screening O
patients O
for O
subsequent O
therapy O
with O
beta O
blockers O
. O
Those O
who O
tolerate O
the O
esmolol O
infusion O

(A) O
cyclosporine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
receptor O
(IL-2 O
R) O
expression O
was O
measured O
using O
two O
anti-IL-2 O
R O
monoclonal O
antibodies O
(moAbs) O
, O
anti-Tac O
and O
1HT4-4H3 O
. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O

CsA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
R) O
expression O
was O
measured O
using O
two O
anti-IL-2 O
R O
monoclonal O
antibodies O
(moAbs) O
, O
anti-Tac O
and O
1HT4-4H3 O
. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O
anti-Tac O

prednisone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
was O
measured O
using O
two O
anti-IL-2 O
R O
monoclonal O
antibodies O
(moAbs) O
, O
anti-Tac O
and O
1HT4-4H3 O
. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O
anti-Tac O
(average O
of O

CsA O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
1HT4-4H3 O
. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O
anti-Tac O
(average O
of O
IL-2 O
R-positive O
cells O
at O
day O
of O
peak O
IL-2 O
R O
expression O

prednisone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O
anti-Tac O
(average O
of O
IL-2 O
R-positive O
cells O
at O
day O
of O
peak O
IL-2 O
R O
expression O
56.0 O
+/- O

azathioprine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
chain O
of O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O
anti-Tac O
(average O
of O
IL-2 O
R-positive O
cells O
at O
day O
of O
peak O
IL-2 O
R O
expression O
56.0 O
+/- O
20.8% O
in O
group O
A O
, O
65.2 O
+/- O
26.6% O
in O
group O
B O
, O
21.0 O

prednisone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
the O
IL-2 O
R O
. O
IL-2 B
R I
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received O
: O
(A) O
cyclosporine O
CsA O
and O
prednisone O
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine O
and O
prednisone O
as O
baseline O
immunosuppression O
(n O
= O
5) O
. O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 O
receptors O
despite O
the O
presence O
of O
anti-Tac O
(average O
of O
IL-2 O
R-positive O
cells O
at O
day O
of O
peak O
IL-2 O
R O
expression O
56.0 O
+/- O
20.8% O
in O
group O
A O
, O
65.2 O
+/- O
26.6% O
in O
group O
B O
, O
21.0 O
+/- O
7.4% O

t-butyl O
acts O
as O
NOT O
for O
what O
entity O
? O
of O
myosin B
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O

t-butyl O
acts O
as O
NOT O
for O
what O
entity O
? O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O

t-butyl O
acts O
as O
NOT O
for O
what O
entity O
? O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon B
kinase I
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O

felodipine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin B
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O

Ca2+ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon B
kinase I
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O

Ca2+ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O

Ca2+ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon B
kinase I
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent B
enzymes I
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O

p-chloro O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon B
kinase I
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
( O
p-chloro O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O

p-chloro O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
( O
p-chloro O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O

p-chloro O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent B
enzymes I
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
( O
p-chloro O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O

p-chloro O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
( O
p-chloro O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O

t-butyl O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon B
kinase I
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O

t-butyl O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O

t-butyl O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent B
enzymes I
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O

t-butyl O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase B
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase B
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin B
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O

felodipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin B
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O

dihydropyridine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent B
enzymes I
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase B
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin B
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
processes O
which O
are O
dependent O
on O
myosin B
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dependent O
on O
myosin B
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridine O
calcium O
channel O
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ B
channel I
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
myosin B
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase B
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
myosin B
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin B
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase B
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin B
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent O
enzymes O
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O
Again O
, O
inhibition O
of O
the O
actin-activated O
myosin O
Mg2+-ATPase O
and O
myosin O
filament O
assembly O
by O
felodipine O
and O
the O
p-chloro O
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin O
concentration O
. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine O
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent B
enzymes I
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction O
. O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP B
phosphodiesterase I
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O
was O
inhibited O
completely O
by O
felodipine O
and O
the O
p-chloro O
analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP B
phosphodiesterase I
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
1.5 O
microM O
respectively O
. O
The O
oxidized O
and O
t-butyl O
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP O
phosphodiesterase O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP B
phosphodiesterase I
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
p-chloro O
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon B
kinase I
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) O
activity O
of O
cAMP O
phosphodiesterase O
as O
well O
as O
the O
calmodulin-stimulated O
activity O
. O
Calmodulin O
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon B
kinase I
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin O
light O
chain O
kinase O
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
phosphodiesterase O
by O
felodipine O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin B
light I
chain I
kinase I
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipin O
(a O
dihydropyridine O
calcium B
channel I
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
felodipine O
(a O
dihydropyridin O
calcium B
channel I
blocker) O
and O
analogues O
on O
calmodulin-dependent O
enzymes.We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent O
enzymes O
(cAMP O
phosphodiesterase O
, O
caldesmon O
kinase O
and O
myosin O
light O
chain O
kinase) O
of O
the O
dihydropyridine O
Ca2+ O
channel O
blocker O
felodipine O
and O
three O
analogues O
(p-chloro O
, O
oxidized O
and O
t-butyl) O
exhibiting O
different O
pharmacological O
potencies O
. O
The O
cAMP O
phosphodiesterase O

p-chloro O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
the O
p-chloro O
analogue O
. O
These O
observations O
suggest O
that O
felodipine O
may O
act O
directly O
on O
the O
phosphodiesterase O
as O
well O
as O
through O
calmodulin O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
Ca2+/calmodulin-dependent O
caldesmon O
kinase O
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM) O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
caused O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
myosin B
light I
chain I
kinase I
activity O
whether O
the O
isolated O
20 O
kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin O
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate O
. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin O
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase B
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O

Felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
case O
was O
prevented O
by O
excess O
calmodulin O
. O
The O
oxidized O
and O
t-butyl O
derivatives O
caused O
little O
or O
no O
inhibition O
. O
Finally O
, O
the O
effects O
of O
felodipine O
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin B
phosphorylation O
were O
examined O
, O
namely O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
myosin O
and O
the O
assembly O
of O
myosin O
filaments O
. O
Felodipine O
and O
the O
p-chloro O
analogue O
inhibited O
the O
actin-activated O
Mg2+-ATPase O
activity O
of O
smooth O
muscle O
myosin O
(IC50 O
= O
25.1 O
microM) O
. O
The O
oxidized O
and O
t-butyl O
analogues O
exhibited O
no O
inhibition O
. O
Similarly O
, O
felodipine O
and O
the O
p-chloro O
analogue O
blocked O
myosin O
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin O
, O
whereas O
the O
oxidized O
and O
t-butyl O
analogues O
did O
not O
. O

loperamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
loperamide O
(from O
30 O
+/- O
16.6 O
to O
a O
peak O
of O
108 O
+/- O
31 O
pmol/l) O
and O
placebo O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
significant O
, O
and O
the O
first O
phase O
of O
CRH-induced O
ACTH B
secretion O
was O
significantly O
lower O
after O
loperamide O
. O
These O
data O
demonstrate O
that O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP O
and O
CRH O
on O
ACTH O
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O
mechanisms O
, O
an O
influence O
of O
loperamide O

loperamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP O
and O
CRH O
on O
ACTH B
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O
mechanisms O
, O
an O
influence O
of O
loperamide O
on O
some O
suprapituitary O
factors O
modulating O
the O
ACTH O
response O
is O
suggested O
. O

loperamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
loperamide O
(from O
30 O
+/- O
16.6 O
to O
a O
peak O
of O
108 O
+/- O
31 O
pmol/l) O
and O
placebo O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
significant O
, O
and O
the O
first O
phase O
of O
CRH-induced O
ACTH O
secretion O
was O
significantly O
lower O
after O
loperamide O
. O
These O
data O
demonstrate O
that O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP B
and O
CRH O
on O
ACTH O
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O
mechanisms O
, O
an O
influence O
of O
loperamide O

loperamide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
loperamide O
(from O
30 O
+/- O
16.6 O
to O
a O
peak O
of O
108 O
+/- O
31 O
pmol/l) O
and O
placebo O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
significant O
, O
and O
the O
first O
phase O
of O
CRH-induced O
ACTH O
secretion O
was O
significantly O
lower O
after O
loperamide O
. O
These O
data O
demonstrate O
that O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP O
and O
CRH B
on O
ACTH O
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O
mechanisms O
, O
an O
influence O
of O
loperamide O

loperamide O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
in O
plasma O
ACTH O
after O
both O
loperamide O
(from O
30 O
+/- O
16.6 O
to O
a O
peak O
of O
108 O
+/- O
31 O
pmol/l) O
and O
placebo O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
significant O
, O
and O
the O
first O
phase O
of O
CRH-induced O
ACTH O
secretion O
was O
significantly O
lower O
after O
loperamide O
These O
data O
demonstrate O
that O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP O
and O
CRH B
on O
ACTH O
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O

loperamide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
two O
ACTH B
secretagogues O
, O
lysine O
vasopressin O
(LVP) O
and O
corticotropin-releasing O
hormone O
(CRH) O
, O
were O
investigated O
in O
patients O
with O
Addison's O
disease O
. O
After O
loperamide O
(16 O
mg O
orally) O
or O
placebo O
administration O
, O
5 O
patients O
received O
LVP O
(0.06 O
IU/kg O
i.v O
. O
over O
1 O
h) O
and O
6 O
patients O
received O
oCRH O
(1 O
micrograms/kg O
i.v O
. O
as O
bolus) O
. O
In O
all O
patients O
loperamide O
induced O
a O
significant O
fall O
in O
plasma O
ACTH O
levels O
. O
LVP O
increased O
ACTH O
levels O
after O
both O
loperamide O
(from O
48 O
+/- O
17.3 O
to O
a O
peak O
of O
95 O
+/- O
21 O
pmol/l) O
and O
placebo O
(from O
231 O
+/- O
59.5 O
to O
365 O
+/- O
86.6 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
not O
significant O
. O
CRH O
caused O

Loperamide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Loperamide O
, O
an O
opiate O
analog O
, O
differently O
modifies O
the O
adrenocorticotropin O
responses O
to O
corticotropin-releasing O
hormone O
and O
lysine O
vasopressin O
in O
patients O
with O
Addison's O
disease O
. O
Loperamide O
is O
a O
peripheral O
opiate O
agonist O
able O
to O
inhibit O
ACTH B
secretion O
. O
In O
this O
work O
, O
the O
interactions O
between O
loperamide O
and O
two O
ACTH O
secretagogues O
, O
lysine O
vasopressin O
(LVP) O
and O
corticotropin-releasing O
hormone O
(CRH) O
, O
were O
investigated O
in O
patients O
with O
Addison's O
disease O
. O
After O
loperamide O
(16 O
mg O
orally) O
or O
placebo O
administration O
, O
5 O
patients O
received O
LVP O
(0.06 O
IU/kg O

loperamide O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
in O
plasma O
ACTH B
after O
both O
loperamide O
(from O
30 O
+/- O
16.6 O
to O
a O
peak O
of O
108 O
+/- O
31 O
pmol/l) O
and O
placebo O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l) O
: O
the O
interaction O
between O
treatments O
and O
time O
was O
significant O
, O
and O
the O
first O
phase O
of O
CRH-induced O
ACTH O
secretion O
was O
significantly O
lower O
after O
loperamide O
These O
data O
demonstrate O
that O
loperamide O
differently O
modifies O
the O
stimulatory O
action O
of O
LVP O
and O
CRH O
on O
ACTH O
secretion O
: O
namely O
, O
LVP O
and O
loperamide O
act O
in O
an O
additive O
manner O
, O
while O
CRH O
and O
loperamide O
interact O
in O
a O
non O
additive O
way O
. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting O

naloxone O
estrone O
azine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
naloxone-steroid O
hybrid O
azine O
with O
selective O
and O
long-acting O
opioid O
antagonism O
at O
delta O
receptors O
in O
vitro.The O
interaction O
of O
naloxone O
estrone O
azine O
(N-EH) O
with O
various O
opioid B
receptor I
types O
was O
studied O
in O
vitro O
. O
Its O
potency O
as O
an O
antagonist O
of O
opioid O
effects O
was O
compared O
to O
that O
of O
naloxone O
on O
the O
electrically O
evoked O
contractions O
of O
mouse O
vas O
deferens O
(Mvd) O
and O
guinea O
pig O
ileum O
myenteric O
plexus O
longitudinal O
muscle O
(Gpi) O
preparations O
. O
N-EH O
was O
found O
to O

N-EH O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
A O
naloxone-steroid O
hybrid O
azine O
with O
selective O
and O
long-acting O
opioid O
antagonism O
at O
delta O
receptors O
in O
vitro.The O
interaction O
of O
naloxone O
estrone O
azine O
( O
N-EH O
with O
various O
opioid B
receptor I
types O
was O
studied O
in O
vitro O
. O
Its O
potency O
as O
an O
antagonist O
of O
opioid O
effects O
was O
compared O
to O
that O
of O
naloxone O
on O
the O
electrically O
evoked O
contractions O
of O
mouse O
vas O
deferens O
(Mvd) O
and O
guinea O
pig O
ileum O
myenteric O
plexus O
longitudinal O
muscle O
(Gpi) O
preparations O
. O
N-EH O
was O
found O
to O
be O
9-fold O

naloxone-steroid O
hybrid O
azine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
A O
naloxone-steroid O
hybrid O
azin O
with O
selective O
and O
long-acting O
opioid O
antagonism O
at O
delta B
receptors I
in O
vitro.The O
interaction O
of O
naloxone O
estrone O
azine O
(N-EH) O
with O
various O
opioid O
receptor O
types O
was O
studied O
in O
vitro O
. O
Its O
potency O
as O
an O
antagonist O
of O
opioid O
effects O
was O
compared O
to O
that O
of O
naloxone O
on O
the O
electrically O
evoked O
contractions O
of O
mouse O
vas O

nizatidine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Actions O
of O
nizatidin O
 O
, O
a O
selective O
histamine B
H2-receptor I
antagonist O
, O
on O
gastric O
acid O
secretion O
in O
dogs O
, O
rats O
and O
frogs.Nizatidine O
(LY139037) O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion O
. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine O
on O
histamine O
(10(-5) O
M)-induced O
secretion O
from O
the O
isolated O
gastric O
mucosa O
of O
the O

Nizatidine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Actions O
of O
nizatidine O
, O
a O
selective O
histamine B
H2-receptor I
antagonist O
, O
on O
gastric O
acid O
secretion O
in O
dogs O
, O
rats O
and O
frogs O
. O
Nizatidine O
(LY139037) O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion O
. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine O
on O
histamine O
(10(-5) O
M)-induced O
secretion O
from O
the O
isolated O
gastric O
mucosa O
of O
the O
bullfrog O
. O
Nizatidine O
was O
8.9 O
times O
as O
active O
as O
cimetidine O
on O
basal O
acid O
secretion O
of O
the O

LY139037 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Actions O
of O
nizatidine O
, O
a O
selective O
histamine B
H2-receptor I
antagonist O
, O
on O
gastric O
acid O
secretion O
in O
dogs O
, O
rats O
and O
frogs.Nizatidine O
( O
LY139037 O
 O
, O
a O
selective O
histamine O
H2-receptor O
antagonist O
, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion O
. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine O
on O
histamine O
(10(-5) O
M)-induced O
secretion O
from O
the O
isolated O
gastric O
mucosa O
of O
the O
bullfrog O
. O
Nizatidine O
was O
8.9 O
times O
as O
active O
as O
cimetidine O
on O
basal O
acid O
secretion O
of O
the O

ORF O
17583 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Effects O
of O
ORF O
17583 O
, O
other O
histamine B
H2-receptor I
antagonists O
and O
omeprazole O
on O
gastric O
acid O
secretory O
states O
in O
rats O
and O
dogs O
. O
ORF O
17583 O
a O
histamine O
H2-receptor O
antagonist O
, O
inhibited O
gastric O
acid O
secretion O
in O
pylorus-ligated O
rats O
(ED50 O
= O
4.9 O
mg/kg O
intraduodenal; O
3.4 O
mg/kg O
p.o.; O
and O
0.21 O
mg/kg O
i.p.) O
and O
in O
total O
gastric O
fistula O
or O
Heidenhain O
pouch O
dogs O
stimulated O
by O
betazole O
(ED50 O
= O
0.12 O
mg/kg O
p.o O
. O
and O
0.08 O
mg/kg O
i.v.) O
, O
histamine O
, O
tetragastrin O
, O
bethanechol O
, O
2-deoxy-D-glucose O
or O

ORF O
17583 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Effects O
of O
ORF O
1758 O
 O
, O
other O
histamine B
H2-receptor I
antagonists O
and O
omeprazole O
on O
gastric O
acid O
secretory O
states O
in O
rats O
and O
dogs.ORF O
17583 O
, O
a O
histamine O
H2-receptor O
antagonist O
, O
inhibited O
gastric O
acid O
secretion O
in O
pylorus-ligated O
rats O
(ED50 O
= O
4.9 O
mg/kg O
intraduodenal; O
3.4 O
mg/kg O
p.o.; O
and O
0.21 O
mg/kg O
i.p.) O
and O
in O
total O
gastric O
fistula O
or O
Heidenhain O
pouch O
dogs O

oximes O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE O
from O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O
All O
compounds O
were O
reversible O
inhibitors O
of O
AChE; O

oximes O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE B
from O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O
All O
compounds O
were O
reversible O
inhibitors O
of O
AChE; O

soman O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman O
inhibited O
, O
solubilized O
AChE B
from O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O
All O
compounds O
were O
reversible O
inhibitors O
of O
AChE; O
the O
respective O
dissociation O
constants O
and O
the O
type O
of O
inhibition O
exhibited O
considerable O
differences O
. O
The O
affinities O
to O
both O
the O
active O
and O
the O
allosteric O
site O
were O
considerably O
higher O
for O
suxamethonium O
(Kii O
81.3 O
microM; O
Ki O
15.9 O

organophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE O
from O
human O
erythrocytes O
was O
investigated O

organophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE B
from O
human O
erythrocytes O
was O
investigated O

soman O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE O
from O
human O
erythrocytes O
was O
investigated O
in O

soman O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE B
from O
human O
erythrocytes O
was O
investigated O
in O

1,2,2-trimethyl-propylmethylphosphonofluoridate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
( O
1,2,2-trimethyl-propylmethylphosphonofluoridate O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE O
from O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

1,2,2-trimethyl-propylmethylphosphonofluoridate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soman-inhibited O
human O
acetylcholinesterase O
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
( O
1,2,2-trimethyl-propylmethylphosphonofluoridate O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O
reactivatability O
of O
soman-inhibited O
, O
solubilized O
AChE B
from O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

soman O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Effects O
of O
some O
mono- O
and O
bisquaternary O
ammonium O
compounds O
on O
the O
reactivatability O
of O
soma O
-inhibited O
human B
acetylcholinesterase I
in O
vitro.Acetylcholinesterase O
(AChE) O
inhibited O
by O
the O
organophosphate O
soman O
(1,2,2-trimethyl-propylmethylphosphonofluoridate) O
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes O
due O
to O
dealkylation O
of O
the O
soman-enzyme O
complex O
. O
This O
reaction O
is O
called O
aging O
. O
The O
effect O
of O
the O
four O
mono- O
and O
bisquaternary O
ammonium O
compounds O
tetramethylammonium O
(TMA) O
, O
hexamethonium O
, O
decamethonium O
and O
suxamethonium O
on O
the O

soman O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
aging O
was O
started O
. O
The O
maximal O
increase O
in O
reactivatability O
was O
higher O
in O
the O
presence O
of O
1.6 O
mM O
suxamethonium O
(+35.8%) O
and O
150 O
microM O
decamethonium O
(+40%) O
than O
of O
22 O
mM O
TMA O
(+22.5%) O
and O
8.3 O
mM O
hexamethonium O
(+19.2%) O
. O
If O
the O
effectors O
were O
added O
after O
5 O
min O
of O
aging O
they O
increased O
the O
activity O
of O
soman O
inhibited O
AChE O
, O
but O
to O
a O
considerably O
smaller O
extent O
than O
HI O
6 O
. O
A O
good O
correlation O
of O
the O
respective O
Kii O
values O
and O
the O
effective O
concentrations O
of O
these O
drugs O
was O
observed O
, O
indicating O
that O
an O
allosteric O
binding O
site O
of O
AChE B
might O
be O
involved O
in O
the O
protective O
effect O
of O
these O
drugs O
. O

D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B
receptors I
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O

lorglumide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
( O
lorglumide O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B
receptors I
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O

CR O
1409 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409 O
 O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B
receptors I
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O
contraction O

Lorglumide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O
contraction O
of O
the O
gall O
bladder O
of O
the O
guinea O
pig O
and O
of O
the O
dog O
provoked O
by O
i.v O
. O
CCK-8 O
or O
ceruletide O
(caerulein) O
. O
It O
antagonizes O
the O
satiety O
effect O
of O
CCK-8 O
in O
the O
rat O
and O
is O
protective O
against O
ceruletide- O
, O
taurocholate- O
and O
diet-induced O
pancreatitis O
. O
Lorglumide O
is O
therefore O
a O
useful O
pharmacological O
tool O
to O
study O
the O
functions O
of O
CCK O
. O
For O
its O
pharmacological O
properties O
, O
its O
relatively O
low O
toxicity O
and O
because O
it O
is O
active O
also O
after O
oral O
administration O
, O
lorglumide O
is O
a O
candidate O
for O
diagnostic O
or O
therapeutic O
use O
in O
man O
when O
an O
involvement O
of O
CCK B
is O
suspected O
. O

lorglumide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumid O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin B
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O

D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O

5-(dipentylamino)-5-oxo-pentanoic O
acid O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O

5-(dipentylamino)-5-oxo-pentanoic O
acid O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin B
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O

lorglumide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
( O
lorglumide O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O

CR O
1409 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
lorglumide O
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin O
antagonists.Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic O
acid O
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin O
(CCK) O
antagonists O
. O
The O
most O
potent O
compound O
, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen O
tanoic O
acid O
(lorglumide O
, O
CR O
1409 O
 O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O
contraction O

lorglumide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
tanoic O
acid O
(lorglumide O
, O
CR O
1409) O
, O
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK O
receptors O
and O
is O
a O
competitive O
, O
specific O
and O
potent O
CCK O
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced O
amylase O
secretion O
of O
isolated O
pancreatic O
acini O
. O
In O
vivo O
lorglumide O
antagonizes O
the O
contraction O
of O
the O
gall O
bladder O
of O
the O
guinea O
pig O
and O
of O
the O
dog O
provoked O
by O
i.v O
. O
CCK-8 B
or O
ceruletide O
(caerulein) O
. O
It O
antagonizes O
the O
satiety O
effect O
of O
CCK-8 O
in O
the O
rat O
and O
is O
protective O
against O
ceruletide- O
, O
taurocholate- O
and O
diet-induced O
pancreatitis O
. O
Lorglumide O
is O
therefore O
a O
useful O
pharmacological O
tool O
to O

oleate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
very O
similar O
change O
was O
observed O
in O
the O
value O
of O
B O
beta O
15-42 O
(P O
less O
than O
0.01) O
. O
These O
observations O
indicated O
that O
EIS O
provokes O
transient O
activation O
of O
coagulation O
and O
fibrinolysis O
. O
In O
vitro O
studies O
, O
however O
, O
revealed O
that O
EO O
inhibits O
fibrin O
clot O
formation O
because O
of O
the O
Ca2+-chelating O
ability O
of O
its O
constituent O
ethanolamine O
, O
although O
oleate O
or O
benzyl O
alcohol O
exhibited O
procoagulant O
activity O
in O
FPA B
formation O
in O
vitro O
. O
Nevertheless O
, O
an O
external O
application O
of O
EO O
or O
oleate O
over O
decapsulized O
kidney O
of O
rat O
resulted O
in O
a O
significant O
accumulation O
of O
125I-labelled O
fibrin(ogen) O
. O
From O
these O
results O
it O
was O
suggested O
that O
intravascular O
injection O
of O
EO O
, O
which O
exerts O
an O
inhibitory O
effect O
on O

benzyl O
alcohol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
change O
was O
observed O
in O
the O
value O
of O
B O
beta O
15-42 O
(P O
less O
than O
0.01) O
. O
These O
observations O
indicated O
that O
EIS O
provokes O
transient O
activation O
of O
coagulation O
and O
fibrinolysis O
. O
In O
vitro O
studies O
, O
however O
, O
revealed O
that O
EO O
inhibits O
fibrin O
clot O
formation O
because O
of O
the O
Ca2+-chelating O
ability O
of O
its O
constituent O
ethanolamine O
, O
although O
oleate O
or O
benzyl O
alcohol O
exhibited O
procoagulant O
activity O
in O
FPA B
formation O
in O
vitro O
. O
Nevertheless O
, O
an O
external O
application O
of O
EO O
or O
oleate O
over O
decapsulized O
kidney O
of O
rat O
resulted O
in O
a O
significant O
accumulation O
of O
125I-labelled O
fibrin(ogen) O
. O
From O
these O
results O
it O
was O
suggested O
that O
intravascular O
injection O
of O
EO O
, O
which O
exerts O
an O
inhibitory O
effect O
on O
coagulation O
in O
vitro O
, O

oleate O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
decapsulized O
kidney O
of O
rat O
resulted O
in O
a O
significant O
accumulation O
of O
125I-labelled O
fibrin(ogen) O
. O
From O
these O
results O
it O
was O
suggested O
that O
intravascular O
injection O
of O
EO O
, O
which O
exerts O
an O
inhibitory O
effect O
on O
coagulation O
in O
vitro O
, O
activates O
the O
local O
coagulation O
system O
. O
The O
activation O
may O
be O
accelerated O
by O
an O
acute O
inflammatory O
process O
provoked O
by O
oleate O
which O
is O
supported O
by O
such O
clinical O
manifestations O
as O
mild O
fever O
, O
retrosternal O
pain O
leukocytosis O
and O
an O
increase O
in O
plasma O
fibrinogen B
level O
which O
was O
observed O
in O
all O
during O
the O
period O
. O

EO O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
than O
0.01) O
and O
it O
gradually O
returned O
to O
normal O
range O
by O
48 O
h O
after O
EIS O
. O
A O
very O
similar O
change O
was O
observed O
in O
the O
value O
of O
B O
beta O
15-42 O
(P O
less O
than O
0.01) O
. O
These O
observations O
indicated O
that O
EIS O
provokes O
transient O
activation O
of O
coagulation O
and O
fibrinolysis O
. O
In O
vitro O
studies O
, O
however O
, O
revealed O
that O
EO O
inhibits O
fibrin B
clot O
formation O
because O
of O
the O
Ca2+-chelating O
ability O
of O
its O
constituent O
ethanolamine O
, O
although O
oleate O
or O
benzyl O
alcohol O
exhibited O
procoagulant O
activity O
in O
FPA O
formation O
in O
vitro O
. O
Nevertheless O
, O
an O
external O
application O
of O
EO O
or O
oleate O
over O
decapsulized O
kidney O
of O
rat O
resulted O
in O
a O
significant O
accumulation O
of O
125I-labelled O
fibrin(ogen) O
. O
From O
these O

astemizole O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Astemizole O
, O
a O
potent O
histamine B
H1-receptor I
antagonist O
: O
effect O
in O
allergic O
rhinoconjunctivitis O
, O
on O
antigen O
and O
histamine O
induced O
skin O
weal O
responses O
and O
relationship O
to O
serum O
levels.The O
efficacy O
of O
astemizole O
a O
new O
, O
long O
acting O
, O
oral O
histamine O
H1-receptor O
antagonist O
was O
compared O
to O
placebo O
for O
the O
treatment O
of O
allergic O
rhinitis O
and O
conjunctivitis O
during O
the O
grass O
pollen O
season O
of O
1982 O
. O
Sixty-three O
patients O
with O
a O
positive O
skin O
prick O
test O
to O
grass O
pollen O
and O
current O
symptoms O
participated O
in O
an O
8 O
week O
, O
double-blind O
, O
randomized O
study O
. O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
[3H]aldosterone O
in O
adrenalectomized O
perfused O
rat O
brain O
cytosols O
were O
0.28 O
and O
18.0 O
nM O
at O
4 O
C O
. O
High O
affinity O
sites O
comprised O
15% O
of O
the O
total O
receptor O
number O
. O
A O
small O
contamination O
of O
perfused O
brain O
cytosol O
preparations O
with O
corticosteroid-binding O
globulin O
(CBG) O
was O
found O
. O
However O
, O
due O
to O
the O
very O
high O
affinity O
of O
CBG B
for O
corticosterone O
at O
4 O
C O
, O
this O
slight O
contamination O
resulted O
in O
significant O
alterations O
in O
the O
apparent O
affinity O
of O
steroids O
competing O
for O
aldosterone-binding O
sites O
. O
Selective O
precipitation O
of O
cytosol O
receptors O
with O
36% O
(NH4)2SO4 O
reduced O
CBG O
concentrations O
to O
negligible O
levels O
. O
After O
blockade O
of O
low O
affinity O
sites O
with O
a O
highly O
selective O
glucocorticoid O
(RU O
26988) O
, O
the O
order O

corticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
rat B
brain I
aldosterone I
receptors I
reveals O
high O
affinity O
for O
corticosteron O
.The O
two O
[3H]aldosterone-binding O
proteins O
of O
rat O
brain O
cytosol O
were O
characterized O
by O
a O
dextran-coated O
charcoal O
method O
. O
With O
molybdate O
present O
to O
stabilize O
receptors O
, O
the O
affinities O
of O
the O
two O
sites O
for O
[3H]aldosterone O
in O
adrenalectomized O
perfused O
rat O
brain O
cytosols O
were O
0.28 O
and O
18.0 O
nM O
at O
4 O
C O
. O
High O
affinity O
sites O
comprised O
15% O
of O

steroid O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
a O
highly O
selective O
glucocorticoid O
(RU O
26988) O
, O
the O
order O
of O
steroids O
in O
competing O
for O
the O
high O
affinity O
receptor O
was O
desoxycorticosterone O
greater O
than O
fludrocortisone O
greater O
than O
corticosterone O
greater O
than O
aldosterone O
greater O
than O
progesterone O
greater O
than O
dexamethasone O
. O
Readdition O
of O
a O
small O
quantity O
of O
dialyzed O
serum O
to O
cytosol O
preparations O
yielded O
a O
profile O
of O
steroid O
binding O
similar O
to O
that O
of O
the O
kidney O
mineralocorticoid B
receptor I
(aldosterone O
greater O
than O
desoxycorticosterone O
greater O
than O
corticosterone) O
. O
The O
distribution O
of O
both O
receptors O
in O
brain O
regions O
of O
adrenalectomized O
rats O
was O
determined O
. O
Both O
receptors O
were O
at O
greatest O
density O
in O
the O
hippocampus O
and O
lowest O
density O
in O
the O
hypothalamus O
. O
The O
high O
affinity O
site O
was O

aldosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
competing O
for O
the O
high O
affinity O
receptor O
was O
desoxycorticosterone O
greater O
than O
fludrocortisone O
greater O
than O
corticosterone O
greater O
than O
aldosterone O
greater O
than O
progesterone O
greater O
than O
dexamethasone O
. O
Readdition O
of O
a O
small O
quantity O
of O
dialyzed O
serum O
to O
cytosol O
preparations O
yielded O
a O
profile O
of O
steroid O
binding O
similar O
to O
that O
of O
the O
kidney O
mineralocorticoid B
receptor I
( O
aldosterone O
greater O
than O
desoxycorticosterone O
greater O
than O
corticosterone) O
. O
The O
distribution O
of O
both O
receptors O
in O
brain O
regions O
of O
adrenalectomized O
rats O
was O
determined O
. O
Both O
receptors O
were O
at O
greatest O
density O
in O
the O
hippocampus O
and O
lowest O
density O
in O
the O
hypothalamus O
. O
The O
high O
affinity O
site O
was O
at O
greatest O
density O
in O
limbic O
regions O
, O
whereas O
the O
low O
affinity O

desoxycorticosterone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
high O
affinity O
receptor O
was O
desoxycorticosterone O
greater O
than O
fludrocortisone O
greater O
than O
corticosterone O
greater O
than O
aldosterone O
greater O
than O
progesterone O
greater O
than O
dexamethasone O
. O
Readdition O
of O
a O
small O
quantity O
of O
dialyzed O
serum O
to O
cytosol O
preparations O
yielded O
a O
profile O
of O
steroid O
binding O
similar O
to O
that O
of O
the O
kidney O
mineralocorticoid B
receptor I
(aldosterone O
greater O
than O
desoxycorticosterone O
greater O
than O
corticosterone) O
. O
The O
distribution O
of O
both O
receptors O
in O
brain O
regions O
of O
adrenalectomized O
rats O
was O
determined O
. O
Both O
receptors O
were O
at O
greatest O
density O
in O
the O
hippocampus O
and O
lowest O
density O
in O
the O
hypothalamus O
. O
The O
high O
affinity O
site O
was O
at O
greatest O
density O
in O
limbic O
regions O
, O
whereas O
the O
low O
affinity O
receptor O
, O
apparently O
identical O

(NH4)2SO4 O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
of O
perfused O
brain O
cytosol O
preparations O
with O
corticosteroid-binding O
globulin O
(CBG) O
was O
found O
. O
However O
, O
due O
to O
the O
very O
high O
affinity O
of O
CBG B
for O
corticosterone O
at O
4 O
C O
, O
this O
slight O
contamination O
resulted O
in O
significant O
alterations O
in O
the O
apparent O
affinity O
of O
steroids O
competing O
for O
aldosterone-binding O
sites O
. O
Selective O
precipitation O
of O
cytosol O
receptors O
with O
36% O
(NH4)2SO4 O
reduced O
CBG O
concentrations O
to O
negligible O
levels O
. O
After O
blockade O
of O
low O
affinity O
sites O
with O
a O
highly O
selective O
glucocorticoid O
(RU O
26988) O
, O
the O
order O
of O
steroids O
in O
competing O
for O
the O
high O
affinity O
receptor O
was O
desoxycorticosterone O
greater O
than O
fludrocortisone O
greater O
than O
corticosterone O
greater O
than O
aldosterone O
greater O
than O
progesterone O
greater O
than O
dexamethasone O
. O
Readdition O
of O

RU O
23908 O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
pure O
antiandrogen O
RU O
23908 O
(Anandron) O
, O
a O
candidate O
of O
choice O
for O
the O
combined O
antihormonal O
treatment O
of O
prostatic O
cancer O
: O
a O
review.The O
nonsteroidal O
antiandrogen O
RU O
23908 O
( O
Anandron O
) O
weakly O
interacts O
with O
the O
prostatic O
cytosolic O
androgen B
receptor I
and O
shows O
a O
fast O
dissociation O
rate O
. O
When O
administered O
to O
immature O
castrated O
rats O
up O
to O
the O
daily O
dose O
of O
100 O
mg/kg O
, O
it O
is O
devoid O
of O
any O
androgenic O
activity O
but O
efficiently O
blocks O
the O
growth-promoting O
activity O
of O
androgens O
on O
ventral O
prostate O

Anandron O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
pure O
antiandrogen O
RU O
23908 O
(Anandron) O
, O
a O
candidate O
of O
choice O
for O
the O
combined O
antihormonal O
treatment O
of O
prostatic O
cancer O
: O
a O
review.The O
nonsteroidal O
antiandrogen O
RU O
23908 O
( O
Anandron O
) O
weakly O
interacts O
with O
the O
prostatic O
cytosolic O
androgen B
receptor I
and O
shows O
a O
fast O
dissociation O
rate O
. O
When O
administered O
to O
immature O
castrated O
rats O
up O
to O
the O
daily O
dose O
of O
100 O
mg/kg O
, O
it O
is O
devoid O
of O
any O
androgenic O
activity O
but O
efficiently O
blocks O
the O
growth-promoting O
activity O
of O
androgens O
on O
ventral O
prostate O
and O
seminal O

estrogen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
levels O
are O
increased O
by O
7- O
and O
17-fold O
, O
respectively O
, O
after O
14 O
days O
of O
similar O
daily O
treatment O
. O
Efficient O
neutralization O
of O
the O
androgenic O
action O
at O
the O
prostatic O
level O
in O
intact O
animals O
thus O
requires O
prevention O
of O
this O
escape O
phenomenon O
through O
inhibition O
of O
LH B
secretion O
. O
Although O
inhibition O
of O
LH O
release O
can O
be O
achieved O
by O
estrogen O
and O
progestins O
, O
an O
optimal O
inhibitory O
effect O
on O
the O
prostate O
is O
obtained O
by O
the O
combined O
administration O
of O
the O
antiandrogen O
with O
an O
LHRH O
agonist O
that O
causes O
a O
specific O
blockage O
of O
testicular O
androgen O
biosynthesis O
as O
well O
as O
an O
inhibition O
of O
the O
LH O
responsiveness O
to O
LHRH O
. O

progestins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
increased O
by O
7- O
and O
17-fold O
, O
respectively O
, O
after O
14 O
days O
of O
similar O
daily O
treatment O
. O
Efficient O
neutralization O
of O
the O
androgenic O
action O
at O
the O
prostatic O
level O
in O
intact O
animals O
thus O
requires O
prevention O
of O
this O
escape O
phenomenon O
through O
inhibition O
of O
LH B
secretion O
. O
Although O
inhibition O
of O
LH O
release O
can O
be O
achieved O
by O
estrogen O
and O
progestins O
an O
optimal O
inhibitory O
effect O
on O
the O
prostate O
is O
obtained O
by O
the O
combined O
administration O
of O
the O
antiandrogen O
with O
an O
LHRH O
agonist O
that O
causes O
a O
specific O
blockage O
of O
testicular O
androgen O
biosynthesis O
as O
well O
as O
an O
inhibition O
of O
the O
LH O
responsiveness O
to O
LHRH O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
an O
oligopeptide O
related O
to O
oxytocin O
. O
This O
result O
was O
complemented O
by O
in O
vitro O
translation O
of O
bovine O
hypothalamic O
mRNA O
. O
Among O
the O
primary O
translation O
products O
a O
single O
polypeptide O
of O
Mr O
approximately O
16,500 O
was O
shown O
to O
contain O
antigenic O
determinants O
recognized O
by O
specific O
antisera O
against O
bovine O
neurophysin O
I O
and O
oxytocin O
. O
Here O
we O
report O
the O
amino O
acid O
sequence O
of O
the O
bovine B
oxytocin-neurophysin I
I I
(OT-NpI) I
precursor I
which O
was O
derived O
from O
sequence O
analysis O
of O
the O
cloned O
cDNA O
. O
As O
is O
the O
case O
for O
the O
bovine O
arginine-vasopressin-neurophysin O
II O
(AVP-NpII) O
precursor O
, O
the O
signal O
sequence O
of O
the O
OT-NpI O
precursor O
is O
immediately O
followed O
by O
the O
nonapeptide O
hormone O
which O
is O
connected O
to O
neurophysin O
I O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Deduced O
amino O
aci O
sequence O
from O
the O
bovine B
oxytocin-neurophysin I
I I
precursor I
cDNA.The O
nonapeptide O
hormone O
oxytocin-like O
arginine-vasopressin O
(AVP) O
is O
synthesized O
as O
part O
of O
a O
larger O
precursor O
polypeptide O
. O
The O
precursor O
also O
includes O
the O
neurophysin O
molecule O
with O
which O
the O
hormone O
is O
associated O
in O
the O
neurosecretory O
granules O
of O
the O
hypothalamo-pituitary O
tract O
. O
A O
protein O
of O
molecular O
weight O
(Mr) O

monohydroxytamoxifen O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
micrograms) O
was O
sufficient O
to O
inhibit O
fully O
E2 O
action O
in O
the O
uterus O
for O
up O
to O
4 O
days O
. O
Because O
LY117018 O
has O
a O
shorter O
duration O
of O
action O
than O
monohydroxytamoxifen O
, O
a O
high O
dosage O
ratio O
of O
LY117018 O
over O
monohydroxytamoxifen O
is O
required O
to O
maintain O
effective O
competitive O
antagonism O
in O
the O
uterus O
. O
Overall O
, O
these O
findings O
suggest O
that O
monohydroxytamoxifen O
and O
LY117018 O
probably O
act O
through O
the O
same O
mechanism O
of O
action O
via O
the O
estrogen O
receptor O
. O

LY117018 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
sufficient O
to O
inhibit O
fully O
E2 O
action O
in O
the O
uterus O
for O
up O
to O
4 O
days O
. O
Because O
LY117018 O
has O
a O
shorter O
duration O
of O
action O
than O
monohydroxytamoxifen O
, O
a O
high O
dosage O
ratio O
of O
LY117018 O
over O
monohydroxytamoxifen O
is O
required O
to O
maintain O
effective O
competitive O
antagonism O
in O
the O
uterus O
. O
Overall O
, O
these O
findings O
suggest O
that O
monohydroxytamoxifen O
and O
LY117018 O
probably O
act O
through O
the O
same O
mechanism O
of O
action O
via O
the O
estrogen O
receptor O
. O

LY117018 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
the O
uterotropic O
activity O
of O
estrogens O
and O
antiestrogens O
by O
the O
short O
acting O
antiestrogen O
LY117018.The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
the O
dihydroxylated O
antiestrogen O
LY117018 O
with O
a O
high O
affinity O
for O
the O
estrogen B
receptor I
and O
low O
intrinsic O
estrogenic O
activity O
, O
could O
inhibit O
the O
uterotropic O
actions O
of O
steroidal O
[estradiol-17 O
beta O
(E2)] O
and O
nonsteroidal O
[ICI O
3188 O
and O
trianisylchloroethylene O
(TACE)] O
estrogens O
in O
immature O
rats O
and O
also O
the O
uterotropic O
actions O
of O
tamoxifen O
and O
monohydroxytamoxifen O
in O
the O
ovariectomized O
mouse O
and O
immature O

BMY O
7378 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human B
alpha I
1D-adrenoceptors I
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
compared O
to O
the O

benoxathian O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha B
1A I
and I
alpha I
1D I
adrenoceptors I
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha O
1B O
adrenoceptors O
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O

phentolamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha B
1A I
and I
alpha I
1D I
adrenoceptors I
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha O
1B O
adrenoceptors O
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O

Spiperone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
cloned O
human O
alpha O
1D-adrenoceptors O
(pKi O
= O
8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha B
1B I
adrenoceptors I
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O
rat1D O
adrenoceptors O
were O
almost O
identical O
(r O
= O
0.99 O
, O
slope O
= O
1.08) O
. O
4 O
. O
Prazosin O
, O
doxazosin O
and O
5-methyl-urapidil O
were O

[3H]-prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human B
alpha I
1A-adrenoceptors I
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O

[3H]-prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O

[3H]-prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha O
1D-adrenoceptor O
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha B
1-adrenoceptor I
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
. O
2 O
. O
BMY O
7378 O
displayed O
high O
affinity O
for O
cloned O
human O

5-Methyl-urapidil O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11) O
. O
WB O
4101 O
, O
benoxathian O
and O
phentolamine O
displayed O
high O
affinity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
compared O
to O
the O
alpha O
1B O
subtype O
. O
Spiperone O
displayed O
high O
affinity O
and O
selectivity O
for O
alpha O
1B O
adrenoceptors O
(pKi O
8.8 O
+/- O
0.16) O
. O
5-Methyl-urapidil O
was O
selective O
for O
cloned O
alpha O
1A O
adrenoceptors O
. O
3 O
. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human O
and O
rat1D O
adrenoceptors O
were O
almost O
identical O
(r O
= O
0.99 O
, O
slope O
= O
1.08) O
. O
4 O
. O
Prazosin O
, O
doxazosin O
and O
5-methyl-urapidil O
were O
potent O
, O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
(pA2 O
values O
of O
9.8 O
, O
8.8 O

noradrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Characterization O
of O
an O
alpha B
1D-adrenoceptor I
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenalin O
.1 O
. O
The O
affinities O
of O
a O
number O
of O
alpha O
1-adrenoceptor O
antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin O
binding O
from O
cloned O
human O
alpha O
1A-adrenoceptors O
(previously O
designated O
cloned O
alpha O
1c O
subtype) O
, O
alpha O
1B O
alpha O
1D O
and O
rat O
alpha O
1D-adrenoceptors O
, O
stably O
expressed O
in O
rat-1 O
fibroblasts O
. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O

noradrenaline O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
contractions O
of O
rat O
aorta O
were O
sensitive O
to O
the O
alkylating O
effects O
of O
chlorethylclonidine O
(CEC) O
. O
CEC O
(10 O
microM) O
caused O
a O
small O
rightward O
shift O
in O
the O
noradrenaline O
concentration-response O
curve O
. O
CEC O
at O
100 O
microM O
caused O
a O
further O
shift O
and O
suppression O
of O
the O
maximum O
response O
to O
noradrenaline.7 O
. O
The O
results O
of O
this O
study O
suggest O
that O
noradrenaline O
predominantly O
, O
but O
not O
exclusively O
, O
mediates O
contraction O
of O
rat O
aorta O
through O
the O
activation O
of O
an O
alphalD-adrenoceptor O
. O

Alprenolol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Alprenolol O
and O
bromoacetylalprenololmenthane O
are O
competitive O
slowly O
reversible O
antagonists O
at O
the O
beta O
1-adrenoceptors O
of O
rat O
left O
atria.We O
studied O
the O
effects O
of O
alprenolol O
and O
bromoacetylalprenololmenthane O
(BAAM) O
on O
rat O
left O
atria O
. O
Alprenolol O
and O
BAAM O
at O
10(-7) O
, O
3 O
x O
10(-7) O
, O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly O
, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O
independent O
of O
beta-adrenoceptor B
blockade O
. O
This O
membrane-stabilizing O
activity O
was O
readily O
reversible O
. O
Alprenolol O
and O
BAAM O
also O
caused O
surmountable O
antagonism O
of O
isoprenaline O
responses O
, O
and O
this O
beta O
1-adrenoceptor O
antagonism O
was O
slowly O

BAAM O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Alprenolol O
and O
bromoacetylalprenololmenthane O
are O
competitive O
slowly O
reversible O
antagonists O
at O
the O
beta O
1-adrenoceptors O
of O
rat O
left O
atria.We O
studied O
the O
effects O
of O
alprenolol O
and O
bromoacetylalprenololmenthane O
(BAAM) O
on O
rat O
left O
atria O
. O
Alprenolol O
and O
BAAM O
at O
10(-7) O
, O
3 O
x O
10(-7) O
, O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly O
, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O
independent O
of O
beta-adrenoceptor B
blockade O
. O
This O
membrane-stabilizing O
activity O
was O
readily O
reversible O
. O
Alprenolol O
and O
BAAM O
also O
caused O
surmountable O
antagonism O
of O
isoprenaline O
responses O
, O
and O
this O
beta O
1-adrenoceptor O
antagonism O
was O
slowly O
reversible O
. O
Inhibition O

isoprenaline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
alprenolol O
and O
bromoacetylalprenololmenthane O
(BAAM) O
on O
rat O
left O
atria O
. O
Alprenolol O
and O
BAAM O
at O
10(-7) O
, O
3 O
x O
10(-7) O
, O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly O
, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O
independent O
of O
beta-adrenoceptor O
blockade O
. O
This O
membrane-stabilizing O
activity O
was O
readily O
reversible O
. O
Alprenolol O
and O
BAAM O
also O
caused O
surmountable O
antagonism O
of O
isoprenaline O
responses O
, O
and O
this O
beta B
1-adrenoceptor I
antagonism O
was O
slowly O
reversible O
. O
Inhibition O
of O
the O
isoprenaline O
responses O
with O
alprenolol O
and O
BAAM O
at O
10(-6) O
M O
was O
at O
equilibrium O
after O
60 O
min O
, O
which O
is O
indicative O
of O
reversible O
antagonism O
. O
We O
conclude O
that O
alprenolol O
and O
BAAM O
are O
competitive O
slowly O
reversible O
beta O
1-adrenoceptor O
antagonists O
on O
rat O
left O

alprenolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
activity O
was O
readily O
reversible O
. O
Alprenolol O
and O
BAAM O
also O
caused O
surmountable O
antagonism O
of O
isoprenaline O
responses O
, O
and O
this O
beta B
1-adrenoceptor I
antagonism O
was O
slowly O
reversible O
. O
Inhibition O
of O
the O
isoprenaline O
responses O
with O
alprenolol O
and O
BAAM O
at O
10(-6) O
M O
was O
at O
equilibrium O
after O
60 O
min O
, O
which O
is O
indicative O
of O
reversible O
antagonism O
. O
We O
conclude O
that O
alprenolol O
and O
BAAM O
are O
competitive O
slowly O
reversible O
beta O
1-adrenoceptor O
antagonists O
on O
rat O
left O
atria O
. O

BAAM O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
readily O
reversible O
. O
Alprenolol O
and O
BAAM O
also O
caused O
surmountable O
antagonism O
of O
isoprenaline O
responses O
, O
and O
this O
beta B
1-adrenoceptor I
antagonism O
was O
slowly O
reversible O
. O
Inhibition O
of O
the O
isoprenaline O
responses O
with O
alprenolol O
and O
BAAM O
at O
10(-6) O
M O
was O
at O
equilibrium O
after O
60 O
min O
, O
which O
is O
indicative O
of O
reversible O
antagonism O
. O
We O
conclude O
that O
alprenolol O
and O
BAAM O
are O
competitive O
slowly O
reversible O
beta O
1-adrenoceptor O
antagonists O
on O
rat O
left O
atria O
. O

bromoacetylalprenololmenthane O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Alprenolol O
and O
bromoacetylalprenololmenthan O
are O
competitive O
slowly O
reversible O
antagonists O
at O
the O
beta B
1-adrenoceptors I
of O
rat O
left O
atria.We O
studied O
the O
effects O
of O
alprenolol O
and O
bromoacetylalprenololmenthane O
(BAAM) O
on O
rat O
left O
atria O
. O
Alprenolol O
and O
BAAM O
at O
10(-7) O
, O
3 O
x O
10(-7) O
, O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly O
, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O
independent O

Alprenolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
rat O
left O
atria.We O
studied O
the O
effects O
of O
alprenolol O
and O
bromoacetylalprenololmenthane O
(BAAM) O
on O
rat O
left O
atria O
. O
Alprenolol O
and O
BAAM O
at O
10(-7) O
, O
3 O
x O
10(-7) O
, O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly O
, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O
independent O
of O
beta-adrenoceptor O
blockade O
. O
This O
membrane-stabilizing O
activity O
was O
readily O
reversible O
. O
Alprenolol O
and O
BAAM O
also O
caused O
surmountable O
antagonism O
of O
isoprenaline O
responses O
, O
and O
this O
beta B
1-adrenoceptor I
antagonism O
was O
slowly O
reversible O
. O
Inhibition O
of O
the O
isoprenaline O
responses O
with O
alprenolol O
and O
BAAM O
at O
10(-6) O
M O
was O
at O
equilibrium O
after O
60 O
min O
, O
which O
is O
indicative O
of O
reversible O
antagonism O
. O
We O
conclude O
that O
alprenolol O
and O
BAAM O
are O
competitive O

BAAM O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
left O
atria.We O
studied O
the O
effects O
of O
alprenolol O
and O
bromoacetylalprenololmenthane O
(BAAM) O
on O
rat O
left O
atria O
. O
Alprenolol O
and O
BAAM O
at O
10(-7) O
, O
3 O
x O
10(-7) O
, O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly O
, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O
independent O
of O
beta-adrenoceptor O
blockade O
. O
This O
membrane-stabilizing O
activity O
was O
readily O
reversible O
. O
Alprenolol O
and O
BAAM O
also O
caused O
surmountable O
antagonism O
of O
isoprenaline O
responses O
, O
and O
this O
beta B
1-adrenoceptor I
antagonism O
was O
slowly O
reversible O
. O
Inhibition O
of O
the O
isoprenaline O
responses O
with O
alprenolol O
and O
BAAM O
at O
10(-6) O
M O
was O
at O
equilibrium O
after O
60 O
min O
, O
which O
is O
indicative O
of O
reversible O
antagonism O
. O
We O
conclude O
that O
alprenolol O
and O
BAAM O
are O
competitive O
slowly O
reversible O

tricyclic O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Cloning O
and O
expression O
of O
a O
novel O
serotonin B
receptor I
with O
high O
affinity O
for O
tricycli O
psychotropic O
drugs.We O
have O
used O
the O
polymerase O
chain O
reaction O
technique O
to O
selectively O
amplify O
a O
guanine O
nucleotide-binding O
protein-coupled O
receptor O
cDNA O
sequence O
from O
rat O
striatal O
mRNA O
that O
exhibits O
high O
homology O
to O
previously O
cloned O
serotonin O
receptors O
. O
Sequencing O
of O
a O
full O
length O
clone O
isolated O
from O
a O
rat O
striatal O
cDNA O
library O
revealed O
an O
open O
reading O

[125I]LSD O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cerebral O
cortex O
> O
hippocampus O
. O
Expression O
of O
this O
clone O
in O
COS-7 O
cells O
resulted O
in O
the O
appearance O
of O
high O
affinity O
, O
saturable O
binding O
of O
(+)-[2-125I] O
iodolysergic O
acid O
diethylamide O
([125I]LSD) O
with O
a O
Kd O
of O
1.26 O
nM O
. O
Among O
endogenous O
biogenic O
amines O
, O
only O
5-HT O
completely O
inhibited O
[125I]LSD O
binding O
(Ki O
= O
150 O
nM) O
. O
The O
inhibition O
of O
[125I]LSD O
binding O
by O
other O
serotonergic O
agonists O
and O
antagonists O
revealed O
a O
pharmacological O
profile O
that O
does O
not O
correlate O
with O
that O
of O
any O
previously O
described O
serotonin B
receptor I
subtype O
. O
In O
addition O
, O
this O
receptor O
exhibits O
high O
affinity O
for O
a O
number O
of O
tricyclic O
antipsychotic O
and O
antidepressant O
drugs O
, O
including O
clozapine O
, O
amoxipine O
, O
and O
amitriptyline O
. O
In O
HEK-293 O
cells O
stably O

serotonin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
agonists O
and O
antagonists O
revealed O
a O
pharmacological O
profile O
that O
does O
not O
correlate O
with O
that O
of O
any O
previously O
described O
serotonin O
receptor O
subtype O
. O
In O
addition O
, O
this O
receptor O
exhibits O
high O
affinity O
for O
a O
number O
of O
tricyclic O
antipsychotic O
and O
antidepressant O
drugs O
, O
including O
clozapine O
, O
amoxipine O
, O
and O
amitriptyline O
. O
In O
HEK-293 O
cells O
stably O
transfected O
with O
this O
receptor O
, O
serotonin O
elicits O
a O
potent O
stimulation O
of O
adenylyl B
cyclase I
activity O
, O
which O
is O
blocked O
by O
antipsychotic O
and O
antidepressant O
drugs O
. O
The O
distinct O
structural O
and O
pharmacological O
properties O
of O
this O
receptor O
site O
indicate O
that O
it O
represents O
a O
completely O
novel O
subtype O
of O
serotonin O
receptor O
. O
Based O
on O
its O
affinity O
for O
tricyclic O
psychotropic O
drugs O
and O
its O
localization O
to O

progesterone O
(P4) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin B
(UG) O
and O
progesterone O
receptor O
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O

progesterone O
(P4) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone O
receptor O
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG B
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O

progesterone O
(P4) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone B
receptor I
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O

progesterone O
(P4) O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
prepubertal O
rabbits.Norethisterone O
(NET) O
is O
a O
synthetic O
progestin O
, O
used O
as O
a O
contraceptive O
agent O
, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
, O
which O
possess O
different O
pharmacological O
properties O
. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone O
receptor O
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O

5 O
alpha-NET O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR B
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

3 O
beta,5 O
alpha-NET O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
alpha-NET O
inhibited O
the O
P4-induced O
UG O
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR B
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

5 O
alpha-NET O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR B
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

5 O
alpha-NET O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin O
(UG) O
and O
progesterone O
receptor O
(PR) O
genes O
, O
both O
regulated O
by O
progesterone O
(P4) O
, O
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG B
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O

3 O
beta,5 O
alpha-NET O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG B
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O

estradiol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O
days O
. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses O
, O
5 O
alpha-NET O
inhibited O
the O
P4-induced O
UG B
gene O
expression O
in O
a O
dose-dependent O
manner O
. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486 O
. O
The O
estrogenic O
agent O
3 O
beta,5 O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O

5 O
alpha-NET O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
alpha-NET O
and O
estradiol O
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG B
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

3 O
beta,5 O
alpha-NET O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG B
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

3 O
beta,5 O
alpha-NET O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR B
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

NET O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
also O
inhibited O
the O
UG B
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR O
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

NET O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
also O
inhibited O
the O
UG O
gene O
expression O
induced O
by O
P4 O
. O
Both O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
blocked O
the O
PR B
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods O
. O
The O
inhibition O
of O
UG O
synthesis O
and O
PR O
down-regulation O
by O
5 O
alpha-NET O
and O
3 O
beta,5 O
alpha-NET O
indicates O
that O
these O
NET O
metabolites O
possess O
antiprogestational O
properties O
. O

SCH O
39166 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
trained O
to O
discriminate O
cocaine O
(0.3 O
mg/kg) O
from O
saline O
in O
a O
two-lever O
, O
food-reinforced O
procedure O
. O
Dimethocaine O
(0.1-3.0 O
mg/kg) O
fully O
and O
dose-dependently O
substituted O
for O
cocaine O
. O
Doses O
of O
dimethocaine O
(1.7 O
mg/kg) O
and O
cocaine O
(0.3 O
mg/kg) O
which O
produced O
full O
(> O
80%) O
substitution O
for O
cocaine O
were O
administered O
in O
combination O
with O
the O
dopamine B
D1 I
receptor I
antagonist O
SCH O
39166 O
((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H O
-benzo O
[d]naphtho-(2,1-b)azepine) O
and O
the O
dopamine O
D2 O
receptor O
antagonist O
raclopride O
(both O
at O
0.003-0.03 O
mg/kg) O
. O
SCH O
39166 O
fully O
blocked O
the O
cocaine-like O
discriminative O
stimulus O
effects O
of O
dimethocaine O
and O
cocaine O
, O
but O
raclopride O
produced O
only O
partial O
antagonism O
of O
cocaine-lever O
selection O
. O
In O
addition O
, O
there O
was O
some O
evidence O
that O
raclopride O
blocked O
cocaine-lever O
responding O
produced O
by O

(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H O
-benzo O
[d]naphtho-(2,1-b)azepine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(0.3 O
mg/kg) O
from O
saline O
in O
a O
two-lever O
, O
food-reinforced O
procedure O
. O
Dimethocaine O
(0.1-3.0 O
mg/kg) O
fully O
and O
dose-dependently O
substituted O
for O
cocaine O
. O
Doses O
of O
dimethocaine O
(1.7 O
mg/kg) O
and O
cocaine O
(0.3 O
mg/kg) O
which O
produced O
full O
(> O
80%) O
substitution O
for O
cocaine O
were O
administered O
in O
combination O
with O
the O
dopamine B
D1 I
receptor I
antagonist O
SCH O
39166 O
( O
(-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H O
-benzo O
[d]naphtho-(2,1-b)azepine O
and O
the O
dopamine O
D2 O
receptor O
antagonist O
raclopride O
(both O
at O
0.003-0.03 O
mg/kg) O
. O
SCH O
39166 O
fully O
blocked O
the O
cocaine-like O
discriminative O
stimulus O
effects O
of O
dimethocaine O
and O
cocaine O
, O
but O
raclopride O
produced O
only O
partial O
antagonism O
of O
cocaine-lever O
selection O
. O
In O
addition O
, O
there O
was O
some O
evidence O
that O
raclopride O
blocked O
cocaine-lever O
responding O
produced O
by O
a O
lower O

raclopride O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
food-reinforced O
procedure O
. O
Dimethocaine O
(0.1-3.0 O
mg/kg) O
fully O
and O
dose-dependently O
substituted O
for O
cocaine O
. O
Doses O
of O
dimethocaine O
(1.7 O
mg/kg) O
and O
cocaine O
(0.3 O
mg/kg) O
which O
produced O
full O
(> O
80%) O
substitution O
for O
cocaine O
were O
administered O
in O
combination O
with O
the O
dopamine O
D1 O
receptor O
antagonist O
SCH O
39166 O
((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H O
-benzo O
[d]naphtho-(2,1-b)azepine) O
and O
the O
dopamine B
D2 I
receptor I
antagonist O
raclopride O
(both O
at O
0.003-0.03 O
mg/kg) O
. O
SCH O
39166 O
fully O
blocked O
the O
cocaine-like O
discriminative O
stimulus O
effects O
of O
dimethocaine O
and O
cocaine O
, O
but O
raclopride O
produced O
only O
partial O
antagonism O
of O
cocaine-lever O
selection O
. O
In O
addition O
, O
there O
was O
some O
evidence O
that O
raclopride O
blocked O
cocaine-lever O
responding O
produced O
by O
a O
lower O
dose O
of O
dimethocaine O
. O
In O
substitution O
studies O
, O
neither O
procaine O

S(+)MDMA O
acts O
as O
NOT O
for O
what O
entity O
? O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A B
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O

R(-) O
and O
S(+) O
isomers O
of O
MDMA O
acts O
as O
NOT O
for O
what O
entity O
? O
monophosphate O
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A B
or O
5-HT2C O
receptors O
. O
The O
isomers O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O

MDMA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A B
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

MDMA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
effect O
. O
At O
the O
5-HT2C B
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

MDA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A B
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

MDA O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
5-HT2C B
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

5-HT O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A B
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

5-HT O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C B
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
Despite O
the O
weak O
effect O
of O
these O
compounds O
at O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
these O
substituted O
amphetamines O
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses O
. O

MDA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A B
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O

R(-) O
and O
S(+)MDA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C B
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O

S(+) O
isomer O
of O
MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C B
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O
the O
S(+) O
isomer O
of O
MDMA O
being O
more O
efficacious O
at O
the O
5-HT2C O
receptor O
compared O
with O
the O
R(-) O
isomer O
. O
In O
all O
cases O
at O
both O
the O
5-HT2A O
and O
5-HT2C O
receptors O
, O
the O
affinities O
of O
the O
isomers O
of O
MDMA O
and O
MDA O
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT O
. O
Despite O
the O
weak O
effect O
of O
these O
compounds O

MDA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
MDA O
and O
MDMA O
on O
phosphatidyl O
inositol O
turnover O
in O
cultured O
cells O
expressing O
5-HT2A B
or O
5-HT2C O
receptors.The O
effect O
of O
the O
R(-) O
and O
S(+) O
isomers O
of O
3,4-methylenedioxyamphetamine O
(MDA) O
and O
its O
N-methyl O
analog O
3,4-methylenedioxymethamphetamine O
(MDMA) O
on O
[3H]inositol O
monophosphate O
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A O
or O
5-HT2C O
receptors O
. O
The O
isomers O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O

R(-) O
isomer O
of O
MDA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
R(-) O
and O
S(+) O
isomers O
of O
3,4-methylenedioxyamphetamine O
(MDA) O
and O
its O
N-methyl O
analog O
3,4-methylenedioxymethamphetamine O
(MDMA) O
on O
[3H]inositol O
monophosphate O
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A B
or O
5-HT2C O
receptors O
. O
The O
isomers O
of O
MDA O
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl O
inositol O
(PI) O
hydrolysis O
at O
the O
5-HT2A O
receptors O
, O
with O
the O
R(-) O
isomer O
of O
MDA O
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A O
receptor O
. O
The O
R(-) O
and O
S(+) O
isomers O
of O
MDMA O
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A O
receptor O
as O
compared O
to O
MDA; O
S(+)MDMA O
had O
no O
effect O
. O
At O
the O
5-HT2C O
receptor O
, O
both O
R(-) O
and O
S(+)MDA O
were O
equipotent O
at O
stimulating O
PI O
hydrolysis O
, O
with O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 O
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 B
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O

Indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 B
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 B
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O

Dup-697 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 B
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 B
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O

Dup-697 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 B
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

mefenamic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 B
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

mefenamic O
acid O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
also O
displayed O
competitive O
inhibition O
of O
hCOX-2 O
. O
These O
results O
demonstrate O
the O
ability O
to O
generate O
selective O
non-steroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
, O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease O
. O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Expression O
and O
selective O
inhibition O
of O
the O
constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase.The O
enzyme O
cyclo-oxygenase B
catalyses O
the O
oxygenation O
of O
arachidonic O
acid O
, O
leading O
to O
the O
formation O
of O
prostaglandins O
Recently O
two O
forms O
of O
cyclo-oxygenase O
have O
been O
described O
: O
a O
constitutive O
(COX-1) O
enzyme O
present O
in O
most O
cells O
and O
tissues O
, O
and O
an O
inducible O
(COX-2) O
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines O
. O
Constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase O
(hCOX-1 O
and O
hCOX-2) O
were O
cloned O
and O
expressed O
in O
insect O
cells O
, O

arachidonic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Expression O
and O
selective O
inhibition O
of O
the O
constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase.The O
enzyme O
cyclo-oxygenase B
catalyses O
the O
oxygenation O
of O
arachidonic O
acid O
leading O
to O
the O
formation O
of O
prostaglandins O
. O
Recently O
two O
forms O
of O
cyclo-oxygenase O
have O
been O
described O
: O
a O
constitutive O
(COX-1) O
enzyme O
present O
in O
most O
cells O
and O
tissues O
, O
and O
an O
inducible O
(COX-2) O
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines O
. O
Constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase O
(hCOX-1 O
and O
hCOX-2) O
were O

arachidonate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines O
. O
Constitutive O
and O
inducible O
forms O
of O
human O
cyclo-oxygenase O
(hCOX-1 O
and O
hCOX-2) O
were O
cloned O
and O
expressed O
in O
insect O
cells O
, O
utilizing O
a O
baculovirus O
expression O
system O
. O
hCOX-1 B
had O
a O
specific O
activity O
of O
18.8 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 O
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O

arachidonate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
a O
baculovirus O
expression O
system O
. O
hCOX-1 O
had O
a O
specific O
activity O
of O
18.8 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate O
and O
Vmax O
. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme O
, O
whereas O
hCOX-2 B
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg O
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate O
and O
a O
Vmax O
. O
of O
1090 O
nmol O
of O
O2/nmol O
of O
enzyme O
. O
Indomethacin O
inhibited O
both O
hCOX-1 O
and O
hCOX-2 O
, O
whereas O
NS-398 O
and O
Dup-697 O
selectively O
inhibited O
hCOX-2 O
. O
Both O
NS-398 O
and O
Dup-697 O
exhibited O
time-dependent O
inactivation O
of O
hCOX-2 O
, O
as O
did O
indomethacin O
on O
both O
enzymes O
. O
The O
competitive O
inhibitor O
of O
hCOX-1 O
, O
mefenamic O
acid O
, O
also O
displayed O
competitive O
inhibition O

p-aminobenzamidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
transitions O
linked O
to O
active O
site O
ligation O
in O
human O
thrombin O
: O
effect O
on O
the O
interaction O
with O
fibrinogen O
and O
the O
cleavable O
platelet O
receptor.An O
experimental O
strategy O
based O
on O
solution O
viscosity O
perturbation O
allowed O
us O
to O
study O
the O
energetics O
of O
amide-substrates O
, O
p-aminobenzamidine O
(p-ABZ) O
and O
proflavin O
binding O
to O
the O
catalytic O
site O
of O
two O
proteolyzed O
forms O
of O
alpha-thrombin O
, O
i.e O
. O
zeta- O
and O
gamma O
T-thrombin O
. O
These O
thrombin O
derivatives O
are O
cleaved O
at O
the O
Leu144-Gly150 O
loop O
and O
at O
the O
fibrinogen O
recognition O
exosite O
(FRS) O
, O
respectively O
. O
A O
phenomenological O
analysis O
of O
thermodynamic O
data O
showed O
that O
the O
amide O
substrates O
and O
p-ABZ O

p-ABZ O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
transitions O
linked O
to O
active O
site O
ligation O
in O
human O
thrombin O
: O
effect O
on O
the O
interaction O
with O
fibrinogen O
and O
the O
cleavable O
platelet O
receptor.An O
experimental O
strategy O
based O
on O
solution O
viscosity O
perturbation O
allowed O
us O
to O
study O
the O
energetics O
of O
amide-substrates O
, O
p-aminobenzamidine O
( O
p-ABZ O
and O
proflavin O
binding O
to O
the O
catalytic O
site O
of O
two O
proteolyzed O
forms O
of O
alpha-thrombin O
, O
i.e O
. O
zeta- O
and O
gamma O
T-thrombin O
. O
These O
thrombin O
derivatives O
are O
cleaved O
at O
the O
Leu144-Gly150 O
loop O
and O
at O
the O
fibrinogen O
recognition O
exosite O
(FRS) O
, O
respectively O
. O
A O
phenomenological O
analysis O
of O
thermodynamic O
data O
showed O
that O
the O
amide O
substrates O
and O
p-ABZ O
interactions O

proflavin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Conformational O
transitions O
linked O
to O
active O
site O
ligation O
in O
human O
thrombin O
: O
effect O
on O
the O
interaction O
with O
fibrinogen O
and O
the O
cleavable O
platelet O
receptor.An O
experimental O
strategy O
based O
on O
solution O
viscosity O
perturbation O
allowed O
us O
to O
study O
the O
energetics O
of O
amide-substrates O
, O
p-aminobenzamidine O
(p-ABZ) O
and O
proflavin O
binding O
to O
the O
catalytic O
site O
of O
two O
proteolyzed O
forms O
of O
alpha-thrombin O
, O
i.e O
. O
zeta- O
and O
gamma O
T-thrombin O
. O
These O
thrombin O
derivatives O
are O
cleaved O
at O
the O
Leu144-Gly150 O
loop O
and O
at O
the O
fibrinogen O
recognition O
exosite O
(FRS) O
, O
respectively O
. O
A O
phenomenological O
analysis O
of O
thermodynamic O
data O
showed O
that O
the O
amide O
substrates O
and O
p-ABZ O
interactions O
with O
zeta-thrombin O

p-aminobenzamidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
gamma O
T-thrombin O
interaction O
with O
p-ABZ O
were O
found O
to O
be O
linearly O
correlated O
to O
the O
free O
energy O
of O
activation O
for O
both O
fibrinogen O
and O
CPR O
cleavage O
. O
In O
conclusion O
, O
these O
data O
demonstrate O
that O
: O
(1) O
the O
Leu144-Gly150 O
loop O
and O
the O
FRS O
are O
both O
involved O
in O
the O
conformational O
transition O
linked O
to O
the O
binding O
of O
p-aminobenzamidine O
to O
the O
thrombin B
active O
site; O
(2) O
the O
extent O
of O
thrombin's O
capacity O
to O
undergo O
conformational O
transitions O
in O
alpha- O
, O
zeta- O
and O
gamma O
T O
forms O
is O
positively O
correlated O
to O
the O
free O
energy O
of O
activation O
for O
hydrolysis O
of O
macromolecular O
substrates O
interacting O
with O
both O
the O
catalytic O
domain O
and O
the O
FRS O
. O

p-ABZ O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
p-aminobenzamidine O
(p-ABZ) O
and O
proflavin O
binding O
to O
the O
catalytic O
site O
of O
two O
proteolyzed O
forms O
of O
alpha-thrombin O
, O
i.e O
. O
zeta- O
and O
gamma O
T-thrombin O
. O
These O
thrombin O
derivatives O
are O
cleaved O
at O
the O
Leu144-Gly150 O
loop O
and O
at O
the O
fibrinogen O
recognition O
exosite O
(FRS) O
, O
respectively O
. O
A O
phenomenological O
analysis O
of O
thermodynamic O
data O
showed O
that O
the O
amide O
substrates O
and O
p-ABZ O
interactions O
with O
zeta-thrombin B
were O
respectively O
, O
associated O
with O
a O
chemical O
compensation O
(i.e O
. O
the O
linear O
relationship O
between O
entropy O
and O
enthalpy O
of O
binding) O
and O
a O
hydrophobic O
phenomenon O
(i.e O
. O
a O
change O
in O
the O
standard O
heat O
capacity) O
. O
The O
latter O
was O
slightly O
lower O
than O
that O
previously O
observed O
for O
a O
alpha-thrombin O
(0.78 O
+/- O
0.25 O
versus O
1.01 O

Ala O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl O
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala O
->Gly O
replacement O
has O
less O
impact O
in O
protecting O
the O
chloride B
channel I
from O
the O
action O
of O
insecticidal O
blockers O
. O
Each O
of O
the O
resistant O
strains O
has O
the O
same O
level O
of O
resistance O
to O
the O
lethal O
action O
of O
the O
five O
channel O
blockers O
examined O
but O
none O
to O
avermectins O
and O
muscimol O
. O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl O
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala--> O
Gly O
replacement O
has O
less O
impact O
in O
protecting O
the O
chloride B
channel I
from O
the O
action O
of O
insecticidal O
blockers O
. O
Each O
of O
the O
resistant O
strains O
has O
the O
same O
level O
of O
resistance O
to O
the O
lethal O
action O
of O
the O
five O
channel O
blockers O
examined O
but O
none O
to O
avermectins O
and O
muscimol O
. O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(lindane O
, O
alpha-endosulfan O
, O
dieldrin O
, O
12-ketoendrin O
, O
fipronil O
, O
and O
a O
representative O
bicycloorthobenzoate O
and O
dithiane) O
or O
200 O
nM O
(picrotoxinin); O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302--> O
Ser O
replacement O
in O
the O
Rdl B
GABA I
receptor I
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala-->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O

Ala O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(picrotoxinin); O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser O
replacement O
in O
the O
Rdl B
GABA I
receptor I
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala O
->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser O
replacement O
in O
the O
Rdl B
GABA I
receptor I
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala--> O
Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
insecticidal O
channel O
activators O
avermectin O
and O
moxidectin O
at O
20 O
nM; O
muscimol O
at O
30 O
microM O
and O
GABA O
at O
300 O
microM O
. O
Cyclodiene O
resistance O
in O
D O
. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser O
replacement O
in O
the O
Rdl B
GABA I
receptor I
subunit O
and O
in O
D O
. O
simulans O
to O
an O
homologous O
Ala-->Ser O
or O
Gly O
replacement O
. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB O
binding O
, O
i.e O
. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites O
. O
The O
Ala-->Ser O
replacement O
with O
both O
melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O
GABA O
. O
The O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gl O
mutants O
of O
Rdl B
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated O
chloride O
ion O
channel O
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O
by O
: O
a O

Ala O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Al O
-->Ser O
or O
Gly O
mutants O
of O
Rdl B
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated O
chloride O
ion O
channel O
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O

Ser O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-- O
>Se O
or O
Gly O
mutants O
of O
Rdl B
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated O
chloride O
ion O
channel O
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O

4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gly O
mutants O
of O
Rdl O
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated B
chloride I
ion I
channel I
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O
by O
: O
a O
large O
number O
and O
variety O
of O
insecticidal O
channel O
blockers O
at O
20 O
nM O
(lindane O
, O
alpha-endosulfan O
, O
dieldrin O
, O
12-ketoendrin O
, O
fipronil O
, O
and O
a O
representative O
bicycloorthobenzoate O
and O
dithiane) O
or O
200 O

[3H]EBOB O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBOB O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gly O
mutants O
of O
Rdl O
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated B
chloride I
ion I
channel I
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
( O
[3H]EBOB O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O
of O
[3H]EBOB O
is O
strongly O
inhibited O
by O
: O
a O
large O
number O
and O
variety O
of O
insecticidal O
channel O
blockers O
at O
20 O
nM O
(lindane O
, O
alpha-endosulfan O
, O
dieldrin O
, O
12-ketoendrin O
, O
fipronil O
, O
and O
a O
representative O
bicycloorthobenzoate O
and O
dithiane) O
or O
200 O
nM O

[3H]EBOB O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Drosophila O
GABA-gated O
chloride O
channel O
: O
modified O
[3H]EBO O
binding O
site O
associated O
with O
Ala-->Ser O
or O
Gly O
mutants O
of O
Rdl O
subunit.The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated O
chloride O
ion O
channel O
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate O
([3H]EBOB) O
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O
BmaxS O
of O
171-181 O
fmol/mg O
protein O
. O
This O
specific O
binding O

avermectin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O
GABA O
. O
The O
Ala-->Gly O
replacement O
in O
D O
. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser O
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol O
and O
GABA O
. O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl B
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala-->Gly O
replacement O
has O
less O

moxidectin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB O
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol O
and O
GABA O
. O
The O
Ala-->Gly O
replacement O
in O
D O
. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser O
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol O
and O
GABA O
. O
The O
channel O
activators O
avermectin O
and O
moxidectin O
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl B
subunit O
mutants O
. O
Thus O
, O
it O
appears O
that O
replacement O
of O
Ala O
by O
Ser O
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition O
site O
with O
less O
effect O
on O
the O
channel O
activator O
site O
. O
In O
contrast O
, O
the O
Ala-->Gly O
replacement O
has O
less O
impact O
in O

Agmatine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
and O
stimulates O
release O
of O
catecholamines O
from O
adrenal O
chromaffin O
cells O
. O
Its O
biosynthetic O
enzyme O
, O
arginine O
decarboxylase O
, O
is O
present O
in O
brain O
. O
Agmatine O
locally O
synthesized O
, O
is O
an O
endogenous O
agonist O
at O
imidazoline O
receptors O
, O
a O
noncatecholamine O
ligand O
at O
alpha B
2-adrenergic I
receptors I
and O
may O
act O
as O
a O
neurotransmitter O
. O

Clonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Agmatine O
: O
an O
endogenous O
clonidine-displacing O
substance O
in O
the O
brain O
. O
Clonidine O
an O
antihypertensive O
drug O
, O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
. O
The O
endogenous O
ligand O
for O
imidazoline O
receptors O
may O
be O
a O
clonidine-displacing O
substance O
, O
a O
small O
molecule O
isolated O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O

clonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Agmatine O
: O
an O
endogenous O
clonidine-displacing O
substance O
in O
the O
brain.Clonidine O
, O
an O
antihypertensive O
drug O
, O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
. O
The O
endogenous O
ligand O
for O
imidazoline B
receptors I
may O
be O
a O
clonidine O
displacing O
substance O
, O
a O
small O
molecule O
isolated O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
and O
stimulates O
release O
of O
catecholamines O
from O
adrenal O
chromaffin O
cells O
. O
Its O
biosynthetic O
enzyme O
, O

Agmatine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
brain.Clonidine O
, O
an O
antihypertensive O
drug O
, O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline O
receptors O
. O
The O
endogenous O
ligand O
for O
imidazoline O
receptors O
may O
be O
a O
clonidine-displacing O
substance O
, O
a O
small O
molecule O
isolated O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha B
2-adrenergic I
and I
imidazoline I
receptors I
and O
stimulates O
release O
of O
catecholamines O
from O
adrenal O
chromaffin O
cells O
. O
Its O
biosynthetic O
enzyme O
, O
arginine O
decarboxylase O
, O
is O
present O
in O
brain O
. O
Agmatine O
, O
locally O
synthesized O
, O
is O
an O
endogenous O
agonist O
at O
imidazoline O
receptors O
, O
a O
noncatecholamine O
ligand O
at O
alpha O
2-adrenergic O
receptors O
and O
may O
act O
as O
a O
neurotransmitter O
. O

Agmatine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
from O
bovine O
brain O
. O
This O
clonidine-displacing O
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine O
(decarboxylated O
arginine) O
, O
heretofore O
not O
detected O
in O
brain O
. O
Agmatine O
binds O
to O
alpha O
2-adrenergic O
and O
imidazoline B
receptors I
and O
stimulates O
release O
of O
catecholamines O
from O
adrenal O
chromaffin O
cells O
. O
Its O
biosynthetic O
enzyme O
, O
arginine O
decarboxylase O
, O
is O
present O
in O
brain O
. O
Agmatine O
locally O
synthesized O
, O
is O
an O
endogenous O
agonist O
at O
imidazoline O
receptors O
, O
a O
noncatecholamine O
ligand O
at O
alpha O
2-adrenergic O
receptors O
and O
may O
act O
as O
a O
neurotransmitter O
. O

BRL O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
doses O
of O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O
beta B
2-adrenoceptor I
agonist O
salbutamol O
8 O
mg O
(SAL) O
, O
after O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O
selective O
beta O
1-adrenoceptor O
antagonist O
, O
or O
nadolol O
20 O
mg O
(N20) O
to O
block O
beta O
1- O
and O
beta O
2- O
but O
not O
beta O
3-receptors O
. O
Both O
BRL O
and O
SAL O
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O
with O
beta O
2-adrenoceptor O
stimulation O
, O
and O
this O
response O
was O
totally O
abolished O
by O
pretreatment O
with O
N20 O
. O
Significant O
increases O
in O
systolic O
blood O
pressure O
and O
Doppler O
stroke O
distance O
occurred O
with O
BRL O
and O
SAL O
which O
were O
unaffected O
by O
pretreatment O
with O
B5 O
and O

SAL O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O
beta B
2-adrenoceptor I
agonist O
salbutamol O
8 O
mg O
(SAL) O
, O
after O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O
selective O
beta O
1-adrenoceptor O
antagonist O
, O
or O
nadolol O
20 O
mg O
(N20) O
to O
block O
beta O
1- O
and O
beta O
2- O
but O
not O
beta O
3-receptors O
. O
Both O
BRL O
and O
SAL O
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O
with O
beta O
2-adrenoceptor O
stimulation O
, O
and O
this O
response O
was O
totally O
abolished O
by O
pretreatment O
with O
N20 O
. O
Significant O
increases O
in O
systolic O
blood O
pressure O
and O
Doppler O
stroke O
distance O
occurred O
with O
BRL O
and O
SAL O
which O
were O
unaffected O
by O
pretreatment O
with O
B5 O
and O
completely O
blocked O

BRL35135 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Cardiac O
effects O
of O
the O
beta B
3-adrenoceptor I
agonist O
BRL3513 O
in O
man.The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiac O
effects O
of O
the O
beta O
3-adrenoceptor O
agonist O
BRL35135 O
, O
and O
determine O
whether O
beta O
3-receptors O
are O
involved O
in O
mediating O
chronotropic O
or O
inotropic O
responses O
in O
man O
. O
Eight O
normal O
males O
received O
single O
oral O
doses O
of O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O

BRL35135 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Cardiac O
effects O
of O
the O
beta B
3-adrenoceptor I
agonist O
BRL35135 O
in O
man.The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiac O
effects O
of O
the O
beta O
3-adrenoceptor O
agonist O
BRL35135 O
and O
determine O
whether O
beta O
3-receptors O
are O
involved O
in O
mediating O
chronotropic O
or O
inotropic O
responses O
in O
man O
. O
Eight O
normal O
males O
received O
single O
oral O
doses O
of O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O
beta O
2-adrenoceptor O
agonist O
salbutamol O
8 O
mg O
(SAL) O
, O
after O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O

salbutamol O
acts O
as O
AGONIST O
for O
what O
entity O
? O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiac O
effects O
of O
the O
beta O
3-adrenoceptor O
agonist O
BRL35135 O
, O
and O
determine O
whether O
beta O
3-receptors O
are O
involved O
in O
mediating O
chronotropic O
or O
inotropic O
responses O
in O
man O
. O
Eight O
normal O
males O
received O
single O
oral O
doses O
of O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O
beta B
2-adrenoceptor I
agonist O
salbutamol O
8 O
mg O
(SAL) O
, O
after O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O
selective O
beta O
1-adrenoceptor O
antagonist O
, O
or O
nadolol O
20 O
mg O
(N20) O
to O
block O
beta O
1- O
and O
beta O
2- O
but O
not O
beta O
3-receptors O
. O
Both O
BRL O
and O
SAL O
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O

SAL O
acts O
as O
AGONIST O
for O
what O
entity O
? O
was O
to O
evaluate O
the O
cardiac O
effects O
of O
the O
beta O
3-adrenoceptor O
agonist O
BRL35135 O
, O
and O
determine O
whether O
beta O
3-receptors O
are O
involved O
in O
mediating O
chronotropic O
or O
inotropic O
responses O
in O
man O
. O
Eight O
normal O
males O
received O
single O
oral O
doses O
of O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O
beta B
2-adrenoceptor I
agonist O
salbutamol O
8 O
mg O
( O
SAL O
 O
, O
after O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O
selective O
beta O
1-adrenoceptor O
antagonist O
, O
or O
nadolol O
20 O
mg O
(N20) O
to O
block O
beta O
1- O
and O
beta O
2- O
but O
not O
beta O
3-receptors O
. O
Both O
BRL O
and O
SAL O
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O
with O
beta O

bisoprolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
the O
beta O
3-adrenoceptor O
agonist O
BRL35135 O
, O
and O
determine O
whether O
beta O
3-receptors O
are O
involved O
in O
mediating O
chronotropic O
or O
inotropic O
responses O
in O
man O
. O
Eight O
normal O
males O
received O
single O
oral O
doses O
of O
BRL35135 O
8 O
mg O
(BRL) O
or O
the O
selective O
beta O
2-adrenoceptor O
agonist O
salbutamol O
8 O
mg O
(SAL) O
, O
after O
pretreatment O
with O
either O
placebo O
(PL) O
, O
bisoprolol O
5 O
mg O
(B5) O
as O
a O
selective O
beta B
1-adrenoceptor I
antagonist O
, O
or O
nadolol O
20 O
mg O
(N20) O
to O
block O
beta O
1- O
and O
beta O
2- O
but O
not O
beta O
3-receptors O
. O
Both O
BRL O
and O
SAL O
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O
with O
beta O
2-adrenoceptor O
stimulation O
, O
and O
this O
response O
was O
totally O
abolished O

NH2 O
acts O
as O
PART-OF O
for O
what O
entity O
? O
as O
well O
as O
two O
different O
NH2-terminal O
truncated O
genes O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli O
. O
The O
carbonic O
anhydrase O
V O
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2-terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino-terminal O
ends O
. O
The O
two O
NH2 O
terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29-amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
, O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic B
anhydrase I
(CA) I
V I
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions O
. O
These O
latter O
two O
forms O
of O
CA O
V O
had O
identical O
steady-state O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli O
. O
The O
carbonic O
anhydrase O
V O
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2-terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino-terminal O
ends O
. O
The O
two O
NH2-terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29- O
amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
, O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic B
anhydrase I
(CA) I
V I
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions O
. O
These O
latter O
two O
forms O
of O
CA O
V O
had O
identical O
steady-state O
constants O
for O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
The O
carbonic O
anhydrase O
V O
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2-terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino-terminal O
ends O
. O
The O
two O
NH2-terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29-amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic B
anhydrase I
(CA) I
V I
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions O
. O
These O
latter O
two O
forms O
of O
CA O
V O
had O
identical O
steady-state O
constants O
for O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O

His O
acts O
as O
PART-OF O
for O
what O
entity O
? O
ethoxzolamide O
, O
and O
cyanate O
, O
CA B
V I
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64--> O
His O
showed O
that O
the O
unique O
kinetic O
properties O
of O
CA O
V O
are O
not O
due O
to O
the O
presence O
of O
tyrosine O
at O
position O
64 O
. O

tyrosine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA B
V I
containing O
the O
replacement O
Tyr64-->His O
showed O
that O
the O
unique O
kinetic O
properties O
of O
CA O
V O
are O
not O
due O
to O
the O
presence O
of O
tyrosine O
at O
position O
64 O
. O

NH2 O
acts O
as O
PART-OF O
for O
what O
entity O
? O
reverse O
transcription O
and O
polymerase O
chain O
reaction O
from O
BALB/c O
mouse O
liver O
mRNA O
. O
Vectors O
containing O
the O
full O
coding O
sequence O
as O
well O
as O
two O
different O
NH2-terminal O
truncated O
genes O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli O
. O
The B
carbonic I
anhydrase I
V I
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2 O
terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino-terminal O
ends O
. O
The O
two O
NH2-terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29-amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
, O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic O
anhydrase O
(CA) O
V O
isolated O
from O
mouse O
liver O
mitochondria; O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
full O
coding O
sequence O
as O
well O
as O
two O
different O
NH2-terminal O
truncated O
genes O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli O
. O
The B
carbonic I
anhydrase I
V I
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence O
, O
which O
includes O
a O
possible O
NH2-terminal O
mitochondrial O
targeting O
signal O
, O
was O
proteolytically O
processed O
by O
E O
. O
coli O
and O
contained O
several O
amino O
terminal O
ends O
. O
The O
two O
NH2-terminal O
truncated O
vectors O
deleted O
, O
respectively O
, O
1) O
the O
29-amino O
acid O
putative O
targeting O
sequence O
and O
2) O
51 O
amino O
acids O
, O
yielding O
a O
protein O
equivalent O
to O
a O
carbonic O
anhydrase O
(CA) O
V O
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions O
. O
These O
latter O
two O
forms O
of O
CA O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
for O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA B
V I
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
ethoxzolamide O
, O
and O
cyanate O
, O
CA O
V O
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
for O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA O
V O
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
ethoxzolamide O
, O
and O
cyanate O
, O
CA O
V O
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O

ethoxzolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA B
V I
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
, O
ethoxzolamide O
and O
cyanate O
, O
CA O
V O
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O
showed O

ethoxzolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
hydration O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA O
V O
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
, O
ethoxzolamide O
and O
cyanate O
, O
CA O
V O
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O
showed O

cyanate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA B
V I
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
, O
ethoxzolamide O
, O
and O
cyanate O
CA O
V O
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O
showed O
that O
the O

cyanate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
CO2 O
, O
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O
10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km O
. O
In O
catalytic O
properties O
, O
mouse O
CA O
V O
is O
closest O
to O
CA O
I; O
however O
, O
in O
inhibition O
by O
acetazolamide O
, O
ethoxzolamide O
, O
and O
cyanate O
CA O
V O
is O
very O
similar O
to O
CA O
II O
. O
Mouse O
CA O
V O
has O
a O
tyrosine O
at O
position O
64 O
, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine O
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway O
. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA O
V O
containing O
the O
replacement O
Tyr64-->His O
showed O
that O
the O

(+/-)-pindolol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A B
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O

(+/-)-pindolol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B B
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O

D-1997 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like B
receptors I
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

D-1997 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A B
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

D-1997 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B B
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

(+/-)-pindolol O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor B
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O

D-1997 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
2-(2-Aminoethyl)-quinoline O
(D-199 O
) O
: O
a O
novel O
agonist O
at O
5-hydroxytryptamine1-like B
receptors I
in O
the O
canine O
basilar O
artery.This O
study O
aimed O
to O
investigate O
the O
mechanisms O
involved O
in O
the O
contractile O
effects O
produced O
by O
the O
novel O
quinoline O
derivative O
, O
2-(2-aminoethyl)-quinoline O
(D-1997) O
, O
in O
the O
canine O
isolated O
basilar O
artery O
. O
For O
comparison O
, O
the O
effects O
of O
D-1997 O
were O
also O
evaluated O
on O
rat O
aorta O
. O

D-1997 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997 O
induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like B
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O

D-1997 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
5-HT2 B
receptor I
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997 O
induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O

methiothepin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like B
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

methiothepin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 B
receptor I
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O
to O
be O
devoid O
of O
5-HT2 O
receptor O
agonist O
properties O
in O
rat O
aorta O
. O

ketanserin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
5-HT O
> O
D-1997 O
> O
quipazine O
. O
5-HT O
and O
D-1997 O
exhibited O
similar O
maximum O
effects O
which O
were O
higher O
than O
that O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 B
receptor I
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O

tropisetron O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
effects O
which O
were O
higher O
than O
that O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 B
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
( O
tropisetron O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O

tropisetron O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
effects O
which O
were O
higher O
than O
that O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 B
receptor O
antagonist O
ICS205930 O
( O
tropisetron O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O

spiroxatrine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
quipazine O
. O
Similar O
concentrations O
of O
D-1997 O
failed O
to O
produce O
contraction O
in O
rat O
aorta O
. O
The O
effects O
of O
D-1997 O
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A B
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha O
1-adrenoceptor O
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O

prazosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
modified O
by O
incubation O
with O
either O
the O
5-HT2 O
receptor O
antagonist O
ketanserin O
(0.01-1 O
microM) O
, O
the O
5-HT3 O
and O
5-HT4 O
receptor O
antagonist O
ICS205930 O
(tropisetron; O
0.1-10 O
microM) O
, O
the O
5-HT1A O
receptor O
antagonist O
spiroxatrine O
(0.01-1 O
microM) O
, O
the O
beta-adrenoceptor O
blocker O
with O
high O
affinity O
for O
5-HT1A O
and O
5-HT1B O
binding O
sites O
(+/-)-pindolol O
(0.01-1 O
microM) O
, O
or O
the O
alpha B
1-adrenoceptor I
antagonist O
prazosin O
(0.01-1 O
microM) O
. O
In O
contrast O
, O
the O
D-1997-induced O
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like O
and O
5-HT2 O
receptor O
antagonist O
methiothepin O
(0.01-1 O
microM) O
. O
It O
is O
concluded O
that O
D-1997 O
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like O
receptors O
unrelated O
to O
either O
the O
5-HT1A O
or O
5-HT1B O
receptor O
subtypes O
. O
The O
compound O
seems O

sucralfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Sucralfate O
: O
the O
Bangkok O
review.Sucralfate O
is O
a O
site-protective O
ulcer O
healing O
drug O
with O
a O
remarkable O
range O
of O
mechanisms O
of O
action O
. O
Recent O
studies O
highlight O
the O
capacity O
of O
sucralfate O
to O
bind O
basic B
fibroblast I
growth I
factor I
(bFGF) O
and O
deliver O
it O
in O
high O
concentration O
to O
the O
ulcer O
. O
Basic O
fibroblast O
growth O
factor O
stimulates O
the O
production O
of O
granulation O
tissue O
, O
angiogenesis O
and O
re-epithelization O
, O
thus O
improving O
the O
quality O
of O
ulcer O
healing O
. O
The O
effect O
of O
sucralfate O
in O
reducing O
parietal O
cell O
sensitivity O
may O
be O
another O
factor O

sucralfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Sucralfate O
: O
the O
Bangkok O
review.Sucralfate O
is O
a O
site-protective O
ulcer O
healing O
drug O
with O
a O
remarkable O
range O
of O
mechanisms O
of O
action O
. O
Recent O
studies O
highlight O
the O
capacity O
of O
sucralfate O
to O
bind O
basic O
fibroblast O
growth O
factor O
(bFGF) O
and O
deliver O
it O
in O
high O
concentration O
to O
the O
ulcer O
. O
Basic O
fibroblast O
growth O
factor O
stimulates O
the O
production O
of O
granulation O
tissue O
, O
angiogenesis O
and O
re-epithelization O
, O
thus O
improving O
the O
quality O
of O
ulcer O
healing O
. O
The O
effect O
of O
sucralfate O
in O
reducing O
parietal O
cell O
sensitivity O
may O
be O
another O
factor O

morphine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Murine O
chromosomal O
location O
of O
the O
mu O
and O
kappa O
opioid O
receptor O
genes.Opioid O
receptors O
are O
the O
membrane O
proteins O
that O
mediate O
the O
pain-relieving O
effect O
of O
opioid O
drugs O
, O
such O
as O
morphine O
and O
fentanyl O
as O
well O
as O
endogenous O
opioid O
peptides O
enkephalins O
and O
endorphins O
. O
Using O
cDNAs O
for O
the O
mu O
and O
the O
kappa O
opioid O
receptors O
, O
we O
mapped O
the O
chromosomal O
locations O
of O
their O
genes O
in O
mouse O
. O
Multilocus O
cross O
analysis O
located O
the O
mu O
receptor O
gene O
Oprm O
on O
Chr O
10 O
and O
the O
kappa O
receptor O
gene O
Oprk1 O

fentanyl O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Murine O
chromosomal O
location O
of O
the O
mu O
and O
kappa O
opioid O
receptor O
genes.Opioid O
receptors O
are O
the O
membrane O
proteins O
that O
mediate O
the O
pain-relieving O
effect O
of O
opioid O
drugs O
, O
such O
as O
morphine O
and O
fentanyl O
as O
well O
as O
endogenous O
opioid O
peptides O
enkephalins O
and O
endorphins O
. O
Using O
cDNAs O
for O
the O
mu O
and O
the O
kappa O
opioid O
receptors O
, O
we O
mapped O
the O
chromosomal O
locations O
of O
their O
genes O
in O
mouse O
. O
Multilocus O
cross O
analysis O
located O
the O
mu O
receptor O
gene O
Oprm O
on O
Chr O
10 O
and O
the O
kappa O
receptor O
gene O
Oprk1 O
on O
Chr O

proline O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine B
pancreatic I
ribonuclease I
A I
(RNase O
A) O
and O
its O
proline O
42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O

proline O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline O
42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O

alanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine B
pancreatic I
ribonuclease I
A I
(RNase O
A) O
and O
its O
proline-42-to- O
alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O

alanine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to- O
alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O

2'CMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala B
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial O
, O
indicating O
that O
the O
major O
and O

2'CMP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial O
, O
indicating O
that O
the O
major O
and O

tyrosine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala B
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial O
, O
indicating O
that O
the O
major O
and O
minor O
slow-folding O
species O
of O
Pro42Ala O
fold O
to O
the O
native O
state O
with O
different O
transition-state O
conformations O
in O
the O
rate-determining O
step O
. O

tyrosine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase B
A I
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial O
, O
indicating O
that O
the O
major O
and O
minor O
slow-folding O
species O
of O
Pro42Ala O
fold O
to O
the O
native O
state O
with O
different O
transition-state O
conformations O
in O
the O
rate-determining O
step O
. O

disulfide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfid O
-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine B
pancreatic I
ribonuclease I
A I
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O

disulfide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide O
intact O
bovine B
pancreatic I
ribonuclease I
A I
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O

disulfide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide O
intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O

tyrosine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase B
A I
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial O
, O
indicating O
that O
the O
major O
and O
minor O
slow-folding O
species O
of O
Pro42Ala O
fold O
to O
the O
native O
state O
with O
different O
transition-state O
conformations O
in O
the O
rate-determining O
step O
. O

2'CMP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine O

2'-cytidine O
monophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine B
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O

2'-cytidine O
monophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O

2'-cytidine O
monophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine B
pancreatic I
ribonuclease I
A I
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O

2'-cytidine O
monophosphate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine B
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
( O
2'CMP O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
( O
2'CMP O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala B

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine B
pancreatic I
ribonuclease I
A I
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
( O
2'CMP O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase O
A O
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Folding O
pathway O
of O
guanidine-denatured O
disulfide-intact O
wild-type O
and O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
( O
2'CMP O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O

2'CMP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mutant O
bovine O
pancreatic O
ribonuclease O
A.The O
refolding O
kinetics O
of O
guanidine-denatured O
disulfide-intact O
bovine O
pancreatic O
ribonuclease O
A O
(RNase O
A) O
and O
its O
proline-42-to-alanine O
mutant O
(Pro42Ala) O
have O
been O
studied O
by O
monitoring O
tyrosine O
burial O
and O
2'-cytidine O
monophosphate O
(2'CMP) O
inhibitor O
binding O
. O
The O
folding O
rate O
for O
wild-type O
RNase B
A I
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP O
than O
in O
its O
absence O
, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP O
. O
The O
folding O
rate O
monitored O
by O
2'CMP O
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala O
RNase O
A O
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine O
burial; O
however O
, O
the O
folding O
rate O
monitored O
by O

sodium O
salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
NF-kappa B
B I
by O
sodium O
salicylate O
and O
aspirin.The O
transcription O
factor O
nuclear O
factor-kappa O
B O
(NF-kappa O
B) O
is O
critical O
for O
the O
inducible O
expression O
of O
multiple O
cellular O
and O
viral O
genes O
involved O
in O
inflammation O
and O
infection O
including O
interleukin-1 O
(IL-1) O
, O
IL-6 O
, O
and O
adhesion O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Inhibition O
of O
NF-kappa B
B I
by O
sodium O
salicylate O
and O
aspirin.The O
transcription O
factor O
nuclear O
factor-kappa O
B O
(NF-kappa O
B) O
is O
critical O
for O
the O
inducible O
expression O
of O
multiple O
cellular O
and O
viral O
genes O
involved O
in O
inflammation O
and O
infection O
including O
interleukin-1 O
(IL-1) O
, O
IL-6 O
, O
and O
adhesion O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O
from O
the O

Sodium O
salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
IL-6 O
, O
and O
adhesion O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa B
B I
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O
from O
the O
Ig O
kappa O
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells O
. O

Sodium O
salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
IL-6 O
, O
and O
adhesion O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O
from O
the O
Ig B
kappa I
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells O
. O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa B
B I
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O
from O
the O
Ig O
kappa O
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells O
. O

aspirin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
molecules O
. O
The O
anti-inflammatory O
drugs O
sodium O
salicylate O
and O
aspirin O
inhibited O
the O
activation O
of O
NF-kappa O
B O
, O
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs O
. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa O
B O
inhibitor O
, O
I O
kappa O
B O
, O
and O
therefore O
NF-kappa O
B O
was O
retained O
in O
the O
cytosol O
. O
Sodium O
salicylate O
and O
aspirin O
also O
inhibited O
NF-kappa O
B-dependent O
transcription O
from O
the O
Ig B
kappa I
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells O
. O

R-enantiomer O
of O
timolol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Comparisons O
of O
beta-adrenergic O
blocking O
properties O
of O
S- O
and O
R-timolol O
in O
humans.In O
animals O
, O
the O
R-enantiomer O
of O
timolol O
causes O
a O
significant O
reduction O
in O
intraocular O
pressure O
but O
had O
only O
1/80 O
the O
activity O
of O
the O
S-enantiomer O
at O
extraocular O
receptors O
. O
The O
beta O
1- O
and O
beta O
2-adrenoceptor O
blocking O
properties O
of O
orally O
administered O
R- O
and O
S-timolol O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
trial O
in O
two O
groups O
of O
healthy O
men O
. O
Each O

ergotamine O
acts O
as O
NOT O
for O
what O
entity O
? O
with O
15 O
healthy O
controls O
. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O
rate O
density O
were O
calculated O
as O
a O
semiquantitative O
measurement O
for O
striatal O
dopamine O
D2-receptor O
binding O
potential O
. O
No O
differences O
were O
found O
in O
striatal O
uptake O
of O
123I-IBZM O
between O
healthy O
controls O
and O
the O
patients O
when O
on O
or O
off O
ergotamine O
. O
Preliminary O
evidence O
suggests O
that O
ergotamine O
may O
not O
occupy O
striatal O
dopamine B
D2-receptors I
to O
a O
large O
extent O
and O
thus O
may O
not O
cross O
the O
blood O
brain O
barrier O
in O
large O
quantities O
. O

123I-iodobenzamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dopamine B
D2-receptor I
imaging O
with O
123I-iodobenzamid O
SPECT O
in O
migraine O
patients O
abusing O
ergotamine O
: O
does O
ergotamine O
cross O
the O
blood O
brain O
barrier?Two O
migraine O
patients O
were O
studied O
by O
in O
vivo O
SPECT O
using O
the O
dopamine O
D2-receptor O
specific O
radioligand O
123I-3-iodo-6-methoxybenzamide O
(123I-IBZM) O
during O
ergotamine O
abuse O
and O
after O
withdrawal O
. O
Results O
were O
compared O
with O
15 O
healthy O
controls O
. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O

123I-3-iodo-6-methoxybenzamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dopamine O
D2-receptor O
imaging O
with O
123I-iodobenzamide O
SPECT O
in O
migraine O
patients O
abusing O
ergotamine O
: O
does O
ergotamine O
cross O
the O
blood O
brain O
barrier?Two O
migraine O
patients O
were O
studied O
by O
in O
vivo O
SPECT O
using O
the O
dopamine B
D2-receptor I
specific O
radioligand O
123I-3-iodo-6-methoxybenzamide O
(123I-IBZM) O
during O
ergotamine O
abuse O
and O
after O
withdrawal O
. O
Results O
were O
compared O
with O
15 O
healthy O
controls O
. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O
rate O
density O
were O
calculated O
as O
a O
semiquantitative O
measurement O
for O
striatal O
dopamine O
D2-receptor O
binding O
potential O
. O
No O
differences O
were O
found O
in O
striatal O
uptake O
of O
123I-IBZM O
between O
healthy O
controls O
and O
the O

123I-IBZM O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Dopamine O
D2-receptor O
imaging O
with O
123I-iodobenzamide O
SPECT O
in O
migraine O
patients O
abusing O
ergotamine O
: O
does O
ergotamine O
cross O
the O
blood O
brain O
barrier?Two O
migraine O
patients O
were O
studied O
by O
in O
vivo O
SPECT O
using O
the O
dopamine B
D2-receptor I
specific O
radioligand O
123I-3-iodo-6-methoxybenzamide O
( O
123I-IBZM O
during O
ergotamine O
abuse O
and O
after O
withdrawal O
. O
Results O
were O
compared O
with O
15 O
healthy O
controls O
. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O
rate O
density O
were O
calculated O
as O
a O
semiquantitative O
measurement O
for O
striatal O
dopamine O
D2-receptor O
binding O
potential O
. O
No O
differences O
were O
found O
in O
striatal O
uptake O
of O
123I-IBZM O
between O
healthy O
controls O
and O
the O
patients O

ergotamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Dopamine B
D2-receptor I
imaging O
with O
123I-iodobenzamide O
SPECT O
in O
migraine O
patients O
abusing O
ergotamin O
 O
: O
does O
ergotamine O
cross O
the O
blood O
brain O
barrier?Two O
migraine O
patients O
were O
studied O
by O
in O
vivo O
SPECT O
using O
the O
dopamine O
D2-receptor O
specific O
radioligand O
123I-3-iodo-6-methoxybenzamide O
(123I-IBZM) O
during O
ergotamine O
abuse O
and O
after O
withdrawal O
. O
Results O
were O
compared O
with O
15 O
healthy O
controls O
. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O
rate O
density O
were O
calculated O
as O

ergotamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Dopamine O
D2-receptor O
imaging O
with O
123I-iodobenzamide O
SPECT O
in O
migraine O
patients O
abusing O
ergotamine O
: O
does O
ergotamine O
cross O
the O
blood O
brain O
barrier?Two O
migraine O
patients O
were O
studied O
by O
in O
vivo O
SPECT O
using O
the O
dopamine B
D2-receptor I
specific O
radioligand O
123I-3-iodo-6-methoxybenzamide O
(123I-IBZM) O
during O
ergotamine O
abuse O
and O
after O
withdrawal O
. O
Results O
were O
compared O
with O
15 O
healthy O
controls O
. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O
rate O
density O
were O
calculated O
as O
a O
semiquantitative O
measurement O
for O
striatal O
dopamine O
D2-receptor O
binding O
potential O
. O
No O
differences O
were O
found O
in O
striatal O
uptake O
of O
123I-IBZM O
between O
healthy O
controls O
and O
the O
patients O
when O
on O

cirazoline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 B
imidazol(in)e I
receptor I
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 B
imidazol(in)e I
receptor I
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O

moxonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 B
imidazol(in)e I
receptor I
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O

clonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 B
imidazol(in)e I
receptor I
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O
amiloride O
> O
moxonidine O
> O
clonidine O
 O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline O
receptors O
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O

moxonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
binding O
studies O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O

clonidine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O

cirazoline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
presence O
of O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O

IDX O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
a O
10 O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride) O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O
> O
IDX O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
microM O
norepinephrine O
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O
plasma O
membranes O
for O
[125I]PIC O
. O
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC O
binding O
site O
were O
highly O
comparable O
to O
human B
subtype-I1 I
imidazol(in)e I
receptor I
sites O
in O
the O
brain O
stem O
(rank O
order O
: O
moxonidine O
> O
clonidine O
> O
cirazoline O
> O
IDX O
> O
amiloride O
 O
. O
However O
, O
the O
minor O
component O
of O
[125I]PIC O
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney O
, O
having O
low O
affinities O
for O
all O
compounds O
tested O
, O
except O
guanabenz O
. O
Finally O
, O
a O
third O
nonadrenergic O
internal O
membrane O
site O
, O
labeled O
by O
[3H]IDX O
, O
was O
consistent O
with O
a O
subtype-I2 O
imidazol(in)e O
receptor O
site O
(rank O
order O
: O
cirazoline O
> O
IDX O
>> O

clonidine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline B
receptors I
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine O
and O
endogenous O
clonidine O
displacing O
substance(s) O
, O
and O
may O
serve O
as O
markers O
of O
imidazoline O
receptors O
in O
humans O
. O

clonidine O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
clonidine) O
. O
Thus O
, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants O
, O
human O
platelets O
appear O
to O
possess O
imidazoline B
receptors I
(subtype-I1 O
imidazol(in)e O
receptor O
and O
subtype-I2 O
imidazol(in)e O
receptor) O
, O
plus O
a O
novel O
guanabenz-sensitive O
site O
, O
as O
well O
as O
an O
alpha-2A O
adrenoceptor O
. O
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine O
and O
endogenous O
clonidine-displacing O
substance(s) O
, O
and O
may O
serve O
as O
markers O
of O
imidazoline O
receptors O
in O
humans O
. O

monoamines O
acts O
as O
NOT O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine-sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 B
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O
transporters O
. O
Interestingly O
, O
the O
pharmacological O
properties O
of O
dSERT1 O
, O
including O
sensitivity O
to O
antidepressants O
, O
are O
more O
similar O
to O
those O
of O
mammalian O
catecholamine O
transporters O
than O
to O
mammalian O

cocaine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
cocain O
-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine-sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 O
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O

Na+ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine-sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 B
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O
transporters O
. O
Interestingly O
, O
the O
pharmacological O
properties O
of O
dSERT1 O
, O
including O
sensitivity O
to O
antidepressants O
, O
are O
more O
similar O
to O
those O
of O
mammalian O
catecholamine O
transporters O
than O
to O
mammalian O
5HT O
transporters O
. O
Two-electrode O

Cl- O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine-sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 B
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O
transporters O
. O
Interestingly O
, O
the O
pharmacological O
properties O
of O
dSERT1 O
, O
including O
sensitivity O
to O
antidepressants O
, O
are O
more O
similar O
to O
those O
of O
mammalian O
catecholamine O
transporters O
than O
to O
mammalian O
5HT O
transporters O
. O
Two-electrode O
voltage-clamp O
analysis O

cocaine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine O
sensitive O
, O
high-affinity O
Drosophila O
serotonin O
(5-hydroxytryptamine; O
5HT) O
transporter O
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 B
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O

cocaine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
A O
cocaine-sensitive O
Drosophila O
serotonin O
transporter O
: O
cloning O
, O
expression O
, O
and O
electrophysiological O
characterization.A O
cocaine O
sensitive O
, O
high-affinity O
Drosophila B
serotonin I
(5-hydroxytryptamine; I
5HT) I
transporter I
cDNA O
, O
denoted O
dSERT1 O
, O
was O
isolated O
and O
characterized O
in O
oocytes O
. O
dSERT1 O
shows O
little O
transport O
of O
other O
monoamines O
and O
is O
Na+ O
and O
Cl- O
dependent O
. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 O
and O
mammalian O
5HT O
, O
norepinephrine O
, O
and O
dopamine O

GCS O
acts O
as O
NOT O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O

GCS O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 B
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O

GCS O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R B
alpha I
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O

DEX O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 B
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

DEX O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R B
alpha I
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O

DEX O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma B
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O

DEX O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 B
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
( O
DEX O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 B
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
( O
DEX O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 B
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
( O
DEX O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma B
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O

GCS O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 B
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O

GCS O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O

GCS O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones O
, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 B
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 B
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 O
production O
and O
IL-2R B
alpha I
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O
the O
effects O
of O
GCS O
on O
IL-2 B
production O
and O
IL-2R O
alpha O
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 O
producers O
DEX O
blocked O
IL-2 O
production O
and O
decreased O
IL-2R O
alpha O
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 O
producers O
DEX O
inhibited O
IL-2 O
production O
partially O
and O
enhanced O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 B
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 O
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 B
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 O
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

DEX O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
IL-2R O
alpha O
expression O
and O
proliferation O
. O
Anti-IL-2 O
and O
anti-IL2R O
alpha O
blocked O
the O
DEX-induced O
increase O
in O
proliferation O
. O
High O
levels O
of O
added O
IL-2 O
induced O
the O
second O
type O
of O
response O
. O
In O
conclusion O
, O
the O
production O
of O
IL-4 O
and O
IL-5 O
by O
T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX O
than O
that O
of O
IFN-gamma O
, O
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma O
. O
The O
differential O
effects O
of O
DEX O
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 O
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids O
. O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 B
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 B
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O

Dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma B
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O

DEX O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
( O
DEX O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O
clones O

GCS O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
Th1 O
profile O
through O
two O
mechanisms.Glucocorticosteroids O
(GCS) O
are O
beneficial O
in O
allergic O
asthma O
. O
GCS O
therapy O
results O
in O
reduced O
mRNA O
expression O
of O
interleukin-4 O
(IL-4) O
and O
IL-5 O
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines B
by O
GCS O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O

Dexamethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma O
. O
In O
vitro O
studies O
with O
blood-derived O
T O
cells O
, O
however O
, O
show O
inhibition O
of O
all O
three O
cytokines O
by O
GCS O
. O
We O
studied O
the O
effects O
of O
GCS O
on O
T O
cells O
from O
BAL O
in O
vitro O
, O
namely O
Th0- O
, O
Th1 O
, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones O
. O
Dexamethasone O
(DEX) O
inhibited O
the O
anti-CD3-induced O
production O
of O
IL-4 O
, O
IL-5 O
and O
IFN-gamma O
in O
all O
20 O
clones O
tested O
. O
IFN-gamma O
production O
was O
inhibited O
significantly O
less O
than O
IL-4 O
and O
IL-5 O
. O
DEX O
enhanced O
the O
ratio O
IFN-gamma/IL-4 O
(mean O
+/- O
SEM O
: O
control O
, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX O
, O
55.0 O
+/- O
27.5 O
, O
P<0.005) O
. O
Interestingly O
, O
two O
categories O
of O

CP O
55,940 O
acts O
as O
NOT O
for O
what O
entity O
? O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 B
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O

CP O
55,940 O
acts O
as O
NOT O
for O
what O
entity O
? O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 B
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

SR O
141716A O
acts O
as O
NOT O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 B
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O

cysteine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
CB1 O
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 B
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O

serine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 B
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 O
domain O
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 B
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
. O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 B
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716 O
.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O

CP O
55,940 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 B
domain I
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O
binding O
, O
but O
replacement O
of O
those O
in O
CB1 O
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm O
. O
The O
e2 B
domain I
thus O
plays O
some O
role O
in O
CP O
55,940 O
binding O
but O
none O
in O
SR O
141716A O
recognition O
, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices O
. O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 B
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 O
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716A.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid B
receptor I
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O
CB1 O
implicated O

SR O
141716A O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
were O
transiently O
expressed O
in O
COS-3 O
cells O
, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR O
141716A O
and O
with O
CP O
55,940 O
, O
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors O
. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 B
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR O
141716A O
The O
CB1 O
and O
CB2 O
second O
extracellular O
loops O
, O
e2 O
, O
were O
exchanged O
, O
modifications O
that O
had O
no O
effect O
on O
SR O
141716A O
binding O
in O
the O
CB1 O
variant O
but O
that O
eliminated O
CP O
55,940 O
binding O
in O
both O
mutants O
. O
The O
replacement O
of O
the O
conserved O
cysteine O
residues O
in O
e2 O
of O
CB2 O
by O
serine O
also O
eliminated O
CP O
55,940 O

SR O
141716A O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Structural O
features O
of O
the O
central O
cannabinoid O
CB1 B
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 O
antagonist O
SR O
141716 O
.The O
antagonist O
SR O
141716A O
has O
a O
high O
specificity O
for O
the O
central O
CB1 O
cannabinoid O
receptor O
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 O
receptor O
, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships O
. O
From O
binding O
experiments O
with O
mutated O
CB1 O
and O
with O
chimeric O
CB1/CB2 O
receptors O
we O
have O
begun O
to O
identify O
the O

fluticasone O
propionate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
therapy O
for O
bronchial O
asthma O
and O
allergic O
rhinitis O
. O
This O
agent O
has O
a O
good O
safety O
profile O
with O
a O
low O
propensity O
for O
systemic O
side O
effects O
, O
such O
as O
suppression O
of O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
, O
and O
a O
low O
incidence O
of O
local O
side O
effects O
such O
as O
pruritus O
, O
burning O
, O
or O
skin O
atrophy O
. O
The O
pharmacologic O
properties O
of O
fluticasone O
propionate O
including O
high O
lipophilicity O
, O
high O
selectivity O
and O
affinity O
for O
the O
glucocorticoid O
receptor O
, O
low O
systemic O
absorption O
, O
and O
rapid O
metabolism O
and O
clearance-combine O
to O
give O
fluticasone O
propionate O
a O
high O
therapeutic O
index O
. O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activated O
CA B
I I
and O
CA O
II O
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA O
I O
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O
by O
the O
pH O
modifications O
induced O
by O
CA O
activation O
. O
In O
this O
way O
, O
cyclooxygenase O
, O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
activated O
CA O
I O
and O
CA B
II I
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA O
I O
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O
by O
the O
pH O
modifications O
induced O
by O
CA O
activation O
. O
In O
this O
way O
, O
cyclooxygenase O
, O

Ca O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
effects O
on O
these O
isozymes O
of O
NSAIDs O
associated O
to O
histamine O
, O
Ca O
, O
PGE2 O
and O
acetazolamide O
. O
The O
results O
show O
that O
the O
NSAIDs O
used O
here O
, O
which O
reduce O
the O
activity O
of O
cyclooxygenase O
and O
PG O
production O
, O
activated O
CA O
I O
and O
CA B
II I
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA O
I O
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O

acetazolamide O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
NSAIDs O
used O
here O
, O
which O
reduce O
the O
activity O
of O
cyclooxygenase O
and O
PG O
production O
, O
activated O
CA B
I I
and O
CA O
II O
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA O
I O
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O

acetazolamide O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
NSAIDs O
used O
here O
, O
which O
reduce O
the O
activity O
of O
cyclooxygenase O
and O
PG O
production O
, O
activated O
CA O
I O
and O
CA B
II I
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA O
I O
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA B
I I
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O
by O
the O
pH O
modifications O
induced O
by O
CA O
activation O
. O
In O
this O
way O
, O
cyclooxygenase O
, O
inhibition O
occurs O
"via O
CA," O
with O
the O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type O
. O
Histamine O
and O
Ca O
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA O
II O
. O
Association O
of O
PGE2 O
or O
acetazolamide O
to O
NSAIDs O
reduced O
NSAID-induced O
activation O
of O
CA O
I O
and O
CA O
II O
. O
Indomethacin O
abolished O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
I O
and O
CA O
II O
. O
Our O
data O
imply O
that O
between O
CA O
and O
cyclooxygenase O
there O
is O
an O
inverse O
relationship O
, O
CA O
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase O
activity O
, O
a O
reduction O
achieved O
by O
the O
pH O
modifications O
induced O
by O
CA O
activation O
. O
In O
this O
way O
, O
cyclooxygenase O
, O
inhibition O
occurs O
"via O
CA," O
with O
the O

prostaglandins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic B
anhydrase I
by O
a O
direct O
mechanism O
of O
action.Previous O
studies O
by O
this O
research O
team O
proved O
that O
vasodilating O
prostaglandins O
(PGs) O
E1 O
, O
E2 O
and O
I2 O
inhibit O
carbonic O
anhydrase O
(CA) O
in O
vitro O
and O
in O
vivo O
, O
which O
suggested O
involvement O
of O
CA O
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs O
. O
Relying O
on O
these O
findings O
, O
as O
well O
as O
on O
our O
clinical O
observations O
, O

prostaglandins O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic O
anhydrase O
by O
a O
direct O
mechanism O
of O
action.Previous O
studies O
by O
this O
research O
team O
proved O
that O
vasodilating O
prostaglandins O
(PGs) O
E1 O
, O
E2 O
and O
I2 O
inhibit O
carbonic O
anhydrase O
(CA) O
in O
vitro O
and O
in O
vivo O
, O
which O
suggested O
involvement O
of O
CA B
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs O
. O
Relying O
on O
these O
findings O
, O
as O
well O
as O
on O
our O
clinical O
observations O
, O

PGs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic B
anhydrase I
by O
a O
direct O
mechanism O
of O
action.Previous O
studies O
by O
this O
research O
team O
proved O
that O
vasodilating O
prostaglandins O
( O
PGs O
E1 O
, O
E2 O
and O
I2 O
inhibit O
carbonic O
anhydrase O
(CA) O
in O
vitro O
and O
in O
vivo O
, O
which O
suggested O
involvement O
of O
CA O
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs O
. O
Relying O
on O
these O
findings O
, O
as O
well O
as O
on O
our O
clinical O
observations O
, O
we O

PGs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic O
anhydrase O
by O
a O
direct O
mechanism O
of O
action.Previous O
studies O
by O
this O
research O
team O
proved O
that O
vasodilating O
prostaglandins O
( O
PGs O
E1 O
, O
E2 O
and O
I2 O
inhibit O
carbonic O
anhydrase O
(CA) O
in O
vitro O
and O
in O
vivo O
, O
which O
suggested O
involvement O
of O
CA B
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs O
. O
Relying O
on O
these O
findings O
, O
as O
well O
as O
on O
our O
clinical O
observations O
, O
we O

prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potent O
, O
insurmountable O
antagonist O
of O
noradrenaline-mediated O
contractions O
of O
human O
prostate O
, O
yielding O
an O
approximate O
pA2 O
estimate O
of O
9.8 O
at O
1 O
nM O
. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker O
. O
SL O
89,0591 O
, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha O
1A O
binding O
affinities O
. O
The O
affinity O
estimate O
for O
prazosin O
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha B
1A I
adrenoceptors I
and O
RS O
17053 O
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human O
alpha O
1A O
adrenoceptors O
. O
5 O
. O
In O
the O
anaesthetized O
dog O
, O

(+)-Tamsulosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O

RS O
17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
1 O
nM O
. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker O
. O
SL O
89,0591 O
, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha O
1A O
binding O
affinities O
. O
The O
affinity O
estimate O
for O
prazosin O
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha O
1A O
adrenoceptors O
and O
RS O
17053 O
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human O
alpha O
1A O
adrenoceptors O
. O
5 O
. O
In O
the O
anaesthetized O
dog O
, O
in O
vivo O
pseudo O
"pA2' O
values O
showed O
that O
doxazosin O
, O
(+)- O
and O
(-)-tamsulosin O
inhibited O
phenylephrine-induced O
increases O
in O
prostatic O
and O
blood O

quinazoline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
1A O
, O
alpha O
1B O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O

(-)-tamsulosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O

prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
1B O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O

doxazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
alpha O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O

alfuzosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
1D O
adrenoceptors O
and O
against O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
and O
human O
prostate O
. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O

RS O
17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha B
1D I
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O

RS O
17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha B
1A I
adrenoceptors I
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O

RS O
17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha B
1B I
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O

SL O
89,0591 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O

Rec O
15/2739 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O

SNAP O
1069 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O

RS O
17053 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O
15/2739 O
> O
RS O

noradrenaline O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
moderately O
selective O
(3 O
and O
6 O
fold O
respectively) O
for O
prostatic O
pressure O
relative O
to O
blood O
pressure O
. O
Rec O
15/2739 O
was O
a O
more O
potent O
antagonist O
of O
phenylephrine-mediated O
increases O
in O
prostatic O
pressure O
("pA2' O
= O
8.74) O
compared O
to O
blood O
pressure O
("pA2' O
= O
7.51) O
. O
6 O
. O
Data O
in O
this O
study O
suggest O
that O
the O
alpha B
1 I
adrenoceptor I
mediating O
noradrenaline O
induced O
contractions O
of O
human O
prostate O
, O
whilst O
having O
some O
of O
the O
characteristics O
of O
an O
alpha O
1A O
adrenoceptor O
, O
cannot O
be O
satisfactorily O
aligned O
with O
cloned O
alpha O
1A O
, O
alpha O
1B O
or O
alpha O
1D O
adrenoceptors O
. O
In O
addition O
, O
studies O
in O
the O
anaesthetized O
dog O
have O
shown O
that O
agents O
having O
high O
affinity O
and O
selectivity O
for O
prostatic O
alpha O

Indoramin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O

SNAP O
1069 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
was O
determined O
in O
an O
anaesthetized O
dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O

Rec O
15/2739 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
increases O
in O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O

WB O
4101 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
blood O
pressure O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O

SL O
89,0591 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
prostatic O
pressure O
. O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O

(+)- O
and O
(-)- O
tamsulosin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
2 O
. O
The O
quinazoline O
antagonists O
, O
prazosin O
, O
doxazosin O
and O
alfuzosin O
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human O
alpha O
1 O
adrenoceptors O
. O
Indoramin O
and O
SNAP O
1069 O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1B O
adrenoceptors O
relative O
to O
the O
alpha O
1D O
subtype O
. O
Rec O
15/2739 O
, O
WB O
4101 O
, O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O

(+)-Tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
SL O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O

(-)-tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
89,0591 O
, O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O

SL O
89,0591 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(+)- O
and O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O

Rec O
15/2739 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(-)- O
tamsulosin O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O

SNAP O
1069 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
showed O
selectivity O
for O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O

RS O
17053 O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
alpha O
1A O
and O
alpha O
1D O
adrenoceptors O
relative O
to O
the O
alpha O
1B O
subtype O
. O
RS O
17053 O
showed O
high O
affinity O
and O
selectivity O
for O
alpha O
1A O
adrenoceptors O
(pKi O
8.6) O
relative O
to O
alpha O
1B O
(pKi O
= O
7.3) O
and O
alpha O
1D O
(pKi O
= O
7.1) O
subtypes O
. O
3 O
. O
(+)-Tamsulosin O
, O
(-)-tamsulosin O
, O
SL O
89,0591 O
, O
Rec O
15/2739 O
, O
SNAP O
1069 O
and O
RS O
17053 O
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated O
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human O
alpha O
1D O
adrenoceptors O
. O
The O
following O
rank O
order O
was O
obtained O
: O
prazosin O
= O
(-)-tamsulosin O
> O
doxazosin O
> O
SL O
89,0591 O
= O
(+)-tamsulosin O
> O
Rec O
15/2739 O
> O
RS O

cAMP O
acts O
as O
NOT O
for O
what O
entity O
? O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries O
, O
suggesting O
the O
alpha-2D O
adrenoceptor O
subtype O
mediates O
NO-induced O
relaxation O
in O
rat O
arteries O
. O
We O
used O
forskolin O
to O
oppose O
alpha-2 O
adrenoceptor-mediated O
inhibition O
of O
cAMP O
formation O
by O
directly O
stimulating O
cAMP O
formation O
in O
endothelium O
. O
Forskolin O
did O
not O
affect O
the O
relaxant O
response O
to O
UK14,304 O
, O
suggesting O
that O
cAMP O
is O
not O
involved O
in O
the O
coupling O
of O
alpha-2 B
adrenoceptors I
to O
nitric O
oxide-induced O
vascular O
relaxation O
. O

rauwolscine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
> O
epinephrine O
(F) O
> O
norepinephrine O
(F) O
. O
Affinities O
(Ka) O
of O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D B
adrenoceptor I
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O

WB-4101 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(F) O
> O
norepinephrine O
(F) O
. O
Affinities O
(Ka) O
of O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D B
adrenoceptor I
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O

SKF-104078 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
norepinephrine O
(F) O
. O
Affinities O
(Ka) O
of O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D B
adrenoceptor I
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O

spiroxatrine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Affinities O
(Ka) O
of O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D B
adrenoceptor I
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O

prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
alpha-2 O
adrenoceptor O
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries O
. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A O
adrenoceptor O
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D B
adrenoceptor I
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries O
, O
suggesting O
the O

rauwolscine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A B
adrenoceptor I
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D O
adrenoceptor O
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
, O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries O
, O
suggesting O
the O
alpha-2D O
adrenoceptor O
subtype O
mediates O
NO-induced O
relaxation O
in O
rat O
arteries O
. O
We O
used O
forskolin O
to O
oppose O
alpha-2 O
adrenoceptor-mediated O
inhibition O
of O
cAMP O
formation O
by O
directly O
stimulating O

WB-4101 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A B
adrenoceptor I
subtype O
. O
Ka O
values O
in O
nM O
for O
rauwolscine O
(19) O
, O
WB-4101 O
(265) O
, O
SKF-104078 O
(197) O
, O
spiroxatrine O
(128) O
, O
and O
prazosin O
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D O
adrenoceptor O
subtype O
. O
Ka O
values O
for O
rauwolscine O
and O
WB-4101 O
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A O
adrenoceptor O
subtype O
, O
were O
significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries O
, O
suggesting O
the O
alpha-2D O
adrenoceptor O
subtype O
mediates O
NO-induced O
relaxation O
in O
rat O
arteries O
. O
We O
used O
forskolin O
to O
oppose O
alpha-2 O
adrenoceptor-mediated O
inhibition O
of O
cAMP O
formation O
by O
directly O
stimulating O
cAMP O
formation O

Chlorpheniramine O
acts O
as O
NOT O
for O
what O
entity O
? O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT B
receptor I
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O

Epinastine O
acts O
as O
NOT O
for O
what O
entity O
? O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance B
P I
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O

Epinastine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic B
receptors I
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O

Epinastine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin B
(5-HT) I
receptor I
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O

WAL O
801CL O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
( O
WAL O
801CL O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic B
receptors I
and O
various O
serotonin O
(5-HT) O
receptor O
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O

WAL O
801CL O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801CL) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
( O
WAL O
801CL O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors O
, O
including O
alpha-adrenergic O
receptors O
and O
various O
serotonin B
(5-HT) I
receptor I
subtypes O
. O
It O
is O
used O
in O
asthma O
treatment; O
however O
, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined O
. O
We O
have O
investigated O
whether O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O

WAL O
801CL O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Epinastine O
(WAL O
801C O
) O
modulates O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like O
receptor.Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways O
, O
in O
vitro O
, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings O
. O
Epinastine O
(WAL O
801CL) O
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O

epinastine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 O
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

epinastine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
although O
identified O
as O
a O
5-HT O
antagonist O
, O
acts O
as O
a O
5-HT1 B
agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like O
receptor O
, O
located O
to O
sensory O
nerves O
. O

epinastine O
acts O
as O
AGONIST-INHIBITOR O
for O
what O
entity O
? O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O

epinastine O
acts O
as O
AGONIST-INHIBITOR O
for O
what O
entity O
? O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 B
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O

methysergide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O

methysergide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
epinastine O
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 B
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O

methiothepin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O

methiothepin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro O
, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism O
. O
Epinastine O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 B
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O

tropisetron O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 B
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O

ketanserin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
of O
the O
noncholinergic O
contraction O
, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 B
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O

thioperamide O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM O
. O
Pretreatment O
of O
the O
tissues O
with O
combined O
5-HT1/5-HT2 O
antagonists O
, O
methysergide O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine B
H3 I
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine O
H1 O
receptor O
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O

Chlorpheniramine O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(1 O
microM) O
or O
methiothepin O
(0.1 O
microM) O
, O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine O
on O
the O
noncholinergic O
contraction O
. O
Pretreatment O
with O
tropisetron O
(1 O
microM) O
, O
a O
5-HT3 O
antagonist O
, O
ketanserin O
(10 O
microM) O
, O
a O
5-HT2 O
antagonist O
, O
thioperamide O
(10 O
microM) O
, O
a O
histamine O
H3 O
antagonist O
, O
or O
phentolamine O
(10 O
microM) O
, O
an O
alpha-adrenergic O
antagonist O
, O
however O
, O
had O
no O
effect O
. O
Chlorpheniramine O
(10 O
microM) O
, O
another O
histamine B
H1 I
receptor I
antagonist O
without O
significant O
5-HT O
receptor O
binding O
affinity O
, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction O
. O
Epinastine O
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance O
P O
(0.01-10 O
microM) O
. O
These O
results O
suggest O
that O
epinastine O
, O
although O
identified O
as O
a O
5-HT O
antagonist O
, O

inositol O
phosphates O
acts O
as O
NOT O
for O
what O
entity O
? O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol O
monophosphate O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin- O
and O
oxymetazoline-sensitive O
subtype O
of O
alpha O
1-adrenoceptors O
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphates O

oxymetazoline O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha B
1A-adrenoceptor I
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha O
1-adrenoceptors O
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
. O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O

(+/-)-bupranolol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha B
1-adrenoceptors I
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
. O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner O
, O
the O
slope O
of O
the O
regression O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O

S(-)-timolol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha B
1-adrenoceptors I
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner O
, O
the O
slope O
of O
the O
regression O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O
at O
10 O

chlorethylclonidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha B
1B-adrenoceptors I
by O
treatment O
with O
chlorethylclonidine O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O

Phenylephrine O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
, O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha B
1-adrenoceptors I
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O
in O
the O
presence O
of O
either O
(+/-)-bupranolol O
or O
S(-)-timolol O
. O
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin O
on O
the O
effect O
of O
phenylephrine O
was O
dependent O
or O
the O
concentration O
applied O
: O
(+/-)-tamsulosin O
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner O
, O
the O
slope O
of O

oxymetazoline O
acts O
as O
AGONIST O
for O
what O
entity O
? O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol O
monophosphate O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin- O
and O
oxymetazoline O
sensitive O
subtype O
of O
alpha O
1-adrenoceptors O
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphates O
. O

phenylephrine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
the O
pA2 O
value O
being O
9.12; O
at O
10 O
nM O
, O
it O
shifted O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha B
1B-adrenoceptors I
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O

(+/-)-tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
(+/-)-tamsulosin O
, O
an O
alpha B
1A-adrenoceptor I
antagonist O
, O
inhibits O
the O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol O
phosphates O
in O
rabbit O
heart.The O
influence O
of O
(+/-)-tamsulosin O
a O
selective O
alpha O
1A-adrenoceptor O
antagonist O
, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol O
phosphates O
that O
are O
induced O
via O
alpha O
1-adrenoceptors O
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha O
1A-adrenoceptor O
ligand O
oxymetazoline O
in O
the O
rabbit O
ventricular O
myocardium O
. O
Phenylephrine O
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha O
1-adrenoceptors O

(+/-)-tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol O
monophosphate O
induced O
by O
phenylephrine O
. O
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect O
, O
mediated O
via O
(+/-)-tamsulosin O
and O
oxymetazoline-sensitive O
subtype O
of O
alpha O
1-adrenoceptors O
, O
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol O
phosphates O
. O

(+/-)-Tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O
at O
10 O
nM O
, O
it O
shifted O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha B
1B-adrenoceptors I
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
, O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O

(+/-)-Tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
less O
than O
unity O
. O
At O
100 O
nM O
and O
higher O
, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine O
. O
(+/-)-Tamsulosin O
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
even O
after O
inactivation O
of O
alpha O
1B-adrenoceptors O
by O
treatment O
with O
chlorethylclonidine O
, O
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive O
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine O
. O
(+/-)-Tamsulosin O
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O
the O
positive O
inotropic O
effect O
mediated O
by O
alpha O
1-adrenoceptors O
, O
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol O
phosphates O
that O
was O
induced O
by O
10 O
microM O
phenylephrine O
. O
Oxymetazoline O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine O
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O

risperidone O
acts O
as O
NOT O
for O
what O
entity O
? O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha B
1-adrenoceptors I
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

Prazosin O
acts O
as O
NOT O
for O
what O
entity O
? O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O

risperidone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

prazosin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O
confirmed O
, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype O
. O

prazosin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha B
1A-adrenoceptors I
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O
1-adrenoceptors O
could O
not O
be O

risperidone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidon O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O

2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O

WB O
4101 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
( O
WB O
4101 O
 O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O

5-methyl-urapidil O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O

indoramin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
antipsychotic O
drug O
, O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O

(+)-niguldipine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
risperidone O
, O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha O
1A-adrenoceptors O
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O

Risperidone O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O
were O
confirmed O
as O
selective O
for O
the O
alpha O
1A-adrenoceptor O
, O
whereas O
spiperone O
was O
weakly O
alpha O
1B-selective O
. O
Risperidone O
was O
equipotent O
to O
prazosin O
at O
alpha B
1A-adrenoceptors I
in O
rat O
vas O
deferens O
and O
kidney O
. O
However O
, O
at O
guinea-pig O
and O
mouse O
splenic O
alpha O
1B-adrenoceptors O
, O
the O
affinity O
values O
of O
risperidone O
were O
10-fold O
lower O
than O
those O
of O
prazosin O
. O
Thus O
, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone O
for O
the O
B O
subtype O
of O
alpha O

risperidone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O

risperidone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha B
1-adrenoceptor I
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O

risperidone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
In O
functional O
experiments O
, O
risperidone O
is O
selective O
, O
not O
for O
the O
B O
, O
but O
for O
the O
A O
subtype O
of O
alpha O
1-adrenoceptors.The O
potency O
of O
the O
antipsychotic O
drug O
, O
risperidone O
to O
antagonize O
alpha O
1A-adrenoceptor-mediated O
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney O
, O
and O
alpha O
1B-adrenoceptor-mediated O
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha O
1-adrenoceptor O
subtype-discriminating O
antagonists O
. O
Prazosin O
was O
found O
to O
be O
unselective; O
2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane O
(WB O
4101) O
, O
5-methyl-urapidil O
, O
indoramin O
and O
(+)-niguldipine O

quinine O
acts O
as O
NOT O
for O
what O
entity O
? O
This O
structural O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 O
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O
by O
TREK-1 B
are O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 O
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 O
activity O
such O
as O
quinine O
and O
quinidine O
. O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
. O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O

quinidine O
acts O
as O
NOT O
for O
what O
entity O
? O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 O
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O
by O
TREK-1 B
are O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 O
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 O
activity O
such O
as O
quinine O
and O
quinidine O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
. O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O
tissue O
has O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cloning O
, O
functional O
expression O
and O
brain O
localization O
of O
a O
novel O
unconventional O
outward O
rectifier O
K+ O
channel.Human O
TWIK-1 O
, O
which O
has O
been O
cloned O
recently O
, O
is O
a O
new O
structural O
type O
of O
weak O
inward O
rectifier O
K+ O
channel O
. O
Here O
we O
report O
the O
structural O
and O
functional O
properties O
of O
TREK-1 O
, O
a O
mammalian O
TWIK-1-related O
K+ O
channel O
. O
Despite O
a O
low O
amino O
acid O
identity O
between O
TWIK-1 B
and O
TREK-1 O
(approximately O
28%) O
, O
both O
channel O
proteins O
share O
the O
same O
overall O
structural O
arrangement O
consisting O
of O
two O
pore-forming O
domains O
and O
four O
transmembrane O
segments O
(TMS) O
. O
This O
structural O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 O
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Cloning O
, O
functional O
expression O
and O
brain O
localization O
of O
a O
novel O
unconventional O
outward O
rectifier O
K+ O
channel.Human O
TWIK-1 O
, O
which O
has O
been O
cloned O
recently O
, O
is O
a O
new O
structural O
type O
of O
weak O
inward O
rectifier O
K+ O
channel O
. O
Here O
we O
report O
the O
structural O
and O
functional O
properties O
of O
TREK-1 O
, O
a O
mammalian O
TWIK-1-related O
K+ O
channel O
. O
Despite O
a O
low O
amino O
acid O
identity O
between O
TWIK-1 O
and O
TREK-1 B
(approximately O
28%) O
, O
both O
channel O
proteins O
share O
the O
same O
overall O
structural O
arrangement O
consisting O
of O
two O
pore-forming O
domains O
and O
four O
transmembrane O
segments O
(TMS) O
. O
This O
structural O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 O
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O

K+ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
TREK-1 B
are O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 O
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 O
activity O
such O
as O
quinine O
and O
quinidine O
. O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
. O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O
tissue O
has O
been O
studied O
by O
in O
situ O
hybridization O
. O
TREK-1 O
expression O
is O
high O
in O
the O
olfactory O
bulb O
, O
hippocampus O
and O
cerebellum O
. O
These O
results O
provide O
the O
first O

Na+ O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 B
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 O
activity O
such O
as O
quinine O
and O
quinidine O
. O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O
tissue O
has O
been O
studied O
by O
in O
situ O
hybridization O
. O
TREK-1 O
expression O
is O
high O
in O
the O
olfactory O
bulb O
, O
hippocampus O
and O
cerebellum O
. O
These O
results O
provide O
the O
first O
evidence O
for O

quinine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
This O
structural O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 B
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O
by O
TREK-1 O
are O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 O
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 O
activity O
such O
as O
quinine O
and O
quinidine O
. O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
. O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O

quinidine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
similarity O
does O
not O
give O
rise O
to O
a O
functional O
analogy O
. O
K+ O
currents O
generated O
by O
TWIK-1 B
are O
inwardly O
rectifying O
while O
K+ O
currents O
generated O
by O
TREK-1 O
are O
outwardly O
rectifying O
. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS O
. O
TREK-1 O
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 O
activity O
such O
as O
quinine O
and O
quinidine O
Extensive O
inhibitions O
of O
TREK-1 O
activity O
are O
observed O
after O
activation O
of O
protein O
kinases O
A O
and O
C O
. O
TREK-1 O
currents O
are O
sensitive O
to O
extracellular O
K+ O
and O
Na+ O
. O
TREK-1 O
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain O
. O
Its O
localization O
in O
this O
latter O
tissue O
has O

remoxipride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 B
receptor I
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 B
receptor I
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O

perlapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 B
receptor I
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O

seroquel O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 B
receptor I
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O
5 O

melperone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 B
receptor I
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O
5 O
nM O
at O

dopamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
30 O
to O
90 O
nM) O
. O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine O
in O
the O
caudate O
or O
putamen O
. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O
5 O
nM O
at O
dopamine O
D2 O
receptors O
, O
making O
them O
more O
resistant O
to O
displacement O
by O
endogenous O
dopamine O
Finally O
, O
a O
relation O
was O
found O
between O
the O
neuroleptic O
doses O
for O
rat O
catalepsy O
and O
the O
D2:D4 O
ratio O
of O
the O
radioligand-independent O
K O
values O
for O
these O
two O
receptors O
. O
Thus O
, O
the O
atypical O
neuroleptics O
appear O
to O
fall O
into O
two O
groups O
, O
those O
that O
have O
a O
low O
affinity O
for O
dopamine B
D2 I
receptors I
and O
those O
that O
are O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
"zero" O
ligand O
solubility O
. O
The O
extrapolated O
value O
represents O
the O
radioligand-independent O
dissociation O
constant O
of O
the O
antipsychotic O
. O
These O
values O
are O
here O
given O
for O
dopamine O
D2 O
and O
D4 O
receptors O
, O
as O
well O
as O
for O
serotonin O
5-HT2A O
receptors O
. O
These O
values O
, O
moreover O
, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O

[3H]-clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
dopamine O
D2 O
and O
D4 B
receptors O
, O
as O
well O
as O
for O
serotonin O
5-HT2A O
receptors O
. O
These O
values O
, O
moreover O
, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
as O
well O
as O
for O
serotonin O
5-HT2A O
receptors O
. O
These O
values O
, O
moreover O
, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O

dopamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
serotonin O
5-HT2A O
receptors O
. O
These O
values O
, O
moreover O
, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O

clozapine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself O
. O
For O
example O
, O
clozapine O
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine O
D4 O
receptor O
, O
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine O
at O
D4 O
. O
However O
, O
because O
clozapine O
competes O
with O
endogenous O
dopamine O
, O
the O
in O
vivo O
concentration O
of O
clozapine O
(to O
occupy O
dopamine O
D4 O
receptors) O
can O
be O
derived O
to O
be O
about O
13 O
nM O
, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients O
. O
The O
atypical O
neuroleptics O
remoxipride O
, O
clozapine O
, O
perlapine O
, O
seroquel O
, O
and O
melperone O
had O
low O
affinity O
for O
the O
dopamine O
D2 O

naloxone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
beta-endorphin O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O
morphine O
have O
been O
found O
to O
increase O
, O
and O
higher O
doses O
of O
the O
opiate O
to O
decrease O
, O
alcohol O
consumption O
. O
Conversely O
, O
opioid O
antagonists O
such O
as O
naloxone O
and O
naltrexone O
(which O
bind O
to O
non-selectively O
opioid O
receptors) O
have O
been O
shown O
to O
decrease O
alcohol O
consumption O
under O
various O
experimental O
conditions O
. O
Similar O
results O
have O
been O
reported O
when O
selective O
mu- O
or O
delta-receptor O
antagonists O
are O
administered O
. O
Results O
obtained O
in O
genetic O
models O
of O
high O
preference O
for O
alcohol O
also O
support O
the O
view O
that O
alcohol O
intake O

naltrexone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O
morphine O
have O
been O
found O
to O
increase O
, O
and O
higher O
doses O
of O
the O
opiate O
to O
decrease O
, O
alcohol O
consumption O
. O
Conversely O
, O
opioid O
antagonists O
such O
as O
naloxone O
and O
naltrexone O
(which O
bind O
to O
non-selectively O
opioid O
receptors) O
have O
been O
shown O
to O
decrease O
alcohol O
consumption O
under O
various O
experimental O
conditions O
. O
Similar O
results O
have O
been O
reported O
when O
selective O
mu- O
or O
delta-receptor O
antagonists O
are O
administered O
. O
Results O
obtained O
in O
genetic O
models O
of O
high O
preference O
for O
alcohol O
also O
support O
the O
view O
that O
alcohol O
intake O
depends O
on O

alcohol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
evidence O
indicate O
that O
alcohol O
interferes O
with O
endogenous O
opioid O
mechanisms O
which O
are O
closely O
linked O
with O
dopamine O
transmission O
in O
the O
mesolimbic O
pathway O
. O
The O
view O
that O
condensation O
products O
of O
dopamine O
and O
alcohol-derived O
aldehyde O
(tetrahydroisoquinolines) O
play O
a O
role O
remains O
controversial O
. O
There O
is O
, O
however O
, O
much O
information O
on O
the O
direct O
(acute O
and O
chronic) O
effects O
of O
alcohol O
on O
the O
binding O
properties O
of O
opioid O
receptors O
, O
as O
well O
as O
modulation O
of O
opioid O
peptide O
synthesis O
and O
secretion O
(e.g O
. O
a O
suggested O
increase O
in O
beta-endorphin O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O

alcohol O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
evidence O
indicate O
that O
alcohol O
interferes O
with O
endogenous O
opioid O
mechanisms O
which O
are O
closely O
linked O
with O
dopamine O
transmission O
in O
the O
mesolimbic O
pathway O
. O
The O
view O
that O
condensation O
products O
of O
dopamine O
and O
alcohol-derived O
aldehyde O
(tetrahydroisoquinolines) O
play O
a O
role O
remains O
controversial O
. O
There O
is O
, O
however O
, O
much O
information O
on O
the O
direct O
(acute O
and O
chronic) O
effects O
of O
alcohol O
on O
the O
binding O
properties O
of O
opioid O
receptors O
, O
as O
well O
as O
modulation O
of O
opioid B
peptide I
synthesis O
and O
secretion O
(e.g O
. O
a O
suggested O
increase O
in O
beta-endorphin O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O

naltrexone O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O
morphine O
have O
been O
found O
to O
increase O
, O
and O
higher O
doses O
of O
the O
opiate O
to O
decrease O
, O
alcohol O
consumption O
. O
Conversely O
, O
opioid O
antagonists O
such O
as O
naloxone O
and O
naltrexone O
(which O
bind O
to O
non-selectively O
opioid O
receptors) O
have O
been O
shown O
to O
decrease O
alcohol O
consumption O
under O
various O
experimental O
conditions O
. O
Similar O
results O
have O
been O
reported O
when O
selective O
mu- O
or O
delta-receptor O
antagonists O
are O
administered O
. O
Results O
obtained O
in O
genetic O
models O
of O
high O
preference O
for O
alcohol O
also O
support O
the O
view O
that O
alcohol O
intake O
depends O
on O

alcohol O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
evidence O
indicate O
that O
alcohol O
interferes O
with O
endogenous O
opioid O
mechanisms O
which O
are O
closely O
linked O
with O
dopamine O
transmission O
in O
the O
mesolimbic O
pathway O
. O
The O
view O
that O
condensation O
products O
of O
dopamine O
and O
alcohol-derived O
aldehyde O
(tetrahydroisoquinolines) O
play O
a O
role O
remains O
controversial O
. O
There O
is O
, O
however O
, O
much O
information O
on O
the O
direct O
(acute O
and O
chronic) O
effects O
of O
alcohol O
on O
the O
binding O
properties O
of O
opioid O
receptors O
, O
as O
well O
as O
modulation O
of O
opioid O
peptide O
synthesis O
and O
secretion O
(e.g O
. O
a O
suggested O
increase O
in O
beta-endorphin B
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O

naloxone O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
in O
beta-endorphin O
release) O
. O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol O
, O
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol O
self-administration O
in O
rodents O
and O
primates O
. O
Low O
doses O
of O
morphine O
have O
been O
found O
to O
increase O
, O
and O
higher O
doses O
of O
the O
opiate O
to O
decrease O
, O
alcohol O
consumption O
. O
Conversely O
, O
opioid O
antagonists O
such O
as O
naloxone O
and O
naltrexone O
(which O
bind O
to O
non-selectively O
opioid O
receptors) O
have O
been O
shown O
to O
decrease O
alcohol O
consumption O
under O
various O
experimental O
conditions O
. O
Similar O
results O
have O
been O
reported O
when O
selective O
mu- O
or O
delta-receptor O
antagonists O
are O
administered O
. O
Results O
obtained O
in O
genetic O
models O
of O
high O
preference O
for O
alcohol O
also O
support O
the O
view O
that O
alcohol O
intake O

5-dimethylaminonaphthalene-1sulfonyl O
(dansyl) O
Glu-Gly-Arg-(DEGR)-chloromethylketone O
acts O
as O
PART-OF O
for O
what O
entity O
? O
exposure O
of O
the O
inter-EGF O
sequence O
Leu83-Leu88 O
in O
factor B
Xa I
mediates O
ligand O
binding O
to O
effector O
cell O
protease O
receptor-1.Binding O
of O
factor O
Xa O
to O
human O
umbilical O
vein O
endothelial O
cells O
(HUVEC) O
is O
contributed O
by O
effector O
cell O
protease O
receptor-1 O
(EPR-1) O
. O
The O
structural O
requirements O
of O
this O
recognition O
were O
investigated O
. O
Factor O
Xa O
or O
catalytically O
inactive O
5-dimethylaminonaphthalene-1sulfonyl O
(dansyl) O
Glu-Gly-Arg-(DEGR)-chloromethylketone O
factor O
Xa O
bound O
indistinguishably O
to O
HUVEC O
and O
EPR-1 O
transfectants O
, O
and O
inhibited O
equally O
well O
the O
binding O
of O
125I-factor O
Xa O
to O
these O
cells O
. O
Similarly O
, O
factor O
Xa O
active O
site O
inhibitors O
TAP O
or O
NAP5 O
did O
not O
reduce O
ligand O
binding O
to O
EPR-1 O
. O
A O
factor O
X O
peptide O
duplicating O
the O
inter-EGF O
sequence O
Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- O
(Gly) O
inhibited O

Gly O
acts O
as O
PART-OF O
for O
what O
entity O
? O
5-dimethylaminonaphthalene-1sulfonyl O
(dansyl) O
Glu-Gly-Arg-(DEGR)-chloromethylketone-factor O
Xa O
bound O
indistinguishably O
to O
HUVEC O
and O
EPR-1 O
transfectants O
, O
and O
inhibited O
equally O
well O
the O
binding O
of O
125I-factor O
Xa O
to O
these O
cells O
. O
Similarly O
, O
factor O
Xa O
active O
site O
inhibitors O
TAP O
or O
NAP5 O
did O
not O
reduce O
ligand O
binding O
to O
EPR-1 O
. O
A O
factor B
X I
peptide O
duplicating O
the O
inter-EGF O
sequence O
Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- O
( O
Gly O
inhibited O
factor O
V/Va-independent O
prothrombin O
activation O
by O
HUVEC O
and O
blocked O
binding O
of O
125I-factor O
Xa O
to O
these O
cells O
in O
a O
dose-dependent O
manner O
(IC50 O
approximately O
20-40 O
microM) O
. O
In O
contrast O
, O
none O
of O
the O
other O
factor O
X O
peptides O
tested O
or O
a O
control O
peptide O
with O
the O
inter-EGF O
sequence O
in O
scrambled O
order O
was O
effective O
. O
A O
recombinant O

sulfate O
acts O
as O
NOT O
for O
what O
entity O
? O
FGF O
species O
bind O
to O
tissue O
mast O
cells O
and O
to O
epithelial O
cell O
membranes O
. O
Binding O
to O
basement O
membrane O
heparan O
sulfate O
is O
tissue O
source O
dependent O
and O
specific O
. O
Although O
FGF-2 O
strongly O
binds O
to O
basement O
membrane O
heparan O
sulfate O
in O
skin O
and O
most O
other O
tissue O
sites O
examined O
, O
FGF-7 B
fails O
to O
bind O
to O
basement O
membrane O
heparan O
sulfate O
in O
most O
locations O
. O
However O
, O
in O
subendothelial O
matrix O
in O
blood O
vessels O
and O
in O
the O
basement O
membrane O
of O
a O
papillary O
renal O
cell O
carcinoma O
, O
strong O
FGF-7 O
binding O
is O
seen O
. O
In O
summary O
, O
distinct O
and O
specific O
affinities O
of O
heparan O
sulfates O
for O
different O
FGFs O
were O
identified O
that O
may O
affect O
growth O
factor O
activation O
and O
local O
distribution O
. O

sulfates O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
most O
other O
tissue O
sites O
examined O
, O
FGF-7 O
fails O
to O
bind O
to O
basement O
membrane O
heparan O
sulfate O
in O
most O
locations O
. O
However O
, O
in O
subendothelial O
matrix O
in O
blood O
vessels O
and O
in O
the O
basement O
membrane O
of O
a O
papillary O
renal O
cell O
carcinoma O
, O
strong O
FGF-7 O
binding O
is O
seen O
. O
In O
summary O
, O
distinct O
and O
specific O
affinities O
of O
heparan O
sulfates O
for O
different O
FGFs B
were O
identified O
that O
may O
affect O
growth O
factor O
activation O
and O
local O
distribution O
. O
Heparan O
sulfate O
may O
have O
a O
gatekeeper O
function O
to O
either O
restrict O
or O
permit O
diffusion O
of O
heparin-binding O
growth O
factors O
across O
the O
basement O
membrane O
. O

sulfates O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
through O
transmembrane O
receptor O
tyrosine O
kinases O
, O
but O
heparan O
sulfate O
is O
also O
required O
for O
signaling O
by O
members O
of O
the O
FGF O
family O
. O
In O
addition O
, O
heparan O
sulfate O
may O
be O
involved O
in O
determining O
tissue O
distribution O
of O
FGFs O
. O
Using O
biotinylated O
FGF-2 O
and O
FGF-7 O
(KGF) O
as O
probes O
, O
we O
have O
identified O
specific O
interactions O
between O
FGFs B
and O
heparan O
sulfates O
in O
human O
tissues O
. O
Both O
FGF O
species O
bind O
to O
tissue O
mast O
cells O
and O
to O
epithelial O
cell O
membranes O
. O
Binding O
to O
basement O
membrane O
heparan O
sulfate O
is O
tissue O
source O
dependent O
and O
specific O
. O
Although O
FGF-2 O
strongly O
binds O
to O
basement O
membrane O
heparan O
sulfate O
in O
skin O
and O
most O
other O
tissue O
sites O
examined O
, O
FGF-7 O
fails O
to O
bind O

sulfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(KGF) O
as O
probes O
, O
we O
have O
identified O
specific O
interactions O
between O
FGFs O
and O
heparan O
sulfates O
in O
human O
tissues O
. O
Both O
FGF O
species O
bind O
to O
tissue O
mast O
cells O
and O
to O
epithelial O
cell O
membranes O
. O
Binding O
to O
basement O
membrane O
heparan O
sulfate O
is O
tissue O
source O
dependent O
and O
specific O
. O
Although O
FGF-2 B
strongly O
binds O
to O
basement O
membrane O
heparan O
sulfate O
in O
skin O
and O
most O
other O
tissue O
sites O
examined O
, O
FGF-7 O
fails O
to O
bind O
to O
basement O
membrane O
heparan O
sulfate O
in O
most O
locations O
. O
However O
, O
in O
subendothelial O
matrix O
in O
blood O
vessels O
and O
in O
the O
basement O
membrane O
of O
a O
papillary O
renal O
cell O
carcinoma O
, O
strong O
FGF-7 O
binding O
is O
seen O
. O
In O
summary O
, O
distinct O
and O
specific O
affinities O

sulfate O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Differential O
binding O
of O
fibroblast O
growth O
factor-2 O
and O
-7 O
to O
basement O
membrane O
heparan O
sulfate O
: O
comparison O
of O
normal O
and O
abnormal O
human O
tissues.Fibroblast O
growth O
factors O
(FGFs) O
play O
multiple O
roles O
during O
development O
and O
in O
adult O
tissues O
as O
paracrine O
regulators O
of O
growth O
and O
differentiation O
. O
FGFs O
signal O
through O
transmembrane O
receptor O
tyrosine O
kinases O
, O
but O
heparan O
sulfate O
is O
also O
required O
for O
signaling O
by O
members O
of O
the O
FGF B
family O
. O
In O
addition O
, O
heparan O
sulfate O
may O
be O
involved O
in O
determining O
tissue O
distribution O
of O
FGFs O
. O
Using O
biotinylated O
FGF-2 O
and O
FGF-7 O
(KGF) O
as O
probes O
, O
we O
have O
identified O
specific O
interactions O
between O
FGFs O
and O
heparan O
sulfates O
in O
human O
tissues O
. O
Both O
FGF O
species O
bind O

Felodipine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
(PDE O
1A2) O
CaMPDE B
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O
but O
bring O
about O
different O
levels O
of O
enzyme O
inhibition O
, O
suggesting O
the O
possibility O
of O
designing O
specific O
drugs O
that O
can O
protect O
the O
enzyme O
from O
inhibition O
by O
dihydropyridine O
Ca2+-channel O
blockers O
. O

nicardipine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
CaMPDE B
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O
but O
bring O
about O
different O
levels O
of O
enzyme O
inhibition O
, O
suggesting O
the O
possibility O
of O
designing O
specific O
drugs O
that O
can O
protect O
the O
enzyme O
from O
inhibition O
by O
dihydropyridine O
Ca2+-channel O
blockers O
. O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CaMPDE O
exists O
as O
tissue-specific O
isozymes O
, O
and O
initially O
these O
isozymes O
were O
designated O
according O
to O
their O
respective O
subunit O
molecular O
mass O
. O
A O
variety O
of O
pharmacological O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel B
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O

nicardipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
as O
tissue-specific O
isozymes O
, O
and O
initially O
these O
isozymes O
were O
designated O
according O
to O
their O
respective O
subunit O
molecular O
mass O
. O
A O
variety O
of O
pharmacological O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel B
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O

felodipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE B
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O

nicardipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O

nicardipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O

nicardipine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel O
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE B
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE B
isozymes O
but O
bring O
about O
different O
levels O
of O
enzyme O
inhibition O
, O
suggesting O
the O
possibility O
of O
designing O
specific O
drugs O
that O
can O
protect O
the O
enzyme O
from O
inhibition O
by O
dihydropyridine O
Ca2+-channel O
blockers O
. O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
specific O
site O
, O
distinct O
from O
the O
active O
site O
on O
CaMPDE O
, O
that O
exhibits O
high-affinity O
binding O
of O
these O
drugs O
. O
Felodipine O
and O
nicardipine O
have O
similar O
affinities O
for O
60-kDa O
CaMPDE O
isozymes O
but O
bring O
about O
different O
levels O
of O
enzyme O
inhibition O
, O
suggesting O
the O
possibility O
of O
designing O
specific O
drugs O
that O
can O
protect O
the O
enzyme O
from O
inhibition O
by O
dihydropyridine O
Ca2+-channel B
blockers O
. O

dihydropyridine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Ca2+ O
second-messenger O
systems O
. O
CaMPDE O
exists O
as O
tissue-specific O
isozymes O
, O
and O
initially O
these O
isozymes O
were O
designated O
according O
to O
their O
respective O
subunit O
molecular O
mass O
. O
A O
variety O
of O
pharmacological O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE O
, O
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent O
association O
with O
the O
proteins O
. O
We O
have O
examined O
the O
effect O
of O
dihydropyridine O
Ca2+-channel B
blockers O
felodipine O
and O
nicardipine O
on O
CaMPDE O
. O
The O
results O
suggest O
that O
the O
63-kDa O
(PDE O
1B1) O
and O
60-kDa O
(PDE O
1A2) O
CaMPDE O
isozymes O
are O
inhibited O
by O
felodipine O
and O
nicardipine O
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ O
antagonists O
appear O
to O
counteract O
each O
other O
. O
This O
study O
further O
demonstrates O
the O
existence O
of O

zolmitriptan O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O
5HT1B/1D B
receptor O
partial O
agonist O
activity O
with O
robust O
oral O
pharmacokinetics O
and O
an O
ability O
to O
inhibit O
trigeminovascular O
activation O
centrally O
as O
well O
as O
peripherally O
in O
preclinical O
studies O
. O
Consistent O
with O
its O
selectivity O
for O
5HT1B/1D O
receptors O
, O
zolmitriptan O
produces O
constriction O
of O
various O
isolated O
blood O
vessels O
, O
most O
notably O
cranial O
arteries O
. O
In O
anaesthetized O
animals O
, O
these O
vascular O
effects O
manifest O
as O
a O
selective O
constriction O
of O
cranial O
arterio-venous O
anastomoses O
resulting O
in O
a O
redistribution O
of O
carotid O
arterial O
blood O
flow O
. O
This O
effect O
is O
produced O
without O
significant O
effects O
on O
heart O
rate O
, O
blood O
pressure O
or O
blood O

zolmitriptan O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
lungs O
. O
Zolmitriptan O
also O
inhibits O
trigeminal-evoked O
increases O
in O
cerebral O
blood O
flow O
in O
anaesthetized O
cats O
and O
blocks O
trigeminal-evoked O
plasma O
protein O
extravasation O
in O
the O
dura O
of O
guinea-pigs O
. O
These O
actions O
are O
consistent O
with O
a O
pre-junctional O
inhibition O
of O
neuropeptide O
release O
from O
perivascular O
afferents O
of O
the O
trigeminal O
nerve O
, O
as O
confirmed O
by O
independent O
studies O
showing O
that O
zolmitriptan O
blocks O
elevations O
of O
calcitonin-gene-related B
peptide I
in O
jugular O
venous O
blood O
during O
electrical O
stimulation O
of O
the O
trigeminal O
ganglion O
. O
In O
all O
of O
these O
effects O
, O
zolmitriptan O
is O
three O
to O
four O
times O
more O
potent O
than O
sumatriptan O
, O
but O
produces O
the O
same O
maximum O
response O
. O
Zolmitriptan O
crosses O
the O
intact O
blood-brain O
barrier O
to O
inhibit O
trigeminovascular O
activation O
in O
the O

311C90 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitriptan O
(Zomig; O
formerly O
311C90) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D O
agonist O
for O
migraine.Zolmitriptan O
(Zomig; O
formerly O
311C90 O
is O
a O
novel O
5-hydroxytryptamine B
(5HT)1B/1D I
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O
5HT1B/1D O
receptor O
partial O
agonist O
activity O
with O
robust O
oral O
pharmacokinetics O
and O
an O
ability O
to O

zolmitriptan O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitripta O
(Zomig; O
formerly O
311C90) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D B
agonist O
for O
migraine.Zolmitriptan O
(Zomig; O
formerly O
311C90) O
is O
a O
novel O
5-hydroxytryptamine O
(5HT)1B/1D O
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O

Zolmitriptan O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitriptan O
(Zomig; O
formerly O
311C90) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D O
agonist O
for O
migraine O
. O
Zolmitriptan O
(Zomig; O
formerly O
311C90) O
is O
a O
novel O
5-hydroxytryptamine B
(5HT)1B/1D I
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O
5HT1B/1D O
receptor O
partial O
agonist O
activity O
with O
robust O
oral O
pharmacokinetics O
and O

Zomig O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitriptan O
(Zomi O
; O
formerly O
311C90) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D B
agonist O
for O
migraine.Zolmitriptan O
(Zomig; O
formerly O
311C90) O
is O
a O
novel O
5-hydroxytryptamine O
(5HT)1B/1D O
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O

311C90 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitriptan O
(Zomig; O
formerly O
311C9 O
) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D B
agonist O
for O
migraine.Zolmitriptan O
(Zomig; O
formerly O
311C90) O
is O
a O
novel O
5-hydroxytryptamine O
(5HT)1B/1D O
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O

Zomig O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Pre-clinical O
pharmacology O
of O
zolmitriptan O
(Zomig; O
formerly O
311C90) O
, O
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D O
agonist O
for O
migraine.Zolmitriptan O
( O
Zomig O
formerly O
311C90) O
is O
a O
novel O
5-hydroxytryptamine B
(5HT)1B/1D I
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura O
. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O
5HT1B/1D O
receptor O
partial O
agonist O
activity O
with O
robust O
oral O
pharmacokinetics O
and O
an O

ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide-induced O
SRE O
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac B
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O

C2-ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Exogenous O
C2-ceramid O
activates O
c-fos O
serum O
response O
element O
via O
Rac-dependent O
signalling O
pathway.Ceramide O
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O

C2-ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 B
in O
C2-ceramide O
induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O

C2-ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 B
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

C2-ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

ceramide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide O
signalling O
to O
nucleus O
. O

C2-ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O
ceramide O
, O
activates O
c-fos O
serum O
response O
element O
(SRE) O
. O
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide O
caused O
the O
stimulation O
of O
c-fos O
SRE-dependent O
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide-induced O
signalling O
to O
SRE O
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O

ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
whether O
C2-ceramide O
, O
a O
cell O
permeable O
ceramide O
, O
activates O
c-fos O
serum O
response O
element O
(SRE) O
. O
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide O
caused O
the O
stimulation O
of O
c-fos O
SRE-dependent O
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide O
induced O
signalling O
to O
SRE B
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide-induced O
SRE O
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac O
activity O
is O

C2-ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O
transfection O
analysis O
. O
Next O
, O
we O
examined O
the O
role O
of O
Rho O
family O
GTPases O
in O
the O
ceramide-induced O
signalling O
to O
SRE B
activation O
. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42 O
, O
Rac1 O
or O
RhoA O
, O
C2-ceramide O
induced O
SRE O
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1 O
, O
suggesting O
that O
Rac O
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O

C2-ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Exogenous O
C2-ceramid O
activates O
c-fos B
serum I
response I
element I
via O
Rac-dependent O
signalling O
pathway.Ceramide O
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines O
. O
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide O
to O
the O
nucleus O
, O
in O
the O
present O
study O
, O
we O
examined O
whether O
C2-ceramide O
, O
a O
cell O
permeable O

C2-ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
the O
signalling O
cascade O
of O
ceramide O
to O
the O
nucleus O
. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac O
in O
the O
ceramide-signalling O
pathway O
, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine O
, O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase O
A2 O
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide O
induced O
SRE B
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O

ceramide O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
, O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide O
signalling O
to O
nucleus O
. O

arachidonic O
acid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2 O
, O
or O
co-transfection O
with O
antisense O
cytosolic O
phospholipase B
A2 I
(cPLA2) O
oligonucleotide O
repressed O
the O
C2-ceramide-induced O
SRE O
activation O
selectively O
, O
implying O
a O
critical O
role O
of O
cPLA2 O
in O
C2-ceramide-induced O
signalling O
to O
nucleus O
. O
Consistent O
with O
these O
results O
, O
the O
translocation O
of O
cPLA2 O
protein O
as O
well O
as O
the O
release O
of O
arachidonic O
acid O
a O
principal O
product O
of O
phospholipase O
A2 O
, O
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide O
in O
a O
Rac-dependent O
manner O
. O
Together O
, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac O
and O
subsequent O
activation O
of O
phospholipase O
A2' O
in O
ceramide-signalling O
to O
nucleus O
. O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
VIII O
exhibits O
stable O
interaction O
with O
protein O
chaperones O
identified O
as O
the O
immunoglobulin-binding O
protein O
(BiP) O
, O
calnexin O
and O
calreticulin O
. O
BiP O
is O
a O
peptide-dependent O
ATPase O
that O
interacts O
with O
exposed O
hydrophobic O
surfaces O
on O
unfolded O
proteins O
or O
unassembled O
protein O
subunits O
. O
A O
potential O
BiP B
binding I
site I
within O
factor O
VIII O
has O
been O
identified O
. O
Mutation O
of O
a O
single O
amino O
acid O
residue O
in O
the O
potential O
BiP O
binding O
site O
increased O
the O
secretion O
efficiency O
of O
factor O
VIII O
by O
threefold O
. O
Interestingly O
, O
the O
proposed O
BiP O
binding O
site O
is O
adjacent O
to O
a O
type-1 O
copper O
binding O
site O
within O
the O
A1 O
domain O
that O
is O
required O
for O
interaction O
between O
the O
factor O
VIII O
A1 O
domain O
and O
the O
A3 O
domain O
. O

Cu(I) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potential O
BiP O
binding O
site O
increased O
the O
secretion O
efficiency O
of O
factor O
VIII O
by O
threefold O
. O
Interestingly O
, O
the O
proposed O
BiP O
binding O
site O
is O
adjacent O
to O
a O
type-1 O
copper O
binding O
site O
within O
the O
A1 O
domain O
that O
is O
required O
for O
interaction O
between O
the O
factor O
VIII O
A1 O
domain O
and O
the O
A3 O
domain O
. O
We O
propose O
that O
Cu(I) O
binds O
the O
type-1 B
copper I
ion-binding I
site I
in O
the O
A1 O
domain O
and O
provides O
the O
essential O
requirement O
for O
a O
stable O
interaction O
between O
the O
heavy O
and O
light O
chains O
. O
Calnexin O
and O
calreticulin O
are O
transmembrane O
and O
lumenal O
proteins O
, O
respectively O
, O
localized O
to O
the O
endoplasmic O
reticulum O
, O
which O
associate O
transiently O
with O
many O
soluble O
and O
membrane O
glycoproteins O
during O

Cu(I) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
potential O
BiP O
binding O
site O
increased O
the O
secretion O
efficiency O
of O
factor O
VIII O
by O
threefold O
. O
Interestingly O
, O
the O
proposed O
BiP O
binding O
site O
is O
adjacent O
to O
a O
type-1 O
copper O
binding O
site O
within O
the O
A1 B
domain I
that O
is O
required O
for O
interaction O
between O
the O
factor O
VIII O
A1 O
domain O
and O
the O
A3 O
domain O
. O
We O
propose O
that O
Cu(I) O
binds O
the O
type-1 O
copper O
ion-binding O
site O
in O
the O
A1 O
domain O
and O
provides O
the O
essential O
requirement O
for O
a O
stable O
interaction O
between O
the O
heavy O
and O
light O
chains O
. O
Calnexin O
and O
calreticulin O
are O
transmembrane O
and O
lumenal O
proteins O
, O
respectively O
, O
localized O
to O
the O
endoplasmic O
reticulum O
, O
which O
associate O
transiently O
with O
many O
soluble O
and O
membrane O
glycoproteins O
during O

benserazide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase O
(COMT) O
. O
Because O
gastric O
AADC B
and O
COMT O
degrade O
levodopa O
, O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide O
 O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O
decarboxylation O
of O
exogenous O
levodopa O
to O
dopamine O
in O
the O
brain O
is O
unknown O
, O
most O
striatal O
AADC O
is O
located O
in O
nigrostriatal O
dopaminergic O
nerve O
terminals O
. O
Newly O
synthesized O
dopamine O
is O
stored O
in O
the O
terminals O
and O
then O
released O
, O
stimulating O
postsynaptic O

carbidopa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase O
(COMT) O
. O
Because O
gastric O
AADC B
and O
COMT O
degrade O
levodopa O
, O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
( O
carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O
decarboxylation O
of O
exogenous O
levodopa O
to O
dopamine O
in O
the O
brain O
is O
unknown O
, O
most O
striatal O
AADC O
is O
located O
in O
nigrostriatal O
dopaminergic O
nerve O
terminals O
. O
Newly O
synthesized O
dopamine O
is O
stored O
in O
the O
terminals O
and O
then O
released O
, O
stimulating O

Levodopa O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
dopaminergic O
agents O
in O
Parkinson's O
disease.As O
the O
substantia O
nigra O
degenerates O
in O
Parkinson's O
disease O
(PD) O
, O
the O
nigrostriatal O
pathway O
is O
disrupted O
, O
reducing O
striatal O
dopamine O
and O
producing O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid B
decarboxylase I
(AADC) O
and O
catechol-O-methyltransferase O
(COMT) O
. O
Because O
gastric O
AADC O
and O
COMT O
degrade O
levodopa O
, O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O

Levodopa O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
dopaminergic O
agents O
in O
Parkinson's O
disease.As O
the O
substantia O
nigra O
degenerates O
in O
Parkinson's O
disease O
(PD) O
, O
the O
nigrostriatal O
pathway O
is O
disrupted O
, O
reducing O
striatal O
dopamine O
and O
producing O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase O
(COMT) O
. O
Because O
gastric O
AADC B
and O
COMT O
degrade O
levodopa O
, O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O

Levodopa O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
dopaminergic O
agents O
in O
Parkinson's O
disease.As O
the O
substantia O
nigra O
degenerates O
in O
Parkinson's O
disease O
(PD) O
, O
the O
nigrostriatal O
pathway O
is O
disrupted O
, O
reducing O
striatal O
dopamine O
and O
producing O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase B
(COMT) O
. O
Because O
gastric O
AADC O
and O
COMT O
degrade O
levodopa O
, O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O

Levodopa O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
dopaminergic O
agents O
in O
Parkinson's O
disease.As O
the O
substantia O
nigra O
degenerates O
in O
Parkinson's O
disease O
(PD) O
, O
the O
nigrostriatal O
pathway O
is O
disrupted O
, O
reducing O
striatal O
dopamine O
and O
producing O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase O
(COMT) O
. O
Because O
gastric O
AADC O
and O
COMT B
degrade O
levodopa O
, O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O

levodopa O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
nigrostriatal O
pathway O
is O
disrupted O
, O
reducing O
striatal O
dopamine O
and O
producing O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase O
(COMT) O
. O
Because O
gastric O
AADC B
and O
COMT O
degrade O
levodopa O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O
decarboxylation O
of O
exogenous O
levodopa O
to O
dopamine O
in O
the O
brain O
is O
unknown O
, O
most O
striatal O
AADC O
is O
located O
in O
nigrostriatal O
dopaminergic O
nerve O
terminals O
. O
Newly O
synthesized O
dopamine O

levodopa O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
nigrostriatal O
pathway O
is O
disrupted O
, O
reducing O
striatal O
dopamine O
and O
producing O
PD O
symptoms O
. O
Although O
dopamine O
does O
not O
readily O
cross O
the O
blood-brain O
barrier O
, O
its O
precursor O
, O
levodopa O
, O
does O
. O
Levodopa O
is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid O
decarboxylase O
(AADC) O
and O
catechol-O-methyltransferase O
(COMT) O
. O
Because O
gastric O
AADC O
and O
COMT B
degrade O
levodopa O
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC O
(carbidopa O
or O
benserazide) O
, O
and O
inhibitors O
of O
COMT O
will O
also O
enter O
clinical O
use O
. O
Although O
the O
exact O
site O
of O
decarboxylation O
of O
exogenous O
levodopa O
to O
dopamine O
in O
the O
brain O
is O
unknown O
, O
most O
striatal O
AADC O
is O
located O
in O
nigrostriatal O
dopaminergic O
nerve O
terminals O
. O
Newly O
synthesized O
dopamine O

A77 O
1726 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
leflunomide O
in O
rheumatoid O
arthritis.Leflunomide O
, O
a O
novel O
drug O
with O
proven O
efficacy O
in O
rheumatoid O
arthritis O
, O
is O
an O
isoxazol O
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs O
. O
Leflunomide O
is O
rapidly O
metabolized O
to O
its O
active O
form O
, O
A77 O
1726 O
. O
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 O
1726 O
inhibition O
of O
dihydroorotate B
dehydrogenase I
(DHODH) O
and O
inhibition O
of O
tyrosine O
kinases O
. O
DHODH O
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 O
1726 O
than O
that O
of O
tyrosine O
kinases O
and O
is O
currently O
considered O
the O
major O
mode O
of O
action O
. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O
before O
proceeding O
from O
the O
G1 O
into O

A77 O
1726 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
leflunomide O
in O
rheumatoid O
arthritis.Leflunomide O
, O
a O
novel O
drug O
with O
proven O
efficacy O
in O
rheumatoid O
arthritis O
, O
is O
an O
isoxazol O
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs O
. O
Leflunomide O
is O
rapidly O
metabolized O
to O
its O
active O
form O
, O
A77 O
1726 O
. O
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 O
1726 O
inhibition O
of O
dihydroorotate O
dehydrogenase O
(DHODH) O
and O
inhibition O
of O
tyrosine O
kinases O
. O
DHODH B
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 O
1726 O
than O
that O
of O
tyrosine O
kinases O
and O
is O
currently O
considered O
the O
major O
mode O
of O
action O
. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O
before O
proceeding O
from O
the O
G1 O
into O

A77 O
1726 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Mechanism O
of O
action O
of O
leflunomide O
in O
rheumatoid O
arthritis.Leflunomide O
, O
a O
novel O
drug O
with O
proven O
efficacy O
in O
rheumatoid O
arthritis O
, O
is O
an O
isoxazol O
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs O
. O
Leflunomide O
is O
rapidly O
metabolized O
to O
its O
active O
form O
, O
A77 O
1726 O
. O
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 O
1726 O
inhibition O
of O
dihydroorotate O
dehydrogenase O
(DHODH) O
and O
inhibition O
of O
tyrosine O
kinases O
. O
DHODH O
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 O
1726 O
than O
that O
of O
tyrosine B
kinases I
and O
is O
currently O
considered O
the O
major O
mode O
of O
action O
. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O
before O
proceeding O
from O
the O
G1 O
into O

A77 O
1726 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
rheumatoid O
arthritis O
, O
is O
an O
isoxazol O
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs O
. O
Leflunomide O
is O
rapidly O
metabolized O
to O
its O
active O
form O
, O
A77 O
1726 O
. O
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 O
1726 O
: O
inhibition O
of O
dihydroorotate O
dehydrogenase O
(DHODH) O
and O
inhibition O
of O
tyrosine O
kinases O
. O
DHODH B
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 O
1726 O
than O
that O
of O
tyrosine O
kinases O
and O
is O
currently O
considered O
the O
major O
mode O
of O
action O
. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O
before O
proceeding O
from O
the O
G1 O
into O
the O
S O
phase O
. O
Increased O
levels O
of O
ribonucleotides O
can O
only O
be O
met O
by O
de O
novo O
ribonucleotide O
synthesis O
. O
At O
low O
levels O

A77 O
1726 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
rheumatoid O
arthritis O
, O
is O
an O
isoxazol O
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs O
. O
Leflunomide O
is O
rapidly O
metabolized O
to O
its O
active O
form O
, O
A77 O
1726 O
. O
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 O
1726 O
: O
inhibition O
of O
dihydroorotate O
dehydrogenase O
(DHODH) O
and O
inhibition O
of O
tyrosine O
kinases O
. O
DHODH O
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 O
1726 O
than O
that O
of O
tyrosine B
kinases I
and O
is O
currently O
considered O
the O
major O
mode O
of O
action O
. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O
before O
proceeding O
from O
the O
G1 O
into O
the O
S O
phase O
. O
Increased O
levels O
of O
ribonucleotides O
can O
only O
be O
met O
by O
de O
novo O
ribonucleotide O
synthesis O
. O
At O
low O
levels O

venlafaxine O
acts O
as O
NOT O
for O
what O
entity O
? O
reuptake O
inhibitors O
paroxetine O
, O
indalpine O
and O
fluvoxamine O
displayed O
a O
high O
affinity O
for O
the O
5-HT O
transporter O
, O
whereas O
the O
norepinephrine O
reuptake O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
only O
a O
moderate O
affinity O
for O
the O
5-HT O
transporter O
(Ki O
= O
74 O
nM) O
and O
a O
very O
low O
affinity O
for O
the O
norepinephrine B
transporter I
(Ki O
= O
1.26 O
microM) O
. O
The O
relatively O
low O
affinities O
of O
venlafaxine O
contrast O
with O
its O
potent O
in O
vivo O
5-HT O
and O
norepinephrine O
reuptake O

paroxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
reuptake O
inhibitors O
for O
the O
serotonin O
and O
norepinephrine O
transporters.In O
vitro O
radioligand O
binding O
studies O
were O
carried O
out O
in O
rat O
brain O
membranes O
to O
assess O
the O
affinity O
of O
various O
reuptake O
inhibitors O
for O
the O
serotonin O
(5-hydroxytryptamine O
, O
5-HT) O
and O
the O
norepinephrine O
transporters O
using O
the O
selective O
ligands O
[3H]cyanoimipramine O
and O
[3H]nisoxetine O
, O
respectively O
. O
The O
selective O
5-HT O
reuptake O
inhibitors O
paroxetine O
indalpine O
and O
fluvoxamine O
displayed O
a O
high O
affinity O
for O
the O
5-HT O
transporter O
, O
whereas O
the O
norepinephrine O
reuptake O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
, O
a O
dual O

indalpine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inhibitors O
for O
the O
serotonin O
and O
norepinephrine O
transporters.In O
vitro O
radioligand O
binding O
studies O
were O
carried O
out O
in O
rat O
brain O
membranes O
to O
assess O
the O
affinity O
of O
various O
reuptake O
inhibitors O
for O
the O
serotonin O
(5-hydroxytryptamine O
, O
5-HT) O
and O
the O
norepinephrine O
transporters O
using O
the O
selective O
ligands O
[3H]cyanoimipramine O
and O
[3H]nisoxetine O
, O
respectively O
. O
The O
selective O
5-HT O
reuptake O
inhibitors O
paroxetine O
, O
indalpine O
and O
fluvoxamine O
displayed O
a O
high O
affinity O
for O
the O
5-HT O
transporter O
, O
whereas O
the O
norepinephrine O
reuptake O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
, O
a O
dual O
5-HT O

fluvoxamine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
serotonin O
and O
norepinephrine O
transporters.In O
vitro O
radioligand O
binding O
studies O
were O
carried O
out O
in O
rat O
brain O
membranes O
to O
assess O
the O
affinity O
of O
various O
reuptake O
inhibitors O
for O
the O
serotonin O
(5-hydroxytryptamine O
, O
5-HT) O
and O
the O
norepinephrine O
transporters O
using O
the O
selective O
ligands O
[3H]cyanoimipramine O
and O
[3H]nisoxetine O
, O
respectively O
. O
The O
selective O
5-HT O
reuptake O
inhibitors O
paroxetine O
, O
indalpine O
and O
fluvoxamine O
displayed O
a O
high O
affinity O
for O
the O
5-HT O
transporter O
, O
whereas O
the O
norepinephrine O
reuptake O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
, O
a O
dual O
5-HT O
and O
norepinephrine O

desipramine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
brain O
membranes O
to O
assess O
the O
affinity O
of O
various O
reuptake O
inhibitors O
for O
the O
serotonin O
(5-hydroxytryptamine O
, O
5-HT) O
and O
the O
norepinephrine O
transporters O
using O
the O
selective O
ligands O
[3H]cyanoimipramine O
and O
[3H]nisoxetine O
, O
respectively O
. O
The O
selective O
5-HT O
reuptake O
inhibitors O
paroxetine O
, O
indalpine O
and O
fluvoxamine O
displayed O
a O
high O
affinity O
for O
the O
5-HT O
transporter O
, O
whereas O
the O
norepinephrine O
reuptake O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
only O
a O
moderate O
affinity O
for O
the O
5-HT O
transporter O
(Ki O
= O
74 O

venlafaxine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
reuptake O
inhibitors O
paroxetine O
, O
indalpine O
and O
fluvoxamine O
displayed O
a O
high O
affinity O
for O
the O
5-HT O
transporter O
, O
whereas O
the O
norepinephrine O
reuptake O
inhibitor O
desipramine O
had O
a O
high O
affinity O
for O
the O
norepinephrine O
transporter O
. O
Duloxetine O
, O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT O
and O
the O
norepinephrine O
transporters O
. O
Interestingly O
, O
venlafaxine O
a O
dual O
5-HT O
and O
norepinephrine O
reuptake O
inhibitor O
, O
displayed O
only O
a O
moderate O
affinity O
for O
the O
5-HT B
transporter I
(Ki O
= O
74 O
nM) O
and O
a O
very O
low O
affinity O
for O
the O
norepinephrine O
transporter O
(Ki O
= O
1.26 O
microM) O
. O
The O
relatively O
low O
affinities O
of O
venlafaxine O
contrast O
with O
its O
potent O
in O
vivo O
5-HT O
and O
norepinephrine O
reuptake O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
disulfide-linked O
homodimers O
. O
A O
soluble O
form O
of O
the O
enzyme O
, O
isolated O
from O
fetal O
bovine O
serum O
, O
showed O
the O
same O
subunit O
structure O
. O
Both O
forms O
of O
the O
enzyme O
reacted O
with O
a O
rabbit O
antibody O
raised O
to O
the O
amino-terminal O
peptide O
of O
the O
liver O
enzyme O
, O
suggesting O
that O
phosphodiester B
alpha-GlcNAcase I
is O
a O
type O
I O
membrane-spanning O
glycoprotein O
with O
its O
amino O
terminus O
in O
the O
lumen O
of O
the O
Golgi O
apparatus O
. O

amino O
acts O
as O
PART-OF O
for O
what O
entity O
? O
disulfide-linked O
homodimers O
. O
A O
soluble O
form O
of O
the O
enzyme O
, O
isolated O
from O
fetal O
bovine O
serum O
, O
showed O
the O
same O
subunit O
structure O
. O
Both O
forms O
of O
the O
enzyme O
reacted O
with O
a O
rabbit O
antibody O
raised O
to O
the O
amino-terminal O
peptide O
of O
the O
liver O
enzyme O
, O
suggesting O
that O
phosphodiester O
alpha-GlcNAcase O
is O
a O
type B
I I
membrane-spanning I
glycoprotein I
with O
its O
amino O
terminus O
in O
the O
lumen O
of O
the O
Golgi O
apparatus O
. O

mannose O
6-phosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Purification O
and O
multimeric O
structure O
of O
bovine O
N-acetylglucosamine-1-phosphodiester O
alpha-N-acetylglucosaminidase.N-Acetylglucosamine-1-phosphodiester O
alpha-N-Acetylglucosaminidase O
(EC O
3.1.4.45; O
phosphodiester O
alpha-GlcNAcase) O
catalyzes O
the O
second O
step O
in O
the O
synthesis O
of O
the O
mannose O
6-phosphate O
determinant O
required O
for O
efficient O
intracellular O
targeting O
of O
newly O
synthesized O
lysosomal O
hydrolases O
to O
the O
lysosome O
. O
A O
partially O
purified O
preparation O
of O
phosphodiester O
alpha-GlcNAcase O
from O
bovine O
pancreas O
was O
used O
to O
generate O
a O
panel O
of O
murine O
monoclonal O
antibodies O
. O
The O
anti-phosphodiester O
alpha-GlcNAcase O
monoclonal O
antibody O
UC1 O
was O
coupled O
to O
a O
solid O
support O
and O
used O
to O

mannose O
6-phosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Purification O
and O
multimeric O
structure O
of O
bovine O
N-acetylglucosamine-1-phosphodiester O
alpha-N-acetylglucosaminidase.N-Acetylglucosamine-1-phosphodiester O
alpha-N-Acetylglucosaminidase O
(EC O
3.1.4.45; O
phosphodiester O
alpha-GlcNAcase) O
catalyzes O
the O
second O
step O
in O
the O
synthesis O
of O
the O
mannose O
6-phosphate O
determinant O
required O
for O
efficient O
intracellular O
targeting O
of O
newly O
synthesized O
lysosomal O
hydrolases O
to O
the O
lysosome O
. O
A O
partially O
purified O
preparation O
of O
phosphodiester O
alpha-GlcNAcase O
from O
bovine O
pancreas O
was O
used O
to O
generate O
a O
panel O
of O
murine O
monoclonal O
antibodies O
. O
The O
anti-phosphodiester O
alpha-GlcNAcase O
monoclonal O
antibody O
UC1 O
was O
coupled O
to O
a O
solid O
support O
and O
used O
to O

mannose O
6-phosphate O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Purification O
and O
multimeric O
structure O
of O
bovine O
N-acetylglucosamine-1-phosphodiester O
alpha-N-acetylglucosaminidase.N-Acetylglucosamine-1-phosphodiester O
alpha-N-Acetylglucosaminidase O
(EC O
3.1.4.45; O
phosphodiester O
alpha-GlcNAcase) O
catalyzes O
the O
second O
step O
in O
the O
synthesis O
of O
the O
mannose O
6-phosphate O
determinant O
required O
for O
efficient O
intracellular O
targeting O
of O
newly O
synthesized O
lysosomal O
hydrolases O
to O
the O
lysosome O
. O
A O
partially O
purified O
preparation O
of O
phosphodiester B
alpha-GlcNAcase I
from O
bovine O
pancreas O
was O
used O
to O
generate O
a O
panel O
of O
murine O
monoclonal O
antibodies O
. O
The O
anti-phosphodiester O
alpha-GlcNAcase O
monoclonal O
antibody O
UC1 O
was O
coupled O
to O
a O
solid O
support O
and O
used O
to O

[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
murine O
monoclonal O
antibodies O
. O
The O
anti-phosphodiester O
alpha-GlcNAcase O
monoclonal O
antibody O
UC1 O
was O
coupled O
to O
a O
solid O
support O
and O
used O
to O
immunopurify O
the O
bovine O
liver O
enzyme O
670,000-fold O
in O
two O
steps O
to O
apparent O
homogeneity O
with O
an O
overall O
yield O
of O
14% O
. O
The O
purified O
phosphodiester B
alpha-GlcNAcase I
has O
a O
specific O
activity O
of O
498 O
micromol O
of O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
cleaved O
per O
h O
per O
mg O
of O
protein O
using O
0.5 O
mM O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
as O
substrate O
. O
The O
subunit O
structure O
of O
the O
enzyme O
was O
determined O
using O
a O
combination O
of O
analytical O
gel O
filtration O
chromatography O
, O
SDS-polyacrylamide O
gel O
electrophoresis O
, O
and O
amino-terminal O
sequencing O
. O
The O
data O
indicate O
that O
bovine O
phosphodiester O
alpha-GlcNAcase O
is O
a O
272,000-Da O
complex O
of O
four O
identical O

[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
coupled O
to O
a O
solid O
support O
and O
used O
to O
immunopurify O
the O
bovine O
liver O
enzyme O
670,000-fold O
in O
two O
steps O
to O
apparent O
homogeneity O
with O
an O
overall O
yield O
of O
14% O
. O
The O
purified O
phosphodiester B
alpha-GlcNAcase I
has O
a O
specific O
activity O
of O
498 O
micromol O
of O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
cleaved O
per O
h O
per O
mg O
of O
protein O
using O
0.5 O
mM O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl O
as O
substrate O
. O
The O
subunit O
structure O
of O
the O
enzyme O
was O
determined O
using O
a O
combination O
of O
analytical O
gel O
filtration O
chromatography O
, O
SDS-polyacrylamide O
gel O
electrophoresis O
, O
and O
amino-terminal O
sequencing O
. O
The O
data O
indicate O
that O
bovine O
phosphodiester O
alpha-GlcNAcase O
is O
a O
272,000-Da O
complex O
of O
four O
identical O
68,000-Da O
glycoprotein O
subunits O
arranged O
as O
two O
disulfide-linked O
homodimers O
. O
A O
soluble O
form O

finasteride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
hyperplasia O
(BPH) O
has O
prompted O
research O
into O
alternative O
medical O
therapies O
. O
Phytotherapy O
involves O
the O
use O
of O
herbal O
formulations O
, O
where O
the O
mechanisms O
of O
action O
are O
usually O
obscure O
and O
although O
studies O
have O
confirmed O
their O
effectiveness O
in O
symptom O
relief O
and O
improving O
quality O
of O
life O
(QOL) O
, O
few O
placebo-controlled O
trials O
exist O
. O
Both O
the O
5 B
alpha-reductase I
inhibitor O
finasteride O
and O
alpha O
1-adrenoceptor O
antagonists O
(e.g O
. O
alfuzosin O
, O
doxazosin O
, O
prazosin O
, O
tamsulosin O
and O
terazosin) O
have O
been O
recommended O
as O
appropriate O
treatment O
options O
for O
patients O
with O
lower O
urinary O
tract O
symptoms O
(LUTS) O
associated O
with O
benign O
prostatic O
obstruction O
(BPO) O
, O
and O
their O
efficacy O
has O
been O
proven O
in O
several O
placebo-controlled O
trials O
. O
Finasteride O
reduces O
the O
static O
component O
of O
BPO--by O

alfuzosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
alternative O
medical O
therapies O
. O
Phytotherapy O
involves O
the O
use O
of O
herbal O
formulations O
, O
where O
the O
mechanisms O
of O
action O
are O
usually O
obscure O
and O
although O
studies O
have O
confirmed O
their O
effectiveness O
in O
symptom O
relief O
and O
improving O
quality O
of O
life O
(QOL) O
, O
few O
placebo-controlled O
trials O
exist O
. O
Both O
the O
5 O
alpha-reductase O
inhibitor O
finasteride O
and O
alpha B
1-adrenoceptor I
antagonists O
(e.g O
. O
alfuzosin O
doxazosin O
, O
prazosin O
, O
tamsulosin O
and O
terazosin) O
have O
been O
recommended O
as O
appropriate O
treatment O
options O
for O
patients O
with O
lower O
urinary O
tract O
symptoms O
(LUTS) O
associated O
with O
benign O
prostatic O
obstruction O
(BPO) O
, O
and O
their O
efficacy O
has O
been O
proven O
in O
several O
placebo-controlled O
trials O
. O
Finasteride O
reduces O
the O
static O
component O
of O
BPO--by O
reducing O
the O
size O
of O
the O
prostate--and O
, O

doxazosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
medical O
therapies O
. O
Phytotherapy O
involves O
the O
use O
of O
herbal O
formulations O
, O
where O
the O
mechanisms O
of O
action O
are O
usually O
obscure O
and O
although O
studies O
have O
confirmed O
their O
effectiveness O
in O
symptom O
relief O
and O
improving O
quality O
of O
life O
(QOL) O
, O
few O
placebo-controlled O
trials O
exist O
. O
Both O
the O
5 O
alpha-reductase O
inhibitor O
finasteride O
and O
alpha B
1-adrenoceptor I
antagonists O
(e.g O
. O
alfuzosin O
, O
doxazosin O
prazosin O
, O
tamsulosin O
and O
terazosin) O
have O
been O
recommended O
as O
appropriate O
treatment O
options O
for O
patients O
with O
lower O
urinary O
tract O
symptoms O
(LUTS) O
associated O
with O
benign O
prostatic O
obstruction O
(BPO) O
, O
and O
their O
efficacy O
has O
been O
proven O
in O
several O
placebo-controlled O
trials O
. O
Finasteride O
reduces O
the O
static O
component O
of O
BPO--by O
reducing O
the O
size O
of O
the O
prostate--and O
, O
as O

prazosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
therapies O
. O
Phytotherapy O
involves O
the O
use O
of O
herbal O
formulations O
, O
where O
the O
mechanisms O
of O
action O
are O
usually O
obscure O
and O
although O
studies O
have O
confirmed O
their O
effectiveness O
in O
symptom O
relief O
and O
improving O
quality O
of O
life O
(QOL) O
, O
few O
placebo-controlled O
trials O
exist O
. O
Both O
the O
5 O
alpha-reductase O
inhibitor O
finasteride O
and O
alpha B
1-adrenoceptor I
antagonists O
(e.g O
. O
alfuzosin O
, O
doxazosin O
, O
prazosin O
tamsulosin O
and O
terazosin) O
have O
been O
recommended O
as O
appropriate O
treatment O
options O
for O
patients O
with O
lower O
urinary O
tract O
symptoms O
(LUTS) O
associated O
with O
benign O
prostatic O
obstruction O
(BPO) O
, O
and O
their O
efficacy O
has O
been O
proven O
in O
several O
placebo-controlled O
trials O
. O
Finasteride O
reduces O
the O
static O
component O
of O
BPO--by O
reducing O
the O
size O
of O
the O
prostate--and O
, O
as O
a O

tamsulosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Phytotherapy O
involves O
the O
use O
of O
herbal O
formulations O
, O
where O
the O
mechanisms O
of O
action O
are O
usually O
obscure O
and O
although O
studies O
have O
confirmed O
their O
effectiveness O
in O
symptom O
relief O
and O
improving O
quality O
of O
life O
(QOL) O
, O
few O
placebo-controlled O
trials O
exist O
. O
Both O
the O
5 O
alpha-reductase O
inhibitor O
finasteride O
and O
alpha B
1-adrenoceptor I
antagonists O
(e.g O
. O
alfuzosin O
, O
doxazosin O
, O
prazosin O
, O
tamsulosin O
and O
terazosin) O
have O
been O
recommended O
as O
appropriate O
treatment O
options O
for O
patients O
with O
lower O
urinary O
tract O
symptoms O
(LUTS) O
associated O
with O
benign O
prostatic O
obstruction O
(BPO) O
, O
and O
their O
efficacy O
has O
been O
proven O
in O
several O
placebo-controlled O
trials O
. O
Finasteride O
reduces O
the O
static O
component O
of O
BPO--by O
reducing O
the O
size O
of O
the O
prostate--and O
, O
as O
a O
result O
, O

terazosin O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
the O
use O
of O
herbal O
formulations O
, O
where O
the O
mechanisms O
of O
action O
are O
usually O
obscure O
and O
although O
studies O
have O
confirmed O
their O
effectiveness O
in O
symptom O
relief O
and O
improving O
quality O
of O
life O
(QOL) O
, O
few O
placebo-controlled O
trials O
exist O
. O
Both O
the O
5 O
alpha-reductase O
inhibitor O
finasteride O
and O
alpha B
1-adrenoceptor I
antagonists O
(e.g O
. O
alfuzosin O
, O
doxazosin O
, O
prazosin O
, O
tamsulosin O
and O
terazosin O
have O
been O
recommended O
as O
appropriate O
treatment O
options O
for O
patients O
with O
lower O
urinary O
tract O
symptoms O
(LUTS) O
associated O
with O
benign O
prostatic O
obstruction O
(BPO) O
, O
and O
their O
efficacy O
has O
been O
proven O
in O
several O
placebo-controlled O
trials O
. O
Finasteride O
reduces O
the O
static O
component O
of O
BPO--by O
reducing O
the O
size O
of O
the O
prostate--and O
, O
as O
a O
result O
, O
symptom O
relief O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
. O
Alterations O
in O
highly O
conserved O
Ig B
module I
II I
in O
the O
heparin O
binding O
domain O
and O
substitution O
of O
individual O
sequence O
domains O
spanning O
the O
entire O
sequence O
of O
Ig O
module O
II O
with O
those O
from O
Ig O
module O
I O
obliterated O
FGF O
binding O
. O
Addition O
of O
a O
specific O
number O
of O
FGFR O
sequences O
to O
the O
C O
terminus O
of O
Ig O
module O
II O
resulted O
in O
a O
gain O
in O
affinity O
for O
FGF-7 O
. O
Several O
site-specific O
alterations O
in O
the O
C-terminus O
of O
full-length O
FGFR1IIIc O
, O
an O
isoform O
that O
otherwise O
absolutely O
rejects O
FGF-7 O
, O
resulted O
in O
gain O
of O
FGF-7 O
binding O
. O
These O
results O
suggest O
that O
a O
complex O
of O
Ig O
module O
II O
and O
heparan O
sulfate O
is O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
individual O
sequence O
domains O
spanning O
the O
entire O
sequence O
of O
Ig O
module O
II O
with O
those O
from O
Ig O
module O
I O
obliterated O
FGF O
binding O
. O
Addition O
of O
a O
specific O
number O
of O
FGFR O
sequences O
to O
the O
C-terminus O
of O
Ig O
module O
II O
resulted O
in O
a O
gain O
in O
affinity O
for O
FGF-7 O
. O
Several O
site-specific O
alterations O
in O
the O
C O
terminus O
of O
full-length O
FGFR1IIIc O
, O
an O
isoform O
that O
otherwise O
absolutely O
rejects O
FGF-7 O
, O
resulted O
in O
gain O
of O
FGF-7 O
binding O
. O
These O
results O
suggest O
that O
a O
complex O
of O
Ig O
module O
II O
and O
heparan O
sulfate O
is O
the O
base O
common O
active O
core O
of O
the O
FGFR O
ectodomain O
and O
that O
flanking O
structural O
domains O
modify O
FGF O
affinity O
and O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
module O
II O
of O
FGFR1 O
supports O
the O
binding O
of O
FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
in O
respective O
order O
of O
affinity O
. O
None O
of O
the O
three O
FGFs O
detectably O
bind O
Ig O
module O
I O
or O
the O
IIIb O
and O
IIIc O
splice O
variants O
of O
Ig B
module I
III I
in O
the O
absence O
of O
flanking O
sequences O
. O
Ig O
module O
I O
and O
the O
C O
terminus O
of O
Ig O
module O
III O
are O
dispensable O
for O
high-affinity O
binding O
of O
FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
. O
Alterations O
in O
highly O
conserved O
Ig O
module O
II O
in O
the O
heparin O
binding O
domain O
and O
substitution O
of O
individual O
sequence O
domains O
spanning O
the O
entire O
sequence O
of O
Ig O
module O
II O
with O
those O
from O
Ig O
module O
I O
obliterated O
FGF O

sulfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
the O
C-terminus O
of O
Ig B
module I
II I
resulted O
in O
a O
gain O
in O
affinity O
for O
FGF-7 O
. O
Several O
site-specific O
alterations O
in O
the O
C-terminus O
of O
full-length O
FGFR1IIIc O
, O
an O
isoform O
that O
otherwise O
absolutely O
rejects O
FGF-7 O
, O
resulted O
in O
gain O
of O
FGF-7 O
binding O
. O
These O
results O
suggest O
that O
a O
complex O
of O
Ig O
module O
II O
and O
heparan O
sulfate O
is O
the O
base O
common O
active O
core O
of O
the O
FGFR O
ectodomain O
and O
that O
flanking O
structural O
domains O
modify O
FGF O
affinity O
and O
determine O
specificity O
. O

sulfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
heparan O
sulfate O
transmit O
intracellular O
signals O
regulating O
growth O
and O
function O
of O
cells O
. O
An O
understanding O
of O
the O
structural O
relationships O
between O
the O
three O
subunits O
and O
their O
redundancy O
and O
specificity O
is O
essential O
for O
understanding O
the O
ubiquitous O
FGF O
signaling O
system O
in O
health O
and O
disease O
. O
Previously O
, O
we O
reported O
that O
a O
primary O
heparin O
or O
heparan O
sulfate O
binding O
site O
resides O
in O
a O
distinct O
sequence O
in O
immunoglobulin B
(Ig)-like I
module I
II I
of O
the O
three O
modules O
of O
FGFR O
. O
Here O
we O
report O
that O
in O
the O
absence O
of O
flanking O
sequences O
, O
isolated O
Ig O
module O
II O
of O
FGFR1 O
supports O
the O
binding O
of O
FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
in O
respective O
order O
of O
affinity O
. O
None O
of O

sulfate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
heparan O
sulfate O
transmit O
intracellular O
signals O
regulating O
growth O
and O
function O
of O
cells O
. O
An O
understanding O
of O
the O
structural O
relationships O
between O
the O
three O
subunits O
and O
their O
redundancy O
and O
specificity O
is O
essential O
for O
understanding O
the O
ubiquitous O
FGF O
signaling O
system O
in O
health O
and O
disease O
. O
Previously O
, O
we O
reported O
that O
a O
primary O
heparin O
or O
heparan O
sulfate O
binding O
site O
resides O
in O
a O
distinct O
sequence O
in O
immunoglobulin O
(Ig)-like O
module O
II O
of O
the O
three O
modules O
of O
FGFR O
. O
Here O
we O
report O
that O
in O
the O
absence O
of O
flanking O
sequences O
, O
isolated O
Ig O
module O
II O
of O
FGFR1 O
supports O
the O
binding O
of O
FGF-1 O
, O
FGF-2 O
, O
and O
FGF-7 O
in O
respective O
order O
of O
affinity O
. O
None O
of O

cyanopindolol O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
CA3 O
region O
, O
but O
prolonged O
the O
clearance O
of O
5-HT O
in O
the O
dentate O
gyrus; O
this O
effect O
was O
absent O
in O
rats O
pretreated O
with O
6-hydroxydopamine O
. O
From O
these O
data O
, O
it O
is O
inferred O
that O
both O
the O
SERT O
and O
NET O
contribute O
to O
the O
active O
clearance O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
an O
antagonist O
of O
the O
serotonin O
terminal O
autoreceptor O
, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin O
autoreceptor O
enhances O
the O
kinetics O
of O
5-HT O
uptake O
through O
an O
effect O
on O
the O
serotonin O
transporter O
. O

5-HT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
did O
not O
alter O
the O
5-HT O
signal O
in O
the O
CA3 O
region O
, O
but O
prolonged O
the O
clearance O
of O
5-HT O
in O
the O
dentate O
gyrus; O
this O
effect O
was O
absent O
in O
rats O
pretreated O
with O
6-hydroxydopamine O
. O
From O
these O
data O
, O
it O
is O
inferred O
that O
both O
the O
SERT B
and O
NET O
contribute O
to O
the O
active O
clearance O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
, O
an O
antagonist O
of O
the O
serotonin O
terminal O
autoreceptor O
, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin O
autoreceptor O
enhances O
the O
kinetics O
of O
5-HT O
uptake O
through O
an O

5-HT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
did O
not O
alter O
the O
5-HT O
signal O
in O
the O
CA3 O
region O
, O
but O
prolonged O
the O
clearance O
of O
5-HT O
in O
the O
dentate O
gyrus; O
this O
effect O
was O
absent O
in O
rats O
pretreated O
with O
6-hydroxydopamine O
. O
From O
these O
data O
, O
it O
is O
inferred O
that O
both O
the O
SERT O
and O
NET B
contribute O
to O
the O
active O
clearance O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
, O
an O
antagonist O
of O
the O
serotonin O
terminal O
autoreceptor O
, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin O
autoreceptor O
enhances O
the O
kinetics O
of O
5-HT O
uptake O
through O
an O

5-HT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
, O
an O
antagonist O
of O
the O
serotonin O
terminal O
autoreceptor O
, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin O
autoreceptor O
enhances O
the O
kinetics O
of O
5-HT O
uptake O
through O
an O
effect O
on O
the O
serotonin O
transporter O
. O

5-HT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
of O
exogenously O
applied O
5-HT O
in O
the O
dentate O
gyrus O
. O
In O
another O
experiment O
, O
cyanopindolol O
, O
an O
antagonist O
of O
the O
serotonin O
terminal O
autoreceptor O
, O
also O
prolonged O
the O
clearance O
of O
5-HT O
from O
the O
CA3 O
region O
. O
These O
and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin B
autoreceptor I
enhances O
the O
kinetics O
of O
5-HT O
uptake O
through O
an O
effect O
on O
the O
serotonin O
transporter O
. O

Paclitaxel O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Furanodiene O
Presents O
Synergistic O
Anti-proliferative O
Activity O
With O
Paclitaxe O
Via O
Altering O
Cell O
Cycle O
and O
Integrin O
Signaling O
in O
95-D O
Lung O
Cancer O
Cells.Furanodiene O
(FUR) O
is O
a O
natural O
terpenoid O
isolated O
from O
Rhizoma O
Curcumae O
, O
a O
well-known O
Chinese O
medicinal O
herb O
that O
presents O
anti-proliferative O
activities O
in O
several O
cancer O
cell O
lines O
. O
Recently O
, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR O
with O
paclitaxel O
(TAX) O
showed O
synergetic O

Furanodiene O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
partially O
contribute O
to O
the O
synergic O
effect O
. O
Though O
FUR O
alone O
obviously O
induced O
endoplasmic O
reticulum O
stress O
, O
this O
signaling O
pathway O
may O
not O
contribute O
to O
the O
synergetic O
anti-proliferative O
effect O
as O
the O
protein O
expression O
of O
CHOP O
and O
BIP O
was O
similar O
in O
FUR O
alone O
and O
combined O
treatment O
group O
. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons O
, O
Ltd O
Presents O
Synergistic O
Anti-proliferative O
Activity O
With O
Paclitaxel O
Via O
Altering O
Cell O
Cycle O
and O
Integrin O
Signaling O
in O
95-D O
Lung O
Cancer O
Cells.Furanodiene O
(FUR) O
is O
a O
natural O
terpenoid O
isolated O
from O
Rhizoma O
Curcumae O
, O
a O
well-known O
Chinese O
medicinal O
herb O
that O
presents O
anti-proliferative O
activities O
in O
several O
cancer O
cell O
lines O
. O
Recently O
, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR O

CysLTs O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

pranlukast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
eosinophilia O
during O
late O
asthmatic O
response O
in O
guinea-pigs.BACKGROUND O
: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl O
leukotriene O
(CysLT) O
receptor O
(CysLT1 O
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs O
, O
suggesting O
that O
CysLTs O
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response O
. O
OBJECTIVE O
: O
We O
examined O
the O
effect O
of O
CysLT O
antagonists O
( O
pranlukast O
and O
MCI-826) O
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung O
, O
and O
on O
IL-5 O
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response O
, O
LAR) O
in O
sensitized O
guinea-pigs O
. O
METHODS O
: O
Guinea-pigs O
inhaled O
ovalbumin O
(OVA) O
+ O
Al(OH)3 O
and O
OVA O
mists O
alternately O
for O
sensitization O
and O
challenge O
, O
respectively O
, O
once O
every O
2 O

MCI-826 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
during O
late O
asthmatic O
response O
in O
guinea-pigs.BACKGROUND O
: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl O
leukotriene O
(CysLT) O
receptor O
(CysLT1 O
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs O
, O
suggesting O
that O
CysLTs O
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response O
. O
OBJECTIVE O
: O
We O
examined O
the O
effect O
of O
CysLT O
antagonists O
(pranlukast O
and O
MCI-826 O
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung O
, O
and O
on O
IL-5 O
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response O
, O
LAR) O
in O
sensitized O
guinea-pigs O
. O
METHODS O
: O
Guinea-pigs O
inhaled O
ovalbumin O
(OVA) O
+ O
Al(OH)3 O
and O
OVA O
mists O
alternately O
for O
sensitization O
and O
challenge O
, O
respectively O
, O
once O
every O
2 O
weeks O
. O
At O

CysLTs O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

pranlukast O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Sera O
obtained O
from O
sensitized O
, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

MCI-826 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
from O
sensitized O
, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

pranlukast O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
eosinophilia O
during O
late O
asthmatic O
response O
in O
guinea-pigs.BACKGROUND O
: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl O
leukotriene O
(CysLT) O
receptor O
(CysLT1 O
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs O
, O
suggesting O
that O
CysLTs O
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response O
. O
OBJECTIVE O
: O
We O
examined O
the O
effect O
of O
CysLT O
antagonists O
( O
pranlukast O
and O
MCI-826) O
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung O
, O
and O
on O
IL-5 O
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response O
, O
LAR) O
in O
sensitized O
guinea-pigs O
. O
METHODS O
: O
Guinea-pigs O
inhaled O
ovalbumin O
(OVA) O
+ O
Al(OH)3 O
and O
OVA O
mists O
alternately O
for O
sensitization O
and O
challenge O
, O
respectively O
, O
once O
every O
2 O

pranlukast O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Sera O
obtained O
from O
sensitized O
, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

MCI-826 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
during O
late O
asthmatic O
response O
in O
guinea-pigs.BACKGROUND O
: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl O
leukotriene O
(CysLT) O
receptor O
(CysLT1 O
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs O
, O
suggesting O
that O
CysLTs O
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response O
. O
OBJECTIVE O
: O
We O
examined O
the O
effect O
of O
CysLT O
antagonists O
(pranlukast O
and O
MCI-826 O
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung O
, O
and O
on O
IL-5 O
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response O
, O
LAR) O
in O
sensitized O
guinea-pigs O
. O
METHODS O
: O
Guinea-pigs O
inhaled O
ovalbumin O
(OVA) O
+ O
Al(OH)3 O
and O
OVA O
mists O
alternately O
for O
sensitization O
and O
challenge O
, O
respectively O
, O
once O
every O
2 O
weeks O
. O
At O

MCI-826 O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
from O
sensitized O
, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

ramelteon O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
( O
ramelteon O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O

ramelteon O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
ramelteo O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O

(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O

TAK-375 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375 O
 O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O

TAK-375 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Effect O
of O
ramelteon O
(TAK-37 O
) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O

N-acetyl-5-hydroxytryptamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
of O
ramelteon O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
(N-acetyl-5-HT) O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O
se O
. O
However O
, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam O
(3mg/kg O
, O
p.o.) O
, O
treatment O
with O
melatonin O
and O
N-acetyl-5-HT O
exacerbated O
the O
impairment O
by O
diazepam O
. O
Ramelteon O
had O
no O
significant O
effect O
on O
the O
diazepam-induced O
impairment O
of O
motor O
coordination O
. O

N-acetyl-5-HT O
acts O
as O
AGONIST O
for O
what O
entity O
? O
(TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
performance O
in O
mice.Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide O
(ramelteon O
, O
TAK-375) O
, O
a O
selective O
MT1/MT2 O
receptor O
agonist O
, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice O
. O
Ramelteon O
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3 O
, O
10 O
and O
30 O
mg/kg O
, O
p.o O
. O
Melatonin O
and O
N-acetyl-5-hydroxytryptamine O
( O
N-acetyl-5-HT O
 O
, O
a O
ligand O
of O
MT3 O
biding O
site O
, O
also O
had O
no O
impairment O
on O
the O
performance O
, O
per O
se O
. O
However O
, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam O
(3mg/kg O
, O
p.o.) O
, O
treatment O
with O
melatonin O
and O
N-acetyl-5-HT O
exacerbated O
the O
impairment O
by O
diazepam O
. O
Ramelteon O
had O
no O
significant O
effect O
on O
the O
diazepam-induced O
impairment O
of O
motor O
coordination O
. O
